CTID,Title,Conditions,Study Type,Results First Posted,Company,Intervention
NCT02756624,"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution",Healthy Subjects,Interventional,26-Jul-17,"Nicox Ophthalmics, Inc.",Drug: AC-170 0.24%
NCT02756624,"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution",Healthy Subjects,Interventional,26-Jul-17,"Nicox Ophthalmics, Inc.",Drug: AC-170 Vehicle
NCT02756624,"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution",Healthy Subjects,Interventional,26-Jul-17,"ORA, Inc.",Drug: AC-170 0.24%
NCT02756624,"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution",Healthy Subjects,Interventional,26-Jul-17,"ORA, Inc.",Drug: AC-170 Vehicle
NCT02334436,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002,Glabellar Frown Lines,Interventional,27-Feb-19,"Evolus, Inc.","Biological: Botulinum toxin, Type A"
NCT02334436,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002,Glabellar Frown Lines,Interventional,27-Feb-19,"Evolus, Inc.","Other: 0.9% sterile, unpreserved saline"
NCT02334436,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002,Glabellar Frown Lines,Interventional,27-Feb-19,PPD,"Biological: Botulinum toxin, Type A"
NCT02334436,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002,Glabellar Frown Lines,Interventional,27-Feb-19,PPD,"Other: 0.9% sterile, unpreserved saline"
NCT02334423,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001,Glabellar Frown Lines,Interventional,26-Feb-19,"Evolus, Inc.","Biological: Botulinum toxin, Type A"
NCT02334423,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001,Glabellar Frown Lines,Interventional,26-Feb-19,"Evolus, Inc.","Other: 0.9% sterile, unpreserved saline"
NCT02334423,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001,Glabellar Frown Lines,Interventional,26-Feb-19,PPD,"Biological: Botulinum toxin, Type A"
NCT02334423,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001,Glabellar Frown Lines,Interventional,26-Feb-19,PPD,"Other: 0.9% sterile, unpreserved saline"
NCT02194933,Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity,Schizophrenia With Impulsivity,Interventional,11-Sep-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Brexpiprazole
NCT02194933,Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity,Schizophrenia With Impulsivity,Interventional,11-Sep-18,"Otsuka Pharmaceutical Co., Ltd.",Drug: Brexpiprazole
NCT02110238,Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA,Osteoarthritis,Interventional,23-Jun-16,Bioventus LLC,Device: Supartz
NCT02110238,Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA,Osteoarthritis,Interventional,23-Jun-16,Bioventus LLC,Device: Euflexxa
NCT02110238,Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA,Osteoarthritis,Interventional,23-Jun-16,Seikagaku Corporation,Device: Supartz
NCT02110238,Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA,Osteoarthritis,Interventional,23-Jun-16,Seikagaku Corporation,Device: Euflexxa
NCT02096861,Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease,Crohn's Disease,Interventional,11-Apr-18,Celltrion,Biological: CT-P13
NCT02096861,Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease,Crohn's Disease,Interventional,11-Apr-18,Celltrion,Biological: Remicade
NCT02096861,Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease,Crohn's Disease,Interventional,11-Apr-18,Pfizer,Biological: CT-P13
NCT02096861,Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease,Crohn's Disease,Interventional,11-Apr-18,Pfizer,Biological: Remicade
NCT01959035,Aripiprazole Once-monthly in Patients With Schizophrenia,Schizophrenia,Interventional,16-May-16,H. Lundbeck A/S,Drug: Aripiprazole once-monthly
NCT01959035,Aripiprazole Once-monthly in Patients With Schizophrenia,Schizophrenia,Interventional,16-May-16,"Otsuka Pharmaceutical Co., Ltd.",Drug: Aripiprazole once-monthly
NCT01810380,Brexpiprazole in Patients With Acute Schizophrenia,Schizophrenia,Interventional,29-Mar-16,H. Lundbeck A/S,Drug: Placebo
NCT01810380,Brexpiprazole in Patients With Acute Schizophrenia,Schizophrenia,Interventional,29-Mar-16,H. Lundbeck A/S,Drug: Brexpiprazole
NCT01810380,Brexpiprazole in Patients With Acute Schizophrenia,Schizophrenia,Interventional,29-Mar-16,H. Lundbeck A/S,Drug: Quetiapine extended release
NCT01810380,Brexpiprazole in Patients With Acute Schizophrenia,Schizophrenia,Interventional,29-Mar-16,"Otsuka Pharmaceutical Co., Ltd.",Drug: Placebo
NCT01810380,Brexpiprazole in Patients With Acute Schizophrenia,Schizophrenia,Interventional,29-Mar-16,"Otsuka Pharmaceutical Co., Ltd.",Drug: Brexpiprazole
NCT01810380,Brexpiprazole in Patients With Acute Schizophrenia,Schizophrenia,Interventional,29-Mar-16,"Otsuka Pharmaceutical Co., Ltd.",Drug: Quetiapine extended release
NCT01053312,PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus,Normal Pressure Hydrocephalus,Interventional,5-Jun-12,GE Healthcare,Drug: [18F] Flutemetamol
NCT01053312,PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus,Normal Pressure Hydrocephalus,Interventional,5-Jun-12,i3 Statprobe,Drug: [18F] Flutemetamol
NCT00817206,Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily,Renal Failure,Interventional,10-Sep-15,Veloxis Pharmaceuticals,Drug: LCP-Tacro
NCT00817206,Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily,Renal Failure,Interventional,10-Sep-15,Veloxis Pharmaceuticals,Drug: Prograf
NCT00817206,Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily,Renal Failure,Interventional,10-Sep-15,PPD,Drug: LCP-Tacro
NCT00817206,Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily,Renal Failure,Interventional,10-Sep-15,PPD,Drug: Prograf
NCT00662038,Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Interventional,29-Mar-17,"Genentech, Inc.",Drug: pirfenidone
NCT00662038,Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Interventional,29-Mar-17,Hoffmann-La Roche,Drug: pirfenidone
NCT00623636,Phase 3 Study of MAP0004 in Adult Migraineurs,Migraine Disorders,Interventional,29-Oct-13,Allergan,Drug: MAP0004
NCT00623636,Phase 3 Study of MAP0004 in Adult Migraineurs,Migraine Disorders,Interventional,29-Oct-13,Allergan,Drug: Placebo
NCT00623636,Phase 3 Study of MAP0004 in Adult Migraineurs,Migraine Disorders,Interventional,29-Oct-13,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Drug: MAP0004
NCT00623636,Phase 3 Study of MAP0004 in Adult Migraineurs,Migraine Disorders,Interventional,29-Oct-13,"MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Drug: Placebo
NCT00566501,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Alzheimer's Disease,Interventional,19-Jun-12,Eisai Inc.,Drug: 23 mg SR in Study 326
NCT00566501,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Alzheimer's Disease,Interventional,19-Jun-12,Eisai Inc.,Drug: 10 mg IR in Study 326
NCT00566501,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Alzheimer's Disease,Interventional,19-Jun-12,Eisai Limited,Drug: 23 mg SR in Study 326
NCT00566501,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Alzheimer's Disease,Interventional,19-Jun-12,Eisai Limited,Drug: 10 mg IR in Study 326
NCT00478205,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,Alzheimer's Disease,Interventional,5-Feb-13,Eisai Inc.,Drug: Aricept (donepezil SR 23 mg)
NCT00478205,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,Alzheimer's Disease,Interventional,5-Feb-13,Eisai Inc.,Drug: Aricept (donepezil IR 10 mg)
NCT00478205,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,Alzheimer's Disease,Interventional,5-Feb-13,Eisai Limited,Drug: Aricept (donepezil SR 23 mg)
NCT00478205,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,Alzheimer's Disease,Interventional,5-Feb-13,Eisai Limited,Drug: Aricept (donepezil IR 10 mg)
NCT00460746,Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.,HIV,Interventional,10-Nov-09,"Tibotec, Inc","Drug: TMC125, Darunavir; Ritonavir"
NCT00460746,Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.,HIV,Interventional,10-Nov-09,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","Drug: TMC125, Darunavir; Ritonavir"
NCT00428584,RNF and Betaseron® Tolerability Study,Relapsing Remitting Multiple Sclerosis (RRMS),Interventional,4-Mar-10,EMD Serono,Drug: New Formulation of rebif - human interferon beta-1a
NCT00428584,RNF and Betaseron® Tolerability Study,Relapsing Remitting Multiple Sclerosis (RRMS),Interventional,4-Mar-10,EMD Serono,Drug: Interferon beta -1b
NCT00428584,RNF and Betaseron® Tolerability Study,Relapsing Remitting Multiple Sclerosis (RRMS),Interventional,4-Mar-10,Pfizer,Drug: New Formulation of rebif - human interferon beta-1a
NCT00428584,RNF and Betaseron® Tolerability Study,Relapsing Remitting Multiple Sclerosis (RRMS),Interventional,4-Mar-10,Pfizer,Drug: Interferon beta -1b
NCT01265394,Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects,Healthy,Interventional,21-Jun-13,GE Healthcare,Drug: [18F] Flutemetamol
NCT01265394,Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects,Healthy,Interventional,21-Jun-13,i3 Statprobe,Drug: [18F] Flutemetamol
NCT01265394,Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects,Healthy,Interventional,21-Jun-13,"Medpace, Inc.",Drug: [18F] Flutemetamol
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Reckitt Benckiser LLC,Drug: Ibuprofen/acetaminophen
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Reckitt Benckiser LLC,Drug: Ibuprofen/acetaminophen (higher dose)
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Reckitt Benckiser LLC,Drug: Nurofen Plus®
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Reckitt Benckiser LLC,Drug: Panadeine® Extra
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Reckitt Benckiser LLC,Drug: Placebo
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Premier Research Group plc,Drug: Ibuprofen/acetaminophen
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Premier Research Group plc,Drug: Ibuprofen/acetaminophen (higher dose)
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Premier Research Group plc,Drug: Nurofen Plus®
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Premier Research Group plc,Drug: Panadeine® Extra
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Premier Research Group plc,Drug: Placebo
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Aptuit Inc.,Drug: Ibuprofen/acetaminophen
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Aptuit Inc.,Drug: Ibuprofen/acetaminophen (higher dose)
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Aptuit Inc.,Drug: Nurofen Plus®
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Aptuit Inc.,Drug: Panadeine® Extra
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Post-operative Pain,Interventional,17-Sep-18,Aptuit Inc.,Drug: Placebo
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,Novartis Pharmaceuticals,Drug: Verteporfin photodynamic therapy
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,Novartis Pharmaceuticals,Drug: Pegaptanib
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,Novartis Pharmaceuticals,Drug: Triamcinolone acetonide
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,QLT Inc.,Drug: Verteporfin photodynamic therapy
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,QLT Inc.,Drug: Pegaptanib
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,QLT Inc.,Drug: Triamcinolone acetonide
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,Novartis,Drug: Verteporfin photodynamic therapy
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,Novartis,Drug: Pegaptanib
NCT00242580,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Macular Degeneration|Choroidal Neovascularization,Interventional,2-May-11,Novartis,Drug: Triamcinolone acetonide
NCT01165554,Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels,Brain Fibrillarab Levels,Interventional,4-Dec-13,GE Healthcare,Drug: [18F] Flutemetamol
NCT01165554,Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels,Brain Fibrillarab Levels,Interventional,4-Dec-13,i3 Statprobe,Drug: [18F] Flutemetamol
NCT01165554,Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels,Brain Fibrillarab Levels,Interventional,4-Dec-13,Covance,Drug: [18F] Flutemetamol
NCT00110396,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,Multiple Sclerosis,Interventional,9-Jul-10,EMD Serono,Biological: Interferon-beta-1a FBS-free/HSA-free
NCT00110396,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,Multiple Sclerosis,Interventional,9-Jul-10,Pfizer,Biological: Interferon-beta-1a FBS-free/HSA-free
NCT00097591,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,Coronary Arteriosclerosis|Acute Coronary Syndromes,Interventional,16-Sep-10,Eli Lilly and Company,Drug: Prasugrel
NCT00097591,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,Coronary Arteriosclerosis|Acute Coronary Syndromes,Interventional,16-Sep-10,Eli Lilly and Company,Drug: Clopidogrel
NCT00097591,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,Coronary Arteriosclerosis|Acute Coronary Syndromes,Interventional,16-Sep-10,"Daiichi Sankyo, Inc.",Drug: Prasugrel
NCT00097591,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,Coronary Arteriosclerosis|Acute Coronary Syndromes,Interventional,16-Sep-10,"Daiichi Sankyo, Inc.",Drug: Clopidogrel
NCT02130063,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Iron Deficiency Anaemia,Interventional,22-May-18,Pharmacosmos A/S,Drug: iron isomaltoside 1000 (Monofer®)
NCT02130063,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Iron Deficiency Anaemia,Interventional,22-May-18,Pharmacosmos A/S,Drug: iron sucrose (Venofer®)
NCT02130063,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Iron Deficiency Anaemia,Interventional,22-May-18,BioStata,Drug: iron isomaltoside 1000 (Monofer®)
NCT02130063,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Iron Deficiency Anaemia,Interventional,22-May-18,BioStata,Drug: iron sucrose (Venofer®)
NCT02130063,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Iron Deficiency Anaemia,Interventional,22-May-18,"ClinStar, LLC",Drug: iron isomaltoside 1000 (Monofer®)
NCT02130063,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Iron Deficiency Anaemia,Interventional,22-May-18,"ClinStar, LLC",Drug: iron sucrose (Venofer®)
NCT02130063,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Iron Deficiency Anaemia,Interventional,22-May-18,LabCorp,Drug: iron isomaltoside 1000 (Monofer®)
NCT02130063,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Iron Deficiency Anaemia,Interventional,22-May-18,LabCorp,Drug: iron sucrose (Venofer®)
NCT01795547,Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia,Schizophrenia,Interventional,3-Dec-15,H. Lundbeck A/S,Drug: Aripiprazole and aripiprazole once-monthly
NCT01795547,Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia,Schizophrenia,Interventional,3-Dec-15,H. Lundbeck A/S,Drug: Paliperidone and paliperidone palmitate
NCT01795547,Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia,Schizophrenia,Interventional,3-Dec-15,"Otsuka Pharmaceutical Co., Ltd.",Drug: Aripiprazole and aripiprazole once-monthly
NCT01795547,Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia,Schizophrenia,Interventional,3-Dec-15,"Otsuka Pharmaceutical Co., Ltd.",Drug: Paliperidone and paliperidone palmitate
NCT00707057,Ibuprofen Extended-Release Dental Pain Study,Pain|Post-Operative Pain|Third Molar Extraction,Interventional,23-Mar-11,"SCOLR Pharma, Inc.",Drug: Ibuprofen 600 mg Extended-Release Tablets
NCT00707057,Ibuprofen Extended-Release Dental Pain Study,Pain|Post-Operative Pain|Third Molar Extraction,Interventional,23-Mar-11,"SCOLR Pharma, Inc.",Drug: Placebo
NCT00707057,Ibuprofen Extended-Release Dental Pain Study,Pain|Post-Operative Pain|Third Molar Extraction,Interventional,23-Mar-11,AAIPharma,Drug: Ibuprofen 600 mg Extended-Release Tablets
NCT00707057,Ibuprofen Extended-Release Dental Pain Study,Pain|Post-Operative Pain|Third Molar Extraction,Interventional,23-Mar-11,AAIPharma,Drug: Placebo
NCT00707057,Ibuprofen Extended-Release Dental Pain Study,Pain|Post-Operative Pain|Third Molar Extraction,Interventional,23-Mar-11,Jean Brown Research,Drug: Ibuprofen 600 mg Extended-Release Tablets
NCT00707057,Ibuprofen Extended-Release Dental Pain Study,Pain|Post-Operative Pain|Third Molar Extraction,Interventional,23-Mar-11,Jean Brown Research,Drug: Placebo
NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,"Macular Edema, Cystoid|Retinal Vein Occlusion",Interventional,19-Jan-11,"The Emmes Company, LLC",Other: Standard Care
NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,"Macular Edema, Cystoid|Retinal Vein Occlusion",Interventional,19-Jan-11,"The Emmes Company, LLC",Drug: intravitreal triamcinolone injection
NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,"Macular Edema, Cystoid|Retinal Vein Occlusion",Interventional,19-Jan-11,National Eye Institute (NEI),Other: Standard Care
NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,"Macular Edema, Cystoid|Retinal Vein Occlusion",Interventional,19-Jan-11,National Eye Institute (NEI),Drug: intravitreal triamcinolone injection
NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,"Macular Edema, Cystoid|Retinal Vein Occlusion",Interventional,19-Jan-11,Allergan,Other: Standard Care
NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,"Macular Edema, Cystoid|Retinal Vein Occlusion",Interventional,19-Jan-11,Allergan,Drug: intravitreal triamcinolone injection
NCT01844830,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients",Anesthesia,Interventional,30-Aug-17,"St. Renatus, LLC",Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01844830,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients",Anesthesia,Interventional,30-Aug-17,"St. Renatus, LLC",Drug: Placebo
NCT01844830,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients",Anesthesia,Interventional,30-Aug-17,Triligent International,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01844830,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients",Anesthesia,Interventional,30-Aug-17,Triligent International,Drug: Placebo
NCT01844830,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients",Anesthesia,Interventional,30-Aug-17,"Rho, Inc.",Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01844830,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients",Anesthesia,Interventional,30-Aug-17,"Rho, Inc.",Drug: Placebo
NCT00563368,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,Obesity,Interventional,3-Sep-12,"VIVUS, Inc.",Drug: VI-0521
NCT00563368,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,Obesity,Interventional,3-Sep-12,"VIVUS, Inc.",Drug: topiramate
NCT00563368,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,Obesity,Interventional,3-Sep-12,"VIVUS, Inc.",Drug: phentermine
NCT00563368,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,Obesity,Interventional,3-Sep-12,"Medpace, Inc.",Drug: VI-0521
NCT00563368,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,Obesity,Interventional,3-Sep-12,"Medpace, Inc.",Drug: topiramate
NCT00563368,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,Obesity,Interventional,3-Sep-12,"Medpace, Inc.",Drug: phentermine
NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,11-Sep-14,GE Healthcare,Drug: Flutemetamol (18F) Injection
NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,11-Sep-14,"Medpace, Inc.",Drug: Flutemetamol (18F) Injection
NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,11-Sep-14,i3 Statprobe,Drug: Flutemetamol (18F) Injection
NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,11-Sep-14,i3 Research,Drug: Flutemetamol (18F) Injection
NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,11-Sep-14,"Quintiles, Inc.",Drug: Flutemetamol (18F) Injection
NCT03198000,A Study to Evaluate the Efficacy of Investigational OTC Eye Drops,Ophthalmic Solutions,Interventional,8-Aug-18,Johnson & Johnson Consumer Inc. (J&JCI),Drug: F# 13418-148 Eye Drops
NCT03198000,A Study to Evaluate the Efficacy of Investigational OTC Eye Drops,Ophthalmic Solutions,Interventional,8-Aug-18,Johnson & Johnson Consumer Inc. (J&JCI),Drug: F#13418-158 Eye Drops
NCT03198000,A Study to Evaluate the Efficacy of Investigational OTC Eye Drops,Ophthalmic Solutions,Interventional,8-Aug-18,Johnson & Johnson Consumer Inc. (J&JCI),Drug: F# PF-004390 Eye Drops
NCT03198000,A Study to Evaluate the Efficacy of Investigational OTC Eye Drops,Ophthalmic Solutions,Interventional,8-Aug-18,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: F# 13418-148 Eye Drops
NCT03198000,A Study to Evaluate the Efficacy of Investigational OTC Eye Drops,Ophthalmic Solutions,Interventional,8-Aug-18,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: F#13418-158 Eye Drops
NCT03198000,A Study to Evaluate the Efficacy of Investigational OTC Eye Drops,Ophthalmic Solutions,Interventional,8-Aug-18,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: F# PF-004390 Eye Drops
NCT03128307,OTC Mouthpiece for Snoring,Snoring,Interventional,14-Dec-17,"Zyppah, Inc.",Device: Zyppah Anti-snoring Appliance
NCT03095456,Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD,"Chronic Obstructive Pulmonary Disease, COPD|Low Peak Inspiratory Flow Rate (PIFR)",Interventional,31-Dec-18,Theravance Biopharma,Drug: Revefenacin
NCT03095456,Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD,"Chronic Obstructive Pulmonary Disease, COPD|Low Peak Inspiratory Flow Rate (PIFR)",Interventional,31-Dec-18,Theravance Biopharma,Combination Product: Spiriva Handihaler®
NCT03095456,Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD,"Chronic Obstructive Pulmonary Disease, COPD|Low Peak Inspiratory Flow Rate (PIFR)",Interventional,31-Dec-18,Theravance Biopharma,Drug: Placebo for Revefenacin
NCT03095456,Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD,"Chronic Obstructive Pulmonary Disease, COPD|Low Peak Inspiratory Flow Rate (PIFR)",Interventional,31-Dec-18,Theravance Biopharma,Drug: Placebo for Spiriva Handihaler®
NCT03088267,Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study,Attention Deficit Hyperactivity Disorder,Interventional,9-Jul-19,"Tris Pharma, Inc.","Drug: amphetamine extended-release oral suspension, 2.5 mg/mL"
NCT03088267,Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study,Attention Deficit Hyperactivity Disorder,Interventional,9-Jul-19,"Tris Pharma, Inc.",Drug: Placebo extended-release oral suspension
NCT02970162,Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Lambert-Eaton Myasthenic Syndrome,Interventional,24-Dec-18,"Catalyst Pharmaceuticals, Inc.",Drug: Amifampridine Phosphate
NCT02970162,Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Lambert-Eaton Myasthenic Syndrome,Interventional,24-Dec-18,"Catalyst Pharmaceuticals, Inc.",Drug: Placebo Oral Tablet
NCT02933866,Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis,Scalp Psoriasis,Interventional,6-Dec-18,Taro Pharmaceuticals USA,Drug: DSXS topical
NCT02933866,Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis,Scalp Psoriasis,Interventional,6-Dec-18,Taro Pharmaceuticals USA,Drug: Vehicle topical
NCT02912650,A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain,Post-surgical Pain Following Extraction of Molar Teeth,Interventional,30-Aug-17,Pfizer,Drug: Ibuprofen 250 mg / Acetaminophen 500 mg
NCT02912650,A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain,Post-surgical Pain Following Extraction of Molar Teeth,Interventional,30-Aug-17,Pfizer,Drug: Ibuprofen 250 mg
NCT02912650,A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain,Post-surgical Pain Following Extraction of Molar Teeth,Interventional,30-Aug-17,Pfizer,Drug: Acetaminophen 650 mg
NCT02912650,A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain,Post-surgical Pain Following Extraction of Molar Teeth,Interventional,30-Aug-17,Pfizer,Drug: Placebo
NCT02872103,Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,Breast Cancer|Neutropenia,Interventional,26-Mar-19,Generon (Shanghai) Corporation Ltd.,Drug: F-627
NCT02872103,Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,Breast Cancer|Neutropenia,Interventional,26-Mar-19,Generon (Shanghai) Corporation Ltd.,Drug: Placebo
NCT02863575,A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine,Pain,Interventional,8-Apr-19,Pfizer,Drug: Ibuprofen/Caffeine
NCT02863575,A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine,Pain,Interventional,8-Apr-19,Pfizer,Drug: Ibuprofen
NCT02863575,A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine,Pain,Interventional,8-Apr-19,Pfizer,Drug: Placebo
NCT02837952,A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain,Pain,Interventional,5-Mar-18,Pfizer,Drug: FDC IBU/APAP 250 mg/500 mg
NCT02837952,A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain,Pain,Interventional,5-Mar-18,Pfizer,Drug: Placebo
NCT02832375,Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity,Dentin Sensitivity,Interventional,27-Feb-17,GlaxoSmithKline,Drug: stannous fluoride
NCT02832375,Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity,Dentin Sensitivity,Interventional,27-Feb-17,GlaxoSmithKline,Drug: sodium monofluorophosphate
NCT02761980,A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers,Fever,Interventional,7-Dec-18,Pfizer,Drug: Ibuprofen 250 mg / Acetaminophen 500 mg
NCT02761980,A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers,Fever,Interventional,7-Dec-18,Pfizer,Drug: Ibuprofen 250 mg
NCT02761980,A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers,Fever,Interventional,7-Dec-18,Pfizer,Drug: Acetaminophen 500 mg
NCT02761980,A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers,Fever,Interventional,7-Dec-18,Pfizer,Drug: Placebo
NCT02722278,A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Hypogonadism,Interventional,23-Feb-18,"Clarus Therapeutics, Inc.",Drug: Oral Testosterone Undecanoate
NCT02722278,A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Hypogonadism,Interventional,23-Feb-18,"Clarus Therapeutics, Inc.",Drug: Axiron Testosterone Topical Solution
NCT02722278,A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Hypogonadism,Interventional,23-Feb-18,Syneos Health,Drug: Oral Testosterone Undecanoate
NCT02722278,A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Hypogonadism,Interventional,23-Feb-18,Syneos Health,Drug: Axiron Testosterone Topical Solution
NCT02674854,Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,1-May-19,Aerie Pharmaceuticals,Drug: PG324 Ophthalmic Solution 0.02%/0.005%
NCT02674854,Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,1-May-19,Aerie Pharmaceuticals,Drug: Netarsudil (AR-13324) ophthalmic solution 0.02%
NCT02674854,Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,1-May-19,Aerie Pharmaceuticals,Drug: Latanoprost ophthalmic solution 0.005%
NCT02667288,An Open-Label Safety Study of A-101 Solution,Seborrheic Keratosis,Interventional,17-Nov-17,"Aclaris Therapeutics, Inc.",Drug: A-101 Solution
NCT02667275,"A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis",Seborrheic Keratosis,Interventional,13-Nov-17,"Aclaris Therapeutics, Inc.",Drug: A-101 Solution
NCT02667275,"A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis",Seborrheic Keratosis,Interventional,13-Nov-17,"Aclaris Therapeutics, Inc.",Other: Vehicle Solution
NCT02667236,A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.,Seborrheic Keratosis,Interventional,13-Nov-17,"Aclaris Therapeutics, Inc.",Drug: A-101 Solution
NCT02667236,A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.,Seborrheic Keratosis,Interventional,13-Nov-17,"Aclaris Therapeutics, Inc.",Other: Vehicle Solution
NCT02618759,Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis,Plaque Psoriasis,Interventional,10-Dec-18,Taro Pharmaceuticals USA,Drug: DSXS
NCT02618759,Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis,Plaque Psoriasis,Interventional,10-Dec-18,Taro Pharmaceuticals USA,Drug: Placebo
NCT02595073,Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis,Atopic Dermatitis,Interventional,7-Dec-18,Taro Pharmaceuticals USA,Drug: DSXS
NCT02595073,Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis,Atopic Dermatitis,Interventional,7-Dec-18,Taro Pharmaceuticals USA,Drug: Placebo
NCT02558400,Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,4-Jun-19,Aerie Pharmaceuticals,Drug: PG324 Ophthalmic Solution 0.02%/0.005%
NCT02558400,Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,4-Jun-19,Aerie Pharmaceuticals,Drug: Netarsudil (AR-13324) Ophthalmic Solution 0.02%
NCT02558400,Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,4-Jun-19,Aerie Pharmaceuticals,Drug: Latanoprost Ophthalmic Solution 0.005%
NCT02558374,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,6-Apr-18,Aerie Pharmaceuticals,Drug: AR-13324 Ophthalmic Solution 0.02%
NCT02558374,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,6-Apr-18,Aerie Pharmaceuticals,Drug: Timolol Maleate Ophthalmic Solution 0.5% BID
NCT02558374,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,Open-angle Glaucoma|Ocular Hypertension,Interventional,6-Apr-18,Aerie Pharmaceuticals,Other: Placebo
NCT02549339,Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up,Actinic Keratosis,Interventional,14-Nov-18,LEO Pharma,Drug: LEO 43204 gel
NCT02549339,Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up,Actinic Keratosis,Interventional,14-Nov-18,LEO Pharma,Drug: Vehicle gel
NCT02547363,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up,Actinic Keratosis,Interventional,25-Dec-18,LEO Pharma,Drug: LEO 43204 gel
NCT02547363,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up,Actinic Keratosis,Interventional,25-Dec-18,LEO Pharma,Drug: Vehicle gel
NCT02547233,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up,Actinic Keratosis,Interventional,25-Dec-18,LEO Pharma,Drug: LEO 43204 gel
NCT02547233,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up,Actinic Keratosis,Interventional,25-Dec-18,LEO Pharma,Drug: Vehicle gel
NCT02518139,A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,31-Dec-18,Theravance Biopharma,Drug: TD-4208
NCT02518139,A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,31-Dec-18,Theravance Biopharma,Drug: Tiotropium
NCT02512510,Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,31-Dec-18,Theravance Biopharma,Drug: TD-4208
NCT02512510,Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,31-Dec-18,Theravance Biopharma,Drug: Placebo
NCT02500836,"Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia",Any Ear Nose or Throat Conditions|With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities,Interventional,16-May-17,"Lannett Company, Inc.",Drug: Cocaine HCl 4% Topical Solution
NCT02500836,"Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia",Any Ear Nose or Throat Conditions|With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities,Interventional,16-May-17,"Lannett Company, Inc.",Drug: Cocaine HCl 10% Topical Solution
NCT02500836,"Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia",Any Ear Nose or Throat Conditions|With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities,Interventional,16-May-17,"Lannett Company, Inc.",Drug: Placebo Topical Solution
NCT02476422,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Post Operative Dental Pain,Interventional,17-Oct-16,Novartis Pharmaceuticals,Drug: Diclofenac potassium
NCT02476422,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Post Operative Dental Pain,Interventional,17-Oct-16,Novartis Pharmaceuticals,Drug: Ibuprofen
NCT02476422,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Post Operative Dental Pain,Interventional,17-Oct-16,Novartis Pharmaceuticals,Drug: Placebo to ibuprofen
NCT02476422,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Post Operative Dental Pain,Interventional,17-Oct-16,Novartis Pharmaceuticals,Drug: Placebo to diclofenac potassium
NCT02476422,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Post Operative Dental Pain,Interventional,17-Oct-16,Novartis,Drug: Diclofenac potassium
NCT02476422,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Post Operative Dental Pain,Interventional,17-Oct-16,Novartis,Drug: Ibuprofen
NCT02476422,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Post Operative Dental Pain,Interventional,17-Oct-16,Novartis,Drug: Placebo to ibuprofen
NCT02476422,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Post Operative Dental Pain,Interventional,17-Oct-16,Novartis,Drug: Placebo to diclofenac potassium
NCT02459080,Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,31-Dec-18,Theravance Biopharma,Drug: TD-4208
NCT02459080,Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,31-Dec-18,Theravance Biopharma,Drug: Placebo
NCT02455050,A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief,Dry Eye Syndromes,Interventional,4-Jan-17,Allergan,Drug: Carboxymethylcellulose Sodium Based Eye Drops
NCT02455050,A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief,Dry Eye Syndromes,Interventional,4-Jan-17,Allergan,Drug: Systane® Gel Drops
NCT02455050,A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief,Dry Eye Syndromes,Interventional,4-Jan-17,Allergan,Drug: Genteal® Lubricant Gel Drops
NCT02387801,A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis,Psoriasis,Interventional,21-Oct-16,Eli Lilly and Company,Drug: Ixekizumab
NCT02361216,"Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest",Actinic Keratosis,Interventional,3-Oct-18,LEO Pharma,Drug: Ingenol Mebutate
NCT02361216,"Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest",Actinic Keratosis,Interventional,3-Oct-18,LEO Pharma,Other: Vehicle
NCT02339246,Pharmacokinetic Comparison Of All FK-506 Formulations,Renal Failure,Interventional,18-Jan-16,Veloxis Pharmaceuticals,Drug: Prograf vs Envarsus XR vs Astagraf XL
NCT02339246,Pharmacokinetic Comparison Of All FK-506 Formulations,Renal Failure,Interventional,18-Jan-16,Veloxis Pharmaceuticals,Drug: Prograf vs Astagraf XL vs Envarsus XR
NCT02305797,EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD),Generalized Anxiety Disorder (GAD),Interventional,26-Sep-18,"Edgemont Pharmaceuticals, LLC",Drug: Extended-release lorazepam
NCT02305797,EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD),Generalized Anxiety Disorder (GAD),Interventional,26-Sep-18,"Edgemont Pharmaceuticals, LLC",Drug: Placebo
NCT02271854,A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness,Muscle Soreness,Interventional,5-Apr-16,Novartis,Drug: Diclofenac sodium gel 1%
NCT02271854,A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness,Muscle Soreness,Interventional,5-Apr-16,Novartis,Drug: Placebo
NCT02246764,Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Ocular Hypertension|Glaucoma,Interventional,6-Apr-18,Aerie Pharmaceuticals,Drug: AR-13324 Ophthalmic Solution 0.02%
NCT02246764,Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Ocular Hypertension|Glaucoma,Interventional,6-Apr-18,Aerie Pharmaceuticals,Drug: AR-13324 Ophthalmic Solution 0.02% BID
NCT02246764,Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Ocular Hypertension|Glaucoma,Interventional,6-Apr-18,Aerie Pharmaceuticals,Drug: Timolol maleate Ophthalmic Solution 0.5% BID
NCT02246764,Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Ocular Hypertension|Glaucoma,Interventional,6-Apr-18,Aerie Pharmaceuticals,Other: Placebo
NCT02224625,Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth,Surgery,Interventional,30-May-16,Medline Industries,Drug: 2% CHG Cloth solution
NCT02224625,Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth,Surgery,Interventional,30-May-16,Medline Industries,Device: Vehicle Cloth
NCT02224625,Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth,Surgery,Interventional,30-May-16,Medline Industries,Drug: Active Comparator
NCT02224625,Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth,Surgery,Interventional,30-May-16,Medline Industries,Other: Saline
NCT02224625,Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth,Surgery,Interventional,30-May-16,Medline Industries,Other: SLS
NCT02220725,A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban,Bleeding,Interventional,25-Sep-18,Portola Pharmaceuticals,Biological: Andexanet
NCT02220725,A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban,Bleeding,Interventional,25-Sep-18,Portola Pharmaceuticals,Other: Placebo
NCT02207725,A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban,Bleeding,Interventional,27-Sep-18,Portola Pharmaceuticals,Biological: Andexanet
NCT02207725,A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban,Bleeding,Interventional,27-Sep-18,Portola Pharmaceuticals,Other: Placebo
NCT02207621,Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension,Ocular Hypertension|Open-angle Glaucoma,Interventional,6-Apr-18,Aerie Pharmaceuticals,Drug: AR-13324 Ophthalmic Solution 0.02%
NCT02207621,Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension,Ocular Hypertension|Open-angle Glaucoma,Interventional,6-Apr-18,Aerie Pharmaceuticals,Drug: Timolol maleate Ophthalmic Solution 0.5% BID
NCT02207621,Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension,Ocular Hypertension|Open-angle Glaucoma,Interventional,6-Apr-18,Aerie Pharmaceuticals,Other: Placebo
NCT02207621,Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension,Ocular Hypertension|Open-angle Glaucoma,Interventional,6-Apr-18,Aerie Pharmaceuticals,Drug: AR-13324 Ophthalmic Solution 0.02% BID
NCT02207491,Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Ocular Hypertension|Open-angle Glaucoma,Interventional,13-Apr-18,Aerie Pharmaceuticals,Drug: Timolol maleate Ophthalmic Solution 0.5% BID
NCT02207491,Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Ocular Hypertension|Open-angle Glaucoma,Interventional,13-Apr-18,Aerie Pharmaceuticals,Drug: AR-13324 Ophthalmic Solution 0.02%
NCT02207491,Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Ocular Hypertension|Open-angle Glaucoma,Interventional,13-Apr-18,Aerie Pharmaceuticals,Other: Placebo
NCT02132169,A Multi-Center Study Evaluating the Safety of AC-170 0.24%,Atopic Disease (Including Allergic Conjunctivitis),Interventional,26-Jul-17,"Aciex Therapeutics, Inc.",Drug: Drug: AC-170 0.24%
NCT02132169,A Multi-Center Study Evaluating the Safety of AC-170 0.24%,Atopic Disease (Including Allergic Conjunctivitis),Interventional,26-Jul-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0%
NCT02132117,Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea,Erythema|Rosacea,Interventional,2-Aug-16,Allergan,Drug: Oxymetazoline HCL Cream 1.0%
NCT02132117,Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea,Erythema|Rosacea,Interventional,2-Aug-16,Allergan,Drug: Vehicle to Oxymetazoline HCL Cream
NCT02131636,Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea,Erythema|Rosacea,Interventional,10-Mar-16,Allergan,Drug: AGN-199201
NCT02131636,Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea,Erythema|Rosacea,Interventional,10-Mar-16,Allergan,Drug: Vehicle to AGN-199201
NCT02118792,"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis","Dermatitis, Atopic",Interventional,6-Mar-17,Pfizer,"Drug: AN2728 Topical Ointment, 2%"
NCT02118792,"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis","Dermatitis, Atopic",Interventional,6-Mar-17,Pfizer,Drug: Matching vehicle control
NCT02118766,"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis","Dermatitis, Atopic",Interventional,6-Mar-17,Pfizer,"Drug: AN2728 Topical Ointment, 2%"
NCT02118766,"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis","Dermatitis, Atopic",Interventional,6-Mar-17,Pfizer,Drug: Matching vehicle control
NCT02095158,A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea,Erythema|Rosacea,Interventional,21-Sep-16,Allergan,Drug: Oxymetazoline HCL Cream 1.0%
NCT02089113,Second Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery,Post Ocular Surgical Inflammation and Pain,Interventional,30-Mar-16,"Ocular Therapeutix, Inc.",Drug: Dexamethasone
NCT02089113,Second Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery,Post Ocular Surgical Inflammation and Pain,Interventional,30-Mar-16,"Ocular Therapeutix, Inc.",Device: Punctum Plug
NCT02059278,Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,Primary Open Angle Glaucoma|Ocular Hypertension,Interventional,22-Aug-18,Nephron Pharmaceuticals Corporation,Drug: T-2345
NCT02059278,Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,Primary Open Angle Glaucoma|Ocular Hypertension,Interventional,22-Aug-18,Nephron Pharmaceuticals Corporation,Drug: Xalatan
NCT02007434,Patient Experience Study of Deoxycholic Acid Injection,Moderate or Severe Submental Fullness,Interventional,3-Jul-15,Kythera Biopharmaceuticals,Drug: Deoxycholic Acid Injection
NCT02007434,Patient Experience Study of Deoxycholic Acid Injection,Moderate or Severe Submental Fullness,Interventional,3-Jul-15,Kythera Biopharmaceuticals,Drug: Placebo
NCT02007434,Patient Experience Study of Deoxycholic Acid Injection,Moderate or Severe Submental Fullness,Interventional,3-Jul-15,Kythera Biopharmaceuticals,Other: Cold Compress
NCT02007434,Patient Experience Study of Deoxycholic Acid Injection,Moderate or Severe Submental Fullness,Interventional,3-Jul-15,Kythera Biopharmaceuticals,Drug: Lidocaine / Epinephrine
NCT02007434,Patient Experience Study of Deoxycholic Acid Injection,Moderate or Severe Submental Fullness,Interventional,3-Jul-15,Kythera Biopharmaceuticals,Drug: Loratadine
NCT02007434,Patient Experience Study of Deoxycholic Acid Injection,Moderate or Severe Submental Fullness,Interventional,3-Jul-15,Kythera Biopharmaceuticals,Drug: Ibuprofen
NCT02007434,Patient Experience Study of Deoxycholic Acid Injection,Moderate or Severe Submental Fullness,Interventional,3-Jul-15,Kythera Biopharmaceuticals,Other: Compression Chin Strap
NCT02006888,The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery,Inflammation|Cataracts,Interventional,23-Apr-18,ICON Bioscience Inc,Drug: IBI-10090
NCT02006888,The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery,Inflammation|Cataracts,Interventional,23-Apr-18,ICON Bioscience Inc,Drug: Placebo
NCT01991860,US Phase III Study of APD421 in PONV,PONV,Interventional,6-Sep-18,Acacia Pharma Ltd,Drug: APD421- Amisulpride for IV injection
NCT01991860,US Phase III Study of APD421 in PONV,PONV,Interventional,6-Sep-18,Acacia Pharma Ltd,Drug: Placebo
NCT01986361,Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method,Acute Pharyngitis|Sore Throat,Interventional,24-Aug-17,Reckitt Benckiser LLC,Drug: flurbiprofen
NCT01986361,Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method,Acute Pharyngitis|Sore Throat,Interventional,24-Aug-17,Reckitt Benckiser LLC,Drug: placebo
NCT01959945,"Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)",Influenza,Interventional,2-Aug-16,Protein Sciences Corporation,Biological: Flublok® Quadrivalent Influenza Virus Vaccine
NCT01959945,"Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)",Influenza,Interventional,2-Aug-16,Protein Sciences Corporation,Biological: Fluarix Quadrivalent® Influenza Virus Vaccine
NCT01959880,CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study),Breast Augmentation|Breast Reconstruction|Breast Revision,Interventional,11-Nov-16,"Mentor Worldwide, LLC",Device: The Contour Profile Gel (CPG) breast implants
NCT01949155,OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement,Otitis Media With Effusion,Interventional,11-Nov-16,"Otonomy, Inc.",Drug: OTO-201
NCT01949155,OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement,Otitis Media With Effusion,Interventional,11-Nov-16,"Otonomy, Inc.",Drug: Sham
NCT01949142,OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement,Otitis Media With Effusion,Interventional,15-Jun-16,"Otonomy, Inc.",Drug: OTO-201
NCT01949142,OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement,Otitis Media With Effusion,Interventional,15-Jun-16,"Otonomy, Inc.",Drug: Sham
NCT01934582,A Pharmacokinetic Substudy of the TDE-PH-304 Protocol,Pulmonary Arterial Hypertension,Interventional,27-Oct-16,United Therapeutics,Drug: UT-15C SR
NCT01934582,A Pharmacokinetic Substudy of the TDE-PH-304 Protocol,Pulmonary Arterial Hypertension,Interventional,27-Oct-16,United Therapeutics,Drug: treprostinil diethanolamine
NCT01934010,AM-101 in the Treatment of Post-Acute Tinnitus 1,Tinnitus,Interventional,9-Mar-18,"Auris Medical, Inc.",Drug: AM-101
NCT01929031,Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain,"Pain, Postoperative|Tooth Diseases",Interventional,16-Nov-16,Boehringer Ingelheim,Drug: ibuprofen + caffeine
NCT01929031,Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain,"Pain, Postoperative|Tooth Diseases",Interventional,16-Nov-16,Boehringer Ingelheim,Drug: ibuprofen
NCT01929031,Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain,"Pain, Postoperative|Tooth Diseases",Interventional,16-Nov-16,Boehringer Ingelheim,Drug: caffeine
NCT01929031,Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain,"Pain, Postoperative|Tooth Diseases",Interventional,16-Nov-16,Boehringer Ingelheim,Drug: placebo
NCT01895972,Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT,Glaucoma|Ocular Hypertension,Interventional,5-Jun-18,Bausch & Lomb Incorporated,Drug: Latanoprostene bunod
NCT01881113,"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",Allergic Conjunctivitis,Interventional,9-Nov-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0.24%
NCT01881113,"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",Allergic Conjunctivitis,Interventional,9-Nov-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0%
NCT01866163,LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris,Psoriasis Vulgaris|Plaque Psoriasis,Interventional,9-May-16,LEO Pharma,Drug: LEO 90100
NCT01866163,LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris,Psoriasis Vulgaris|Plaque Psoriasis,Interventional,9-May-16,LEO Pharma,Drug: Vehicle
NCT01844388,A Study to Compare a New Eye Drop Formulation With Refresh Contacts®,Contact Lens Lubrication,Interventional,29-Sep-14,Allergan,Drug: carboxymethylcellulose based eye drop formula
NCT01844388,A Study to Compare a New Eye Drop Formulation With Refresh Contacts®,Contact Lens Lubrication,Interventional,29-Sep-14,Allergan,Drug: carboxymethylcellulose sodium based eye drop solution
NCT01827670,Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity,Dentine Hypersensitivity,Interventional,26-Jan-15,GlaxoSmithKline,Drug: Stannous fluoride
NCT01827670,Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity,Dentine Hypersensitivity,Interventional,26-Jan-15,GlaxoSmithKline,Drug: Sodium monofluorophosphate
NCT01817790,Assessment of Fluticasone Propionate on Ocular Allergy Symptoms,Allergic Rhinitis|Seasonal Allergic Rhinitis,Interventional,3-Apr-14,GlaxoSmithKline,Drug: Fluticasone propionate
NCT01817790,Assessment of Fluticasone Propionate on Ocular Allergy Symptoms,Allergic Rhinitis|Seasonal Allergic Rhinitis,Interventional,3-Apr-14,GlaxoSmithKline,Drug: Placebo
NCT01803646,AM-101 in the Treatment of Acute Tinnitus 2,Tinnitus,Interventional,28-May-18,"Auris Medical, Inc.",Drug: AM-101
NCT01803646,AM-101 in the Treatment of Acute Tinnitus 2,Tinnitus,Interventional,28-May-18,"Auris Medical, Inc.",Drug: Placebo
NCT01749930,Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Open-Angle Glaucoma|Ocular Hypertension,Interventional,21-Nov-18,Bausch & Lomb Incorporated,Drug: BOL-303259-X
NCT01749930,Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Open-Angle Glaucoma|Ocular Hypertension,Interventional,21-Nov-18,Bausch & Lomb Incorporated,Drug: Timolol
NCT01749904,Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Open-Angle Glaucoma|Ocular Hypertension,Interventional,7-Nov-18,Bausch & Lomb Incorporated,Drug: BOL-303259-X
NCT01749904,Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Open-Angle Glaucoma|Ocular Hypertension,Interventional,7-Nov-18,Bausch & Lomb Incorporated,Drug: Timolol
NCT01704079,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Interventional,17-Aug-16,"OPKO IP Holdings II, Inc.",Drug: CTAP101 30 μg capsules
NCT01704079,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Interventional,17-Aug-16,"OPKO IP Holdings II, Inc.",Other: Sugar pill to CTAP101 30 μg capsules
NCT01704079,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Interventional,17-Aug-16,"OPKO Health, Inc.",Drug: CTAP101 30 μg capsules
NCT01704079,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Interventional,17-Aug-16,"OPKO Health, Inc.",Other: Sugar pill to CTAP101 30 μg capsules
NCT01685242,"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",Allergic Conjunctivitis,Interventional,10-Oct-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0.24%
NCT01685242,"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",Allergic Conjunctivitis,Interventional,10-Oct-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0%
NCT01663363,Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors,Myopia,Interventional,26-Jun-15,Abbott Medical Optics,Device: LASIK correction of myopic refractive errors
NCT01660763,Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery,Post Operative Pain,Interventional,3-Feb-14,"AcelRx Pharmaceuticals, Inc.",Drug: Sufentanil NanoTab PCA System/15 mcg
NCT01660763,Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery,Post Operative Pain,Interventional,3-Feb-14,"AcelRx Pharmaceuticals, Inc.",Drug: Placebo Sufentanil NanoTab PCA System
NCT01651000,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Interventional,17-Aug-16,"OPKO IP Holdings II, Inc.",Drug: CTAP101 30 μg capsules
NCT01651000,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Interventional,17-Aug-16,"OPKO IP Holdings II, Inc.",Other: Sugar pill to CTAP101 30 μg capsules
NCT01651000,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Interventional,17-Aug-16,"OPKO Health, Inc.",Drug: CTAP101 30 μg capsules
NCT01651000,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Interventional,17-Aug-16,"OPKO Health, Inc.",Other: Sugar pill to CTAP101 30 μg capsules
NCT01641237,Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions,Enamel Erosion,Interventional,31-Jul-13,GlaxoSmithKline,Drug: sodium fluoride
NCT01641237,Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions,Enamel Erosion,Interventional,31-Jul-13,GlaxoSmithKline,Drug: no added fluoride in a silica base
NCT01635881,Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter,Coronary Artery Disease,Interventional,6-Nov-13,Boston Scientific Corporation,Device: Emerge™ 1.20 mm PTCA Dilatation Catheter
NCT01607411,A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model,Dental Caries,Interventional,26-Aug-13,GlaxoSmithKline,Drug: Fluoride
NCT01607411,A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model,Dental Caries,Interventional,26-Aug-13,GlaxoSmithKline,Drug: Placebo
NCT01592864,The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity,Dentine Hypersensitivity,Interventional,10-Mar-14,GlaxoSmithKline,Drug: Stannous Fluoride
NCT01592864,The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity,Dentine Hypersensitivity,Interventional,10-Mar-14,GlaxoSmithKline,Drug: Sodium Monofluorophosphate
NCT01592851,Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity,Dentine Hypersensitivity,Interventional,3-Jun-14,GlaxoSmithKline,Drug: Stannous Fluoride
NCT01592851,Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity,Dentine Hypersensitivity,Interventional,3-Jun-14,GlaxoSmithKline,Drug: Sodium Monofluorophosphate
NCT01569841,A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01569841,A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin glargine
NCT01568112,Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate,Healthy,Interventional,13-Jun-16,Biogen,Drug: BG00012 (dimethyl fumarate)
NCT01568112,Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate,Healthy,Interventional,13-Jun-16,Biogen,Drug: BG00012 placebo
NCT01568112,Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate,Healthy,Interventional,13-Jun-16,Biogen,Drug: ASA
NCT01568112,Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate,Healthy,Interventional,13-Jun-16,Biogen,Drug: ASA placebo
NCT01551056,A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC),Allergic Conjunctivitis,Interventional,3-Oct-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0.24%
NCT01551056,A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC),Allergic Conjunctivitis,Interventional,3-Oct-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0%
NCT01515657,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients,"Diabetes Mellitus, Type 2",Interventional,4-Sep-15,PLx Pharma,Drug: PL2200 Aspirin Capsules
NCT01515657,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients,"Diabetes Mellitus, Type 2",Interventional,4-Sep-15,PLx Pharma,Drug: Immediate-Release Aspirin Tablets
NCT01515657,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients,"Diabetes Mellitus, Type 2",Interventional,4-Sep-15,PLx Pharma,Drug: Enteric-coated aspirin caplets
NCT01500226,Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Rolapitant
NCT01500226,Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Granisetron
NCT01500226,Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Dexamethasone
NCT01500226,Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Placebo
NCT01500213,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Rolapitant
NCT01500213,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Granisetron
NCT01500213,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Dexamethasone
NCT01500213,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Placebo
NCT01499849,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Rolapitant
NCT01499849,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Granisetron
NCT01499849,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: dexamethasone
NCT01499849,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Chemotherapy-induced Nausea and Vomiting,Interventional,4-Nov-15,"Tesaro, Inc.",Drug: Placebo
NCT01475643,Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.,Cataract,Interventional,11-Jun-19,Bausch & Lomb Incorporated,Drug: Loteprednol etabonate
NCT01475643,Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.,Cataract,Interventional,11-Jun-19,Bausch & Lomb Incorporated,Drug: Prednisolones acetate
NCT01459588,"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",Dry Eye Syndromes,Interventional,14-Mar-13,Allergan,Drug: Carboxymethylcellulose Based Eye Drop Formulation A
NCT01459588,"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",Dry Eye Syndromes,Interventional,14-Mar-13,Allergan,Drug: Carboxymethylcellulose Based Eye Drop Formulation B
NCT01459588,"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",Dry Eye Syndromes,Interventional,14-Mar-13,Allergan,Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
NCT01459588,"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",Dry Eye Syndromes,Interventional,14-Mar-13,Allergan,Drug: Carboxymethylcellulose Based Lubricant Eye Drops
NCT01396525,Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery,Peripheral Vascular Disease,Interventional,1-Oct-12,Abbott Medical Devices,Device: Omnilink Elite™ Peripheral Balloon-Expandable Stent System
NCT01389284,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,"Pain, Postoperative",Interventional,7-May-13,Bayer,Drug: Naproxen Sodium ER (BAYH6689)
NCT01389284,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,"Pain, Postoperative",Interventional,7-May-13,Bayer,"Drug: Naproxen Sodium IR (Aleve, BAYH6689)"
NCT01389284,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,"Pain, Postoperative",Interventional,7-May-13,Bayer,Drug: Naproxen Sodium ER Placebo
NCT01389284,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,"Pain, Postoperative",Interventional,7-May-13,Bayer,Drug: Naproxen Sodium IR Placebo
NCT01367249,Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery,Pain|Inflammation|Cataract,Interventional,6-May-14,Bausch & Lomb Incorporated,Drug: Bromfenac Ophthalmic Solution
NCT01367249,Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery,Pain|Inflammation|Cataract,Interventional,6-May-14,Bausch & Lomb Incorporated,Drug: Placebo
NCT01366209,Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Interventional,12-Mar-15,"Genentech, Inc.",Drug: Pirfenidone
NCT01366209,Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Interventional,12-Mar-15,"Genentech, Inc.",Drug: Placebo
NCT01362491,Ibuprofen Sodium Tension Headache Study,Pain,Interventional,30-Jul-14,Pfizer,Drug: Ibuprofen Sodium
NCT01362491,Ibuprofen Sodium Tension Headache Study,Pain,Interventional,30-Jul-14,Pfizer,Drug: Standard Ibuprofen
NCT01362491,Ibuprofen Sodium Tension Headache Study,Pain,Interventional,30-Jul-14,Pfizer,Drug: Placebo
NCT01353079,Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy,Allergy,Interventional,5-Feb-15,Greer Laboratories,Biological: Short Ragweed Pollen Allergenic Extract
NCT01353079,Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy,Allergy,Interventional,5-Feb-15,Greer Laboratories,Biological: Placebo
NCT01304706,Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study,Diabetic Macular Edema,Interventional,4-May-15,Alimera Sciences,Drug: Fluocinolone Acetonide
NCT01243450,"Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo",Acne,Interventional,18-Nov-14,Spear Pharmaceuticals,Drug: Tretinoin
NCT01243450,"Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo",Acne,Interventional,18-Nov-14,Spear Pharmaceuticals,Drug: placebo
NCT01230060,One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction,Aphakia|Cataract,Interventional,22-Aug-13,Bausch & Lomb Incorporated,Device: enVista
NCT01216163,Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain,Pain,Interventional,20-Aug-12,Pfizer,Drug: Novel Ibuprofen
NCT01216163,Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain,Pain,Interventional,20-Aug-12,Pfizer,Drug: Acetaminophen
NCT01216163,Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain,Pain,Interventional,20-Aug-12,Pfizer,Drug: Placebo
NCT01206660,Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis,Psoriasis,Interventional,3-Jul-14,Taro Pharmaceuticals USA,Drug: Desoximetasone Spray 0.25%
NCT01206660,Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis,Psoriasis,Interventional,3-Jul-14,Taro Pharmaceuticals USA,Drug: placebo
NCT01201798,Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis,Endogenous Anterior Uveitis,Interventional,15-Nov-12,Alcon Research,Drug: Difluprednate 0.05% ophthalmic emulsion
NCT01201798,Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis,Endogenous Anterior Uveitis,Interventional,15-Nov-12,Alcon Research,Drug: Prednisolone acetate 1.0% ophthalmic suspension
NCT01175590,Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle,Bacterial Conjunctivitis,Interventional,1-May-13,Bausch & Lomb Incorporated,Drug: Besivance
NCT01175590,Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle,Bacterial Conjunctivitis,Interventional,1-May-13,Bausch & Lomb Incorporated,Drug: Vehicle
NCT01158157,VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV,Smallpox Vaccine Adverse Reaction,Interventional,26-Mar-19,Cangene Corporation,Biological: ACAM2000
NCT01158157,VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV,Smallpox Vaccine Adverse Reaction,Interventional,26-Mar-19,Centers for Disease Control and Prevention,Biological: ACAM2000
NCT01156571,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome,Interventional,18-Jun-13,The Medicines Company,Drug: cangrelor P2Y12 (platelet) inhibitor
NCT01156571,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome,Interventional,18-Jun-13,The Medicines Company,Drug: Clopidogrel - 300 or 600 mg (study arm)
NCT01156571,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome,Interventional,18-Jun-13,The Medicines Company,Drug: Clopidogrel 600 mg post cangrelor
NCT01139450,Study of 0417 Ointment in the Treatment of Atopic Dermatitis,Atopic Dermatitis,Interventional,30-Sep-14,Fougera Pharmaceuticals Inc.,Drug: 0417
NCT01139450,Study of 0417 Ointment in the Treatment of Atopic Dermatitis,Atopic Dermatitis,Interventional,30-Sep-14,Fougera Pharmaceuticals Inc.,Drug: Vehicle of 0417 test product
NCT01139450,Study of 0417 Ointment in the Treatment of Atopic Dermatitis,Atopic Dermatitis,Interventional,30-Sep-14,Fougera Pharmaceuticals Inc.,Drug: Tacrolimus Ointment 0.03%
NCT01135069,"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo",Acne,Interventional,16-Oct-14,Spear Pharmaceuticals,Drug: Tretinoin microsphere 0.1%
NCT01135069,"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo",Acne,Interventional,16-Oct-14,Spear Pharmaceuticals,Drug: Brand Retin-A Micro tretinoin microsphere gel 0.1%
NCT01135069,"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo",Acne,Interventional,16-Oct-14,Spear Pharmaceuticals,Drug: placebo microsphere gel
NCT01124045,Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery,Cataracts|Inflammation,Interventional,19-Jun-13,Alcon Research,"Drug: Difluprednate ophthalmic emulsion, 0.05%"
NCT01124045,Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery,Cataracts|Inflammation,Interventional,19-Jun-13,Alcon Research,"Drug: Prednisolone acetate ophthalmic suspension, 1.0%"
NCT01115673,To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery,Pain,Interventional,28-May-12,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Drug: Acetaminophen
NCT01115673,To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery,Pain,Interventional,28-May-12,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Drug: Placebo Control
NCT01115673,To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery,Pain,Interventional,28-May-12,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: Acetaminophen
NCT01115673,To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery,Pain,Interventional,28-May-12,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: Placebo Control
NCT01115582,Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis,Inborn Errors of Bile Acid Synthesis,Interventional,9-Dec-16,"Retrophin, Inc.",Drug: Cholic acid
NCT01109173,Confirmatory Study Nepafenac 0.3%,Cataract,Interventional,30-Nov-12,Alcon Research,"Drug: Nepafenac Ophthalmic Suspension, 0.3%"
NCT01109173,Confirmatory Study Nepafenac 0.3%,Cataract,Interventional,30-Nov-12,Alcon Research,"Drug: Nepafenac Ophthalmic Suspension, 0.1%"
NCT01109173,Confirmatory Study Nepafenac 0.3%,Cataract,Interventional,30-Nov-12,Alcon Research,Other: Nepafenac Ophthalmic Suspension 0.3% Vehicle
NCT01109173,Confirmatory Study Nepafenac 0.3%,Cataract,Interventional,30-Nov-12,Alcon Research,Other: NEVANAC Vehicle
NCT01099774,Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Glaucoma|Ocular Hypertension,Interventional,27-Apr-12,Allergan,Drug: Bimatoprost 0.03% Formulation B Ophthalmic Solution
NCT01099774,Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Glaucoma|Ocular Hypertension,Interventional,27-Apr-12,Allergan,Drug: Bimatoprost 0.03% Ophthalmic Solution
NCT01098812,Clinical Evaluation of a 1-Piece Intraocular Lens,Cataract,Interventional,2-Jul-13,Abbott Medical Optics,Device: Tecnis ZCB00 IOL (control)
NCT01098812,Clinical Evaluation of a 1-Piece Intraocular Lens,Cataract,Interventional,2-Jul-13,Abbott Medical Optics,Device: Toric Intraocular lens
NCT01087801,A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers,Pancreatic Disease,Interventional,2-Dec-11,"ChiRhoClin, Inc.",Drug: ChiRhoStim
NCT01087801,A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers,Pancreatic Disease,Interventional,2-Dec-11,"ChiRhoClin, Inc.",Drug: Placebo
NCT01072188,Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste,Hypersensitivity,Interventional,19-Feb-10,Colgate Palmolive,Device: Arginine/Calcium Carbonate
NCT01072188,Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste,Hypersensitivity,Interventional,19-Feb-10,Colgate Palmolive,Device: Nupro - Fluoride Free
NCT01060072,Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery,Inflammation|Pain,Interventional,13-Jan-12,Bausch & Lomb Incorporated,Drug: Loteprednol etabonate
NCT01060072,Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery,Inflammation|Pain,Interventional,13-Jan-12,Bausch & Lomb Incorporated,Drug: Vehicle of Loteprednol Etabonate
NCT01053247,Study of 0416 Ointment in the Treatment of Atopic Dermatitis,Atopic Dermatitis,Interventional,3-Oct-14,Fougera Pharmaceuticals Inc.,Drug: 0416
NCT01053247,Study of 0416 Ointment in the Treatment of Atopic Dermatitis,Atopic Dermatitis,Interventional,3-Oct-14,Fougera Pharmaceuticals Inc.,Drug: Vehicle of 0416 test product
NCT01053247,Study of 0416 Ointment in the Treatment of Atopic Dermatitis,Atopic Dermatitis,Interventional,3-Oct-14,Fougera Pharmaceuticals Inc.,Drug: tacrolimus ointment 0.1%
NCT01049334,A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis,Pharyngitis,Interventional,21-Sep-17,Reckitt Benckiser LLC,Drug: Placebo
NCT01049334,A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis,Pharyngitis,Interventional,21-Sep-17,Reckitt Benckiser LLC,Drug: Flurbiprofen
NCT01048866,A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis,Pharyngitis,Interventional,21-Sep-17,Reckitt Benckiser LLC,Drug: placebo
NCT01048866,A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis,Pharyngitis,Interventional,21-Sep-17,Reckitt Benckiser LLC,Drug: flurbiprofen
NCT01048866,A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis,Pharyngitis,Interventional,21-Sep-17,Reckitt Benckiser LLC,Drug: acetaminophen 650mg
NCT01036165,"A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study",Multiple Sclerosis,Interventional,22-Dec-10,EMD Serono,Device: RebiSmart™
NCT01024738,Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse,Dental Plaque,Interventional,3-Dec-09,Colgate Palmolive,Drug: Fluoride
NCT01024738,Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse,Dental Plaque,Interventional,3-Dec-09,Colgate Palmolive,"Drug: Triclosan, fluoride"
NCT01024738,Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse,Dental Plaque,Interventional,3-Dec-09,Colgate Palmolive,Drug: Chlorhexidine Gluconate
NCT01021007,Clinical Research Study Efficacy of a Prototype Oral Rinse,Dental Plaque,Interventional,26-Nov-09,Colgate Palmolive,Drug: Iodine
NCT01021007,Clinical Research Study Efficacy of a Prototype Oral Rinse,Dental Plaque,Interventional,26-Nov-09,Colgate Palmolive,Other: water
NCT01012674,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Cerebral Arterial Diseases,Interventional,25-Aug-15,Guerbet,Drug: Dotarem
NCT01012674,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Cerebral Arterial Diseases,Interventional,25-Aug-15,Guerbet,Other: TOF MRA
NCT01010932,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Cerebral Arterial Diseases,Interventional,25-Aug-15,Guerbet,Drug: Dotarem
NCT01010932,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Cerebral Arterial Diseases,Interventional,25-Aug-15,Guerbet,Other: TOF MRA
NCT01010633,Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery,Inflammation|Pain,Interventional,9-Jan-12,Bausch & Lomb Incorporated,Drug: Vehicle of Loteprednol Etabonate
NCT01010633,Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery,Inflammation|Pain,Interventional,9-Jan-12,Bausch & Lomb Incorporated,Drug: Loteprednol Etabonate
NCT00995410,Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers,Aspirin-Associated Gastric Ulcers,Interventional,17-Feb-16,POZEN,Drug: PA32540
NCT00982007,Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA),Iron Deficiency Anemia,Interventional,18-Oct-13,"American Regent, Inc.",Drug: Ferric Carboxymaltose (FCM)
NCT00982007,Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA),Iron Deficiency Anemia,Interventional,18-Oct-13,"American Regent, Inc.",Drug: Ferrous Sulfate Tablets
NCT00982007,Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA),Iron Deficiency Anemia,Interventional,18-Oct-13,"American Regent, Inc.",Drug: IV Iron (standard of care)
NCT00981045,Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function,Iron Deficiency Anemia|Impaired Renal Function,Interventional,18-Oct-13,"American Regent, Inc.",Drug: Ferric Carboxymaltose (FCM)
NCT00981045,Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function,Iron Deficiency Anemia|Impaired Renal Function,Interventional,18-Oct-13,"American Regent, Inc.",Drug: Iron Sucrose (Venofer)
NCT00966953,Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.,Gingival Diseases,Interventional,27-Aug-09,Colgate Palmolive,Drug: Fluoride
NCT00966953,Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.,Gingival Diseases,Interventional,27-Aug-09,Colgate Palmolive,Drug: Triclosan/Fluoride toothpaste
NCT00966953,Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.,Gingival Diseases,Interventional,27-Aug-09,Colgate Palmolive,Other: antibacterial plant extract
NCT00961350,A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,Gastric Ulcer,Interventional,21-Jan-16,POZEN,Drug: PA32540
NCT00961350,A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,Gastric Ulcer,Interventional,21-Jan-16,POZEN,Drug: EC Aspirin 325
NCT00960869,Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,Gastric Ulcer,Interventional,17-Feb-16,POZEN,Drug: PA32540
NCT00960869,Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,Gastric Ulcer,Interventional,17-Feb-16,POZEN,Drug: EC-Aspirin 325 mg
NCT00958009,"The Multicenter, Open-label, Single-use Autoinjector Convenience Study",Multiple Sclerosis,Interventional,30-Dec-10,EMD Serono,Device: Rebidose®
NCT00956254,Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis,"Mucositis|Pain|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,5-Sep-13,INSYS Therapeutics Inc,Drug: Fentanyl sublingual spray
NCT00947661,Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension,Open Angle Glaucoma|Ocular Hypertension,Interventional,30-May-16,Sun Pharma Advanced Research Company Limited,Drug: SPARC0912
NCT00947661,Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension,Open Angle Glaucoma|Ocular Hypertension,Interventional,30-May-16,Sun Pharma Advanced Research Company Limited,Drug: Reference0912
NCT00945958,Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension,Open Angle Glaucoma|Ocular Hypertension,Interventional,5-May-16,Sun Pharma Advanced Research Company Limited,Drug: SPARC0913
NCT00926029,Compare the Clinical Efficacy of Prototype Toothpastes,Dental Plaque,Interventional,23-Jun-09,Colgate Palmolive,Drug: Fluoride
NCT00926029,Compare the Clinical Efficacy of Prototype Toothpastes,Dental Plaque,Interventional,23-Jun-09,Colgate Palmolive,"Drug: Triclosan, fluoride"
NCT00926029,Compare the Clinical Efficacy of Prototype Toothpastes,Dental Plaque,Interventional,23-Jun-09,Colgate Palmolive,Other: Metal salt
NCT00890682,Study of Postoperative Analgesia in Bunionectomy,Bunion|Hallux Valgus,Interventional,5-Aug-13,"Pacira Pharmaceuticals, Inc",Drug: SKY0402
NCT00890682,Study of Postoperative Analgesia in Bunionectomy,Bunion|Hallux Valgus,Interventional,5-Aug-13,"Pacira Pharmaceuticals, Inc",Drug: Placebo
NCT00889252,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Allergic Conjunctivitis,Interventional,23-Nov-10,Vistakon Pharmaceuticals,Device: contact lens with ketotifen
NCT00889252,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Allergic Conjunctivitis,Interventional,23-Nov-10,Vistakon Pharmaceuticals,Device: contact lens
NCT00853970,Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery,Pain|Inflammation,Interventional,26-Jan-11,Bausch & Lomb Incorporated,Drug: Bromfenac Ophthalmic Solution
NCT00853970,Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery,Pain|Inflammation,Interventional,26-Jan-11,Bausch & Lomb Incorporated,Drug: Placebo Comparator
NCT00844532,Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.,Peripheral Vascular Disease,Interventional,7-Sep-12,Abbott Medical Devices,Device: Absolute Pro™ Peripheral Self-Expanding Stent System
NCT00830947,Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement,Malocclusion,Interventional,23-Dec-13,OrthoAccel Technologies Inc.,Device: OrthoAccel Device
NCT00830947,Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement,Malocclusion,Interventional,23-Dec-13,OrthoAccel Technologies Inc.,Device: Sham Device
NCT00829413,SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization,Liver Neoplasms,Interventional,3-Aug-18,"Bracco Diagnostics, Inc",Drug: SonoVue®
NCT00812097,Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial,Breast Augmentation|Breast Reconstruction|Breast Revision,Interventional,5-Apr-16,"Mentor Worldwide, LLC",Device: Mentor Siltex® Contour Profile Gel Mammary Prosthesis
NCT00791934,Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide,Sinusitis,Interventional,14-Jul-14,Acclarent,Device: Stratus Microflow Ethmoid Spacer
NCT00788697,SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization,Liver Neoplasms,Interventional,14-Jun-17,"Bracco Diagnostics, Inc",Drug: SonoVue-enhanced ultrasound
NCT00788697,SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization,Liver Neoplasms,Interventional,14-Jun-17,"Bracco Diagnostics, Inc",Other: Unenhanced ultrasound
NCT00783432,Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis,Chronic Allergic Rhinitis|Nonallergic Rhinitis,Interventional,2-Oct-09,Meda Pharmaceuticals,Drug: Astepro Nasal Spray (0.1% azelastine hydrochloride)
NCT00783432,Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis,Chronic Allergic Rhinitis|Nonallergic Rhinitis,Interventional,2-Oct-09,Meda Pharmaceuticals,Drug: Astelin Nasal Spray (0.1% azelastine hydrochloride)
NCT00763269,The Efficacy of a Toothpaste to Reduce Sensitivity,Dentin Hypersensitivity,Interventional,17-Sep-10,Colgate Palmolive,"Drug: Triclosan, Silicon dioxide, fluoride"
NCT00763269,The Efficacy of a Toothpaste to Reduce Sensitivity,Dentin Hypersensitivity,Interventional,17-Sep-10,Colgate Palmolive,"Drug: Triclosan, fluoride"
NCT00763048,Collection of Gingival Crevicular Fluid From Periodontitis Patients,Gingival Diseases,Interventional,1-Mar-11,Colgate Palmolive,Drug: Fluoride
NCT00763048,Collection of Gingival Crevicular Fluid From Periodontitis Patients,Gingival Diseases,Interventional,1-Mar-11,Colgate Palmolive,"Drug: Fluoride, triclosan"
NCT00762515,Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes,Dental Plaque,Interventional,14-Dec-10,Colgate Palmolive,Drug: Fluoride
NCT00762515,Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes,Dental Plaque,Interventional,14-Dec-10,Colgate Palmolive,Drug: Triclosan
NCT00762177,Investigate Oral Bacteria in Adult Population,Oral Bacteria,Interventional,14-Feb-11,Colgate Palmolive,Drug: Fluoride
NCT00762177,Investigate Oral Bacteria in Adult Population,Oral Bacteria,Interventional,14-Feb-11,Colgate Palmolive,"Drug: Fluoride, Triclosan"
NCT00762177,Investigate Oral Bacteria in Adult Population,Oral Bacteria,Interventional,14-Feb-11,Colgate Palmolive,Drug: Stannous Fluoride
NCT00761930,Compare the Clinical Efficacy of Prototype Toothpastes.,Gingival Diseases,Interventional,20-Oct-10,Colgate Palmolive,Drug: Fluoride
NCT00761930,Compare the Clinical Efficacy of Prototype Toothpastes.,Gingival Diseases,Interventional,20-Oct-10,Colgate Palmolive,Drug: Triclosan and fluoride
NCT00761930,Compare the Clinical Efficacy of Prototype Toothpastes.,Gingival Diseases,Interventional,20-Oct-10,Colgate Palmolive,Drug: Herbal Ingredient and fluoride
NCT00759681,"ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial",Vascular Disease,Interventional,31-Jan-13,"Tenaxis Medical, Inc.",Device: ArterX Surgical Sealant
NCT00759681,"ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial",Vascular Disease,Interventional,31-Jan-13,"Tenaxis Medical, Inc.",Device: Gelfoam and Thrombin
NCT00759187,Evaluate Clinical Research From Commerical Oral Care Products,Gingival Diseases,Interventional,18-Nov-08,Colgate Palmolive,Drug: Fluoride
NCT00759187,Evaluate Clinical Research From Commerical Oral Care Products,Gingival Diseases,Interventional,18-Nov-08,Colgate Palmolive,Drug: Triclosan/Fluoride
NCT00759187,Evaluate Clinical Research From Commerical Oral Care Products,Gingival Diseases,Interventional,18-Nov-08,Colgate Palmolive,Drug: Chlorhexidine Gluconate
NCT00759031,Investigation of Dental Plaque and Gingival Index,Dental Plaque,Interventional,25-Nov-08,Colgate Palmolive,Drug: Sodium Monofluorophosphate
NCT00759031,Investigation of Dental Plaque and Gingival Index,Dental Plaque,Interventional,25-Nov-08,Colgate Palmolive,Drug: Triclosan/Fluoride/Copolymer
NCT00758563,Train New Examiners Via Modified Gingival Margin Plaque,Dental Plaque,Interventional,20-Nov-08,Colgate Palmolive,Drug: Fluoride
NCT00758563,Train New Examiners Via Modified Gingival Margin Plaque,Dental Plaque,Interventional,20-Nov-08,Colgate Palmolive,Drug: Triclosan/Fluoride
NCT00758394,Clinical Study to Compare Dental Plaque Control,Dental Plaque,Interventional,19-Nov-08,Colgate Palmolive,Drug: Fluoride
NCT00758394,Clinical Study to Compare Dental Plaque Control,Dental Plaque,Interventional,19-Nov-08,Colgate Palmolive,Drug: Triclosan/Fluoride
NCT00758290,Clinical Study to Evaluate Dental Plaque,Gingival Diseases,Interventional,25-Nov-08,Colgate Palmolive,Drug: Triclosan/Fluoride
NCT00758290,Clinical Study to Evaluate Dental Plaque,Gingival Diseases,Interventional,25-Nov-08,Colgate Palmolive,Drug: Fluoride/triclosan
NCT00753922,Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses,Breast Reconstruction|Breast Augmentation|Breast Revision,Interventional,23-Aug-13,"Mentor Worldwide, LLC","Device: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface"
NCT00732225,DisCoVisc Comparative Evaluation,Cataracts,Interventional,30-Jul-10,Alcon Research,Device: DisCoVisc
NCT00732225,DisCoVisc Comparative Evaluation,Cataracts,Interventional,30-Jul-10,Alcon Research,Device: DuoVisc
NCT00732225,DisCoVisc Comparative Evaluation,Cataracts,Interventional,30-Jul-10,Alcon Research,Device: BioVisc
NCT00732225,DisCoVisc Comparative Evaluation,Cataracts,Interventional,30-Jul-10,Alcon Research,Device: Healon5
NCT00732225,DisCoVisc Comparative Evaluation,Cataracts,Interventional,30-Jul-10,Alcon Research,Device: Amvisc Plus
NCT00708305,Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes,Dental Caries,Interventional,10-Jun-13,GlaxoSmithKline,Drug: Sodium Fluoride (NaF)
NCT00708305,Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes,Dental Caries,Interventional,10-Jun-13,GlaxoSmithKline,Drug: Placebo
NCT00708097,In Situ Caries Efficacy of Fluoride Toothpastes,Caries,Interventional,24-Jun-13,GlaxoSmithKline,Drug: NaF
NCT00708097,In Situ Caries Efficacy of Fluoride Toothpastes,Caries,Interventional,24-Jun-13,GlaxoSmithKline,Drug: Placebo
NCT00708097,In Situ Caries Efficacy of Fluoride Toothpastes,Caries,Interventional,24-Jun-13,GlaxoSmithKline,Drug: NaMFP
NCT00704418,Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery,Cataract,Interventional,26-Jan-11,Bausch & Lomb Incorporated,Drug: Bromfenac
NCT00704418,Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery,Cataract,Interventional,26-Jan-11,Bausch & Lomb Incorporated,Drug: Placebo
NCT00704353,Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia,Anemia,Interventional,25-Nov-13,"American Regent, Inc.",Drug: Ferric Carboxymaltose
NCT00704353,Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia,Anemia,Interventional,25-Nov-13,"American Regent, Inc.",Drug: Standard Medical Care (SMC)
NCT00704028,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia,Anemia,Interventional,25-Nov-13,"American Regent, Inc.",Drug: Ferric Carboxymaltose
NCT00704028,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia,Anemia,Interventional,25-Nov-13,"American Regent, Inc.",Drug: Iron Dextran
NCT00703937,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia,Anemia,Interventional,25-Nov-13,"American Regent, Inc.",Drug: Ferric Carboxymaltose (FCM)
NCT00703937,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia,Anemia,Interventional,25-Nov-13,"American Regent, Inc.",Drug: Standard Medical Care (SMC) for the treatment of IDA
NCT00703781,Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery,Cataract,Interventional,9-Dec-11,Bausch & Lomb Incorporated,Drug: bromfenac ophthalmic solution
NCT00703781,Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery,Cataract,Interventional,9-Dec-11,Bausch & Lomb Incorporated,Drug: placebo
NCT00699153,Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery,Ocular Inflammation,Interventional,23-Sep-10,Bausch & Lomb Incorporated,Drug: Loteprednol Etabonate
NCT00699153,Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery,Ocular Inflammation,Interventional,23-Sep-10,Bausch & Lomb Incorporated,Drug: Vehicle of Ophthalmic Loteprednol Etabonate
NCT00665431,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Osteoarthritis,Interventional,6-Dec-11,POZEN,Drug: PN 400 (VIMOVO)
NCT00665431,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Osteoarthritis,Interventional,6-Dec-11,POZEN,Drug: celebrex
NCT00665431,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Osteoarthritis,Interventional,6-Dec-11,POZEN,Other: Placebo
NCT00665431,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Osteoarthritis,Interventional,6-Dec-11,POZEN,Drug: Rescue Antacid
NCT00664560,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Osteoarthritis,Interventional,27-Feb-12,POZEN,Drug: PN 400 (VIMOVO)
NCT00664560,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Osteoarthritis,Interventional,27-Feb-12,POZEN,Drug: celebrex
NCT00664560,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Osteoarthritis,Interventional,27-Feb-12,POZEN,Drug: Placebo
NCT00664560,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Osteoarthritis,Interventional,27-Feb-12,POZEN,Drug: Rescue Antacid
NCT00648895,A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients,Hypertension,Interventional,20-Sep-10,Forest Laboratories,Drug: Nebivolol
NCT00648895,A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients,Hypertension,Interventional,20-Sep-10,Forest Laboratories,Drug: Metoprolol ER (TM)
NCT00647556,Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage,Photoaging,Interventional,24-Feb-11,"Galderma Laboratories, L.P.","Drug: adapalene gel, 0.3%"
NCT00647556,Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage,Photoaging,Interventional,24-Feb-11,"Galderma Laboratories, L.P.",Drug: tretinoin 0.05% emollient cream
NCT00645671,Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery,Ocular Inflammation,Interventional,23-Sep-10,Bausch & Lomb Incorporated,Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment
NCT00645671,Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery,Ocular Inflammation,Interventional,23-Sep-10,Bausch & Lomb Incorporated,Drug: Vehicle of Loteprednol Etabonate Ophthalmic Ointment
NCT00628589,Staccato Loxapine in Agitated Patients With Schizophrenia,Patients With Schizophrenia and Acute Agitation,Interventional,29-Jun-17,"Alexza Pharmaceuticals, Inc.",Drug: Inhaled loxapine 5 mg
NCT00628589,Staccato Loxapine in Agitated Patients With Schizophrenia,Patients With Schizophrenia and Acute Agitation,Interventional,29-Jun-17,"Alexza Pharmaceuticals, Inc.",Drug: Inhaled loxapine 10 mg
NCT00628589,Staccato Loxapine in Agitated Patients With Schizophrenia,Patients With Schizophrenia and Acute Agitation,Interventional,29-Jun-17,"Alexza Pharmaceuticals, Inc.",Drug: Inhaled placebo
NCT00620282,The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,15-Jun-11,Novo Nordisk A/S,Drug: liraglutide
NCT00620282,The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,15-Jun-11,Novo Nordisk A/S,Drug: placebo
NCT00620282,The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,15-Jun-11,Novo Nordisk A/S,Drug: glimepiride
NCT00613106,Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216),Osteoarthritis|Rheumatoid Arthritis|Chronic Low Back Pain|Chronic Regional Pain Syndrome|Chronic Soft Tissue Pain,Interventional,17-Jun-11,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: HZT-501
NCT00613106,Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216),Osteoarthritis|Rheumatoid Arthritis|Chronic Low Back Pain|Chronic Regional Pain Syndrome|Chronic Soft Tissue Pain,Interventional,17-Jun-11,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: Ibuprofen
NCT00608959,Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects,Infection,Interventional,25-Jan-10,Mallinckrodt,Drug: omiganan 1% gel
NCT00608959,Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects,Infection,Interventional,25-Jan-10,Mallinckrodt,Drug: chlorhexidine 2% solution
NCT00604383,Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study,Diabetic Retinopathy,Interventional,28-Jan-16,"Chromaderm, Inc.",Drug: ruboxistaurin
NCT00604383,Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study,Diabetic Retinopathy,Interventional,28-Jan-16,"Chromaderm, Inc.",Drug: placebo
NCT00603902,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,Obesity,Interventional,7-Feb-13,Arena Pharmaceuticals,Drug: Lorcaserin 10 mg QD
NCT00603902,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,Obesity,Interventional,7-Feb-13,Arena Pharmaceuticals,Drug: Lorcaserin 10 mg BID
NCT00603902,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,Obesity,Interventional,7-Feb-13,Arena Pharmaceuticals,Drug: Matching Placebo
NCT00603291,BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus,Obesity,Interventional,7-Feb-13,Arena Pharmaceuticals,Drug: Lorcaserin 10 mg QD
NCT00603291,BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus,Obesity,Interventional,7-Feb-13,Arena Pharmaceuticals,Drug: Lorcaserin 10 mg BID
NCT00603291,BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus,Obesity,Interventional,7-Feb-13,Arena Pharmaceuticals,Drug: Matching Placebo
NCT00586664,Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis,Allergic Conjunctivitis,Interventional,26-Mar-12,Bausch & Lomb Incorporated,Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%
NCT00586664,Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis,Allergic Conjunctivitis,Interventional,26-Mar-12,Bausch & Lomb Incorporated,Drug: placebo comparator
NCT00586664,Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis,Allergic Conjunctivitis,Interventional,26-Mar-12,Bausch & Lomb Incorporated,Drug: Bepotastine Besilate Ophthalmic Solution 1.0%
NCT00578929,Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients,Seasonal Allergic Rhinitis,Interventional,9-Feb-10,Alcon Research,Drug: Olopatadine Hydrochloride Nasal Spray 0.6%
NCT00578929,Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients,Seasonal Allergic Rhinitis,Interventional,9-Feb-10,Alcon Research,Drug: Vehicle
NCT00578331,Safety Study of Olopatadine Nasal Spray,Perennial Allergic Rhinitis,Interventional,3-Feb-10,Alcon Research,Drug: Olopatadine 0.6% nasal spray
NCT00578331,Safety Study of Olopatadine Nasal Spray,Perennial Allergic Rhinitis,Interventional,3-Feb-10,Alcon Research,Drug: Placebo Nasal Spray
NCT00576251,TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension,Ocular Inflammation Associated With Blepharaconjunctivitis,Interventional,14-Jan-10,Alcon Research,Drug: Tobramycin 0.3%/Dexamethasone 0.05%
NCT00576251,TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension,Ocular Inflammation Associated With Blepharaconjunctivitis,Interventional,14-Jan-10,Alcon Research,Drug: TOBRADEX
NCT00564629,Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males,Fever,Interventional,21-Sep-10,Mallinckrodt,Drug: Intravenous acetaminophen plus oral placebo
NCT00564629,Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males,Fever,Interventional,21-Sep-10,Mallinckrodt,Drug: Oral acetaminophen plus IV placebo
NCT00564629,Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males,Fever,Interventional,21-Sep-10,Mallinckrodt,Biological: Reference standard endotoxin (RSE)
NCT00548860,Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients,Anemia,Interventional,29-May-15,"American Regent, Inc.",Drug: Ferric Carboxymaltose
NCT00548860,Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients,Anemia,Interventional,29-May-15,"American Regent, Inc.",Drug: Standard Medical Care (SMC)
NCT00548691,Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients,Anemia,Interventional,13-May-15,"American Regent, Inc.",Drug: Ferric Carboxymaltose
NCT00548691,Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients,Anemia,Interventional,13-May-15,"American Regent, Inc.",Drug: Standard Medical Care (SMC)
NCT00538850,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,Cancer,Interventional,5-Mar-14,INSYS Therapeutics Inc,Drug: Fentanyl sublingual spray
NCT00538850,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,Cancer,Interventional,5-Mar-14,INSYS Therapeutics Inc,Drug: Placebo
NCT00538850,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,Cancer,Interventional,5-Mar-14,National Cancer Institute (NCI),Drug: Fentanyl sublingual spray
NCT00538850,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,Cancer,Interventional,5-Mar-14,National Cancer Institute (NCI),Drug: Placebo
NCT00527904,"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",Gastric Ulcer,Interventional,20-Aug-10,POZEN,Drug: PN400 (VIMOVO)
NCT00527904,"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",Gastric Ulcer,Interventional,20-Aug-10,POZEN,Drug: PN 400 (VIMOVO)
NCT00527787,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen,Gastric Ulcer,Interventional,28-Dec-10,POZEN,Drug: PN400 (VIMOVO)
NCT00527787,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen,Gastric Ulcer,Interventional,28-Dec-10,POZEN,Drug: Naproxen
NCT00524264,A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery,Cataract Extraction|Pain|Inflammation,Interventional,1-Oct-09,Allergan,Drug: ketorolac
NCT00521456,A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery,Cataract Extraction,Interventional,1-Oct-09,Allergan,Drug: ketorolac eye drops
NCT00509873,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Bacterial Conjunctivitis,Interventional,30-Nov-11,Allergan,Drug: Gatifloxacin 0.5% eye drops
NCT00509873,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Bacterial Conjunctivitis,Interventional,30-Nov-11,Allergan,Drug: placebo eye drops
NCT00493311,Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males,Fever,Interventional,21-Sep-10,Mallinckrodt,Drug: IV Placebo
NCT00493311,Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males,Fever,Interventional,21-Sep-10,Mallinckrodt,Drug: IV Acetaminophen
NCT00493311,Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males,Fever,Interventional,21-Sep-10,Mallinckrodt,Biological: Reference Standard Endotoxin (RSE)
NCT00491608,Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis,Spinal Surgery|Vascular Surgery,Interventional,12-Jan-12,ZymoGenetics,Biological: rThrombin
NCT00491530,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",Mixed Dyslipidemia,Interventional,7-Dec-09,Abbott,Drug: ABT-335
NCT00491530,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",Mixed Dyslipidemia,Interventional,7-Dec-09,Abbott,Drug: rosuvastatin calcium
NCT00491530,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",Mixed Dyslipidemia,Interventional,7-Dec-09,Abbott,Drug: simvastatin
NCT00491530,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",Mixed Dyslipidemia,Interventional,7-Dec-09,Abbott,Drug: atorvastatin calcium
NCT00490815,Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema,Diabetic Macular Edema,Interventional,13-Feb-14,Alimera Sciences,Drug: Fluocinolone Acetonide
NCT00472797,Rebif New Formulation (RNF) Quality of Life (QOL) Study,Relapsing Multiple Sclerosis,Interventional,2-Sep-09,EMD Serono,Drug: Rebif New Formulation Non Titrated
NCT00472797,Rebif New Formulation (RNF) Quality of Life (QOL) Study,Relapsing Multiple Sclerosis,Interventional,2-Sep-09,EMD Serono,Drug: Rebif New Formulation Titrated
NCT00467870,Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men,Hypogonadism|Primary Hypogonadism|Secondary Hypogonadism,Interventional,7-Mar-17,Endo Pharmaceuticals,Drug: Testosterone Undecanoate 750 mg
NCT00467870,Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men,Hypogonadism|Primary Hypogonadism|Secondary Hypogonadism,Interventional,7-Mar-17,Endo Pharmaceuticals,Drug: Testosterone Undecanoate 1000 mg
NCT00466193,A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia,Insomnia,Interventional,20-Jan-12,Transcept Pharmaceuticals,Drug: zolpidem tartrate sublingual tablet
NCT00466193,A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia,Insomnia,Interventional,20-Jan-12,Transcept Pharmaceuticals,Drug: Placebo
NCT00450112,Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee,Osteoarthritis of the Knee,Interventional,22-Aug-11,Seikagaku Corporation,Device: Gel-200
NCT00449696,Gel-200 Versus Placebo in Osteoarthritis of the Knee,Osteoarthritis of the Knee,Interventional,15-Sep-11,Seikagaku Corporation,Device: Gel-200
NCT00449696,Gel-200 Versus Placebo in Osteoarthritis of the Knee,Osteoarthritis of the Knee,Interventional,15-Sep-11,Seikagaku Corporation,Device: Placebo
NCT00430092,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b),Inflammation,Interventional,2-Jul-09,"Sirion Therapeutics, Inc.",Drug: Difluprednate
NCT00430092,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b),Inflammation,Interventional,2-Jul-09,"Sirion Therapeutics, Inc.",Drug: Placebo
NCT00429923,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a),Inflammation,Interventional,2-Jul-09,"Sirion Therapeutics, Inc.",Drug: Difluprednate
NCT00429923,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a),Inflammation,Interventional,2-Jul-09,"Sirion Therapeutics, Inc.",Drug: Placebo
NCT00427921,Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS),Crohn's Disease,Interventional,23-Oct-09,Abbott,Biological: adalimumab
NCT00407030,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia,Cervical Dystonia,Interventional,31-Dec-10,Merz Pharmaceuticals GmbH,Drug: incobotulinumtoxinA (Xeomin) (240 Units)
NCT00407030,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia,Cervical Dystonia,Interventional,31-Dec-10,Merz Pharmaceuticals GmbH,Drug: incobotulinumtoxinA (Xeomin) (120 Units)
NCT00407030,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia,Cervical Dystonia,Interventional,31-Dec-10,Merz Pharmaceuticals GmbH,Drug: Placebo
NCT00402987,Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat,Pharyngitis,Interventional,12-Mar-09,Pfizer,Drug: celecoxib
NCT00402987,Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat,Pharyngitis,Interventional,12-Mar-09,Pfizer,Drug: celecoxib followed by placebo
NCT00402987,Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat,Pharyngitis,Interventional,12-Mar-09,Pfizer,Drug: placebo
NCT00396292,Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia,Anemia,Interventional,10-Dec-13,"American Regent, Inc.",Drug: Oral iron tablets
NCT00396292,Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia,Anemia,Interventional,10-Dec-13,"American Regent, Inc.",Drug: VIT-45
NCT00395993,Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding,Anemia,Interventional,18-Nov-13,"American Regent, Inc.",Drug: Ferric Carboxymaltose (FCM)
NCT00395993,Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding,Anemia,Interventional,18-Nov-13,"American Regent, Inc.",Drug: Ferrous Sulfate tablets
NCT00395135,BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management,Obesity,Interventional,7-Feb-13,Arena Pharmaceuticals,Drug: Lorcaserin 10 mg BID
NCT00395135,BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management,Obesity,Interventional,7-Feb-13,Arena Pharmaceuticals,Drug: Matching Placebo BID
NCT00385008,TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine,Migraine Disorders,Interventional,12-Feb-18,GlaxoSmithKline,Drug: Combination Product (sumatriptan succinate / naproxen sodium)
NCT00385008,TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine,Migraine Disorders,Interventional,12-Feb-18,GlaxoSmithKline,Drug: RELPAX(eletriptan) 40mg Tablet
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Hypertension,Interventional,25-Mar-11,Novartis Pharmaceuticals,Drug: Aliskiren
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Hypertension,Interventional,25-Mar-11,Novartis Pharmaceuticals,Drug: Ramipril
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Hypertension,Interventional,25-Mar-11,Novartis Pharmaceuticals,Drug: Hydrochlorothiazide
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Hypertension,Interventional,25-Mar-11,Novartis Pharmaceuticals,Drug: Amlodipine
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Hypertension,Interventional,25-Mar-11,Novartis,Drug: Aliskiren
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Hypertension,Interventional,25-Mar-11,Novartis,Drug: Ramipril
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Hypertension,Interventional,25-Mar-11,Novartis,Drug: Hydrochlorothiazide
NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Hypertension,Interventional,25-Mar-11,Novartis,Drug: Amlodipine
NCT00358917,Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects,Human Immunodeficiency Virus Infections,Interventional,1-Feb-10,Abbott,Drug: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
NCT00354484,Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients,Postpartum Anemia,Interventional,5-Dec-13,"American Regent, Inc.",Drug: Ferric Carboxymaltose (FCM)
NCT00354484,Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients,Postpartum Anemia,Interventional,5-Dec-13,"American Regent, Inc.",Drug: Ferrous Sulfate tablets
NCT00344968,Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema,Diabetic Macular Edema,Interventional,7-May-14,Alimera Sciences,Drug: fluocinolone acetonide
NCT00344968,Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema,Diabetic Macular Edema,Interventional,7-May-14,Alimera Sciences,Drug: Fluocinolone Acetonide
NCT00344968,Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema,Diabetic Macular Edema,Interventional,7-May-14,Alimera Sciences,Procedure: Standard of care laser photocoagulation
NCT00317239,VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease,Anemia,Interventional,25-Nov-13,"American Regent, Inc.",Drug: Ferrous Sulfate tablets
NCT00317239,VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease,Anemia,Interventional,25-Nov-13,"American Regent, Inc.",Drug: Ferric Carboxymaltose (FCM)
NCT00317226,Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease,Anemia,Interventional,10-Jun-15,"American Regent, Inc.",Drug: Ferric Carboxymaltose (FCM)
NCT00300482,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: ABT-335
NCT00300482,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: Rosuvastatin Calcium
NCT00300482,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: Placebo
NCT00300469,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Mixed Dyslipidemia|Coronary Heart Disease|Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: ABT-335
NCT00300469,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Mixed Dyslipidemia|Coronary Heart Disease|Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: Atorvastatin
NCT00300469,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Mixed Dyslipidemia|Coronary Heart Disease|Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: Placebo
NCT00300456,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: ABT-335
NCT00300456,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: Simvastatin
NCT00300456,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,25-Mar-09,Abbott,Drug: Placebo
NCT00300430,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,23-Jul-09,Abbott,Drug: ABT-335 and rosuvastatin calcium
NCT00300430,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,23-Jul-09,Abbott,Drug: ABT-335 and atorvastatin calcium
NCT00300430,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Interventional,23-Jul-09,Abbott,Drug: ABT-335 and simvastatin
NCT00297167,Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Interventional,4-Apr-14,Forest Laboratories,Drug: EUR-1008 (APT-1008)
NCT00297167,Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Interventional,4-Apr-14,Forest Laboratories,Drug: Placebo
NCT00293020,Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy,Pain|Cancer,Interventional,5-Oct-12,BioDelivery Sciences International,Drug: BEMA Fentanyl
NCT00287729,Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Interventional,13-Jun-11,"Genentech, Inc.",Drug: Pirfenidone
NCT00287729,Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Interventional,13-Jun-11,"Genentech, Inc.",Drug: Placebo
NCT00287716,Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Interventional,13-Jun-11,"Genentech, Inc.",Drug: Pirfenidone
NCT00287716,Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Interventional,13-Jun-11,"Genentech, Inc.",Drug: Placebo
NCT00262080,Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE),Hereditary Angioedema (HAE),Interventional,11-May-10,Shire,Drug: ecallantide
NCT00262080,Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE),Hereditary Angioedema (HAE),Interventional,11-May-10,Shire,"Drug: Phosphate Buffer Saline (PBS),"
NCT00251004,Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients,Kidney Transplantation|Graft Rejection,Interventional,10-May-11,Novartis,Drug: Everolimus
NCT00251004,Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients,Kidney Transplantation|Graft Rejection,Interventional,10-May-11,Novartis,Drug: Mycophenolic Acid (MPA)
NCT00251004,Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients,Kidney Transplantation|Graft Rejection,Interventional,10-May-11,Novartis,Drug: Cyclosporine A (CsA)
NCT00251004,Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients,Kidney Transplantation|Graft Rejection,Interventional,10-May-11,Novartis,Drug: Basiliximab
NCT00251004,Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients,Kidney Transplantation|Graft Rejection,Interventional,10-May-11,Novartis,Drug: Corticosteroids
NCT00236977,Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia,Anemia,Interventional,9-Mar-10,"American Regent, Inc.",Drug: Venofer
NCT00236977,Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia,Anemia,Interventional,9-Mar-10,"American Regent, Inc.",Drug: Ferrous Sulfate
NCT00236197,E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers,Heartburn,Interventional,5-Nov-09,Eisai Inc.,Drug: rabeprazole sodium
NCT00236197,E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers,Heartburn,Interventional,5-Nov-09,Eisai Inc.,Drug: placebo
NCT00236184,E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers,Heartburn,Interventional,1-Oct-09,Eisai Inc.,Drug: rabeprazole sodium
NCT00236184,E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers,Heartburn,Interventional,1-Oct-09,Eisai Inc.,Other: Placebo
NCT00234832,A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients,Obesity,Interventional,15-Apr-10,Abbott,Drug: Sibutramine hydrochloride
NCT00234832,A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients,Obesity,Interventional,15-Apr-10,Abbott,Drug: Placebo
NCT00232739,Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions,Coronary Artery Disease,Interventional,8-Feb-10,Cordis Corporation,Device: CYPHER Sirolimus-eluting Coronary Stent
NCT00231283,NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions,Coronary Artery Disease,Interventional,23-Mar-10,Cordis Corporation,Device: CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
NCT00132808,"Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older",Osteopenia,Interventional,10-Jan-11,Novartis Pharmaceuticals,Drug: Zoledronic Acid
NCT00132808,"Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older",Osteopenia,Interventional,10-Jan-11,Novartis Pharmaceuticals,Drug: Placebo
NCT00132808,"Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older",Osteopenia,Interventional,10-Jan-11,Novartis,Drug: Zoledronic Acid
NCT00132808,"Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older",Osteopenia,Interventional,10-Jan-11,Novartis,Drug: Placebo
NCT00126438,Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,"Heart Failure, Congestive",Interventional,5-May-17,GE Healthcare,Drug: 123I-mIBG (meta-iodobenzylguanidine)
NCT00126425,Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,"Heart Failure, Congestive",Interventional,13-Dec-16,GE Healthcare,Drug: 123I-mIBG (meta-iodobenzylguanidine)
NCT00125164,Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency,Growth Disorders|Insulin-Like Growth Factor-1 Deficiency,Interventional,30-Apr-10,Ipsen,"Drug: rhIGF-1 (mecasermin, Tercica, Inc.)"
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,Hoffmann-La Roche,Biological: Bevacizumab
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,Hoffmann-La Roche,Drug: Capecitabine
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,Hoffmann-La Roche,Drug: 5-Fluorouracil (5-FU)
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,Hoffmann-La Roche,Drug: Leucovorin calcium
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,Hoffmann-La Roche,Drug: Oxaliplatin
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,National Cancer Institute (NCI),Biological: Bevacizumab
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,National Cancer Institute (NCI),Drug: Capecitabine
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,National Cancer Institute (NCI),Drug: 5-Fluorouracil (5-FU)
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,National Cancer Institute (NCI),Drug: Leucovorin calcium
NCT00112918,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Colorectal Cancer,Interventional,6-Sep-12,National Cancer Institute (NCI),Drug: Oxaliplatin
NCT00107978,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,Staphylococcal Skin Infection,Interventional,1-Feb-10,Cumberland Pharmaceuticals,Drug: Telavancin
NCT00107978,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,Staphylococcal Skin Infection,Interventional,1-Feb-10,Cumberland Pharmaceuticals,Drug: Vancomycin
NCT00107952,Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus,Bacterial Pneumonia,Interventional,8-Dec-09,Cumberland Pharmaceuticals,Drug: Telavancin
NCT00107952,Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus,Bacterial Pneumonia,Interventional,8-Dec-09,Cumberland Pharmaceuticals,Drug: Vancomycin
NCT00104234,Study of rhASB in Patients With Mucopolysaccharidosis VI,Mucopolysaccharidosis VI,Interventional,6-Mar-09,BioMarin Pharmaceutical,Drug: N-acetylgalactosamine 4-sulfatase
NCT00104234,Study of rhASB in Patients With Mucopolysaccharidosis VI,Mucopolysaccharidosis VI,Interventional,6-Mar-09,BioMarin Pharmaceutical,Drug: Placebo/rhASB
NCT00097695,Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema,Angioedema,Interventional,24-Dec-13,Shire,Drug: Icatibant
NCT00097695,Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema,Angioedema,Interventional,24-Dec-13,Shire,Drug: Placebo
NCT00095121,Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B,Chronic Hepatitis B,Interventional,3-Jun-11,Gilead Sciences,Drug: Placebo (PLB)
NCT00095121,Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B,Chronic Hepatitis B,Interventional,3-Jun-11,Gilead Sciences,Drug: Adefovir Dipivoxil (ADV)
NCT00095121,Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B,Chronic Hepatitis B,Interventional,3-Jun-11,Gilead Sciences,Drug: Lamivudine
NCT00091819,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,Staphylococcal Skin Infection,Interventional,8-Dec-09,Cumberland Pharmaceuticals,Drug: Telavancin
NCT00091819,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,Staphylococcal Skin Infection,Interventional,8-Dec-09,Cumberland Pharmaceuticals,Drug: Vancomycin
NCT00089479,A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer,Breast Cancer,Interventional,23-Jun-11,Hoffmann-La Roche,Drug: capecitabine [Xeloda]
NCT00089479,A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer,Breast Cancer,Interventional,23-Jun-11,Hoffmann-La Roche,Drug: Taxotere
NCT00067470,Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI,Mucopolysaccharidosis VI,Interventional,17-Aug-09,BioMarin Pharmaceutical,Drug: Placebo
NCT00067470,Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI,Mucopolysaccharidosis VI,Interventional,17-Aug-09,BioMarin Pharmaceutical,Drug: N-acetylgalactosamine 4-sulfatase
NCT00051168,A Long-term Safety Study of Once-daily Travatan,"Glaucoma, Open-angle|Ocular Hypertension",Interventional,12-Apr-10,Alcon Research,Drug: Travatan
NCT03331042,SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.,Transient Insomnia,Interventional,5-Jun-19,Sequential Medicine Ltd,Drug: SM-1
NCT03331042,SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.,Transient Insomnia,Interventional,5-Jun-19,Sequential Medicine Ltd,Drug: D+Z
NCT03331042,SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.,Transient Insomnia,Interventional,5-Jun-19,Sequential Medicine Ltd,Drug: D+L
NCT03331042,SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.,Transient Insomnia,Interventional,5-Jun-19,Sequential Medicine Ltd,Drug: Placebo
NCT02662556,"A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain",Acute Moderate-to-severe Pain,Interventional,15-Mar-17,"AcelRx Pharmaceuticals, Inc.",Drug: sufentanil sublingual tablet 30 mcg
NCT02247765,Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion,Healthy|Hypoxia,Interventional,5-May-17,Medtronic - MITG,Device: Arterial line
NCT02247765,Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion,Healthy|Hypoxia,Interventional,5-May-17,Medtronic - MITG,Device: Motion
NCT02120833,A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin,Eczema,Interventional,7-Sep-15,Johnson & Johnson Consumer and Personal Products Worldwide,Device: EpiCeram® Skin Barrier Emulsion
NCT02120833,A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin,Eczema,Interventional,7-Sep-15,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: Colloidal Oatmeal Cream
NCT02110147,Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria,Hereditary Orotic Aciduria,Interventional,28-Jun-17,Wellstat Therapeutics,Drug: uridine triacetate
NCT01830140,A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension,Glaucoma|Ocular Hypertension,Interventional,6-May-15,Allergan,Drug: Bimatoprost 0.01%
NCT01830140,A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension,Glaucoma|Ocular Hypertension,Interventional,6-May-15,Allergan,Drug: Bimatoprost 0.03%
NCT01702532,Nicotine Mouth Film for Craving Relief.,Smoking Cessation,Interventional,30-Jan-14,GlaxoSmithKline,Drug: Nicotine
NCT02532647,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Colonoscopy,Interventional,23-Jan-19,Paion UK Ltd.,Drug: Remimazolam
NCT02532647,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Colonoscopy,Interventional,23-Jan-19,Paion UK Ltd.,Drug: Midazolam
NCT02532647,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Colonoscopy,Interventional,23-Jan-19,Paion UK Ltd.,Drug: Placebo
NCT02532647,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Colonoscopy,Interventional,23-Jan-19,Premier Research Group plc,Drug: Remimazolam
NCT02532647,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Colonoscopy,Interventional,23-Jan-19,Premier Research Group plc,Drug: Midazolam
NCT02532647,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Colonoscopy,Interventional,23-Jan-19,Premier Research Group plc,Drug: Placebo
NCT01974141,A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Acne Vulgaris,Interventional,6-Feb-17,"Almirall, S.A.",Drug: Dapsone Gel
NCT01974141,A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Acne Vulgaris,Interventional,6-Feb-17,"Almirall, S.A.",Drug: Dapsone Gel Vehicle
NCT01974141,A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Acne Vulgaris,Interventional,6-Feb-17,Allergan,Drug: Dapsone Gel
NCT01974141,A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Acne Vulgaris,Interventional,6-Feb-17,Allergan,Drug: Dapsone Gel Vehicle
NCT01495858,Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,"Pain, Postoperative",Interventional,17-Jun-14,Bayer,Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)
NCT01495858,Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,"Pain, Postoperative",Interventional,17-Jun-14,Bayer,Drug: Naproxen Sodium 440 mg (BAYH6689)
NCT01495858,Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,"Pain, Postoperative",Interventional,17-Jun-14,Bayer,Drug: DPH 50 mg
NCT01280591,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,"Pain, Postoperative",Interventional,17-Jun-14,Bayer,Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)
NCT01280591,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,"Pain, Postoperative",Interventional,17-Jun-14,Bayer,Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)
NCT01280591,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,"Pain, Postoperative",Interventional,17-Jun-14,Bayer,Drug: Naproxen sodium 440 mg (BAYH6689)
NCT01280591,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,"Pain, Postoperative",Interventional,17-Jun-14,Bayer,Drug: DPH 50 mg
NCT01266161,Multiple Dose Dental Pain Study Of Ibuprofen Extended Release,Pain,Interventional,15-Aug-18,Pfizer,Drug: Ibuprofen 600 mg ER
NCT01266161,Multiple Dose Dental Pain Study Of Ibuprofen Extended Release,Pain,Interventional,15-Aug-18,Pfizer,Drug: Placebo
NCT01008605,Caverject User Study,Erectile Dysfunction,Interventional,28-Mar-12,Pfizer,Other: delivery system
NCT00927472,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",Pediculosis,Interventional,4-Aug-14,Taro Pharmaceuticals USA,Drug: Malathion gel 0.5%
NCT00927472,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",Pediculosis,Interventional,4-Aug-14,Taro Pharmaceuticals USA,Drug: Permethrin 1% rinse
NCT00904670,Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder,Interventional,26-Jun-14,Pfizer,Drug: Quillivant Oral Suspension XR
NCT00904670,Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder,Interventional,26-Jun-14,Pfizer,Drug: Placebo
NCT00889330,Safety and Efficacy Study of a Eye Drop for Eye Allergy,Allergic Conjunctivitis,Interventional,8-Dec-11,Vistakon Pharmaceuticals,Drug: alcaftadine
NCT00889330,Safety and Efficacy Study of a Eye Drop for Eye Allergy,Allergic Conjunctivitis,Interventional,8-Dec-11,Vistakon Pharmaceuticals,Drug: Placebo
NCT00707486,"A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing",Tooth Extractions,Interventional,9-Jan-13,"HemCon Medical Technologies, Inc",Device: Hemcon Dental Dressing
NCT00707486,"A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing",Tooth Extractions,Interventional,9-Jan-13,"HemCon Medical Technologies, Inc",Device: Gauze with Pressure and/or Gelfoam
NCT00697073,Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients,Friedreich's Ataxia,Interventional,4-Aug-11,Santhera Pharmaceuticals,Drug: Idebenone
NCT00594100,GORE Embolic Protection With Reverse Flow,Carotid Artery Stenosis,Interventional,5-May-09,W.L.Gore & Associates,Device: GORE Flow Reversal System (GFRS)
NCT00537680,"Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia",Friedreich's Ataxia,Interventional,29-Dec-11,Santhera Pharmaceuticals,Drug: Idebenone
NCT00537680,"Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia",Friedreich's Ataxia,Interventional,29-Dec-11,Santhera Pharmaceuticals,Drug: Placebo
NCT00434057,Evaluation of Pigmented Skin Lesions With MelaFind(R) System,Melanoma,Interventional,11-Nov-09,"MELA Sciences, Inc.",Device: MelaFind(R)
NCT01160380,A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma,Fatigue|Multiple Myeloma,Interventional,6-Nov-14,Oncotherapeutics,Drug: armodafinil
NCT01160380,A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma,Fatigue|Multiple Myeloma,Interventional,6-Nov-14,Oncotherapeutics,Drug: Placebo
NCT01160380,A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma,Fatigue|Multiple Myeloma,Interventional,6-Nov-14,Cephalon,Drug: armodafinil
NCT01160380,A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma,Fatigue|Multiple Myeloma,Interventional,6-Nov-14,Cephalon,Drug: Placebo
NCT00382408,"A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001",Respiratory Tract Diseases,Interventional,25-May-12,Duramed Research,Biological: DR-5001
NCT00382408,"A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001",Respiratory Tract Diseases,Interventional,25-May-12,Duramed Research,Other: Placebo
NCT00382408,"A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001",Respiratory Tract Diseases,Interventional,25-May-12,Teva Pharmaceutical Industries,Biological: DR-5001
NCT00382408,"A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001",Respiratory Tract Diseases,Interventional,25-May-12,Teva Pharmaceutical Industries,Other: Placebo
NCT01745380,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,31-Jan-17,"St. Renatus, LLC",Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01745380,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,31-Jan-17,"St. Renatus, LLC",Drug: Placebo
NCT01745380,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,31-Jan-17,Triligent International,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01745380,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,31-Jan-17,Triligent International,Drug: Placebo
NCT01745380,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,31-Jan-17,"Rho, Inc.",Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01745380,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,31-Jan-17,"Rho, Inc.",Drug: Placebo
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,"St. Renatus, LLC",Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,"St. Renatus, LLC",Drug: Tetracaine HCl 3%
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,"St. Renatus, LLC",Drug: Placebo
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,Triligent International,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,Triligent International,Drug: Tetracaine HCl 3%
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,Triligent International,Drug: Placebo
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,"Rho, Inc.",Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,"Rho, Inc.",Drug: Tetracaine HCl 3%
NCT01710787,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Anesthesia,Interventional,30-Aug-17,"Rho, Inc.",Drug: Placebo
NCT01499199,A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects,"Infection, Human Immunodeficiency Virus",Interventional,25-Nov-13,ViiV Healthcare,Drug: Dolutegravir
NCT01499199,A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects,"Infection, Human Immunodeficiency Virus",Interventional,25-Nov-13,Shionogi,Drug: Dolutegravir
NCT01499199,A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects,"Infection, Human Immunodeficiency Virus",Interventional,25-Nov-13,GlaxoSmithKline,Drug: Dolutegravir
NCT00556478,"Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation",Premature Ejaculation,Interventional,26-Sep-16,Plethora Solutions Ltd,"Drug: PSD502, contains a mixture of lidocaine and prilocaine"
NCT00556478,"Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation",Premature Ejaculation,Interventional,26-Sep-16,Plethora Solutions Ltd,Drug: Placebo
NCT00556478,"Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation",Premature Ejaculation,Interventional,26-Sep-16,Shionogi Inc.,"Drug: PSD502, contains a mixture of lidocaine and prilocaine"
NCT00556478,"Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation",Premature Ejaculation,Interventional,26-Sep-16,Shionogi Inc.,Drug: Placebo
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Inc.,Drug: Placebo
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Inc.,Drug: E2007 (2 mg)
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Inc.,Drug: E2007 (4 mg)
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Inc.,Drug: E2007 (6 mg)
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Inc.,Drug: E2007 (8 mg)
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Limited,Drug: Placebo
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Limited,Drug: E2007 (2 mg)
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Limited,Drug: E2007 (4 mg)
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Limited,Drug: E2007 (6 mg)
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Diabetic Neuropathy,Interventional,8-Feb-13,Eisai Limited,Drug: E2007 (8 mg)
NCT00384930,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Interventional,19-Aug-09,Eli Lilly and Company,Drug: tadalafil
NCT00384930,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Interventional,19-Aug-09,Eli Lilly and Company,Drug: placebo
NCT00384930,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Interventional,19-Aug-09,ICOS Corporation,Drug: tadalafil
NCT00384930,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Interventional,19-Aug-09,ICOS Corporation,Drug: placebo
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,Domenick Zero,"Drug: 0 ppm F (placebo, negative control)"
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,Domenick Zero,Drug: 250 ppm F as NaF (dose-response control)
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,Domenick Zero,Drug: 500 ppm F as NaF (dose-response control)
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,Domenick Zero,Drug: 1100 ppm F as NaF (positive control)
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,GlaxoSmithKline,"Drug: 0 ppm F (placebo, negative control)"
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,GlaxoSmithKline,Drug: 250 ppm F as NaF (dose-response control)
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,GlaxoSmithKline,Drug: 500 ppm F as NaF (dose-response control)
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,GlaxoSmithKline,Drug: 1100 ppm F as NaF (positive control)
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,Indiana University,"Drug: 0 ppm F (placebo, negative control)"
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,Indiana University,Drug: 250 ppm F as NaF (dose-response control)
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,Indiana University,Drug: 500 ppm F as NaF (dose-response control)
NCT03383783,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Caries,Interventional,20-May-19,Indiana University,Drug: 1100 ppm F as NaF (positive control)
NCT02497976,Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis,"Cystitis, Interstitial",Interventional,22-Mar-18,"ICStudy, LLC",Biological: Certolizumab pegol
NCT02497976,Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis,"Cystitis, Interstitial",Interventional,22-Mar-18,"ICStudy, LLC",Drug: Placebo
NCT02497976,Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis,"Cystitis, Interstitial",Interventional,22-Mar-18,UCB Pharma,Biological: Certolizumab pegol
NCT02497976,Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis,"Cystitis, Interstitial",Interventional,22-Mar-18,UCB Pharma,Drug: Placebo
NCT02338193,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Diabetes Prevention in Women After GDM Who Are at High-risk,Interventional,30-Apr-19,Woman's,Drug: DAPA/MET XR
NCT02338193,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Diabetes Prevention in Women After GDM Who Are at High-risk,Interventional,30-Apr-19,Woman's,Drug: DAPA
NCT02338193,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Diabetes Prevention in Women After GDM Who Are at High-risk,Interventional,30-Apr-19,Woman's,Drug: MET XR
NCT02338193,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Diabetes Prevention in Women After GDM Who Are at High-risk,Interventional,30-Apr-19,AstraZeneca,Drug: DAPA/MET XR
NCT02338193,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Diabetes Prevention in Women After GDM Who Are at High-risk,Interventional,30-Apr-19,AstraZeneca,Drug: DAPA
NCT02338193,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Diabetes Prevention in Women After GDM Who Are at High-risk,Interventional,30-Apr-19,AstraZeneca,Drug: MET XR
NCT02165111,Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome,Scleroderma|Raynaud's Syndrome,Interventional,22-Dec-16,Johns Hopkins University,Drug: Onabotulinumtoxin A
NCT02165111,Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome,Scleroderma|Raynaud's Syndrome,Interventional,22-Dec-16,Johns Hopkins University,Drug: sterile saline solution
NCT02165111,Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome,Scleroderma|Raynaud's Syndrome,Interventional,22-Dec-16,Allergan,Drug: Onabotulinumtoxin A
NCT02165111,Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome,Scleroderma|Raynaud's Syndrome,Interventional,22-Dec-16,Allergan,Drug: sterile saline solution
NCT02022007,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,Polycystic Ovary Syndrome|Disorder of Glucose Regulation,Interventional,28-Jun-17,Woman's,Drug: Metformin XR
NCT02022007,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,Polycystic Ovary Syndrome|Disorder of Glucose Regulation,Interventional,28-Jun-17,Woman's,Drug: Saxagliptin
NCT02022007,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,Polycystic Ovary Syndrome|Disorder of Glucose Regulation,Interventional,28-Jun-17,Woman's,Drug: Saxagliptin-Metformin XR
NCT02022007,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,Polycystic Ovary Syndrome|Disorder of Glucose Regulation,Interventional,28-Jun-17,AstraZeneca,Drug: Metformin XR
NCT02022007,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,Polycystic Ovary Syndrome|Disorder of Glucose Regulation,Interventional,28-Jun-17,AstraZeneca,Drug: Saxagliptin
NCT02022007,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,Polycystic Ovary Syndrome|Disorder of Glucose Regulation,Interventional,28-Jun-17,AstraZeneca,Drug: Saxagliptin-Metformin XR
NCT01931150,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Interventional,13-Jan-17,Memorial Sloan Kettering Cancer Center,Drug: Topical Dapsone 5% Gel
NCT01931150,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Interventional,13-Jan-17,Memorial Sloan Kettering Cancer Center,Other: Moisturizer
NCT01931150,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Interventional,13-Jan-17,Memorial Sloan Kettering Cancer Center,Drug: oral antibiotics
NCT01931150,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Interventional,13-Jan-17,Bristol-Myers Squibb,Drug: Topical Dapsone 5% Gel
NCT01931150,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Interventional,13-Jan-17,Bristol-Myers Squibb,Other: Moisturizer
NCT01931150,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Interventional,13-Jan-17,Bristol-Myers Squibb,Drug: oral antibiotics
NCT01829243,"Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial",Fibromyalgia|Neurocognition,Interventional,29-Aug-14,Duke University,Drug: Milnacipran
NCT01829243,"Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial",Fibromyalgia|Neurocognition,Interventional,29-Aug-14,Duke University,Drug: Placebo
NCT01829243,"Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial",Fibromyalgia|Neurocognition,Interventional,29-Aug-14,Forest Laboratories,Drug: Milnacipran
NCT01829243,"Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial",Fibromyalgia|Neurocognition,Interventional,29-Aug-14,Forest Laboratories,Drug: Placebo
NCT01760473,Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone,Heroin Dependence,Interventional,8-Sep-17,New York State Psychiatric Institute,Drug: Intranasal challenge drug
NCT01760473,Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone,Heroin Dependence,Interventional,8-Sep-17,Indivior Inc.,Drug: Intranasal challenge drug
NCT01722266,Liraglutide in the Treatment of Type 1 Diabetes Mellitus,Type 1 Diabetes,Interventional,13-Mar-15,Kaleida Health,Drug: Liraglutide
NCT01722266,Liraglutide in the Treatment of Type 1 Diabetes Mellitus,Type 1 Diabetes,Interventional,13-Mar-15,Kaleida Health,Drug: Placebo
NCT01722266,Liraglutide in the Treatment of Type 1 Diabetes Mellitus,Type 1 Diabetes,Interventional,13-Mar-15,Novo Nordisk A/S,Drug: Liraglutide
NCT01722266,Liraglutide in the Treatment of Type 1 Diabetes Mellitus,Type 1 Diabetes,Interventional,13-Mar-15,Novo Nordisk A/S,Drug: Placebo
NCT01704651,Accelerating Gastrointestinal Recovery,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Interventional,24-Oct-16,Jamie N. Bakkum-Gamez,Drug: Alvimopan
NCT01704651,Accelerating Gastrointestinal Recovery,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Interventional,24-Oct-16,Jamie N. Bakkum-Gamez,Drug: Placebo
NCT01704651,Accelerating Gastrointestinal Recovery,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Interventional,24-Oct-16,Cubist Pharmaceuticals LLC,Drug: Alvimopan
NCT01704651,Accelerating Gastrointestinal Recovery,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Interventional,24-Oct-16,Cubist Pharmaceuticals LLC,Drug: Placebo
NCT01704651,Accelerating Gastrointestinal Recovery,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Interventional,24-Oct-16,Mayo Clinic,Drug: Alvimopan
NCT01704651,Accelerating Gastrointestinal Recovery,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Interventional,24-Oct-16,Mayo Clinic,Drug: Placebo
NCT01689779,High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status,Hypovitaminosis D,Interventional,28-Sep-17,Massachusetts General Hospital,"Drug: 100,000 IU cholecalciferol"
NCT01689779,High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status,Hypovitaminosis D,Interventional,28-Sep-17,Massachusetts General Hospital,Drug: Placebo
NCT01689779,High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status,Hypovitaminosis D,Interventional,28-Sep-17,"Bio-Tech Pharmacal, Inc.","Drug: 100,000 IU cholecalciferol"
NCT01689779,High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status,Hypovitaminosis D,Interventional,28-Sep-17,"Bio-Tech Pharmacal, Inc.",Drug: Placebo
NCT01664806,Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode Causing Thermal Injury at Port Site Skin,Intraoperative Complications|Thermal Injury|Electrocoagulation,Interventional,1-Mar-13,"University of Colorado, Denver",Device: Covidien Triad monopolar generator
NCT01664806,Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode Causing Thermal Injury at Port Site Skin,Intraoperative Complications|Thermal Injury|Electrocoagulation,Interventional,1-Mar-13,Medtronic - MITG,Device: Covidien Triad monopolar generator
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,EMD Serono,Drug: Cilengitide
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,EMD Serono,Drug: Temozolomide
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,EMD Serono,Radiation: Radiotherapy
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,European Organisation for Research and Treatment of Cancer - EORTC,Drug: Cilengitide
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,European Organisation for Research and Treatment of Cancer - EORTC,Drug: Temozolomide
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,European Organisation for Research and Treatment of Cancer - EORTC,Radiation: Radiotherapy
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,"Merck KGaA, Darmstadt, Germany",Drug: Cilengitide
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,"Merck KGaA, Darmstadt, Germany",Drug: Temozolomide
NCT00689221,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Glioblastoma,Interventional,4-Nov-14,"Merck KGaA, Darmstadt, Germany",Radiation: Radiotherapy
NCT01499134,Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure,Peripheral Artery Disease|Hypertension,Interventional,3-Dec-14,Thomas Jefferson University,Drug: nebivolol
NCT01499134,Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure,Peripheral Artery Disease|Hypertension,Interventional,3-Dec-14,Thomas Jefferson University,Drug: Metoprolol succinate
NCT01499134,Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure,Peripheral Artery Disease|Hypertension,Interventional,3-Dec-14,Forest Laboratories,Drug: nebivolol
NCT01499134,Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure,Peripheral Artery Disease|Hypertension,Interventional,3-Dec-14,Forest Laboratories,Drug: Metoprolol succinate
NCT01465178,Improving the Understanding of the Response to Vitamin D Supplementation,Vitamin D Deficiency,Interventional,25-Nov-16,"University of Wisconsin, Madison",Dietary Supplement: cholecalciferol
NCT01465178,Improving the Understanding of the Response to Vitamin D Supplementation,Vitamin D Deficiency,Interventional,25-Nov-16,"University of Wisconsin, Madison",Dietary Supplement: Placebo
NCT01465178,Improving the Understanding of the Response to Vitamin D Supplementation,Vitamin D Deficiency,Interventional,25-Nov-16,Merck Sharp & Dohme Corp.,Dietary Supplement: cholecalciferol
NCT01465178,Improving the Understanding of the Response to Vitamin D Supplementation,Vitamin D Deficiency,Interventional,25-Nov-16,Merck Sharp & Dohme Corp.,Dietary Supplement: Placebo
NCT01449682,Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.,Retinal Vein Occlusion|Macular Edema,Interventional,31-May-17,Retina Macula Institute,Drug: Ozurdex
NCT01449682,Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.,Retinal Vein Occlusion|Macular Edema,Interventional,31-May-17,Allergan,Drug: Ozurdex
NCT01422161,Study of Botulinum Toxin and Recovery of Hand Function After Stroke,Stroke With Hemiparesis,Interventional,31-May-19,NYU Langone Health,Drug: Botulinum Toxin commonly known as BOTOX®
NCT01422161,Study of Botulinum Toxin and Recovery of Hand Function After Stroke,Stroke With Hemiparesis,Interventional,31-May-19,NYU Langone Health,Drug: Placebo
NCT01422161,Study of Botulinum Toxin and Recovery of Hand Function After Stroke,Stroke With Hemiparesis,Interventional,31-May-19,Allergan,Drug: Botulinum Toxin commonly known as BOTOX®
NCT01422161,Study of Botulinum Toxin and Recovery of Hand Function After Stroke,Stroke With Hemiparesis,Interventional,31-May-19,Allergan,Drug: Placebo
NCT01401595,Brain Imaging and Treatment Studies of the Night Eating Syndrome,Night Eating Syndrome,Interventional,9-May-17,University of Pennsylvania,Drug: escitalopram oxalate
NCT01401595,Brain Imaging and Treatment Studies of the Night Eating Syndrome,Night Eating Syndrome,Interventional,9-May-17,Forest Laboratories,Drug: escitalopram oxalate
NCT01391858,Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica,Post-operative Pain,Interventional,11-Jun-14,University of Texas Southwestern Medical Center,Drug: lyrica
NCT01391858,Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica,Post-operative Pain,Interventional,11-Jun-14,Pfizer,Drug: lyrica
NCT01351480,Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients,Rheumatoid Arthritis,Interventional,13-Mar-17,Arthritis & Rheumatic Disease Specialties Research,Biological: abatacept
NCT01351480,Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients,Rheumatoid Arthritis,Interventional,13-Mar-17,Bristol-Myers Squibb,Biological: abatacept
NCT01304589,Savella in Treatment for Provoked Vestibulodynia,Vestibulodynia|Vulvodynia,Interventional,2-Apr-14,University of Tennessee,Drug: Milnacipran
NCT01304589,Savella in Treatment for Provoked Vestibulodynia,Vestibulodynia|Vulvodynia,Interventional,2-Apr-14,Forest Laboratories,Drug: Milnacipran
NCT01295814,Efficacy Study of Adalimumab to Treat Interstitial Cystitis,Interstitial Cystitis,Interventional,16-Jul-15,"ICStudy, LLC",Drug: Adalimumab
NCT01295814,Efficacy Study of Adalimumab to Treat Interstitial Cystitis,Interstitial Cystitis,Interventional,16-Jul-15,"ICStudy, LLC",Other: inactive drug
NCT01295814,Efficacy Study of Adalimumab to Treat Interstitial Cystitis,Interstitial Cystitis,Interventional,16-Jul-15,Abbott,Drug: Adalimumab
NCT01295814,Efficacy Study of Adalimumab to Treat Interstitial Cystitis,Interstitial Cystitis,Interventional,16-Jul-15,Abbott,Other: inactive drug
NCT01242085,Preoperative Alignment of Total Knee Replacement,Knee Arthritis,Interventional,8-May-13,VA Palo Alto Health Care System,Procedure: trumatch group
NCT01242085,Preoperative Alignment of Total Knee Replacement,Knee Arthritis,Interventional,8-May-13,VA Palo Alto Health Care System,Procedure: control group
NCT01242085,Preoperative Alignment of Total Knee Replacement,Knee Arthritis,Interventional,8-May-13,DePuy Orthopaedics,Procedure: trumatch group
NCT01242085,Preoperative Alignment of Total Knee Replacement,Knee Arthritis,Interventional,8-May-13,DePuy Orthopaedics,Procedure: control group
NCT01234649,Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM),Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation,Interventional,26-Jul-19,Woman's,Drug: Metformin XR plus placebo
NCT01234649,Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM),Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation,Interventional,26-Jul-19,Woman's,Drug: Metformin XR plus liraglutide
NCT01234649,Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM),Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation,Interventional,26-Jul-19,Novo Nordisk A/S,Drug: Metformin XR plus placebo
NCT01234649,Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM),Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation,Interventional,26-Jul-19,Novo Nordisk A/S,Drug: Metformin XR plus liraglutide
NCT01219881,Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery,Cystoscopes|Baxter Anaesthesia Brand of Desflurane|Sevoflurane,Interventional,29-Nov-12,Ohio State University,Drug: Desflurane
NCT01219881,Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery,Cystoscopes|Baxter Anaesthesia Brand of Desflurane|Sevoflurane,Interventional,29-Nov-12,Ohio State University,Drug: Sevoflurane
NCT01219881,Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery,Cystoscopes|Baxter Anaesthesia Brand of Desflurane|Sevoflurane,Interventional,29-Nov-12,Baxter Healthcare Corporation,Drug: Desflurane
NCT01219881,Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery,Cystoscopes|Baxter Anaesthesia Brand of Desflurane|Sevoflurane,Interventional,29-Nov-12,Baxter Healthcare Corporation,Drug: Sevoflurane
NCT01191762,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Hyperparathyroidism|Chronic Kidney Disease,Interventional,31-Jul-14,"Kenneth R. Phelps, M.D.",Drug: sevelamer carbonate
NCT01191762,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Hyperparathyroidism|Chronic Kidney Disease,Interventional,31-Jul-14,"Kenneth R. Phelps, M.D.",Drug: placebo
NCT01191762,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Hyperparathyroidism|Chronic Kidney Disease,Interventional,31-Jul-14,"Genzyme, a Sanofi Company",Drug: sevelamer carbonate
NCT01191762,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Hyperparathyroidism|Chronic Kidney Disease,Interventional,31-Jul-14,"Genzyme, a Sanofi Company",Drug: placebo
NCT01191762,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Hyperparathyroidism|Chronic Kidney Disease,Interventional,31-Jul-14,"Phelps, Kenneth R., M.D.",Drug: sevelamer carbonate
NCT01191762,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Hyperparathyroidism|Chronic Kidney Disease,Interventional,31-Jul-14,"Phelps, Kenneth R., M.D.",Drug: placebo
NCT01174173,Ranolazine and Pulmonary Hypertension,Angina|Pulmonary Arterial Hypertension,Interventional,23-Apr-15,Northwestern University,Drug: Ranolazine
NCT01174173,Ranolazine and Pulmonary Hypertension,Angina|Pulmonary Arterial Hypertension,Interventional,23-Apr-15,Gilead Sciences,Drug: Ranolazine
NCT01169467,Cerebral Perfusion Pressure Using Precedex and Other Sedatives,Endotracheal Intubation|Continuous IV Sedation|ICP Monitoring,Interventional,2-Nov-15,Duke University,Drug: Standard-of-Care plus Dexmedetomidine
NCT01169467,Cerebral Perfusion Pressure Using Precedex and Other Sedatives,Endotracheal Intubation|Continuous IV Sedation|ICP Monitoring,Interventional,2-Nov-15,Duke University,Other: Standard-of-Care
NCT01169467,Cerebral Perfusion Pressure Using Precedex and Other Sedatives,Endotracheal Intubation|Continuous IV Sedation|ICP Monitoring,Interventional,2-Nov-15,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Standard-of-Care plus Dexmedetomidine
NCT01169467,Cerebral Perfusion Pressure Using Precedex and Other Sedatives,Endotracheal Intubation|Continuous IV Sedation|ICP Monitoring,Interventional,2-Nov-15,"Hospira, now a wholly owned subsidiary of Pfizer",Other: Standard-of-Care
NCT01156597,Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes,Type 2 Diabetes Mellitus,Interventional,11-Nov-14,University of Miami,Drug: pioglitazone
NCT01156597,Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes,Type 2 Diabetes Mellitus,Interventional,11-Nov-14,"Takeda Pharmaceuticals North America, Inc.",Drug: pioglitazone
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,"Kerstyn C. Zalesin, M.D.",Drug: Paricalcitol
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,"Kerstyn C. Zalesin, M.D.",Drug: Cholecalciferol
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,"Kerstyn C. Zalesin, M.D.",Drug: Placebo
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,Abbott,Drug: Paricalcitol
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,Abbott,Drug: Cholecalciferol
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,Abbott,Drug: Placebo
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,William Beaumont Hospitals,Drug: Paricalcitol
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,William Beaumont Hospitals,Drug: Cholecalciferol
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,Interventional,22-Mar-17,William Beaumont Hospitals,Drug: Placebo
NCT01048242,Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375),Insomnia|Obstructive Sleep Apnea,Interventional,3-May-17,University of Pennsylvania,Drug: rozerem
NCT01048242,Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375),Insomnia|Obstructive Sleep Apnea,Interventional,3-May-17,University of Pennsylvania,Drug: Placebo
NCT01048242,Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375),Insomnia|Obstructive Sleep Apnea,Interventional,3-May-17,Takeda,Drug: rozerem
NCT01048242,Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375),Insomnia|Obstructive Sleep Apnea,Interventional,3-May-17,Takeda,Drug: Placebo
NCT01007071,Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency,Hypopituitarism,Interventional,17-Nov-17,Stanford University,Drug: Human Growth Hormone (1-134)
NCT01007071,Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency,Hypopituitarism,Interventional,17-Nov-17,Stanford University,Drug: Placebo
NCT01007071,Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency,Hypopituitarism,Interventional,17-Nov-17,"Genentech, Inc.",Drug: Human Growth Hormone (1-134)
NCT01007071,Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency,Hypopituitarism,Interventional,17-Nov-17,"Genentech, Inc.",Drug: Placebo
NCT00994110,"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",Pancreatic Cancer,Interventional,1-Feb-16,Memorial Sloan Kettering Cancer Center,Drug: Pasireotide (SOM230)
NCT00994110,"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",Pancreatic Cancer,Interventional,1-Feb-16,Memorial Sloan Kettering Cancer Center,Other: placebo
NCT00994110,"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",Pancreatic Cancer,Interventional,1-Feb-16,Novartis Pharmaceuticals,Drug: Pasireotide (SOM230)
NCT00994110,"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",Pancreatic Cancer,Interventional,1-Feb-16,Novartis Pharmaceuticals,Other: placebo
NCT00904995,Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis,Leukemia|Fungal Infection,Interventional,12-May-11,M.D. Anderson Cancer Center,Drug: Voriconazole
NCT00904995,Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis,Leukemia|Fungal Infection,Interventional,12-May-11,Pfizer,Drug: Voriconazole
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,Duke University,Drug: Nicotine Patches
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,Duke University,"Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,Duke University,"Drug: Nicotine patches, then varenicline (Pre-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,Duke University,"Drug: Nicotine patches, then nicotine patches (Pre-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,Duke University,"Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,Duke University,"Drug: Nicotine patches, then varenicline (Post-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,Duke University,"Drug: Nicotine patches, then nicotine patches (Post-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,"Philip Morris USA, Inc.",Drug: Nicotine Patches
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,"Philip Morris USA, Inc.","Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,"Philip Morris USA, Inc.","Drug: Nicotine patches, then varenicline (Pre-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,"Philip Morris USA, Inc.","Drug: Nicotine patches, then nicotine patches (Pre-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,"Philip Morris USA, Inc.","Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,"Philip Morris USA, Inc.","Drug: Nicotine patches, then varenicline (Post-Quit)"
NCT00894166,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Smoking Cessation,Interventional,26-Dec-12,"Philip Morris USA, Inc.","Drug: Nicotine patches, then nicotine patches (Post-Quit)"
NCT00887679,Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS,Anxiety Disorders|HIV Infections,Interventional,10-Mar-14,Duke University,Drug: Escitalopram
NCT00887679,Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS,Anxiety Disorders|HIV Infections,Interventional,10-Mar-14,Forest Laboratories,Drug: Escitalopram
NCT00829179,Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma,Allergic Asthma,Interventional,21-Oct-09,Duke University,Drug: RhuMab-E25
NCT00829179,Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma,Allergic Asthma,Interventional,21-Oct-09,"Genentech, Inc.",Drug: RhuMab-E25
NCT00824993,Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients,Hematological Malignancies,Interventional,11-May-18,M.D. Anderson Cancer Center,Drug: Ibandronate
NCT00824993,Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients,Hematological Malignancies,Interventional,11-May-18,M.D. Anderson Cancer Center,Drug: Vitamin Supplements
NCT00824993,Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients,Hematological Malignancies,Interventional,11-May-18,Roche Pharma AG,Drug: Ibandronate
NCT00824993,Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients,Hematological Malignancies,Interventional,11-May-18,Roche Pharma AG,Drug: Vitamin Supplements
NCT00750737,Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC),Invasive Fungal Infections|Hematologic Malignancies,Interventional,6-Jan-16,M.D. Anderson Cancer Center,Drug: Posaconazole
NCT00750737,Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC),Invasive Fungal Infections|Hematologic Malignancies,Interventional,6-Jan-16,M.D. Anderson Cancer Center,Drug: ABLC
NCT00750737,Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC),Invasive Fungal Infections|Hematologic Malignancies,Interventional,6-Jan-16,"Enzon Pharmaceuticals, Inc.",Drug: Posaconazole
NCT00750737,Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC),Invasive Fungal Infections|Hematologic Malignancies,Interventional,6-Jan-16,"Enzon Pharmaceuticals, Inc.",Drug: ABLC
NCT00729690,Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement,PAIN,Interventional,19-Dec-12,Asokumar Buvanendran,Drug: Pregabalin
NCT00729690,Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement,PAIN,Interventional,19-Dec-12,Asokumar Buvanendran,Drug: Placebo
NCT00729690,Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement,PAIN,Interventional,19-Dec-12,Pfizer,Drug: Pregabalin
NCT00729690,Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement,PAIN,Interventional,19-Dec-12,Pfizer,Drug: Placebo
NCT00729690,Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement,PAIN,Interventional,19-Dec-12,Rush University Medical Center,Drug: Pregabalin
NCT00729690,Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement,PAIN,Interventional,19-Dec-12,Rush University Medical Center,Drug: Placebo
NCT00727597,A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT,Human Immunodeficiency Virus Infections,Interventional,2-Jul-13,Georgetown University,Drug: Efavirenz 600mg
NCT00727597,A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT,Human Immunodeficiency Virus Infections,Interventional,2-Jul-13,Georgetown University,Drug: Boosted Lexiva
NCT00727597,A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT,Human Immunodeficiency Virus Infections,Interventional,2-Jul-13,GlaxoSmithKline,Drug: Efavirenz 600mg
NCT00727597,A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT,Human Immunodeficiency Virus Infections,Interventional,2-Jul-13,GlaxoSmithKline,Drug: Boosted Lexiva
NCT00722761,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,Acne Vulgaris,Interventional,5-Mar-13,Massachusetts General Hospital,Drug: drospirenone and ethinyl estradiol
NCT00722761,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,Acne Vulgaris,Interventional,5-Mar-13,Massachusetts General Hospital,Drug: Placebo tablet
NCT00722761,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,Acne Vulgaris,Interventional,5-Mar-13,Bayer,Drug: drospirenone and ethinyl estradiol
NCT00722761,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,Acne Vulgaris,Interventional,5-Mar-13,Bayer,Drug: Placebo tablet
NCT00712985,Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL),Breast Cancer,Interventional,24-Apr-14,Milton S. Hershey Medical Center,Drug: Zometa
NCT00712985,Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL),Breast Cancer,Interventional,24-Apr-14,Novartis,Drug: Zometa
NCT00711867,Comparison of Intraoperative Warming Devices,Total Knee Arthroplasty,Interventional,2-Dec-09,Mayo Clinic,Device: VH2
NCT00711867,Comparison of Intraoperative Warming Devices,Total Knee Arthroplasty,Interventional,2-Dec-09,Mayo Clinic,Device: Bair Hugger
NCT00711867,Comparison of Intraoperative Warming Devices,Total Knee Arthroplasty,Interventional,2-Dec-09,Dynatherm Medical Inc.,Device: VH2
NCT00711867,Comparison of Intraoperative Warming Devices,Total Knee Arthroplasty,Interventional,2-Dec-09,Dynatherm Medical Inc.,Device: Bair Hugger
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,New York State Psychiatric Institute,Drug: Heroin
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,New York State Psychiatric Institute,Drug: Naloxone
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,New York State Psychiatric Institute,Drug: Low Bup Dose
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,New York State Psychiatric Institute,Drug: High Bup Dose
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,New York State Psychiatric Institute,Drug: Low Bup/Nal Dose
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,New York State Psychiatric Institute,Drug: High Bup/Nal Dose
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,New York State Psychiatric Institute,Drug: Placebo (PCB)
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,Schering-Plough,Drug: Heroin
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,Schering-Plough,Drug: Naloxone
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,Schering-Plough,Drug: Low Bup Dose
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,Schering-Plough,Drug: High Bup Dose
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,Schering-Plough,Drug: Low Bup/Nal Dose
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,Schering-Plough,Drug: High Bup/Nal Dose
NCT00710385,Abuse Liability of Suboxone Versus Subutex,Opioid-related Disorders,Interventional,5-Dec-16,Schering-Plough,Drug: Placebo (PCB)
NCT00694122,Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon,Type 1 Diabetes|Dawn Phenomenon,Interventional,21-Oct-14,Massachusetts General Hospital,Drug: Lantus (glargine)
NCT00694122,Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon,Type 1 Diabetes|Dawn Phenomenon,Interventional,21-Oct-14,Sanofi,Drug: Lantus (glargine)
NCT00683852,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Major Depressive Disorder,Interventional,19-Jul-17,Massachusetts General Hospital,Drug: Aripiprazole 5mg
NCT00683852,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Major Depressive Disorder,Interventional,19-Jul-17,Massachusetts General Hospital,Drug: Aripiprazole 2mg
NCT00683852,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Major Depressive Disorder,Interventional,19-Jul-17,Massachusetts General Hospital,Drug: Placebo
NCT00683852,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Major Depressive Disorder,Interventional,19-Jul-17,Bristol-Myers Squibb,Drug: Aripiprazole 5mg
NCT00683852,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Major Depressive Disorder,Interventional,19-Jul-17,Bristol-Myers Squibb,Drug: Aripiprazole 2mg
NCT00683852,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Major Depressive Disorder,Interventional,19-Jul-17,Bristol-Myers Squibb,Drug: Placebo
NCT00681590,Safety of Vitamin D Supplementation in Older Persons,Vitamin D Deficiency,Interventional,7-Mar-16,University of Miami,Dietary Supplement: cholecalciferol (vitamin D)
NCT00681590,Safety of Vitamin D Supplementation in Older Persons,Vitamin D Deficiency,Interventional,7-Mar-16,Merck Sharp & Dohme Corp.,Dietary Supplement: cholecalciferol (vitamin D)
NCT00656448,A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS,Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Leukemia,Interventional,23-Dec-13,M.D. Anderson Cancer Center,Drug: Procrit
NCT00656448,A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS,Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Leukemia,Interventional,23-Dec-13,"Centocor, Inc.",Drug: Procrit
NCT00599326,Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda,Porphyria Cutanea Tarda,Interventional,10-Feb-14,University of Texas Southwestern Medical Center,Drug: Deferasirox
NCT00599326,Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda,Porphyria Cutanea Tarda,Interventional,10-Feb-14,Novartis Pharmaceuticals,Drug: Deferasirox
NCT00566735,The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning,Major Depression|Bipolar Depression|Schizoaffective Disorder,Interventional,3-Dec-12,Massachusetts General Hospital,Drug: Razadyne
NCT00566735,The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning,Major Depression|Bipolar Depression|Schizoaffective Disorder,Interventional,3-Dec-12,Massachusetts General Hospital,Drug: Placebo
NCT00566735,The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning,Major Depression|Bipolar Depression|Schizoaffective Disorder,Interventional,3-Dec-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: Razadyne
NCT00566735,The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning,Major Depression|Bipolar Depression|Schizoaffective Disorder,Interventional,3-Dec-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: Placebo
NCT00561431,High Dose CVVHDF Compared to Standard Dose CVVHDF,Acute Renal Failure,Interventional,12-Mar-10,University of Alabama at Birmingham,Device: Standard dose of dialysis
NCT00561431,High Dose CVVHDF Compared to Standard Dose CVVHDF,Acute Renal Failure,Interventional,12-Mar-10,University of Alabama at Birmingham,Device: High dose of dialysis
NCT00561431,High Dose CVVHDF Compared to Standard Dose CVVHDF,Acute Renal Failure,Interventional,12-Mar-10,Pfizer,Device: Standard dose of dialysis
NCT00561431,High Dose CVVHDF Compared to Standard Dose CVVHDF,Acute Renal Failure,Interventional,12-Mar-10,Pfizer,Device: High dose of dialysis
NCT00556140,The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression,Psychotic Depression,Interventional,20-Aug-12,Massachusetts General Hospital,Drug: Aripiprazole
NCT00556140,The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression,Psychotic Depression,Interventional,20-Aug-12,Bristol-Myers Squibb,Drug: Aripiprazole
NCT00549562,Study of Paliperidone ER in Adolescents and Young Adults With Autism,Autism,Interventional,16-May-17,Indiana University School of Medicine,Drug: Paliperidone ER
NCT00549562,Study of Paliperidone ER in Adolescents and Young Adults With Autism,Autism,Interventional,16-May-17,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: Paliperidone ER
NCT00549562,Study of Paliperidone ER in Adolescents and Young Adults With Autism,Autism,Interventional,16-May-17,Indiana University,Drug: Paliperidone ER
NCT00506285,Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD,Attention Deficit Hyperactivity Disorder,Interventional,16-Jan-15,University of Utah,Drug: Methylphenidate Transdermal System (MTS)
NCT00506285,Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD,Attention Deficit Hyperactivity Disorder,Interventional,16-Jan-15,University of Utah,Other: placebo patch
NCT00506285,Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD,Attention Deficit Hyperactivity Disorder,Interventional,16-Jan-15,Shire,Drug: Methylphenidate Transdermal System (MTS)
NCT00506285,Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD,Attention Deficit Hyperactivity Disorder,Interventional,16-Jan-15,Shire,Other: placebo patch
NCT00463346,Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism,Alcohol Dependence|Schizophrenia,Interventional,15-Jan-16,Yale University,Drug: Acamprosate
NCT00463346,Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism,Alcohol Dependence|Schizophrenia,Interventional,15-Jan-16,Yale University,Drug: Placebo
NCT00463346,Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism,Alcohol Dependence|Schizophrenia,Interventional,15-Jan-16,Forest Laboratories,Drug: Acamprosate
NCT00463346,Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism,Alcohol Dependence|Schizophrenia,Interventional,15-Jan-16,Forest Laboratories,Drug: Placebo
NCT00459056,The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients,Abdominal Obesity|Hypertension,Interventional,8-Nov-13,St. Paul Heart Clinic,Drug: Carvedilol CR + Lisinopril
NCT00459056,The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients,Abdominal Obesity|Hypertension,Interventional,8-Nov-13,St. Paul Heart Clinic,Drug: Lisinopril + HCTZ
NCT00459056,The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients,Abdominal Obesity|Hypertension,Interventional,8-Nov-13,GlaxoSmithKline,Drug: Carvedilol CR + Lisinopril
NCT00459056,The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients,Abdominal Obesity|Hypertension,Interventional,8-Nov-13,GlaxoSmithKline,Drug: Lisinopril + HCTZ
NCT00432835,Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis,Gastroparesis,Interventional,3-Dec-12,University of Mississippi Medical Center,"Device: Gastric Electrical Stimulator, Enterra, Medtronics, Inc."
NCT00432835,Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis,Gastroparesis,Interventional,3-Dec-12,Medtronic,"Device: Gastric Electrical Stimulator, Enterra, Medtronics, Inc."
NCT00421954,Open-label Ziprasidone Study for Psychosis Treatment in Adolescents,"Schizophreniform Disorder|Schizoaffective Disorder|Psychosis|Depressive Disorder, Major|Bipolar Disorder",Interventional,13-Jan-17,New York State Psychiatric Institute,Drug: Ziprasidone
NCT00421954,Open-label Ziprasidone Study for Psychosis Treatment in Adolescents,"Schizophreniform Disorder|Schizoaffective Disorder|Psychosis|Depressive Disorder, Major|Bipolar Disorder",Interventional,13-Jan-17,Pfizer,Drug: Ziprasidone
NCT00413244,The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery,Coronary Artery Disease,Interventional,5-Jan-17,Icahn School of Medicine at Mount Sinai,Drug: AndroGel 5 Grams
NCT00413244,The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery,Coronary Artery Disease,Interventional,5-Jan-17,Icahn School of Medicine at Mount Sinai,Drug: Placebo
NCT00413244,The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery,Coronary Artery Disease,Interventional,5-Jan-17,Abbott,Drug: AndroGel 5 Grams
NCT00413244,The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery,Coronary Artery Disease,Interventional,5-Jan-17,Abbott,Drug: Placebo
NCT00352846,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Non-Hodgkin's Lymphoma|Lymphoma,Interventional,20-Jun-13,M.D. Anderson Cancer Center,Drug: Zoledronic Acid
NCT00352846,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Non-Hodgkin's Lymphoma|Lymphoma,Interventional,20-Jun-13,M.D. Anderson Cancer Center,Drug: Vitamin D
NCT00352846,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Non-Hodgkin's Lymphoma|Lymphoma,Interventional,20-Jun-13,M.D. Anderson Cancer Center,Drug: Calcium Carbonate
NCT00352846,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Non-Hodgkin's Lymphoma|Lymphoma,Interventional,20-Jun-13,Novartis,Drug: Zoledronic Acid
NCT00352846,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Non-Hodgkin's Lymphoma|Lymphoma,Interventional,20-Jun-13,Novartis,Drug: Vitamin D
NCT00352846,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Non-Hodgkin's Lymphoma|Lymphoma,Interventional,20-Jun-13,Novartis,Drug: Calcium Carbonate
NCT00345969,Exercise and Testosterone Therapy in Elderly Men With Physical Frailty,Physical Frailty|Hip Fracture|Elective Hip Replacement|Hypogonadism,Interventional,21-Feb-18,Washington University School of Medicine,Drug: Transdermal Testosterone gel (1%)
NCT00345969,Exercise and Testosterone Therapy in Elderly Men With Physical Frailty,Physical Frailty|Hip Fracture|Elective Hip Replacement|Hypogonadism,Interventional,21-Feb-18,Washington University School of Medicine,Behavioral: Supervised exercise training
NCT00345969,Exercise and Testosterone Therapy in Elderly Men With Physical Frailty,Physical Frailty|Hip Fracture|Elective Hip Replacement|Hypogonadism,Interventional,21-Feb-18,Solvay Pharmaceuticals,Drug: Transdermal Testosterone gel (1%)
NCT00345969,Exercise and Testosterone Therapy in Elderly Men With Physical Frailty,Physical Frailty|Hip Fracture|Elective Hip Replacement|Hypogonadism,Interventional,21-Feb-18,Solvay Pharmaceuticals,Behavioral: Supervised exercise training
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,Vanderbilt University,Drug: Lansoprazole Tablet
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,Vanderbilt University,Procedure: PH and impedence testing
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,Vanderbilt University,Procedure: manometry
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,Vanderbilt University,Drug: lansoprazole
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,Vanderbilt University,Drug: placebo
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,TAP Pharmaceutical Products Inc.,Drug: Lansoprazole Tablet
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,TAP Pharmaceutical Products Inc.,Procedure: PH and impedence testing
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,TAP Pharmaceutical Products Inc.,Procedure: manometry
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,TAP Pharmaceutical Products Inc.,Drug: lansoprazole
NCT00335283,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Larynx Disease,Interventional,21-Aug-12,TAP Pharmaceutical Products Inc.,Drug: placebo
NCT00302068,Exercise to Treat Depression in Individuals With Coronary Heart Disease,Depression|Heart Diseases,Interventional,24-Jan-13,Duke University,Behavioral: Supervised Aerobic Exercise
NCT00302068,Exercise to Treat Depression in Individuals With Coronary Heart Disease,Depression|Heart Diseases,Interventional,24-Jan-13,Duke University,Drug: Sertraline
NCT00302068,Exercise to Treat Depression in Individuals With Coronary Heart Disease,Depression|Heart Diseases,Interventional,24-Jan-13,Duke University,Drug: Placebo Pill.
NCT00302068,Exercise to Treat Depression in Individuals With Coronary Heart Disease,Depression|Heart Diseases,Interventional,24-Jan-13,Pfizer,Behavioral: Supervised Aerobic Exercise
NCT00302068,Exercise to Treat Depression in Individuals With Coronary Heart Disease,Depression|Heart Diseases,Interventional,24-Jan-13,Pfizer,Drug: Sertraline
NCT00302068,Exercise to Treat Depression in Individuals With Coronary Heart Disease,Depression|Heart Diseases,Interventional,24-Jan-13,Pfizer,Drug: Placebo Pill.
NCT00279916,Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays,"Otitis Media, Serous|Negative Middle Ear Pressure|Rhinitis|Otitis Media With Effusion|Otitis Media, Secretory",Interventional,15-Aug-11,Mayo Clinic,Drug: Triamcinolone acetonide nasal spray
NCT00279916,Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays,"Otitis Media, Serous|Negative Middle Ear Pressure|Rhinitis|Otitis Media With Effusion|Otitis Media, Secretory",Interventional,15-Aug-11,Mayo Clinic,Drug: Placebo nasal spray
NCT00279916,Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays,"Otitis Media, Serous|Negative Middle Ear Pressure|Rhinitis|Otitis Media With Effusion|Otitis Media, Secretory",Interventional,15-Aug-11,Aventis Pharmaceuticals,Drug: Triamcinolone acetonide nasal spray
NCT00279916,Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays,"Otitis Media, Serous|Negative Middle Ear Pressure|Rhinitis|Otitis Media With Effusion|Otitis Media, Secretory",Interventional,15-Aug-11,Aventis Pharmaceuticals,Drug: Placebo nasal spray
NCT00275275,Pramipexole Conversion to Ropinirole Controlled Release (CR),Parkinson Disease,Interventional,24-Aug-12,"Rajesh Pahwa, MD",Drug: Requip PR
NCT00275275,Pramipexole Conversion to Ropinirole Controlled Release (CR),Parkinson Disease,Interventional,24-Aug-12,"Rajesh Pahwa, MD",Drug: Mirapex
NCT00275275,Pramipexole Conversion to Ropinirole Controlled Release (CR),Parkinson Disease,Interventional,24-Aug-12,GlaxoSmithKline,Drug: Requip PR
NCT00275275,Pramipexole Conversion to Ropinirole Controlled Release (CR),Parkinson Disease,Interventional,24-Aug-12,GlaxoSmithKline,Drug: Mirapex
NCT00275275,Pramipexole Conversion to Ropinirole Controlled Release (CR),Parkinson Disease,Interventional,24-Aug-12,University of Kansas Medical Center,Drug: Requip PR
NCT00275275,Pramipexole Conversion to Ropinirole Controlled Release (CR),Parkinson Disease,Interventional,24-Aug-12,University of Kansas Medical Center,Drug: Mirapex
NCT00240487,Nitric Oxide Administration for Acute Respiratory Distress Syndrome,Acute Respiratory Distress Syndrome,Interventional,24-Apr-15,Children's Hospital of Philadelphia,Drug: Nitric Oxide
NCT00240487,Nitric Oxide Administration for Acute Respiratory Distress Syndrome,Acute Respiratory Distress Syndrome,Interventional,24-Apr-15,Children's Hospital of Philadelphia,Other: No Intervention
NCT00240487,Nitric Oxide Administration for Acute Respiratory Distress Syndrome,Acute Respiratory Distress Syndrome,Interventional,24-Apr-15,Mallinckrodt,Drug: Nitric Oxide
NCT00240487,Nitric Oxide Administration for Acute Respiratory Distress Syndrome,Acute Respiratory Distress Syndrome,Interventional,24-Apr-15,Mallinckrodt,Other: No Intervention
NCT00227370,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,Cytomegalovirus Infections,Interventional,29-Apr-13,Scott Palmer,Drug: valganciclovir
NCT00227370,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,Cytomegalovirus Infections,Interventional,29-Apr-13,Scott Palmer,Other: Placebo
NCT00227370,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,Cytomegalovirus Infections,Interventional,29-Apr-13,Roche Pharma AG,Drug: valganciclovir
NCT00227370,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,Cytomegalovirus Infections,Interventional,29-Apr-13,Roche Pharma AG,Other: Placebo
NCT00227370,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,Cytomegalovirus Infections,Interventional,29-Apr-13,Duke University,Drug: valganciclovir
NCT00227370,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,Cytomegalovirus Infections,Interventional,29-Apr-13,Duke University,Other: Placebo
NCT00194116,"Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression",Bipolar Disorder,Interventional,17-Jul-19,University Hospitals Cleveland Medical Center,Drug: Divalproex Sodium ER
NCT00194116,"Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression",Bipolar Disorder,Interventional,17-Jul-19,University Hospitals Cleveland Medical Center,Drug: Placebo
NCT00194116,"Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression",Bipolar Disorder,Interventional,17-Jul-19,Abbott,Drug: Divalproex Sodium ER
NCT00194116,"Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression",Bipolar Disorder,Interventional,17-Jul-19,Abbott,Drug: Placebo
NCT00194077,Study of Aripiprazole (Abilify) in Children With Symptoms of Mania,Bipolar Disorder,Interventional,5-Dec-13,University Hospitals Cleveland Medical Center,Drug: Aripiprazole
NCT00194077,Study of Aripiprazole (Abilify) in Children With Symptoms of Mania,Bipolar Disorder,Interventional,5-Dec-13,University Hospitals Cleveland Medical Center,Drug: Placebo
NCT00194077,Study of Aripiprazole (Abilify) in Children With Symptoms of Mania,Bipolar Disorder,Interventional,5-Dec-13,Bristol-Myers Squibb,Drug: Aripiprazole
NCT00194077,Study of Aripiprazole (Abilify) in Children With Symptoms of Mania,Bipolar Disorder,Interventional,5-Dec-13,Bristol-Myers Squibb,Drug: Placebo
NCT00194012,Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder,Bipolar Disorder,Interventional,5-May-14,University Hospitals Cleveland Medical Center,Drug: Aripiprazole
NCT00194012,Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder,Bipolar Disorder,Interventional,5-May-14,University Hospitals Cleveland Medical Center,Drug: Placebo
NCT00194012,Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder,Bipolar Disorder,Interventional,5-May-14,Bristol-Myers Squibb,Drug: Aripiprazole
NCT00194012,Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder,Bipolar Disorder,Interventional,5-May-14,Bristol-Myers Squibb,Drug: Placebo
NCT01974323,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Acne Vulgaris,Interventional,6-Feb-17,"Almirall, S.A.",Drug: Dapsone Gel
NCT01974323,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Acne Vulgaris,Interventional,6-Feb-17,"Almirall, S.A.",Drug: Dapsone Gel Vehicle
NCT01974323,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Acne Vulgaris,Interventional,6-Feb-17,Allergan,Drug: Dapsone Gel
NCT01974323,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Acne Vulgaris,Interventional,6-Feb-17,Allergan,Drug: Dapsone Gel Vehicle
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Thalidomide
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Ara-C
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: BCNU
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Cisplatin
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Cytoxan
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Dexamethasone
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Doxorubicin
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Etoposide
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Filgrastim
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Recombinant GM-CSF
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Interferon-alpha-2b
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Melphalan
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,University of Arkansas,Drug: Vincristine
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Thalidomide
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Ara-C
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: BCNU
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Cisplatin
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Cytoxan
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Dexamethasone
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Doxorubicin
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Etoposide
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Filgrastim
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Recombinant GM-CSF
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Interferon-alpha-2b
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Melphalan
NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Multiple Myeloma,Interventional,22-Sep-15,Celgene Corporation,Drug: Vincristine
NCT01936467,Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions,Pancreatic Solid Lesions|Pancreatic Mass,Interventional,13-Apr-17,Johns Hopkins University,Device: Standard technique EUS-FNA
NCT01936467,Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions,Pancreatic Solid Lesions|Pancreatic Mass,Interventional,13-Apr-17,Johns Hopkins University,Device: Capillary suction technique for EUS FNA
NCT01936467,Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions,Pancreatic Solid Lesions|Pancreatic Mass,Interventional,13-Apr-17,Boston Scientific Corporation,Device: Standard technique EUS-FNA
NCT01936467,Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions,Pancreatic Solid Lesions|Pancreatic Mass,Interventional,13-Apr-17,Boston Scientific Corporation,Device: Capillary suction technique for EUS FNA
NCT01738984,A Home Exercise Program for Women With Infants & Young Children,MomZing Exercise Videos Online|Standard Exercise DVD,Interventional,12-Apr-16,University of Hawaii,Behavioral: MomZing Web Program
NCT01738984,A Home Exercise Program for Women With Infants & Young Children,MomZing Exercise Videos Online|Standard Exercise DVD,Interventional,12-Apr-16,University of Hawaii,Behavioral: Standard Exercise DVD
NCT01738984,A Home Exercise Program for Women With Infants & Young Children,MomZing Exercise Videos Online|Standard Exercise DVD,Interventional,12-Apr-16,"Klein Buendel, Inc.",Behavioral: MomZing Web Program
NCT01738984,A Home Exercise Program for Women With Infants & Young Children,MomZing Exercise Videos Online|Standard Exercise DVD,Interventional,12-Apr-16,"Klein Buendel, Inc.",Behavioral: Standard Exercise DVD
NCT01528891,Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation,Tonsillectomy,Interventional,25-Nov-15,Peter Davis,Drug: Dexmedetomidine
NCT01528891,Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation,Tonsillectomy,Interventional,25-Nov-15,Peter Davis,Other: Placebo
NCT01528891,Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation,Tonsillectomy,Interventional,25-Nov-15,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Dexmedetomidine
NCT01528891,Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation,Tonsillectomy,Interventional,25-Nov-15,"Hospira, now a wholly owned subsidiary of Pfizer",Other: Placebo
NCT01528891,Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation,Tonsillectomy,Interventional,25-Nov-15,University of Pittsburgh,Drug: Dexmedetomidine
NCT01528891,Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation,Tonsillectomy,Interventional,25-Nov-15,University of Pittsburgh,Other: Placebo
NCT01089647,Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA),Obstructive Sleep Apnea,Interventional,3-Dec-18,Romaker & Associates,Drug: budesonide and montelukast
NCT01089647,Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA),Obstructive Sleep Apnea,Interventional,3-Dec-18,Romaker & Associates,Drug: Placebo
NCT01089647,Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA),Obstructive Sleep Apnea,Interventional,3-Dec-18,Merck Sharp & Dohme Corp.,Drug: budesonide and montelukast
NCT01089647,Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA),Obstructive Sleep Apnea,Interventional,3-Dec-18,Merck Sharp & Dohme Corp.,Drug: Placebo
NCT00813319,Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females,Vaccination,Interventional,12-Aug-14,Emory University,Behavioral: Girls OnGuard
NCT00813319,Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females,Vaccination,Interventional,12-Aug-14,Merck Sharp & Dohme Corp.,Behavioral: Girls OnGuard
NCT00393042,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Attention Deficit Hyperactivity Disorder,Interventional,19-Apr-17,Seattle Children's Hospital,Drug: Dexmethylphenidate
NCT00393042,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Attention Deficit Hyperactivity Disorder,Interventional,19-Apr-17,Seattle Children's Hospital,"Drug: Mixed Amphetamine Salts, ER"
NCT00393042,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Attention Deficit Hyperactivity Disorder,Interventional,19-Apr-17,Seattle Children's Hospital,Drug: placebo
NCT00393042,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Attention Deficit Hyperactivity Disorder,Interventional,19-Apr-17,Novartis,Drug: Dexmethylphenidate
NCT00393042,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Attention Deficit Hyperactivity Disorder,Interventional,19-Apr-17,Novartis,"Drug: Mixed Amphetamine Salts, ER"
NCT00393042,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Attention Deficit Hyperactivity Disorder,Interventional,19-Apr-17,Novartis,Drug: placebo
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,"Cardiovascular Research Foundation, New York",Drug: Bivalirudin
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,"Cardiovascular Research Foundation, New York",Drug: Unfractionated heparin
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,"Cardiovascular Research Foundation, New York",Device: Bare metal stent
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,"Cardiovascular Research Foundation, New York",Device: Paclitaxel-eluting stent
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,Boston Scientific Corporation,Drug: Bivalirudin
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,Boston Scientific Corporation,Drug: Unfractionated heparin
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,Boston Scientific Corporation,Device: Bare metal stent
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,Boston Scientific Corporation,Device: Paclitaxel-eluting stent
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,The Medicines Company,Drug: Bivalirudin
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,The Medicines Company,Drug: Unfractionated heparin
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,The Medicines Company,Device: Bare metal stent
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,Interventional,4-Dec-17,The Medicines Company,Device: Paclitaxel-eluting stent
NCT00260429,Collagenase in the Treatment of Dupuytrens Disease,Dupuytren's Disease,Interventional,9-Dec-10,Stony Brook University,Biological: collagenase clostridium histolyticum
NCT00260429,Collagenase in the Treatment of Dupuytrens Disease,Dupuytren's Disease,Interventional,9-Dec-10,Biospecifics Technologies Corp.,Biological: collagenase clostridium histolyticum
NCT00260429,Collagenase in the Treatment of Dupuytrens Disease,Dupuytren's Disease,Interventional,9-Dec-10,Endo Pharmaceuticals,Biological: collagenase clostridium histolyticum
NCT02688556,Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Keratoconjunctivitis Sicca,Interventional,8-Apr-19,Sun Pharma Global FZE,Drug: cyclosporine
NCT02688556,Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Keratoconjunctivitis Sicca,Interventional,8-Apr-19,Sun Pharma Global FZE,Drug: vehicle of OTX-101
NCT01999322,A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,31-Oct-17,Novo Nordisk A/S,Drug: Faster-acting insulin aspart
NCT01999322,A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,31-Oct-17,Novo Nordisk A/S,Drug: insulin aspart
NCT02447848,Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain,Moderate-to-severe Acute Pain,Interventional,19-Oct-17,"AcelRx Pharmaceuticals, Inc.",Drug: sufentanil sublingual 30 mcg tablet
NCT02447848,Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain,Moderate-to-severe Acute Pain,Interventional,19-Oct-17,U.S. Army Medical Research and Development Command,Drug: sufentanil sublingual 30 mcg tablet
NCT02402933,Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents,Hypoglycemia|Diabetes Mellitus,Interventional,26-Jun-17,Eli Lilly and Company,Drug: Nasal Glucagon
NCT03296072,In Situ Erosion Study to Investigate the Effectiveness of an Experimental Toothpaste,Tooth Erosion,Interventional,20-Feb-19,GlaxoSmithKline,Drug: 0.254% w/w sodium fluoride and 5% KNO3
NCT03296072,In Situ Erosion Study to Investigate the Effectiveness of an Experimental Toothpaste,Tooth Erosion,Interventional,20-Feb-19,GlaxoSmithKline,Drug: 0.454% w/w stannous fluoride
NCT03296072,In Situ Erosion Study to Investigate the Effectiveness of an Experimental Toothpaste,Tooth Erosion,Interventional,20-Feb-19,GlaxoSmithKline,Drug: 5% KNO3
NCT01765764,Bimatoprost for the Treatment of Eyebrow Hypotrichosis,Eyebrow Hypotrichosis,Interventional,26-Jan-15,Allergan,Drug: bimatoprost solution
NCT01765764,Bimatoprost for the Treatment of Eyebrow Hypotrichosis,Eyebrow Hypotrichosis,Interventional,26-Jan-15,Allergan,Drug: Vehicle to bimatoprost solution
NCT01746979,Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Interventional,2-Dec-17,Threshold Pharmaceuticals,Drug: TH-302
NCT01746979,Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Interventional,2-Dec-17,Threshold Pharmaceuticals,Drug: Gemcitabine
NCT01746979,Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Interventional,2-Dec-17,Threshold Pharmaceuticals,Drug: Placebo (5 percent dextrose - D5W)
NCT01744782,Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis,Cystinosis,Interventional,16-Jan-18,"Horizon Pharma USA, Inc.",Drug: RP103
NCT02008942,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients,"Diabetes Mellitus, Type 2",Interventional,4-Sep-15,PLx Pharma,Drug: PL2200 Aspirin Capsules
NCT02008942,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients,"Diabetes Mellitus, Type 2",Interventional,4-Sep-15,PLx Pharma,Drug: Enteric-coated aspirin caplets
NCT01962922,Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.,Renal Failure,Interventional,15-Aug-16,Veloxis Pharmaceuticals,Drug: LCP-Tacro
NCT01962922,Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.,Renal Failure,Interventional,15-Aug-16,Veloxis Pharmaceuticals,Drug: Tacrolimus -IR
NCT02777931,Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD,Attention Deficit Disorder With Hyperactivity,Interventional,29-Mar-18,Aevi Genomic Medicine,Drug: NFC-1
NCT02777931,Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD,Attention Deficit Disorder With Hyperactivity,Interventional,29-Mar-18,Aevi Genomic Medicine,Drug: Placebo
NCT01341912,Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs),Severe Hemophilia A,Interventional,3-Feb-14,Octapharma,Biological: Human-cl rhFVIII
NCT02254265,Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Keratoconjunctivitis Sicca|Dry Eye Disease,Interventional,14-Dec-18,Sun Pharma Global FZE,Drug: OTX-101 0.05%
NCT02254265,Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Keratoconjunctivitis Sicca|Dry Eye Disease,Interventional,14-Dec-18,Sun Pharma Global FZE,Drug: OTX-101 0.09%
NCT02254265,Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Keratoconjunctivitis Sicca|Dry Eye Disease,Interventional,14-Dec-18,Sun Pharma Global FZE,Drug: Vehicle
NCT00910845,Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Overactive Bladder,Interventional,5-Mar-13,Allergan,Biological: onabotulinumtoxinA
NCT00910845,Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Overactive Bladder,Interventional,5-Mar-13,Allergan,Drug: normal saline
NCT00907426,Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin,Hypotrichosis,Interventional,19-Sep-12,Allergan,Drug: Bimatoprost 0.03% solution
NCT00907426,Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin,Hypotrichosis,Interventional,19-Sep-12,Allergan,Drug: Vehicle solution
NCT01214811,Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing,Inflammation|Burns|Ulcers,Interventional,26-Feb-13,Molnlycke Health Care AB,Device: Mepilex Border Ag
NCT00762619,Clinical Study to Examine Brushing on Dental Implants,Gingival Diseases,Interventional,25-Jan-11,Colgate Palmolive,Drug: Fluoride
NCT00762619,Clinical Study to Examine Brushing on Dental Implants,Gingival Diseases,Interventional,25-Jan-11,Colgate Palmolive,"Drug: Triclosan, fluoride"
NCT01133626,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,4-Jul-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo Nasal Aerosol
NCT01133626,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,4-Jul-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Prednisone capsules
NCT01133626,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,4-Jul-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo Prednisone Capsules
NCT01133626,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,4-Jul-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate
NCT01133626,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,4-Jul-12,Teva Pharmaceutical Industries,Drug: Placebo Nasal Aerosol
NCT01133626,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,4-Jul-12,Teva Pharmaceutical Industries,Drug: Prednisone capsules
NCT01133626,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,4-Jul-12,Teva Pharmaceutical Industries,Drug: Placebo Prednisone Capsules
NCT01133626,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,4-Jul-12,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate
NCT00693420,Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence,Eyelashes,Interventional,12-May-09,Allergan,Drug: Bimatoprost 0.03% sterile solution
NCT00693420,Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence,Eyelashes,Interventional,12-May-09,Allergan,Drug: vehicle sterile solution
NCT00518089,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Bacterial Conjunctivitis,Interventional,30-Nov-11,Allergan,Drug: Gatifloxacin 0.5% eye drops
NCT00518089,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Bacterial Conjunctivitis,Interventional,30-Nov-11,Allergan,Drug: placebo eye drops
NCT00406367,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm,Blepharospasm,Interventional,16-Nov-10,Merz Pharmaceuticals GmbH,Drug: incobotulinumtoxinA (Xeomin)
NCT00406367,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm,Blepharospasm,Interventional,16-Nov-10,Merz Pharmaceuticals GmbH,Drug: Placebo
NCT00720057,Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.,Toothache,Interventional,25-Jan-11,Bayer,Drug: Naproxen Sodium ER (BAYH6689)
NCT00720057,Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.,Toothache,Interventional,25-Jan-11,Bayer,Drug: Placebo
NCT01332188,Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model,Allergic Conjunctivitis,Interventional,30-Aug-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0.05%
NCT01332188,Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model,Allergic Conjunctivitis,Interventional,30-Aug-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0.1%
NCT01332188,Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model,Allergic Conjunctivitis,Interventional,30-Aug-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0.24%
NCT01332188,Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model,Allergic Conjunctivitis,Interventional,30-Aug-17,"Aciex Therapeutics, Inc.",Drug: AC-170 0%
NCT01227421,Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza,Influenza,Interventional,8-Jan-14,Romark Laboratories L.C.,Drug: Nitazoxanide
NCT01227421,Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza,Influenza,Interventional,8-Jan-14,Romark Laboratories L.C.,Drug: Placebo
NCT01219855,Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,Interventional,25-Aug-16,"OPKO Health, Inc.",Drug: Cohort 1 CTAP101 Capsules- 60µg
NCT01219855,Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,Interventional,25-Aug-16,"OPKO Health, Inc.",Drug: Cohort 1 CTAP101 Capsules - 90µg
NCT01219855,Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,Interventional,25-Aug-16,"OPKO Health, Inc.",Drug: Cohort 1 Matching Sugar Capsule
NCT01219855,Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,Interventional,25-Aug-16,"OPKO Health, Inc.",Drug: Cohort 2 CTAP101 Capsules - 30µg
NCT01219855,Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,Interventional,25-Aug-16,"OPKO Health, Inc.",Drug: Cohort 2 Matching Sugar Capsule
NCT00569777,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Allergic Conjunctivitis,Interventional,23-Nov-10,Vistakon Pharmaceuticals,Device: K-Lens (generic name not established) and Ketotifen
NCT00569777,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Allergic Conjunctivitis,Interventional,23-Nov-10,Vistakon Pharmaceuticals,Device: Placebo Lens
NCT01167140,Cryo-Touch II for the Treatment of Wrinkles,Facial Wrinkles,Interventional,1-Oct-12,"MyoScience, Inc",Device: Cryo-Touch II
NCT00513682,Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI),Cystic Fibrosis|Pancreatic Insufficiency,Interventional,10-Apr-14,Forest Laboratories,Drug: Ultrase® MT20
NCT00156910,A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches,Migraine Disorders,Interventional,7-Dec-10,Allergan,Biological: Botulinum Toxin Type A
NCT00156910,A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches,Migraine Disorders,Interventional,7-Dec-10,Allergan,Other: Placebo (saline)
NCT01060592,LapBand Adjustment to Improve Early Weight Loss,Obesity,Interventional,4-Apr-13,Crospon,Device: EndoFLIP device (FDA Device Listing Number : D091203)
NCT00972777,Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis,Bacterial Conjunctivitis,Interventional,29-Mar-12,Bausch & Lomb Incorporated,Drug: Besifloxacin
NCT00972777,Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis,Bacterial Conjunctivitis,Interventional,29-Mar-12,Bausch & Lomb Incorporated,Drug: Vehicle (Placebo)
NCT00374907,A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,21-Jan-11,AstraZeneca,Drug: Saxagliptin
NCT00374907,A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,21-Jan-11,AstraZeneca,Drug: Placebo
NCT00374907,A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,21-Jan-11,AstraZeneca,Drug: Metformin (blinded)
NCT00374907,A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,21-Jan-11,AstraZeneca,Drug: Metformin (open-label)
NCT00336505,Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP),Pneumonia,Interventional,26-Feb-10,"Advanced Life Sciences, Inc.",Drug: Cethromycin
NCT00336505,Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP),Pneumonia,Interventional,26-Feb-10,"Advanced Life Sciences, Inc.",Drug: Clarithromycin
NCT00691197,Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear,Ametropia,Interventional,10-Dec-09,Allergan,Device: Carboxymethylcellulose sodium and Glycerin
NCT00691197,Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear,Ametropia,Interventional,10-Dec-09,Allergan,Device: Carboxymethylcellulose sodium
NCT00646399,Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis,Staphylococcal Sepsis,Interventional,24-Oct-11,Biosynexus Incorporated,Drug: Placebo
NCT00646399,Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis,Staphylococcal Sepsis,Interventional,24-Oct-11,Biosynexus Incorporated,Drug: Pagibaximab 50 mg/mL
NCT00592904,Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN),Neuralgia,Interventional,8-Feb-13,Eisai Inc.,Drug: E2007
NCT00424398,Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis,"Conjunctivitis, Allergic",Interventional,26-Mar-12,Bausch & Lomb Incorporated,Drug: Bepreve
NCT00424398,Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis,"Conjunctivitis, Allergic",Interventional,26-Mar-12,Bausch & Lomb Incorporated,Drug: Placebo
NCT00424398,Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis,"Conjunctivitis, Allergic",Interventional,26-Mar-12,Bausch & Lomb Incorporated,Drug: Bepotastine Besilate
NCT00125190,Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency,Insulin-Like Growth Factor-1 Deficiency|Growth Disorders,Interventional,15-Apr-10,Ipsen,Drug: rhIGF-1 (mecasermin) for a period of 86 weeks
NCT02250443,"Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis",Sporadic Inclusion Body Myositis (sIBM),Interventional,10-Apr-18,Novartis Pharmaceuticals,Drug: BYM338 (Bimagrumab)
NCT02250443,"Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis",Sporadic Inclusion Body Myositis (sIBM),Interventional,10-Apr-18,Novartis,Drug: BYM338 (Bimagrumab)
NCT01471041,Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae,End Stage Renal Disease|AV Fistula|Kidney Failure,Interventional,3-Jun-16,Vital Access Corp.,Device: Venous Window Needle Guide
NCT00752973,Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice,Pediculosis,Interventional,3-Apr-14,Taro Pharmaceuticals USA,Drug: MALG (malathion) Treatment
NCT00255970,Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects,Periodontal Diseases,Interventional,5-Aug-11,RTI Surgical,Other: DFDBA
NCT00255970,Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects,Periodontal Diseases,Interventional,5-Aug-11,RTI Surgical,Device: Regenafil
NCT02720198,Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD,Major Depressive Disorder,Interventional,2-Jul-19,Duke University,Drug: Levomilnacipran
NCT02720198,Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD,Major Depressive Disorder,Interventional,2-Jul-19,Duke University,Drug: Quetiapine
NCT02720198,Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD,Major Depressive Disorder,Interventional,2-Jul-19,Forest Laboratories,Drug: Levomilnacipran
NCT02720198,Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD,Major Depressive Disorder,Interventional,2-Jul-19,Forest Laboratories,Drug: Quetiapine
NCT02720198,Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD,Major Depressive Disorder,Interventional,2-Jul-19,"Institute for Advanced Medical Research, Alpharetta, GA",Drug: Levomilnacipran
NCT02720198,Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD,Major Depressive Disorder,Interventional,2-Jul-19,"Institute for Advanced Medical Research, Alpharetta, GA",Drug: Quetiapine
NCT03585504,Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents,Contraceptive Usage,Interventional,4-Oct-18,Medical University of South Carolina,Drug: Etonogestrel contraceptive implant
NCT03585504,Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents,Contraceptive Usage,Interventional,4-Oct-18,American College of Obstetricians and Gynecologists,Drug: Etonogestrel contraceptive implant
NCT03585504,Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents,Contraceptive Usage,Interventional,4-Oct-18,Bayer,Drug: Etonogestrel contraceptive implant
NCT01528709,Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial),Saphenous Vein Graft Disease,Interventional,9-Aug-18,Boca Raton Regional Hospital,Drug: Atorvastatin 80 mg daily
NCT01528709,Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial),Saphenous Vein Graft Disease,Interventional,9-Aug-18,Boca Raton Regional Hospital,Drug: Atorvastatin 10 mg daily
NCT01528709,Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial),Saphenous Vein Graft Disease,Interventional,9-Aug-18,Pfizer,Drug: Atorvastatin 80 mg daily
NCT01528709,Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial),Saphenous Vein Graft Disease,Interventional,9-Aug-18,Pfizer,Drug: Atorvastatin 10 mg daily
NCT01511939,Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants,Osteoarthritis of the Knee|Coagulopathy,Interventional,26-Jun-14,"Nathan Wei, MD, FACP, FACR:",Drug: Pennsaid
NCT01511939,Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants,Osteoarthritis of the Knee|Coagulopathy,Interventional,26-Jun-14,Medtronic - MITG,Drug: Pennsaid
NCT01511939,Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants,Osteoarthritis of the Knee|Coagulopathy,Interventional,26-Jun-14,"Arthritis Treatment Center, Maryland",Drug: Pennsaid
NCT02579057,Sub-Q Versus IV Furosemide in Acute Heart Failure,Congestive Heart Failure,Interventional,17-Nov-17,Johns Hopkins University,Drug: Furosemide Injection Solution (SCP-101)
NCT02579057,Sub-Q Versus IV Furosemide in Acute Heart Failure,Congestive Heart Failure,Interventional,17-Nov-17,Johns Hopkins University,"Drug: Furosemide Injection Solution, USP"
NCT02579057,Sub-Q Versus IV Furosemide in Acute Heart Failure,Congestive Heart Failure,Interventional,17-Nov-17,"scPharmaceuticals, Inc.",Drug: Furosemide Injection Solution (SCP-101)
NCT02579057,Sub-Q Versus IV Furosemide in Acute Heart Failure,Congestive Heart Failure,Interventional,17-Nov-17,"scPharmaceuticals, Inc.","Drug: Furosemide Injection Solution, USP"
NCT02185729,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,"Diseases, Metabolic|Insulin Sensitivity",Interventional,31-Dec-14,Emory University,Drug: Intralipid
NCT02185729,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,"Diseases, Metabolic|Insulin Sensitivity",Interventional,31-Dec-14,Emory University,Drug: ClinOleic
NCT02185729,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,"Diseases, Metabolic|Insulin Sensitivity",Interventional,31-Dec-14,Emory University,Drug: Dextrose
NCT02185729,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,"Diseases, Metabolic|Insulin Sensitivity",Interventional,31-Dec-14,Emory University,Other: Saline (control)
NCT02185729,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,"Diseases, Metabolic|Insulin Sensitivity",Interventional,31-Dec-14,Baxter Healthcare Corporation,Drug: Intralipid
NCT02185729,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,"Diseases, Metabolic|Insulin Sensitivity",Interventional,31-Dec-14,Baxter Healthcare Corporation,Drug: ClinOleic
NCT02185729,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,"Diseases, Metabolic|Insulin Sensitivity",Interventional,31-Dec-14,Baxter Healthcare Corporation,Drug: Dextrose
NCT02185729,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,"Diseases, Metabolic|Insulin Sensitivity",Interventional,31-Dec-14,Baxter Healthcare Corporation,Other: Saline (control)
NCT02020031,Regional Prophylactic Vancomycin in Revision Total Knee Replacement,Arthropathy of Knee Joint,Interventional,25-Nov-16,Mayo Clinic,Drug: Vancomycin
NCT02020031,Regional Prophylactic Vancomycin in Revision Total Knee Replacement,Arthropathy of Knee Joint,Interventional,25-Nov-16,Vidacare Corporation,Drug: Vancomycin
NCT01853280,L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults,Attention Deficit Hyperactivity Disorder,Interventional,14-Nov-17,Massachusetts General Hospital,Drug: L-methylfolate
NCT01853280,L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults,Attention Deficit Hyperactivity Disorder,Interventional,14-Nov-17,Massachusetts General Hospital,Drug: OROS-Methylphenidate
NCT01853280,L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults,Attention Deficit Hyperactivity Disorder,Interventional,14-Nov-17,Massachusetts General Hospital,Drug: Placebo
NCT01853280,L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults,Attention Deficit Hyperactivity Disorder,Interventional,14-Nov-17,"Pamlab, Inc.",Drug: L-methylfolate
NCT01853280,L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults,Attention Deficit Hyperactivity Disorder,Interventional,14-Nov-17,"Pamlab, Inc.",Drug: OROS-Methylphenidate
NCT01853280,L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults,Attention Deficit Hyperactivity Disorder,Interventional,14-Nov-17,"Pamlab, Inc.",Drug: Placebo
NCT01790685,Ozurdex for Retinal Vein Occlusion Study (ORVO Study),Retinal Vein Occlusion,Interventional,3-Apr-15,Johns Hopkins University,Drug: dexamethasone implant
NCT01790685,Ozurdex for Retinal Vein Occlusion Study (ORVO Study),Retinal Vein Occlusion,Interventional,3-Apr-15,Allergan,Drug: dexamethasone implant
NCT01741701,A Pilot Study of Oxaloacetate in Subjects With Treated PD,Parkinson's Disease,Interventional,17-Mar-16,University of Kansas Medical Center,Drug: Oxaloacetate (OAA)
NCT01741701,A Pilot Study of Oxaloacetate in Subjects With Treated PD,Parkinson's Disease,Interventional,17-Mar-16,University of Kansas Medical Center,Drug: Placebo
NCT01741701,A Pilot Study of Oxaloacetate in Subjects With Treated PD,Parkinson's Disease,Interventional,17-Mar-16,Terra Biological LLC,Drug: Oxaloacetate (OAA)
NCT01741701,A Pilot Study of Oxaloacetate in Subjects With Treated PD,Parkinson's Disease,Interventional,17-Mar-16,Terra Biological LLC,Drug: Placebo
NCT01469819,Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation,Chronic Idiopathic Constipation,Interventional,1-Aug-16,"Texas Tech University Health Sciences Center, El Paso",Drug: Lubiprostone
NCT01469819,Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation,Chronic Idiopathic Constipation,Interventional,1-Aug-16,"Takeda Pharmaceuticals North America, Inc.",Drug: Lubiprostone
NCT01191788,"Building Recovery By Improving Goals, Habits, and Thoughts",Depression|Substance Use,Interventional,25-Jun-12,RAND,Behavioral: Group Cognitive Behavioral Therapy
NCT01191788,"Building Recovery By Improving Goals, Habits, and Thoughts",Depression|Substance Use,Interventional,25-Jun-12,RAND,Behavioral: Group CBT for Depression
NCT01191788,"Building Recovery By Improving Goals, Habits, and Thoughts",Depression|Substance Use,Interventional,25-Jun-12,"Behavioral Health Services, Inc.",Behavioral: Group Cognitive Behavioral Therapy
NCT01191788,"Building Recovery By Improving Goals, Habits, and Thoughts",Depression|Substance Use,Interventional,25-Jun-12,"Behavioral Health Services, Inc.",Behavioral: Group CBT for Depression
NCT01172145,Treatment of Apathy in Alzheimer's Disease With Modafinil,Apathy|Alzheimer's Disease,Interventional,4-Mar-11,Brown University,Drug: Modafinil
NCT01172145,Treatment of Apathy in Alzheimer's Disease With Modafinil,Apathy|Alzheimer's Disease,Interventional,4-Mar-11,Brown University,Drug: Placebo
NCT01172145,Treatment of Apathy in Alzheimer's Disease With Modafinil,Apathy|Alzheimer's Disease,Interventional,4-Mar-11,National Institute of Mental Health (NIMH),Drug: Modafinil
NCT01172145,Treatment of Apathy in Alzheimer's Disease With Modafinil,Apathy|Alzheimer's Disease,Interventional,4-Mar-11,National Institute of Mental Health (NIMH),Drug: Placebo
NCT01172145,Treatment of Apathy in Alzheimer's Disease With Modafinil,Apathy|Alzheimer's Disease,Interventional,4-Mar-11,Cephalon,Drug: Modafinil
NCT01172145,Treatment of Apathy in Alzheimer's Disease With Modafinil,Apathy|Alzheimer's Disease,Interventional,4-Mar-11,Cephalon,Drug: Placebo
NCT01056640,Telemonitoring Versus Usual Care,Health Care Quality|Health Care Access,Interventional,8-Feb-13,Mayo Clinic,Device: Intel Health Guide
NCT01056640,Telemonitoring Versus Usual Care,Health Care Quality|Health Care Access,Interventional,8-Feb-13,Mayo Clinic,Other: Usual Care
NCT01056640,Telemonitoring Versus Usual Care,Health Care Quality|Health Care Access,Interventional,8-Feb-13,GE Healthcare,Device: Intel Health Guide
NCT01056640,Telemonitoring Versus Usual Care,Health Care Quality|Health Care Access,Interventional,8-Feb-13,GE Healthcare,Other: Usual Care
NCT00989157,Effects of Gastric Bypass on Blood Levels of Duloxetine,Bariatric Surgery,Interventional,11-Aug-14,"Neuropsychiatric Research Institute, Fargo, North Dakota",Drug: Duloxetine
NCT00989157,Effects of Gastric Bypass on Blood Levels of Duloxetine,Bariatric Surgery,Interventional,11-Aug-14,University of North Dakota,Drug: Duloxetine
NCT00989157,Effects of Gastric Bypass on Blood Levels of Duloxetine,Bariatric Surgery,Interventional,11-Aug-14,Eli Lilly and Company,Drug: Duloxetine
NCT00943579,Open-Label Extension Study of Kuvan for Autism,Autistic Disorder,Interventional,4-Jul-13,The Children's Health Council,Drug: Kuvan®
NCT00943579,Open-Label Extension Study of Kuvan for Autism,Autistic Disorder,Interventional,4-Jul-13,BioMarin Pharmaceutical,Drug: Kuvan®
NCT00870727,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Pervasive Developmental Disorder,Interventional,28-Nov-18,Indiana University,Drug: Aripiprazole oral product
NCT00870727,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Pervasive Developmental Disorder,Interventional,28-Nov-18,Indiana University,Drug: Placebo oral capsule
NCT00870727,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Pervasive Developmental Disorder,Interventional,28-Nov-18,National Institute of Mental Health (NIMH),Drug: Aripiprazole oral product
NCT00870727,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Pervasive Developmental Disorder,Interventional,28-Nov-18,National Institute of Mental Health (NIMH),Drug: Placebo oral capsule
NCT00870727,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Pervasive Developmental Disorder,Interventional,28-Nov-18,Bristol-Myers Squibb,Drug: Aripiprazole oral product
NCT00870727,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Pervasive Developmental Disorder,Interventional,28-Nov-18,Bristol-Myers Squibb,Drug: Placebo oral capsule
NCT00853905,Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?,Glaucoma,Interventional,21-Mar-16,Wills Eye,Drug: Triesence
NCT00853905,Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?,Glaucoma,Interventional,21-Mar-16,Wills Eye,Drug: balanced salt solution BSS
NCT00853905,Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?,Glaucoma,Interventional,21-Mar-16,Alcon Research,Drug: Triesence
NCT00853905,Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?,Glaucoma,Interventional,21-Mar-16,Alcon Research,Drug: balanced salt solution BSS
NCT00844519,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections,Interventional,19-Jun-14,"University of California, San Francisco",Drug: Maraviroc
NCT00844519,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections,Interventional,19-Jun-14,"University of California, San Francisco",Drug: placebo
NCT00844519,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections,Interventional,19-Jun-14,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Maraviroc
NCT00844519,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections,Interventional,19-Jun-14,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: placebo
NCT00844519,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections,Interventional,19-Jun-14,Pfizer,Drug: Maraviroc
NCT00844519,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections,Interventional,19-Jun-14,Pfizer,Drug: placebo
NCT00831129,A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs,Pre-diabetes,Interventional,12-Sep-13,University of Chicago,Drug: Rosiglitazone
NCT00831129,A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs,Pre-diabetes,Interventional,12-Sep-13,University of Chicago,Drug: Placebo Rosiglitazone
NCT00831129,A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs,Pre-diabetes,Interventional,12-Sep-13,University of Chicago,Drug: Simvastatin
NCT00831129,A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs,Pre-diabetes,Interventional,12-Sep-13,GlaxoSmithKline,Drug: Rosiglitazone
NCT00831129,A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs,Pre-diabetes,Interventional,12-Sep-13,GlaxoSmithKline,Drug: Placebo Rosiglitazone
NCT00831129,A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs,Pre-diabetes,Interventional,12-Sep-13,GlaxoSmithKline,Drug: Simvastatin
NCT00829296,Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries,Hypertension|Diabetes,Interventional,5-Nov-14,University of Chicago,Drug: nebivolol
NCT00829296,Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries,Hypertension|Diabetes,Interventional,5-Nov-14,University of Chicago,Drug: Metoprolol
NCT00829296,Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries,Hypertension|Diabetes,Interventional,5-Nov-14,Forest Laboratories,Drug: nebivolol
NCT00829296,Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries,Hypertension|Diabetes,Interventional,5-Nov-14,Forest Laboratories,Drug: Metoprolol
NCT00791102,Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC),Allergic Rhinitis,Interventional,10-Jul-13,University of Chicago,Drug: ASP-1001 nasal spray
NCT00791102,Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC),Allergic Rhinitis,Interventional,10-Jul-13,University of Chicago,Drug: Placebo for ASP-1001
NCT00791102,Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC),Allergic Rhinitis,Interventional,10-Jul-13,Asphelia Pharmaceuticals,Drug: ASP-1001 nasal spray
NCT00791102,Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC),Allergic Rhinitis,Interventional,10-Jul-13,Asphelia Pharmaceuticals,Drug: Placebo for ASP-1001
NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,"Myocardial Infarction|Death, Sudden, Cardiac",Interventional,1-Jun-17,Brigham and Women's Hospital,Drug: Omega-3 Fatty Acids (Fish Oil Supplements)
NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,"Myocardial Infarction|Death, Sudden, Cardiac",Interventional,1-Jun-17,Brigham and Women's Hospital,Drug: Placebo
NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,"Myocardial Infarction|Death, Sudden, Cardiac",Interventional,1-Jun-17,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Omega-3 Fatty Acids (Fish Oil Supplements)
NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,"Myocardial Infarction|Death, Sudden, Cardiac",Interventional,1-Jun-17,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Placebo
NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,"Myocardial Infarction|Death, Sudden, Cardiac",Interventional,1-Jun-17,GlaxoSmithKline,Drug: Omega-3 Fatty Acids (Fish Oil Supplements)
NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,"Myocardial Infarction|Death, Sudden, Cardiac",Interventional,1-Jun-17,GlaxoSmithKline,Drug: Placebo
NCT00728481,The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis,Eosinophilic Esophagitis|Gastroesophageal Reflux Disease|EE|GERD,Interventional,6-Dec-12,Mayo Clinic,Drug: Esomeprazole
NCT00728481,The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis,Eosinophilic Esophagitis|Gastroesophageal Reflux Disease|EE|GERD,Interventional,6-Dec-12,Mayo Clinic,Drug: Budesonide
NCT00728481,The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis,Eosinophilic Esophagitis|Gastroesophageal Reflux Disease|EE|GERD,Interventional,6-Dec-12,AstraZeneca,Drug: Esomeprazole
NCT00728481,The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis,Eosinophilic Esophagitis|Gastroesophageal Reflux Disease|EE|GERD,Interventional,6-Dec-12,AstraZeneca,Drug: Budesonide
NCT00671853,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Interventional,11-Oct-13,University Hospitals Cleveland Medical Center,Drug: Quetiapine XR
NCT00671853,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Interventional,11-Oct-13,University Hospitals Cleveland Medical Center,Drug: Placebo for quetiapine XR
NCT00671853,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Interventional,11-Oct-13,National Alliance for Research on Schizophrenia and Depression,Drug: Quetiapine XR
NCT00671853,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Interventional,11-Oct-13,National Alliance for Research on Schizophrenia and Depression,Drug: Placebo for quetiapine XR
NCT00671853,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Interventional,11-Oct-13,AstraZeneca,Drug: Quetiapine XR
NCT00671853,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Interventional,11-Oct-13,AstraZeneca,Drug: Placebo for quetiapine XR
NCT00658736,Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis,Chronic Pancreatitis,Interventional,14-Jun-17,The Cleveland Clinic,Drug: Triamcinolone
NCT00658736,Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis,Chronic Pancreatitis,Interventional,14-Jun-17,The Cleveland Clinic,Drug: Bupivicaine alone
NCT00658736,Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis,Chronic Pancreatitis,Interventional,14-Jun-17,American Society for Gastrointestinal Endoscopy,Drug: Triamcinolone
NCT00658736,Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis,Chronic Pancreatitis,Interventional,14-Jun-17,American Society for Gastrointestinal Endoscopy,Drug: Bupivicaine alone
NCT00658736,Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis,Chronic Pancreatitis,Interventional,14-Jun-17,TAP Pharmaceutical Products Inc.,Drug: Triamcinolone
NCT00658736,Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis,Chronic Pancreatitis,Interventional,14-Jun-17,TAP Pharmaceutical Products Inc.,Drug: Bupivicaine alone
NCT00539305,Hormone and Information Processing Study,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,14-Jul-14,University of Washington,Drug: testosterone gel
NCT00539305,Hormone and Information Processing Study,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,14-Jul-14,University of Washington,Drug: placebo gel
NCT00539305,Hormone and Information Processing Study,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,14-Jul-14,National Institute on Aging (NIA),Drug: testosterone gel
NCT00539305,Hormone and Information Processing Study,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,14-Jul-14,National Institute on Aging (NIA),Drug: placebo gel
NCT00539305,Hormone and Information Processing Study,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,14-Jul-14,Solvay Pharmaceuticals,Drug: testosterone gel
NCT00539305,Hormone and Information Processing Study,Mild Cognitive Impairment|Alzheimer's Disease,Interventional,14-Jul-14,Solvay Pharmaceuticals,Drug: placebo gel
NCT00531843,The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients,Venous Thromboembolism,Interventional,24-Dec-13,"Mary Knudson, M.D.",Drug: fondaparinux sodium
NCT00531843,The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients,Venous Thromboembolism,Interventional,24-Dec-13,"Mary Knudson, M.D.",Device: sequential compression devices
NCT00531843,The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients,Venous Thromboembolism,Interventional,24-Dec-13,GlaxoSmithKline,Drug: fondaparinux sodium
NCT00531843,The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients,Venous Thromboembolism,Interventional,24-Dec-13,GlaxoSmithKline,Device: sequential compression devices
NCT00531843,The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients,Venous Thromboembolism,Interventional,24-Dec-13,"University of California, San Francisco",Drug: fondaparinux sodium
NCT00531843,The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients,Venous Thromboembolism,Interventional,24-Dec-13,"University of California, San Francisco",Device: sequential compression devices
NCT00457730,A Study to Test the Use of Duloxetine for Pain in MS,Multiple Sclerosis,Interventional,6-Apr-15,"Brown, Theodore R., M.D., MPH",Drug: Duloxetine
NCT00457730,A Study to Test the Use of Duloxetine for Pain in MS,Multiple Sclerosis,Interventional,6-Apr-15,"Brown, Theodore R., M.D., MPH",Drug: Placebo
NCT00457730,A Study to Test the Use of Duloxetine for Pain in MS,Multiple Sclerosis,Interventional,6-Apr-15,Eli Lilly and Company,Drug: Duloxetine
NCT00457730,A Study to Test the Use of Duloxetine for Pain in MS,Multiple Sclerosis,Interventional,6-Apr-15,Eli Lilly and Company,Drug: Placebo
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,University of Kansas Medical Center,Behavioral: High intensity disease management
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,University of Kansas Medical Center,Behavioral: Low intensity disease management
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,University of Kansas Medical Center,Behavioral: Comparison group
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,University of Kansas Medical Center,Drug: Bupropion
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,National Cancer Institute (NCI),Behavioral: High intensity disease management
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,National Cancer Institute (NCI),Behavioral: Low intensity disease management
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,National Cancer Institute (NCI),Behavioral: Comparison group
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,National Cancer Institute (NCI),Drug: Bupropion
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,GlaxoSmithKline,Behavioral: High intensity disease management
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,GlaxoSmithKline,Behavioral: Low intensity disease management
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,GlaxoSmithKline,Behavioral: Comparison group
NCT00440115,Disease Management for Smoking Cessation,Smoking Cessation,Interventional,7-Jun-17,GlaxoSmithKline,Drug: Bupropion
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,"Hospital for Special Surgery, New York",Drug: Synvisc (Hylan G-F20; hyaluronan injection)
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,"Hospital for Special Surgery, New York",Drug: Bupivicaine (local anesthesia injection)
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,"Hospital for Special Surgery, New York",Drug: Kenalog (triamcinolone; corticosteroid injection)
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Drug: Synvisc (Hylan G-F20; hyaluronan injection)
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Drug: Bupivicaine (local anesthesia injection)
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Drug: Kenalog (triamcinolone; corticosteroid injection)
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,"Genzyme, a Sanofi Company",Drug: Synvisc (Hylan G-F20; hyaluronan injection)
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,"Genzyme, a Sanofi Company",Drug: Bupivicaine (local anesthesia injection)
NCT00398866,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Osteoarthritis,Interventional,7-Jul-17,"Genzyme, a Sanofi Company",Drug: Kenalog (triamcinolone; corticosteroid injection)
NCT00398983,Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML),Acute Myelogenous Leukemia,Interventional,4-Mar-13,M.D. Anderson Cancer Center,Drug: Decitabine
NCT00398983,Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML),Acute Myelogenous Leukemia,Interventional,4-Mar-13,Eisai Inc.,Drug: Decitabine
NCT00384449,Lucentis (Ranibizumab) for Eales' Disease,Eales' Disease,Interventional,11-Jun-19,Oregon Health and Science University,Drug: Ranibizumab
NCT00384449,Lucentis (Ranibizumab) for Eales' Disease,Eales' Disease,Interventional,11-Jun-19,"Genentech, Inc.",Drug: Ranibizumab
NCT00375973,Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome,"Fatigue Syndrome, Chronic",Interventional,27-Jul-15,University of Cincinnati,Drug: Duloxetine
NCT00375973,Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome,"Fatigue Syndrome, Chronic",Interventional,27-Jul-15,University of Cincinnati,Drug: Placebo
NCT00375973,Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome,"Fatigue Syndrome, Chronic",Interventional,27-Jul-15,Eli Lilly and Company,Drug: Duloxetine
NCT00375973,Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome,"Fatigue Syndrome, Chronic",Interventional,27-Jul-15,Eli Lilly and Company,Drug: Placebo
NCT00297830,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Heart Transplantation|Liver Transplantation|Bone Resorption,Interventional,15-Sep-16,Columbia University,Drug: Zoledronic acid
NCT00297830,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Heart Transplantation|Liver Transplantation|Bone Resorption,Interventional,15-Sep-16,Columbia University,Drug: Alendronate
NCT00297830,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Heart Transplantation|Liver Transplantation|Bone Resorption,Interventional,15-Sep-16,Columbia University,Other: Placebo Zoledronic Acid
NCT00297830,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Heart Transplantation|Liver Transplantation|Bone Resorption,Interventional,15-Sep-16,Columbia University,Other: Placebo Alendronate
NCT00297830,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Heart Transplantation|Liver Transplantation|Bone Resorption,Interventional,15-Sep-16,Novartis Pharmaceuticals,Drug: Zoledronic acid
NCT00297830,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Heart Transplantation|Liver Transplantation|Bone Resorption,Interventional,15-Sep-16,Novartis Pharmaceuticals,Drug: Alendronate
NCT00297830,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Heart Transplantation|Liver Transplantation|Bone Resorption,Interventional,15-Sep-16,Novartis Pharmaceuticals,Other: Placebo Zoledronic Acid
NCT00297830,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Heart Transplantation|Liver Transplantation|Bone Resorption,Interventional,15-Sep-16,Novartis Pharmaceuticals,Other: Placebo Alendronate
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Alzheimer Disease,Interventional,7-Apr-17,Stanford University,Drug: Memantine
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Alzheimer Disease,Interventional,7-Apr-17,Stanford University,Drug: Placebo pill
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Alzheimer Disease,Interventional,7-Apr-17,Palo Alto Veterans Institute for Research,Drug: Memantine
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Alzheimer Disease,Interventional,7-Apr-17,Palo Alto Veterans Institute for Research,Drug: Placebo pill
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Alzheimer Disease,Interventional,7-Apr-17,Forest Laboratories,Drug: Memantine
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Alzheimer Disease,Interventional,7-Apr-17,Forest Laboratories,Drug: Placebo pill
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,University Hospitals Cleveland Medical Center,Drug: Lithium
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,University Hospitals Cleveland Medical Center,Drug: Divalproex
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,University Hospitals Cleveland Medical Center,Drug: Placebo
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,National Institute of Mental Health (NIMH),Drug: Lithium
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,National Institute of Mental Health (NIMH),Drug: Divalproex
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,National Institute of Mental Health (NIMH),Drug: Placebo
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,Abbott,Drug: Lithium
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,Abbott,Drug: Divalproex
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Bipolar Disorder,Interventional,23-Dec-13,Abbott,Drug: Placebo
NCT00189202,"Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans",End Stage Renal Disease|Kidney Transplantation,Interventional,5-Apr-17,University of Michigan,Drug: Sirolimus
NCT00189202,"Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans",End Stage Renal Disease|Kidney Transplantation,Interventional,5-Apr-17,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Sirolimus
NCT01217827,Implantable Cardioverter-Defibrillator Use in the VA System,Cardiomyopathies,Interventional,7-Dec-16,Stanford University,Behavioral: Clinical Reminder
NCT01217827,Implantable Cardioverter-Defibrillator Use in the VA System,Cardiomyopathies,Interventional,7-Dec-16,Medtronic,Behavioral: Clinical Reminder
NCT01217827,Implantable Cardioverter-Defibrillator Use in the VA System,Cardiomyopathies,Interventional,7-Dec-16,VA Palo Alto Health Care System,Behavioral: Clinical Reminder
NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Opiate Dependence,Interventional,7-Apr-16,NYU Langone Health,Drug: Extended-Release Naltrexone
NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Opiate Dependence,Interventional,7-Apr-16,NYU Langone Health,Behavioral: Motivational Enhancement Counseling
NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Opiate Dependence,Interventional,7-Apr-16,"Alkermes, Inc.",Drug: Extended-Release Naltrexone
NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Opiate Dependence,Interventional,7-Apr-16,"Alkermes, Inc.",Behavioral: Motivational Enhancement Counseling
NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Opiate Dependence,Interventional,7-Apr-16,New York City Department of Health and Mental Hygiene,Drug: Extended-Release Naltrexone
NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Opiate Dependence,Interventional,7-Apr-16,New York City Department of Health and Mental Hygiene,Behavioral: Motivational Enhancement Counseling
NCT00578565,Rituximab in Rheumatoid Arthritis Lung Disease,Rheumatoid Arthritis|Interstitial Pneumonia,Interventional,25-Sep-12,Eric Matteson,Drug: Rituximab
NCT00578565,Rituximab in Rheumatoid Arthritis Lung Disease,Rheumatoid Arthritis|Interstitial Pneumonia,Interventional,25-Sep-12,"Genentech, Inc.",Drug: Rituximab
NCT00578565,Rituximab in Rheumatoid Arthritis Lung Disease,Rheumatoid Arthritis|Interstitial Pneumonia,Interventional,25-Sep-12,National Center for Research Resources (NCRR),Drug: Rituximab
NCT00578565,Rituximab in Rheumatoid Arthritis Lung Disease,Rheumatoid Arthritis|Interstitial Pneumonia,Interventional,25-Sep-12,Mayo Clinic,Drug: Rituximab
NCT00887653,Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy,HIV|Hyperlipidemia|Hypertriglyceridemia|HIV Infections,Interventional,10-Oct-14,The Miriam Hospital,Drug: raltegravir
NCT00887653,Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy,HIV|Hyperlipidemia|Hypertriglyceridemia|HIV Infections,Interventional,10-Oct-14,Tufts Medical Center,Drug: raltegravir
NCT00887653,Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy,HIV|Hyperlipidemia|Hypertriglyceridemia|HIV Infections,Interventional,10-Oct-14,Merck Sharp & Dohme Corp.,Drug: raltegravir
NCT00823901,Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea,Rosacea,Interventional,15-Jun-12,Massachusetts General Hospital,Drug: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel
NCT00823901,Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea,Rosacea,Interventional,15-Jun-12,Massachusetts General Hospital,Drug: Placebo gel
NCT00823901,Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea,Rosacea,Interventional,15-Jun-12,Medicis Pharmaceutical Corporation,Drug: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel
NCT00823901,Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea,Rosacea,Interventional,15-Jun-12,Medicis Pharmaceutical Corporation,Drug: Placebo gel
NCT00722124,S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence,Tobacco Dependence,Interventional,9-Sep-11,Mayo Clinic,Drug: S-Adenosyl-L-Methionine
NCT00722124,S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence,Tobacco Dependence,Interventional,9-Sep-11,Mayo Clinic,Other: placebo
NCT00722124,S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence,Tobacco Dependence,Interventional,9-Sep-11,Pharmavite,Drug: S-Adenosyl-L-Methionine
NCT00722124,S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence,Tobacco Dependence,Interventional,9-Sep-11,Pharmavite,Other: placebo
NCT00697463,Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women,Menopause|Fracture|Osteoporosis,Interventional,26-Jul-18,Columbia University,Drug: Teriparatide (PTH 1-34)
NCT00697463,Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women,Menopause|Fracture|Osteoporosis,Interventional,26-Jul-18,Eli Lilly and Company,Drug: Teriparatide (PTH 1-34)
NCT00672854,Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN,Parenteral Nutrition,Interventional,1-Aug-14,Emory University,Drug: ClinOleic 20% Intravenous Emulsion
NCT00672854,Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN,Parenteral Nutrition,Interventional,1-Aug-14,Emory University,"Drug: Intralipid, 20% Intravenous Emulsion"
NCT00672854,Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN,Parenteral Nutrition,Interventional,1-Aug-14,Baxter Healthcare Corporation,Drug: ClinOleic 20% Intravenous Emulsion
NCT00672854,Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN,Parenteral Nutrition,Interventional,1-Aug-14,Baxter Healthcare Corporation,"Drug: Intralipid, 20% Intravenous Emulsion"
NCT00266864,Testosterone Replacement Therapy in Chronic Spinal Cord Injury,Spinal Cord Injury|Hypogonadism,Interventional,7-Apr-14,VA Office of Research and Development,Drug: Testosterone Transdermal System (Androderm 5 mg patch)
NCT00266864,Testosterone Replacement Therapy in Chronic Spinal Cord Injury,Spinal Cord Injury|Hypogonadism,Interventional,7-Apr-14,Kessler Institute for Rehabilitation,Drug: Testosterone Transdermal System (Androderm 5 mg patch)
NCT00912925,Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I,Mucopolysaccharidosis I|Hurlers Syndrome|Hurler-Scheie Syndrome,Interventional,19-Aug-09,"Genzyme, a Sanofi Company",Biological: rhIDU (recombinant human-Alpha-L-Iduronidase)
NCT00912925,Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I,Mucopolysaccharidosis I|Hurlers Syndrome|Hurler-Scheie Syndrome,Interventional,19-Aug-09,"Genzyme, a Sanofi Company",Biological: Placebo
NCT00912925,Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I,Mucopolysaccharidosis I|Hurlers Syndrome|Hurler-Scheie Syndrome,Interventional,19-Aug-09,BioMarin/Genzyme LLC,Biological: rhIDU (recombinant human-Alpha-L-Iduronidase)
NCT00912925,Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I,Mucopolysaccharidosis I|Hurlers Syndrome|Hurler-Scheie Syndrome,Interventional,19-Aug-09,BioMarin/Genzyme LLC,Biological: Placebo
NCT00912925,Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I,Mucopolysaccharidosis I|Hurlers Syndrome|Hurler-Scheie Syndrome,Interventional,19-Aug-09,Sanofi,Biological: rhIDU (recombinant human-Alpha-L-Iduronidase)
NCT00912925,Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I,Mucopolysaccharidosis I|Hurlers Syndrome|Hurler-Scheie Syndrome,Interventional,19-Aug-09,Sanofi,Biological: Placebo
NCT01234870,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,"Heart Disease, Ischemic|Atherosclerosis, Coronary",Interventional,26-Sep-14,Northwestern University,Drug: Gadolinium
NCT01234870,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,"Heart Disease, Ischemic|Atherosclerosis, Coronary",Interventional,26-Sep-14,Northwestern University,Drug: Adenosine
NCT01234870,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,"Heart Disease, Ischemic|Atherosclerosis, Coronary",Interventional,26-Sep-14,"Astellas Pharma US, Inc.",Drug: Gadolinium
NCT01234870,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,"Heart Disease, Ischemic|Atherosclerosis, Coronary",Interventional,26-Sep-14,"Astellas Pharma US, Inc.",Drug: Adenosine
NCT01234870,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,"Heart Disease, Ischemic|Atherosclerosis, Coronary",Interventional,26-Sep-14,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Drug: Gadolinium
NCT01234870,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,"Heart Disease, Ischemic|Atherosclerosis, Coronary",Interventional,26-Sep-14,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Drug: Adenosine
NCT00774202,"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",Immune Thrombocytopenic Purpura,Interventional,14-Nov-18,Weill Medical College of Cornell University,"Drug: Rituxan, Cyclophosphamide, Vincristine, Prednisone"
NCT00774202,"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",Immune Thrombocytopenic Purpura,Interventional,14-Nov-18,Weill Medical College of Cornell University,Drug: Higher Dose of Rituximab
NCT00774202,"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",Immune Thrombocytopenic Purpura,Interventional,14-Nov-18,Biogen,"Drug: Rituxan, Cyclophosphamide, Vincristine, Prednisone"
NCT00774202,"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",Immune Thrombocytopenic Purpura,Interventional,14-Nov-18,Biogen,Drug: Higher Dose of Rituximab
NCT00774202,"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",Immune Thrombocytopenic Purpura,Interventional,14-Nov-18,"Genentech, Inc.","Drug: Rituxan, Cyclophosphamide, Vincristine, Prednisone"
NCT00774202,"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",Immune Thrombocytopenic Purpura,Interventional,14-Nov-18,"Genentech, Inc.",Drug: Higher Dose of Rituximab
NCT00626782,Lucentis Versus Mitomycin C During Glaucoma Surgery,Glaucoma,Interventional,13-Mar-15,Wills Eye,Drug: Ranibizumab
NCT00626782,Lucentis Versus Mitomycin C During Glaucoma Surgery,Glaucoma,Interventional,13-Mar-15,Wills Eye,Drug: Mitomycin (MMC)
NCT00626782,Lucentis Versus Mitomycin C During Glaucoma Surgery,Glaucoma,Interventional,13-Mar-15,"Genentech, Inc.",Drug: Ranibizumab
NCT00626782,Lucentis Versus Mitomycin C During Glaucoma Surgery,Glaucoma,Interventional,13-Mar-15,"Genentech, Inc.",Drug: Mitomycin (MMC)
NCT00626782,Lucentis Versus Mitomycin C During Glaucoma Surgery,Glaucoma,Interventional,13-Mar-15,Novartis Pharmaceuticals,Drug: Ranibizumab
NCT00626782,Lucentis Versus Mitomycin C During Glaucoma Surgery,Glaucoma,Interventional,13-Mar-15,Novartis Pharmaceuticals,Drug: Mitomycin (MMC)
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,"Hebrew Rehabilitation Center, Boston",Drug: alendronate with cholecalciferol
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,"Hebrew Rehabilitation Center, Boston",Drug: calcium carbonate with cholecalciferol
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,"Hebrew Rehabilitation Center, Boston",Behavioral: Falls prevention measures
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,National Institute on Aging (NIA),Drug: alendronate with cholecalciferol
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,National Institute on Aging (NIA),Drug: calcium carbonate with cholecalciferol
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,National Institute on Aging (NIA),Behavioral: Falls prevention measures
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,Merck Sharp & Dohme Corp.,Drug: alendronate with cholecalciferol
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,Merck Sharp & Dohme Corp.,Drug: calcium carbonate with cholecalciferol
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,Merck Sharp & Dohme Corp.,Behavioral: Falls prevention measures
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,GlaxoSmithKline,Drug: alendronate with cholecalciferol
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,GlaxoSmithKline,Drug: calcium carbonate with cholecalciferol
NCT00421343,Secondary Prevention of Osteoporosis,Osteoporosis,Interventional,10-Jun-11,GlaxoSmithKline,Behavioral: Falls prevention measures
NCT02797080,Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia,Friedreich's Ataxia,Interventional,1-May-18,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: interferon γ-1b
NCT02797080,Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia,Friedreich's Ataxia,Interventional,1-May-18,Friedreich's Ataxia Research Alliance,Drug: interferon γ-1b
NCT02698566,A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS),Macular Edema,Interventional,26-Jul-17,"Genentech, Inc.",Drug: Ranibizumab
NCT02678286,Evaluation of N1539 Following Abdominoplasty Surgery,"Pain, Post-operative",Interventional,14-Feb-18,"Recro Pharma, Inc.",Drug: N1539
NCT02678286,Evaluation of N1539 Following Abdominoplasty Surgery,"Pain, Post-operative",Interventional,14-Feb-18,"Recro Pharma, Inc.",Drug: Intravenous Placebo
NCT02675907,Evaluation of N1539 Following Bunionectomy Surgery,"Pain, Post-operative",Interventional,29-Sep-17,"Recro Pharma, Inc.",Drug: N1539
NCT02675907,Evaluation of N1539 Following Bunionectomy Surgery,"Pain, Post-operative",Interventional,29-Sep-17,"Recro Pharma, Inc.",Drug: Intravenous Placebo
NCT02634788,Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain,Pain,Interventional,14-Aug-17,INSYS Therapeutics Inc,Drug: Buprenorphine
NCT02634788,Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain,Pain,Interventional,14-Aug-17,INSYS Therapeutics Inc,Drug: Placebo
NCT02593773,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study",Friedreich's Ataxia,Interventional,18-May-18,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: Interferon γ-1b
NCT02593773,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study",Friedreich's Ataxia,Interventional,18-May-18,Friedreich's Ataxia Research Alliance,Drug: Interferon γ-1b
NCT02415127,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia",Friedreich's Ataxia,Interventional,8-Dec-17,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: Interferon γ-1b
NCT02415127,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia",Friedreich's Ataxia,Interventional,8-Dec-17,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: Placebo
NCT02415127,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia",Friedreich's Ataxia,Interventional,8-Dec-17,Friedreich's Ataxia Research Alliance,Drug: Interferon γ-1b
NCT02415127,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia",Friedreich's Ataxia,Interventional,8-Dec-17,Friedreich's Ataxia Research Alliance,Drug: Placebo
NCT02356588,A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery,Post-Operative Pain,Interventional,13-Feb-17,"AcelRx Pharmaceuticals, Inc.",Drug: Sufentanil Tablet 30 mcg
NCT02356588,A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery,Post-Operative Pain,Interventional,13-Feb-17,"AcelRx Pharmaceuticals, Inc.",Drug: Placebo Tablet
NCT02230566,A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7),MPS 7|Sly Syndrome|Mucopolysaccharidosis|MPS VII,Interventional,16-Feb-18,Ultragenyx Pharmaceutical Inc,Drug: UX003
NCT02230566,A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7),MPS 7|Sly Syndrome|Mucopolysaccharidosis|MPS VII,Interventional,16-Feb-18,Ultragenyx Pharmaceutical Inc,Other: Placebo
NCT01835548,NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,17-Jan-18,"Neos Therapeutics, Inc",Drug: NT0102
NCT01835548,NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,17-Jan-18,"Neos Therapeutics, Inc",Drug: Placebo
NCT01659853,Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea,Erythema|Rosacea,Interventional,10-Jul-14,"Galderma Laboratories, L.P.",Drug: CD07805/47 gel 0.5%/CD07805/47 Vehicle
NCT01659853,Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea,Erythema|Rosacea,Interventional,10-Jul-14,"Galderma Laboratories, L.P.",Drug: azelaic acid gel 15%
NCT01626118,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,17-Mar-14,"Iroko Pharmaceuticals, LLC",Drug: Indomethacin
NCT01626118,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,17-Mar-14,"Iroko Pharmaceuticals, LLC",Drug: Placebo
NCT01202747,Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction,Chalazion|Dry Eye Syndromes,Interventional,6-Dec-11,"TearScience, Inc.",Device: LipiFlow System
NCT01543685,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,19-Dec-13,"Iroko Pharmaceuticals, LLC",Drug: Indomethacin
NCT01543685,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,19-Dec-13,"Iroko Pharmaceuticals, LLC",Drug: Celecoxib
NCT01543685,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,19-Dec-13,"Iroko Pharmaceuticals, LLC",Drug: Placebo
NCT01491607,Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults,Anthrax,Interventional,28-Nov-13,Emergent BioSolutions,Biological: BioThrax
NCT01491607,Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults,Anthrax,Interventional,28-Nov-13,Department of Health and Human Services,Biological: BioThrax
NCT01462435,Study of Diclofenac Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,19-Dec-13,"Iroko Pharmaceuticals, LLC",Drug: Diclofenac Test (lower dose)
NCT01462435,Study of Diclofenac Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,19-Dec-13,"Iroko Pharmaceuticals, LLC",Drug: Diclofenac Test (upper dose)
NCT01462435,Study of Diclofenac Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,19-Dec-13,"Iroko Pharmaceuticals, LLC",Drug: Celecoxib
NCT01462435,Study of Diclofenac Capsules to Treat Pain Following Bunionectomy,Other Acute Postoperative Pain,Interventional,19-Dec-13,"Iroko Pharmaceuticals, LLC",Drug: Placebo
NCT01210716,Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device,Autoimmune Diseases|Renal Disorders|Hematologic Disorders|Oncologic Disorders,Interventional,23-Sep-13,"Fenwal, Inc.",Device: Therapeutic plasma exchange
NCT01087528,Evaluation of PillCam™ Colon 2 in Visualization of the Colon,Colonic Diseases|Bowel Diseases,Interventional,8-Jun-12,Given Imaging Ltd.,Device: PillCam™ (Capsule Endoscopy) Colon 2 capsule
NCT01024608,Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis|Hay Fever,Interventional,23-May-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate
NCT01024608,Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis|Hay Fever,Interventional,23-May-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo Nasal Aerosol
NCT01024608,Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis|Hay Fever,Interventional,23-May-12,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate
NCT01024608,Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis|Hay Fever,Interventional,23-May-12,Teva Pharmaceutical Industries,Drug: Placebo Nasal Aerosol
NCT00984815,Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment,Osteoarthritis|Rheumatoid Arthritis|Chronic Low Back Pain|Chronic Regional Pain Syndrome|Chronic Soft Tissue Pain,Interventional,25-Jul-13,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: HZT-501
NCT00839306,Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,16-Nov-15,Eisai Inc.,Drug: Rabeprazole ER
NCT00839306,Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,16-Nov-15,Eisai Inc.,Drug: Ranitidine
NCT00838526,Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,23-Jun-15,Eisai Inc.,Drug: Rabeprazole ER
NCT00838526,Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,23-Jun-15,Eisai Inc.,Drug: Ranitidine
NCT00821873,Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.,Knee Injury,Interventional,6-Nov-13,RTI Surgical,Other: CR Plug
NCT00790023,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis,Seasonal Allergic Rhinitis,Interventional,8-Jun-12,Sunovion,Drug: 80 mcg Ciclesonide
NCT00790023,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis,Seasonal Allergic Rhinitis,Interventional,8-Jun-12,Sunovion,Drug: 160 mcg Ciclesonide
NCT00790023,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis,Seasonal Allergic Rhinitis,Interventional,8-Jun-12,Sunovion,Drug: Placebo
NCT00758498,Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder,Excessive Sleepiness,Interventional,8-Jul-10,Cephalon,Drug: armodafinil
NCT00758498,Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder,Excessive Sleepiness,Interventional,8-Jul-10,Cephalon,Drug: placebo
NCT00758498,Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder,Excessive Sleepiness,Interventional,8-Jul-10,Teva Pharmaceutical Industries,Drug: armodafinil
NCT00758498,Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder,Excessive Sleepiness,Interventional,8-Jul-10,Teva Pharmaceutical Industries,Drug: placebo
NCT00719680,Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID),Primary Immune Deficiency,Interventional,25-Jan-13,CSL Behring,Biological: IgPro20
NCT00675103,Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients,Chronic Gout Refractory to Conventional Therapy,Interventional,28-Jun-11,Savient Pharmaceuticals,Drug: pegloticase 8 mg i.v.
NCT00662532,Antibiotic Study for Dental Implants,Periodontitis,Interventional,27-May-10,OraPharma,Drug: Minocycline HCl
NCT00591591,Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers,Obstructive Sleep Apnea Syndrome,Interventional,11-Mar-11,"ISS, Inc.",Device: OxiplexTS
NCT00591591,Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers,Obstructive Sleep Apnea Syndrome,Interventional,11-Mar-11,National Institute of Neurological Disorders and Stroke (NINDS),Device: OxiplexTS
NCT00591591,Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers,Obstructive Sleep Apnea Syndrome,Interventional,11-Mar-11,Carle Foundation Hospital,Device: OxiplexTS
NCT00591591,Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers,Obstructive Sleep Apnea Syndrome,Interventional,11-Mar-11,University of Illinois at Chicago,Device: OxiplexTS
NCT00591591,Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers,Obstructive Sleep Apnea Syndrome,Interventional,11-Mar-11,"University of California, Irvine",Device: OxiplexTS
NCT00587834,Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration,Gingival Recession,Interventional,8-Nov-12,Organogenesis,Device: Gintuit
NCT00587834,Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration,Gingival Recession,Interventional,8-Nov-12,Organogenesis,Other: Autologous palatal tissue
NCT00544882,A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021,Healthy,Interventional,10-Jun-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: DR-1021
NCT00544882,A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021,Healthy,Interventional,10-Jun-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Mircette®
NCT00544882,A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021,Healthy,Interventional,10-Jun-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Kariva®
NCT00544882,A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021,Healthy,Interventional,10-Jun-14,Teva Pharmaceutical Industries,Drug: DR-1021
NCT00544882,A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021,Healthy,Interventional,10-Jun-14,Teva Pharmaceutical Industries,Drug: Mircette®
NCT00544882,A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021,Healthy,Interventional,10-Jun-14,Teva Pharmaceutical Industries,Drug: Kariva®
NCT00408876,Duloxetine Versus Placebo in Chronic Low Back Pain,Back Pain Without Radiation,Interventional,29-Dec-09,Eli Lilly and Company,Drug: Duloxetine
NCT00408876,Duloxetine Versus Placebo in Chronic Low Back Pain,Back Pain Without Radiation,Interventional,29-Dec-09,Eli Lilly and Company,Drug: Placebo
NCT00408317,Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI),Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Interventional,12-Mar-14,Forest Laboratories,Drug: Ultrase® MT20
NCT00408317,Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI),Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Interventional,12-Mar-14,Forest Laboratories,Drug: Placebo
NCT00375934,Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery,"Pain, Postoperative",Interventional,22-Jun-10,Xanodyne Pharmaceuticals,Drug: diclofenac potassium (XP21L)
NCT00375934,Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery,"Pain, Postoperative",Interventional,22-Jun-10,Xanodyne Pharmaceuticals,Drug: Placebo
NCT01751165,Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older,Herpes Zoster,Interventional,31-Mar-17,GlaxoSmithKline,Biological: Herpes zoster vaccine GSK1437173A
NCT03014674,A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug,Asthma,Interventional,14-Aug-18,GlaxoSmithKline,Biological: Lyophilized mepolizumab
NCT03014674,A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug,Asthma,Interventional,14-Aug-18,GlaxoSmithKline,Biological: Liquid mepolizumab
NCT03014674,A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug,Asthma,Interventional,14-Aug-18,GlaxoSmithKline,Device: Prefilled autoinjector
NCT03014674,A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug,Asthma,Interventional,14-Aug-18,GlaxoSmithKline,Device: Prefilled Safety Syringe
NCT02132637,A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Apr-18,Eli Lilly and Company,Drug: Insulin Peglispro
NCT02132637,A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Apr-18,Eli Lilly and Company,Drug: Insulin Glargine
NCT00667992,Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma,Asthma,Interventional,7-Nov-12,AstraZeneca,Drug: Budesonide HFA
NCT00667992,Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma,Asthma,Interventional,7-Nov-12,AstraZeneca,Drug: Budesonide CFC
NCT00268983,Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma,"Lymphoma, Non-Hodgkin",Interventional,2-Aug-10,GlaxoSmithKline,Biological: Tositumomab and Iodine I 131 Tositumomab
NCT00268983,Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma,"Lymphoma, Non-Hodgkin",Interventional,2-Aug-10,GlaxoSmithKline,Biological: Rituximab
NCT00130208,Effect of Sulodexide in Early Diabetic Nephropathy,Diabetic Nephropathy,Interventional,23-Mar-18,Keryx Biopharmaceuticals,Drug: Sulodexide
NCT00130208,Effect of Sulodexide in Early Diabetic Nephropathy,Diabetic Nephropathy,Interventional,23-Mar-18,Keryx Biopharmaceuticals,Drug: Placebo
NCT00130208,Effect of Sulodexide in Early Diabetic Nephropathy,Diabetic Nephropathy,Interventional,23-Mar-18,Collaborative Study Group (CSG),Drug: Sulodexide
NCT00130208,Effect of Sulodexide in Early Diabetic Nephropathy,Diabetic Nephropathy,Interventional,23-Mar-18,Collaborative Study Group (CSG),Drug: Placebo
NCT03108482,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Acute Post-surgical Pain,Interventional,9-Jan-19,"Laboratorios del Dr. Esteve, S.A.",Drug: Co-crystal E-58425 (Tramadol/Celecoxib)
NCT03108482,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Acute Post-surgical Pain,Interventional,9-Jan-19,"Laboratorios del Dr. Esteve, S.A.",Drug: Tramadol (Ultram®)
NCT03108482,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Acute Post-surgical Pain,Interventional,9-Jan-19,"Laboratorios del Dr. Esteve, S.A.",Drug: Celecoxib (Celebrex®)
NCT03108482,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Acute Post-surgical Pain,Interventional,9-Jan-19,"Laboratorios del Dr. Esteve, S.A.",Drug: Placebo
NCT03108482,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Acute Post-surgical Pain,Interventional,9-Jan-19,Premier Research Group plc,Drug: Co-crystal E-58425 (Tramadol/Celecoxib)
NCT03108482,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Acute Post-surgical Pain,Interventional,9-Jan-19,Premier Research Group plc,Drug: Tramadol (Ultram®)
NCT03108482,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Acute Post-surgical Pain,Interventional,9-Jan-19,Premier Research Group plc,Drug: Celecoxib (Celebrex®)
NCT03108482,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Acute Post-surgical Pain,Interventional,9-Jan-19,Premier Research Group plc,Drug: Placebo
NCT02282930,Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression,Progressive IgA Nephropathy|Proteinuria,Interventional,26-Jun-19,Mayo Clinic,Drug: ACTH (Acthar) Gel
NCT02282930,Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression,Progressive IgA Nephropathy|Proteinuria,Interventional,26-Jun-19,Mallinckrodt,Drug: ACTH (Acthar) Gel
NCT01748292,Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab,Macular Degeneration,Interventional,20-Oct-17,"Charles C Wykoff, PhD, MD",Drug: 0.5 mg ranibizumab
NCT01748292,Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab,Macular Degeneration,Interventional,20-Oct-17,"Genentech, Inc.",Drug: 0.5 mg ranibizumab
NCT01748292,Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab,Macular Degeneration,Interventional,20-Oct-17,Greater Houston Retina Research,Drug: 0.5 mg ranibizumab
NCT02449291,Study of APD421 as PONV Treatment (no Prior Prophylaxis),Postoperative Nausea and Vomiting,Interventional,18-Dec-18,Acacia Pharma Ltd,Drug: APD421
NCT02449291,Study of APD421 as PONV Treatment (no Prior Prophylaxis),Postoperative Nausea and Vomiting,Interventional,18-Dec-18,Acacia Pharma Ltd,Drug: Placebo
NCT00584701,Pharmacogenomics in Autism Treatment,Autism,Interventional,24-Jul-12,"University of California, San Francisco",Drug: Risperidone
NCT00584701,Pharmacogenomics in Autism Treatment,Autism,Interventional,24-Jul-12,"Janssen, LP",Drug: Risperidone
NCT00584701,Pharmacogenomics in Autism Treatment,Autism,Interventional,24-Jul-12,National Institute of Mental Health (NIMH),Drug: Risperidone
NCT01478971,Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis,Chronic Kidney Disease|Anemia,Interventional,26-May-14,Takeda,Drug: Epoetin
NCT01478971,Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis,Chronic Kidney Disease|Anemia,Interventional,26-May-14,Takeda,Drug: Peginesatide
NCT01478971,Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis,Chronic Kidney Disease|Anemia,Interventional,26-May-14,Affymax,Drug: Epoetin
NCT01478971,Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis,Chronic Kidney Disease|Anemia,Interventional,26-May-14,Affymax,Drug: Peginesatide
NCT00426153,Octreotide in Severe Polycystic Liver Disease,"Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain",Interventional,21-Nov-12,Mayo Clinic,Drug: Octreotide
NCT00426153,Octreotide in Severe Polycystic Liver Disease,"Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain",Interventional,21-Nov-12,Mayo Clinic,Drug: Placebo
NCT00426153,Octreotide in Severe Polycystic Liver Disease,"Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain",Interventional,21-Nov-12,Novartis,Drug: Octreotide
NCT00426153,Octreotide in Severe Polycystic Liver Disease,"Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain",Interventional,21-Nov-12,Novartis,Drug: Placebo
NCT00426153,Octreotide in Severe Polycystic Liver Disease,"Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain",Interventional,21-Nov-12,National Center for Research Resources (NCRR),Drug: Octreotide
NCT00426153,Octreotide in Severe Polycystic Liver Disease,"Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain",Interventional,21-Nov-12,National Center for Research Resources (NCRR),Drug: Placebo
NCT00291226,Glycine vs Placebo for the Schizophrenia Prodrome,Schizophrenia Prodrome,Interventional,29-Dec-16,Yale University,Drug: Glycine
NCT00291226,Glycine vs Placebo for the Schizophrenia Prodrome,Schizophrenia Prodrome,Interventional,29-Dec-16,Yale University,Drug: Placebo
NCT00291226,Glycine vs Placebo for the Schizophrenia Prodrome,Schizophrenia Prodrome,Interventional,29-Dec-16,"Glytech, Inc",Drug: Glycine
NCT00291226,Glycine vs Placebo for the Schizophrenia Prodrome,Schizophrenia Prodrome,Interventional,29-Dec-16,"Glytech, Inc",Drug: Placebo
NCT00291226,Glycine vs Placebo for the Schizophrenia Prodrome,Schizophrenia Prodrome,Interventional,29-Dec-16,National Alliance for Research on Schizophrenia and Depression,Drug: Glycine
NCT00291226,Glycine vs Placebo for the Schizophrenia Prodrome,Schizophrenia Prodrome,Interventional,29-Dec-16,National Alliance for Research on Schizophrenia and Depression,Drug: Placebo
NCT00893113,An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms,Erectile Dysfunction|Lower Urinary Tract Symptoms,Interventional,1-Aug-16,Chesapeake Urology Research Associates,Drug: Placebo
NCT00893113,An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms,Erectile Dysfunction|Lower Urinary Tract Symptoms,Interventional,1-Aug-16,Chesapeake Urology Research Associates,Drug: Alfuzosin
NCT00893113,An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms,Erectile Dysfunction|Lower Urinary Tract Symptoms,Interventional,1-Aug-16,Sanofi,Drug: Placebo
NCT00893113,An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms,Erectile Dysfunction|Lower Urinary Tract Symptoms,Interventional,1-Aug-16,Sanofi,Drug: Alfuzosin
NCT01094886,Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement,"Arthritis|Osteoarthritis, Knee|Osteoarthritis, Hip|Thromboembolism",Interventional,27-Feb-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: Rivaroxaban
NCT01094886,Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement,"Arthritis|Osteoarthritis, Knee|Osteoarthritis, Hip|Thromboembolism",Interventional,27-Feb-12,Bayer,Drug: Rivaroxaban
NCT01052428,Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease),Mitral Regurgitation,Interventional,16-Apr-12,University of Alabama at Birmingham,Drug: metoprolol succinate (Toprol XL)
NCT01052428,Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease),Mitral Regurgitation,Interventional,16-Apr-12,University of Alabama at Birmingham,Drug: Placebo
NCT01052428,Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease),Mitral Regurgitation,Interventional,16-Apr-12,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: metoprolol succinate (Toprol XL)
NCT01052428,Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease),Mitral Regurgitation,Interventional,16-Apr-12,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Placebo
NCT01052428,Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease),Mitral Regurgitation,Interventional,16-Apr-12,AstraZeneca,Drug: metoprolol succinate (Toprol XL)
NCT01052428,Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease),Mitral Regurgitation,Interventional,16-Apr-12,AstraZeneca,Drug: Placebo
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,University of Alabama at Birmingham,Drug: Ramipril
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,University of Alabama at Birmingham,Drug: Candesartan cilexetil
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,University of Alabama at Birmingham,Drug: Allopurinol
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Ramipril
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Candesartan cilexetil
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Allopurinol
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,AstraZeneca,Drug: Ramipril
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,AstraZeneca,Drug: Candesartan cilexetil
NCT01052272,Impact of Diabetes on Left Ventricular Remodeling,Diabetes,Interventional,17-Dec-12,AstraZeneca,Drug: Allopurinol
NCT00993824,Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Jun-14,HealthPartners Institute,Drug: colesevelam HCl
NCT00993824,Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Jun-14,HealthPartners Institute,Drug: placebo
NCT00993824,Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Jun-14,International Diabetes Center at Park Nicollet,Drug: colesevelam HCl
NCT00993824,Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Jun-14,International Diabetes Center at Park Nicollet,Drug: placebo
NCT00993824,Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Jun-14,"Daiichi Sankyo, Inc.",Drug: colesevelam HCl
NCT00993824,Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Jun-14,"Daiichi Sankyo, Inc.",Drug: placebo
NCT01253811,Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Interventional,24-Jun-16,Novo Nordisk A/S,Drug: catridecacog
NCT00891982,A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash,Acne Vulgaris,Interventional,25-Jul-11,"Stiefel, a GSK Company",Drug: CTGel/ BPO Wash
NCT00891982,A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash,Acne Vulgaris,Interventional,25-Jul-11,"Stiefel, a GSK Company",Drug: Soap Free Cleanser and CTGel
NCT00891982,A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash,Acne Vulgaris,Interventional,25-Jul-11,GlaxoSmithKline,Drug: CTGel/ BPO Wash
NCT00891982,A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash,Acne Vulgaris,Interventional,25-Jul-11,GlaxoSmithKline,Drug: Soap Free Cleanser and CTGel
NCT00554216,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,Obesity,Interventional,6-Sep-12,"VIVUS, Inc.",Drug: VI-0521
NCT00554216,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,Obesity,Interventional,6-Sep-12,"VIVUS, Inc.",Drug: Placebo matched phentermine/topiramate
NCT00554216,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,Obesity,Interventional,6-Sep-12,"Medpace, Inc.",Drug: VI-0521
NCT00554216,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,Obesity,Interventional,6-Sep-12,"Medpace, Inc.",Drug: Placebo matched phentermine/topiramate
NCT00324896,"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone",Parkinson's Disease|Insomnia,Interventional,31-May-13,University of Medicine and Dentistry of New Jersey,Drug: eszopiclone
NCT00324896,"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone",Parkinson's Disease|Insomnia,Interventional,31-May-13,University of Medicine and Dentistry of New Jersey,Other: placebo
NCT00324896,"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone",Parkinson's Disease|Insomnia,Interventional,31-May-13,Sunovion,Drug: eszopiclone
NCT00324896,"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone",Parkinson's Disease|Insomnia,Interventional,31-May-13,Sunovion,Other: placebo
NCT00324896,"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone",Parkinson's Disease|Insomnia,Interventional,31-May-13,"Rutgers, The State University of New Jersey",Drug: eszopiclone
NCT00324896,"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone",Parkinson's Disease|Insomnia,Interventional,31-May-13,"Rutgers, The State University of New Jersey",Other: placebo
NCT00177164,Risperdal Consta for Bipolar Disorder,Bipolar I Disorder,Interventional,8-Feb-16,University of Pittsburgh,Drug: Injectable Risperidone (Consta) or oral antipsychotic
NCT00177164,Risperdal Consta for Bipolar Disorder,Bipolar I Disorder,Interventional,8-Feb-16,Janssen Pharmaceuticals,Drug: Injectable Risperidone (Consta) or oral antipsychotic
NCT00329433,Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery,Deep Venous Thrombosis,Interventional,13-Jun-11,Washington University School of Medicine,Drug: Desirudin (Iprivask™)
NCT00329433,Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery,Deep Venous Thrombosis,Interventional,13-Jun-11,Washington University School of Medicine,Drug: Heparin
NCT00329433,Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery,Deep Venous Thrombosis,Interventional,13-Jun-11,Barnes-Jewish Hospital,Drug: Desirudin (Iprivask™)
NCT00329433,Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery,Deep Venous Thrombosis,Interventional,13-Jun-11,Barnes-Jewish Hospital,Drug: Heparin
NCT00329433,Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery,Deep Venous Thrombosis,Interventional,13-Jun-11,"Canyon Pharmaceuticals, Inc.",Drug: Desirudin (Iprivask™)
NCT00329433,Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery,Deep Venous Thrombosis,Interventional,13-Jun-11,"Canyon Pharmaceuticals, Inc.",Drug: Heparin
NCT01157845,Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis,Cirrhosis,Interventional,4-Mar-14,Virginia Commonwealth University,Device: BreathID (Methacetin breath test)
NCT01157845,Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis,Cirrhosis,Interventional,4-Mar-14,Exalenz Bioscience LTD.,Device: BreathID (Methacetin breath test)
NCT00582010,Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation,Reperfusion Injury|Liver Injury,Interventional,6-Nov-14,University of Alabama at Birmingham,Drug: inhaled nitric oxide
NCT00582010,Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation,Reperfusion Injury|Liver Injury,Interventional,6-Nov-14,University of Alabama at Birmingham,Drug: nitrogen gas
NCT00582010,Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation,Reperfusion Injury|Liver Injury,Interventional,6-Nov-14,Mallinckrodt,Drug: inhaled nitric oxide
NCT00582010,Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation,Reperfusion Injury|Liver Injury,Interventional,6-Nov-14,Mallinckrodt,Drug: nitrogen gas
NCT00582010,Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation,Reperfusion Injury|Liver Injury,Interventional,6-Nov-14,University of Washington,Drug: inhaled nitric oxide
NCT00582010,Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation,Reperfusion Injury|Liver Injury,Interventional,6-Nov-14,University of Washington,Drug: nitrogen gas
NCT01067339,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Endothelial Dysfunction,Interventional,15-Mar-17,Mayo Clinic,Drug: darapladib
NCT01067339,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Endothelial Dysfunction,Interventional,15-Mar-17,Mayo Clinic,Drug: placebo
NCT01067339,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Endothelial Dysfunction,Interventional,15-Mar-17,GlaxoSmithKline,Drug: darapladib
NCT01067339,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Endothelial Dysfunction,Interventional,15-Mar-17,GlaxoSmithKline,Drug: placebo
NCT01067339,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Endothelial Dysfunction,Interventional,15-Mar-17,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: darapladib
NCT01067339,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Endothelial Dysfunction,Interventional,15-Mar-17,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: placebo
NCT01067339,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Endothelial Dysfunction,Interventional,15-Mar-17,National Institute on Aging (NIA),Drug: darapladib
NCT01067339,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Endothelial Dysfunction,Interventional,15-Mar-17,National Institute on Aging (NIA),Drug: placebo
NCT00701636,Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery,Late Effects of Surgery|Staphylococcus Aureus|Surgical Site Infection,Interventional,29-Aug-16,Los Angeles Biomedical Research Institute,Drug: daptomycin
NCT00701636,Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery,Late Effects of Surgery|Staphylococcus Aureus|Surgical Site Infection,Interventional,29-Aug-16,Cubist Pharmaceuticals LLC,Drug: daptomycin
NCT00701636,Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery,Late Effects of Surgery|Staphylococcus Aureus|Surgical Site Infection,Interventional,29-Aug-16,Hartford Hospital,Drug: daptomycin
NCT00701636,Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery,Late Effects of Surgery|Staphylococcus Aureus|Surgical Site Infection,Interventional,29-Aug-16,Western University of Health Sciences,Drug: daptomycin
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Metastatic,Interventional,19-Oct-17,Amgen,Drug: Carboplatin
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Metastatic,Interventional,19-Oct-17,Amgen,Drug: Paclitaxel
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Metastatic,Interventional,19-Oct-17,Amgen,Drug: ABP 215
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Metastatic,Interventional,19-Oct-17,Amgen,Drug: Bevacizumab
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Metastatic,Interventional,19-Oct-17,Actavis Inc.,Drug: Carboplatin
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Metastatic,Interventional,19-Oct-17,Actavis Inc.,Drug: Paclitaxel
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Metastatic,Interventional,19-Oct-17,Actavis Inc.,Drug: ABP 215
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Metastatic,Interventional,19-Oct-17,Actavis Inc.,Drug: Bevacizumab
NCT01324999,Tadalafil for Sarcoidosis Associated Pulmonary Hypertension,Pulmonary Hypertension,Interventional,24-Jul-17,"University of North Carolina, Chapel Hill",Drug: Tadalafil
NCT01324999,Tadalafil for Sarcoidosis Associated Pulmonary Hypertension,Pulmonary Hypertension,Interventional,24-Jul-17,Eli Lilly and Company,Drug: Tadalafil
NCT01324999,Tadalafil for Sarcoidosis Associated Pulmonary Hypertension,Pulmonary Hypertension,Interventional,24-Jul-17,United Therapeutics,Drug: Tadalafil
NCT01324999,Tadalafil for Sarcoidosis Associated Pulmonary Hypertension,Pulmonary Hypertension,Interventional,24-Jul-17,University of Cincinnati,Drug: Tadalafil
NCT01508455,"Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age",Anesthesia,Interventional,11-Dec-13,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Dexmedetomidine
NCT01508455,"Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age",Anesthesia,Interventional,11-Dec-13,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Midazolam
NCT01508455,"Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age",Anesthesia,Interventional,11-Dec-13,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Fentanyl
NCT01508455,"Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age",Anesthesia,Interventional,11-Dec-13,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Morphine
NCT01202578,Evaluation of the Tympanostomy Tube Delivery System,Otitis Media With Effusion|Acute Otitis Media,Interventional,11-Jul-14,Acclarent,Device: tympanostomy tube
NCT02683772,Astral VAPS AutoEPAP Clinical Trial,Upper Airway Obstruction|Respiratory Insufficiency|Respiratory Failure,Interventional,26-Jul-19,ResMed,Device: Astral
NCT02032875,"Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant",Hepatitis C,Interventional,20-Oct-15,Bristol-Myers Squibb,Drug: Daclatasvir
NCT02032875,"Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant",Hepatitis C,Interventional,20-Oct-15,Bristol-Myers Squibb,Drug: Sofosbuvir
NCT02032875,"Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant",Hepatitis C,Interventional,20-Oct-15,Bristol-Myers Squibb,Drug: Ribavirin
NCT00935649,PinPointe FootLaser for the Treatment of Onychomycosis,Infected Toenails|Onychomycosis,Interventional,9-Apr-13,"PathoLase, Inc.",Device: PinPointe FootLaser
NCT01560403,"A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021",Short Bowel Syndrome,Interventional,25-Dec-14,Shire,Drug: Teduglutide
NCT01484652,Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension,"Pain, Postoperative|Bunion",Interventional,2-Jul-14,Mallinckrodt,Drug: COV795
NCT01484652,Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension,"Pain, Postoperative|Bunion",Interventional,2-Jul-14,Mallinckrodt,Drug: Placebo
NCT01371565,Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome,Cushing's Disease|Cushing's Syndrome,Interventional,20-Nov-13,Corcept Therapeutics,Drug: Mifepristone
NCT00856843,BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,Colonoscopy,Interventional,10-Nov-10,Braintree Laboratories,Drug: BLI800
NCT00856843,BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,Colonoscopy,Interventional,10-Nov-10,Braintree Laboratories,Drug: Polyethylene glycol 3350 based bowel preparation
NCT00777556,Emergency Contraception Actual Use Study,Emergency Contraception,Interventional,18-Oct-12,Duramed Research,Drug: DR-104
NCT00777556,Emergency Contraception Actual Use Study,Emergency Contraception,Interventional,18-Oct-12,Teva Pharmaceutical Industries,Drug: DR-104
NCT00697515,Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD),ADHD,Interventional,1-Feb-10,Shire,Drug: LDX
NCT00697515,Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD),ADHD,Interventional,1-Feb-10,Shire,Drug: Placebo
NCT00539864,"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV",Influenza,Interventional,27-Jul-11,Protein Sciences Corporation,Biological: FluBlok Influenza Vaccination
NCT00539864,"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV",Influenza,Interventional,27-Jul-11,Protein Sciences Corporation,Biological: TIV (Fluzone) Influenza Vaccination
NCT00211536,Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration,Type 1 Diabetes,Interventional,23-Jun-11,Medtronic Diabetes,Drug: Medtronic MiniMed Implantable Pump Human Recombinant Insulin
NCT00211536,Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration,Type 1 Diabetes,Interventional,23-Jun-11,Medtronic Diabetes,Device: Medtronic MiniMed Implantable Pump System
NCT00211536,Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration,Type 1 Diabetes,Interventional,23-Jun-11,Medtronic Diabetes,Drug: Aventis HOE21PH U400
NCT00112047,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,HIV Infections,Interventional,13-Oct-10,Gilead Sciences,Drug: Emtricitabine (FTC)
NCT00112047,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,HIV Infections,Interventional,13-Oct-10,Gilead Sciences,Drug: Tenofovir Disoproxil Fumarate (TDF)
NCT00112047,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,HIV Infections,Interventional,13-Oct-10,Gilead Sciences,Drug: Efavirenz (EFV)
NCT00112047,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,HIV Infections,Interventional,13-Oct-10,Gilead Sciences,Drug: FTC/TDF
NCT00112047,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,HIV Infections,Interventional,13-Oct-10,Gilead Sciences,Drug: FTC/TDF/EFV
NCT00112047,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,HIV Infections,Interventional,13-Oct-10,Gilead Sciences,Drug: Lamivudine/zidovudine
NCT00640614,Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy,Contact Dermatitis,Interventional,22-Dec-15,Allerderm,Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
NCT00365989,MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication,Uterine Leiomyoma|Uterine Fibroids,Interventional,5-Feb-19,InSightec,Device: ExAblate Enhanced Sonication
NCT01656772,Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study,Atrial Fibrillation,Interventional,4-Jun-15,Stereotaxis,Device: Vdrive Lasso navigation
NCT01656772,Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study,Atrial Fibrillation,Interventional,4-Jun-15,Stereotaxis,Procedure: Manual Lasso navigation
NCT01152190,A Study in Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Interventional,20-May-13,Eli Lilly and Company,Drug: Tadalafil
NCT01152190,A Study in Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Interventional,20-May-13,Eli Lilly and Company,Drug: Placebo
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,Duke University,Drug: Varenicline
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,Duke University,Drug: Bupropion
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,Duke University,Drug: Nicotine patches
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,Duke University,Drug: Nicotine Inhaler
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,National Institute on Drug Abuse (NIDA),Drug: Varenicline
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,National Institute on Drug Abuse (NIDA),Drug: Bupropion
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,National Institute on Drug Abuse (NIDA),Drug: Nicotine patches
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,National Institute on Drug Abuse (NIDA),Drug: Nicotine Inhaler
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,"Philip Morris USA, Inc.",Drug: Varenicline
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,"Philip Morris USA, Inc.",Drug: Bupropion
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,"Philip Morris USA, Inc.",Drug: Nicotine patches
NCT01303861,Concurrent Bupropion / Varenicline for Smoking Cessation,Nicotine Dependence,Interventional,1-Aug-14,"Philip Morris USA, Inc.",Drug: Nicotine Inhaler
NCT01016678,Treximet Early Intervention Adolescent Migraine,Migraine,Interventional,4-May-16,Premiere Research Institute,Drug: Treximet
NCT01016678,Treximet Early Intervention Adolescent Migraine,Migraine,Interventional,4-May-16,Premiere Research Institute,Drug: Placebo
NCT01016678,Treximet Early Intervention Adolescent Migraine,Migraine,Interventional,4-May-16,GlaxoSmithKline,Drug: Treximet
NCT01016678,Treximet Early Intervention Adolescent Migraine,Migraine,Interventional,4-May-16,GlaxoSmithKline,Drug: Placebo
NCT02174848,Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration,Pantothenate Kinase-Associated Neurodegeneration,Interventional,17-Jul-19,ApoPharma,Drug: Deferiprone oral solution
NCT01741532,Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN),Pantothenate Kinase-Associated Neurodegeneration,Interventional,23-May-19,ApoPharma,Drug: Deferiprone oral solution
NCT01741532,Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN),Pantothenate Kinase-Associated Neurodegeneration,Interventional,23-May-19,ApoPharma,Drug: Placebo
NCT01741532,Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN),Pantothenate Kinase-Associated Neurodegeneration,Interventional,23-May-19,Food and Drug Administration (FDA),Drug: Deferiprone oral solution
NCT01741532,Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN),Pantothenate Kinase-Associated Neurodegeneration,Interventional,23-May-19,Food and Drug Administration (FDA),Drug: Placebo
NCT01698554,Bimatoprost in the Treatment of Eyelash Hypotrichosis,Idiopathic Eyelash Hypotrichosis,Interventional,10-Feb-15,Allergan,Drug: bimatoprost formulation A solution
NCT01698554,Bimatoprost in the Treatment of Eyelash Hypotrichosis,Idiopathic Eyelash Hypotrichosis,Interventional,10-Feb-15,Allergan,Drug: bimatoprost solution 0.03 %
NCT01698554,Bimatoprost in the Treatment of Eyelash Hypotrichosis,Idiopathic Eyelash Hypotrichosis,Interventional,10-Feb-15,Allergan,Drug: vehicle of bimatoprost formulation A solution
NCT01698554,Bimatoprost in the Treatment of Eyelash Hypotrichosis,Idiopathic Eyelash Hypotrichosis,Interventional,10-Feb-15,Allergan,Drug: vehicle of bimatoprost solution 0.03 %
NCT01420653,Maxigesic 325 Acute Dental Pain Study,Dental Pain,Interventional,6-Dec-18,"AFT Pharmaceuticals, Ltd.",Drug: Maxigesic 325
NCT01420653,Maxigesic 325 Acute Dental Pain Study,Dental Pain,Interventional,6-Dec-18,"AFT Pharmaceuticals, Ltd.",Drug: Acetaminophen
NCT01420653,Maxigesic 325 Acute Dental Pain Study,Dental Pain,Interventional,6-Dec-18,"AFT Pharmaceuticals, Ltd.",Drug: Ibuprofen
NCT01420653,Maxigesic 325 Acute Dental Pain Study,Dental Pain,Interventional,6-Dec-18,"AFT Pharmaceuticals, Ltd.",Drug: Placebo
NCT01224015,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Interventional,25-Feb-14,Allergan,Drug: normal saline
NCT01224015,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Interventional,25-Feb-14,Allergan,Biological: onabotulinumtoxinA 44 U
NCT01224015,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Interventional,25-Feb-14,Allergan,Biological: onabotulinumtoxinA 24 U
NCT01189760,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Interventional,3-Dec-13,Allergan,Biological: onabotulinumtoxinA 24 U
NCT01189760,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Interventional,3-Dec-13,Allergan,Biological: onabotulinumtoxinA 44 U
NCT01189760,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Interventional,3-Dec-13,Allergan,Drug: normal saline
NCT01189747,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines,Lateral Canthus Rhytides|Crow's Feet Lines,Interventional,3-Dec-13,Allergan,Biological: onabotulinumtoxinA
NCT01189747,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines,Lateral Canthus Rhytides|Crow's Feet Lines,Interventional,3-Dec-13,Allergan,Drug: normal saline
NCT00765076,Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older,Influenza,Interventional,5-Apr-12,GlaxoSmithKline,Biological: GSK Biologicals' influenza vaccine GSK2186877A
NCT00765076,Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older,Influenza,Interventional,5-Apr-12,GlaxoSmithKline,Biological: GSK Biologicals' Fluarix
NCT00386607,"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.",Hypertension,Interventional,10-May-11,Novartis,Drug: Aliskiren
NCT00386607,"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.",Hypertension,Interventional,10-May-11,Novartis,Drug: Valsartan
NCT00386607,"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.",Hypertension,Interventional,10-May-11,Novartis,Drug: Hydrochlorothiazide (HCTZ)
NCT00609466,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Interventional,25-Nov-09,Grünenthal GmbH,Drug: CG5503 IR
NCT00609466,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Interventional,25-Nov-09,Grünenthal GmbH,Drug: Morphine
NCT00609466,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Interventional,25-Nov-09,Grünenthal GmbH,Drug: Placebo
NCT00609466,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Interventional,25-Nov-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: CG5503 IR
NCT00609466,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Interventional,25-Nov-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Morphine
NCT00609466,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Interventional,25-Nov-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00553787,Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions,Obesity|Type 2 Diabetes,Interventional,6-Sep-12,"VIVUS, Inc.",Drug: VI-0521
NCT00553787,Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions,Obesity|Type 2 Diabetes,Interventional,6-Sep-12,"Medpace, Inc.",Drug: VI-0521
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,"Genzyme, a Sanofi Company",Device: Dermal Gel Extra (DGE)
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,"Genzyme, a Sanofi Company",Device: Restylane
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,"Genzyme, a Sanofi Company",Drug: EMLA Cream
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,"Mentor Worldwide, LLC",Device: Dermal Gel Extra (DGE)
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,"Mentor Worldwide, LLC",Device: Restylane
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,"Mentor Worldwide, LLC",Drug: EMLA Cream
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,Sanofi,Device: Dermal Gel Extra (DGE)
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,Sanofi,Device: Restylane
NCT00444626,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Facial Wrinkles at the Nasolabial Folds,Interventional,22-Apr-15,Sanofi,Drug: EMLA Cream
NCT03439072,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Interventional,30-May-19,Xeris Pharmaceuticals,Drug: G-Pen
NCT03439072,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Interventional,30-May-19,Xeris Pharmaceuticals,Drug: Lilly Glucagon
NCT03439072,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Interventional,30-May-19,SGS S.A.,Drug: G-Pen
NCT03439072,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Interventional,30-May-19,SGS S.A.,Drug: Lilly Glucagon
NCT03439072,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Interventional,30-May-19,Integrated Medical Development,Drug: G-Pen
NCT03439072,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Interventional,30-May-19,Integrated Medical Development,Drug: Lilly Glucagon
NCT00880919,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Borderline Personality Disorder,Interventional,28-Dec-16,University of Minnesota - Clinical and Translational Science Institute,Drug: quetiapine extended-release
NCT00880919,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Borderline Personality Disorder,Interventional,28-Dec-16,University of Minnesota - Clinical and Translational Science Institute,Drug: Placebo
NCT00880919,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Borderline Personality Disorder,Interventional,28-Dec-16,AstraZeneca,Drug: quetiapine extended-release
NCT00880919,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Borderline Personality Disorder,Interventional,28-Dec-16,AstraZeneca,Drug: Placebo
NCT00880919,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Borderline Personality Disorder,Interventional,28-Dec-16,University of Iowa,Drug: quetiapine extended-release
NCT00880919,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Borderline Personality Disorder,Interventional,28-Dec-16,University of Iowa,Drug: Placebo
NCT00880919,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Borderline Personality Disorder,Interventional,28-Dec-16,Mclean Hospital,Drug: quetiapine extended-release
NCT00880919,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Borderline Personality Disorder,Interventional,28-Dec-16,Mclean Hospital,Drug: Placebo
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Northwell Health,Drug: Budesonide
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Northwell Health,Drug: albuterol
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Northwell Health,Drug: Ipratropium bromide
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Northwell Health,Drug: Prednisone
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,AstraZeneca,Drug: Budesonide
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,AstraZeneca,Drug: albuterol
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,AstraZeneca,Drug: Ipratropium bromide
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,AstraZeneca,Drug: Prednisone
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Jacobi Medical Center,Drug: Budesonide
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Jacobi Medical Center,Drug: albuterol
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Jacobi Medical Center,Drug: Ipratropium bromide
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Jacobi Medical Center,Drug: Prednisone
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Nassau University Medical Center,Drug: Budesonide
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Nassau University Medical Center,Drug: albuterol
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Nassau University Medical Center,Drug: Ipratropium bromide
NCT00588406,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Asthma,Interventional,21-Jan-16,Nassau University Medical Center,Drug: Prednisone
NCT00621842,Lamotrigine for Symptoms of Geriatric Bipolar Depression,"Bipolar Disorder|Depression, Bipolar",Interventional,25-Oct-11,University Hospitals Cleveland Medical Center,Drug: Lamotrigine regular tablet formulation
NCT00621842,Lamotrigine for Symptoms of Geriatric Bipolar Depression,"Bipolar Disorder|Depression, Bipolar",Interventional,25-Oct-11,University Hospitals Cleveland Medical Center,Drug: Lamotrigine novel formulation
NCT00621842,Lamotrigine for Symptoms of Geriatric Bipolar Depression,"Bipolar Disorder|Depression, Bipolar",Interventional,25-Oct-11,GlaxoSmithKline,Drug: Lamotrigine regular tablet formulation
NCT00621842,Lamotrigine for Symptoms of Geriatric Bipolar Depression,"Bipolar Disorder|Depression, Bipolar",Interventional,25-Oct-11,GlaxoSmithKline,Drug: Lamotrigine novel formulation
NCT01510327,PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK),Coronary Artery Disease,Interventional,5-Apr-12,Boston Scientific Corporation,Device: PROMUS Element Everolimus-Eluting Coronary Stent System
NCT01510327,PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK),Coronary Artery Disease,Interventional,5-Apr-12,Boston Scientific Corporation,Drug: Aspirin
NCT01510327,PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK),Coronary Artery Disease,Interventional,5-Apr-12,Boston Scientific Corporation,Drug: Thienopyridine
NCT00606489,Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients,Burns,Interventional,11-Aug-11,Cumberland Pharmaceuticals,Drug: Caldolor
NCT00606489,Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients,Burns,Interventional,11-Aug-11,Cumberland Pharmaceuticals,Drug: Placebo
NCT03475875,Contact Lenses With New UV-blocker Manufactured With Different Techniques,Correction of Refraction Error|Attenuation of Bright Light,Interventional,4-Jun-19,"Johnson & Johnson Vision Care, Inc.",Device: senofilcon A TEST Lens
NCT03475875,Contact Lenses With New UV-blocker Manufactured With Different Techniques,Correction of Refraction Error|Attenuation of Bright Light,Interventional,4-Jun-19,"Johnson & Johnson Vision Care, Inc.",Device: senofilcon A CONTROL Lens
NCT03178942,"Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies",Scabies,Interventional,14-Mar-19,Encube Ethicals Pvt. Ltd.,"Drug: Permethrin Cream, 5%"
NCT03178942,"Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies",Scabies,Interventional,14-Mar-19,Encube Ethicals Pvt. Ltd.,Drug: Elimite™ Cream (permethrin) 5%
NCT03178942,"Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies",Scabies,Interventional,14-Mar-19,Novum Pharmaceutical Research Services,"Drug: Permethrin Cream, 5%"
NCT03178942,"Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies",Scabies,Interventional,14-Mar-19,Novum Pharmaceutical Research Services,Drug: Elimite™ Cream (permethrin) 5%
NCT03054428,"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic",Interventional,23-Jul-19,Regeneron Pharmaceuticals,Drug: Dupilumab
NCT03054428,"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic",Interventional,23-Jul-19,Regeneron Pharmaceuticals,Drug: Placebo
NCT03054428,"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic",Interventional,23-Jul-19,Sanofi,Drug: Dupilumab
NCT03054428,"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic",Interventional,23-Jul-19,Sanofi,Drug: Placebo
NCT03091673,Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients,"Diabetes Mellitus, Type 1",Interventional,16-Nov-18,Xeris Pharmaceuticals,Drug: Glucagon
NCT03091673,Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients,"Diabetes Mellitus, Type 1",Interventional,16-Nov-18,"The Emmes Company, LLC",Drug: Glucagon
NCT02912468,A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps,Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP),Interventional,25-Jul-19,Sanofi,Drug: Dupilumab SAR231893 (REGN668)
NCT02912468,A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps,Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP),Interventional,25-Jul-19,Sanofi,Drug: Placebo
NCT02912468,A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps,Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP),Interventional,25-Jul-19,Sanofi,Drug: Mometasone furoate 50 micrograms
NCT02912468,A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps,Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP),Interventional,25-Jul-19,Regeneron Pharmaceuticals,Drug: Dupilumab SAR231893 (REGN668)
NCT02912468,A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps,Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP),Interventional,25-Jul-19,Regeneron Pharmaceuticals,Drug: Placebo
NCT02912468,A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps,Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP),Interventional,25-Jul-19,Regeneron Pharmaceuticals,Drug: Mometasone furoate 50 micrograms
NCT02744755,Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,18-Dec-18,Sandoz,Biological: Adalimumab - GP2017
NCT02744755,Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,18-Dec-18,Sandoz,Biological: Adalimumab - US licensed Humira
NCT02744755,Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,18-Dec-18,Hexal AG,Biological: Adalimumab - GP2017
NCT02744755,Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,18-Dec-18,Hexal AG,Biological: Adalimumab - US licensed Humira
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Interventional,30-Jul-18,Eli Lilly and Company,Drug: Lasmiditan 50 mg
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Interventional,30-Jul-18,Eli Lilly and Company,Drug: Lasmiditan 100 mg
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Interventional,30-Jul-18,Eli Lilly and Company,Drug: Lasmiditan 200 mg
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Interventional,30-Jul-18,Eli Lilly and Company,Drug: Placebo
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Interventional,30-Jul-18,CoLucid Pharmaceuticals,Drug: Lasmiditan 50 mg
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Interventional,30-Jul-18,CoLucid Pharmaceuticals,Drug: Lasmiditan 100 mg
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Interventional,30-Jul-18,CoLucid Pharmaceuticals,Drug: Lasmiditan 200 mg
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Migraine With or Without Aura,Interventional,30-Jul-18,CoLucid Pharmaceuticals,Drug: Placebo
NCT02586805,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Interventional,24-Apr-18,Shire,Drug: DX-2930 - 300mg/2wk
NCT02586805,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Interventional,24-Apr-18,Shire,Drug: DX-2930 - 300mg/4wk
NCT02586805,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Interventional,24-Apr-18,Shire,Drug: DX-2930 - 150mg/4wk
NCT02586805,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Interventional,24-Apr-18,Shire,Drug: Placebo
NCT02586805,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Interventional,24-Apr-18,Dyax Corp.,Drug: DX-2930 - 300mg/2wk
NCT02586805,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Interventional,24-Apr-18,Dyax Corp.,Drug: DX-2930 - 300mg/4wk
NCT02586805,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Interventional,24-Apr-18,Dyax Corp.,Drug: DX-2930 - 150mg/4wk
NCT02586805,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Interventional,24-Apr-18,Dyax Corp.,Drug: Placebo
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Hypercholesterolaemia,Interventional,17-May-18,Sanofi,Drug: Alirocumab
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Hypercholesterolaemia,Interventional,17-May-18,Sanofi,Drug: Placebo
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Hypercholesterolaemia,Interventional,17-May-18,Sanofi,Drug: Lipid-Modifying Therapy (LMT)
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Hypercholesterolaemia,Interventional,17-May-18,Sanofi,Drug: Antihyperglycemic Drug
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Hypercholesterolaemia,Interventional,17-May-18,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Hypercholesterolaemia,Interventional,17-May-18,Regeneron Pharmaceuticals,Drug: Placebo
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Hypercholesterolaemia,Interventional,17-May-18,Regeneron Pharmaceuticals,Drug: Lipid-Modifying Therapy (LMT)
NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Hypercholesterolaemia,Interventional,17-May-18,Regeneron Pharmaceuticals,Drug: Antihyperglycemic Drug
NCT02580591,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),"Diabetes Mellitus, Type 1",Interventional,2-Nov-18,Boehringer Ingelheim,Drug: Empagliflozin
NCT02580591,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),"Diabetes Mellitus, Type 1",Interventional,2-Nov-18,Boehringer Ingelheim,Drug: Placebo
NCT02580591,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),"Diabetes Mellitus, Type 1",Interventional,2-Nov-18,Eli Lilly and Company,Drug: Empagliflozin
NCT02580591,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),"Diabetes Mellitus, Type 1",Interventional,2-Nov-18,Eli Lilly and Company,Drug: Placebo
NCT02560584,A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting,Bladder Cancer,Interventional,2-Jul-18,Photocure,Drug: Hexaminolevulinate hydrochloride
NCT02560584,A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting,Bladder Cancer,Interventional,2-Jul-18,Photocure,Device: KARL STORZ D-Light C PDD Flexible Videoscope System
NCT02560584,A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting,Bladder Cancer,Interventional,2-Jul-18,"KARL STORZ Endoscopy-America, Inc.",Drug: Hexaminolevulinate hydrochloride
NCT02560584,A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting,Bladder Cancer,Interventional,2-Jul-18,"KARL STORZ Endoscopy-America, Inc.",Device: KARL STORZ D-Light C PDD Flexible Videoscope System
NCT02712320,Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg,Prostatic Neoplasms,Interventional,12-Sep-18,"Foresee Pharmaceuticals Co., Ltd.",Drug: LMIS 50 mg
NCT02712320,Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg,Prostatic Neoplasms,Interventional,12-Sep-18,QPS-Qualitix,Drug: LMIS 50 mg
NCT02514772,"GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®",Rheumatoid Arthritis,Interventional,28-Dec-17,Sandoz,Biological: GP2013 - A Proposed biosimilar rituximab
NCT02514772,"GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®",Rheumatoid Arthritis,Interventional,28-Dec-17,Sandoz,Biological: Originator rituximab - Rituxan ® or MabThera ®
NCT02514772,"GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®",Rheumatoid Arthritis,Interventional,28-Dec-17,Hexal AG,Biological: GP2013 - A Proposed biosimilar rituximab
NCT02514772,"GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®",Rheumatoid Arthritis,Interventional,28-Dec-17,Hexal AG,Biological: Originator rituximab - Rituxan ® or MabThera ®
NCT02504294,A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Interventional,13-Jun-18,Pfizer,Biological: Epoetin Hospira Arm
NCT02504294,A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Interventional,13-Jun-18,Pfizer,Other: Standard of Care Arm
NCT02504294,A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Interventional,13-Jun-18,Pfizer,Drug: IV Iron
NCT02504294,A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Interventional,13-Jun-18,"Hospira, now a wholly owned subsidiary of Pfizer",Biological: Epoetin Hospira Arm
NCT02504294,A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Interventional,13-Jun-18,"Hospira, now a wholly owned subsidiary of Pfizer",Other: Standard of Care Arm
NCT02504294,A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Interventional,13-Jun-18,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: IV Iron
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Sanofi,Drug: Dupilumab
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Sanofi,Drug: Placebo
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Sanofi,Drug: Oral corticosteroid therapy (prednisone/prednisolone)
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Sanofi,Drug: Inhaled corticosteroid (ICS) therapy
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Sanofi,Drug: Albuterol/Salbutamol
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Sanofi,Drug: Levalbuterol/Levosalbutamol
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Dupilumab
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Placebo
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Oral corticosteroid therapy (prednisone/prednisolone)
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Inhaled corticosteroid (ICS) therapy
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Albuterol/Salbutamol
NCT02528214,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Levalbuterol/Levosalbutamol
NCT02460978,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,6-Nov-18,AstraZeneca,Drug: Dapagliflozin
NCT02460978,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,6-Nov-18,AstraZeneca,Other: Placebo for dapagliflozin
NCT02460978,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,6-Nov-18,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT02460978,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,6-Nov-18,Bristol-Myers Squibb,Other: Placebo for dapagliflozin
NCT02452190,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Interventional,6-Feb-19,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Reslizumab
NCT02452190,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Interventional,6-Feb-19,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT02452190,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Interventional,6-Feb-19,PPD,Drug: Reslizumab
NCT02452190,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Interventional,6-Feb-19,PPD,Drug: Placebo
NCT02452190,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Interventional,6-Feb-19,Teva Pharmaceutical Industries,Drug: Reslizumab
NCT02452190,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Interventional,6-Feb-19,Teva Pharmaceutical Industries,Drug: Placebo
NCT02502149,"Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale",Severe Hemophilia A,Interventional,6-Apr-18,Bioverativ Therapeutics Inc.,Biological: rFVIIIFc
NCT02502149,"Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale",Severe Hemophilia A,Interventional,6-Apr-18,Swedish Orphan Biovitrum,Biological: rFVIIIFc
NCT02414958,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),"Diabetes Mellitus, Type 1",Interventional,20-Nov-18,Boehringer Ingelheim,Drug: Empagliflozin
NCT02414958,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),"Diabetes Mellitus, Type 1",Interventional,20-Nov-18,Boehringer Ingelheim,Drug: Placebo
NCT02414958,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),"Diabetes Mellitus, Type 1",Interventional,20-Nov-18,Eli Lilly and Company,Drug: Empagliflozin
NCT02414958,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),"Diabetes Mellitus, Type 1",Interventional,20-Nov-18,Eli Lilly and Company,Drug: Placebo
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Sanofi,Drug: Dupilumab
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Sanofi,Drug: Placebo
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Sanofi,Drug: Inhaled corticosteroid (ICS) therapy
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Sanofi,Drug: Albuterol/Salbutamol
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Sanofi,Drug: Levalbuterol/Levosalbutamol
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Dupilumab
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Placebo
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Inhaled corticosteroid (ICS) therapy
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Albuterol/Salbutamol
NCT02414854,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Asthma,Interventional,23-Oct-18,Regeneron Pharmaceuticals,Drug: Levalbuterol/Levosalbutamol
NCT02413346,A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris,Acne Vulgaris,Interventional,4-May-18,"Almirall, S.A.",Drug: Sarecycline
NCT02413346,A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris,Acne Vulgaris,Interventional,4-May-18,Allergan,Drug: Sarecycline
NCT02398188,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),Central Abdominal Bulging,Interventional,7-Jan-19,Evofem Inc.,Drug: LIPO-202
NCT02398188,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),Central Abdominal Bulging,Interventional,7-Jan-19,Evofem Inc.,Drug: Placebo
NCT02398188,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),Central Abdominal Bulging,Interventional,7-Jan-19,"Neothetics, Inc",Drug: LIPO-202
NCT02398188,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),Central Abdominal Bulging,Interventional,7-Jan-19,"Neothetics, Inc",Drug: Placebo
NCT02395653,Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants,"Pain, Postoperative",Interventional,18-Sep-17,The Medicines Company,Drug: fentanyl
NCT02395653,Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants,"Pain, Postoperative",Interventional,18-Sep-17,"Incline Therapeutics, Inc.",Drug: fentanyl
NCT02384460,ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa,Epidermolysis Bullosa,Interventional,16-Oct-18,"Scioderm, Inc.",Drug: SD-101-6.0 cream
NCT02384460,ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa,Epidermolysis Bullosa,Interventional,16-Oct-18,"Scioderm, Inc.",Drug: Placebo (SD-101-0.0) cream
NCT02384460,ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa,Epidermolysis Bullosa,Interventional,16-Oct-18,Amicus Therapeutics,Drug: SD-101-6.0 cream
NCT02384460,ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa,Epidermolysis Bullosa,Interventional,16-Oct-18,Amicus Therapeutics,Drug: Placebo (SD-101-0.0) cream
NCT03172481,PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD,ADHD,Interventional,4-Jun-19,"Purdue Pharma, Canada",Drug: PRC-063 oral capsules
NCT03172481,PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD,ADHD,Interventional,4-Jun-19,"Purdue Pharma, Canada",Drug: Placebo oral capsules
NCT02322866,"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",Acne Vulgaris,Interventional,7-May-18,"Almirall, S.A.",Drug: Sarecycline
NCT02322866,"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",Acne Vulgaris,Interventional,7-May-18,"Almirall, S.A.",Drug: Placebo
NCT02322866,"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",Acne Vulgaris,Interventional,7-May-18,Allergan,Drug: Sarecycline
NCT02322866,"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",Acne Vulgaris,Interventional,7-May-18,Allergan,Drug: Placebo
NCT02320149,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Acne Vulgaris,Interventional,17-May-18,"Almirall, S.A.",Drug: Sarecycline
NCT02320149,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Acne Vulgaris,Interventional,17-May-18,"Almirall, S.A.",Drug: Placebo
NCT02320149,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Acne Vulgaris,Interventional,17-May-18,Allergan,Drug: Sarecycline
NCT02320149,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Acne Vulgaris,Interventional,17-May-18,Allergan,Drug: Placebo
NCT02296892,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Bronchoscopy,Interventional,12-Mar-19,Paion UK Ltd.,Drug: Remimazolam
NCT02296892,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Bronchoscopy,Interventional,12-Mar-19,Paion UK Ltd.,Drug: Placebo
NCT02296892,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Bronchoscopy,Interventional,12-Mar-19,Paion UK Ltd.,Drug: Midazolam
NCT02296892,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Bronchoscopy,Interventional,12-Mar-19,Premier Research Group plc,Drug: Remimazolam
NCT02296892,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Bronchoscopy,Interventional,12-Mar-19,Premier Research Group plc,Drug: Placebo
NCT02296892,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Bronchoscopy,Interventional,12-Mar-19,Premier Research Group plc,Drug: Midazolam
NCT02302716,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,24-Oct-17,Eli Lilly and Company,Drug: LY2963016
NCT02302716,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,24-Oct-17,Eli Lilly and Company,Drug: LANTUS®
NCT02302716,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,24-Oct-17,Eli Lilly and Company,Drug: Oral Antihyperglycemic Medication
NCT02302716,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,24-Oct-17,Boehringer Ingelheim,Drug: LY2963016
NCT02302716,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,24-Oct-17,Boehringer Ingelheim,Drug: LANTUS®
NCT02302716,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,24-Oct-17,Boehringer Ingelheim,Drug: Oral Antihyperglycemic Medication
NCT02291679,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Interventional,19-May-17,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide
NCT02291679,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Interventional,19-May-17,"Ironwood Pharmaceuticals, Inc.",Drug: Matching Placebo
NCT02291679,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Interventional,19-May-17,Forest Laboratories,Drug: Linaclotide
NCT02291679,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Interventional,19-May-17,Forest Laboratories,Drug: Matching Placebo
NCT02290873,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Colonoscopy,Interventional,9-Nov-18,Paion UK Ltd.,Drug: Remimazolam
NCT02290873,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Colonoscopy,Interventional,9-Nov-18,Paion UK Ltd.,Drug: Midazolam
NCT02290873,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Colonoscopy,Interventional,9-Nov-18,Paion UK Ltd.,Drug: Placebo
NCT02290873,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Colonoscopy,Interventional,9-Nov-18,Premier Research Group plc,Drug: Remimazolam
NCT02290873,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Colonoscopy,Interventional,9-Nov-18,Premier Research Group plc,Drug: Midazolam
NCT02290873,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Colonoscopy,Interventional,9-Nov-18,Premier Research Group plc,Drug: Placebo
NCT02277769,Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Interventional,16-Oct-17,Regeneron Pharmaceuticals,Drug: Dupilumab
NCT02277769,Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Interventional,16-Oct-17,Regeneron Pharmaceuticals,Drug: Placebo (for Dupilumab)
NCT02277769,Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Interventional,16-Oct-17,Sanofi,Drug: Dupilumab
NCT02277769,Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Interventional,16-Oct-17,Sanofi,Drug: Placebo (for Dupilumab)
NCT02277743,Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Interventional,21-Nov-17,Regeneron Pharmaceuticals,Drug: Dupilumab
NCT02277743,Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Interventional,21-Nov-17,Regeneron Pharmaceuticals,Drug: Placebo (for Dupilumab)
NCT02277743,Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Interventional,21-Nov-17,Sanofi,Drug: Dupilumab
NCT02277743,Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,"Dermatitis, Atopic",Interventional,21-Nov-17,Sanofi,Drug: Placebo (for Dupilumab)
NCT02660580,MSB11022 in Moderate to Severe Chronic Plaque Psoriasis,Psoriasis|Plaque Type Psoriasis|Moderate to Severe Plaque Psoriasis,Interventional,19-Feb-19,Fresenius Kabi SwissBioSim GmbH,Drug: MSB11022
NCT02660580,MSB11022 in Moderate to Severe Chronic Plaque Psoriasis,Psoriasis|Plaque Type Psoriasis|Moderate to Severe Plaque Psoriasis,Interventional,19-Feb-19,Fresenius Kabi SwissBioSim GmbH,Drug: Humira®
NCT02660580,MSB11022 in Moderate to Severe Chronic Plaque Psoriasis,Psoriasis|Plaque Type Psoriasis|Moderate to Severe Plaque Psoriasis,Interventional,19-Feb-19,"Merck KGaA, Darmstadt, Germany",Drug: MSB11022
NCT02660580,MSB11022 in Moderate to Severe Chronic Plaque Psoriasis,Psoriasis|Plaque Type Psoriasis|Moderate to Severe Plaque Psoriasis,Interventional,19-Feb-19,"Merck KGaA, Darmstadt, Germany",Drug: Humira®
NCT02269241,"Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles",Contraception,Interventional,23-Jul-19,"Laboratories Leon Farma, S.A.",Drug: LF111 (drospirenone)
NCT02269241,"Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles",Contraception,Interventional,23-Jul-19,Chemo France,Drug: LF111 (drospirenone)
NCT02269241,"Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles",Contraception,Interventional,23-Jul-19,Insud Pharma,Drug: LF111 (drospirenone)
NCT02268214,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,29-Mar-18,AstraZeneca,Drug: Dapagliflozin
NCT02268214,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,29-Mar-18,AstraZeneca,Drug: Placebo for dapagliflozin
NCT02268214,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,29-Mar-18,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT02268214,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,29-Mar-18,Bristol-Myers Squibb,Drug: Placebo for dapagliflozin
NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Interventional,17-Oct-17,Regeneron Pharmaceuticals,Drug: Dupilumab
NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Interventional,17-Oct-17,Regeneron Pharmaceuticals,Drug: Placebo (for Dupilumab)
NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Interventional,17-Oct-17,Regeneron Pharmaceuticals,Other: Topical Corticosteroid (TCS)
NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Interventional,17-Oct-17,Sanofi,Drug: Dupilumab
NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Interventional,17-Oct-17,Sanofi,Drug: Placebo (for Dupilumab)
NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Interventional,17-Oct-17,Sanofi,Other: Topical Corticosteroid (TCS)
NCT02229227,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,29-Jun-18,GlaxoSmithKline,Drug: Albiglutide
NCT02229227,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,29-Jun-18,GlaxoSmithKline,Drug: Insulin Glargine and Insulin Lispro
NCT02229227,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,29-Jun-18,PPD,Drug: Albiglutide
NCT02229227,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,29-Jun-18,PPD,Drug: Insulin Glargine and Insulin Lispro
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Astellas Pharma Europe B.V.,Drug: Fidaxomicin oral suspension
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Astellas Pharma Europe B.V.,Drug: Fidaxomicin tablets
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Astellas Pharma Europe B.V.,Drug: Vancomycin oral liquid
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Astellas Pharma Europe B.V.,Drug: Vancomycin capsules
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Merck Sharp & Dohme Corp.,Drug: Fidaxomicin oral suspension
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Merck Sharp & Dohme Corp.,Drug: Fidaxomicin tablets
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Merck Sharp & Dohme Corp.,Drug: Vancomycin oral liquid
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Merck Sharp & Dohme Corp.,Drug: Vancomycin capsules
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Astellas Pharma Inc,Drug: Fidaxomicin oral suspension
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Astellas Pharma Inc,Drug: Fidaxomicin tablets
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Astellas Pharma Inc,Drug: Vancomycin oral liquid
NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile-associated Diarrhea (CDAD),Interventional,7-Dec-18,Astellas Pharma Inc,Drug: Vancomycin capsules
NCT02196506,Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,21-Aug-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo + ADT
NCT02196506,Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,21-Aug-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Brexpiprazole +ADT
NCT02196506,Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,21-Aug-18,H. Lundbeck A/S,Drug: Placebo + ADT
NCT02196506,Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,21-Aug-18,H. Lundbeck A/S,Drug: Brexpiprazole +ADT
NCT02195986,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Atrophic Vaginitis,Interventional,6-Sep-17,Mylan Inc.,"Drug: Estradiol Vaginal Cream, 0.01%"
NCT02195986,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Atrophic Vaginitis,Interventional,6-Sep-17,Mylan Inc.,Drug: Estrace® 0.01% cream
NCT02195986,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Atrophic Vaginitis,Interventional,6-Sep-17,Mylan Inc.,Drug: Placebo Vaginal Cream
NCT02195986,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Atrophic Vaginitis,Interventional,6-Sep-17,Mylan Pharmaceuticals,"Drug: Estradiol Vaginal Cream, 0.01%"
NCT02195986,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Atrophic Vaginitis,Interventional,6-Sep-17,Mylan Pharmaceuticals,Drug: Estrace® 0.01% cream
NCT02195986,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Atrophic Vaginitis,Interventional,6-Sep-17,Mylan Pharmaceuticals,Drug: Placebo Vaginal Cream
NCT02182830,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2|Hypertension",Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Empagliflozin low dose
NCT02182830,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2|Hypertension",Interventional,31-Jul-18,Boehringer Ingelheim,Drug: placebo
NCT02182830,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2|Hypertension",Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Empagliflozin high dose
NCT02182830,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2|Hypertension",Interventional,31-Jul-18,Eli Lilly and Company,Drug: Empagliflozin low dose
NCT02182830,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2|Hypertension",Interventional,31-Jul-18,Eli Lilly and Company,Drug: placebo
NCT02182830,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2|Hypertension",Interventional,31-Jul-18,Eli Lilly and Company,Drug: Empagliflozin high dose
NCT02155660,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,26-Jun-19,AstraZeneca,Drug: Benralizumab Arm A
NCT02155660,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,26-Jun-19,AstraZeneca,Drug: Benralizumab Arm B
NCT02155660,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,26-Jun-19,AstraZeneca,Drug: Benralizumab Arm C
NCT02155660,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,26-Jun-19,AstraZeneca,Drug: Placebo
NCT02155660,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,26-Jun-19,MedImmune LLC,Drug: Benralizumab Arm A
NCT02155660,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,26-Jun-19,MedImmune LLC,Drug: Benralizumab Arm B
NCT02155660,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,26-Jun-19,MedImmune LLC,Drug: Benralizumab Arm C
NCT02155660,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,26-Jun-19,MedImmune LLC,Drug: Placebo
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Rhodes Pharmaceuticals, L.P.",Drug: Placebo
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Rhodes Pharmaceuticals, L.P.",Drug: PRC-063 25 mg
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Rhodes Pharmaceuticals, L.P.",Drug: PRC-063 45 mg
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Rhodes Pharmaceuticals, L.P.",Drug: PRC-063 70 mg
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Rhodes Pharmaceuticals, L.P.",Drug: PRC-063 100 mg
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Purdue Pharma, Canada",Drug: Placebo
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Purdue Pharma, Canada",Drug: PRC-063 25 mg
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Purdue Pharma, Canada",Drug: PRC-063 45 mg
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Purdue Pharma, Canada",Drug: PRC-063 70 mg
NCT02139124,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,ADHD,Interventional,7-May-19,"Purdue Pharma, Canada",Drug: PRC-063 100 mg
NCT02138916,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,13-Jun-19,AstraZeneca,Drug: Benralizumab Arm A
NCT02138916,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,13-Jun-19,AstraZeneca,Drug: Benralizumab Arm B
NCT02138916,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,13-Jun-19,AstraZeneca,Drug: Placebo
NCT02138916,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,13-Jun-19,MedImmune LLC,Drug: Benralizumab Arm A
NCT02138916,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,13-Jun-19,MedImmune LLC,Drug: Benralizumab Arm B
NCT02138916,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Interventional,13-Jun-19,MedImmune LLC,Drug: Placebo
NCT02134210,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO),Plaque Psoriasis,Interventional,13-May-19,"Coherus Biosciences, Inc.",Drug: Etanercept
NCT02134210,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO),Plaque Psoriasis,Interventional,13-May-19,"Coherus Biosciences, Inc.",Drug: CHS-0214
NCT02134210,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO),Plaque Psoriasis,Interventional,13-May-19,Shire,Drug: Etanercept
NCT02134210,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO),Plaque Psoriasis,Interventional,13-May-19,Shire,Drug: CHS-0214
NCT02121210,To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,20-Jun-17,Sanofi,Drug: sarilumab SAR153191 (REGN88)
NCT02121210,To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,20-Jun-17,Regeneron Pharmaceuticals,Drug: sarilumab SAR153191 (REGN88)
NCT02115750,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,26-Jun-19,"Coherus Biosciences, Inc.",Drug: Etanercept
NCT02115750,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,26-Jun-19,"Coherus Biosciences, Inc.",Drug: CHS-0214
NCT02115750,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,26-Jun-19,"Daiichi Sankyo Co., Ltd.",Drug: Etanercept
NCT02115750,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,26-Jun-19,"Daiichi Sankyo Co., Ltd.",Drug: CHS-0214
NCT02106832,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Bronchiectasis,Interventional,1-Sep-17,Bayer,Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation
NCT02106832,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Bronchiectasis,Interventional,1-Sep-17,Bayer,Drug: Placebo
NCT02106832,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Bronchiectasis,Interventional,1-Sep-17,Novartis,Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation
NCT02106832,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Bronchiectasis,Interventional,1-Sep-17,Novartis,Drug: Placebo
NCT02097745,A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies,Rheumatoid Arthritis,Interventional,7-Nov-14,Hoffmann-La Roche,Drug: methotrexate
NCT02097745,A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies,Rheumatoid Arthritis,Interventional,7-Nov-14,Hoffmann-La Roche,Drug: rituximab [MabThera/Rituxan]
NCT02097745,A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies,Rheumatoid Arthritis,Interventional,7-Nov-14,Biogen,Drug: methotrexate
NCT02097745,A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies,Rheumatoid Arthritis,Interventional,7-Nov-14,Biogen,Drug: rituximab [MabThera/Rituxan]
NCT02064439,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Pulmonary Embolism|Thromboembolism|Thrombosis|Venous Thrombosis|Venous Thromboembolism,Interventional,19-Dec-17,Bayer,Drug: BAY 59-7939
NCT02064439,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Pulmonary Embolism|Thromboembolism|Thrombosis|Venous Thrombosis|Venous Thromboembolism,Interventional,19-Dec-17,Bayer,Drug: ASA
NCT02064439,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Pulmonary Embolism|Thromboembolism|Thrombosis|Venous Thrombosis|Venous Thromboembolism,Interventional,19-Dec-17,"Janssen Scientific Affairs, LLC",Drug: BAY 59-7939
NCT02064439,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Pulmonary Embolism|Thromboembolism|Thrombosis|Venous Thrombosis|Venous Thromboembolism,Interventional,19-Dec-17,"Janssen Scientific Affairs, LLC",Drug: ASA
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Sanofi,Drug: Sarilumab
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Sanofi,Device: Auto-Injector Device (AID)
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Sanofi,Device: Pre-filled Syringe (PFS)
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Sanofi,Drug: Methotrexate
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Sanofi,Drug: Sulfasalazine
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Sanofi,Drug: Leflunomide
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Sanofi,Drug: Hydroxychloroquine
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Regeneron Pharmaceuticals,Drug: Sarilumab
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Regeneron Pharmaceuticals,Device: Auto-Injector Device (AID)
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Regeneron Pharmaceuticals,Device: Pre-filled Syringe (PFS)
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Regeneron Pharmaceuticals,Drug: Methotrexate
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Regeneron Pharmaceuticals,Drug: Sulfasalazine
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Regeneron Pharmaceuticals,Drug: Leflunomide
NCT02057250,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,RA,Interventional,20-Jun-17,Regeneron Pharmaceuticals,Drug: Hydroxychloroquine
NCT02058563,"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",Rubella|Mumps|Measles,Interventional,10-Apr-17,GlaxoSmithKline,Biological: Priorix®
NCT02058563,"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",Rubella|Mumps|Measles,Interventional,10-Apr-17,GlaxoSmithKline,"Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine"
NCT02058563,"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",Rubella|Mumps|Measles,Interventional,10-Apr-17,Parexel,Biological: Priorix®
NCT02058563,"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",Rubella|Mumps|Measles,Interventional,10-Apr-17,Parexel,"Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine"
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,14-Sep-17,"Janssen Research & Development, LLC",Biological: adalimumab 40 mg
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,14-Sep-17,"Janssen Research & Development, LLC",Biological: sirukumab 100 mg
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,14-Sep-17,"Janssen Research & Development, LLC",Biological: sirukumab 50 mg
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,14-Sep-17,"Janssen Research & Development, LLC",Drug: Placebo
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,14-Sep-17,GlaxoSmithKline,Biological: adalimumab 40 mg
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,14-Sep-17,GlaxoSmithKline,Biological: sirukumab 100 mg
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,14-Sep-17,GlaxoSmithKline,Biological: sirukumab 50 mg
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,14-Sep-17,GlaxoSmithKline,Drug: Placebo
NCT02016105,Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira,Plaque Type Psoriasis,Interventional,7-Apr-17,Sandoz,Drug: GP2017 Adalimumab
NCT02016105,Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira,Plaque Type Psoriasis,Interventional,7-Apr-17,Sandoz,Drug: Humira ® Adalimumab
NCT02016105,Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira,Plaque Type Psoriasis,Interventional,7-Apr-17,Hexal AG,Drug: GP2017 Adalimumab
NCT02016105,Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira,Plaque Type Psoriasis,Interventional,7-Apr-17,Hexal AG,Drug: Humira ® Adalimumab
NCT02013622,Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia,Schizophrenia,Interventional,29-Mar-16,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Brexpiprazole
NCT02013622,Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia,Schizophrenia,Interventional,29-Mar-16,"Otsuka Pharmaceutical Co., Ltd.",Drug: Brexpiprazole
NCT02013609,"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment",MDD,Interventional,29-Mar-16,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Brexpiprazole
NCT02013609,"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment",MDD,Interventional,29-Mar-16,"Otsuka Pharmaceutical Co., Ltd.",Drug: Brexpiprazole
NCT02013531,Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms,Major Depressive Disorder|Anxiety,Interventional,29-Mar-16,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Brexpiprazole
NCT02013531,Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms,Major Depressive Disorder|Anxiety,Interventional,29-Mar-16,"Otsuka Pharmaceutical Co., Ltd.",Drug: Brexpiprazole
NCT02012218,Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy,Major Depressive Disorder (MDD),Interventional,8-Oct-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: ADT
NCT02012218,Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy,Major Depressive Disorder (MDD),Interventional,8-Oct-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Brexpiprazole
NCT02012218,Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy,Major Depressive Disorder (MDD),Interventional,8-Oct-15,"Otsuka Pharmaceutical Co., Ltd.",Drug: ADT
NCT02012218,Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy,Major Depressive Disorder (MDD),Interventional,8-Oct-15,"Otsuka Pharmaceutical Co., Ltd.",Drug: Brexpiprazole
NCT02006654,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,Alzheimer's Disease,Interventional,7-Feb-18,H. Lundbeck A/S,Drug: Placebo
NCT02006654,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,Alzheimer's Disease,Interventional,7-Feb-18,H. Lundbeck A/S,Drug: Idalopirdine
NCT02006654,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,Alzheimer's Disease,Interventional,7-Feb-18,"Otsuka Pharmaceutical Co., Ltd.",Drug: Placebo
NCT02006654,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,Alzheimer's Disease,Interventional,7-Feb-18,"Otsuka Pharmaceutical Co., Ltd.",Drug: Idalopirdine
NCT02006641,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Interventional,20-Feb-18,H. Lundbeck A/S,Drug: Placebo
NCT02006641,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Interventional,20-Feb-18,H. Lundbeck A/S,Drug: Idalopirdine
NCT02006641,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Interventional,20-Feb-18,"Otsuka Pharmaceutical Co., Ltd.",Drug: Placebo
NCT02006641,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Interventional,20-Feb-18,"Otsuka Pharmaceutical Co., Ltd.",Drug: Idalopirdine
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Hypercholesterolemia,Interventional,15-Mar-17,Sanofi,Drug: Alirocumab
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Hypercholesterolemia,Interventional,15-Mar-17,Sanofi,Drug: Placebo (for Alirocumab)
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Hypercholesterolemia,Interventional,15-Mar-17,Sanofi,Drug: Non-statin LMT
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Hypercholesterolemia,Interventional,15-Mar-17,Sanofi,Other: Diet Alone
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Hypercholesterolemia,Interventional,15-Mar-17,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Hypercholesterolemia,Interventional,15-Mar-17,Regeneron Pharmaceuticals,Drug: Placebo (for Alirocumab)
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Hypercholesterolemia,Interventional,15-Mar-17,Regeneron Pharmaceuticals,Drug: Non-statin LMT
NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Hypercholesterolemia,Interventional,15-Mar-17,Regeneron Pharmaceuticals,Other: Diet Alone
NCT01955161,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Interventional,19-Sep-17,H. Lundbeck A/S,Drug: Placebo
NCT01955161,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Interventional,19-Sep-17,H. Lundbeck A/S,Drug: Idalopirdine
NCT01955161,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Interventional,19-Sep-17,"Otsuka Pharmaceutical Co., Ltd.",Drug: Placebo
NCT01955161,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Alzheimer's Disease,Interventional,19-Sep-17,"Otsuka Pharmaceutical Co., Ltd.",Drug: Idalopirdine
NCT01954394,Open Label Study of Long Term Safety Evaluation of Alirocumab,Hypercholesterolemia,Interventional,24-Jul-18,Sanofi,Drug: Alirocumab
NCT01954394,Open Label Study of Long Term Safety Evaluation of Alirocumab,Hypercholesterolemia,Interventional,24-Jul-18,Sanofi,Drug: Lipid-Modifying Therapy (LMT)
NCT01954394,Open Label Study of Long Term Safety Evaluation of Alirocumab,Hypercholesterolemia,Interventional,24-Jul-18,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01954394,Open Label Study of Long Term Safety Evaluation of Alirocumab,Hypercholesterolemia,Interventional,24-Jul-18,Regeneron Pharmaceuticals,Drug: Lipid-Modifying Therapy (LMT)
NCT01945593,BAX 855 Continuation,Hemophilia A,Interventional,1-May-19,Baxalta now part of Shire,Biological: BAX855
NCT01945593,BAX 855 Continuation,Hemophilia A,Interventional,1-May-19,"Baxalta Innovations GmbH, now part of Shire",Biological: BAX855
NCT01945593,BAX 855 Continuation,Hemophilia A,Interventional,1-May-19,Shire,Biological: BAX855
NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),Hypercholesterolemia,Interventional,21-Mar-17,Regeneron Pharmaceuticals,Drug: Placebo (for alirocumab)
NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),Hypercholesterolemia,Interventional,21-Mar-17,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),Hypercholesterolemia,Interventional,21-Mar-17,Regeneron Pharmaceuticals,Drug: Statin
NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),Hypercholesterolemia,Interventional,21-Mar-17,Sanofi,Drug: Placebo (for alirocumab)
NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),Hypercholesterolemia,Interventional,21-Mar-17,Sanofi,Drug: Alirocumab
NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),Hypercholesterolemia,Interventional,21-Mar-17,Sanofi,Drug: Statin
NCT01919801,Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Interventional,10-Oct-16,Shire,Drug: Icatibant
NCT01919801,Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Interventional,10-Oct-16,Shire,Drug: Placebo
NCT01919801,Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Interventional,10-Oct-16,PPD,Drug: Icatibant
NCT01919801,Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Interventional,10-Oct-16,PPD,Drug: Placebo
NCT01880424,"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",Irritable Bowel Syndrome With Constipation (IBS-C),Interventional,27-Sep-16,AstraZeneca,Drug: Placebo
NCT01880424,"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",Irritable Bowel Syndrome With Constipation (IBS-C),Interventional,27-Sep-16,AstraZeneca,Drug: Linaclotide
NCT01880424,"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",Irritable Bowel Syndrome With Constipation (IBS-C),Interventional,27-Sep-16,"Ironwood Pharmaceuticals, Inc.",Drug: Placebo
NCT01880424,"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",Irritable Bowel Syndrome With Constipation (IBS-C),Interventional,27-Sep-16,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure|Coronary Artery Disease,Interventional,10-May-19,"Janssen Research & Development, LLC",Drug: Rivaroxaban
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure|Coronary Artery Disease,Interventional,10-May-19,"Janssen Research & Development, LLC",Drug: Placebo
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure|Coronary Artery Disease,Interventional,10-May-19,"Janssen Research & Development, LLC",Other: Standard of care for heart failure and coronary artery disease
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure|Coronary Artery Disease,Interventional,10-May-19,Bayer,Drug: Rivaroxaban
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure|Coronary Artery Disease,Interventional,10-May-19,Bayer,Drug: Placebo
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure|Coronary Artery Disease,Interventional,10-May-19,Bayer,Other: Standard of care for heart failure and coronary artery disease
NCT01856309,Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003,"Arthritis, Rheumatoid",Interventional,6-May-19,"Janssen Research & Development, LLC",Drug: Sirukumab 100 mg
NCT01856309,Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003,"Arthritis, Rheumatoid",Interventional,6-May-19,"Janssen Research & Development, LLC",Drug: Sirukumab 50 mg
NCT01856309,Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003,"Arthritis, Rheumatoid",Interventional,6-May-19,"Janssen Research & Development, LLC",Drug: Placebo
NCT01856309,Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003,"Arthritis, Rheumatoid",Interventional,6-May-19,GlaxoSmithKline,Drug: Sirukumab 100 mg
NCT01856309,Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003,"Arthritis, Rheumatoid",Interventional,6-May-19,GlaxoSmithKline,Drug: Sirukumab 50 mg
NCT01856309,Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003,"Arthritis, Rheumatoid",Interventional,6-May-19,GlaxoSmithKline,Drug: Placebo
NCT01846611,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms,Interventional,6-Feb-19,"Janssen Research & Development, LLC",Drug: Trabectedin
NCT01846611,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms,Interventional,6-Feb-19,"Janssen Research & Development, LLC",Drug: DOXIL
NCT01846611,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms,Interventional,6-Feb-19,"Janssen Research & Development, LLC",Drug: Dexamethasone
NCT01846611,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms,Interventional,6-Feb-19,PharmaMar,Drug: Trabectedin
NCT01846611,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms,Interventional,6-Feb-19,PharmaMar,Drug: DOXIL
NCT01846611,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms,Interventional,6-Feb-19,PharmaMar,Drug: Dexamethasone
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,"Janssen Scientific Affairs, LLC",Drug: rivaroxaban 2.5 mg
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,"Janssen Scientific Affairs, LLC",Drug: rivaroxaban 15 mg
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,"Janssen Scientific Affairs, LLC",Drug: rivaroxaban 10 mg
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,"Janssen Scientific Affairs, LLC",Drug: aspirin (ASA)
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,"Janssen Scientific Affairs, LLC",Drug: vitamin K antagonist (VKA)
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,"Janssen Scientific Affairs, LLC",Drug: clopidogrel
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,"Janssen Scientific Affairs, LLC",Drug: prasugrel
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,"Janssen Scientific Affairs, LLC",Drug: ticagrelor
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,Bayer,Drug: rivaroxaban 2.5 mg
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,Bayer,Drug: rivaroxaban 15 mg
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,Bayer,Drug: rivaroxaban 10 mg
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,Bayer,Drug: aspirin (ASA)
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,Bayer,Drug: vitamin K antagonist (VKA)
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,Bayer,Drug: clopidogrel
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,Bayer,Drug: prasugrel
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-17,Bayer,Drug: ticagrelor
NCT02485717,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,Interventional,16-Jan-19,ParaPRO LLC,"Drug: spinosad topical suspension, 0.9%"
NCT02485717,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,Interventional,16-Jan-19,ParaPRO LLC,Other: Placebo
NCT02485717,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,Interventional,16-Jan-19,Concentrics Research,"Drug: spinosad topical suspension, 0.9%"
NCT02485717,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,Interventional,16-Jan-19,Concentrics Research,Other: Placebo
NCT01810783,Brexpiprazole in Patients With Schizophrenia,Schizophrenia,Interventional,23-Feb-17,H. Lundbeck A/S,Drug: Brexpiprazole
NCT01810783,Brexpiprazole in Patients With Schizophrenia,Schizophrenia,Interventional,23-Feb-17,"Otsuka Pharmaceutical Co., Ltd.",Drug: Brexpiprazole
NCT01799993,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Interventional,26-Jun-18,Bayer,Drug: Amikacin Inhalation Solution (BAY41-6551)
NCT01799993,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Interventional,26-Jun-18,Bayer,Drug: Aerosolized Placebo
NCT01799993,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Interventional,26-Jun-18,Nektar Therapeutics,Drug: Amikacin Inhalation Solution (BAY41-6551)
NCT01799993,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,"Pneumonia, Bacterial",Interventional,26-Jun-18,Nektar Therapeutics,Drug: Aerosolized Placebo
NCT01792518,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","Diabetes Mellitus, Type 2",Interventional,6-Mar-17,Boehringer Ingelheim,Drug: Placebo
NCT01792518,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","Diabetes Mellitus, Type 2",Interventional,6-Mar-17,Boehringer Ingelheim,Drug: Linagliptin 5mg
NCT01792518,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","Diabetes Mellitus, Type 2",Interventional,6-Mar-17,Eli Lilly and Company,Drug: Placebo
NCT01792518,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","Diabetes Mellitus, Type 2",Interventional,6-Mar-17,Eli Lilly and Company,Drug: Linagliptin 5mg
NCT01838681,Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment,Major Depressive Disorder,Interventional,9-Aug-17,H. Lundbeck A/S,Drug: Placebo
NCT01838681,Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment,Major Depressive Disorder,Interventional,9-Aug-17,H. Lundbeck A/S,Drug: Brexpiprazole
NCT01838681,Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment,Major Depressive Disorder,Interventional,9-Aug-17,H. Lundbeck A/S,Drug: ADT
NCT01838681,Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment,Major Depressive Disorder,Interventional,9-Aug-17,"Otsuka Pharmaceutical Co., Ltd.",Drug: Placebo
NCT01838681,Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment,Major Depressive Disorder,Interventional,9-Aug-17,"Otsuka Pharmaceutical Co., Ltd.",Drug: Brexpiprazole
NCT01838681,Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment,Major Depressive Disorder,Interventional,9-Aug-17,"Otsuka Pharmaceutical Co., Ltd.",Drug: ADT
NCT02454959,Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD,COPD,Interventional,19-Apr-17,"Pearl Therapeutics, Inc.",Device: GFF MDI (PT003) with Aerochamber
NCT02454959,Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD,COPD,Interventional,19-Apr-17,"Pearl Therapeutics, Inc.",Device: GFF MDI (PT003) without Aerochamber
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Apr-16,Boehringer Ingelheim,Drug: BI 10773
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Apr-16,Boehringer Ingelheim,Drug: BI 10773 Placebo
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Apr-16,Boehringer Ingelheim,Drug: BI 10773 / BI 1356
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Apr-16,Boehringer Ingelheim,Drug: BI 10773 / BI 1356 Placebo
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Apr-16,Eli Lilly and Company,Drug: BI 10773
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Apr-16,Eli Lilly and Company,Drug: BI 10773 Placebo
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Apr-16,Eli Lilly and Company,Drug: BI 10773 / BI 1356
NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Apr-16,Eli Lilly and Company,Drug: BI 10773 / BI 1356 Placebo
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Sanofi,Drug: sarilumab SAR153191 (REGN88)
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Sanofi,Drug: tocilizumab
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Sanofi,Drug: hydroxychloroquine
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Sanofi,Drug: methotrexate
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Sanofi,Drug: sulfasalazine
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Sanofi,Drug: leflunomide
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Sanofi,Drug: subcutaneous placebo
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Sanofi,Drug: intravenous placebo
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Regeneron Pharmaceuticals,Drug: sarilumab SAR153191 (REGN88)
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Regeneron Pharmaceuticals,Drug: tocilizumab
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Regeneron Pharmaceuticals,Drug: hydroxychloroquine
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Regeneron Pharmaceuticals,Drug: methotrexate
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Regeneron Pharmaceuticals,Drug: sulfasalazine
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Regeneron Pharmaceuticals,Drug: leflunomide
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Regeneron Pharmaceuticals,Drug: subcutaneous placebo
NCT01768572,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Rheumatoid Arthritis,Interventional,26-Jun-17,Regeneron Pharmaceuticals,Drug: intravenous placebo
NCT01764841,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Bronchiectasis,Interventional,24-May-17,Bayer,Drug: Ciprofloxacin DPI (BAYQ3939)
NCT01764841,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Bronchiectasis,Interventional,24-May-17,Bayer,Drug: Placebo
NCT01764841,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Bronchiectasis,Interventional,24-May-17,Novartis,Drug: Ciprofloxacin DPI (BAYQ3939)
NCT01764841,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Bronchiectasis,Interventional,24-May-17,Novartis,Drug: Placebo
NCT02390219,Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease,Cystic Fibrosis|Advanced Lung Disease,Interventional,1-Nov-17,Vertex Pharmaceuticals Incorporated,Drug: Lumacaftor
NCT02390219,Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease,Cystic Fibrosis|Advanced Lung Disease,Interventional,1-Nov-17,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01734785,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,18-Apr-16,Boehringer Ingelheim,Drug: Linagliptin
NCT01734785,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,18-Apr-16,Boehringer Ingelheim,Drug: Empagliflozin + Linagliptin
NCT01734785,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,18-Apr-16,Boehringer Ingelheim,Drug: Empaglifozin placebo + Linagliptin placebo
NCT01734785,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,18-Apr-16,Eli Lilly and Company,Drug: Linagliptin
NCT01734785,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,18-Apr-16,Eli Lilly and Company,Drug: Empagliflozin + Linagliptin
NCT01734785,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,18-Apr-16,Eli Lilly and Company,Drug: Empaglifozin placebo + Linagliptin placebo
NCT01731938,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries,Soft Tissue Surgical Bleeding,Interventional,23-Feb-17,"Grifols Biologicals, LLC",Biological: Fibrin Sealant (FS) Grifols
NCT01731938,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries,Soft Tissue Surgical Bleeding,Interventional,23-Feb-17,"Grifols Biologicals, LLC",Device: Surgicel®
NCT01731938,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries,Soft Tissue Surgical Bleeding,Interventional,23-Feb-17,"Instituto Grifols, S.A.",Biological: Fibrin Sealant (FS) Grifols
NCT01731938,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries,Soft Tissue Surgical Bleeding,Interventional,23-Feb-17,"Instituto Grifols, S.A.",Device: Surgicel®
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Hypercholesterolemia,Interventional,28-Oct-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Hypercholesterolemia,Interventional,28-Oct-15,Regeneron Pharmaceuticals,Drug: Rosuvastatin
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Hypercholesterolemia,Interventional,28-Oct-15,Regeneron Pharmaceuticals,Drug: Ezetimibe
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Hypercholesterolemia,Interventional,28-Oct-15,Regeneron Pharmaceuticals,Drug: Placebo
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Hypercholesterolemia,Interventional,28-Oct-15,Sanofi,Drug: Alirocumab
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Hypercholesterolemia,Interventional,28-Oct-15,Sanofi,Drug: Rosuvastatin
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Hypercholesterolemia,Interventional,28-Oct-15,Sanofi,Drug: Ezetimibe
NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Hypercholesterolemia,Interventional,28-Oct-15,Sanofi,Drug: Placebo
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Regeneron Pharmaceuticals,Drug: Atorvastatin
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Regeneron Pharmaceuticals,Drug: Ezetimibe
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Regeneron Pharmaceuticals,Drug: Rosuvastatin
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Regeneron Pharmaceuticals,Drug: Placebo
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Sanofi,Drug: Alirocumab
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Sanofi,Drug: Atorvastatin
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Sanofi,Drug: Ezetimibe
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Sanofi,Drug: Rosuvastatin
NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Hypercholesterolemia,Interventional,31-Aug-15,Sanofi,Drug: Placebo
NCT01729871,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,Atrial Fibrillation,Interventional,10-Nov-15,"Janssen Scientific Affairs, LLC",Drug: rivaroxaban
NCT01729871,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,Atrial Fibrillation,Interventional,10-Nov-15,"Janssen Scientific Affairs, LLC",Drug: uninterrupted vitamin K antagonist (VKA)
NCT01729871,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,Atrial Fibrillation,Interventional,10-Nov-15,Bayer,Drug: rivaroxaban
NCT01729871,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,Atrial Fibrillation,Interventional,10-Nov-15,Bayer,Drug: uninterrupted vitamin K antagonist (VKA)
NCT01722487,Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Interventional,4-May-16,Pharmacyclics LLC.,Drug: Ibrutinib
NCT01722487,Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Interventional,4-May-16,Pharmacyclics LLC.,Drug: Chlorambucil
NCT01722487,Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Interventional,4-May-16,"Janssen Research & Development, LLC",Drug: Ibrutinib
NCT01722487,Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Interventional,4-May-16,"Janssen Research & Development, LLC",Drug: Chlorambucil
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Boehringer Ingelheim,Drug: Metformin 500 mg bid
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Boehringer Ingelheim,Drug: Metformin 1000 mg bid
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Boehringer Ingelheim,Drug: Empagliflozin low dose qd
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Boehringer Ingelheim,Drug: Empagliflozin high dose qd
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Boehringer Ingelheim,Drug: Empagliflozin low dose bid
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Boehringer Ingelheim,Drug: Empagliflozin high dose bid
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Eli Lilly and Company,Drug: Metformin 500 mg bid
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Eli Lilly and Company,Drug: Metformin 1000 mg bid
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Eli Lilly and Company,Drug: Empagliflozin low dose qd
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Eli Lilly and Company,Drug: Empagliflozin high dose qd
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Eli Lilly and Company,Drug: Empagliflozin low dose bid
NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2|Hyperglycemia",Interventional,19-Feb-16,Eli Lilly and Company,Drug: Empagliflozin high dose bid
NCT01710709,Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder,Bipolar I,Interventional,8-Aug-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT01710709,Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder,Bipolar I,Interventional,8-Aug-18,H. Lundbeck A/S,Drug: Aripiprazole
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Sanofi,Drug: Sarilumab
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Sanofi,Drug: placebo
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Sanofi,Drug: hydroxychloroquine
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Sanofi,Drug: methotrexate
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Sanofi,Drug: sulfasalazine
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Sanofi,Drug: leflunomide
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Regeneron Pharmaceuticals,Drug: Sarilumab
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Regeneron Pharmaceuticals,Drug: placebo
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Regeneron Pharmaceuticals,Drug: hydroxychloroquine
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Regeneron Pharmaceuticals,Drug: methotrexate
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Regeneron Pharmaceuticals,Drug: sulfasalazine
NCT01709578,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Rheumatoid Arthritis,Interventional,8-Aug-17,Regeneron Pharmaceuticals,Drug: leflunomide
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Hypercholesterolemia,Interventional,28-Aug-15,Regeneron Pharmaceuticals,Drug: Atorvastatin
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Hypercholesterolemia,Interventional,28-Aug-15,Regeneron Pharmaceuticals,Drug: Ezetimibe
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Hypercholesterolemia,Interventional,28-Aug-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Hypercholesterolemia,Interventional,28-Aug-15,Regeneron Pharmaceuticals,Drug: Placebo
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Hypercholesterolemia,Interventional,28-Aug-15,Sanofi,Drug: Atorvastatin
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Hypercholesterolemia,Interventional,28-Aug-15,Sanofi,Drug: Ezetimibe
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Hypercholesterolemia,Interventional,28-Aug-15,Sanofi,Drug: Alirocumab
NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Hypercholesterolemia,Interventional,28-Aug-15,Sanofi,Drug: Placebo
NCT01701024,Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne,Acne,Interventional,10-Jan-17,"Bausch Health Americas, Inc.",Drug: ACYC
NCT01701024,Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne,Acne,Interventional,10-Jan-17,"Bausch Health Americas, Inc.",Drug: ACYC vehicle
NCT01701024,Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne,Acne,Interventional,10-Jan-17,Dow Pharmaceutical Sciences,Drug: ACYC
NCT01701024,Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne,Acne,Interventional,10-Jan-17,Dow Pharmaceutical Sciences,Drug: ACYC vehicle
NCT01674647,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,Atrial Fibrillation,Interventional,3-Feb-15,Bayer,"Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT01674647,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,Atrial Fibrillation,Interventional,3-Feb-15,Bayer,Drug: Vitamin K antagonist (VKA)
NCT01674647,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,Atrial Fibrillation,Interventional,3-Feb-15,"Janssen Research & Development, LLC","Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT01674647,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,Atrial Fibrillation,Interventional,3-Feb-15,"Janssen Research & Development, LLC",Drug: Vitamin K antagonist (VKA)
NCT02905825,Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics,Helicobacter Pylori Infection,Interventional,4-Jul-18,Exalenz Bioscience LTD.,Device: BreathID® Hp System
NCT02905825,Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics,Helicobacter Pylori Infection,Interventional,4-Jul-18,Exalenz Bioscience LTD.,Drug: BreathID® Hp Lab System
NCT02905825,Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics,Helicobacter Pylori Infection,Interventional,4-Jul-18,Exalenz Bioscience LTD.,Diagnostic Test: Stool Test
NCT01668797,"Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",Acute Schizophrenia,Interventional,13-Jan-17,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Brexpiprazole
NCT01668797,"Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",Acute Schizophrenia,Interventional,13-Jan-17,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT01668797,"Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",Acute Schizophrenia,Interventional,13-Jan-17,"Quintiles, Inc.",Drug: Brexpiprazole
NCT01668797,"Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",Acute Schizophrenia,Interventional,13-Jan-17,"Quintiles, Inc.",Drug: Placebo
NCT01663623,Belimumab in Remission of VASculitis,Vasculitis,Interventional,17-Apr-18,"Human Genome Sciences Inc., a GSK Company",Biological: Placebo
NCT01663623,Belimumab in Remission of VASculitis,Vasculitis,Interventional,17-Apr-18,"Human Genome Sciences Inc., a GSK Company",Biological: Belimumab 10 mg/kg
NCT01663623,Belimumab in Remission of VASculitis,Vasculitis,Interventional,17-Apr-18,"Human Genome Sciences Inc., a GSK Company",Drug: Azathioprine
NCT01663623,Belimumab in Remission of VASculitis,Vasculitis,Interventional,17-Apr-18,GlaxoSmithKline,Biological: Placebo
NCT01663623,Belimumab in Remission of VASculitis,Vasculitis,Interventional,17-Apr-18,GlaxoSmithKline,Biological: Belimumab 10 mg/kg
NCT01663623,Belimumab in Remission of VASculitis,Vasculitis,Interventional,17-Apr-18,GlaxoSmithKline,Drug: Azathioprine
NCT01663402,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Atherosclerotic Cardiovascular Disease,Interventional,18-Mar-19,Sanofi,Drug: Alirocumab
NCT01663402,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Atherosclerotic Cardiovascular Disease,Interventional,18-Mar-19,Sanofi,Drug: Placebo
NCT01663402,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Atherosclerotic Cardiovascular Disease,Interventional,18-Mar-19,Sanofi,Drug: LMT
NCT01663402,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Atherosclerotic Cardiovascular Disease,Interventional,18-Mar-19,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01663402,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Atherosclerotic Cardiovascular Disease,Interventional,18-Mar-19,Regeneron Pharmaceuticals,Drug: Placebo
NCT01663402,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Atherosclerotic Cardiovascular Disease,Interventional,18-Mar-19,Regeneron Pharmaceuticals,Drug: LMT
NCT01656889,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers,Venous Leg Ulcers,Interventional,14-Mar-16,Healthpoint,Biological: HP-802-247
NCT01656889,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers,Venous Leg Ulcers,Interventional,14-Mar-16,Healthpoint,Biological: Vehicle
NCT01656889,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers,Venous Leg Ulcers,Interventional,14-Mar-16,"Smith & Nephew, Inc.",Biological: HP-802-247
NCT01656889,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers,Venous Leg Ulcers,Interventional,14-Mar-16,"Smith & Nephew, Inc.",Biological: Vehicle
NCT02537431,Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH),X-linked Hypophosphatemia,Interventional,25-Sep-18,Ultragenyx Pharmaceutical Inc,Biological: burosumab
NCT02537431,Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH),X-linked Hypophosphatemia,Interventional,25-Sep-18,"Kyowa Kirin Co., Ltd.",Biological: burosumab
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Alirocumab
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Placebo (for alirocumab)
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Ezetimibe
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Placebo (for ezetimibe)
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Lipid Modifying Therapy (LMT)
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Placebo (for alirocumab)
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Ezetimibe
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Placebo (for ezetimibe)
NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Lipid Modifying Therapy (LMT)
NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Placebo (for alirocumab)
NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Alirocumab
NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Lipid-Modifying Therapy (LMT)
NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Placebo (for alirocumab)
NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Lipid-Modifying Therapy (LMT)
NCT01642914,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation|Constipation,Interventional,26-Apr-16,Forest Laboratories,Drug: Linaclotide 290 micrograms
NCT01642914,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation|Constipation,Interventional,26-Apr-16,Forest Laboratories,Drug: Linaclotide 145 micrograms
NCT01642914,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation|Constipation,Interventional,26-Apr-16,Forest Laboratories,Drug: Matching placebo
NCT01642914,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation|Constipation,Interventional,26-Apr-16,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide 290 micrograms
NCT01642914,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation|Constipation,Interventional,26-Apr-16,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide 145 micrograms
NCT01642914,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation|Constipation,Interventional,26-Apr-16,"Ironwood Pharmaceuticals, Inc.",Drug: Matching placebo
NCT01634152,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma,Asthma,Interventional,21-Dec-15,Boehringer Ingelheim,Drug: Placebo
NCT01634152,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma,Asthma,Interventional,21-Dec-15,Boehringer Ingelheim,Drug: Tiotropium low dose mcg
NCT01634152,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma,Asthma,Interventional,21-Dec-15,Boehringer Ingelheim,Drug: Tiotropium high dose
NCT01634152,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma,Asthma,Interventional,21-Dec-15,Pfizer,Drug: Placebo
NCT01634152,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma,Asthma,Interventional,21-Dec-15,Pfizer,Drug: Tiotropium low dose mcg
NCT01634152,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma,Asthma,Interventional,21-Dec-15,Pfizer,Drug: Tiotropium high dose
NCT01625182,Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Interventional,19-Sep-17,Novartis Pharmaceuticals,Drug: Fingolimod
NCT01625182,Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Interventional,19-Sep-17,Novartis Pharmaceuticals,Drug: Placebo Comparator
NCT01625182,Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Interventional,19-Sep-17,Mitsubishi Tanabe Pharma Corporation,Drug: Fingolimod
NCT01625182,Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Interventional,19-Sep-17,Mitsubishi Tanabe Pharma Corporation,Drug: Placebo Comparator
NCT01625182,Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Interventional,19-Sep-17,Novartis,Drug: Fingolimod
NCT01625182,Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Interventional,19-Sep-17,Novartis,Drug: Placebo Comparator
NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,Hypercholesterolemia,Interventional,4-Nov-15,Sanofi,Drug: Alirocumab
NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,Hypercholesterolemia,Interventional,4-Nov-15,Sanofi,Drug: Placebo (for alirocumab)
NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,Hypercholesterolemia,Interventional,4-Nov-15,Sanofi,Drug: Lipid Modifying Therapy (LMT)
NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,Hypercholesterolemia,Interventional,4-Nov-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,Hypercholesterolemia,Interventional,4-Nov-15,Regeneron Pharmaceuticals,Drug: Placebo (for alirocumab)
NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,Hypercholesterolemia,Interventional,4-Nov-15,Regeneron Pharmaceuticals,Drug: Lipid Modifying Therapy (LMT)
NCT01617655,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),Hypercholesterolaemia,Interventional,6-Nov-15,Sanofi,Drug: Alirocumab
NCT01617655,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),Hypercholesterolaemia,Interventional,6-Nov-15,Sanofi,Drug: Placebo (for alirocumab)
NCT01617655,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),Hypercholesterolaemia,Interventional,6-Nov-15,Sanofi,Drug: Lipid Modifying Therapy (LMT)
NCT01617655,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),Hypercholesterolaemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01617655,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),Hypercholesterolaemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Placebo (for alirocumab)
NCT01617655,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),Hypercholesterolaemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Lipid Modifying Therapy (LMT)
NCT01606761,"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","Arthritis, Rheumatoid",Interventional,5-Feb-18,"Janssen Research & Development, LLC",Drug: Placebo
NCT01606761,"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","Arthritis, Rheumatoid",Interventional,5-Feb-18,"Janssen Research & Development, LLC",Drug: Sirukumab
NCT01606761,"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","Arthritis, Rheumatoid",Interventional,5-Feb-18,GlaxoSmithKline,Drug: Placebo
NCT01606761,"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","Arthritis, Rheumatoid",Interventional,5-Feb-18,GlaxoSmithKline,Drug: Sirukumab
NCT01604343,"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","Arthritis, Rheumatoid",Interventional,11-Jan-18,"Janssen Research & Development, LLC",Drug: Placebo
NCT01604343,"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","Arthritis, Rheumatoid",Interventional,11-Jan-18,"Janssen Research & Development, LLC",Drug: Sirukumab
NCT01604343,"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","Arthritis, Rheumatoid",Interventional,11-Jan-18,GlaxoSmithKline,Drug: Placebo
NCT01604343,"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","Arthritis, Rheumatoid",Interventional,11-Jan-18,GlaxoSmithKline,Drug: Sirukumab
NCT01578707,A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Relapsed or Refractory Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Interventional,12-Oct-15,Pharmacyclics LLC.,Drug: ofatumumab
NCT01578707,A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Relapsed or Refractory Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Interventional,12-Oct-15,Pharmacyclics LLC.,Drug: ibrutinib
NCT01578707,A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Relapsed or Refractory Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Interventional,12-Oct-15,"Janssen Research & Development, LLC",Drug: ofatumumab
NCT01578707,A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Relapsed or Refractory Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Interventional,12-Oct-15,"Janssen Research & Development, LLC",Drug: ibrutinib
NCT01571284,Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,Colorectal Cancer Metastatic,Interventional,27-Feb-18,Sanofi,Drug: AFLIBERCEPT AVE0005
NCT01571284,Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,Colorectal Cancer Metastatic,Interventional,27-Feb-18,Sanofi,Drug: FOLFIRI
NCT01571284,Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,Colorectal Cancer Metastatic,Interventional,27-Feb-18,Regeneron Pharmaceuticals,Drug: AFLIBERCEPT AVE0005
NCT01571284,Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,Colorectal Cancer Metastatic,Interventional,27-Feb-18,Regeneron Pharmaceuticals,Drug: FOLFIRI
NCT01567527,"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients",Bipolar I Disorder,Interventional,24-Aug-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Intramuscular (IM) Depot Aripiprazole
NCT01567527,"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients",Bipolar I Disorder,Interventional,24-Aug-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Intramuscular (IM) Depot Placebo
NCT01567527,"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients",Bipolar I Disorder,Interventional,24-Aug-18,H. Lundbeck A/S,Drug: Intramuscular (IM) Depot Aripiprazole
NCT01567527,"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients",Bipolar I Disorder,Interventional,24-Aug-18,H. Lundbeck A/S,Drug: Intramuscular (IM) Depot Placebo
NCT01574612,Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old,Herpes Labialis,Interventional,22-May-14,Meda Pharmaceuticals,Drug: acyclovir/hydrocortisone cream
NCT01574612,Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old,Herpes Labialis,Interventional,22-May-14,"TKL Research, Inc.",Drug: acyclovir/hydrocortisone cream
NCT01564784,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Interventional,17-Jan-18,Pfizer,Drug: inotuzumab ozogamicin
NCT01564784,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Interventional,17-Jan-18,Pfizer,"Drug: FLAG (fludarabine, cytarabine and G-CSF)"
NCT01564784,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Interventional,17-Jan-18,Pfizer,Drug: HIDAC (high dose cytarabine)
NCT01564784,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Interventional,17-Jan-18,Pfizer,Drug: cytarabine and mitoxantrone
NCT01564784,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Interventional,17-Jan-18,UCB Pharma,Drug: inotuzumab ozogamicin
NCT01564784,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Interventional,17-Jan-18,UCB Pharma,"Drug: FLAG (fludarabine, cytarabine and G-CSF)"
NCT01564784,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Interventional,17-Jan-18,UCB Pharma,Drug: HIDAC (high dose cytarabine)
NCT01564784,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Interventional,17-Jan-18,UCB Pharma,Drug: cytarabine and mitoxantrone
NCT01559922,Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction,Atrophic Acne Scar,Interventional,14-Feb-17,"Suneva Medical, Inc.",Drug: Normal Saline
NCT01559922,Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction,Atrophic Acne Scar,Interventional,14-Feb-17,"Suneva Medical, Inc.",Device: Artefill
NCT01559922,Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction,Atrophic Acne Scar,Interventional,14-Feb-17,ethica Clinical Research Inc.,Drug: Normal Saline
NCT01559922,Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction,Atrophic Acne Scar,Interventional,14-Feb-17,ethica Clinical Research Inc.,Device: Artefill
NCT01545076,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Interventional,4-Jul-18,CSL Behring,Biological: IgPro20 (low dose)
NCT01545076,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Interventional,4-Jul-18,CSL Behring,Biological: Placebo
NCT01545076,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Interventional,4-Jul-18,CSL Behring,Biological: IgPro10
NCT01545076,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Interventional,4-Jul-18,CSL Behring,Biological: IgPro20 (high dose)
NCT01545076,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Interventional,4-Jul-18,ICON Clinical Research,Biological: IgPro20 (low dose)
NCT01545076,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Interventional,4-Jul-18,ICON Clinical Research,Biological: Placebo
NCT01545076,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Interventional,4-Jul-18,ICON Clinical Research,Biological: IgPro10
NCT01545076,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Interventional,4-Jul-18,ICON Clinical Research,Biological: IgPro20 (high dose)
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,"Millennium Pharmaceuticals, Inc.",Drug: Brentuximab Vedotin
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,"Millennium Pharmaceuticals, Inc.",Drug: Methotrexate
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,"Millennium Pharmaceuticals, Inc.",Drug: Bexarotene
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,"Seattle Genetics, Inc.",Drug: Brentuximab Vedotin
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,"Seattle Genetics, Inc.",Drug: Methotrexate
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,"Seattle Genetics, Inc.",Drug: Bexarotene
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,Takeda,Drug: Brentuximab Vedotin
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,Takeda,Drug: Methotrexate
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Interventional,16-Mar-18,Takeda,Drug: Bexarotene
NCT01521559,Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO),Branch Retinal Vein Occlusion,Interventional,13-Nov-14,Regeneron Pharmaceuticals,Procedure: Macular Laser Photocoagulation
NCT01521559,Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO),Branch Retinal Vein Occlusion,Interventional,13-Nov-14,Regeneron Pharmaceuticals,Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
NCT01521559,Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO),Branch Retinal Vein Occlusion,Interventional,13-Nov-14,Bayer,Procedure: Macular Laser Photocoagulation
NCT01521559,Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO),Branch Retinal Vein Occlusion,Interventional,13-Nov-14,Bayer,Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
NCT01516736,Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim,Chemotherapy-induced Neutropenia|Breast Cancer,Interventional,28-Jun-17,Sandoz,Drug: LA-EP2006
NCT01516736,Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim,Chemotherapy-induced Neutropenia|Breast Cancer,Interventional,28-Jun-17,Sandoz,Drug: Neulasta®
NCT01516736,Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim,Chemotherapy-induced Neutropenia|Breast Cancer,Interventional,28-Jun-17,Sandoz GmbH,Drug: LA-EP2006
NCT01516736,Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim,Chemotherapy-induced Neutropenia|Breast Cancer,Interventional,28-Jun-17,Sandoz GmbH,Drug: Neulasta®
NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Hypercholesterolemia,Interventional,22-Dec-15,Sanofi,Drug: Placebo (for alirocumab)
NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Hypercholesterolemia,Interventional,22-Dec-15,Sanofi,Drug: Alirocumab
NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Hypercholesterolemia,Interventional,22-Dec-15,Sanofi,Drug: Lipid-Modifying Therapy (LMT)
NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Hypercholesterolemia,Interventional,22-Dec-15,Regeneron Pharmaceuticals,Drug: Placebo (for alirocumab)
NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Hypercholesterolemia,Interventional,22-Dec-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Hypercholesterolemia,Interventional,22-Dec-15,Regeneron Pharmaceuticals,Drug: Lipid-Modifying Therapy (LMT)
NCT01500135,Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery,Bleeding,Interventional,8-Feb-17,Takeda,Drug: TachoSil®
NCT01500135,Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery,Bleeding,Interventional,8-Feb-17,Takeda,Drug: Surgicel® Original
NCT01500135,Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery,Bleeding,Interventional,8-Feb-17,Baxter Healthcare Corporation,Drug: TachoSil®
NCT01500135,Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery,Bleeding,Interventional,8-Feb-17,Baxter Healthcare Corporation,Drug: Surgicel® Original
NCT01499277,Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,Complicated Skin and Soft Tissue Infection,Interventional,9-Nov-15,Pfizer,Drug: Ceftaroline fosamil
NCT01499277,Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,Complicated Skin and Soft Tissue Infection,Interventional,9-Nov-15,Pfizer,Drug: Vancomycin
NCT01499277,Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,Complicated Skin and Soft Tissue Infection,Interventional,9-Nov-15,Pfizer,Drug: Aztreonam
NCT01499277,Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,Complicated Skin and Soft Tissue Infection,Interventional,9-Nov-15,Forest Laboratories,Drug: Ceftaroline fosamil
NCT01499277,Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,Complicated Skin and Soft Tissue Infection,Interventional,9-Nov-15,Forest Laboratories,Drug: Vancomycin
NCT01499277,Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,Complicated Skin and Soft Tissue Infection,Interventional,9-Nov-15,Forest Laboratories,Drug: Aztreonam
NCT01484496,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Interventional,25-Jul-17,"Human Genome Sciences Inc., a GSK Company",Biological: Placebo
NCT01484496,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Interventional,25-Jul-17,"Human Genome Sciences Inc., a GSK Company",Biological: Belimumab 200 mg SC
NCT01484496,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Interventional,25-Jul-17,"Human Genome Sciences Inc., a GSK Company",Drug: Standard therapy
NCT01484496,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Interventional,25-Jul-17,GlaxoSmithKline,Biological: Placebo
NCT01484496,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Interventional,25-Jul-17,GlaxoSmithKline,Biological: Belimumab 200 mg SC
NCT01484496,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Interventional,25-Jul-17,GlaxoSmithKline,Drug: Standard therapy
NCT01473420,A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Chronic Renal Failure|Chronic Kidney Disease,Interventional,20-Jun-18,Pfizer,Biological: Epoetin Hospira
NCT01473420,A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Chronic Renal Failure|Chronic Kidney Disease,Interventional,20-Jun-18,Pfizer,Biological: Epogen Amgen
NCT01473420,A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Chronic Renal Failure|Chronic Kidney Disease,Interventional,20-Jun-18,"Hospira, now a wholly owned subsidiary of Pfizer",Biological: Epoetin Hospira
NCT01473420,A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Chronic Renal Failure|Chronic Kidney Disease,Interventional,20-Jun-18,"Hospira, now a wholly owned subsidiary of Pfizer",Biological: Epogen Amgen
NCT01473407,A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Chronic Kidney Disease|Chronic Renal Failure,Interventional,13-Jul-18,Pfizer,Biological: Epoetin Hospira
NCT01473407,A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Chronic Kidney Disease|Chronic Renal Failure,Interventional,13-Jul-18,Pfizer,Biological: Epogen (Amgen)
NCT01473407,A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Chronic Kidney Disease|Chronic Renal Failure,Interventional,13-Jul-18,"Hospira, now a wholly owned subsidiary of Pfizer",Biological: Epoetin Hospira
NCT01473407,A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Chronic Kidney Disease|Chronic Renal Failure,Interventional,13-Jul-18,"Hospira, now a wholly owned subsidiary of Pfizer",Biological: Epogen (Amgen)
NCT01463293,B. Lactis HN019 for Functional Constipation,Constipation,Interventional,24-Jul-14,Fonterra Research Centre,Dietary Supplement: B. lactis HN019
NCT01463293,B. Lactis HN019 for Functional Constipation,Constipation,Interventional,24-Jul-14,Fonterra Research Centre,Dietary Supplement: Placebo
NCT01463293,B. Lactis HN019 for Functional Constipation,Constipation,Interventional,24-Jul-14,DuPont Nutrition and Health,Dietary Supplement: B. lactis HN019
NCT01463293,B. Lactis HN019 for Functional Constipation,Constipation,Interventional,24-Jul-14,DuPont Nutrition and Health,Dietary Supplement: Placebo
NCT01458106,"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A",Hemophilia A,Interventional,12-Dec-14,Bioverativ Therapeutics Inc.,Drug: BIIB031 (rFVIIIFc)
NCT01458106,"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A",Hemophilia A,Interventional,12-Dec-14,Bioverativ Therapeutics Inc.,Drug: FVIII (PK subgroup only)
NCT01458106,"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A",Hemophilia A,Interventional,12-Dec-14,Swedish Orphan Biovitrum,Drug: BIIB031 (rFVIIIFc)
NCT01458106,"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A",Hemophilia A,Interventional,12-Dec-14,Swedish Orphan Biovitrum,Drug: FVIII (PK subgroup only)
NCT01449929,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","Infection, Human Immunodeficiency Virus",Interventional,27-Mar-14,ViiV Healthcare,Drug: dolutegravir 50 mg OAD
NCT01449929,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","Infection, Human Immunodeficiency Virus",Interventional,27-Mar-14,ViiV Healthcare,Drug: darunavir 800mg OAD
NCT01449929,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","Infection, Human Immunodeficiency Virus",Interventional,27-Mar-14,ViiV Healthcare,Drug: ritonavir 100mg OAD
NCT01449929,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","Infection, Human Immunodeficiency Virus",Interventional,27-Mar-14,GlaxoSmithKline,Drug: dolutegravir 50 mg OAD
NCT01449929,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","Infection, Human Immunodeficiency Virus",Interventional,27-Mar-14,GlaxoSmithKline,Drug: darunavir 800mg OAD
NCT01449929,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","Infection, Human Immunodeficiency Virus",Interventional,27-Mar-14,GlaxoSmithKline,Drug: ritonavir 100mg OAD
NCT01465997,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,Epilepsy|Monotherapy,Interventional,2-Aug-17,UCB BIOSCIENCES GmbH,Drug: Lacosamide
NCT01465997,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,Epilepsy|Monotherapy,Interventional,2-Aug-17,UCB BIOSCIENCES GmbH,Drug: Carbamazepine-Controlled Release (CBZ-CR)
NCT01465997,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,Epilepsy|Monotherapy,Interventional,2-Aug-17,Eden Sarl,Drug: Lacosamide
NCT01465997,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,Epilepsy|Monotherapy,Interventional,2-Aug-17,Eden Sarl,Drug: Carbamazepine-Controlled Release (CBZ-CR)
NCT01465997,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,Epilepsy|Monotherapy,Interventional,2-Aug-17,UCB Pharma,Drug: Lacosamide
NCT01465997,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,Epilepsy|Monotherapy,Interventional,2-Aug-17,UCB Pharma,Drug: Carbamazepine-Controlled Release (CBZ-CR)
NCT01440569,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: COBI
NCT01440569,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: DRV
NCT01440569,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: NRTIs
NCT01440569,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,28-Oct-14,"Janssen Research & Development, LLC",Drug: COBI
NCT01440569,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,28-Oct-14,"Janssen Research & Development, LLC",Drug: DRV
NCT01440569,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,28-Oct-14,"Janssen Research & Development, LLC",Drug: NRTIs
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: high dose FDC
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: BI 10773 high dose
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: high dose FDC placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: low dose FDC placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: high dose BI 10773 placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: low dose FDC
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: BI 10773 low dose
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: linagliptin
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: linagliptin placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: BI 10773 low dose placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Boehringer Ingelheim,Drug: low dose BI 10773 placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: high dose FDC
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: BI 10773 high dose
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: high dose FDC placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: low dose FDC placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: high dose BI 10773 placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: low dose FDC
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: BI 10773 low dose
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: linagliptin
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: linagliptin placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: BI 10773 low dose placebo
NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Interventional,2-Apr-15,Eli Lilly and Company,Drug: low dose BI 10773 placebo
NCT01421459,A Study in Adults With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,9-Oct-14,Eli Lilly and Company,Drug: LY2963016
NCT01421459,A Study in Adults With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,9-Oct-14,Eli Lilly and Company,Drug: Lantus
NCT01421459,A Study in Adults With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,9-Oct-14,Eli Lilly and Company,Drug: OAMs
NCT01421459,A Study in Adults With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,9-Oct-14,Boehringer Ingelheim,Drug: LY2963016
NCT01421459,A Study in Adults With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,9-Oct-14,Boehringer Ingelheim,Drug: Lantus
NCT01421459,A Study in Adults With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,9-Oct-14,Boehringer Ingelheim,Drug: OAMs
NCT01421147,A Study in Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,9-Oct-14,Eli Lilly and Company,Drug: LY2963016
NCT01421147,A Study in Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,9-Oct-14,Eli Lilly and Company,Drug: Lantus
NCT01421147,A Study in Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,9-Oct-14,Eli Lilly and Company,Drug: Insulin Lispro
NCT01421147,A Study in Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,9-Oct-14,Boehringer Ingelheim,Drug: LY2963016
NCT01421147,A Study in Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,9-Oct-14,Boehringer Ingelheim,Drug: Lantus
NCT01421147,A Study in Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,9-Oct-14,Boehringer Ingelheim,Drug: Insulin Lispro
NCT01412060,A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia,Schizophrenia,Interventional,6-Jul-18,Forest Laboratories,Drug: Placebo
NCT01412060,A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia,Schizophrenia,Interventional,6-Jul-18,Forest Laboratories,Drug: Cariprazine
NCT01412060,A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia,Schizophrenia,Interventional,6-Jul-18,Gedeon Richter Ltd.,Drug: Placebo
NCT01412060,A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia,Schizophrenia,Interventional,6-Jul-18,Gedeon Richter Ltd.,Drug: Cariprazine
NCT01376297,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Helsinn Healthcare SA,Drug: Netupitant and Palonosetron
NCT01376297,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Helsinn Healthcare SA,Drug: Aprepitant
NCT01376297,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Helsinn Healthcare SA,Drug: Palonosetron
NCT01376297,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Helsinn Healthcare SA,Drug: Dexamethasone
NCT01376297,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Parexel,Drug: Netupitant and Palonosetron
NCT01376297,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Parexel,Drug: Aprepitant
NCT01376297,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Parexel,Drug: Palonosetron
NCT01376297,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Parexel,Drug: Dexamethasone
NCT01370005,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Hypertension",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: Placebo
NCT01370005,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Hypertension",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: BI 10773
NCT01370005,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Hypertension",Interventional,17-Jun-14,Eli Lilly and Company,Drug: Placebo
NCT01370005,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Hypertension",Interventional,17-Jun-14,Eli Lilly and Company,Drug: BI 10773
NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,Diabetic Macular Edema,Interventional,20-Apr-15,Regeneron Pharmaceuticals,Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,Diabetic Macular Edema,Interventional,20-Apr-15,Regeneron Pharmaceuticals,Procedure: Macular Laser Photocoagulation
NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,Diabetic Macular Edema,Interventional,20-Apr-15,Bayer,Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,Diabetic Macular Edema,Interventional,20-Apr-15,Bayer,Procedure: Macular Laser Photocoagulation
NCT01361607,Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer,Pain|Advanced Cancer,Interventional,23-Apr-18,GW Pharmaceuticals Ltd.,Drug: Nabiximols
NCT01361607,Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer,Pain|Advanced Cancer,Interventional,23-Apr-18,GW Pharmaceuticals Ltd.,Drug: Placebo (GA-0034)
NCT01361607,Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer,Pain|Advanced Cancer,Interventional,23-Apr-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Nabiximols
NCT01361607,Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer,Pain|Advanced Cancer,Interventional,23-Apr-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo (GA-0034)
NCT01363479,An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Helsinn Healthcare SA,Drug: Oral palonosetron
NCT01363479,An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Helsinn Healthcare SA,Drug: I.V. palonosetron
NCT01363479,An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Helsinn Healthcare SA,Drug: Dexamethasone
NCT01363479,An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Parexel,Drug: Oral palonosetron
NCT01363479,An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Parexel,Drug: I.V. palonosetron
NCT01363479,An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,17-Nov-14,Parexel,Drug: Dexamethasone
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Interventional,7-Mar-18,Amgen,Drug: Denosumab
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Interventional,7-Mar-18,Amgen,Drug: Zoledronic acid
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Interventional,7-Mar-18,Amgen,Drug: Placebo to Denosumab
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Interventional,7-Mar-18,Amgen,Drug: Placebo to zoledronic acid
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Interventional,7-Mar-18,"Daiichi Sankyo, Inc.",Drug: Denosumab
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Interventional,7-Mar-18,"Daiichi Sankyo, Inc.",Drug: Zoledronic acid
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Interventional,7-Mar-18,"Daiichi Sankyo, Inc.",Drug: Placebo to Denosumab
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Interventional,7-Mar-18,"Daiichi Sankyo, Inc.",Drug: Placebo to zoledronic acid
NCT01343277,A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma,Advanced Liposarcoma or Leiomyosarcoma,Interventional,28-Jan-16,"Janssen Research & Development, LLC",Drug: Trabectedin
NCT01343277,A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma,Advanced Liposarcoma or Leiomyosarcoma,Interventional,28-Jan-16,"Janssen Research & Development, LLC",Drug: Dacarbazine
NCT01343277,A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma,Advanced Liposarcoma or Leiomyosarcoma,Interventional,28-Jan-16,PharmaMar,Drug: Trabectedin
NCT01343277,A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma,Advanced Liposarcoma or Leiomyosarcoma,Interventional,28-Jan-16,PharmaMar,Drug: Dacarbazine
NCT01634139,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma,Asthma,Interventional,12-Jul-16,Boehringer Ingelheim,Drug: Tiotropium low dose QD
NCT01634139,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma,Asthma,Interventional,12-Jul-16,Boehringer Ingelheim,Drug: Tiotropium high dose QD
NCT01634139,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma,Asthma,Interventional,12-Jul-16,Boehringer Ingelheim,Drug: Placebo
NCT01634139,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma,Asthma,Interventional,12-Jul-16,Pfizer,Drug: Tiotropium low dose QD
NCT01634139,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma,Asthma,Interventional,12-Jul-16,Pfizer,Drug: Tiotropium high dose QD
NCT01634139,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma,Asthma,Interventional,12-Jul-16,Pfizer,Drug: Placebo
NCT01339260,An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,26-Nov-14,Helsinn Healthcare SA,Drug: Netupitant and Palonosetron
NCT01339260,An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,26-Nov-14,Helsinn Healthcare SA,Drug: Palonosetron
NCT01339260,An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,26-Nov-14,Helsinn Healthcare SA,Drug: Dexamethasone
NCT01339260,An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,26-Nov-14,Parexel,Drug: Netupitant and Palonosetron
NCT01339260,An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,26-Nov-14,Parexel,Drug: Palonosetron
NCT01339260,An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,26-Nov-14,Parexel,Drug: Dexamethasone
NCT01337089,Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain,Pain|Advanced Cancer,Interventional,23-Apr-18,GW Pharmaceuticals Ltd.,Drug: Nabiximols
NCT01337089,Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain,Pain|Advanced Cancer,Interventional,23-Apr-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Nabiximols
NCT01440946,"Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B",Hemophilia B,Interventional,18-Jun-15,Bioverativ Therapeutics Inc.,Drug: rFIXFc
NCT01440946,"Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B",Hemophilia B,Interventional,18-Jun-15,Bioverativ Therapeutics Inc.,Drug: FIX
NCT01440946,"Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B",Hemophilia B,Interventional,18-Jun-15,Swedish Orphan Biovitrum,Drug: rFIXFc
NCT01440946,"Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B",Hemophilia B,Interventional,18-Jun-15,Swedish Orphan Biovitrum,Drug: FIX
NCT01434186,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","Diabetes Mellitus, Type 2",Interventional,18-Apr-17,AstraZeneca,Drug: Placebo matching with Saxagliptin
NCT01434186,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","Diabetes Mellitus, Type 2",Interventional,18-Apr-17,AstraZeneca,Drug: Metformin IR
NCT01434186,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","Diabetes Mellitus, Type 2",Interventional,18-Apr-17,AstraZeneca,Drug: Metformin XR
NCT01434186,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","Diabetes Mellitus, Type 2",Interventional,18-Apr-17,AstraZeneca,Drug: Saxagliptin
NCT01434186,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","Diabetes Mellitus, Type 2",Interventional,18-Apr-17,Bristol-Myers Squibb,Drug: Placebo matching with Saxagliptin
NCT01434186,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","Diabetes Mellitus, Type 2",Interventional,18-Apr-17,Bristol-Myers Squibb,Drug: Metformin IR
NCT01434186,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","Diabetes Mellitus, Type 2",Interventional,18-Apr-17,Bristol-Myers Squibb,Drug: Metformin XR
NCT01434186,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","Diabetes Mellitus, Type 2",Interventional,18-Apr-17,Bristol-Myers Squibb,Drug: Saxagliptin
NCT01306214,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Obesity",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: Placebo
NCT01306214,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Obesity",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: BI 10773
NCT01306214,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Obesity",Interventional,17-Jun-14,Eli Lilly and Company,Drug: Placebo
NCT01306214,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Obesity",Interventional,17-Jun-14,Eli Lilly and Company,Drug: BI 10773
NCT01289990,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,15-Jul-14,Boehringer Ingelheim,Drug: BI 10773
NCT01289990,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,15-Jul-14,Boehringer Ingelheim,Drug: Placebo
NCT01289990,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,15-Jul-14,Boehringer Ingelheim,Drug: Sitagliptin 100mg
NCT01289990,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,15-Jul-14,Eli Lilly and Company,Drug: BI 10773
NCT01289990,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,15-Jul-14,Eli Lilly and Company,Drug: Placebo
NCT01289990,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,15-Jul-14,Eli Lilly and Company,Drug: Sitagliptin 100mg
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Interventional,7-Jun-17,Bayer,Drug: Tedizolid (BAY119-2631)
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Interventional,7-Jun-17,Bayer,Drug: Placebo Tedizolid (BAY119-2631)
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Interventional,7-Jun-17,Bayer,Drug: Linezolid
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Interventional,7-Jun-17,Bayer,Drug: Placebo Linezolid
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Interventional,7-Jun-17,Merck Sharp & Dohme Corp.,Drug: Tedizolid (BAY119-2631)
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Interventional,7-Jun-17,Merck Sharp & Dohme Corp.,Drug: Placebo Tedizolid (BAY119-2631)
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Interventional,7-Jun-17,Merck Sharp & Dohme Corp.,Drug: Linezolid
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Bacterial Infections,Interventional,7-Jun-17,Merck Sharp & Dohme Corp.,Drug: Placebo Linezolid
NCT01280981,A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding,Menorrhagia,Interventional,26-Jul-11,Ferring Pharmaceuticals,Drug: Tranexamic acid
NCT01280981,A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding,Menorrhagia,Interventional,26-Jul-11,Xanodyne Pharmaceuticals,Drug: Tranexamic acid
NCT01262651,Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer,Pain|Advanced Cancer,Interventional,23-Apr-18,GW Pharmaceuticals Ltd.,Drug: Nabiximols
NCT01262651,Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer,Pain|Advanced Cancer,Interventional,23-Apr-18,GW Pharmaceuticals Ltd.,Drug: Placebo (GA-0034)
NCT01262651,Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer,Pain|Advanced Cancer,Interventional,23-Apr-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Nabiximols
NCT01262651,Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer,Pain|Advanced Cancer,Interventional,23-Apr-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo (GA-0034)
NCT02020369,Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors,Hemophilia A With Inhibitors|Hemophilia B With Inhibitors,Interventional,14-Jun-17,rEVO Biologics,Biological: Coagulation Factor VIIa (Recombinant)
NCT02020369,Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors,Hemophilia A With Inhibitors|Hemophilia B With Inhibitors,Interventional,14-Jun-17,Laboratoire français de Fractionnement et de Biotechnologies,Biological: Coagulation Factor VIIa (Recombinant)
NCT01353976,Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis,Tinea Pedis|Athlete's Foot,Interventional,9-Jan-13,AmDerma,Drug: Econazole Nitrate Foam 1%
NCT01353976,Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis,Tinea Pedis|Athlete's Foot,Interventional,9-Jan-13,AmDerma,Other: Vehicle Foam
NCT01353976,Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis,Tinea Pedis|Athlete's Foot,Interventional,9-Jan-13,"AmDerma Pharmaceuticals, LLC",Drug: Econazole Nitrate Foam 1%
NCT01353976,Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis,Tinea Pedis|Athlete's Foot,Interventional,9-Jan-13,"AmDerma Pharmaceuticals, LLC",Other: Vehicle Foam
NCT01791972,Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB),Exercise-Induced Bronchoconstriction (EIB),Interventional,19-May-15,Teva Pharmaceutical Industries,Drug: Albuterol Spiromax
NCT01791972,Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB),Exercise-Induced Bronchoconstriction (EIB),Interventional,19-May-15,Teva Pharmaceutical Industries,Drug: Placebo Spiromax
NCT01243944,Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial),Polycythemia Vera,Interventional,6-Mar-15,Incyte Corporation,Drug: ruxolitinib tablets
NCT01243944,Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial),Polycythemia Vera,Interventional,6-Mar-15,Incyte Corporation,Other: Best Available Therapy (BAT)
NCT01243944,Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial),Polycythemia Vera,Interventional,6-Mar-15,Novartis Pharmaceuticals,Drug: ruxolitinib tablets
NCT01243944,Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial),Polycythemia Vera,Interventional,6-Mar-15,Novartis Pharmaceuticals,Other: Best Available Therapy (BAT)
NCT01243177,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,Epilepsy|Monotherapy,Interventional,23-Feb-16,UCB BIOSCIENCES GmbH,Drug: Lacosamide
NCT01243177,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,Epilepsy|Monotherapy,Interventional,23-Feb-16,UCB BIOSCIENCES GmbH,Drug: Carbamazepine-Controlled Release
NCT01243177,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,Epilepsy|Monotherapy,Interventional,23-Feb-16,Eden Sarl,Drug: Lacosamide
NCT01243177,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,Epilepsy|Monotherapy,Interventional,23-Feb-16,Eden Sarl,Drug: Carbamazepine-Controlled Release
NCT01243177,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,Epilepsy|Monotherapy,Interventional,23-Feb-16,UCB Pharma,Drug: Lacosamide
NCT01243177,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,Epilepsy|Monotherapy,Interventional,23-Feb-16,UCB Pharma,Drug: Carbamazepine-Controlled Release
NCT01788228,Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure,Influenza,Interventional,7-Apr-15,GlaxoSmithKline,"Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)"
NCT01241760,VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection,Genotype 1 Chronic Hepatitis C|Treatment Naive,Interventional,4-Jun-14,Janssen Infectious Diseases BVBA,Drug: Ribavirin
NCT01241760,VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection,Genotype 1 Chronic Hepatitis C|Treatment Naive,Interventional,4-Jun-14,Janssen Infectious Diseases BVBA,Drug: Telaprevir
NCT01241760,VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection,Genotype 1 Chronic Hepatitis C|Treatment Naive,Interventional,4-Jun-14,Janssen Infectious Diseases BVBA,Drug: Pegylated interferon alfa-2a
NCT01241760,VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection,Genotype 1 Chronic Hepatitis C|Treatment Naive,Interventional,4-Jun-14,Vertex Pharmaceuticals Incorporated,Drug: Ribavirin
NCT01241760,VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection,Genotype 1 Chronic Hepatitis C|Treatment Naive,Interventional,4-Jun-14,Vertex Pharmaceuticals Incorporated,Drug: Telaprevir
NCT01241760,VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection,Genotype 1 Chronic Hepatitis C|Treatment Naive,Interventional,4-Jun-14,Vertex Pharmaceuticals Incorporated,Drug: Pegylated interferon alfa-2a
NCT01277523,Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma,Asthma,Interventional,20-Oct-14,Boehringer Ingelheim,Drug: tiotropium high dose
NCT01277523,Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma,Asthma,Interventional,20-Oct-14,Boehringer Ingelheim,Drug: placebo
NCT01277523,Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma,Asthma,Interventional,20-Oct-14,Boehringer Ingelheim,Drug: tiotropium low dose
NCT01277523,Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma,Asthma,Interventional,20-Oct-14,Pfizer,Drug: tiotropium high dose
NCT01277523,Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma,Asthma,Interventional,20-Oct-14,Pfizer,Drug: placebo
NCT01277523,Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma,Asthma,Interventional,20-Oct-14,Pfizer,Drug: tiotropium low dose
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,Breast Cancer,Interventional,3-Sep-15,Bayer,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,Breast Cancer,Interventional,3-Sep-15,Bayer,Drug: Placebo
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,Breast Cancer,Interventional,3-Sep-15,Bayer,Drug: Capecitabine
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,Breast Cancer,Interventional,3-Sep-15,"Onyx Therapeutics, Inc.","Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,Breast Cancer,Interventional,3-Sep-15,"Onyx Therapeutics, Inc.",Drug: Placebo
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,Breast Cancer,Interventional,3-Sep-15,"Onyx Therapeutics, Inc.",Drug: Capecitabine
NCT01226459,Clinical Trial in Females for Female Pattern Hair Loss,Androgenetic Alopecia,Interventional,3-Jun-14,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",Drug: 5% Minoxidil Topical Foam
NCT01226459,Clinical Trial in Females for Female Pattern Hair Loss,Androgenetic Alopecia,Interventional,3-Jun-14,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",Drug: Vehicle Topical Foam
NCT01226459,Clinical Trial in Females for Female Pattern Hair Loss,Androgenetic Alopecia,Interventional,3-Jun-14,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: 5% Minoxidil Topical Foam
NCT01226459,Clinical Trial in Females for Female Pattern Hair Loss,Androgenetic Alopecia,Interventional,3-Jun-14,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: Vehicle Topical Foam
NCT01257230,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma,Asthma,Interventional,8-Aug-14,Boehringer Ingelheim,Drug: tiotropium Respimat low dose
NCT01257230,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma,Asthma,Interventional,8-Aug-14,Boehringer Ingelheim,Drug: placebo Respimat
NCT01257230,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma,Asthma,Interventional,8-Aug-14,Boehringer Ingelheim,Drug: tiotropium Respimat high dose
NCT01257230,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma,Asthma,Interventional,8-Aug-14,Pfizer,Drug: tiotropium Respimat low dose
NCT01257230,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma,Asthma,Interventional,8-Aug-14,Pfizer,Drug: placebo Respimat
NCT01257230,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma,Asthma,Interventional,8-Aug-14,Pfizer,Drug: tiotropium Respimat high dose
NCT01210001,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: Placebo
NCT01210001,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: BI 10773
NCT01210001,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Eli Lilly and Company,Drug: Placebo
NCT01210001,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Eli Lilly and Company,Drug: BI 10773
NCT01195662,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Type 2 Diabetes,Interventional,23-May-14,AstraZeneca,Drug: Dapagliflozin
NCT01195662,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Type 2 Diabetes,Interventional,23-May-14,AstraZeneca,Drug: Placebo matching Dapagliflozin
NCT01195662,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Type 2 Diabetes,Interventional,23-May-14,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT01195662,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Type 2 Diabetes,Interventional,23-May-14,Bristol-Myers Squibb,Drug: Placebo matching Dapagliflozin
NCT01194830,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,"Diabetes Mellitus, Type 2",Interventional,26-Oct-12,Boehringer Ingelheim,Drug: Linagliptin
NCT01194830,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,"Diabetes Mellitus, Type 2",Interventional,26-Oct-12,Boehringer Ingelheim,Drug: Placebo
NCT01194830,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,"Diabetes Mellitus, Type 2",Interventional,26-Oct-12,Eli Lilly and Company,Drug: Linagliptin
NCT01194830,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,"Diabetes Mellitus, Type 2",Interventional,26-Oct-12,Eli Lilly and Company,Drug: Placebo
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,Eli Lilly and Company,Biological: Ramucirumab
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,Eli Lilly and Company,Biological: Placebo
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,Eli Lilly and Company,Drug: Irinotecan
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,Eli Lilly and Company,Drug: Folinic Acid
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,Eli Lilly and Company,Drug: 5-Fluorouracil
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,ImClone LLC,Biological: Ramucirumab
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,ImClone LLC,Biological: Placebo
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,ImClone LLC,Drug: Irinotecan
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,ImClone LLC,Drug: Folinic Acid
NCT01183780,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,15-Jul-15,ImClone LLC,Drug: 5-Fluorouracil
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Boehringer Ingelheim,Drug: Pioglitazone 15 mg
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Boehringer Ingelheim,Drug: Pioglitazone 45 mg
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Boehringer Ingelheim,Drug: Pioglitazone 30 mg
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Boehringer Ingelheim,Drug: Linagliptin 5mg / Pioglitazone 45 mg FDC
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Boehringer Ingelheim,Drug: Linagliptin 5mg / Pioglitazone 30 mg FDC
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Boehringer Ingelheim,Drug: Linagliptin 5mg
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Boehringer Ingelheim,Drug: Linagliptin 5mg / Pioglitazone 15 mg FDC
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Eli Lilly and Company,Drug: Pioglitazone 15 mg
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Eli Lilly and Company,Drug: Pioglitazone 45 mg
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Eli Lilly and Company,Drug: Pioglitazone 30 mg
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Eli Lilly and Company,Drug: Linagliptin 5mg / Pioglitazone 45 mg FDC
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Eli Lilly and Company,Drug: Linagliptin 5mg / Pioglitazone 30 mg FDC
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Eli Lilly and Company,Drug: Linagliptin 5mg
NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","Diabetes Mellitus, Type 2",Interventional,21-Apr-14,Eli Lilly and Company,Drug: Linagliptin 5mg / Pioglitazone 15 mg FDC
NCT01181128,"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A",Severe Hemophilia A,Interventional,29-Aug-14,Bioverativ Therapeutics Inc.,Drug: Factor VIII (rFVIIIFc)
NCT01181128,"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A",Severe Hemophilia A,Interventional,29-Aug-14,Bioverativ Therapeutics Inc.,Drug: Advate®
NCT01181128,"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A",Severe Hemophilia A,Interventional,29-Aug-14,Swedish Orphan Biovitrum,Drug: Factor VIII (rFVIIIFc)
NCT01181128,"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A",Severe Hemophilia A,Interventional,29-Aug-14,Swedish Orphan Biovitrum,Drug: Advate®
NCT01178073,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),"Hypertension, Pulmonary",Interventional,28-Apr-15,GlaxoSmithKline,Drug: ambrisentan
NCT01178073,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),"Hypertension, Pulmonary",Interventional,28-Apr-15,GlaxoSmithKline,Drug: tadalafil
NCT01178073,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),"Hypertension, Pulmonary",Interventional,28-Apr-15,Gilead Sciences,Drug: ambrisentan
NCT01178073,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),"Hypertension, Pulmonary",Interventional,28-Apr-15,Gilead Sciences,Drug: tadalafil
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: Placebo identical to BI10773 high dose
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: BI 10773
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: BI 10773 open label
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: Placebo identical to BI10773 low dose
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: Placebo identical to Sitagliptin 100mg
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: BI10773
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: Sitagliptin
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Eli Lilly and Company,Drug: Placebo identical to BI10773 high dose
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Eli Lilly and Company,Drug: BI 10773
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Eli Lilly and Company,Drug: BI 10773 open label
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Eli Lilly and Company,Drug: Placebo identical to BI10773 low dose
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Eli Lilly and Company,Drug: Placebo identical to Sitagliptin 100mg
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Eli Lilly and Company,Drug: BI10773
NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Jun-14,Eli Lilly and Company,Drug: Sitagliptin
NCT01172821,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Asthma,Interventional,7-Feb-14,Boehringer Ingelheim,Drug: placebo
NCT01172821,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Asthma,Interventional,7-Feb-14,Boehringer Ingelheim,Drug: tiotropium Respimat® low dose
NCT01172821,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Asthma,Interventional,7-Feb-14,Boehringer Ingelheim,Drug: tiotropium Respimat® high dose
NCT01172821,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Asthma,Interventional,7-Feb-14,Boehringer Ingelheim,Drug: 50 mcg salmeterol HFA MDI
NCT01172821,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Asthma,Interventional,7-Feb-14,Pfizer,Drug: placebo
NCT01172821,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Asthma,Interventional,7-Feb-14,Pfizer,Drug: tiotropium Respimat® low dose
NCT01172821,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Asthma,Interventional,7-Feb-14,Pfizer,Drug: tiotropium Respimat® high dose
NCT01172821,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Asthma,Interventional,7-Feb-14,Pfizer,Drug: 50 mcg salmeterol HFA MDI
NCT01172808,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Asthma,Interventional,7-Feb-14,Boehringer Ingelheim,Drug: Placebo
NCT01172808,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Asthma,Interventional,7-Feb-14,Boehringer Ingelheim,Drug: tiotropium Respimat® low dose
NCT01172808,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Asthma,Interventional,7-Feb-14,Boehringer Ingelheim,Drug: tiotropium Respimat® high dose
NCT01172808,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Asthma,Interventional,7-Feb-14,Boehringer Ingelheim,Drug: 50 mcg salmeterol HFA MDI
NCT01172808,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Asthma,Interventional,7-Feb-14,Pfizer,Drug: Placebo
NCT01172808,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Asthma,Interventional,7-Feb-14,Pfizer,Drug: tiotropium Respimat® low dose
NCT01172808,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Asthma,Interventional,7-Feb-14,Pfizer,Drug: tiotropium Respimat® high dose
NCT01172808,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Asthma,Interventional,7-Feb-14,Pfizer,Drug: 50 mcg salmeterol HFA MDI
NCT01168973,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Non-Small Cell Lung Cancer,Interventional,29-Dec-14,Eli Lilly and Company,Biological: Ramucirumab
NCT01168973,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Non-Small Cell Lung Cancer,Interventional,29-Dec-14,Eli Lilly and Company,Drug: Placebo (for Ramucirumab)
NCT01168973,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Non-Small Cell Lung Cancer,Interventional,29-Dec-14,Eli Lilly and Company,Drug: Docetaxel
NCT01168973,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Non-Small Cell Lung Cancer,Interventional,29-Dec-14,ImClone LLC,Biological: Ramucirumab
NCT01168973,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Non-Small Cell Lung Cancer,Interventional,29-Dec-14,ImClone LLC,Drug: Placebo (for Ramucirumab)
NCT01168973,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Non-Small Cell Lung Cancer,Interventional,29-Dec-14,ImClone LLC,Drug: Docetaxel
NCT01167881,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,8-Aug-14,Boehringer Ingelheim,Drug: BI 10773
NCT01167881,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,8-Aug-14,Boehringer Ingelheim,Drug: Glimepiride
NCT01167881,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,8-Aug-14,Boehringer Ingelheim,Drug: Placebo
NCT01167881,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,8-Aug-14,Eli Lilly and Company,Drug: BI 10773
NCT01167881,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,8-Aug-14,Eli Lilly and Company,Drug: Glimepiride
NCT01167881,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,8-Aug-14,Eli Lilly and Company,Drug: Placebo
NCT01164501,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,"Diabetes Mellitus, Type 2|Renal Insufficiency",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: BI 10773
NCT01164501,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,"Diabetes Mellitus, Type 2|Renal Insufficiency",Interventional,16-Jun-14,Boehringer Ingelheim,Drug: Placebo
NCT01164501,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,"Diabetes Mellitus, Type 2|Renal Insufficiency",Interventional,16-Jun-14,Eli Lilly and Company,Drug: BI 10773
NCT01164501,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,"Diabetes Mellitus, Type 2|Renal Insufficiency",Interventional,16-Jun-14,Eli Lilly and Company,Drug: Placebo
NCT01697956,Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR),Allergic Rhinitis,Interventional,8-Oct-15,Teva Pharmaceutical Industries,Drug: BDP
NCT01697956,Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR),Allergic Rhinitis,Interventional,8-Oct-15,Teva Pharmaceutical Industries,Drug: Placebo
NCT01159600,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: Placebo identical to BI 10773 high dose
NCT01159600,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: Placebo identical to BI 10773 low dose
NCT01159600,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: BI 10773
NCT01159600,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Eli Lilly and Company,Drug: Placebo identical to BI 10773 high dose
NCT01159600,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Eli Lilly and Company,Drug: Placebo identical to BI 10773 low dose
NCT01159600,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,17-Jun-14,Eli Lilly and Company,Drug: BI 10773
NCT01157078,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD),Major Depressive Disorder|Depression,Interventional,20-Nov-12,AstraZeneca,Drug: TC-5214
NCT01157078,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD),Major Depressive Disorder|Depression,Interventional,20-Nov-12,AstraZeneca,Drug: Placebo
NCT01157078,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD),Major Depressive Disorder|Depression,Interventional,20-Nov-12,Targacept Inc.,Drug: TC-5214
NCT01157078,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD),Major Depressive Disorder|Depression,Interventional,20-Nov-12,Targacept Inc.,Drug: Placebo
NCT01153347,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Major Depressive Disorder|Depression,Interventional,20-Nov-12,AstraZeneca,Drug: TC-5214
NCT01153347,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Major Depressive Disorder|Depression,Interventional,20-Nov-12,AstraZeneca,Drug: Placebo
NCT01153347,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Major Depressive Disorder|Depression,Interventional,20-Nov-12,Targacept Inc.,Drug: TC-5214
NCT01153347,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Major Depressive Disorder|Depression,Interventional,20-Nov-12,Targacept Inc.,Drug: Placebo
NCT01152554,A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Major Depressive Disorder|MDD|Depression,Interventional,29-Oct-12,AstraZeneca,Drug: TC-5214
NCT01152554,A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Major Depressive Disorder|MDD|Depression,Interventional,29-Oct-12,AstraZeneca,Drug: Placebo
NCT01152554,A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Major Depressive Disorder|MDD|Depression,Interventional,29-Oct-12,Targacept Inc.,Drug: TC-5214
NCT01152554,A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Major Depressive Disorder|MDD|Depression,Interventional,29-Oct-12,Targacept Inc.,Drug: Placebo
NCT01148017,Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,14-May-14,Novartis Vaccines,"Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine"
NCT01148017,Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,14-May-14,GlaxoSmithKline,"Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine"
NCT01148017,Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,14-May-14,Novartis,"Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine"
NCT02478632,Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen,HIV Infections,Interventional,20-Oct-17,ViiV Healthcare,Drug: Subjects do not receive study medication in this study 202094
NCT02478632,Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen,HIV Infections,Interventional,20-Oct-17,Janssen Pharmaceuticals,Drug: Subjects do not receive study medication in this study 202094
NCT02478632,Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen,HIV Infections,Interventional,20-Oct-17,GlaxoSmithKline,Drug: Subjects do not receive study medication in this study 202094
NCT01139580,The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis,Psoriasis,Interventional,23-Sep-11,"Stiefel, a GSK Company",Drug: Calcipotriene Foam
NCT01139580,The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis,Psoriasis,Interventional,23-Sep-11,"Stiefel, a GSK Company",Drug: Vehicle Foam
NCT01139580,The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis,Psoriasis,Interventional,23-Sep-11,GlaxoSmithKline,Drug: Calcipotriene Foam
NCT01139580,The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis,Psoriasis,Interventional,23-Sep-11,GlaxoSmithKline,Drug: Vehicle Foam
NCT01137474,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,Type 2 Diabetes,Interventional,1-May-14,AstraZeneca,Drug: Dapagliflozin
NCT01137474,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,Type 2 Diabetes,Interventional,1-May-14,AstraZeneca,Drug: Placebo-matching dapagliflozin
NCT01137474,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,Type 2 Diabetes,Interventional,1-May-14,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT01137474,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,Type 2 Diabetes,Interventional,1-May-14,Bristol-Myers Squibb,Drug: Placebo-matching dapagliflozin
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"Diabetes Mellitus, Type 2",Interventional,16-May-16,Boehringer Ingelheim,Drug: BI 10773 low dose
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"Diabetes Mellitus, Type 2",Interventional,16-May-16,Boehringer Ingelheim,Drug: Placebo BI 10773 high dose
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"Diabetes Mellitus, Type 2",Interventional,16-May-16,Boehringer Ingelheim,Drug: BI 10773 high dose
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"Diabetes Mellitus, Type 2",Interventional,16-May-16,Boehringer Ingelheim,Drug: Placebo BI 10773 low dose
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"Diabetes Mellitus, Type 2",Interventional,16-May-16,Eli Lilly and Company,Drug: BI 10773 low dose
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"Diabetes Mellitus, Type 2",Interventional,16-May-16,Eli Lilly and Company,Drug: Placebo BI 10773 high dose
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"Diabetes Mellitus, Type 2",Interventional,16-May-16,Eli Lilly and Company,Drug: BI 10773 high dose
NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"Diabetes Mellitus, Type 2",Interventional,16-May-16,Eli Lilly and Company,Drug: Placebo BI 10773 low dose
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,Hoffmann-La Roche,Drug: docetaxel
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,Hoffmann-La Roche,Drug: paclitaxel
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,Hoffmann-La Roche,Drug: pertuzumab
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,Hoffmann-La Roche,Drug: pertuzumab-placebo
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,Hoffmann-La Roche,Drug: trastuzumab [Herceptin]
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,Hoffmann-La Roche,Drug: trastuzumab emtansine
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,"Genentech, Inc.",Drug: docetaxel
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,"Genentech, Inc.",Drug: paclitaxel
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,"Genentech, Inc.",Drug: pertuzumab
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,"Genentech, Inc.",Drug: pertuzumab-placebo
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,"Genentech, Inc.",Drug: trastuzumab [Herceptin]
NCT01120184,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Breast Cancer,Interventional,23-Feb-17,"Genentech, Inc.",Drug: trastuzumab emtansine
NCT01104792,Long-term Study of Cariprazine in Patients With Schizophrenia,Schizophrenia,Interventional,26-Jul-19,Forest Laboratories,Drug: Cariprazine
NCT01104792,Long-term Study of Cariprazine in Patients With Schizophrenia,Schizophrenia,Interventional,26-Jul-19,Gedeon Richter Ltd.,Drug: Cariprazine
NCT01104766,Safety and Efficacy of Cariprazine in Patients With Schizophrenia,Schizophrenia,Interventional,29-Oct-18,Forest Laboratories,Drug: Cariprazine
NCT01104766,Safety and Efficacy of Cariprazine in Patients With Schizophrenia,Schizophrenia,Interventional,29-Oct-18,Forest Laboratories,Drug: Aripiprazole
NCT01104766,Safety and Efficacy of Cariprazine in Patients With Schizophrenia,Schizophrenia,Interventional,29-Oct-18,Forest Laboratories,Drug: Placebo
NCT01104766,Safety and Efficacy of Cariprazine in Patients With Schizophrenia,Schizophrenia,Interventional,29-Oct-18,Gedeon Richter Ltd.,Drug: Cariprazine
NCT01104766,Safety and Efficacy of Cariprazine in Patients With Schizophrenia,Schizophrenia,Interventional,29-Oct-18,Gedeon Richter Ltd.,Drug: Aripiprazole
NCT01104766,Safety and Efficacy of Cariprazine in Patients With Schizophrenia,Schizophrenia,Interventional,29-Oct-18,Gedeon Richter Ltd.,Drug: Placebo
NCT01104779,Safety and Efficacy of Cariprazine in Schizophrenia,Schizophrenia,Interventional,14-Nov-18,Forest Laboratories,Drug: Cariprazine
NCT01104779,Safety and Efficacy of Cariprazine in Schizophrenia,Schizophrenia,Interventional,14-Nov-18,Forest Laboratories,Drug: Placebo
NCT01104779,Safety and Efficacy of Cariprazine in Schizophrenia,Schizophrenia,Interventional,14-Nov-18,Gedeon Richter Ltd.,Drug: Cariprazine
NCT01104779,Safety and Efficacy of Cariprazine in Schizophrenia,Schizophrenia,Interventional,14-Nov-18,Gedeon Richter Ltd.,Drug: Placebo
NCT01087502,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,17-Oct-13,Boehringer Ingelheim,Drug: Glimepiride
NCT01087502,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,17-Oct-13,Boehringer Ingelheim,Drug: Placebo
NCT01087502,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,17-Oct-13,Boehringer Ingelheim,Drug: Linagliptin
NCT01087502,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,17-Oct-13,Eli Lilly and Company,Drug: Glimepiride
NCT01087502,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,17-Oct-13,Eli Lilly and Company,Drug: Placebo
NCT01087502,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,17-Oct-13,Eli Lilly and Company,Drug: Linagliptin
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,11-Jul-16,Biogen,Biological: BIIB019 (Daclizumab High Yield Process)
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,11-Jul-16,Biogen,Drug: Interferon beta-1a Placebo
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,11-Jul-16,Biogen,Biological: Interferon beta-1a
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,11-Jul-16,Biogen,Drug: Daclizumab High Yield Process Placebo
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,11-Jul-16,AbbVie,Biological: BIIB019 (Daclizumab High Yield Process)
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,11-Jul-16,AbbVie,Drug: Interferon beta-1a Placebo
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,11-Jul-16,AbbVie,Biological: Interferon beta-1a
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,11-Jul-16,AbbVie,Drug: Daclizumab High Yield Process Placebo
NCT01059630,"A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)",Non-Hodgkin's Lymphoma,Interventional,17-Nov-16,"Genentech, Inc.",Drug: Obinutuzumab
NCT01059630,"A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)",Non-Hodgkin's Lymphoma,Interventional,17-Nov-16,"Genentech, Inc.",Drug: Bendamustine
NCT01059630,"A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)",Non-Hodgkin's Lymphoma,Interventional,17-Nov-16,Roche Pharma AG,Drug: Obinutuzumab
NCT01059630,"A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)",Non-Hodgkin's Lymphoma,Interventional,17-Nov-16,Roche Pharma AG,Drug: Bendamustine
NCT01059539,Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder,Bipolar I Disorder,Interventional,13-Jun-19,Forest Laboratories,Drug: Cariprazine
NCT01059539,Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder,Bipolar I Disorder,Interventional,13-Jun-19,Gedeon Richter Ltd.,Drug: Cariprazine
NCT01058668,Safety and Efficacy of Cariprazine for Bipolar I Disorder,Mania|Bipolar I Disorder,Interventional,12-Apr-17,Forest Laboratories,Drug: Cariprazine
NCT01058668,Safety and Efficacy of Cariprazine for Bipolar I Disorder,Mania|Bipolar I Disorder,Interventional,12-Apr-17,Forest Laboratories,Drug: Placebo
NCT01058668,Safety and Efficacy of Cariprazine for Bipolar I Disorder,Mania|Bipolar I Disorder,Interventional,12-Apr-17,Gedeon Richter Ltd.,Drug: Cariprazine
NCT01058668,Safety and Efficacy of Cariprazine for Bipolar I Disorder,Mania|Bipolar I Disorder,Interventional,12-Apr-17,Gedeon Richter Ltd.,Drug: Placebo
NCT01054573,VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo,"Hepatitis C, Chronic",Interventional,19-Apr-13,Janssen Infectious Diseases BVBA,Drug: Telaprevir
NCT01054573,VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo,"Hepatitis C, Chronic",Interventional,19-Apr-13,Janssen Infectious Diseases BVBA,Drug: pegylated interferon (Peg-IFN) alfa-2a
NCT01054573,VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo,"Hepatitis C, Chronic",Interventional,19-Apr-13,Janssen Infectious Diseases BVBA,Drug: ribavirin (RBV)
NCT01054573,VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo,"Hepatitis C, Chronic",Interventional,19-Apr-13,Vertex Pharmaceuticals Incorporated,Drug: Telaprevir
NCT01054573,VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo,"Hepatitis C, Chronic",Interventional,19-Apr-13,Vertex Pharmaceuticals Incorporated,Drug: pegylated interferon (Peg-IFN) alfa-2a
NCT01054573,VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo,"Hepatitis C, Chronic",Interventional,19-Apr-13,Vertex Pharmaceuticals Incorporated,Drug: ribavirin (RBV)
NCT01058096,Safety and Efficacy of Cariprazine for Mania,Bipolar Disorder|Mania,Interventional,17-Apr-17,Forest Laboratories,Drug: Cariprazine
NCT01058096,Safety and Efficacy of Cariprazine for Mania,Bipolar Disorder|Mania,Interventional,17-Apr-17,Forest Laboratories,Drug: Placebo
NCT01058096,Safety and Efficacy of Cariprazine for Mania,Bipolar Disorder|Mania,Interventional,17-Apr-17,Gedeon Richter Ltd.,Drug: Cariprazine
NCT01058096,Safety and Efficacy of Cariprazine for Mania,Bipolar Disorder|Mania,Interventional,17-Apr-17,Gedeon Richter Ltd.,Drug: Placebo
NCT01042977,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control,Interventional,23-Aug-13,AstraZeneca,Drug: Dapagliflozin
NCT01042977,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control,Interventional,23-Aug-13,AstraZeneca,Drug: Placebo
NCT01042977,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control,Interventional,23-Aug-13,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT01042977,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control,Interventional,23-Aug-13,Bristol-Myers Squibb,Drug: Placebo
NCT01041859,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy",Diabetic Peripheral Neuropathy,Interventional,14-May-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Tapentadol extended release (ER)
NCT01041859,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy",Diabetic Peripheral Neuropathy,Interventional,14-May-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT01041859,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy",Diabetic Peripheral Neuropathy,Interventional,14-May-12,Grünenthal GmbH,Drug: Tapentadol extended release (ER)
NCT01041859,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy",Diabetic Peripheral Neuropathy,Interventional,14-May-12,Grünenthal GmbH,Drug: Placebo
NCT01031680,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control,Interventional,23-Aug-13,AstraZeneca,Drug: Dapagliflozin
NCT01031680,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control,Interventional,23-Aug-13,AstraZeneca,Drug: Placebo
NCT01031680,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control,Interventional,23-Aug-13,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT01031680,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control,Interventional,23-Aug-13,Bristol-Myers Squibb,Drug: Placebo
NCT01017146,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301",Acne Vulgaris,Interventional,6-Jul-12,"Stiefel, a GSK Company",Drug: Tazarotene foam
NCT01017146,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301",Acne Vulgaris,Interventional,6-Jul-12,"Stiefel, a GSK Company",Drug: Vehicle Foam
NCT01017146,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301",Acne Vulgaris,Interventional,6-Jul-12,GlaxoSmithKline,Drug: Tazarotene foam
NCT01017146,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301",Acne Vulgaris,Interventional,6-Jul-12,GlaxoSmithKline,Drug: Vehicle Foam
NCT01017120,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne",Acne Vulgaris,Interventional,6-Jul-12,"Stiefel, a GSK Company",Drug: Tazarotene Foam
NCT01017120,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne",Acne Vulgaris,Interventional,6-Jul-12,"Stiefel, a GSK Company",Drug: Vehicle Foam
NCT01017120,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne",Acne Vulgaris,Interventional,6-Jul-12,GlaxoSmithKline,Drug: Tazarotene Foam
NCT01017120,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne",Acne Vulgaris,Interventional,6-Jul-12,GlaxoSmithKline,Drug: Vehicle Foam
NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Interventional,8-Jan-19,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Drug: Nicotine Spray
NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Interventional,8-Jan-19,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.",Drug: Placebo
NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Interventional,8-Jan-19,GlaxoSmithKline,Drug: Nicotine Spray
NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Interventional,8-Jan-19,GlaxoSmithKline,Drug: Placebo
NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Interventional,8-Jan-19,McNeil AB,Drug: Nicotine Spray
NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Interventional,8-Jan-19,McNeil AB,Drug: Placebo
NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Interventional,8-Jan-19,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: Nicotine Spray
NCT02355665,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Tobacco Dependence,Interventional,8-Jan-19,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: Placebo
NCT01027364,Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B,Severe Hemophilia B,Interventional,4-Sep-14,Bioverativ Therapeutics Inc.,Drug: Factor IX (rFIXFc)
NCT01027364,Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B,Severe Hemophilia B,Interventional,4-Sep-14,Bioverativ Therapeutics Inc.,Drug: rFIX
NCT01027364,Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B,Severe Hemophilia B,Interventional,4-Sep-14,Swedish Orphan Biovitrum,Drug: Factor IX (rFIXFc)
NCT01027364,Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B,Severe Hemophilia B,Interventional,4-Sep-14,Swedish Orphan Biovitrum,Drug: rFIX
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,"Janssen Biotech, Inc.",Drug: Golimumab 50 mg SC
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,"Janssen Biotech, Inc.",Drug: Golimumab 2 mg/kg IV
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,"Janssen Biotech, Inc.",Drug: Methotrexate (MTX)
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,"Janssen Biotech, Inc.",Drug: Placebo SC
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,"Janssen Biotech, Inc.",Drug: Placebo IV
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,Merck Sharp & Dohme Corp.,Drug: Golimumab 50 mg SC
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,Merck Sharp & Dohme Corp.,Drug: Golimumab 2 mg/kg IV
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,Merck Sharp & Dohme Corp.,Drug: Methotrexate (MTX)
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,Merck Sharp & Dohme Corp.,Drug: Placebo SC
NCT01004432,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Interventional,13-May-14,Merck Sharp & Dohme Corp.,Drug: Placebo IV
NCT00996658,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,"Diabetes Mellitus, Type 2",Interventional,26-Mar-13,Boehringer Ingelheim,Drug: Placebo
NCT00996658,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,"Diabetes Mellitus, Type 2",Interventional,26-Mar-13,Boehringer Ingelheim,Drug: Linagliptin
NCT00996658,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,"Diabetes Mellitus, Type 2",Interventional,26-Mar-13,Eli Lilly and Company,Drug: Placebo
NCT00996658,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,"Diabetes Mellitus, Type 2",Interventional,26-Mar-13,Eli Lilly and Company,Drug: Linagliptin
NCT00992589,Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,22-May-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Rabeprazole sodium 5 mg
NCT00992589,Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,22-May-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Rabeprazole sodium 10 mg
NCT00992589,Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,22-May-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00992589,Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,22-May-13,Eisai Inc.,Drug: Rabeprazole sodium 5 mg
NCT00992589,Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,22-May-13,Eisai Inc.,Drug: Rabeprazole sodium 10 mg
NCT00992589,Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,22-May-13,Eisai Inc.,Drug: Placebo
NCT00986180,NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain,Pain|Back Pain|Low Back Pain|Back Pain With Radiation,Interventional,29-Feb-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: NUCYNTA
NCT00986180,NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain,Pain|Back Pain|Low Back Pain|Back Pain With Radiation,Interventional,29-Feb-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: Oxycodone IR
NCT00986180,NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain,Pain|Back Pain|Low Back Pain|Back Pain With Radiation,Interventional,29-Feb-12,Grünenthal GmbH,Drug: NUCYNTA
NCT00986180,NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain,Pain|Back Pain|Low Back Pain|Back Pain With Radiation,Interventional,29-Feb-12,Grünenthal GmbH,Drug: Oxycodone IR
NCT00984867,Dapagliflozin DPPIV Inhibitor add-on Study,Type 2 Diabetes,Interventional,14-Oct-13,AstraZeneca,Drug: Dapagliflozin
NCT00984867,Dapagliflozin DPPIV Inhibitor add-on Study,Type 2 Diabetes,Interventional,14-Oct-13,AstraZeneca,Drug: Placebo
NCT00984867,Dapagliflozin DPPIV Inhibitor add-on Study,Type 2 Diabetes,Interventional,14-Oct-13,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT00984867,Dapagliflozin DPPIV Inhibitor add-on Study,Type 2 Diabetes,Interventional,14-Oct-13,Bristol-Myers Squibb,Drug: Placebo
NCT00984282,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,Interventional,10-Dec-13,Bayer,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00984282,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,Interventional,10-Dec-13,Bayer,Drug: Placebo
NCT00984282,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,Interventional,10-Dec-13,Amgen,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00984282,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,Interventional,10-Dec-13,Amgen,Drug: Placebo
NCT00964795,"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)",Neovascular Age-related Macular Degeneration,Interventional,23-Mar-15,Regeneron Pharmaceuticals,Drug: Intravitreal Aflibercept Injection 2mg
NCT00964795,"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)",Neovascular Age-related Macular Degeneration,Interventional,23-Mar-15,Bayer,Drug: Intravitreal Aflibercept Injection 2mg
NCT00960076,An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,27-Sep-11,AstraZeneca,Drug: Saxagliptin
NCT00960076,An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,27-Sep-11,AstraZeneca,Drug: Metformin XR
NCT00960076,An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,27-Sep-11,Bristol-Myers Squibb,Drug: Saxagliptin
NCT00960076,An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,27-Sep-11,Bristol-Myers Squibb,Drug: Metformin XR
NCT00973479,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,"Arthritis, Rheumatoid",Interventional,14-Oct-13,"Centocor, Inc.",Drug: Golimumab
NCT00973479,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,"Arthritis, Rheumatoid",Interventional,14-Oct-13,"Centocor, Inc.",Other: Placebo
NCT00973479,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,"Arthritis, Rheumatoid",Interventional,14-Oct-13,"Centocor, Inc.",Drug: methotrexate (MTX)
NCT00973479,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,"Arthritis, Rheumatoid",Interventional,14-Oct-13,Schering-Plough,Drug: Golimumab
NCT00973479,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,"Arthritis, Rheumatoid",Interventional,14-Oct-13,Schering-Plough,Other: Placebo
NCT00973479,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,"Arthritis, Rheumatoid",Interventional,14-Oct-13,Schering-Plough,Drug: methotrexate (MTX)
NCT00954447,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,27-Sep-12,Boehringer Ingelheim,Drug: Placebo
NCT00954447,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,27-Sep-12,Boehringer Ingelheim,Drug: Linagliptin
NCT00954447,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,27-Sep-12,Eli Lilly and Company,Drug: Placebo
NCT00954447,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,27-Sep-12,Eli Lilly and Company,Drug: Linagliptin
NCT00948818,Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation,Irritable Bowel Syndrome Characterized by Constipation,Interventional,30-Jan-13,Forest Laboratories,Drug: Linaclotide 290 micrograms
NCT00948818,Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation,Irritable Bowel Syndrome Characterized by Constipation,Interventional,30-Jan-13,Forest Laboratories,Drug: Matching placebo
NCT00948818,Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation,Irritable Bowel Syndrome Characterized by Constipation,Interventional,30-Jan-13,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide 290 micrograms
NCT00948818,Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation,Irritable Bowel Syndrome Characterized by Constipation,Interventional,30-Jan-13,"Ironwood Pharmaceuticals, Inc.",Drug: Matching placebo
NCT00943072,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),Macular Edema Secondary to Central Retinal Vein Occlusion,Interventional,27-May-13,Regeneron Pharmaceuticals,Biological: VEGF Trap-Eye 2.0mg
NCT00943072,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),Macular Edema Secondary to Central Retinal Vein Occlusion,Interventional,27-May-13,Regeneron Pharmaceuticals,Drug: Sham
NCT00943072,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),Macular Edema Secondary to Central Retinal Vein Occlusion,Interventional,27-May-13,Bayer,Biological: VEGF Trap-Eye 2.0mg
NCT00943072,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),Macular Edema Secondary to Central Retinal Vein Occlusion,Interventional,27-May-13,Bayer,Drug: Sham
NCT00938717,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Interventional,30-Jan-13,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide or Matching Placebo
NCT00938717,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome With Constipation,Interventional,30-Jan-13,Forest Laboratories,Drug: Linaclotide or Matching Placebo
NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Multiple Sclerosis, Relapsing-Remitting",Interventional,15-May-17,"Genzyme, a Sanofi Company",Biological: alemtuzumab
NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Multiple Sclerosis, Relapsing-Remitting",Interventional,15-May-17,Bayer,Biological: alemtuzumab
NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Multiple Sclerosis, Relapsing-Remitting",Interventional,15-May-17,Sanofi,Biological: alemtuzumab
NCT01012323,"A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases",Primary Immunodeficiency Diseases,Interventional,16-Mar-17,Octapharma,Biological: NewGam
NCT01012323,"A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases",Primary Immunodeficiency Diseases,Interventional,16-Mar-17,Premier Research Group plc,Biological: NewGam
NCT00877890,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,AstraZeneca,Drug: exenatide once weekly
NCT00877890,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,AstraZeneca,Drug: exenatide twice daily
NCT00877890,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,Eli Lilly and Company,Drug: exenatide once weekly
NCT00877890,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,Eli Lilly and Company,Drug: exenatide twice daily
NCT02105987,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","Infection, Human Immunodeficiency Virus",Interventional,25-Feb-16,ViiV Healthcare,Drug: ABC/DTG/3TC FDC
NCT02105987,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","Infection, Human Immunodeficiency Virus",Interventional,25-Feb-16,ViiV Healthcare,Drug: Ongoing cART regimen
NCT02105987,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","Infection, Human Immunodeficiency Virus",Interventional,25-Feb-16,PPD,Drug: ABC/DTG/3TC FDC
NCT02105987,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","Infection, Human Immunodeficiency Virus",Interventional,25-Feb-16,PPD,Drug: Ongoing cART regimen
NCT02105987,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","Infection, Human Immunodeficiency Virus",Interventional,25-Feb-16,GlaxoSmithKline,Drug: ABC/DTG/3TC FDC
NCT02105987,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","Infection, Human Immunodeficiency Virus",Interventional,25-Feb-16,GlaxoSmithKline,Drug: Ongoing cART regimen
NCT00866697,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer,Interventional,19-Dec-13,Novartis Pharmaceuticals,Drug: Pazopanib
NCT00866697,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer,Interventional,19-Dec-13,Novartis Pharmaceuticals,Drug: Placebo
NCT00866697,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer,Interventional,19-Dec-13,GlaxoSmithKline,Drug: Pazopanib
NCT00866697,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer,Interventional,19-Dec-13,GlaxoSmithKline,Drug: Placebo
NCT00866697,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer,Interventional,19-Dec-13,Novartis,Drug: Pazopanib
NCT00866697,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer,Interventional,19-Dec-13,Novartis,Drug: Placebo
NCT00863798,Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-May-11,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Desvenlafaxine Succinate Sustained-Release 10mg
NCT00863798,Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-May-11,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Desvenlafaxine Succinate Sustained-Release 50 mg
NCT00863798,Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-May-11,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: placebo
NCT00863798,Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-May-11,Pfizer,Drug: Desvenlafaxine Succinate Sustained-Release 10mg
NCT00863798,Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-May-11,Pfizer,Drug: Desvenlafaxine Succinate Sustained-Release 50 mg
NCT00863798,Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-May-11,Pfizer,Drug: placebo
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,AstraZeneca,Drug: Dapagliflozin
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,AstraZeneca,Drug: Metformin XR
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,AstraZeneca,Drug: dapagliflozin matching Placebo
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,AstraZeneca,Drug: metformin HCl Modified Release matching Placebo
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,Bristol-Myers Squibb,Drug: Metformin XR
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,Bristol-Myers Squibb,Drug: dapagliflozin matching Placebo
NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,Bristol-Myers Squibb,Drug: metformin HCl Modified Release matching Placebo
NCT00856297,Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,22-Jan-14,Novartis Vaccines,Biological: MenACWY-CRM conjugate vaccine
NCT00856297,Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,22-Jan-14,Novartis Vaccines,Biological: Licensed comparator
NCT00856297,Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,22-Jan-14,GlaxoSmithKline,Biological: MenACWY-CRM conjugate vaccine
NCT00856297,Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,22-Jan-14,GlaxoSmithKline,Biological: Licensed comparator
NCT00856297,Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,22-Jan-14,Novartis,Biological: MenACWY-CRM conjugate vaccine
NCT00856297,Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine,Meningococcal Meningitis,Interventional,22-Jan-14,Novartis,Biological: Licensed comparator
NCT00852540,Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA,"Skin Infections, Bacterial",Interventional,26-Aug-11,"Stiefel, a GSK Company","Drug: Retpamulin Ointment, 1%"
NCT00852540,Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA,"Skin Infections, Bacterial",Interventional,26-Aug-11,"Stiefel, a GSK Company",Drug: Linezolid
NCT00852540,Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA,"Skin Infections, Bacterial",Interventional,26-Aug-11,GlaxoSmithKline,"Drug: Retpamulin Ointment, 1%"
NCT00852540,Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA,"Skin Infections, Bacterial",Interventional,26-Aug-11,GlaxoSmithKline,Drug: Linezolid
NCT00838110,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,8-Feb-13,Pfizer,Drug: Dimebon
NCT00838110,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,8-Feb-13,Pfizer,Drug: Placebo
NCT00838110,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,8-Feb-13,"Medivation, Inc.",Drug: Dimebon
NCT00838110,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,8-Feb-13,"Medivation, Inc.",Drug: Placebo
NCT01332253,Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy,Tonsillectomy,Interventional,3-Nov-16,Cumberland Pharmaceuticals,Drug: Intravenous ibuprofen
NCT01332253,Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy,Tonsillectomy,Interventional,3-Nov-16,Cumberland Pharmaceuticals,Other: Normal Saline
NCT00817063,Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema,Eczema,Interventional,9-Nov-17,"Stiefel, a GSK Company",Drug: alitretinoin
NCT00817063,Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema,Eczema,Interventional,9-Nov-17,"Stiefel, a GSK Company",Drug: Placebo
NCT00817063,Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema,Eczema,Interventional,9-Nov-17,Basilea Pharmaceutica,Drug: alitretinoin
NCT00817063,Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema,Eczema,Interventional,9-Nov-17,Basilea Pharmaceutica,Drug: Placebo
NCT00817063,Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema,Eczema,Interventional,9-Nov-17,GlaxoSmithKline,Drug: alitretinoin
NCT00817063,Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema,Eczema,Interventional,9-Nov-17,GlaxoSmithKline,Drug: Placebo
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Interventional,2-Jun-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Rivaroxaban 2.5 mg
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Interventional,2-Jun-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Rivaroxaban 5 mg
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Interventional,2-Jun-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Interventional,2-Jun-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Standard of care
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Interventional,2-Jun-14,Bayer,Drug: Rivaroxaban 2.5 mg
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Interventional,2-Jun-14,Bayer,Drug: Rivaroxaban 5 mg
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Interventional,2-Jun-14,Bayer,Drug: Placebo
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Interventional,2-Jun-14,Bayer,Drug: Standard of care
NCT01313507,High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam),Primary Immunodeficiency Disease,Interventional,29-Mar-17,Octapharma,Biological: NewGam
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis,Biological: MenACWY-CRM197
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis,"Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine"
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis,Biological: Hib (Haemophilus influenza b) Vaccine
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis,Biological: IPV (Inactivated Polio Vaccine) Vaccine
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis,Biological: Pneumococcal conjugate Vaccine
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis,"Biological: MMR (Measles, Mumps, and Rubella) Vaccine"
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis,Biological: Varicella Vaccine
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis,Biological: Hepatitis A Virus
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis Vaccines,Biological: MenACWY-CRM197
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis Vaccines,"Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine"
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis Vaccines,Biological: Hib (Haemophilus influenza b) Vaccine
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis Vaccines,Biological: IPV (Inactivated Polio Vaccine) Vaccine
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis Vaccines,Biological: Pneumococcal conjugate Vaccine
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis Vaccines,"Biological: MMR (Measles, Mumps, and Rubella) Vaccine"
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis Vaccines,Biological: Varicella Vaccine
NCT00806195,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis|Meningococcal Infection,Interventional,9-Jul-13,Novartis Vaccines,Biological: Hepatitis A Virus
NCT00798967,Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects,Short Bowel Syndrome,Interventional,1-Feb-12,Shire,Drug: teduglutide
NCT00798967,Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects,Short Bowel Syndrome,Interventional,1-Feb-12,Shire,Drug: placebo
NCT00798967,Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects,Short Bowel Syndrome,Interventional,1-Feb-12,Nycomed,Drug: teduglutide
NCT00798967,Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects,Short Bowel Syndrome,Interventional,1-Feb-12,Nycomed,Drug: placebo
NCT01287364,Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis,Perennial Allergic Rhinitis,Interventional,31-Oct-12,Sunovion,Drug: ciclesonide hydrofluoroalkane (HFA) nasal aerosol
NCT01287364,Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis,Perennial Allergic Rhinitis,Interventional,31-Oct-12,Sunovion,Drug: mometasone nasal inhalation
NCT00782340,A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Interventional,16-May-14,Chelsea Therapeutics,Drug: Placebo
NCT00782340,A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Interventional,16-May-14,Chelsea Therapeutics,Drug: Droxidopa
NCT00782340,A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Interventional,16-May-14,Chiltern International Inc.,Drug: Placebo
NCT00782340,A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Interventional,16-May-14,Chiltern International Inc.,Drug: Droxidopa
NCT00776984,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II),Asthma,Interventional,27-Sep-12,Boehringer Ingelheim,Drug: tiotropium 5mcg/day
NCT00776984,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II),Asthma,Interventional,27-Sep-12,Boehringer Ingelheim,Drug: placebo
NCT00776984,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II),Asthma,Interventional,27-Sep-12,Pfizer,Drug: tiotropium 5mcg/day
NCT00776984,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II),Asthma,Interventional,27-Sep-12,Pfizer,Drug: placebo
NCT00794664,Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis,Hypercholesterolemia|Coronary Heart Disease,Interventional,21-Mar-13,"Kastle Therapeutics, LLC",Drug: Mipomersen
NCT00794664,Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis,Hypercholesterolemia|Coronary Heart Disease,Interventional,21-Mar-13,"Kastle Therapeutics, LLC",Drug: Placebo
NCT00794664,Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis,Hypercholesterolemia|Coronary Heart Disease,Interventional,21-Mar-13,"Ionis Pharmaceuticals, Inc.",Drug: Mipomersen
NCT00794664,Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis,Hypercholesterolemia|Coronary Heart Disease,Interventional,21-Mar-13,"Ionis Pharmaceuticals, Inc.",Drug: Placebo
NCT00772603,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,"Epilepsies, Partial",Interventional,11-Feb-14,"Supernus Pharmaceuticals, Inc.",Drug: Placebo
NCT00772603,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,"Epilepsies, Partial",Interventional,11-Feb-14,"Supernus Pharmaceuticals, Inc.",Drug: 2400mg SPN-804
NCT00772603,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,"Epilepsies, Partial",Interventional,11-Feb-14,"Supernus Pharmaceuticals, Inc.",Drug: 1200mg SPN-804
NCT00772603,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,"Epilepsies, Partial",Interventional,11-Feb-14,Parexel,Drug: Placebo
NCT00772603,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,"Epilepsies, Partial",Interventional,11-Feb-14,Parexel,Drug: 2400mg SPN-804
NCT00772603,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,"Epilepsies, Partial",Interventional,11-Feb-14,Parexel,Drug: 1200mg SPN-804
NCT00772538,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I),Asthma,Interventional,27-Sep-12,Boehringer Ingelheim,Drug: tiotropium 5mcg/day
NCT00772538,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I),Asthma,Interventional,27-Sep-12,Boehringer Ingelheim,Drug: placebo
NCT00772538,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I),Asthma,Interventional,27-Sep-12,Pfizer,Drug: tiotropium 5mcg/day
NCT00772538,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I),Asthma,Interventional,27-Sep-12,Pfizer,Drug: placebo
NCT00771758,Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis,Back Pain,Interventional,7-Apr-11,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: oxycodone IR
NCT00771758,Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis,Back Pain,Interventional,7-Apr-11,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: placebo
NCT00771758,Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis,Back Pain,Interventional,7-Apr-11,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: tapentadol IR
NCT00771758,Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis,Back Pain,Interventional,7-Apr-11,Grünenthal GmbH,Drug: oxycodone IR
NCT00771758,Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis,Back Pain,Interventional,7-Apr-11,Grünenthal GmbH,Drug: placebo
NCT00771758,Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis,Back Pain,Interventional,7-Apr-11,Grünenthal GmbH,Drug: tapentadol IR
NCT00770146,Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients,Hypercholesterolemia|Coronary Heart Disease,Interventional,20-Mar-13,"Kastle Therapeutics, LLC",Drug: Mipomersen sodium
NCT00770146,Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients,Hypercholesterolemia|Coronary Heart Disease,Interventional,20-Mar-13,"Kastle Therapeutics, LLC",Drug: Placebo
NCT00770146,Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients,Hypercholesterolemia|Coronary Heart Disease,Interventional,20-Mar-13,"Ionis Pharmaceuticals, Inc.",Drug: Mipomersen sodium
NCT00770146,Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients,Hypercholesterolemia|Coronary Heart Disease,Interventional,20-Mar-13,"Ionis Pharmaceuticals, Inc.",Drug: Placebo
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,Melanoma,Interventional,17-Dec-15,BioVex Limited,Biological: Talimogene laherparepvec
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,Melanoma,Interventional,17-Dec-15,BioVex Limited,Biological: GM-CSF
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,Melanoma,Interventional,17-Dec-15,Amgen,Biological: Talimogene laherparepvec
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,Melanoma,Interventional,17-Dec-15,Amgen,Biological: GM-CSF
NCT00765999,"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Chronic Constipation|Irritable Bowel Syndrome With Constipation,Interventional,15-Feb-19,Forest Laboratories,Drug: Linaclotide
NCT00765999,"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Chronic Constipation|Irritable Bowel Syndrome With Constipation,Interventional,15-Feb-19,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide
NCT00765882,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Chronic Constipation,Interventional,30-Jan-13,Forest Laboratories,Drug: Linaclotide 290 micrograms
NCT00765882,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Chronic Constipation,Interventional,30-Jan-13,Forest Laboratories,Drug: Linaclotide 145 micrograms
NCT00765882,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Chronic Constipation,Interventional,30-Jan-13,Forest Laboratories,Drug: Placebo
NCT00765882,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Chronic Constipation,Interventional,30-Jan-13,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide 290 micrograms
NCT00765882,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Chronic Constipation,Interventional,30-Jan-13,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide 145 micrograms
NCT00765882,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Chronic Constipation,Interventional,30-Jan-13,"Ironwood Pharmaceuticals, Inc.",Drug: Placebo
NCT00765817,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,Type 2 Diabetes,Interventional,26-Jan-11,AstraZeneca,Drug: placebo
NCT00765817,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,Type 2 Diabetes,Interventional,26-Jan-11,AstraZeneca,Drug: exenatide
NCT00765817,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,Type 2 Diabetes,Interventional,26-Jan-11,Eli Lilly and Company,Drug: placebo
NCT00765817,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,Type 2 Diabetes,Interventional,26-Jan-11,Eli Lilly and Company,Drug: exenatide
NCT00758043,A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response,Hepatitis C,Interventional,21-Jul-11,Vertex Pharmaceuticals Incorporated,Drug: telaprevir
NCT00758043,A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response,Hepatitis C,Interventional,21-Jul-11,Vertex Pharmaceuticals Incorporated,Drug: ribavirin
NCT00758043,A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response,Hepatitis C,Interventional,21-Jul-11,Vertex Pharmaceuticals Incorporated,Biological: peginterferon alfa-2a
NCT00758043,A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response,Hepatitis C,Interventional,21-Jul-11,Tibotec Pharmaceutical Limited,Drug: telaprevir
NCT00758043,A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response,Hepatitis C,Interventional,21-Jul-11,Tibotec Pharmaceutical Limited,Drug: ribavirin
NCT00758043,A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response,Hepatitis C,Interventional,21-Jul-11,Tibotec Pharmaceutical Limited,Biological: peginterferon alfa-2a
NCT00751400,Naproxen Sodium Extended-Release Actual Use Study,Pain,Interventional,17-May-11,Bayer,Drug: Naproxen Sodium ER (BAYH6689)
NCT00751400,Naproxen Sodium Extended-Release Actual Use Study,Pain,Interventional,17-May-11,"Pegus Research, Inc.",Drug: Naproxen Sodium ER (BAYH6689)
NCT00753896,Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin,Type 2 Diabetes,Interventional,20-Mar-12,AstraZeneca,Drug: exenatide
NCT00753896,Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin,Type 2 Diabetes,Interventional,20-Mar-12,Eli Lilly and Company,Drug: exenatide
NCT00736879,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,2-May-14,AstraZeneca,Drug: Dapagliflozin
NCT00736879,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,2-May-14,AstraZeneca,Drug: Placebo
NCT00736879,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,2-May-14,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT00736879,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,2-May-14,Bristol-Myers Squibb,Drug: Placebo
NCT00734071,An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,Takeda,Drug: Vortioxetine
NCT00734071,An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,Takeda,Drug: Placebo
NCT00734071,An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Vortioxetine
NCT00734071,An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Placebo
NCT00731549,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,11-Nov-14,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole IM Depot
NCT00731549,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,11-Nov-14,Covance,Drug: Aripiprazole IM Depot
NCT00731120,Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,Takeda,Drug: Vortioxetine
NCT00731120,Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,Takeda,Drug: Placebo
NCT00731120,Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Vortioxetine
NCT00731120,Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Placebo
NCT00730691,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,Takeda,Drug: Placebo
NCT00730691,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,Takeda,Drug: Vortioxetine
NCT00730691,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,Takeda,Drug: Duloxetine
NCT00730691,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Placebo
NCT00730691,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Vortioxetine
NCT00730691,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Generalized Anxiety Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Duloxetine
NCT00730171,"An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Irritable Bowel Syndrome With Constipation|Chronic Constipation,Interventional,16-Feb-18,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide
NCT00730171,"An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Irritable Bowel Syndrome With Constipation|Chronic Constipation,Interventional,16-Feb-18,Forest Laboratories,Drug: Linaclotide
NCT00730015,Trial of Linaclotide in Patients With Chronic Constipation,Chronic Constipation,Interventional,30-Jan-13,"Ironwood Pharmaceuticals, Inc.",Drug: Matching Placebo
NCT00730015,Trial of Linaclotide in Patients With Chronic Constipation,Chronic Constipation,Interventional,30-Jan-13,"Ironwood Pharmaceuticals, Inc.",Drug: Linaclotide
NCT00730015,Trial of Linaclotide in Patients With Chronic Constipation,Chronic Constipation,Interventional,30-Jan-13,Forest Laboratories,Drug: Matching Placebo
NCT00730015,Trial of Linaclotide in Patients With Chronic Constipation,Chronic Constipation,Interventional,30-Jan-13,Forest Laboratories,Drug: Linaclotide
NCT00724867,A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States,Systemic Lupus Erythematosus,Interventional,28-Mar-16,"Human Genome Sciences Inc., a GSK Company",Biological: Belimumab 1 mg/kg
NCT00724867,A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States,Systemic Lupus Erythematosus,Interventional,28-Mar-16,"Human Genome Sciences Inc., a GSK Company",Biological: Belimumab 10 mg/kg
NCT00724867,A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States,Systemic Lupus Erythematosus,Interventional,28-Mar-16,GlaxoSmithKline,Biological: Belimumab 1 mg/kg
NCT00724867,A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States,Systemic Lupus Erythematosus,Interventional,28-Mar-16,GlaxoSmithKline,Biological: Belimumab 10 mg/kg
NCT00711009,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),Human Immunodeficiency Virus Infection,Interventional,2-Feb-11,Abbott,Drug: lopinavir/ritonavir (LPV/r)
NCT00711009,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),Human Immunodeficiency Virus Infection,Interventional,2-Feb-11,Abbott,Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
NCT00711009,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),Human Immunodeficiency Virus Infection,Interventional,2-Feb-11,Abbott,Drug: raltegravir (RAL)
NCT00711009,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),Human Immunodeficiency Virus Infection,Interventional,2-Feb-11,Merck Sharp & Dohme Corp.,Drug: lopinavir/ritonavir (LPV/r)
NCT00711009,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),Human Immunodeficiency Virus Infection,Interventional,2-Feb-11,Merck Sharp & Dohme Corp.,Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
NCT00711009,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),Human Immunodeficiency Virus Infection,Interventional,2-Feb-11,Merck Sharp & Dohme Corp.,Drug: raltegravir (RAL)
NCT00707980,Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,13-Dec-13,Takeda,Drug: Vortioxetine
NCT00707980,Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,13-Dec-13,H. Lundbeck A/S,Drug: Vortioxetine
NCT00706849,Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease,Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease,Interventional,21-Mar-13,"Kastle Therapeutics, LLC",Drug: mipomersen sodium
NCT00706849,Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease,Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease,Interventional,21-Mar-13,"Kastle Therapeutics, LLC",Drug: placebo
NCT00706849,Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease,Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease,Interventional,21-Mar-13,"Ionis Pharmaceuticals, Inc.",Drug: mipomersen sodium
NCT00706849,Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease,Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease,Interventional,21-Mar-13,"Ionis Pharmaceuticals, Inc.",Drug: placebo
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Millennium Pharmaceuticals, Inc.",Drug: Rituximab 375 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Millennium Pharmaceuticals, Inc.",Drug: Cyclophosphamide 750 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Millennium Pharmaceuticals, Inc.",Drug: Doxorubicin 50 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Millennium Pharmaceuticals, Inc.",Drug: VELCADE 1.3 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Millennium Pharmaceuticals, Inc.",Drug: Prednisone 100 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Millennium Pharmaceuticals, Inc.",Drug: Vincristine 1.4 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Rituximab 375 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Cyclophosphamide 750 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Doxorubicin 50 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: VELCADE 1.3 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Prednisone 100 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Vincristine 1.4 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,Takeda,Drug: Rituximab 375 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,Takeda,Drug: Cyclophosphamide 750 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,Takeda,Drug: Doxorubicin 50 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,Takeda,Drug: VELCADE 1.3 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,Takeda,Drug: Prednisone 100 mg/m^2
NCT00722137,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Mantle Cell Lymphoma,Interventional,17-Nov-14,Takeda,Drug: Vincristine 1.4 mg/m^2
NCT00703118,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",Interventional,11-Aug-11,Tibotec BVBA,Drug: Telaprevir
NCT00703118,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",Interventional,11-Aug-11,Tibotec BVBA,Drug: Peg-IFN-alfa-2a
NCT00703118,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",Interventional,11-Aug-11,Tibotec BVBA,Drug: Ribavirin
NCT00703118,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",Interventional,11-Aug-11,Tibotec BVBA,Drug: Placebo
NCT00703118,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",Interventional,11-Aug-11,Tibotec Pharmaceutical Limited,Drug: Telaprevir
NCT00703118,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",Interventional,11-Aug-11,Tibotec Pharmaceutical Limited,Drug: Peg-IFN-alfa-2a
NCT00703118,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",Interventional,11-Aug-11,Tibotec Pharmaceutical Limited,Drug: Ribavirin
NCT00703118,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",Interventional,11-Aug-11,Tibotec Pharmaceutical Limited,Drug: Placebo
NCT00694109,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Interventional,21-Dec-15,"Kastle Therapeutics, LLC",Drug: Mipomersen Sodium
NCT00694109,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Interventional,21-Dec-15,"Ionis Pharmaceuticals, Inc.",Drug: Mipomersen Sodium
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Acne Vulgaris|Acne,Interventional,2-Dec-10,"Stiefel, a GSK Company",Drug: CT Gel
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Acne Vulgaris|Acne,Interventional,2-Dec-10,"Stiefel, a GSK Company",Drug: Clindamycin Gel (clindamycin )
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Acne Vulgaris|Acne,Interventional,2-Dec-10,"Stiefel, a GSK Company",Drug: Tretinoin Gel (tretinoin)
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Acne Vulgaris|Acne,Interventional,2-Dec-10,"Stiefel, a GSK Company",Drug: Vehicle Gel
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Acne Vulgaris|Acne,Interventional,2-Dec-10,GlaxoSmithKline,Drug: CT Gel
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Acne Vulgaris|Acne,Interventional,2-Dec-10,GlaxoSmithKline,Drug: Clindamycin Gel (clindamycin )
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Acne Vulgaris|Acne,Interventional,2-Dec-10,GlaxoSmithKline,Drug: Tretinoin Gel (tretinoin)
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Acne Vulgaris|Acne,Interventional,2-Dec-10,GlaxoSmithKline,Drug: Vehicle Gel
NCT00688519,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies,Psoriasis,Interventional,8-Dec-10,"Stiefel, a GSK Company",Drug: U0267
NCT00688519,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies,Psoriasis,Interventional,8-Dec-10,"Stiefel, a GSK Company",Drug: Vehicle
NCT00688519,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies,Psoriasis,Interventional,8-Dec-10,GlaxoSmithKline,Drug: U0267
NCT00688519,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies,Psoriasis,Interventional,8-Dec-10,GlaxoSmithKline,Drug: Vehicle
NCT00689481,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies,Psoriasis,Interventional,8-Dec-10,"Stiefel, a GSK Company",Drug: U0267 Foam
NCT00689481,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies,Psoriasis,Interventional,8-Dec-10,"Stiefel, a GSK Company",Drug: Vehicle foam
NCT00689481,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies,Psoriasis,Interventional,8-Dec-10,GlaxoSmithKline,Drug: U0267 Foam
NCT00689481,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies,Psoriasis,Interventional,8-Dec-10,GlaxoSmithKline,Drug: Vehicle foam
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Type 2 Diabetes Mellitus,Interventional,26-Nov-12,AstraZeneca,Drug: exenatide once weekly
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Type 2 Diabetes Mellitus,Interventional,26-Nov-12,AstraZeneca,Drug: metformin
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Type 2 Diabetes Mellitus,Interventional,26-Nov-12,AstraZeneca,Drug: sitagliptin
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Type 2 Diabetes Mellitus,Interventional,26-Nov-12,AstraZeneca,Drug: pioglitazone
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Type 2 Diabetes Mellitus,Interventional,26-Nov-12,Eli Lilly and Company,Drug: exenatide once weekly
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Type 2 Diabetes Mellitus,Interventional,26-Nov-12,Eli Lilly and Company,Drug: metformin
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Type 2 Diabetes Mellitus,Interventional,26-Nov-12,Eli Lilly and Company,Drug: sitagliptin
NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Type 2 Diabetes Mellitus,Interventional,26-Nov-12,Eli Lilly and Company,Drug: pioglitazone
NCT00673231,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",Type 2 Diabetes,Interventional,23-Aug-13,AstraZeneca,Drug: Dapagliflozin
NCT00673231,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",Type 2 Diabetes,Interventional,23-Aug-13,AstraZeneca,Drug: Placebo
NCT00673231,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",Type 2 Diabetes,Interventional,23-Aug-13,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT00673231,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",Type 2 Diabetes,Interventional,23-Aug-13,Bristol-Myers Squibb,Drug: Placebo
NCT00672958,Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,13-Dec-13,Takeda,Drug: Vortioxetine
NCT00672958,Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,13-Dec-13,Takeda,Drug: Placebo
NCT00672958,Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,13-Dec-13,H. Lundbeck A/S,Drug: Vortioxetine
NCT00672958,Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,13-Dec-13,H. Lundbeck A/S,Drug: Placebo
NCT00672620,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-Dec-13,Takeda,Drug: Vortioxetine
NCT00672620,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-Dec-13,Takeda,Drug: Duloxetine
NCT00672620,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-Dec-13,Takeda,Drug: Placebo
NCT00672620,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Vortioxetine
NCT00672620,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Duloxetine
NCT00672620,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-Dec-13,H. Lundbeck A/S,Drug: Placebo
NCT00930644,Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS),Short Bowel Syndrome,Interventional,24-Dec-14,Shire,Drug: teduglutide
NCT00930644,Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS),Short Bowel Syndrome,Interventional,24-Dec-14,Nycomed Germany GmbH,Drug: teduglutide
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Levodopa carbidopa intestinal gel (LCIG)
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Placebo Gel
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Placebo (PBO) oral capsules
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: PEG tube
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: J-tube
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Levodopa carbidopa intestinal gel (LCIG)
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Placebo Gel
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Placebo (PBO) oral capsules
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: PEG tube
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: J-tube
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Levodopa carbidopa intestinal gel (LCIG)
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Placebo Gel
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Placebo (PBO) oral capsules
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: PEG tube
NCT00660387,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: J-tube
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Bristol-Myers Squibb,Drug: Enoxaparin
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Bristol-Myers Squibb,Drug: warfarin
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Bristol-Myers Squibb,Drug: Placebo for apixaban
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Bristol-Myers Squibb,Drug: Placebo for enoxaparin
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Bristol-Myers Squibb,Drug: Placebo for warfarin
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Bristol-Myers Squibb,Drug: apixaban
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Pfizer,Drug: Enoxaparin
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Pfizer,Drug: warfarin
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Pfizer,Drug: Placebo for apixaban
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Pfizer,Drug: Placebo for enoxaparin
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Pfizer,Drug: Placebo for warfarin
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,10-Apr-14,Pfizer,Drug: apixaban
NCT00641056,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),Type 2 Diabetes Mellitus,Interventional,4-Jul-12,AstraZeneca,Drug: Exenatide Once Weekly
NCT00641056,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),Type 2 Diabetes Mellitus,Interventional,4-Jul-12,AstraZeneca,Drug: Insulin Glargine
NCT00641056,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),Type 2 Diabetes Mellitus,Interventional,4-Jul-12,Eli Lilly and Company,Drug: Exenatide Once Weekly
NCT00641056,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),Type 2 Diabetes Mellitus,Interventional,4-Jul-12,Eli Lilly and Company,Drug: Insulin Glargine
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,AstraZeneca,Drug: exenatide once weekly
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,AstraZeneca,Drug: sitagliptin
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,AstraZeneca,Drug: pioglitazone
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,AstraZeneca,Drug: placebo tablet
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,AstraZeneca,Drug: placebo once weekly
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,Eli Lilly and Company,Drug: exenatide once weekly
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,Eli Lilly and Company,Drug: sitagliptin
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,Eli Lilly and Company,Drug: pioglitazone
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,Eli Lilly and Company,Drug: placebo tablet
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Type 2 Diabetes Mellitus,Interventional,19-Jun-12,Eli Lilly and Company,Drug: placebo once weekly
NCT00635089,Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis,Eosinophilic Esophagitis,Interventional,23-Mar-17,Ception Therapeutics,Drug: reslizumab
NCT00635089,Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis,Eosinophilic Esophagitis,Interventional,23-Mar-17,Cephalon,Drug: reslizumab
NCT00635089,Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis,Eosinophilic Esophagitis,Interventional,23-Mar-17,Teva Pharmaceutical Industries,Drug: reslizumab
NCT00634049,Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi,Aspergillosis|Invasive Fungal Infections,Interventional,11-Jan-16,Astellas Pharma Inc,Drug: isavuconazole
NCT00634049,Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi,Aspergillosis|Invasive Fungal Infections,Interventional,11-Jan-16,Basilea Pharmaceutica International Ltd,Drug: isavuconazole
NCT00633893,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,25-Oct-13,Bristol-Myers Squibb,Drug: Apixaban
NCT00633893,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,25-Oct-13,Bristol-Myers Squibb,Drug: Placebo
NCT00633893,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,25-Oct-13,Pfizer,Drug: Apixaban
NCT00633893,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Venous Thrombosis,Interventional,25-Oct-13,Pfizer,Drug: Placebo
NCT00633880,Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Interventional,20-May-14,Chelsea Therapeutics,Drug: Placebo
NCT00633880,Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Interventional,20-May-14,Chelsea Therapeutics,Drug: Droxidopa
NCT00633880,Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Interventional,20-May-14,Chiltern International Inc.,Drug: Placebo
NCT00633880,Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Interventional,20-May-14,Chiltern International Inc.,Drug: Droxidopa
NCT00627926,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Hepatitis C,Interventional,21-Jul-11,Vertex Pharmaceuticals Incorporated,Biological: Pegylated Interferon Alfa 2a
NCT00627926,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Hepatitis C,Interventional,21-Jul-11,Vertex Pharmaceuticals Incorporated,Drug: Telaprevir
NCT00627926,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Hepatitis C,Interventional,21-Jul-11,Vertex Pharmaceuticals Incorporated,Drug: Ribavirin
NCT00627926,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Hepatitis C,Interventional,21-Jul-11,Vertex Pharmaceuticals Incorporated,Other: Placebo
NCT00627926,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Hepatitis C,Interventional,21-Jul-11,Tibotec Pharmaceutical Limited,Biological: Pegylated Interferon Alfa 2a
NCT00627926,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Hepatitis C,Interventional,21-Jul-11,Tibotec Pharmaceutical Limited,Drug: Telaprevir
NCT00627926,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Hepatitis C,Interventional,21-Jul-11,Tibotec Pharmaceutical Limited,Drug: Ribavirin
NCT00627926,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Hepatitis C,Interventional,21-Jul-11,Tibotec Pharmaceutical Limited,Other: Placebo
NCT00618956,A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring,Fibromyalgia,Interventional,3-Sep-09,Forest Laboratories,Drug: Milnacipran hydrochloride
NCT00618956,A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring,Fibromyalgia,Interventional,3-Sep-09,Forest Laboratories,Drug: Placebo
NCT00618956,A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring,Fibromyalgia,Interventional,3-Sep-09,"Cypress Bioscience, Inc.",Drug: Milnacipran hydrochloride
NCT00618956,A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring,Fibromyalgia,Interventional,3-Sep-09,"Cypress Bioscience, Inc.",Drug: Placebo
NCT00614939,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,Type 2 Diabetes,Interventional,7-Jul-10,AstraZeneca,Drug: Saxagliptin
NCT00614939,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,Type 2 Diabetes,Interventional,7-Jul-10,AstraZeneca,Drug: Placebo
NCT00614939,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,Type 2 Diabetes,Interventional,7-Jul-10,Bristol-Myers Squibb,Drug: Saxagliptin
NCT00614939,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,Type 2 Diabetes,Interventional,7-Jul-10,Bristol-Myers Squibb,Drug: Placebo
NCT00598442,Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Affymax,Drug: peginesatide
NCT00598442,Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Affymax,Drug: Darbepoetin alfa
NCT00598442,Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Takeda,Drug: peginesatide
NCT00598442,Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Takeda,Drug: Darbepoetin alfa
NCT00598273,Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Affymax,Drug: peginesatide
NCT00598273,Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Affymax,Drug: Darbepoetin alfa
NCT00598273,Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Takeda,Drug: peginesatide
NCT00598273,Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Takeda,Drug: Darbepoetin alfa
NCT00597753,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Affymax,Drug: peginesatide
NCT00597753,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Affymax,Drug: Epoetin Alfa
NCT00597753,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Takeda,Drug: peginesatide
NCT00597753,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Takeda,Drug: Epoetin Alfa
NCT00597584,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Affymax,Drug: peginesatide
NCT00597584,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Affymax,Drug: Epoetin alfa or Epoetin beta
NCT00597584,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Takeda,Drug: peginesatide
NCT00597584,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Interventional,30-Jul-12,Takeda,Drug: Epoetin alfa or Epoetin beta
NCT00597428,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,7-Dec-15,"Sucampo Pharmaceuticals, Inc.",Drug: Lubiprostone
NCT00597428,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,7-Dec-15,"Sucampo Pharmaceuticals, Inc.",Drug: Placebo
NCT00597428,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,7-Dec-15,Takeda,Drug: Lubiprostone
NCT00597428,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,7-Dec-15,Takeda,Drug: Placebo
NCT00597428,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,7-Dec-15,"Sucampo Pharma Americas, LLC",Drug: Lubiprostone
NCT00597428,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,7-Dec-15,"Sucampo Pharma Americas, LLC",Drug: Placebo
NCT00595946,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,3-Feb-16,"Sucampo Pharmaceuticals, Inc.",Drug: Lubiprostone
NCT00595946,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,3-Feb-16,"Sucampo Pharmaceuticals, Inc.",Drug: Placebo
NCT00595946,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,3-Feb-16,Takeda,Drug: Lubiprostone
NCT00595946,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,3-Feb-16,Takeda,Drug: Placebo
NCT00595946,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,3-Feb-16,"Sucampo Pharma Americas, LLC",Drug: Lubiprostone
NCT00595946,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Opioid-Induced Bowel Dysfunction,Interventional,3-Feb-16,"Sucampo Pharma Americas, LLC",Drug: Placebo
NCT00574873,Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML,Chronic Myeloid Leukemia,Interventional,5-Nov-12,Pfizer,Drug: Bosutinib
NCT00574873,Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML,Chronic Myeloid Leukemia,Interventional,5-Nov-12,Pfizer,Drug: imatinib
NCT00574873,Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML,Chronic Myeloid Leukemia,Interventional,5-Nov-12,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Bosutinib
NCT00574873,Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML,Chronic Myeloid Leukemia,Interventional,5-Nov-12,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: imatinib
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,Interventional,27-Jun-12,Bayer,"Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,Interventional,27-Jun-12,Bayer,Drug: Enoxaparin
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,Interventional,27-Jun-12,Bayer,Drug: Rivaroxaban placebo
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,Interventional,27-Jun-12,Bayer,Drug: Enoxaparin placebo
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,Interventional,27-Jun-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,Interventional,27-Jun-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Enoxaparin
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,Interventional,27-Jun-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Rivaroxaban placebo
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,Interventional,27-Jun-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Enoxaparin placebo
NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Metastatic Breast Cancer,Interventional,13-Sep-12,"Genentech, Inc.",Drug: Pertuzumab
NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Metastatic Breast Cancer,Interventional,13-Sep-12,"Genentech, Inc.",Drug: Placebo
NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Metastatic Breast Cancer,Interventional,13-Sep-12,"Genentech, Inc.",Drug: Trastuzumab
NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Metastatic Breast Cancer,Interventional,13-Sep-12,"Genentech, Inc.",Drug: Docetaxel
NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Metastatic Breast Cancer,Interventional,13-Sep-12,Hoffmann-La Roche,Drug: Pertuzumab
NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Metastatic Breast Cancer,Interventional,13-Sep-12,Hoffmann-La Roche,Drug: Placebo
NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Metastatic Breast Cancer,Interventional,13-Sep-12,Hoffmann-La Roche,Drug: Trastuzumab
NCT00567190,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Metastatic Breast Cancer,Interventional,13-Sep-12,Hoffmann-La Roche,Drug: Docetaxel
NCT00552344,A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease,Crohn Disease,Interventional,21-Jan-16,UCB BIOSCIENCES GmbH,Biological: Cimzia
NCT00552344,A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease,Crohn Disease,Interventional,21-Jan-16,PPD,Biological: Cimzia
NCT00552344,A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease,Crohn Disease,Interventional,21-Jan-16,UCB Pharma,Biological: Cimzia
NCT00550459,Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients,Hyponatremia,Interventional,28-Apr-11,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Tolvaptan
NCT00550459,Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients,Hyponatremia,Interventional,28-Apr-11,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT00550459,Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients,Hyponatremia,Interventional,28-Apr-11,"Otsuka Pharmaceutical Co., Ltd.",Drug: Tolvaptan
NCT00550459,Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients,Hyponatremia,Interventional,28-Apr-11,"Otsuka Pharmaceutical Co., Ltd.",Drug: Placebo
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,"Genzyme, a Sanofi Company",Biological: Alemtuzumab 12 mg
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,"Genzyme, a Sanofi Company",Biological: Alemtuzumab 24 mg
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,"Genzyme, a Sanofi Company",Biological: Interferon beta-1a
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,Bayer,Biological: Alemtuzumab 12 mg
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,Bayer,Biological: Alemtuzumab 24 mg
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,Bayer,Biological: Interferon beta-1a
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,Sanofi,Biological: Alemtuzumab 12 mg
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,Sanofi,Biological: Alemtuzumab 24 mg
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",Interventional,8-Jan-15,Sanofi,Biological: Interferon beta-1a
NCT01044498,A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Mar-13,Hoffmann-La Roche,Drug: Tocilizumab
NCT01044498,A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Mar-13,Hoffmann-La Roche,Drug: Ortho-Novum® 1/35
NCT01033825,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Perennial Allergic Rhinitis,Interventional,19-Jul-12,Sunovion,Drug: Ciclesonide HFA Nasal Aerosol 320 mcg
NCT01033825,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Perennial Allergic Rhinitis,Interventional,19-Jul-12,Sunovion,Drug: Ciclesonide HFA Nasal Aerosol 160 mcg
NCT01033825,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Perennial Allergic Rhinitis,Interventional,19-Jul-12,Sunovion,Drug: HFA Nasal Aerosol placebo
NCT01033825,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Perennial Allergic Rhinitis,Interventional,19-Jul-12,Sunovion,Drug: Ciclesonide Aqueous Nasal Spray 200 mcg
NCT01033825,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Perennial Allergic Rhinitis,Interventional,19-Jul-12,Sunovion,Drug: AQ Nasal Spray Placebo
NCT01033825,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Perennial Allergic Rhinitis,Interventional,19-Jul-12,Sunovion,Drug: Placebo plus Dexamethasone HFA
NCT01033825,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Perennial Allergic Rhinitis,Interventional,19-Jul-12,Sunovion,Drug: Placebo AQ plus Dexamethasone 6 mg
NCT01683058,"Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia",Schizophrenia,Interventional,31-Mar-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole IM Depot
NCT01683058,"Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia",Schizophrenia,Interventional,31-Mar-15,H. Lundbeck A/S,Drug: Aripiprazole IM Depot
NCT01683058,"Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia",Schizophrenia,Interventional,31-Mar-15,Otsuka America Pharmaceutical,Drug: Aripiprazole IM Depot
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Multiple Sclerosis, Relapsing-Remitting",Interventional,24-Nov-14,"Genzyme, a Sanofi Company",Biological: Alemtuzumab
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Multiple Sclerosis, Relapsing-Remitting",Interventional,24-Nov-14,"Genzyme, a Sanofi Company",Biological: Interferon beta-1a
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Multiple Sclerosis, Relapsing-Remitting",Interventional,24-Nov-14,Bayer,Biological: Alemtuzumab
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Multiple Sclerosis, Relapsing-Remitting",Interventional,24-Nov-14,Bayer,Biological: Interferon beta-1a
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Multiple Sclerosis, Relapsing-Remitting",Interventional,24-Nov-14,Sanofi,Biological: Alemtuzumab
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Multiple Sclerosis, Relapsing-Remitting",Interventional,24-Nov-14,Sanofi,Biological: Interferon beta-1a
NCT00529087,Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain,Constipation,Interventional,11-May-10,"Bausch Health Americas, Inc.",Drug: N-methylnaltrexone bromide (MOA-728)
NCT00529087,Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain,Constipation,Interventional,11-May-10,"Bausch Health Americas, Inc.",Other: placebo
NCT00529087,Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain,Constipation,Interventional,11-May-10,"Progenics Pharmaceuticals, Inc.",Drug: N-methylnaltrexone bromide (MOA-728)
NCT00529087,Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain,Constipation,Interventional,11-May-10,"Progenics Pharmaceuticals, Inc.",Other: placebo
NCT00796120,An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS),Sarcoma,Interventional,16-Sep-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Trabectedin
NCT00796120,An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS),Sarcoma,Interventional,16-Sep-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Doxorubicin
NCT00796120,An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS),Sarcoma,Interventional,16-Sep-14,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Ifosfamide
NCT00796120,An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS),Sarcoma,Interventional,16-Sep-14,PharmaMar,Drug: Trabectedin
NCT00796120,An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS),Sarcoma,Interventional,16-Sep-14,PharmaMar,Drug: Doxorubicin
NCT00796120,An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS),Sarcoma,Interventional,16-Sep-14,PharmaMar,Drug: Ifosfamide
NCT00528879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,Type 2 Diabetes,Interventional,2-May-14,AstraZeneca,Drug: Dapagliflozin
NCT00528879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,Type 2 Diabetes,Interventional,2-May-14,AstraZeneca,Drug: Placebo
NCT00528879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,Type 2 Diabetes,Interventional,2-May-14,AstraZeneca,Drug: Metformin
NCT00528879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,Type 2 Diabetes,Interventional,2-May-14,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT00528879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,Type 2 Diabetes,Interventional,2-May-14,Bristol-Myers Squibb,Drug: Placebo
NCT00528879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,Type 2 Diabetes,Interventional,2-May-14,Bristol-Myers Squibb,Drug: Metformin
NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,14-May-14,AstraZeneca,Drug: Dapagliflozin
NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,14-May-14,AstraZeneca,Drug: Dapagliflozin placebo
NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,14-May-14,AstraZeneca,Drug: Metformin
NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,14-May-14,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,14-May-14,Bristol-Myers Squibb,Drug: Dapagliflozin placebo
NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Type 2 Diabetes,Interventional,14-May-14,Bristol-Myers Squibb,Drug: Metformin
NCT00523978,A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Interventional,28-Aug-12,Medtronic Cardiac Rhythm and Heart Failure,Device: Arctic Front® Cryoablation Catheter
NCT00523978,A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Interventional,28-Aug-12,Medtronic Cardiac Rhythm and Heart Failure,Drug: Flecainide or Sotalol or Propafenone
NCT00523978,A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Interventional,28-Aug-12,Medtronic,Device: Arctic Front® Cryoablation Catheter
NCT00523978,A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Interventional,28-Aug-12,Medtronic,Drug: Flecainide or Sotalol or Propafenone
NCT01663532,"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",Schizophrenia,Interventional,16-Feb-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole IM Depot
NCT01663532,"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",Schizophrenia,Interventional,16-Feb-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT01663532,"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",Schizophrenia,Interventional,16-Feb-15,H. Lundbeck A/S,Drug: Aripiprazole IM Depot
NCT01663532,"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",Schizophrenia,Interventional,16-Feb-15,H. Lundbeck A/S,Drug: Placebo
NCT01663532,"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",Schizophrenia,Interventional,16-Feb-15,Otsuka America Pharmaceutical,Drug: Aripiprazole IM Depot
NCT01663532,"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",Schizophrenia,Interventional,16-Feb-15,Otsuka America Pharmaceutical,Drug: Placebo
NCT00619957,Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis,Other Osteoporosis,Interventional,28-Oct-11,Warner Chilcott,Drug: Placebo tablet
NCT00619957,Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis,Other Osteoporosis,Interventional,28-Oct-11,Warner Chilcott,Drug: Risedronate
NCT00619957,Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis,Other Osteoporosis,Interventional,28-Oct-11,Sanofi,Drug: Placebo tablet
NCT00619957,Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis,Other Osteoporosis,Interventional,28-Oct-11,Sanofi,Drug: Risedronate
NCT00614445,The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy,Nausea and Vomiting of Pregnancy,Interventional,5-Sep-11,Duchesnay Inc.,Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
NCT00614445,The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy,Nausea and Vomiting of Pregnancy,Interventional,5-Sep-11,Duchesnay Inc.,Drug: Placebo
NCT00614445,The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy,Nausea and Vomiting of Pregnancy,Interventional,5-Sep-11,Premier Research Group plc,Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
NCT00614445,The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy,Nausea and Vomiting of Pregnancy,Interventional,5-Sep-11,Premier Research Group plc,Drug: Placebo
NCT00613938,A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.,Arthralgia|Bunion|Hallux Valgus|Pain,Interventional,23-Apr-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Tapentadol (CG5503)
NCT00613938,A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.,Arthralgia|Bunion|Hallux Valgus|Pain,Interventional,23-Apr-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: oxycodone
NCT00613938,A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.,Arthralgia|Bunion|Hallux Valgus|Pain,Interventional,23-Apr-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: placebo
NCT00613938,A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.,Arthralgia|Bunion|Hallux Valgus|Pain,Interventional,23-Apr-10,Grünenthal GmbH,Drug: Tapentadol (CG5503)
NCT00613938,A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.,Arthralgia|Bunion|Hallux Valgus|Pain,Interventional,23-Apr-10,Grünenthal GmbH,Drug: oxycodone
NCT00613938,A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.,Arthralgia|Bunion|Hallux Valgus|Pain,Interventional,23-Apr-10,Grünenthal GmbH,Drug: placebo
NCT00511147,IGIV Study for Chronic ITP Patients Ages 3-70,Idiopathic Thrombocytopenic Purpura,Interventional,5-May-17,"Grifols Biologicals, LLC",Biological: IGIV3I Grifols 10%
NCT00511147,IGIV Study for Chronic ITP Patients Ages 3-70,Idiopathic Thrombocytopenic Purpura,Interventional,5-May-17,"Instituto Grifols, S.A.",Biological: IGIV3I Grifols 10%
NCT00603239,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,Type 2 Diabetes Mellitus,Interventional,2-Sep-10,AstraZeneca,Drug: exenatide
NCT00603239,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,Type 2 Diabetes Mellitus,Interventional,2-Sep-10,AstraZeneca,Drug: placebo
NCT00603239,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,Type 2 Diabetes Mellitus,Interventional,2-Sep-10,Eli Lilly and Company,Drug: exenatide
NCT00603239,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,Type 2 Diabetes Mellitus,Interventional,2-Sep-10,Eli Lilly and Company,Drug: placebo
NCT00509795,Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD),Macular Degeneration,Interventional,16-Apr-12,Regeneron Pharmaceuticals,Biological: ranibizumab
NCT00509795,Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD),Macular Degeneration,Interventional,16-Apr-12,Regeneron Pharmaceuticals,"Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)"
NCT00509795,Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD),Macular Degeneration,Interventional,16-Apr-12,Bayer,Biological: ranibizumab
NCT00509795,Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD),Macular Degeneration,Interventional,16-Apr-12,Bayer,"Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)"
NCT00999141,Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy,Face-lift|Facial Rhytidectomy,Interventional,27-Aug-12,Baxter Healthcare Corporation,Biological: FS VH S/D 4 s-apr
NCT00501046,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2),Chronic Kidney Disease,Interventional,2-Mar-15,Mitsubishi Tanabe Pharma Corporation,Drug: Placebo
NCT00501046,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2),Chronic Kidney Disease,Interventional,2-Mar-15,Mitsubishi Tanabe Pharma Corporation,Drug: AST-120
NCT00501046,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2),Chronic Kidney Disease,Interventional,2-Mar-15,Kureha Corporation,Drug: Placebo
NCT00501046,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2),Chronic Kidney Disease,Interventional,2-Mar-15,Kureha Corporation,Drug: AST-120
NCT00500682,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1),Chronic Kidney Disease,Interventional,2-Mar-15,Mitsubishi Tanabe Pharma Corporation,Drug: Placebo
NCT00500682,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1),Chronic Kidney Disease,Interventional,2-Mar-15,Mitsubishi Tanabe Pharma Corporation,Drug: AST-120
NCT00500682,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1),Chronic Kidney Disease,Interventional,2-Mar-15,Kureha Corporation,Drug: Placebo
NCT00500682,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1),Chronic Kidney Disease,Interventional,2-Mar-15,Kureha Corporation,Drug: AST-120
NCT00496769,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,Atrial Fibrillation,Interventional,14-Nov-13,Bristol-Myers Squibb,Drug: Apixaban
NCT00496769,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,Atrial Fibrillation,Interventional,14-Nov-13,Bristol-Myers Squibb,Drug: Acetylsalicylic acid
NCT00496769,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,Atrial Fibrillation,Interventional,14-Nov-13,Pfizer,Drug: Apixaban
NCT00496769,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,Atrial Fibrillation,Interventional,14-Nov-13,Pfizer,Drug: Acetylsalicylic acid
NCT00488631,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,11-Nov-13,"Janssen Research & Development, LLC",Biological: Placebo
NCT00488631,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,11-Nov-13,"Janssen Research & Development, LLC",Biological: Golimumab 50 mg
NCT00488631,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,11-Nov-13,"Janssen Research & Development, LLC",Biological: Golimumab 100 mg
NCT00488631,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,11-Nov-13,"Janssen Research & Development, LLC",Biological: Golimumab 200 mg
NCT00488631,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,11-Nov-13,Merck Sharp & Dohme Corp.,Biological: Placebo
NCT00488631,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,11-Nov-13,Merck Sharp & Dohme Corp.,Biological: Golimumab 50 mg
NCT00488631,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,11-Nov-13,Merck Sharp & Dohme Corp.,Biological: Golimumab 100 mg
NCT00488631,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,11-Nov-13,Merck Sharp & Dohme Corp.,Biological: Golimumab 200 mg
NCT00487435,An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain,Pain|Osteoarthritis|Low Back Pain,Interventional,23-Jul-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Tapentadol (CG5503) Extended Release (ER)
NCT00487435,An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain,Pain|Osteoarthritis|Low Back Pain,Interventional,23-Jul-10,Grünenthal GmbH,Drug: Tapentadol (CG5503) Extended Release (ER)
NCT00468546,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,Rheumatoid Arthritis,Interventional,25-Oct-16,Hoffmann-La Roche,Drug: MabThera/Rituxan
NCT00468546,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,Rheumatoid Arthritis,Interventional,25-Oct-16,Hoffmann-La Roche,Drug: Methotrexate
NCT00468546,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,Rheumatoid Arthritis,Interventional,25-Oct-16,Hoffmann-La Roche,Other: Placebo
NCT00468546,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,Rheumatoid Arthritis,Interventional,25-Oct-16,Biogen,Drug: MabThera/Rituxan
NCT00468546,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,Rheumatoid Arthritis,Interventional,25-Oct-16,Biogen,Drug: Methotrexate
NCT00468546,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,Rheumatoid Arthritis,Interventional,25-Oct-16,Biogen,Other: Placebo
NCT01568892,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,HIV Infections,Interventional,19-Feb-14,ViiV Healthcare,Drug: Dolutegravir 50 mg twice daily
NCT01568892,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,HIV Infections,Interventional,19-Feb-14,ViiV Healthcare,Drug: Dolutegravir placebo twice daily
NCT01568892,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,HIV Infections,Interventional,19-Feb-14,Shionogi,Drug: Dolutegravir 50 mg twice daily
NCT01568892,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,HIV Infections,Interventional,19-Feb-14,Shionogi,Drug: Dolutegravir placebo twice daily
NCT01568892,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,HIV Infections,Interventional,19-Feb-14,GlaxoSmithKline,Drug: Dolutegravir 50 mg twice daily
NCT01568892,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,HIV Infections,Interventional,19-Feb-14,GlaxoSmithKline,Drug: Dolutegravir placebo twice daily
NCT00440947,Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection,"Infection, Human Immunodeficiency Virus I|HIV Infection",Interventional,17-Aug-11,ViiV Healthcare,Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)
NCT00440947,Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection,"Infection, Human Immunodeficiency Virus I|HIV Infection",Interventional,17-Aug-11,ViiV Healthcare,Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
NCT00440947,Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection,"Infection, Human Immunodeficiency Virus I|HIV Infection",Interventional,17-Aug-11,GlaxoSmithKline,Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)
NCT00440947,Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection,"Infection, Human Immunodeficiency Virus I|HIV Infection",Interventional,17-Aug-11,GlaxoSmithKline,Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
NCT00440193,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,Venous Thrombosis,Interventional,24-Jan-13,Bayer,"Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00440193,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,Venous Thrombosis,Interventional,24-Jan-13,Bayer,Drug: Enoxaparin followed by VKA
NCT00440193,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,Venous Thrombosis,Interventional,24-Jan-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00440193,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,Venous Thrombosis,Interventional,24-Jan-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Enoxaparin followed by VKA
NCT00439777,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,Pulmonary Embolism,Interventional,24-Jan-13,Bayer,"Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00439777,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,Pulmonary Embolism,Interventional,24-Jan-13,Bayer,Drug: Enoxaparin overlapping with and followed by VKA
NCT00439777,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,Pulmonary Embolism,Interventional,24-Jan-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00439777,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,Pulmonary Embolism,Interventional,24-Jan-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Enoxaparin overlapping with and followed by VKA
NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Venous Thromboembolism,Interventional,12-Apr-12,Bayer,"Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Venous Thromboembolism,Interventional,12-Apr-12,Bayer,Drug: Placebo
NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Venous Thromboembolism,Interventional,12-Apr-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Venous Thromboembolism,Interventional,12-Apr-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00885105,Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age,Influenza,Interventional,1-Jan-10,"Sanofi Pasteur, a Sanofi Company",Biological: Influenza Virus Vaccine
NCT00885105,Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age,Influenza,Interventional,1-Jan-10,Sanofi,Biological: Influenza Virus Vaccine
NCT00428948,Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD),"Polycystic Kidney Disease, Autosomal Dominant",Interventional,2-Jul-17,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Tolvaptan
NCT00428948,Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD),"Polycystic Kidney Disease, Autosomal Dominant",Interventional,2-Jul-17,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT00428948,Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD),"Polycystic Kidney Disease, Autosomal Dominant",Interventional,2-Jul-17,"Otsuka Pharmaceutical Co., Ltd.",Drug: Tolvaptan
NCT00428948,Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD),"Polycystic Kidney Disease, Autosomal Dominant",Interventional,2-Jul-17,"Otsuka Pharmaceutical Co., Ltd.",Drug: Placebo
NCT00876265,"Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.",Facial Wrinkles,Interventional,19-Jan-12,"Merz North America, Inc.",Device: Belotero
NCT00876265,"Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.",Facial Wrinkles,Interventional,19-Jan-12,"Merz North America, Inc.",Device: Zyplast
NCT00422734,Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life,Impotence,Interventional,2-Jun-09,Eli Lilly and Company,Drug: tadalafil
NCT00422734,Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life,Impotence,Interventional,2-Jun-09,Eli Lilly and Company,Drug: Placebo
NCT00422734,Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life,Impotence,Interventional,2-Jun-09,ICOS Corporation,Drug: tadalafil
NCT00422734,Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life,Impotence,Interventional,2-Jun-09,ICOS Corporation,Drug: Placebo
NCT00413218,Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections,"Candidiasis, Invasive|Candidemia|Mycoses",Interventional,1-Aug-17,Astellas Pharma Inc,Drug: Isavuconazole
NCT00413218,Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections,"Candidiasis, Invasive|Candidemia|Mycoses",Interventional,1-Aug-17,Astellas Pharma Inc,Drug: Caspofungin
NCT00413218,Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections,"Candidiasis, Invasive|Candidemia|Mycoses",Interventional,1-Aug-17,Astellas Pharma Inc,Drug: Voriconazole
NCT00413218,Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections,"Candidiasis, Invasive|Candidemia|Mycoses",Interventional,1-Aug-17,Basilea Pharmaceutica,Drug: Isavuconazole
NCT00413218,Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections,"Candidiasis, Invasive|Candidemia|Mycoses",Interventional,1-Aug-17,Basilea Pharmaceutica,Drug: Caspofungin
NCT00413218,Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections,"Candidiasis, Invasive|Candidemia|Mycoses",Interventional,1-Aug-17,Basilea Pharmaceutica,Drug: Voriconazole
NCT00412373,Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.,Schizoaffective Disorder|Psychotic Disorder,Interventional,9-Dec-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00412373,Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.,Schizoaffective Disorder|Psychotic Disorder,Interventional,9-Dec-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Paliperidone ER
NCT00412373,Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.,Schizoaffective Disorder|Psychotic Disorder,Interventional,9-Dec-09,"Janssen, LP",Drug: Placebo
NCT00412373,Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.,Schizoaffective Disorder|Psychotic Disorder,Interventional,9-Dec-09,"Janssen, LP",Drug: Paliperidone ER
NCT00412893,Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis,Aspergillosis|Invasive Fungal Infection,Interventional,31-Mar-15,Astellas Pharma Inc,Drug: Isavuconazole
NCT00412893,Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis,Aspergillosis|Invasive Fungal Infection,Interventional,31-Mar-15,Astellas Pharma Inc,Drug: Voriconazole
NCT00412893,Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis,Aspergillosis|Invasive Fungal Infection,Interventional,31-Mar-15,Basilea Pharmaceutica International Ltd,Drug: Isavuconazole
NCT00412893,Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis,Aspergillosis|Invasive Fungal Infection,Interventional,31-Mar-15,Basilea Pharmaceutica International Ltd,Drug: Voriconazole
NCT00410384,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,5-May-11,Human Genome Sciences Inc.,Drug: Placebo
NCT00410384,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,5-May-11,Human Genome Sciences Inc.,Drug: Belimumab 1 mg/kg
NCT00410384,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,5-May-11,Human Genome Sciences Inc.,Drug: Belimumab 10 mg/kg
NCT00410384,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,5-May-11,GlaxoSmithKline,Drug: Placebo
NCT00410384,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,5-May-11,GlaxoSmithKline,Drug: Belimumab 1 mg/kg
NCT00410384,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,5-May-11,GlaxoSmithKline,Drug: Belimumab 10 mg/kg
NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Non-small Cell Lung Cancer,Interventional,20-Nov-15,EMD Serono,Biological: Tecemotide (L-BLP25)
NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Non-small Cell Lung Cancer,Interventional,20-Nov-15,EMD Serono,Drug: Single low dose cyclophosphamide
NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Non-small Cell Lung Cancer,Interventional,20-Nov-15,EMD Serono,Drug: Placebo
NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Non-small Cell Lung Cancer,Interventional,20-Nov-15,"Merck KGaA, Darmstadt, Germany",Biological: Tecemotide (L-BLP25)
NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Non-small Cell Lung Cancer,Interventional,20-Nov-15,"Merck KGaA, Darmstadt, Germany",Drug: Single low dose cyclophosphamide
NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Non-small Cell Lung Cancer,Interventional,20-Nov-15,"Merck KGaA, Darmstadt, Germany",Drug: Placebo
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation|Stroke|Embolism,Interventional,17-Jul-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Rivaroxaban
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation|Stroke|Embolism,Interventional,17-Jul-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Warfarin
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation|Stroke|Embolism,Interventional,17-Jul-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo)
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation|Stroke|Embolism,Interventional,17-Jul-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo)
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation|Stroke|Embolism,Interventional,17-Jul-12,Bayer,Drug: Rivaroxaban
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation|Stroke|Embolism,Interventional,17-Jul-12,Bayer,Drug: Warfarin
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation|Stroke|Embolism,Interventional,17-Jul-12,Bayer,Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo)
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation|Stroke|Embolism,Interventional,17-Jul-12,Bayer,Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo)
NCT00402688,An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis,Prostatitis,Interventional,16-Jul-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: levofloxacin
NCT00402688,An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis,Prostatitis,Interventional,16-Jul-09,"PriCara, Unit of Ortho-McNeil, Inc.",Drug: levofloxacin
NCT00400179,A Safety and Efficacy Study in Patients With Gastric Cancer,Gastric Cancer,Interventional,23-Apr-12,"Taiho Oncology, Inc.",Drug: S-1/Cisplatin
NCT00400179,A Safety and Efficacy Study in Patients With Gastric Cancer,Gastric Cancer,Interventional,23-Apr-12,"Taiho Oncology, Inc.",Drug: 5-FU/cisplatin
NCT00400179,A Safety and Efficacy Study in Patients With Gastric Cancer,Gastric Cancer,Interventional,23-Apr-12,"Quintiles, Inc.",Drug: S-1/Cisplatin
NCT00400179,A Safety and Efficacy Study in Patients With Gastric Cancer,Gastric Cancer,Interventional,23-Apr-12,"Quintiles, Inc.",Drug: 5-FU/cisplatin
NCT00397839,The Effect Of Oral Ibandronate In Male Osteoporosis,Male Osteoporosis,Interventional,21-Dec-09,Hoffmann-La Roche,Drug: Ibandronate
NCT00397839,The Effect Of Oral Ibandronate In Male Osteoporosis,Male Osteoporosis,Interventional,21-Dec-09,Hoffmann-La Roche,Drug: placebo
NCT00397839,The Effect Of Oral Ibandronate In Male Osteoporosis,Male Osteoporosis,Interventional,21-Dec-09,GlaxoSmithKline,Drug: Ibandronate
NCT00397839,The Effect Of Oral Ibandronate In Male Osteoporosis,Male Osteoporosis,Interventional,21-Dec-09,GlaxoSmithKline,Drug: placebo
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,Encube Ethicals Pvt. Ltd.,Drug: Ketoconazole Cream 2%
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,Encube Ethicals Pvt. Ltd.,Drug: Ketoconazole Cream 2% (G&W Laboratories Inc.)
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,Encube Ethicals Pvt. Ltd.,Drug: Placebo
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,Novum Pharmaceutical Research Services,Drug: Ketoconazole Cream 2%
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,Novum Pharmaceutical Research Services,Drug: Ketoconazole Cream 2% (G&W Laboratories Inc.)
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,Novum Pharmaceutical Research Services,Drug: Placebo
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,ACM Global Laboratories,Drug: Ketoconazole Cream 2%
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,ACM Global Laboratories,Drug: Ketoconazole Cream 2% (G&W Laboratories Inc.)
NCT03824912,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Tinea Pedis,Interventional,13-Jun-19,ACM Global Laboratories,Drug: Placebo
NCT00388726,E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer,Breast Cancer,Interventional,30-Jan-12,Eisai Inc.,Drug: E7389
NCT00388726,E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer,Breast Cancer,Interventional,30-Jan-12,Eisai Inc.,Drug: Physician's Choice
NCT00388726,E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer,Breast Cancer,Interventional,30-Jan-12,Eisai Limited,Drug: E7389
NCT00388726,E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer,Breast Cancer,Interventional,30-Jan-12,Eisai Limited,Drug: Physician's Choice
NCT00381303,"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.",HIV|Infectious,Interventional,19-Oct-10,"Tibotec, Inc",Drug: darunavir
NCT00381303,"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.",HIV|Infectious,Interventional,19-Oct-10,"Tibotec, Inc",Drug: ritonavir
NCT00381303,"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.",HIV|Infectious,Interventional,19-Oct-10,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: darunavir
NCT00381303,"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.",HIV|Infectious,Interventional,19-Oct-10,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: ritonavir
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Hoffmann-La Roche,Drug: Mycophenolate mofetil (MMF)
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Hoffmann-La Roche,Drug: Cyclophosphamide
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Hoffmann-La Roche,Drug: Azathioprine
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Hoffmann-La Roche,Drug: Placebo to Azathioprine
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Hoffmann-La Roche,Drug: Placebo to Mycophenolate mofetil
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Hoffmann-La Roche,Drug: Corticosteroid
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Aspreva Pharmaceuticals,Drug: Mycophenolate mofetil (MMF)
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Aspreva Pharmaceuticals,Drug: Cyclophosphamide
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Aspreva Pharmaceuticals,Drug: Azathioprine
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Aspreva Pharmaceuticals,Drug: Placebo to Azathioprine
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Aspreva Pharmaceuticals,Drug: Placebo to Mycophenolate mofetil
NCT00377637,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Lupus Nephritis,Interventional,6-Dec-11,Aspreva Pharmaceuticals,Drug: Corticosteroid
NCT00375492,Effect on Weight Loss of Exenatide Versus Placebo,Type 2 Diabetes Mellitus,Interventional,4-Sep-09,AstraZeneca,Drug: exenatide
NCT00375492,Effect on Weight Loss of Exenatide Versus Placebo,Type 2 Diabetes Mellitus,Interventional,4-Sep-09,AstraZeneca,Drug: placebo
NCT00375492,Effect on Weight Loss of Exenatide Versus Placebo,Type 2 Diabetes Mellitus,Interventional,4-Sep-09,Eli Lilly and Company,Drug: exenatide
NCT00375492,Effect on Weight Loss of Exenatide Versus Placebo,Type 2 Diabetes Mellitus,Interventional,4-Sep-09,Eli Lilly and Company,Drug: placebo
NCT00365859,Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD),Autistic Disorder|Behavioral Symptoms,Interventional,25-Jan-10,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT00365859,Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD),Autistic Disorder|Behavioral Symptoms,Interventional,25-Jan-10,Otsuka America Pharmaceutical,Drug: Aripiprazole
NCT00361504,A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain,"Osteoarthritis, Hip|Osteoarthritis, Knee|Lower Back Pain|Pain",Interventional,4-Sep-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Oxycodone CR
NCT00361504,A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain,"Osteoarthritis, Hip|Osteoarthritis, Knee|Lower Back Pain|Pain",Interventional,4-Sep-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Tapentadol (CG5503) ER
NCT00361504,A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain,"Osteoarthritis, Hip|Osteoarthritis, Knee|Lower Back Pain|Pain",Interventional,4-Sep-09,Grünenthal GmbH,Drug: Oxycodone CR
NCT00361504,A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain,"Osteoarthritis, Hip|Osteoarthritis, Knee|Lower Back Pain|Pain",Interventional,4-Sep-09,Grünenthal GmbH,Drug: Tapentadol (CG5503) ER
NCT00361335,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,24-Aug-12,"Centocor, Inc.",Drug: Golimumab
NCT00361335,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,24-Aug-12,"Centocor, Inc.",Drug: Methotrexate
NCT00361335,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,24-Aug-12,"Centocor, Inc.",Drug: Placebo
NCT00361335,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,24-Aug-12,Schering-Plough,Drug: Golimumab
NCT00361335,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,24-Aug-12,Schering-Plough,Drug: Methotrexate
NCT00361335,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,24-Aug-12,Schering-Plough,Drug: Placebo
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,AstraZeneca,"Drug: Olive oil, 4g"
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,AstraZeneca,"Drug: omega-3-carboxylic acids, 2g"
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,AstraZeneca,"Drug: omega-3-carboxylic acids, 4g"
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,"Omthera Pharmaceuticals, Inc","Drug: Olive oil, 4g"
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,"Omthera Pharmaceuticals, Inc","Drug: omega-3-carboxylic acids, 2g"
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,"Omthera Pharmaceuticals, Inc","Drug: omega-3-carboxylic acids, 4g"
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,"Medpace, Inc.","Drug: Olive oil, 4g"
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,"Medpace, Inc.","Drug: omega-3-carboxylic acids, 2g"
NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Hypertriglyceridemia|Cardiovascular Disease,Interventional,5-Dec-14,"Medpace, Inc.","Drug: omega-3-carboxylic acids, 4g"
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Levodopa-carbidopa intestinal gel
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: PEG tube
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: J-tube
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Levodopa-carbidopa intestinal gel
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,"Quintiles, Inc.",Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,"Quintiles, Inc.",Device: PEG tube
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,"Quintiles, Inc.",Device: J-tube
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,AbbVie,Drug: Levodopa-carbidopa intestinal gel
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,AbbVie,Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,AbbVie,Device: PEG tube
NCT00360568,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Interventional,16-Jan-15,AbbVie,Device: J-tube
NCT00356915,Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.,Onychomycosis,Interventional,4-Jan-12,"Stiefel, a GSK Company",Drug: Itraconazole 100mg capsules
NCT00356915,Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.,Onychomycosis,Interventional,4-Jan-12,"Stiefel, a GSK Company",Drug: Itraconazole 200mg tablets
NCT00356915,Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.,Onychomycosis,Interventional,4-Jan-12,"Stiefel, a GSK Company",Drug: Placebo tablets
NCT00356915,Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.,Onychomycosis,Interventional,4-Jan-12,GlaxoSmithKline,Drug: Itraconazole 100mg capsules
NCT00356915,Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.,Onychomycosis,Interventional,4-Jan-12,GlaxoSmithKline,Drug: Itraconazole 200mg tablets
NCT00356915,Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.,Onychomycosis,Interventional,4-Jan-12,GlaxoSmithKline,Drug: Placebo tablets
NCT00337571,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Behavioral Symptoms|Autistic Disorder,Interventional,23-Jul-09,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT00337571,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Behavioral Symptoms|Autistic Disorder,Interventional,23-Jul-09,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT00337571,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Behavioral Symptoms|Autistic Disorder,Interventional,23-Jul-09,Otsuka America Pharmaceutical,Drug: Aripiprazole
NCT00337571,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Behavioral Symptoms|Autistic Disorder,Interventional,23-Jul-09,Otsuka America Pharmaceutical,Drug: Placebo
NCT00337285,An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder|Attention Deficit Disorders With Hyperactivity|Attention Deficit Hyperactivity Disorders,Interventional,17-Jul-09,New River Pharmaceuticals,"Drug: Vyvanse (lisdexamfetamine dimesylate), NRP104"
NCT00337285,An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder|Attention Deficit Disorders With Hyperactivity|Attention Deficit Hyperactivity Disorders,Interventional,17-Jul-09,Shire,"Drug: Vyvanse (lisdexamfetamine dimesylate), NRP104"
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Levodopa-carbidopa intestinal gel
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: PEG tube
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: J-tube
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Levodopa-carbidopa intestinal gel
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: PEG tube
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: J-tube
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Levodopa-carbidopa intestinal gel
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: PEG tube
NCT00335153,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: J-tube
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Levodopa carbidopa intestinal gel (LCIG)
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Placebo gel
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Drug: Placebo (PBO) oral capsules
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: PEG tube
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"AbbVie (prior sponsor, Abbott)",Device: J-tube
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Levodopa carbidopa intestinal gel (LCIG)
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Placebo gel
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Drug: Placebo (PBO) oral capsules
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: PEG tube
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,"Quintiles, Inc.",Device: J-tube
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Levodopa carbidopa intestinal gel (LCIG)
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Placebo gel
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Drug: Placebo (PBO) oral capsules
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: CADD-Legacy® 1400 ambulatory infusion pump
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: PEG tube
NCT00357994,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Advanced Parkinson's Disease,Interventional,16-Jan-15,AbbVie,Device: J-tube
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Melanoma,Interventional,10-Mar-14,Bristol-Myers Squibb,Drug: Ipilimumab
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Melanoma,Interventional,10-Mar-14,Bristol-Myers Squibb,Drug: Placebo
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Melanoma,Interventional,10-Mar-14,Bristol-Myers Squibb,Drug: Dacarbazine
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Melanoma,Interventional,10-Mar-14,Medarex,Drug: Ipilimumab
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Melanoma,Interventional,10-Mar-14,Medarex,Drug: Placebo
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Melanoma,Interventional,10-Mar-14,Medarex,Drug: Dacarbazine
NCT00332241,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Autistic Disorder,Interventional,23-Jul-09,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT00332241,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Autistic Disorder,Interventional,23-Jul-09,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT00332241,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Autistic Disorder,Interventional,23-Jul-09,Otsuka America Pharmaceutical,Drug: Aripiprazole
NCT00332241,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Autistic Disorder,Interventional,23-Jul-09,Otsuka America Pharmaceutical,Drug: Placebo
NCT00721955,Staccato Loxapine in Agitated Patients With Bipolar Disorder,Bipolar I Disorder,Interventional,29-Jun-17,"Alexza Pharmaceuticals, Inc.",Drug: Inhaled Placebo
NCT00721955,Staccato Loxapine in Agitated Patients With Bipolar Disorder,Bipolar I Disorder,Interventional,29-Jun-17,"Alexza Pharmaceuticals, Inc.",Drug: Inhaled loxapine 5 mg
NCT00721955,Staccato Loxapine in Agitated Patients With Bipolar Disorder,Bipolar I Disorder,Interventional,29-Jun-17,"Alexza Pharmaceuticals, Inc.",Drug: Inhaled loxapine 10 mg
NCT00314249,Study of Milnacipran for the Treatment of Fibromyalgia,Fibromyalgia,Interventional,2-Nov-09,Forest Laboratories,Drug: Placebo
NCT00314249,Study of Milnacipran for the Treatment of Fibromyalgia,Fibromyalgia,Interventional,2-Nov-09,Forest Laboratories,Drug: Milnacipran 100mg
NCT00314249,Study of Milnacipran for the Treatment of Fibromyalgia,Fibromyalgia,Interventional,2-Nov-09,"Cypress Bioscience, Inc.",Drug: Placebo
NCT00314249,Study of Milnacipran for the Treatment of Fibromyalgia,Fibromyalgia,Interventional,2-Nov-09,"Cypress Bioscience, Inc.",Drug: Milnacipran 100mg
NCT00312845,Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,Non-Hodgkin's Lymphoma,Interventional,26-Jul-11,"Millennium Pharmaceuticals, Inc.",Drug: Bortezomib + Rituximab
NCT00312845,Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,Non-Hodgkin's Lymphoma,Interventional,26-Jul-11,"Millennium Pharmaceuticals, Inc.",Drug: Rituximab
NCT00312845,Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,Non-Hodgkin's Lymphoma,Interventional,26-Jul-11,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Bortezomib + Rituximab
NCT00312845,Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,Non-Hodgkin's Lymphoma,Interventional,26-Jul-11,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Rituximab
NCT00312195,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain,Chronic Non-malignant Pain,Interventional,15-Oct-10,Purdue Pharma LP,Drug: Buprenorphine transdermal patch
NCT00312195,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain,Chronic Non-malignant Pain,Interventional,15-Oct-10,Purdue Pharma LP,Drug: Placebo to match BTDS
NCT00312195,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain,Chronic Non-malignant Pain,Interventional,15-Oct-10,Napp Pharmaceuticals Limited,Drug: Buprenorphine transdermal patch
NCT00312195,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain,Chronic Non-malignant Pain,Interventional,15-Oct-10,Napp Pharmaceuticals Limited,Drug: Placebo to match BTDS
NCT01328041,A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.,"Infection, Human Immunodeficiency Virus",Interventional,21-Jul-14,ViiV Healthcare,Drug: dolutegravir
NCT01328041,A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.,"Infection, Human Immunodeficiency Virus",Interventional,21-Jul-14,Shionogi,Drug: dolutegravir
NCT01328041,A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.,"Infection, Human Immunodeficiency Virus",Interventional,21-Jul-14,GlaxoSmithKline,Drug: dolutegravir
NCT00306592,Natalizumab Re-Initiation of Dosing,"Multiple Sclerosis, Relapsing-Remitting",Interventional,26-Jan-10,Biogen,Biological: BG00002 (natalizumab)
NCT00306592,Natalizumab Re-Initiation of Dosing,"Multiple Sclerosis, Relapsing-Remitting",Interventional,26-Jan-10,Elan Pharmaceuticals,Biological: BG00002 (natalizumab)
NCT00300755,Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,19-May-10,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: pantoprazole sodium enteric-coated spheroid
NCT00300755,Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,19-May-10,Nycomed,Drug: pantoprazole sodium enteric-coated spheroid
NCT00299546,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),"Arthritis, Rheumatoid",Interventional,28-Sep-11,"Centocor, Inc.",Drug: Placebo
NCT00299546,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),"Arthritis, Rheumatoid",Interventional,28-Sep-11,"Centocor, Inc.",Biological: Golimumab 50 mg
NCT00299546,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),"Arthritis, Rheumatoid",Interventional,28-Sep-11,"Centocor, Inc.",Biological: Golimumab 100 mg
NCT00299546,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),"Arthritis, Rheumatoid",Interventional,28-Sep-11,Schering-Plough,Drug: Placebo
NCT00299546,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),"Arthritis, Rheumatoid",Interventional,28-Sep-11,Schering-Plough,Biological: Golimumab 50 mg
NCT00299546,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),"Arthritis, Rheumatoid",Interventional,28-Sep-11,Schering-Plough,Biological: Golimumab 100 mg
NCT00296504,A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects,"Infection, Human Immunodeficiency Virus",Interventional,8-Nov-11,ViiV Healthcare,Drug: fosamprenavir (GW433908)
NCT00296504,A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects,"Infection, Human Immunodeficiency Virus",Interventional,8-Nov-11,ViiV Healthcare,Drug: ritonavir
NCT00296504,A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects,"Infection, Human Immunodeficiency Virus",Interventional,8-Nov-11,GlaxoSmithKline,Drug: fosamprenavir (GW433908)
NCT00296504,A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects,"Infection, Human Immunodeficiency Virus",Interventional,8-Nov-11,GlaxoSmithKline,Drug: ritonavir
NCT00660829,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,28-Jan-10,Meda Pharmaceuticals,Drug: Placebo
NCT00660829,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,28-Jan-10,Meda Pharmaceuticals,Drug: 0.15% Azelastine Hydrochloride
NCT00655356,Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles,Bilateral Nasolabial Fold Wrinkles,Interventional,13-Mar-12,"Fibrocell Technologies, Inc.",Biological: Autologous Human Fibroblasts (azficel-T)
NCT00655356,Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles,Bilateral Nasolabial Fold Wrinkles,Interventional,13-Mar-12,"Fibrocell Technologies, Inc.",Biological: Placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,ViiV Healthcare,Drug: Dolutegravir
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,ViiV Healthcare,Drug: Atripla
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,ViiV Healthcare,Drug: Abacavir/Lamivudine
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,ViiV Healthcare,Drug: Abacavir/Lamivudine Placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,ViiV Healthcare,Drug: Dolutegravir placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,ViiV Healthcare,Drug: Atripla placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,Shionogi,Drug: Dolutegravir
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,Shionogi,Drug: Atripla
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,Shionogi,Drug: Abacavir/Lamivudine
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,Shionogi,Drug: Abacavir/Lamivudine Placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,Shionogi,Drug: Dolutegravir placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,Shionogi,Drug: Atripla placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,GlaxoSmithKline,Drug: Dolutegravir
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,GlaxoSmithKline,Drug: Atripla
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,GlaxoSmithKline,Drug: Abacavir/Lamivudine
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,GlaxoSmithKline,Drug: Abacavir/Lamivudine Placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,GlaxoSmithKline,Drug: Dolutegravir placebo
NCT01263015,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"Infection, Human Immunodeficiency Virus I",Interventional,2-Jul-14,GlaxoSmithKline,Drug: Atripla placebo
NCT00265096,A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,16-Apr-12,"Centocor, Inc.",Biological: golimumab
NCT00265096,A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,16-Apr-12,"Centocor, Inc.",Biological: Placebo; golimumab
NCT00265096,A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,16-Apr-12,Schering-Plough,Biological: golimumab
NCT00265096,A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,16-Apr-12,Schering-Plough,Biological: Placebo; golimumab
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,"Centocor, Inc.",Drug: Placebo injections
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,"Centocor, Inc.",Drug: Placebo capsules
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,"Centocor, Inc.",Drug: Methotrexate capsules
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,"Centocor, Inc.",Biological: Golimumab 50 mg injections
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,"Centocor, Inc.",Biological: Golimumab 100 mg injections
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,Schering-Plough,Drug: Placebo injections
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,Schering-Plough,Drug: Placebo capsules
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,Schering-Plough,Drug: Methotrexate capsules
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,Schering-Plough,Biological: Golimumab 50 mg injections
NCT00264537,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Rheumatoid Arthritis,Interventional,13-Jul-09,Schering-Plough,Biological: Golimumab 100 mg injections
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,"Centocor, Inc.",Drug: Golimumab 100 mg
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,"Centocor, Inc.",Drug: Golimumab 50 mg
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,"Centocor, Inc.",Drug: Methotrexate
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,"Centocor, Inc.",Drug: Placebo injection
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,"Centocor, Inc.",Drug: Placebo capsules
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,Schering-Plough,Drug: Golimumab 100 mg
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,Schering-Plough,Drug: Golimumab 50 mg
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,Schering-Plough,Drug: Methotrexate
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,Schering-Plough,Drug: Placebo injection
NCT00264550,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Rheumatoid Arthritis,Interventional,21-Mar-14,Schering-Plough,Drug: Placebo capsules
NCT00265083,A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis,"Spondylitis, Ankylosing",Interventional,13-Jul-09,"Centocor, Inc.",Biological: golimumab
NCT00265083,A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis,"Spondylitis, Ankylosing",Interventional,13-Jul-09,"Centocor, Inc.",Biological: Golimumab (CNTO 148); placebo
NCT00265083,A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis,"Spondylitis, Ankylosing",Interventional,13-Jul-09,Schering-Plough,Biological: golimumab
NCT00265083,A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis,"Spondylitis, Ankylosing",Interventional,13-Jul-09,Schering-Plough,Biological: Golimumab (CNTO 148); placebo
NCT00259012,Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD,Gastroesophageal Reflux,Interventional,7-May-10,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: pantoprazole sodium enteric-coated spheroid suspension
NCT00259012,Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD,Gastroesophageal Reflux,Interventional,7-May-10,Nycomed,Drug: pantoprazole sodium enteric-coated spheroid suspension
NCT00257010,A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches,Migraine,Interventional,6-Dec-13,Janssen-Ortho LLC,Drug: Almotriptan Malate
NCT00257010,A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches,Migraine,Interventional,6-Dec-13,"Ortho-McNeil Neurologics, Inc.",Drug: Almotriptan Malate
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,3-Nov-16,US Oncology Research,Drug: Fludarabine
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,3-Nov-16,US Oncology Research,Drug: Cyclophosphamide
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,3-Nov-16,US Oncology Research,Drug: Rituximab
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,3-Nov-16,US Oncology Research,Drug: Pentostatin
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,3-Nov-16,Astex Pharmaceuticals,Drug: Fludarabine
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,3-Nov-16,Astex Pharmaceuticals,Drug: Cyclophosphamide
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,3-Nov-16,Astex Pharmaceuticals,Drug: Rituximab
NCT00254163,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,3-Nov-16,Astex Pharmaceuticals,Drug: Pentostatin
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,ViiV Healthcare,Drug: GSK1349572 (dolutegravir)
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,ViiV Healthcare,Drug: raltegravir
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,ViiV Healthcare,Other: GSK1349572 Placebo
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,ViiV Healthcare,Other: ABC/3TC
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,ViiV Healthcare,Other: TDF/FTC
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,ViiV Healthcare,Other: raltegravir Placebo
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,Shionogi,Drug: GSK1349572 (dolutegravir)
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,Shionogi,Drug: raltegravir
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,Shionogi,Other: GSK1349572 Placebo
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,Shionogi,Other: ABC/3TC
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,Shionogi,Other: TDF/FTC
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,Shionogi,Other: raltegravir Placebo
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,GlaxoSmithKline,Drug: GSK1349572 (dolutegravir)
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,GlaxoSmithKline,Drug: raltegravir
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,GlaxoSmithKline,Other: GSK1349572 Placebo
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,GlaxoSmithKline,Other: ABC/3TC
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,GlaxoSmithKline,Other: TDF/FTC
NCT01227824,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"Infection, Human Immunodeficiency Virus I",Interventional,23-Jun-14,GlaxoSmithKline,Other: raltegravir Placebo
NCT00232596,Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy,Seizures,Interventional,25-Oct-11,GlaxoSmithKline,Drug: Retigabine
NCT00232596,Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy,Seizures,Interventional,25-Oct-11,GlaxoSmithKline,Drug: Placebo
NCT00232596,Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy,Seizures,Interventional,25-Oct-11,"Bausch Health Americas, Inc.",Drug: Retigabine
NCT00232596,Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy,Seizures,Interventional,25-Oct-11,"Bausch Health Americas, Inc.",Drug: Placebo
NCT01212991,A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer,Prostate Cancer,Interventional,16-Oct-14,Pfizer,Drug: Enzalutamide
NCT01212991,A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer,Prostate Cancer,Interventional,16-Oct-14,Pfizer,Drug: Placebo
NCT01212991,A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer,Prostate Cancer,Interventional,16-Oct-14,Astellas Pharma Inc,Drug: Enzalutamide
NCT01212991,A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer,Prostate Cancer,Interventional,16-Oct-14,Astellas Pharma Inc,Drug: Placebo
NCT01212991,A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer,Prostate Cancer,Interventional,16-Oct-14,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Drug: Enzalutamide
NCT01212991,A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer,Prostate Cancer,Interventional,16-Oct-14,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Drug: Placebo
NCT00226655,"An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies",Brain Edema|Brain Tumor,Interventional,31-Aug-12,Celtic Pharma Development Services,Drug: hCRF [XERECEPT (corticorelin acetate injection)]
NCT00226655,"An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies",Brain Edema|Brain Tumor,Interventional,31-Aug-12,Neurobiological Technologies,Drug: hCRF [XERECEPT (corticorelin acetate injection)]
NCT00179647,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,Multiple Myeloma,Interventional,3-Mar-10,Celgene Corporation,Drug: lenalidomide
NCT00179647,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,Multiple Myeloma,Interventional,3-Mar-10,Celgene Corporation,Drug: dexamethasone
NCT00179647,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,Multiple Myeloma,Interventional,3-Mar-10,Prologue Research International,Drug: lenalidomide
NCT00179647,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,Multiple Myeloma,Interventional,3-Mar-10,Prologue Research International,Drug: dexamethasone
NCT00179647,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,Multiple Myeloma,Interventional,3-Mar-10,Celgene,Drug: lenalidomide
NCT00179647,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,Multiple Myeloma,Interventional,3-Mar-10,Celgene,Drug: dexamethasone
NCT00574548,"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Pneumococcal Vaccines,Interventional,9-May-11,Wyeth is now a wholly owned subsidiary of Pfizer,Biological: 13 valent Pneumococcal Conjugate Vaccine
NCT00574548,"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Pneumococcal Vaccines,Interventional,9-May-11,Wyeth is now a wholly owned subsidiary of Pfizer,Biological: 23-valent Pneumococcal Polysaccharide Vaccine
NCT00142298,Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies,Chronic Hepatitis B,Interventional,25-Jul-11,Novartis Pharmaceuticals,Drug: Telbivudine (LdT)
NCT00142298,Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies,Chronic Hepatitis B,Interventional,25-Jul-11,Merck Sharp & Dohme Corp.,Drug: Telbivudine (LdT)
NCT00142298,Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies,Chronic Hepatitis B,Interventional,25-Jul-11,Novartis,Drug: Telbivudine (LdT)
NCT00135330,An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,28-Aug-09,AstraZeneca,Drug: exenatide
NCT00135330,An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,28-Aug-09,AstraZeneca,Drug: rosiglitazone
NCT00135330,An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,28-Aug-09,Eli Lilly and Company,Drug: exenatide
NCT00135330,An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,28-Aug-09,Eli Lilly and Company,Drug: rosiglitazone
NCT00545753,Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice,Pediculosis,Interventional,11-Oct-12,ParaPRO LLC,Drug: Spinosad
NCT00545753,Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice,Pediculosis,Interventional,11-Oct-12,ParaPRO LLC,Drug: Permethrin 1%
NCT00545168,Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice,Pediculus Capitis Infestation,Interventional,11-Oct-12,ParaPRO LLC,Drug: Spinosad
NCT00545168,Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice,Pediculus Capitis Infestation,Interventional,11-Oct-12,ParaPRO LLC,Drug: Permethrin 1%
NCT00146770,Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients,Mucopolysaccharidosis I|Hurler's Syndrome|Hurler-Scheie Syndrome|Scheie Syndrome,Interventional,16-Jun-09,"Genzyme, a Sanofi Company",Biological: Aldurazyme
NCT00146770,Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients,Mucopolysaccharidosis I|Hurler's Syndrome|Hurler-Scheie Syndrome|Scheie Syndrome,Interventional,16-Jun-09,"Genzyme, a Sanofi Company",Biological: placebo
NCT00146770,Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients,Mucopolysaccharidosis I|Hurler's Syndrome|Hurler-Scheie Syndrome|Scheie Syndrome,Interventional,16-Jun-09,BioMarin/Genzyme LLC,Biological: Aldurazyme
NCT00146770,Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients,Mucopolysaccharidosis I|Hurler's Syndrome|Hurler-Scheie Syndrome|Scheie Syndrome,Interventional,16-Jun-09,BioMarin/Genzyme LLC,Biological: placebo
NCT00146770,Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients,Mucopolysaccharidosis I|Hurler's Syndrome|Hurler-Scheie Syndrome|Scheie Syndrome,Interventional,16-Jun-09,Sanofi,Biological: Aldurazyme
NCT00146770,Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients,Mucopolysaccharidosis I|Hurler's Syndrome|Hurler-Scheie Syndrome|Scheie Syndrome,Interventional,16-Jun-09,Sanofi,Biological: placebo
NCT00113607,An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer,Ovarian Cancer,Interventional,23-Aug-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Trabectedin
NCT00113607,An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer,Ovarian Cancer,Interventional,23-Aug-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: DOXIL
NCT00113607,An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer,Ovarian Cancer,Interventional,23-Aug-13,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Dexamethasone
NCT00113607,An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer,Ovarian Cancer,Interventional,23-Aug-13,PharmaMar,Drug: Trabectedin
NCT00113607,An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer,Ovarian Cancer,Interventional,23-Aug-13,PharmaMar,Drug: DOXIL
NCT00113607,An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer,Ovarian Cancer,Interventional,23-Aug-13,PharmaMar,Drug: Dexamethasone
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Non-Small-Cell Lung Carcinoma,Interventional,5-Oct-10,Eli Lilly and Company,Drug: Paclitaxel (Taxane)
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Non-Small-Cell Lung Carcinoma,Interventional,5-Oct-10,Eli Lilly and Company,Drug: Docetaxel (Taxane)
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Non-Small-Cell Lung Carcinoma,Interventional,5-Oct-10,Eli Lilly and Company,Drug: Carboplatin
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Non-Small-Cell Lung Carcinoma,Interventional,5-Oct-10,Eli Lilly and Company,Drug: Cetuximab
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Non-Small-Cell Lung Carcinoma,Interventional,5-Oct-10,ImClone LLC,Drug: Paclitaxel (Taxane)
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Non-Small-Cell Lung Carcinoma,Interventional,5-Oct-10,ImClone LLC,Drug: Docetaxel (Taxane)
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Non-Small-Cell Lung Carcinoma,Interventional,5-Oct-10,ImClone LLC,Drug: Carboplatin
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Non-Small-Cell Lung Carcinoma,Interventional,5-Oct-10,ImClone LLC,Drug: Cetuximab
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Melanoma,Interventional,23-Feb-11,Bayer,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Melanoma,Interventional,23-Feb-11,Bayer,Drug: Carboplatin/Paclitaxel
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Melanoma,Interventional,23-Feb-11,Bayer,Drug: Placebo
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Melanoma,Interventional,23-Feb-11,Amgen,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Melanoma,Interventional,23-Feb-11,Amgen,Drug: Carboplatin/Paclitaxel
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Melanoma,Interventional,23-Feb-11,Amgen,Drug: Placebo
NCT00247273,A Study of Monthly Risedronate for Osteoporosis,Postmenopausal Osteoporosis,Interventional,21-Jun-11,Warner Chilcott,Drug: risedronate
NCT00247273,A Study of Monthly Risedronate for Osteoporosis,Postmenopausal Osteoporosis,Interventional,21-Jun-11,Sanofi,Drug: risedronate
NCT00683930,A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV),Pemphigus Vulgaris (PV),Interventional,22-Jun-11,Hoffmann-La Roche,Drug: Mycophenolate Mofetil 2 g/Day
NCT00683930,A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV),Pemphigus Vulgaris (PV),Interventional,22-Jun-11,Hoffmann-La Roche,Drug: Mycophenolate Mofetil (MMF) 3 g/Day
NCT00683930,A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV),Pemphigus Vulgaris (PV),Interventional,22-Jun-11,Hoffmann-La Roche,Drug: Placebo
NCT00683930,A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV),Pemphigus Vulgaris (PV),Interventional,22-Jun-11,Aspreva Pharmaceuticals,Drug: Mycophenolate Mofetil 2 g/Day
NCT00683930,A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV),Pemphigus Vulgaris (PV),Interventional,22-Jun-11,Aspreva Pharmaceuticals,Drug: Mycophenolate Mofetil (MMF) 3 g/Day
NCT00683930,A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV),Pemphigus Vulgaris (PV),Interventional,22-Jun-11,Aspreva Pharmaceuticals,Drug: Placebo
NCT00105196,A Study of Aripiprazole in Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-May-09,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole+ ADT
NCT00105196,A Study of Aripiprazole in Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-May-09,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo+ ADT
NCT00105196,A Study of Aripiprazole in Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-May-09,Otsuka America Pharmaceutical,Drug: Aripiprazole+ ADT
NCT00105196,A Study of Aripiprazole in Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,18-May-09,Otsuka America Pharmaceutical,Drug: Placebo+ ADT
NCT00099268,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,Parkinson's Disease,Interventional,8-Mar-11,Novartis Pharmaceuticals,Drug: Carbidopa/levodopa/entacapone
NCT00099268,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,Parkinson's Disease,Interventional,8-Mar-11,Novartis Pharmaceuticals,Drug: Immediate release carbidopa/levodopa
NCT00099268,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,Parkinson's Disease,Interventional,8-Mar-11,"Orion Corporation, Orion Pharma",Drug: Carbidopa/levodopa/entacapone
NCT00099268,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,Parkinson's Disease,Interventional,8-Mar-11,"Orion Corporation, Orion Pharma",Drug: Immediate release carbidopa/levodopa
NCT00099268,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,Parkinson's Disease,Interventional,8-Mar-11,Novartis,Drug: Carbidopa/levodopa/entacapone
NCT00099268,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,Parkinson's Disease,Interventional,8-Mar-11,Novartis,Drug: Immediate release carbidopa/levodopa
NCT00098293,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",HIV-1,Interventional,5-Oct-12,ViiV Healthcare,Drug: Maraviroc + Zidovudine/Lamivudine
NCT00098293,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",HIV-1,Interventional,5-Oct-12,ViiV Healthcare,Drug: Efavirenz + Zidovudine/Lamivudine
NCT00098293,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",HIV-1,Interventional,5-Oct-12,ViiV Healthcare,"Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine"
NCT00098293,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",HIV-1,Interventional,5-Oct-12,Pfizer,Drug: Maraviroc + Zidovudine/Lamivudine
NCT00098293,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",HIV-1,Interventional,5-Oct-12,Pfizer,Drug: Efavirenz + Zidovudine/Lamivudine
NCT00098293,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",HIV-1,Interventional,5-Oct-12,Pfizer,"Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine"
NCT00097981,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Interventional,27-Nov-08,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Thalidomide
NCT00097981,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Interventional,27-Nov-08,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Dexamethasone
NCT00097981,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Interventional,27-Nov-08,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: DOXIL
NCT00097981,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Interventional,27-Nov-08,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: Thalidomide
NCT00097981,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Interventional,27-Nov-08,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: Dexamethasone
NCT00097981,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Interventional,27-Nov-08,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: DOXIL
NCT01028378,Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia,Myopia|Hyperopia,Interventional,11-Apr-16,"Clinical Research Consultants, Inc.",Device: T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser
NCT01028378,Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia,Myopia|Hyperopia,Interventional,11-Apr-16,Alcon Research,Device: T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser
NCT01028378,Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia,Myopia|Hyperopia,Interventional,11-Apr-16,WaveLight AG,Device: T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser
NCT00095238,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),Congestive Heart Failure,Interventional,8-Jun-10,Bristol-Myers Squibb,Drug: Irbesartan
NCT00095238,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),Congestive Heart Failure,Interventional,8-Jun-10,Bristol-Myers Squibb,Drug: Placebo
NCT00095238,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),Congestive Heart Failure,Interventional,8-Jun-10,Sanofi,Drug: Irbesartan
NCT00095238,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),Congestive Heart Failure,Interventional,8-Jun-10,Sanofi,Drug: Placebo
NCT00095199,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,15-Oct-12,Eli Lilly and Company,Drug: Pemetrexed
NCT00095199,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,15-Oct-12,Eli Lilly and Company,Biological: Cetuximab
NCT00095199,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,15-Oct-12,Eli Lilly and Company,Drug: Docetaxel
NCT00095199,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,15-Oct-12,ImClone LLC,Drug: Pemetrexed
NCT00095199,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,15-Oct-12,ImClone LLC,Biological: Cetuximab
NCT00095199,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,15-Oct-12,ImClone LLC,Drug: Docetaxel
NCT00094458,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,Crohn Disease,Interventional,23-Jun-09,"Centocor Ortho Biotech Services, L.L.C.",Biological: infliximab infusion; AZA placebo caps
NCT00094458,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,Crohn Disease,Interventional,23-Jun-09,"Centocor Ortho Biotech Services, L.L.C.",Other: infliximab (IFX) infusion; azathioprine (AZA) caps
NCT00094458,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,Crohn Disease,Interventional,23-Jun-09,"Centocor Ortho Biotech Services, L.L.C.",Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps
NCT00094458,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,Crohn Disease,Interventional,23-Jun-09,Schering-Plough,Biological: infliximab infusion; AZA placebo caps
NCT00094458,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,Crohn Disease,Interventional,23-Jun-09,Schering-Plough,Other: infliximab (IFX) infusion; azathioprine (AZA) caps
NCT00094458,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,Crohn Disease,Interventional,23-Jun-09,Schering-Plough,Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps
NCT00974311,Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,Castration-Resistant Prostate Cancer,Interventional,30-Oct-12,Pfizer,Drug: Enzalutamide
NCT00974311,Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,Castration-Resistant Prostate Cancer,Interventional,30-Oct-12,Pfizer,Drug: Placebo
NCT00974311,Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,Castration-Resistant Prostate Cancer,Interventional,30-Oct-12,Astellas Pharma Inc,Drug: Enzalutamide
NCT00974311,Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,Castration-Resistant Prostate Cancer,Interventional,30-Oct-12,Astellas Pharma Inc,Drug: Placebo
NCT00974311,Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,Castration-Resistant Prostate Cancer,Interventional,30-Oct-12,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Drug: Enzalutamide
NCT00974311,Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,Castration-Resistant Prostate Cancer,Interventional,30-Oct-12,"Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Drug: Placebo
NCT00088166,XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors,Brain Edema|Brain Tumor,Interventional,13-Aug-14,Celtic Pharma Development Services,Drug: hCRF
NCT00088166,XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors,Brain Edema|Brain Tumor,Interventional,13-Aug-14,Celtic Pharma Development Services,Drug: placebo hCRF
NCT00088166,XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors,Brain Edema|Brain Tumor,Interventional,13-Aug-14,Neurobiological Technologies,Drug: hCRF
NCT00088166,XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors,Brain Edema|Brain Tumor,Interventional,13-Aug-14,Neurobiological Technologies,Drug: placebo hCRF
NCT00366444,Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery,"Pain, Postoperative",Interventional,13-Apr-11,Xanodyne Pharmaceuticals,Drug: diclofenac potassium (XP21L)
NCT00366444,Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery,"Pain, Postoperative",Interventional,13-Apr-11,Xanodyne Pharmaceuticals,Drug: Placebo
NCT00082381,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,"Diabetes Mellitus, Type 2",Interventional,31-Jul-13,AstraZeneca,Drug: Exenatide (AC2993)
NCT00082381,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,"Diabetes Mellitus, Type 2",Interventional,31-Jul-13,AstraZeneca,Drug: Insulin glargine
NCT00082381,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,"Diabetes Mellitus, Type 2",Interventional,31-Jul-13,Eli Lilly and Company,Drug: Exenatide (AC2993)
NCT00082381,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,"Diabetes Mellitus, Type 2",Interventional,31-Jul-13,Eli Lilly and Company,Drug: Insulin glargine
NCT01499290,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,Complicated Intra-Abdominal Infection,Interventional,1-Mar-16,Pfizer,Drug: CAZ-AVI
NCT01499290,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,Complicated Intra-Abdominal Infection,Interventional,1-Mar-16,Pfizer,Drug: Metronidazole
NCT01499290,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,Complicated Intra-Abdominal Infection,Interventional,1-Mar-16,Pfizer,Drug: Meropenem
NCT01499290,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,Complicated Intra-Abdominal Infection,Interventional,1-Mar-16,Forest Laboratories,Drug: CAZ-AVI
NCT01499290,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,Complicated Intra-Abdominal Infection,Interventional,1-Mar-16,Forest Laboratories,Drug: Metronidazole
NCT01499290,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,Complicated Intra-Abdominal Infection,Interventional,1-Mar-16,Forest Laboratories,Drug: Meropenem
NCT00073307,Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer,"Carcinoma, Renal Cell",Interventional,14-Dec-11,Bayer,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00073307,Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer,"Carcinoma, Renal Cell",Interventional,14-Dec-11,Bayer,Drug: Placebo
NCT00073307,Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer,"Carcinoma, Renal Cell",Interventional,14-Dec-11,Amgen,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00073307,Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer,"Carcinoma, Renal Cell",Interventional,14-Dec-11,Amgen,Drug: Placebo
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Erectile Dysfunction,Interventional,21-Jan-11,Bayer,"Drug: Vardenafil ODT (STAXYN, BAY38-9456)"
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Erectile Dysfunction,Interventional,21-Jan-11,Bayer,Drug: Placebo
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Erectile Dysfunction,Interventional,21-Jan-11,GlaxoSmithKline,"Drug: Vardenafil ODT (STAXYN, BAY38-9456)"
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Erectile Dysfunction,Interventional,21-Jan-11,GlaxoSmithKline,Drug: Placebo
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Erectile Dysfunction,Interventional,21-Jan-11,Schering-Plough,"Drug: Vardenafil ODT (STAXYN, BAY38-9456)"
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Erectile Dysfunction,Interventional,21-Jan-11,Schering-Plough,Drug: Placebo
NCT00022672,A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer,Breast Cancer,Interventional,13-Jun-13,Hoffmann-La Roche,Drug: trastuzumab (Herceptin®)
NCT00022672,A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer,Breast Cancer,Interventional,13-Jun-13,Hoffmann-La Roche,Drug: anastrazole (Arimidex®)
NCT00022672,A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer,Breast Cancer,Interventional,13-Jun-13,"Genentech, Inc.",Drug: trastuzumab (Herceptin®)
NCT00022672,A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer,Breast Cancer,Interventional,13-Jun-13,"Genentech, Inc.",Drug: anastrazole (Arimidex®)
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,"Genentech, Inc.",Drug: Bevacizumab
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,"Genentech, Inc.",Drug: Capecitabine
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,"Genentech, Inc.",Drug: Cisplatin
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,"Genentech, Inc.",Drug: Placebo
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,"Genentech, Inc.",Drug: 5-fluorouracil
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Hoffmann-La Roche,Drug: Bevacizumab
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Hoffmann-La Roche,Drug: Capecitabine
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Hoffmann-La Roche,Drug: Cisplatin
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Hoffmann-La Roche,Drug: Placebo
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Hoffmann-La Roche,Drug: 5-fluorouracil
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Chugai Pharmaceutical,Drug: Bevacizumab
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Chugai Pharmaceutical,Drug: Capecitabine
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Chugai Pharmaceutical,Drug: Cisplatin
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Chugai Pharmaceutical,Drug: Placebo
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Adenocarcinoma,Interventional,19-Jan-12,Chugai Pharmaceutical,Drug: 5-fluorouracil
NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Myocardial Infarction,Interventional,15-May-09,"Centocor, Inc.","Drug: abciximab placebo; reteplase placebo, abciximab, abciximab"
NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Myocardial Infarction,Interventional,15-May-09,"Centocor, Inc.",Drug: Abciximab; reteplase; abciximab placebo; abciximab
NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Myocardial Infarction,Interventional,15-May-09,"Centocor, Inc.",Drug: abciximab; reteplase placebo; abciximab placebo; abciximab
NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Myocardial Infarction,Interventional,15-May-09,Eli Lilly and Company,"Drug: abciximab placebo; reteplase placebo, abciximab, abciximab"
NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Myocardial Infarction,Interventional,15-May-09,Eli Lilly and Company,Drug: Abciximab; reteplase; abciximab placebo; abciximab
NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Myocardial Infarction,Interventional,15-May-09,Eli Lilly and Company,Drug: abciximab; reteplase placebo; abciximab placebo; abciximab
NCT00500539,Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.,Asthma,Interventional,27-Apr-11,Novartis,Drug: omalizumab
NCT00500539,Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.,Asthma,Interventional,27-Apr-11,"Genentech, Inc.",Drug: omalizumab
NCT00500539,Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.,Asthma,Interventional,27-Apr-11,Tanox,Drug: omalizumab
NCT00105989,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,"Depressive Disorder, Major",Interventional,17-Jul-09,Eli Lilly and Company,Drug: Duloxetine
NCT00105989,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,"Depressive Disorder, Major",Interventional,17-Jul-09,Eli Lilly and Company,Drug: placebo
NCT00105989,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,"Depressive Disorder, Major",Interventional,17-Jul-09,Boehringer Ingelheim,Drug: Duloxetine
NCT00105989,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,"Depressive Disorder, Major",Interventional,17-Jul-09,Boehringer Ingelheim,Drug: placebo
NCT01994746,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,"Diabetes Mellitus, Type 1",Interventional,10-Oct-16,Eli Lilly and Company,Drug: Nasal Glucagon
NCT01994746,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,"Diabetes Mellitus, Type 1",Interventional,10-Oct-16,Eli Lilly and Company,Drug: Intramuscular Glucagon
NCT01994746,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,"Diabetes Mellitus, Type 1",Interventional,10-Oct-16,Jaeb Center for Health Research,Drug: Nasal Glucagon
NCT01994746,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,"Diabetes Mellitus, Type 1",Interventional,10-Oct-16,Jaeb Center for Health Research,Drug: Intramuscular Glucagon
NCT01994746,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,"Diabetes Mellitus, Type 1",Interventional,10-Oct-16,Locemia Solutions ULC,Drug: Nasal Glucagon
NCT01994746,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,"Diabetes Mellitus, Type 1",Interventional,10-Oct-16,Locemia Solutions ULC,Drug: Intramuscular Glucagon
NCT01620762,Phase III Cat-PAD Study,Rhinoconjunctivitis,Interventional,14-May-18,Circassia Limited,Drug: Cat-PAD
NCT01620762,Phase III Cat-PAD Study,Rhinoconjunctivitis,Interventional,14-May-18,Circassia Limited,Drug: Placebo
NCT01620762,Phase III Cat-PAD Study,Rhinoconjunctivitis,Interventional,14-May-18,inVentiv Health Clinical,Drug: Cat-PAD
NCT01620762,Phase III Cat-PAD Study,Rhinoconjunctivitis,Interventional,14-May-18,inVentiv Health Clinical,Drug: Placebo
NCT01620762,Phase III Cat-PAD Study,Rhinoconjunctivitis,Interventional,14-May-18,Pharm-Olam International,Drug: Cat-PAD
NCT01620762,Phase III Cat-PAD Study,Rhinoconjunctivitis,Interventional,14-May-18,Pharm-Olam International,Drug: Placebo
NCT01403116,Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Male Hypogonadism,Interventional,14-Aug-18,"Clarus Therapeutics, Inc.",Drug: Oral testosterone undecanoate
NCT01403116,Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Male Hypogonadism,Interventional,14-Aug-18,"Clarus Therapeutics, Inc.",Drug: topical testosterone gel
NCT01403116,Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Male Hypogonadism,Interventional,14-Aug-18,PharmaNet,Drug: Oral testosterone undecanoate
NCT01403116,Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Male Hypogonadism,Interventional,14-Aug-18,PharmaNet,Drug: topical testosterone gel
NCT01403116,Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Male Hypogonadism,Interventional,14-Aug-18,Los Angeles Biomedical Research Institute,Drug: Oral testosterone undecanoate
NCT01403116,Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Male Hypogonadism,Interventional,14-Aug-18,Los Angeles Biomedical Research Institute,Drug: topical testosterone gel
NCT02680041,18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment,Prostate Cancer,Interventional,28-Jan-19,Blue Earth Diagnostics,Drug: 18F-fluciclovine PET CT
NCT02680041,18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment,Prostate Cancer,Interventional,28-Jan-19,American College of Radiology,Drug: 18F-fluciclovine PET CT
NCT02680041,18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment,Prostate Cancer,Interventional,28-Jan-19,IND 2 Results LLC,Drug: 18F-fluciclovine PET CT
NCT02680041,18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment,Prostate Cancer,Interventional,28-Jan-19,Syne Qua Non Limited,Drug: 18F-fluciclovine PET CT
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,Hoffmann-La Roche,Drug: obinutuzumab
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,Hoffmann-La Roche,Drug: rituximab
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,Hoffmann-La Roche,Drug: chlorambucil
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,German CLL Study Group,Drug: obinutuzumab
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,German CLL Study Group,Drug: rituximab
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,German CLL Study Group,Drug: chlorambucil
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,"Genentech, Inc.",Drug: obinutuzumab
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,"Genentech, Inc.",Drug: rituximab
NCT02053610,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),"Lymphocytic Leukemia, Chronic",Interventional,10-Oct-14,"Genentech, Inc.",Drug: chlorambucil
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,Hoffmann-La Roche,Drug: obinutuzumab
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,Hoffmann-La Roche,Drug: rituximab
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,Hoffmann-La Roche,Drug: chlorambucil
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,German CLL Study Group,Drug: obinutuzumab
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,German CLL Study Group,Drug: rituximab
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,German CLL Study Group,Drug: chlorambucil
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,"Genentech, Inc.",Drug: obinutuzumab
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,"Genentech, Inc.",Drug: rituximab
NCT01998880,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),"Lymphocytic Leukemia, Chronic",Interventional,28-Jan-14,"Genentech, Inc.",Drug: chlorambucil
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,Hoffmann-La Roche,Drug: Rituximab
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,Hoffmann-La Roche,Drug: Fludarabine Phosphate
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,Hoffmann-La Roche,Drug: Cyclophosphamide
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,Biogen,Drug: Rituximab
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,Biogen,Drug: Fludarabine Phosphate
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,Biogen,Drug: Cyclophosphamide
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,"Genentech, Inc.",Drug: Rituximab
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,"Genentech, Inc.",Drug: Fludarabine Phosphate
NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Chronic Lymphocytic Leukemia,Interventional,23-Jan-12,"Genentech, Inc.",Drug: Cyclophosphamide
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,Eli Lilly and Company,Drug: Clopidogrel
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,Eli Lilly and Company,Drug: Prasugrel
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,Eli Lilly and Company,Drug: Commercially-available Aspirin
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,"Daiichi Sankyo Co., Ltd.",Drug: Clopidogrel
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,"Daiichi Sankyo Co., Ltd.",Drug: Prasugrel
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,"Daiichi Sankyo Co., Ltd.",Drug: Commercially-available Aspirin
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,Duke Clinical Research Institute,Drug: Clopidogrel
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,Duke Clinical Research Institute,Drug: Prasugrel
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Interventional,7-May-13,Duke Clinical Research Institute,Drug: Commercially-available Aspirin
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,Anne Lindblad,Drug: propranolol LA
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,Anne Lindblad,Drug: topiramate
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,Anne Lindblad,Drug: placebo
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,National Institute of Neurological Disorders and Stroke (NINDS),Drug: propranolol LA
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,National Institute of Neurological Disorders and Stroke (NINDS),Drug: topiramate
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,National Institute of Neurological Disorders and Stroke (NINDS),Drug: placebo
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: propranolol LA
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: topiramate
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: placebo
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,"The Emmes Company, LLC",Drug: propranolol LA
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,"The Emmes Company, LLC",Drug: topiramate
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,Chronic Migraine,Interventional,19-Jan-12,"The Emmes Company, LLC",Drug: placebo
NCT01128959,Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy,Epilepsy,Interventional,5-Dec-16,Lundbeck LLC,Drug: Intravenous Carbamazepine (IV CBZ)
NCT01128959,Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy,Epilepsy,Interventional,5-Dec-16,Ligand Pharmaceuticals,Drug: Intravenous Carbamazepine (IV CBZ)
NCT01128959,Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy,Epilepsy,Interventional,5-Dec-16,ICON Clinical Research,Drug: Intravenous Carbamazepine (IV CBZ)
NCT01128959,Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy,Epilepsy,Interventional,5-Dec-16,"Quintiles, Inc.",Drug: Intravenous Carbamazepine (IV CBZ)
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,Sanofi,Drug: Placebo
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,Sanofi,"Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)"
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,Sanofi,"Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)"
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,Regeneron Pharmaceuticals,Drug: Placebo
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,Regeneron Pharmaceuticals,"Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)"
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,Regeneron Pharmaceuticals,"Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)"
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,NSABP Foundation Inc,Drug: Placebo
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,NSABP Foundation Inc,"Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)"
NCT00561470,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Colorectal Neoplasms|Neoplasm Metastasis,Interventional,28-Sep-12,NSABP Foundation Inc,"Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)"
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Stiefel, a GSK Company",Drug: clindamycin / benzoyl peroxide gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Stiefel, a GSK Company",Drug: clindamycin gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Stiefel, a GSK Company",Drug: BPO gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Stiefel, a GSK Company",Drug: vehicle gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Rho, Inc.",Drug: clindamycin / benzoyl peroxide gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Rho, Inc.",Drug: clindamycin gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Rho, Inc.",Drug: BPO gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Rho, Inc.",Drug: vehicle gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Quintiles, Inc.",Drug: clindamycin / benzoyl peroxide gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Quintiles, Inc.",Drug: clindamycin gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Quintiles, Inc.",Drug: BPO gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,"Quintiles, Inc.",Drug: vehicle gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,GlaxoSmithKline,Drug: clindamycin / benzoyl peroxide gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,GlaxoSmithKline,Drug: clindamycin gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,GlaxoSmithKline,Drug: BPO gel
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Acne Vulgaris,Interventional,30-Jan-12,GlaxoSmithKline,Drug: vehicle gel
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Interventional,4-Jul-11,Gilead Sciences,Drug: Aztreonam for Inhalation Solution (AZLI)
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Interventional,4-Jul-11,Gilead Sciences,Drug: Tobramycin Inhalation Solution (TIS)
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Interventional,4-Jul-11,Chiltern International Inc.,Drug: Aztreonam for Inhalation Solution (AZLI)
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Interventional,4-Jul-11,Chiltern International Inc.,Drug: Tobramycin Inhalation Solution (TIS)
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Interventional,4-Jul-11,"ClinPhone, Inc.",Drug: Aztreonam for Inhalation Solution (AZLI)
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Interventional,4-Jul-11,"ClinPhone, Inc.",Drug: Tobramycin Inhalation Solution (TIS)
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Interventional,4-Jul-11,Covance,Drug: Aztreonam for Inhalation Solution (AZLI)
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Interventional,4-Jul-11,Covance,Drug: Tobramycin Inhalation Solution (TIS)
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,Hoffmann-La Roche,Drug: obinutuzumab
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,Hoffmann-La Roche,Drug: rituximab
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,Hoffmann-La Roche,Drug: chlorambucil
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,German CLL Study Group,Drug: obinutuzumab
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,German CLL Study Group,Drug: rituximab
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,German CLL Study Group,Drug: chlorambucil
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,"Genentech, Inc.",Drug: obinutuzumab
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,"Genentech, Inc.",Drug: rituximab
NCT01010061,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),"Lymphocytic Leukemia, Chronic",Interventional,1-Apr-14,"Genentech, Inc.",Drug: chlorambucil
NCT00323037,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,Congestive Heart Failure,Interventional,13-Mar-09,"CTI-1, LLC",Drug: carvedilol controlled release
NCT00323037,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,Congestive Heart Failure,Interventional,13-Mar-09,"CTI-1, LLC",Drug: carvedilol immediate release
NCT00323037,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,Congestive Heart Failure,Interventional,13-Mar-09,CTI Clinical Trial and Consulting Services,Drug: carvedilol controlled release
NCT00323037,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,Congestive Heart Failure,Interventional,13-Mar-09,CTI Clinical Trial and Consulting Services,Drug: carvedilol immediate release
NCT00323037,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,Congestive Heart Failure,Interventional,13-Mar-09,GlaxoSmithKline,Drug: carvedilol controlled release
NCT00323037,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,Congestive Heart Failure,Interventional,13-Mar-09,GlaxoSmithKline,Drug: carvedilol immediate release
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Alirocumab
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Ezetimibe
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Placebo (for Alirocumab)
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Hypercholesterolemia,Interventional,6-Nov-15,Sanofi,Drug: Placebo (for Ezetimibe)
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Alirocumab
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Ezetimibe
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Placebo (for Alirocumab)
NCT01644474,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Hypercholesterolemia,Interventional,6-Nov-15,Regeneron Pharmaceuticals,Drug: Placebo (for Ezetimibe)
NCT01599806,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,2-Mar-16,Pfizer,Drug: Ceftazidime - Avibactam ( CAZ-AVI)
NCT01599806,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,2-Mar-16,Pfizer,Drug: Doripenem
NCT01599806,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,2-Mar-16,Pfizer,Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
NCT01599806,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,2-Mar-16,Pfizer,Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
NCT01599806,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,2-Mar-16,Forest Laboratories,Drug: Ceftazidime - Avibactam ( CAZ-AVI)
NCT01599806,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,2-Mar-16,Forest Laboratories,Drug: Doripenem
NCT01599806,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,2-Mar-16,Forest Laboratories,Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
NCT01599806,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,2-Mar-16,Forest Laboratories,Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
NCT01595438,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,9-Mar-16,Pfizer,Drug: Ceftazidime - Avibactam ( CAZ-AVI)
NCT01595438,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,9-Mar-16,Pfizer,Drug: Doripenem
NCT01595438,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,9-Mar-16,Pfizer,Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
NCT01595438,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,9-Mar-16,Pfizer,Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
NCT01595438,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,9-Mar-16,Forest Laboratories,Drug: Ceftazidime - Avibactam ( CAZ-AVI)
NCT01595438,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,9-Mar-16,Forest Laboratories,Drug: Doripenem
NCT01595438,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,9-Mar-16,Forest Laboratories,Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
NCT01595438,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Interventional,9-Mar-16,Forest Laboratories,Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,US Oncology Research,Drug: Bevacizumab
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,US Oncology Research,Drug: Oxaliplatin
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,US Oncology Research,Drug: Leucovorin
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,US Oncology Research,Drug: Fluorouracil
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,US Oncology Research,Drug: Cetuximab
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Bristol-Myers Squibb,Drug: Bevacizumab
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Bristol-Myers Squibb,Drug: Oxaliplatin
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Bristol-Myers Squibb,Drug: Leucovorin
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Bristol-Myers Squibb,Drug: Fluorouracil
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Bristol-Myers Squibb,Drug: Cetuximab
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Memorial Sloan Kettering Cancer Center,Drug: Bevacizumab
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Memorial Sloan Kettering Cancer Center,Drug: Oxaliplatin
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Memorial Sloan Kettering Cancer Center,Drug: Leucovorin
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Memorial Sloan Kettering Cancer Center,Drug: Fluorouracil
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Memorial Sloan Kettering Cancer Center,Drug: Cetuximab
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Prologue Research International,Drug: Bevacizumab
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Prologue Research International,Drug: Oxaliplatin
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Prologue Research International,Drug: Leucovorin
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Prologue Research International,Drug: Fluorouracil
NCT00252564,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Interventional,14-Mar-11,Prologue Research International,Drug: Cetuximab
NCT00525798,A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D,Osteoporosis,Interventional,18-Oct-12,Nordic Bioscience A/S,Drug: SMC021 Oral calcitonin
NCT00525798,A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D,Osteoporosis,Interventional,18-Oct-12,Nordic Bioscience A/S,Drug: SMC021 Placebo
NCT00525798,A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D,Osteoporosis,Interventional,18-Oct-12,Novartis,Drug: SMC021 Oral calcitonin
NCT00525798,A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D,Osteoporosis,Interventional,18-Oct-12,Novartis,Drug: SMC021 Placebo
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,Samuel Gidding,Drug: Omega-3-acid ethyl esters
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,Samuel Gidding,Drug: Placebo
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,GlaxoSmithKline,Drug: Omega-3-acid ethyl esters
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,GlaxoSmithKline,Drug: Placebo
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,Johns Hopkins University,Drug: Omega-3-acid ethyl esters
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,Johns Hopkins University,Drug: Placebo
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,Thomas Jefferson University,Drug: Omega-3-acid ethyl esters
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,Thomas Jefferson University,Drug: Placebo
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,Nemours Children's Clinic,Drug: Omega-3-acid ethyl esters
NCT00915902,Fish Oil Study for High Triglyceride Levels in Children,Hypertriglyceridemia,Interventional,7-May-14,Nemours Children's Clinic,Drug: Placebo
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,Duke University,Drug: Ziprasidone
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,Duke University,Drug: Sertraline
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,Duke University,Drug: Haloperidol
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,Pfizer,Drug: Ziprasidone
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,Pfizer,Drug: Sertraline
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,Pfizer,Drug: Haloperidol
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,"National Institute of Mental Health and Neuro Sciences, India",Drug: Ziprasidone
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,"National Institute of Mental Health and Neuro Sciences, India",Drug: Sertraline
NCT00340379,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Affective Disorders,Interventional,4-Jun-13,"National Institute of Mental Health and Neuro Sciences, India",Drug: Haloperidol
NCT00549393,Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit,Nosocomial Infections,Interventional,2-Oct-15,Johns Hopkins University,Drug: 2% Chlorhexidine gluconate cloth
NCT00549393,Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit,Nosocomial Infections,Interventional,2-Oct-15,"Sage Products, Inc.",Drug: 2% Chlorhexidine gluconate cloth
NCT00572572,Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors,Germ Cell Tumors,Interventional,6-Apr-16,Hoosier Cancer Research Network,Drug: Aprepitant
NCT00572572,Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors,Germ Cell Tumors,Interventional,6-Apr-16,Hoosier Cancer Research Network,Drug: Placebo
NCT00572572,Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors,Germ Cell Tumors,Interventional,6-Apr-16,Merck Sharp & Dohme Corp.,Drug: Aprepitant
NCT00572572,Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors,Germ Cell Tumors,Interventional,6-Apr-16,Merck Sharp & Dohme Corp.,Drug: Placebo
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Interventional,21-May-15,Nemours Children's Clinic,Drug: Atorvastatin
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Interventional,21-May-15,Nemours Children's Clinic,Drug: Atorvastatin Placebo
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Interventional,21-May-15,Pfizer,Drug: Atorvastatin
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Interventional,21-May-15,Pfizer,Drug: Atorvastatin Placebo
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Interventional,21-May-15,Medtronic,Drug: Atorvastatin
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Interventional,21-May-15,Medtronic,Drug: Atorvastatin Placebo
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Interventional,21-May-15,Quest Diagnostics,Drug: Atorvastatin
NCT01236365,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Interventional,21-May-15,Quest Diagnostics,Drug: Atorvastatin Placebo
NCT01644643,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection,Interventional,14-Dec-15,Pfizer,Drug: Ceftazidime - Avibactam ( CAZ-AVI)
NCT01644643,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection,Interventional,14-Dec-15,Pfizer,Drug: Best Available Therapy
NCT01644643,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection,Interventional,14-Dec-15,Pfizer,Drug: Metronidazole
NCT01644643,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection,Interventional,14-Dec-15,Forest Laboratories,Drug: Ceftazidime - Avibactam ( CAZ-AVI)
NCT01644643,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection,Interventional,14-Dec-15,Forest Laboratories,Drug: Best Available Therapy
NCT01644643,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection,Interventional,14-Dec-15,Forest Laboratories,Drug: Metronidazole
NCT01246479,"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study",Japanese Encephalitis,Interventional,29-Apr-15,Valneva Austria GmbH,Procedure: Blood draw
NCT01246479,"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study",Japanese Encephalitis,Interventional,29-Apr-15,Valneva Austria GmbH,Biological: IC51 has given in the parent study IC51-322
NCT00734747,Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,14-Aug-15,"Aviel Roy-Shapira, M.D.",Device: Medigus SRS endoscopic stapling system
NCT00734747,Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,14-Aug-15,Medigus Ltd,Device: Medigus SRS endoscopic stapling system
NCT00607373,Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Interventional,21-Mar-13,"Kastle Therapeutics, LLC",Drug: mipomersen
NCT00607373,Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Interventional,21-Mar-13,"Kastle Therapeutics, LLC",Drug: Placebo
NCT00607373,Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Interventional,21-Mar-13,"Ionis Pharmaceuticals, Inc.",Drug: mipomersen
NCT00607373,Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Interventional,21-Mar-13,"Ionis Pharmaceuticals, Inc.",Drug: Placebo
NCT03287791,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Rosacea,Interventional,17-Jul-19,Actavis Inc.,Drug: Generic Azelaic Acid Foam
NCT03287791,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Rosacea,Interventional,17-Jul-19,Actavis Inc.,Drug: Finacea® (Azelaic Acid) Foam
NCT03287791,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Rosacea,Interventional,17-Jul-19,Actavis Inc.,Drug: Vehicle Foam
NCT03287791,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Rosacea,Interventional,17-Jul-19,Actavis Inc.,Other: Cleanser
NCT03287791,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Rosacea,Interventional,17-Jul-19,Actavis Inc.,Other: Sunscreen
NCT03287791,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Rosacea,Interventional,17-Jul-19,Actavis Inc.,Other: Towel
NCT03287791,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Rosacea,Interventional,17-Jul-19,Actavis Inc.,Other: Moisturizing Lotion
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,AstraZeneca,Drug: Glycopyrronium/Formoterol Fumarate
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,AstraZeneca,Drug: umeclidinium/vilanterol
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,Parexel International Ltd,Drug: Glycopyrronium/Formoterol Fumarate
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,Parexel International Ltd,Drug: umeclidinium/vilanterol
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,Cognizant Technology Solution,Drug: Glycopyrronium/Formoterol Fumarate
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,Cognizant Technology Solution,Drug: umeclidinium/vilanterol
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,Center for Information & Study on Clinical Research Participation (CISCRP),Drug: Glycopyrronium/Formoterol Fumarate
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,Center for Information & Study on Clinical Research Participation (CISCRP),Drug: umeclidinium/vilanterol
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,eResearchTechnology,Drug: Glycopyrronium/Formoterol Fumarate
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,eResearchTechnology,Drug: umeclidinium/vilanterol
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,QuintilesIMS Limited,Drug: Glycopyrronium/Formoterol Fumarate
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,QuintilesIMS Limited,Drug: umeclidinium/vilanterol
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,Corporate Translations Inc,Drug: Glycopyrronium/Formoterol Fumarate
NCT03162055,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease COPD,Interventional,22-May-19,Corporate Translations Inc,Drug: umeclidinium/vilanterol
NCT03127956,A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,5-Feb-19,"Dermira, Inc.","Drug: Olumacostat Glasaretil Gel, 5.0%"
NCT03118843,Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study,Hepatitis C Virus Infection,Interventional,3-Apr-19,Gilead Sciences,Drug: SOF/VEL/VOX
NCT03099096,Study of Mepolizumab Autoinjector in Asthmatics,Asthma,Interventional,29-Jun-18,GlaxoSmithKline,Drug: Mepolizumab
NCT03073486,A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,5-Feb-19,"Dermira, Inc.","Drug: Olumacostat Glasaretil Gel, 5.0%"
NCT03073486,A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,5-Feb-19,"Dermira, Inc.","Other: Olumacostat Glasaretil Gel, Vehicle"
NCT03069365,A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment,Hepatitis C Virus (HCV),Interventional,4-Mar-19,AbbVie,Drug: Glecaprevir/pibrentasvir
NCT03028363,A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,5-Feb-19,"Dermira, Inc.","Drug: Olumacostat Glasaretil Gel, 5.0%"
NCT03028363,A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,5-Feb-19,"Dermira, Inc.","Other: Olumacostat Glasaretil Gel, Vehicle"
NCT03017235,"A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy",Bowel Preparation,Interventional,14-Nov-18,Ferring Pharmaceuticals,"Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution"
NCT03017235,"A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy",Bowel Preparation,Interventional,14-Nov-18,Ferring Pharmaceuticals,"Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder"
NCT02986854,"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","Infections, Meningococcal",Interventional,3-Aug-18,GlaxoSmithKline,"Biological: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)"
NCT02986139,Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis,"Arthritis, Rheumatoid; Arthritis, Psoriatic",Interventional,31-Oct-18,Amgen,Drug: Commercial Formulation Etanercept
NCT02986139,Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis,"Arthritis, Rheumatoid; Arthritis, Psoriatic",Interventional,31-Oct-18,Amgen,Drug: New Formulation Etanercept
NCT02979639,"Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age",Herpes Zoster,Interventional,16-Oct-18,GlaxoSmithKline,Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
NCT02969408,A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma,Asthma,Interventional,3-May-19,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Albuterol Sulfate
NCT02969408,A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma,Asthma,Interventional,3-May-19,Teva Pharmaceutical Industries,Drug: Albuterol Sulfate
NCT02964247,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.,"Diabetes|Diabetes Mellitus, Type 2",Interventional,10-Jul-19,Novo Nordisk A/S,Drug: liraglutide
NCT02964247,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.,"Diabetes|Diabetes Mellitus, Type 2",Interventional,10-Jul-19,Novo Nordisk A/S,Drug: placebo
NCT02952898,"Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses",Actinic Keratosis,Interventional,10-Jan-19,"Gage Development Company, LLC",Drug: GDC 695
NCT02952898,"Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses",Actinic Keratosis,Interventional,10-Jan-19,"Gage Development Company, LLC","Drug: Diclofenac Sodium Gel, 3%"
NCT02952898,"Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses",Actinic Keratosis,Interventional,10-Jan-19,"Gage Development Company, LLC",Drug: Vehicle gel
NCT02942017,A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C),Postpartum Depression,Interventional,13-Jun-19,Sage Therapeutics,Drug: Placebo
NCT02942017,A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C),Postpartum Depression,Interventional,13-Jun-19,Sage Therapeutics,Drug: SAGE-547 90 μg/kg/h
NCT02942004,A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B),Postpartum Depression,Interventional,13-Jun-19,Sage Therapeutics,Drug: Placebo
NCT02942004,A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B),Postpartum Depression,Interventional,13-Jun-19,Sage Therapeutics,Drug: SAGE-547 60 μg/kg/h
NCT02942004,A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B),Postpartum Depression,Interventional,13-Jun-19,Sage Therapeutics,Drug: SAGE-547 90 μg/kg/h
NCT02918071,"Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home",Asthma,Interventional,2-Nov-18,AstraZeneca,Biological: Benralizumab
NCT02914275,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.,"Influenza, Human",Interventional,23-Jan-19,Seqirus,Biological: Seqirus Quadrivalent Inactivated Influenza Vaccine
NCT02914275,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.,"Influenza, Human",Interventional,23-Jan-19,Seqirus,Biological: Comparator Quadrivalent Inactivated Influenza Vaccine
NCT02906917,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,"Diabetes|Diabetes Mellitus, Type 2",Interventional,28-Sep-18,Novo Nordisk A/S,Drug: Insulin degludec/insulin aspart
NCT02906917,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,"Diabetes|Diabetes Mellitus, Type 2",Interventional,28-Sep-18,Novo Nordisk A/S,Drug: Insulin glargine
NCT02906917,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,"Diabetes|Diabetes Mellitus, Type 2",Interventional,28-Sep-18,Novo Nordisk A/S,Drug: Insulin aspart
NCT02896296,Open-Label Treatment Extension Study,Opioid Use Disorder|Opioid-related Disorders,Interventional,2-Nov-18,Indivior Inc.,Drug: RBP-6000
NCT02886715,A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris,Acne Vulgaris,Interventional,17-Aug-18,Fougera Pharmaceuticals Inc.,Drug: Tazarotene Cream 0.1%
NCT02886715,A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris,Acne Vulgaris,Interventional,17-Aug-18,Fougera Pharmaceuticals Inc.,Drug: Tazorac®
NCT02886715,A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris,Acne Vulgaris,Interventional,17-Aug-18,Fougera Pharmaceuticals Inc.,Drug: Placebo
NCT02886702,A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis,Plaque Psoriasis,Interventional,29-Aug-18,Fougera Pharmaceuticals Inc.,Drug: Tazarotene Cream 0.05%
NCT02886702,A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis,Plaque Psoriasis,Interventional,29-Aug-18,Fougera Pharmaceuticals Inc.,Drug: TAZORAC® (tazarotene) Cream 0.05%
NCT02886702,A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis,Plaque Psoriasis,Interventional,29-Aug-18,Fougera Pharmaceuticals Inc.,Drug: Placebo
NCT02877927,Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI,Bacterial Infections|Skin Structures and Soft Tissue Infections,Interventional,30-Nov-18,Paratek Pharmaceuticals Inc,Drug: Omadacycline
NCT02877927,Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI,Bacterial Infections|Skin Structures and Soft Tissue Infections,Interventional,30-Nov-18,Paratek Pharmaceuticals Inc,Drug: Linezolid
NCT02870205,Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis (SAR),Interventional,6-Apr-18,Glenmark Specialty S.A.,Drug: GSP 301 NS
NCT02870205,Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis (SAR),Interventional,6-Apr-18,Glenmark Specialty S.A.,Drug: GOM-NS
NCT02870205,Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis (SAR),Interventional,6-Apr-18,Glenmark Specialty S.A.,Drug: GMM-2 NS
NCT02870205,Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis (SAR),Interventional,6-Apr-18,Glenmark Specialty S.A.,Drug: GSP 301 placebo NS
NCT02867709,"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine","Migraine, With or Without Aura",Interventional,29-Jan-19,Allergan,Drug: Ubrogepant
NCT02867709,"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine","Migraine, With or Without Aura",Interventional,29-Jan-19,Allergan,Drug: Placebo-matching Ubrogepant
NCT02850965,"Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis",Psoriasis,Interventional,8-Feb-19,Boehringer Ingelheim,Drug: BI 695501
NCT02850965,"Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis",Psoriasis,Interventional,8-Feb-19,Boehringer Ingelheim,Drug: Humira
NCT02839330,"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",Avian Influenza,Interventional,4-Apr-19,Seqirus,Biological: aH5N1c
NCT02839330,"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",Avian Influenza,Interventional,4-Apr-19,Seqirus,Biological: Placebo
NCT02839330,"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",Avian Influenza,Interventional,4-Apr-19,Biomedical Advanced Research and Development Authority,Biological: aH5N1c
NCT02839330,"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",Avian Influenza,Interventional,4-Apr-19,Biomedical Advanced Research and Development Authority,Biological: Placebo
NCT02905331,Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis,Psoriasis,Interventional,6-Sep-18,"Janssen Research & Development, LLC",Drug: Guselkumab
NCT02905331,Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis,Psoriasis,Interventional,6-Sep-18,"Janssen Research & Development, LLC",Drug: Placebo
NCT02828020,"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","Migraine, With or Without Aura",Interventional,3-Jan-19,Allergan,Drug: Ubrogepant
NCT02828020,"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","Migraine, With or Without Aura",Interventional,3-Jan-19,Allergan,Drug: Placebo-matching Ubrogepant
NCT02826603,Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis,Plaque Psoriasis,Interventional,9-Jul-19,Novartis Pharmaceuticals,Drug: Secukinumab
NCT02826603,Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis,Plaque Psoriasis,Interventional,9-Jul-19,Novartis Pharmaceuticals,Drug: Ustekinumab
NCT02826603,Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis,Plaque Psoriasis,Interventional,9-Jul-19,Novartis,Drug: Secukinumab
NCT02826603,Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis,Plaque Psoriasis,Interventional,9-Jul-19,Novartis,Drug: Ustekinumab
NCT02825251,Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,24-Jul-18,Novo Nordisk A/S,Drug: Faster-acting insulin aspart
NCT02825251,Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,24-Jul-18,Novo Nordisk A/S,Drug: insulin aspart
NCT02814643,Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma,Asthma,Interventional,1-Mar-18,AstraZeneca,Drug: Benralizumab
NCT02814643,Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma,Asthma,Interventional,1-Mar-18,AstraZeneca,Drug: Benralizumab Placebo
NCT02814643,Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma,Asthma,Interventional,1-Mar-18,AstraZeneca,Drug: Seasonal influenza virus vaccine
NCT02802345,Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment,Idiopathic Pulmonary Fibrosis,Interventional,11-Jan-19,Boehringer Ingelheim,Drug: Nintedanib
NCT02802345,Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment,Idiopathic Pulmonary Fibrosis,Interventional,11-Jan-19,Boehringer Ingelheim,Drug: Placebo
NCT02802345,Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment,Idiopathic Pulmonary Fibrosis,Interventional,11-Jan-19,Boehringer Ingelheim,Drug: Sildenafil
NCT02797132,"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",Cystic Fibrosis,Interventional,30-Oct-18,Vertex Pharmaceuticals Incorporated,Drug: LUM/IVA
NCT02796677,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,Chronic Obstructive Pulmonary Disease,Interventional,9-Nov-18,AstraZeneca,Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)
NCT02796677,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,Chronic Obstructive Pulmonary Disease,Interventional,9-Nov-18,AstraZeneca,Drug: Aclidinium bromide 400 μg (AB 400 μg)
NCT02796677,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,Chronic Obstructive Pulmonary Disease,Interventional,9-Nov-18,AstraZeneca,Drug: Formoterol fumarate 12 μg (FF 12 μg)
NCT02796677,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,Chronic Obstructive Pulmonary Disease,Interventional,9-Nov-18,AstraZeneca,"Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg"
NCT02796677,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,Chronic Obstructive Pulmonary Disease,Interventional,9-Nov-18,AstraZeneca,Drug: Tiotropium 18 μg (TIO 18 μg)
NCT02796677,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,Chronic Obstructive Pulmonary Disease,Interventional,9-Nov-18,AstraZeneca,Other: Placebo to TIO 18 μg
NCT02793817,Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain,Post Surgical Ocular Inflammation and Pain,Interventional,17-Apr-19,"Kala Pharmaceuticals, Inc.",Drug: KPI-121 1% Ophthalmic Suspension dosed BID
NCT02793817,Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain,Post Surgical Ocular Inflammation and Pain,Interventional,17-Apr-19,"Kala Pharmaceuticals, Inc.",Drug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID
NCT02788279,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),Colorectal Cancer,Interventional,18-Jun-19,Hoffmann-La Roche,"Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody"
NCT02788279,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),Colorectal Cancer,Interventional,18-Jun-19,Hoffmann-La Roche,Drug: Cobimetinib
NCT02788279,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),Colorectal Cancer,Interventional,18-Jun-19,Hoffmann-La Roche,Drug: Regorafenib
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Type 2 Diabetes Mellitus,Interventional,12-Jun-19,Sanofi,Drug: Insulin glargine/lixisenatide fixed ratio combination
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Type 2 Diabetes Mellitus,Interventional,12-Jun-19,Sanofi,Drug: liraglutide
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Type 2 Diabetes Mellitus,Interventional,12-Jun-19,Sanofi,Drug: exenatide
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Type 2 Diabetes Mellitus,Interventional,12-Jun-19,Sanofi,Drug: exenatide extended-release
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Type 2 Diabetes Mellitus,Interventional,12-Jun-19,Sanofi,Drug: albiglutide
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Type 2 Diabetes Mellitus,Interventional,12-Jun-19,Sanofi,Drug: dulaglutide
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Type 2 Diabetes Mellitus,Interventional,12-Jun-19,Sanofi,"Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)"
NCT02773368,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,23-Oct-18,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT02773368,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,23-Oct-18,Novo Nordisk A/S,Drug: insulin glargine
NCT02753699,Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients,Hepatitis C,Interventional,26-Aug-16,Debiopharm International SA,Drug: Alisporivir
NCT02748863,Study of Secukinumab With 2 mL Pre-filled Syringes,Psoriasis,Interventional,26-Jun-19,Novartis Pharmaceuticals,Drug: Placebo
NCT02748863,Study of Secukinumab With 2 mL Pre-filled Syringes,Psoriasis,Interventional,26-Jun-19,Novartis Pharmaceuticals,Drug: Secukinumab 2 mL form
NCT02748863,Study of Secukinumab With 2 mL Pre-filled Syringes,Psoriasis,Interventional,26-Jun-19,Novartis Pharmaceuticals,Drug: Secukinumab 1 mL form
NCT02748863,Study of Secukinumab With 2 mL Pre-filled Syringes,Psoriasis,Interventional,26-Jun-19,Novartis,Drug: Placebo
NCT02748863,Study of Secukinumab With 2 mL Pre-filled Syringes,Psoriasis,Interventional,26-Jun-19,Novartis,Drug: Secukinumab 2 mL form
NCT02748863,Study of Secukinumab With 2 mL Pre-filled Syringes,Psoriasis,Interventional,26-Jun-19,Novartis,Drug: Secukinumab 1 mL form
NCT02742441,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310),Plaque Psoriasis,Interventional,14-Nov-18,"Therapeutics, Inc.",Drug: 122-0551 Foam
NCT02742441,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310),Plaque Psoriasis,Interventional,14-Nov-18,"Therapeutics, Inc.",Drug: Vehicle Foam
NCT02739984,Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia,Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes,Interventional,31-Aug-18,Amgen,Biological: Evolocumab
NCT02739984,Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia,Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes,Interventional,31-Aug-18,Amgen,Drug: Placebo to Evolocumab
NCT02736955,Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia,Tardive Dyskinesia,Interventional,19-Dec-18,Neurocrine Biosciences,Drug: Valbenazine
NCT02734810,SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,Interventional,11-May-18,Anthera Pharmaceuticals,Drug: Liprotamase Powder for Oral Solution
NCT02735044,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Interventional,19-Jun-19,Sanofi,"Drug: Insulin glargine,300 U/mL"
NCT02735044,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Interventional,19-Jun-19,Sanofi,Drug: Insulin glargine (100 units /mL)
NCT02735044,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Interventional,19-Jun-19,Sanofi,Drug: Background therapy
NCT02718898,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis,Genital Psoriasis|Psoriasis,Interventional,23-Mar-18,Eli Lilly and Company,Drug: Ixekizumab
NCT02718898,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis,Genital Psoriasis|Psoriasis,Interventional,23-Mar-18,Eli Lilly and Company,Drug: Placebo
NCT02709538,Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,13-Sep-18,Glenmark Specialty S.A.,Drug: GSP 301 NS
NCT02709538,Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,13-Sep-18,Glenmark Specialty S.A.,Drug: GSP 301 Placebo NS pH 3.7
NCT02709538,Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR),Perennial Allergic Rhinitis,Interventional,13-Sep-18,Glenmark Specialty S.A.,Drug: GSP 301 Placebo NS pH 7.0
NCT02707601,"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment",HIV-1 Infection|HCV Infection,Interventional,9-Oct-18,Gilead Sciences,Drug: E/C/F/TAF
NCT02707601,"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment",HIV-1 Infection|HCV Infection,Interventional,9-Oct-18,Gilead Sciences,Drug: F/R/TAF
NCT02707601,"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment",HIV-1 Infection|HCV Infection,Interventional,9-Oct-18,Gilead Sciences,Drug: LDV/SOF
NCT02697773,Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee,"Osteoarthritis, Knee|Osteoarthritis, Hip",Interventional,23-Apr-19,Pfizer,Other: Placebo
NCT02697773,Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee,"Osteoarthritis, Knee|Osteoarthritis, Hip",Interventional,23-Apr-19,Pfizer,Biological: Tanezumab 2.5 mg
NCT02697773,Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee,"Osteoarthritis, Knee|Osteoarthritis, Hip",Interventional,23-Apr-19,Pfizer,Biological: Tanezumab 2.5mg/5mg
NCT02694978,A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA),Iron Deficiency Anemia,Interventional,11-Jun-18,"AMAG Pharmaceuticals, Inc.",Drug: Ferumoxytol
NCT02694978,A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA),Iron Deficiency Anemia,Interventional,11-Jun-18,"AMAG Pharmaceuticals, Inc.",Drug: FCM
NCT02683746,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,30-May-18,GlaxoSmithKline,Drug: Lyophilized albiglutide DCC pen injector
NCT02683746,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,30-May-18,GlaxoSmithKline,Drug: Lyophilized albiglutide DCC pen injector matching placebo
NCT02683746,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,30-May-18,GlaxoSmithKline,Drug: Albiglutide liquid auto-injector
NCT02683746,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,30-May-18,GlaxoSmithKline,Drug: Albiglutide liquid auto-injector matching placebo
NCT02682381,Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition,Short Bowel Syndrome,Interventional,16-Oct-18,Shire,Drug: Teduglutide 0.05mg/kg
NCT02682381,Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition,Short Bowel Syndrome,Interventional,16-Oct-18,Shire,Drug: Teduglutide 0.025 mg/kg
NCT02682381,Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition,Short Bowel Syndrome,Interventional,16-Oct-18,Shire,Other: Standard of Care
NCT02681094,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",Type 2 Diabetes Mellitus|Inadequate Glycaemic Control,Interventional,10-Oct-18,AstraZeneca,Drug: Dapagliflozin
NCT02681094,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",Type 2 Diabetes Mellitus|Inadequate Glycaemic Control,Interventional,10-Oct-18,AstraZeneca,Drug: Placebo for Dapagliflozin
NCT02681094,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",Type 2 Diabetes Mellitus|Inadequate Glycaemic Control,Interventional,10-Oct-18,AstraZeneca,Drug: Saxagliptin
NCT02681094,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",Type 2 Diabetes Mellitus|Inadequate Glycaemic Control,Interventional,10-Oct-18,AstraZeneca,Drug: Placebo for Saxagliptin
NCT02673489,A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection,Hepatitis C,Interventional,29-Mar-18,Bristol-Myers Squibb,Drug: DCV
NCT02673489,A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection,Hepatitis C,Interventional,29-Mar-18,Bristol-Myers Squibb,Drug: SOF
NCT02673489,A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection,Hepatitis C,Interventional,29-Mar-18,Bristol-Myers Squibb,Drug: RBV
NCT02696434,Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL,Opioid Use Disorder,Interventional,12-Feb-19,"Alkermes, Inc.",Drug: Naltrexone
NCT02696434,Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL,Opioid Use Disorder,Interventional,12-Feb-19,"Alkermes, Inc.",Drug: Placebo
NCT02696434,Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL,Opioid Use Disorder,Interventional,12-Feb-19,"Alkermes, Inc.",Drug: Buprenorphine
NCT02670915,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,4-Apr-19,Novo Nordisk A/S,Drug: Faster-acting insulin aspart
NCT02670915,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,4-Apr-19,Novo Nordisk A/S,Drug: insulin aspart
NCT02670915,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,4-Apr-19,Novo Nordisk A/S,Drug: insulin degludec
NCT02670551,"Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression",Bipolar Disorder|Depression,Interventional,30-Jan-19,Forest Laboratories,Drug: Cariprazine
NCT02670551,"Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression",Bipolar Disorder|Depression,Interventional,30-Jan-19,Forest Laboratories,Drug: Placebo
NCT02670538,Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder,Bipolar Disorder|Depression,Interventional,5-Feb-19,Forest Laboratories,Drug: Cariprazine
NCT02670538,Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder,Bipolar Disorder|Depression,Interventional,5-Feb-19,Forest Laboratories,Drug: Placebo
NCT02669758,A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia,Schizophrenia,Interventional,9-Jul-19,"Alkermes, Inc.",Drug: ALKS 3831
NCT02662764,Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg,Moderate-to-severe Acute Pain,Interventional,8-Aug-18,"AcelRx Pharmaceuticals, Inc.",Drug: Zalviso™ 15 mcg
NCT02662569,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",Interventional,11-Jan-19,Amgen,Biological: Evolocumab
NCT02662569,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",Interventional,11-Jan-19,Amgen,Drug: Atorvastatin
NCT02662569,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",Interventional,11-Jan-19,Amgen,Other: Placebo
NCT02652624,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",HIV-1 Infection,Interventional,2-Nov-18,Gilead Sciences,Drug: E/C/F/TAF
NCT02652624,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",HIV-1 Infection,Interventional,2-Nov-18,Gilead Sciences,Drug: E/C/F/TDF
NCT02652624,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",HIV-1 Infection,Interventional,2-Nov-18,Gilead Sciences,Drug: ATV
NCT02652624,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",HIV-1 Infection,Interventional,2-Nov-18,Gilead Sciences,Drug: RTV
NCT02652624,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",HIV-1 Infection,Interventional,2-Nov-18,Gilead Sciences,Drug: FTC/TDF
NCT02652624,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",HIV-1 Infection,Interventional,2-Nov-18,Gilead Sciences,Drug: B/F/TAF
NCT02648204,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,"Diabetes|Diabetes Mellitus, Type 2",Interventional,8-May-18,Novo Nordisk A/S,Drug: semaglutide
NCT02648204,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,"Diabetes|Diabetes Mellitus, Type 2",Interventional,8-May-18,Novo Nordisk A/S,Drug: Dulaglutide
NCT02640612,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,5-Dec-18,Boehringer Ingelheim,Drug: BI 695501
NCT02639338,Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis,Hepatitis C Virus Infection,Interventional,14-Nov-17,Gilead Sciences,Drug: SOF/VEL/VOX
NCT02639338,Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis,Hepatitis C Virus Infection,Interventional,14-Nov-17,Gilead Sciences,Drug: SOF/VEL
NCT02639247,Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor,Hepatitis C Virus Infection,Interventional,6-Nov-17,Gilead Sciences,Drug: SOF/VEL/VOX
NCT02639247,Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor,Hepatitis C Virus Infection,Interventional,6-Nov-17,Gilead Sciences,Drug: SOF/VEL
NCT02638259,Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,23-Feb-18,Sandoz,Drug: GP2015
NCT02635204,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Psoriasis,Interventional,13-Apr-18,"Promius Pharma, LLC",Drug: DFD06 Cream
NCT02635204,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Psoriasis,Interventional,13-Apr-18,"Promius Pharma, LLC",Drug: Vehicle Cream
NCT02634346,A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study),Schizophrenia,Interventional,27-Jun-18,"Alkermes, Inc.",Drug: ALK3831
NCT02634346,A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study),Schizophrenia,Interventional,27-Jun-18,"Alkermes, Inc.",Drug: Olanzapine
NCT02634346,A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study),Schizophrenia,Interventional,27-Jun-18,"Alkermes, Inc.",Drug: Placebo
NCT02631551,Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,15-Aug-18,Glenmark Specialty S.A.,Drug: GSP 301 NS
NCT02631551,Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,15-Aug-18,Glenmark Specialty S.A.,Drug: Olopatadine HCl NS
NCT02631551,Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,15-Aug-18,Glenmark Specialty S.A.,Drug: Mometasone furoate NS
NCT02631551,Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,15-Aug-18,Glenmark Specialty S.A.,Drug: GSP 301 Placebo NS
NCT02629861,Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine,Migraine,Interventional,8-Nov-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Fremanezumab
NCT02629861,Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine,Migraine,Interventional,8-Nov-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT02629861,Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine,Migraine,Interventional,8-Nov-18,Teva Pharmaceutical Industries,Drug: Fremanezumab
NCT02629861,Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine,Migraine,Interventional,8-Nov-18,Teva Pharmaceutical Industries,Drug: Placebo
NCT02621931,Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine,Migraine,Interventional,6-Dec-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Fremanezumab
NCT02621931,Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine,Migraine,Interventional,6-Dec-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT02621931,Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine,Migraine,Interventional,6-Dec-18,Teva Pharmaceutical Industries,Drug: Fremanezumab
NCT02621931,Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine,Migraine,Interventional,6-Dec-18,Teva Pharmaceutical Industries,Drug: Placebo
NCT02616601,"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis",Actinic Keratosis,Interventional,17-Jul-19,Actavis Inc.,Drug: Generic Fluorouracil Cream
NCT02616601,"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis",Actinic Keratosis,Interventional,17-Jul-19,Actavis Inc.,Drug: Carac® (Fluorouracil) Cream
NCT02616601,"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis",Actinic Keratosis,Interventional,17-Jul-19,Actavis Inc.,Drug: Vehicle Cream
NCT02614196,Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study,Migraine,Interventional,7-Jan-19,Eli Lilly and Company,Drug: Galcanezumab
NCT02614196,Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study,Migraine,Interventional,7-Jan-19,Eli Lilly and Company,Drug: Placebo
NCT02614183,Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Interventional,29-Nov-18,Eli Lilly and Company,Drug: Galcanezumab
NCT02614183,Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Interventional,29-Nov-18,Eli Lilly and Company,Drug: Placebo
NCT02614287,"A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura",Migraine,Interventional,7-Jan-19,Eli Lilly and Company,Drug: Galcanezumab
NCT02607800,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Interventional,8-Nov-17,Gilead Sciences,Drug: SOF/VEL/VOX
NCT02607800,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Interventional,8-Nov-17,Gilead Sciences,Drug: SOF/VEL
NCT02607735,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Interventional,13-Dec-17,Gilead Sciences,Drug: SOF/VEL/VOX
NCT02607735,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy,Hepatitis C,Interventional,13-Dec-17,Gilead Sciences,Drug: Placebo
NCT02607618,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2,Skin Structures and Soft Tissue Infections,Interventional,11-Jul-18,Motif Bio,Drug: Iclaprim
NCT02607618,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2,Skin Structures and Soft Tissue Infections,Interventional,11-Jul-18,Motif Bio,Drug: Vancomycin
NCT02605954,Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults,HIV-1 Infection,Interventional,13-Jul-18,Gilead Sciences,Drug: E/C/F/TAF
NCT02605954,Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults,HIV-1 Infection,Interventional,13-Jul-18,Gilead Sciences,Drug: ABC/3TC
NCT02605954,Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults,HIV-1 Infection,Interventional,13-Jul-18,Gilead Sciences,Drug: Third Antiretroviral Agent
NCT02604407,Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,14-Jun-17,Shire,Drug: SHP465 12.5mg capsules (one capsule daily)
NCT02604407,Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,14-Jun-17,Shire,Other: Placebo
NCT02604407,Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,14-Jun-17,Shire,"Drug: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)"
NCT02600611,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1,Skin Structures and Soft Tissue Infections,Interventional,19-Jun-18,Motif Bio,Drug: iclaprim
NCT02600611,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1,Skin Structures and Soft Tissue Infections,Interventional,19-Jun-18,Motif Bio,Drug: vancomycin
NCT02596451,"To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).",Osteoarthritis,Interventional,28-Jun-17,Glenmark Pharmaceuticals Ltd. India,"Drug: Diclofenac Sodium gel, 1%"
NCT02596451,"To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).",Osteoarthritis,Interventional,28-Jun-17,Glenmark Pharmaceuticals Ltd. India,Drug: Voltaren® Gel
NCT02596451,"To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).",Osteoarthritis,Interventional,28-Jun-17,Glenmark Pharmaceuticals Ltd. India,Drug: Placebo
NCT02597049,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,27-Apr-18,Eli Lilly and Company,Drug: Dulaglutide
NCT02597049,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,27-Apr-18,Eli Lilly and Company,Drug: Placebo
NCT02597049,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,27-Apr-18,Eli Lilly and Company,Drug: SGLT2 inhibitor
NCT02597049,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,27-Apr-18,Eli Lilly and Company,Drug: Metformin
NCT02585934,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,Alzheimer's Disease,Interventional,5-Dec-18,Axovant Sciences Ltd.,Drug: RVT-101
NCT02585934,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,Alzheimer's Disease,Interventional,5-Dec-18,Axovant Sciences Ltd.,Drug: Placebo
NCT02584959,Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema,Hereditary Angioedema (HAE),Interventional,28-Nov-18,Shire,Drug: C1 esterase inhibitor [human] liquid
NCT02584959,Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema,Hereditary Angioedema (HAE),Interventional,28-Nov-18,Shire,Drug: Placebo
NCT02581410,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier,Herpes Zoster,Interventional,26-Sep-17,GlaxoSmithKline,Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
NCT02581345,Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis,Chronic Plaque Psoriasis|Psoriasis,Interventional,12-Sep-18,"Momenta Pharmaceuticals, Inc.",Biological: M923
NCT02581345,Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis,Chronic Plaque Psoriasis|Psoriasis,Interventional,12-Sep-18,"Momenta Pharmaceuticals, Inc.",Biological: Humira
NCT02573467,"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203",Sporadic Inclusion Body Myositis,Interventional,13-Mar-18,Novartis Pharmaceuticals,Drug: Bimagrumab
NCT02573467,"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203",Sporadic Inclusion Body Myositis,Interventional,13-Mar-18,Novartis Pharmaceuticals,Drug: Placebo
NCT02573467,"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203",Sporadic Inclusion Body Myositis,Interventional,13-Mar-18,Novartis,Drug: Bimagrumab
NCT02573467,"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203",Sporadic Inclusion Body Myositis,Interventional,13-Mar-18,Novartis,Drug: Placebo
NCT02569853,DFN-11 Injection in Episodic Migraine With or Without Aura,Episodic Migraine,Interventional,25-Jul-18,Dr. Reddy's Laboratories Limited,Drug: DFN-11
NCT02569853,DFN-11 Injection in Episodic Migraine With or Without Aura,Episodic Migraine,Interventional,25-Jul-18,Dr. Reddy's Laboratories Limited,Other: Placebo
NCT02722044,Usability of an AI for M923 in Subjects With Moderate to Severe RA,Rheumatoid Arthritis,Interventional,1-May-18,"Momenta Pharmaceuticals, Inc.",Biological: M923
NCT02722044,Usability of an AI for M923 in Subjects With Moderate to Severe RA,Rheumatoid Arthritis,Interventional,1-May-18,"Momenta Pharmaceuticals, Inc.",Device: Autoinjector
NCT02553798,Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis,Hyperhidrosis,Interventional,25-Sep-18,"Dermira, Inc.",Drug: Glycopyrronium Topical Wipes
NCT02553317,Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura,Acquired Thrombotic Thrombocytopenic Purpura,Interventional,22-May-19,Ablynx,Biological: Caplacizumab
NCT02553317,Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura,Acquired Thrombotic Thrombocytopenic Purpura,Interventional,22-May-19,Ablynx,Biological: Placebo
NCT02551874,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",Type 2 Diabetes Mellitus,Interventional,18-Sep-18,AstraZeneca,"Drug: Saxagliptin, Onglyza"
NCT02551874,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",Type 2 Diabetes Mellitus,Interventional,18-Sep-18,AstraZeneca,"Drug: Dapagliflozin, Farxiga"
NCT02551874,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",Type 2 Diabetes Mellitus,Interventional,18-Sep-18,AstraZeneca,Drug: Glargine insulin
NCT02551874,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",Type 2 Diabetes Mellitus,Interventional,18-Sep-18,AstraZeneca,Drug: Metformin
NCT02545543,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age,"Influenza, Human",Interventional,18-Apr-17,Seqirus,Biological: Seqirus QIV
NCT02545543,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age,"Influenza, Human",Interventional,18-Apr-17,Seqirus,Biological: Comparator QIV
NCT02553772,A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.,Dry Eye Syndromes,Interventional,17-Nov-17,Allergan,Drug: Carboxymethylcellulose Based Eye Drop
NCT02553772,A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.,Dry Eye Syndromes,Interventional,17-Nov-17,Allergan,Drug: Carboxymethylcellulose Sodium 0.5%
NCT02547623,Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery,Cataract,Interventional,19-Jun-18,ICON Bioscience Inc,Drug: Dexamethasone
NCT02547623,Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery,Cataract,Interventional,19-Jun-18,ICON Bioscience Inc,Drug: Prednisolone
NCT02537574,Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension),Opioid Use Disorder,Interventional,9-Jan-19,"Alkermes, Inc.",Drug: NTX/BUP
NCT02537574,Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension),Opioid Use Disorder,Interventional,9-Jan-19,"Alkermes, Inc.",Drug: NTX/PBO-B
NCT02537574,Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension),Opioid Use Disorder,Interventional,9-Jan-19,"Alkermes, Inc.",Drug: PBO-N/PBO-B
NCT02966795,A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection,Hepatitis C Virus (HCV),Interventional,10-Jul-19,AbbVie,Drug: Glecaprevir/Pibrentasvir
NCT02530294,Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis,Hyperhidrosis,Interventional,14-Aug-18,"Dermira, Inc.",Drug: glycopyrronium Topical Wipes
NCT02530294,Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis,Hyperhidrosis,Interventional,14-Aug-18,"Dermira, Inc.",Other: Vehicle
NCT02530281,Study of Glycopyrronium in Axillary Hyperhydrosis,Hyperhidrosis,Interventional,14-Aug-18,"Dermira, Inc.",Drug: glycopyrronium Topical Wipes
NCT02530281,Study of Glycopyrronium in Axillary Hyperhydrosis,Hyperhidrosis,Interventional,14-Aug-18,"Dermira, Inc.",Other: Vehicle
NCT02531438,Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13),Bacterial Pneumonia|Community-Acquired Infections,Interventional,29-Nov-18,Paratek Pharmaceuticals Inc,Drug: Omadacycline
NCT02531438,Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13),Bacterial Pneumonia|Community-Acquired Infections,Interventional,29-Nov-18,Paratek Pharmaceuticals Inc,Drug: Moxifloxacin
NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",Interventional,27-Jun-19,Biogen,Drug: dimethyl fumarate
NCT02528721,Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection,Helicobacter Pylori Infection,Interventional,3-Mar-17,Exalenz Bioscience LTD.,Device: Dual Mode BreathID Hp System
NCT02516410,"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: VX-661 plus ivacaftor combination
NCT02516410,"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT02516410,"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: Placebo (matched to VX-661 plus ivacaftor combination)
NCT02516410,"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: Placebo (matched to ivacaftor)
NCT02514473,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,23-Oct-17,Vertex Pharmaceuticals Incorporated,Drug: VX-809
NCT02514473,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,23-Oct-17,Vertex Pharmaceuticals Incorporated,Drug: Placebo
NCT02514473,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,23-Oct-17,Vertex Pharmaceuticals Incorporated,Drug: VX-770
NCT02517021,A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,20-Jun-18,Helsinn Healthcare SA,Drug: Pro-netupitant/Palonosetron
NCT02517021,A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,20-Jun-18,Helsinn Healthcare SA,Drug: Netupitant/Palonosetron
NCT02517021,A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,20-Jun-18,Helsinn Healthcare SA,Drug: Dexamethasone
NCT02517021,A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,20-Jun-18,The Physicians' Services Incorporated Foundation,Drug: Pro-netupitant/Palonosetron
NCT02517021,A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,20-Jun-18,The Physicians' Services Incorporated Foundation,Drug: Netupitant/Palonosetron
NCT02517021,A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting,Chemotherapy-Induced Nausea and Vomiting,Interventional,20-Jun-18,The Physicians' Services Incorporated Foundation,Drug: Dexamethasone
NCT02513550,A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Interventional,18-Apr-18,Eli Lilly and Company,Drug: Ixekizumab
NCT02513550,A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Interventional,18-Apr-18,Eli Lilly and Company,Drug: Placebo
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone Dipropionate 640
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate via 320 mcg BAI
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: albuterol/salbutamol
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate via 320 mcg MDI
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,Teva Pharmaceutical Industries,Drug: Beclomethasone Dipropionate 640
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,Teva Pharmaceutical Industries,Drug: Placebo
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate via 320 mcg BAI
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,Teva Pharmaceutical Industries,Drug: albuterol/salbutamol
NCT02513160,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Persistent Asthma,Interventional,11-Sep-17,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate via 320 mcg MDI
NCT02510014,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,Opioid Use Disorder|Opioid-related Disorders,Interventional,29-Mar-18,Indivior Inc.,Drug: SUBOXONE sublingual film
NCT02510014,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,Opioid Use Disorder|Opioid-related Disorders,Interventional,29-Mar-18,Indivior Inc.,Drug: RBP-6000
NCT02504541,Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism,Hypogonadism,Interventional,30-Mar-18,Antares Pharma Inc.,Combination Product: Testosterone enanthate auto-injector
NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Interventional,13-Sep-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Reslizumab
NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Interventional,13-Sep-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Interventional,13-Sep-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication
NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Interventional,13-Sep-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Oral Corticosteroid (OCS)
NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Interventional,13-Sep-18,Teva Pharmaceutical Industries,Drug: Reslizumab
NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Interventional,13-Sep-18,Teva Pharmaceutical Industries,Drug: Placebo
NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Interventional,13-Sep-18,Teva Pharmaceutical Industries,Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication
NCT02501629,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Interventional,13-Sep-18,Teva Pharmaceutical Industries,Drug: Oral Corticosteroid (OCS)
NCT02500706,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,10-Aug-18,Novo Nordisk A/S,Drug: Faster-acting insulin aspart
NCT02500706,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,10-Aug-18,Novo Nordisk A/S,Drug: insulin aspart
NCT02500706,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,10-Aug-18,Novo Nordisk A/S,Drug: insulin degludec
NCT02497287,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Treatment-resistant Depression,Interventional,29-Apr-19,"Janssen Research & Development, LLC",Drug: Esketamine (Intranasal Spray)
NCT02497287,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Treatment-resistant Depression,Interventional,29-Apr-19,"Janssen Research & Development, LLC",Drug: Duloxetine (Oral Antidepressant)
NCT02497287,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Treatment-resistant Depression,Interventional,29-Apr-19,"Janssen Research & Development, LLC",Drug: Escitalopram (Oral Antidepressant)
NCT02497287,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Treatment-resistant Depression,Interventional,29-Apr-19,"Janssen Research & Development, LLC",Drug: Sertraline (Oral Antidepressant)
NCT02497287,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Treatment-resistant Depression,Interventional,29-Apr-19,"Janssen Research & Development, LLC",Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
NCT02493868,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,"Depressive Disorder, Treatment-Resistant",Interventional,21-May-19,"Janssen Research & Development, LLC",Drug: Esketamine
NCT02493868,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,"Depressive Disorder, Treatment-Resistant",Interventional,21-May-19,"Janssen Research & Development, LLC",Drug: Placebo
NCT02493868,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,"Depressive Disorder, Treatment-Resistant",Interventional,21-May-19,"Janssen Research & Development, LLC",Drug: Duloxetine (Oral Antidepressant)
NCT02493868,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,"Depressive Disorder, Treatment-Resistant",Interventional,21-May-19,"Janssen Research & Development, LLC",Drug: Escitalopram (Oral antidepressant)
NCT02493868,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,"Depressive Disorder, Treatment-Resistant",Interventional,21-May-19,"Janssen Research & Development, LLC",Drug: Sertraline (Oral Antidepressant)
NCT02493868,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,"Depressive Disorder, Treatment-Resistant",Interventional,21-May-19,"Janssen Research & Development, LLC",Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
NCT02493452,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Interventional,14-Jun-19,"Bausch Health Americas, Inc.",Drug: Plecanatide
NCT02493452,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Interventional,14-Jun-19,"Bausch Health Americas, Inc.",Drug: Placebo
NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Chronic Obstructive Pulmonary Disease,Interventional,2-Apr-18,Novartis Pharmaceuticals,Drug: QVA149
NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Chronic Obstructive Pulmonary Disease,Interventional,2-Apr-18,Novartis Pharmaceuticals,Drug: Umeclidinium/vilanterol
NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Chronic Obstructive Pulmonary Disease,Interventional,2-Apr-18,Novartis Pharmaceuticals,Drug: Placebo (umeclidinium/vilanterol )
NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Chronic Obstructive Pulmonary Disease,Interventional,2-Apr-18,Novartis Pharmaceuticals,Drug: Placebo (QVA149)
NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Chronic Obstructive Pulmonary Disease,Interventional,2-Apr-18,Novartis,Drug: QVA149
NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Chronic Obstructive Pulmonary Disease,Interventional,2-Apr-18,Novartis,Drug: Umeclidinium/vilanterol
NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Chronic Obstructive Pulmonary Disease,Interventional,2-Apr-18,Novartis,Drug: Placebo (umeclidinium/vilanterol )
NCT02487498,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Chronic Obstructive Pulmonary Disease,Interventional,2-Apr-18,Novartis,Drug: Placebo (QVA149)
NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease,Interventional,26-Dec-17,Novartis Pharmaceuticals,Drug: QVA149
NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease,Interventional,26-Dec-17,Novartis Pharmaceuticals,Drug: Umeclidinium/vilanterol
NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease,Interventional,26-Dec-17,Novartis Pharmaceuticals,Drug: Placebo (umeclidinium/vilanterol)
NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease,Interventional,26-Dec-17,Novartis Pharmaceuticals,Drug: Placebo (QVA149)
NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease,Interventional,26-Dec-17,Novartis,Drug: QVA149
NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease,Interventional,26-Dec-17,Novartis,Drug: Umeclidinium/vilanterol
NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease,Interventional,26-Dec-17,Novartis,Drug: Placebo (umeclidinium/vilanterol)
NCT02487446,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease,Interventional,26-Dec-17,Novartis,Drug: Placebo (QVA149)
NCT02483975,Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma,Asthma,Interventional,8-Mar-17,GlaxoSmithKline,Drug: FF
NCT02483975,Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma,Asthma,Interventional,8-Mar-17,GlaxoSmithKline,Drug: Placebo
NCT02483975,Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma,Asthma,Interventional,8-Mar-17,GlaxoSmithKline,Drug: Montelukast
NCT02483975,Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma,Asthma,Interventional,8-Mar-17,GlaxoSmithKline,Drug: Albuterol/Salbutamol
NCT02483585,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention,Migraine,Interventional,25-Jun-18,Amgen,Drug: Erenumab
NCT02483585,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention,Migraine,Interventional,25-Jun-18,Amgen,Drug: Placebo
NCT02480153,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Interventional,26-Sep-17,Pfizer,Biological: PF-06410293
NCT02480153,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Interventional,26-Sep-17,Pfizer,Biological: Adalimumab
NCT02480712,Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection,Hepatitis C Virus Infection,Interventional,1-Jun-17,Gilead Sciences,Drug: SOF/VEL
NCT02504645,"A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus","Lupus Erythematosus, Systemic",Interventional,11-Apr-19,ImmuPharma,Drug: IPP-201101
NCT02504645,"A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus","Lupus Erythematosus, Systemic",Interventional,11-Apr-19,ImmuPharma,Drug: Placebo
NCT02504645,"A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus","Lupus Erythematosus, Systemic",Interventional,11-Apr-19,ImmuPharma,Other: Standard of Care
NCT02477618,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Interventional,2-May-19,Sage Therapeutics,Drug: SAGE-547
NCT02477618,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Interventional,2-May-19,Sage Therapeutics,Drug: Placebo
NCT02474589,"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat",Smallpox,Interventional,28-Nov-17,SIGA Technologies,Drug: tecovirimat
NCT02474589,"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat",Smallpox,Interventional,28-Nov-17,SIGA Technologies,Other: Placebo
NCT02474589,"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat",Smallpox,Interventional,28-Nov-17,Biomedical Advanced Research and Development Authority,Drug: tecovirimat
NCT02474589,"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat",Smallpox,Interventional,28-Nov-17,Biomedical Advanced Research and Development Authority,Other: Placebo
NCT02471183,Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,28-Dec-17,Actelion,Drug: Selexipag
NCT02469246,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,HIV-1 Infection,Interventional,11-Jun-18,Gilead Sciences,Drug: F/TAF
NCT02469246,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,HIV-1 Infection,Interventional,11-Jun-18,Gilead Sciences,Drug: ABC/3TC
NCT02469246,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,HIV-1 Infection,Interventional,11-Jun-18,Gilead Sciences,Drug: ABC/3TC Placebo
NCT02469246,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,HIV-1 Infection,Interventional,11-Jun-18,Gilead Sciences,Drug: F/TAF Placebo
NCT02469246,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,HIV-1 Infection,Interventional,11-Jun-18,Gilead Sciences,Drug: Third ARV agent
NCT02466425,Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,20-Mar-17,Shire,Drug: SHP465
NCT02466425,Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,20-Mar-17,Shire,Drug: Placebo
NCT02465632,"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.",Acne Vulgaris,Interventional,28-Jun-17,Glenmark Pharmaceuticals Ltd. India,Drug: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
NCT02465632,"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.",Acne Vulgaris,Interventional,28-Jun-17,Glenmark Pharmaceuticals Ltd. India,"Drug: BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%"
NCT02465632,"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.",Acne Vulgaris,Interventional,28-Jun-17,Glenmark Pharmaceuticals Ltd. India,Drug: Placebo
NCT02458287,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",Hyperlipidemia,Interventional,19-Dec-17,Pfizer,Biological: Bococizumab 150mg
NCT02458287,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",Hyperlipidemia,Interventional,19-Dec-17,Pfizer,Biological: Bococizumab 75mg
NCT02458287,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",Hyperlipidemia,Interventional,19-Dec-17,Pfizer,Biological: Bococizumab 150mg placebo
NCT02458287,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",Hyperlipidemia,Interventional,19-Dec-17,Pfizer,Biological: Bococizumab 75mg placebo
NCT00235755,Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy,Seizures,Interventional,7-Nov-11,GlaxoSmithKline,Drug: Retigabine
NCT00235755,Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy,Seizures,Interventional,7-Nov-11,GlaxoSmithKline,Drug: Placebo
NCT00235755,Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy,Seizures,Interventional,7-Nov-11,"Bausch Health Americas, Inc.",Drug: Retigabine
NCT00235755,Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy,Seizures,Interventional,7-Nov-11,"Bausch Health Americas, Inc.",Drug: Placebo
NCT02457546,The EVICEL® Neurosurgery Phase III Study,Cerebrospinal Fluid Leak,Interventional,4-Dec-18,"Ethicon, Inc.",Biological: EVICEL Fibrin Sealant
NCT02457546,The EVICEL® Neurosurgery Phase III Study,Cerebrospinal Fluid Leak,Interventional,4-Dec-18,"Ethicon, Inc.",Device: Hydrogel sealant
NCT02456740,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention,Migraine,Interventional,10-Jul-18,Amgen,Drug: Erenumab
NCT02456740,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention,Migraine,Interventional,10-Jul-18,Amgen,Drug: Placebo
NCT02453256,A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc),Systemic Sclerosis,Interventional,3-Apr-19,Hoffmann-La Roche,Drug: Placebo
NCT02453256,A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc),Systemic Sclerosis,Interventional,3-Apr-19,Hoffmann-La Roche,Drug: Tocilizumab
NCT02445807,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Chronic Stable Plaque Psoriasis,Interventional,13-Apr-18,"Promius Pharma, LLC",Drug: DFD06-Cream
NCT02445807,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Chronic Stable Plaque Psoriasis,Interventional,13-Apr-18,"Promius Pharma, LLC",Drug: Vehicle Cream
NCT02425111,Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease,Crohn's Disease,Interventional,14-Sep-18,Takeda,Drug: Vedolizumab
NCT02422186,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","Depressive Disorder, Treatment-Resistant",Interventional,24-Apr-19,"Janssen Research & Development, LLC",Drug: Esketamine
NCT02422186,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","Depressive Disorder, Treatment-Resistant",Interventional,24-Apr-19,"Janssen Research & Development, LLC",Drug: Placebo
NCT02422186,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","Depressive Disorder, Treatment-Resistant",Interventional,24-Apr-19,"Janssen Research & Development, LLC",Drug: Duloxetine (Oral Antidepressant)
NCT02422186,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","Depressive Disorder, Treatment-Resistant",Interventional,24-Apr-19,"Janssen Research & Development, LLC",Drug: Escitalopram (Oral Antidepressant)
NCT02422186,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","Depressive Disorder, Treatment-Resistant",Interventional,24-Apr-19,"Janssen Research & Development, LLC",Drug: Sertraline (Oral Antidepressant)
NCT02422186,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","Depressive Disorder, Treatment-Resistant",Interventional,24-Apr-19,"Janssen Research & Development, LLC",Drug: Venlafaxine Extended Release (XR) (New Antidepressant)
NCT02420262,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,7-Dec-17,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT02420262,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,7-Dec-17,Novo Nordisk A/S,Drug: insulin glargine
NCT02420262,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,7-Dec-17,Novo Nordisk A/S,Drug: insulin aspart
NCT02417064,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,18-Apr-19,"Janssen Research & Development, LLC",Drug: Esketamine
NCT02417064,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,18-Apr-19,"Janssen Research & Development, LLC",Drug: Placebo
NCT02417064,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,18-Apr-19,"Janssen Research & Development, LLC",Drug: Duloxetine (Oral Antidepressant)
NCT02417064,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,18-Apr-19,"Janssen Research & Development, LLC",Drug: Escitalopram (Oral antidepressant)
NCT02417064,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,18-Apr-19,"Janssen Research & Development, LLC",Drug: Sertraline (Oral Antidepressant)
NCT02417064,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,18-Apr-19,"Janssen Research & Development, LLC",Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
NCT02417961,"Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home",Asthma,Interventional,12-Jun-17,AstraZeneca,Biological: Benralizumab
NCT02413398,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,31-Oct-18,AstraZeneca,Drug: Dapagliflozin 10 mg
NCT02413398,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,Type 2 Diabetes Mellitus,Interventional,31-Oct-18,AstraZeneca,Drug: Matching Placebo for Dapagliflozin
NCT02412111,"A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor",Cystic Fibrosis,Interventional,8-Jan-19,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT02412111,"A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor",Cystic Fibrosis,Interventional,8-Jan-19,Vertex Pharmaceuticals Incorporated,Drug: Tezacaftor/Ivacaftor
NCT02412878,Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma,Multiple Myeloma,Interventional,13-Dec-18,Amgen,Drug: Carfilzomib
NCT02412878,Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma,Multiple Myeloma,Interventional,13-Dec-18,Amgen,Drug: Dexamethasone
NCT02418585,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,19-Apr-19,"Janssen Research & Development, LLC",Drug: Esketamine
NCT02418585,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,19-Apr-19,"Janssen Research & Development, LLC",Drug: Placebo
NCT02418585,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,19-Apr-19,"Janssen Research & Development, LLC",Drug: Duloxetine (Oral Antidepressant)
NCT02418585,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,19-Apr-19,"Janssen Research & Development, LLC",Drug: Escitalopram (Oral antidepressant)
NCT02418585,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,19-Apr-19,"Janssen Research & Development, LLC",Drug: Sertraline (Oral Antidepressant)
NCT02418585,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Treatment-resistant Depression,Interventional,19-Apr-19,"Janssen Research & Development, LLC",Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
NCT02405091,Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Tardive Dyskinesia,Interventional,30-Nov-18,Neurocrine Biosciences,Drug: NBI-98854
NCT02405780,"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients","Arthritis, Rheumatoid",Interventional,26-Mar-19,"Fujifilm Kyowa Kirin Biologics Co., Ltd.",Drug: FKB327
NCT02405780,"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients","Arthritis, Rheumatoid",Interventional,26-Mar-19,"Fujifilm Kyowa Kirin Biologics Co., Ltd.",Drug: Humira®
NCT02404350,"Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis",Psoriatic Arthritis,Interventional,28-Jun-19,Novartis Pharmaceuticals,Biological: Secukinumab
NCT02404350,"Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis",Psoriatic Arthritis,Interventional,28-Jun-19,Novartis,Biological: Secukinumab
NCT02400346,Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment,Major Depression Disorder,Interventional,26-Jun-17,H. Lundbeck A/S,Drug: Adjunct brexpiprazole
NCT02400346,Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment,Major Depression Disorder,Interventional,26-Jun-17,H. Lundbeck A/S,Drug: ADT
NCT02397473,A Study Of Galcanezumab In Participants With Episodic Cluster Headache,Episodic Cluster Headache,Interventional,13-Mar-19,Eli Lilly and Company,Drug: Galcanezumab
NCT02397473,A Study Of Galcanezumab In Participants With Episodic Cluster Headache,Episodic Cluster Headache,Interventional,13-Mar-19,Eli Lilly and Company,Drug: Placebo
NCT02392234,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: VX-661/Ivacaftor
NCT02392234,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT02392234,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: Placebo matched to VX-661/ ivacaftor
NCT02392234,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: Placebo matched to Ivacaftor
NCT02387359,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Interventional,14-Jun-19,"Bausch Health Americas, Inc.",Drug: Plecanatide
NCT02387359,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Interventional,14-Jun-19,"Bausch Health Americas, Inc.",Drug: Placebo
NCT02784704,Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections,Complicated Intra-abdominal Infections|Complicated Appendicitis,Interventional,18-Feb-19,"Tetraphase Pharmaceuticals, Inc.",Drug: Eravacycline
NCT02784704,Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections,Complicated Intra-abdominal Infections|Complicated Appendicitis,Interventional,18-Feb-19,"Tetraphase Pharmaceuticals, Inc.",Drug: Meropenem
NCT02784704,Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections,Complicated Intra-abdominal Infections|Complicated Appendicitis,Interventional,18-Feb-19,"Tetraphase Pharmaceuticals, Inc.",Drug: Placebo
NCT02378480,Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23),Bacterial Infections|Skin Structures and Soft Tissue Infections,Interventional,21-Mar-19,Paratek Pharmaceuticals Inc,Drug: Omadacycline
NCT02378480,Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23),Bacterial Infections|Skin Structures and Soft Tissue Infections,Interventional,21-Mar-19,Paratek Pharmaceuticals Inc,Drug: Linezolid
NCT02376790,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Interventional,22-Feb-19,Amgen,Drug: Etanercept
NCT02376790,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Interventional,22-Feb-19,Amgen,Drug: Methotrexate
NCT02376790,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Interventional,22-Feb-19,Amgen,Drug: Placebo to Etanercept
NCT02376790,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Psoriatic Arthritis,Interventional,22-Feb-19,Amgen,Drug: Placebo to Methotrexate
NCT02375971,RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity,Retinopathy of Prematurity,Interventional,31-Jul-18,Novartis Pharmaceuticals,Drug: Ranibizumab
NCT02375971,RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity,Retinopathy of Prematurity,Interventional,31-Jul-18,Novartis Pharmaceuticals,Procedure: Laser therapy
NCT02375971,RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity,Retinopathy of Prematurity,Interventional,31-Jul-18,Novartis,Drug: Ranibizumab
NCT02375971,RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity,Retinopathy of Prematurity,Interventional,31-Jul-18,Novartis,Procedure: Laser therapy
NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-Small Cell Lung Cancer,Interventional,27-Jun-18,Pfizer,Drug: Bevacizumab-Pfizer
NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-Small Cell Lung Cancer,Interventional,27-Jun-18,Pfizer,Drug: Bevacizumab-EU
NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-Small Cell Lung Cancer,Interventional,27-Jun-18,Pfizer,Drug: Paclitaxel
NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-Small Cell Lung Cancer,Interventional,27-Jun-18,Pfizer,Drug: Carboplatin
NCT02359890,SMART-SF Radiofrequency Ablation Safety Study,Atrial Fibrillation,Interventional,17-Oct-17,"Biosense Webster, Inc.",Device: THERMOCOOL® SMARTTOUCH® (RF ablation treatment)
NCT02357901,Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine,Opioid Dependence|Opioid Related Disorders,Interventional,20-Feb-18,Indivior Inc.,Drug: SUBOXONE
NCT02357901,Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine,Opioid Dependence|Opioid Related Disorders,Interventional,20-Feb-18,Indivior Inc.,Drug: RBP-6000
NCT02357901,Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine,Opioid Dependence|Opioid Related Disorders,Interventional,20-Feb-18,Indivior Inc.,Drug: Placebo
NCT02357459,Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee,Osteoarthritis of the Knee,Interventional,1-Feb-18,"Flexion Therapeutics, Inc.",Drug: FX006
NCT02357459,Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee,Osteoarthritis of the Knee,Interventional,1-Feb-18,"Flexion Therapeutics, Inc.",Drug: Placebo
NCT02357459,Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee,Osteoarthritis of the Knee,Interventional,1-Feb-18,"Flexion Therapeutics, Inc.",Drug: TCA IR 40
NCT02352363,Randomized Safety Study of CVT-301 Compared to an Observational Control Group,Idiopathic Parkinson's Disease,Interventional,10-Jul-18,Acorda Therapeutics,Drug: CVT-301
NCT02352363,Randomized Safety Study of CVT-301 Compared to an Observational Control Group,Idiopathic Parkinson's Disease,Interventional,10-Jul-18,Acorda Therapeutics,Other: Observational cohort
NCT02348632,"""A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA""",Narcolepsy|Obstructive Sleep Apnea,Interventional,25-Jun-19,Jazz Pharmaceuticals,Drug: JZP-110
NCT02348606,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA""",Obstructive Sleep Apnea,Interventional,23-Jul-19,Jazz Pharmaceuticals,Drug: JZP-110
NCT02348606,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA""",Obstructive Sleep Apnea,Interventional,23-Jul-19,Jazz Pharmaceuticals,Drug: Placebo oral tablet
NCT02348593,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy""",Narcolepsy,Interventional,23-Jul-19,Jazz Pharmaceuticals,Drug: JZP-110
NCT02348593,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy""",Narcolepsy,Interventional,23-Jul-19,Jazz Pharmaceuticals,Drug: Placebo oral tablet
NCT02347774,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4),COPD|Chronic Obstructive Pulmonary Disease,Interventional,13-Mar-18,Sunovion Respiratory Development Inc.,Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer
NCT02347774,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4),COPD|Chronic Obstructive Pulmonary Disease,Interventional,13-Mar-18,Sunovion Respiratory Development Inc.,Drug: SUN-101 25 mcg BID eFlow (CS) nebulizer
NCT02347774,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4),COPD|Chronic Obstructive Pulmonary Disease,Interventional,13-Mar-18,Sunovion Respiratory Development Inc.,Drug: Placebo eFlow (CS) nebulizer
NCT02347761,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD,COPD,Interventional,22-Mar-18,Sunovion Respiratory Development Inc.,Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer
NCT02347761,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD,COPD,Interventional,22-Mar-18,Sunovion Respiratory Development Inc.,Drug: SUN-101 25 mcg BID eFlow (CS) nebulizer
NCT02347761,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD,COPD,Interventional,22-Mar-18,Sunovion Respiratory Development Inc.,Drug: Placebo BID eFlow Closed System (CS) nebulizer
NCT02347657,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: VX-661 Plus Ivacaftor Combination
NCT02347657,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT02347657,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: VX-661 Plus Ivacaftor Combination Placebo
NCT02347657,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",Cystic Fibrosis,Interventional,12-Jun-18,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor placebo
NCT02346721,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection,Hepatitis C Virus Infection,Interventional,3-May-17,Gilead Sciences,Drug: SOF/VEL
NCT02346240,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,18-Jul-18,UCB Biopharma S.P.R.L.,Biological: Certolizumab Pegol
NCT02346240,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,18-Jul-18,UCB Biopharma S.P.R.L.,Biological: Etanercept
NCT02346240,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,18-Jul-18,UCB Biopharma S.P.R.L.,Other: Placebo
NCT02346240,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,18-Jul-18,UCB Pharma,Biological: Certolizumab Pegol
NCT02346240,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,18-Jul-18,UCB Pharma,Biological: Etanercept
NCT02346240,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,18-Jul-18,UCB Pharma,Other: Placebo
NCT02345252,Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF),HIV-1 Infection,Interventional,8-Dec-17,Gilead Sciences,Drug: FTC/RPV/TAF
NCT02345252,Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF),HIV-1 Infection,Interventional,8-Dec-17,Gilead Sciences,Drug: FTC/RPV/TDF Placebo
NCT02345252,Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF),HIV-1 Infection,Interventional,8-Dec-17,Gilead Sciences,Drug: FTC/RPV/TDF
NCT02345252,Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF),HIV-1 Infection,Interventional,8-Dec-17,Gilead Sciences,Drug: FTC/RPV/TAF Placebo
NCT02345226,"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",HIV-1 Infection,Interventional,19-Oct-17,Gilead Sciences,Drug: FTC/RPV/TAF
NCT02345226,"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",HIV-1 Infection,Interventional,19-Oct-17,Gilead Sciences,Drug: EFV/FTC/TDF Placebo
NCT02345226,"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",HIV-1 Infection,Interventional,19-Oct-17,Gilead Sciences,Drug: EFV/FTC/TDF
NCT02345226,"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",HIV-1 Infection,Interventional,19-Oct-17,Gilead Sciences,Drug: FTC/RPV/TAF Placebo
NCT02343458,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",Chronic Obstructive Pulmonary Disease,Interventional,20-Feb-19,"Pearl Therapeutics, Inc.",Drug: GFF MDI (PT003)
NCT02343458,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",Chronic Obstructive Pulmonary Disease,Interventional,20-Feb-19,"Pearl Therapeutics, Inc.",Drug: FF MDI (PT005)
NCT02343458,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",Chronic Obstructive Pulmonary Disease,Interventional,20-Feb-19,"Pearl Therapeutics, Inc.",Drug: GP MDI (PT001)
NCT02343458,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",Chronic Obstructive Pulmonary Disease,Interventional,20-Feb-19,"Pearl Therapeutics, Inc.",Drug: Placebo MDI
NCT02367911,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis,Plaque Psoriasis,Interventional,27-Sep-18,"Therapeutics, Inc.",Drug: 122-0551 Foam
NCT02367911,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis,Plaque Psoriasis,Interventional,27-Sep-18,"Therapeutics, Inc.",Drug: Vehicle Foam
NCT02341417,Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis,"Secondary Hyperparathyroidism, Chronic Kidney Disease",Interventional,18-May-18,Amgen,Drug: Cinacalcet
NCT02338843,A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension,Catecholamine-resistant Hypotension (CRH)|Distributive Shock|High Output Shock|Sepsis,Interventional,17-Jan-18,La Jolla Pharmaceutical Company,Drug: LJPC-501
NCT02338843,A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension,Catecholamine-resistant Hypotension (CRH)|Distributive Shock|High Output Shock|Sepsis,Interventional,17-Jan-18,La Jolla Pharmaceutical Company,Drug: Placebo
NCT02337062,Phase IIIb Study of APD421 in Combination as PONV Prophylaxis,PONV,Interventional,4-Aug-17,Acacia Pharma Ltd,Drug: APD421
NCT02337062,Phase IIIb Study of APD421 in Combination as PONV Prophylaxis,PONV,Interventional,4-Aug-17,Acacia Pharma Ltd,Drug: Placebo
NCT02485704,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,Interventional,16-Jan-19,ParaPRO LLC,"Drug: spinosad topical suspension, 0.9%"
NCT02485704,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,Interventional,16-Jan-19,ParaPRO LLC,Other: Placebo
NCT02485704,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,Interventional,16-Jan-19,Concentrics Research,"Drug: spinosad topical suspension, 0.9%"
NCT02485704,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Scabies,Interventional,16-Jan-19,Concentrics Research,Other: Placebo
NCT02326272,A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,13-Aug-18,UCB Biopharma S.P.R.L.,Biological: Certolizumab Pegol
NCT02326272,A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,13-Aug-18,UCB Biopharma S.P.R.L.,Other: Placebo
NCT02326272,A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,13-Aug-18,UCB Pharma,Biological: Certolizumab Pegol
NCT02326272,A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,13-Aug-18,UCB Pharma,Other: Placebo
NCT02325791,Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants,Respiratory Syncytial Virus Infections,Interventional,6-Nov-18,Regeneron Pharmaceuticals,Drug: Suptavumab 30 mg/kg
NCT02325791,Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants,Respiratory Syncytial Virus Infections,Interventional,6-Nov-18,Regeneron Pharmaceuticals,Drug: Placebo Matched to Suptavumab
NCT02325791,Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants,Respiratory Syncytial Virus Infections,Interventional,6-Nov-18,Regeneron Pharmaceuticals,Drug: Suptavumab 30 mg/kg- 1 Dose
NCT02325791,Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants,Respiratory Syncytial Virus Infections,Interventional,6-Nov-18,Regeneron Pharmaceuticals,Drug: Suptavumab 30 mg/kg - 2 Doses
NCT02322775,Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma,Asthma,Interventional,14-Feb-17,AstraZeneca,Biological: Benralizumab
NCT02322775,Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma,Asthma,Interventional,14-Feb-17,AstraZeneca,Biological: Placebo
NCT02320721,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Type 2 Diabetes Mellitus,Interventional,11-Jul-17,Sanofi,Drug: Insulin Glargine (HOE901 - U300)
NCT02320721,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Type 2 Diabetes Mellitus,Interventional,11-Jul-17,Sanofi,Drug: Insulin Glargine (HOE901 - U100)
NCT02320721,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Type 2 Diabetes Mellitus,Interventional,11-Jul-17,Sanofi,Drug: Background therapy
NCT02319005,ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC),"Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related|Familial Transthyretin Cardiac Amyloidosis",Interventional,18-Jul-18,Alnylam Pharmaceuticals,Drug: Revusiran (ALN-TTRSC)
NCT02319005,ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC),"Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related|Familial Transthyretin Cardiac Amyloidosis",Interventional,18-Jul-18,Alnylam Pharmaceuticals,Drug: Sterile Normal Saline (0.9% NaCl)
NCT02318602,Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder,Seizures,Interventional,25-Jul-18,INSYS Therapeutics Inc,Drug: Cannabidiol Oral Solution
NCT02316353,A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema,Hereditary Angioedema Types I and II,Interventional,14-Nov-18,CSL Behring,Biological: C1-esterase inhibitor
NCT02368210,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306),Plaque Psoriasis,Interventional,26-Nov-18,"Therapeutics, Inc.",Drug: 122-0551 Foam
NCT02368210,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306),Plaque Psoriasis,Interventional,26-Nov-18,"Therapeutics, Inc.",Drug: Vehicle Foam
NCT02311881,A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis,Pain,Interventional,7-Apr-17,GlaxoSmithKline,Drug: Paracetamol 1000 mg SR tablets
NCT02311881,A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis,Pain,Interventional,7-Apr-17,GlaxoSmithKline,Drug: Paracetamol 665 mg SR tablets
NCT02311881,A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis,Pain,Interventional,7-Apr-17,GlaxoSmithKline,Drug: Placebo
NCT02305381,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,16-Feb-18,Novo Nordisk A/S,Drug: semaglutide
NCT02305381,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,16-Feb-18,Novo Nordisk A/S,Drug: placebo
NCT02304484,Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab,Hypercholesterolemia,Interventional,19-Mar-19,Amgen,Biological: Evolocumab
NCT02301975,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",Asthma,Interventional,12-Jun-17,GlaxoSmithKline,Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler
NCT02301975,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",Asthma,Interventional,12-Jun-17,GlaxoSmithKline,Drug: Placebo inhalation powders via ELLIPTA inhaler
NCT02301975,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",Asthma,Interventional,12-Jun-17,GlaxoSmithKline,Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler
NCT02301975,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",Asthma,Interventional,12-Jun-17,GlaxoSmithKline,Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler
NCT02301975,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",Asthma,Interventional,12-Jun-17,GlaxoSmithKline,Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
NCT02298192,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms,"Diabetes|Diabetes Mellitus, Type 2",Interventional,23-May-17,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT02296138,Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Jun-18,Boehringer Ingelheim,Drug: olodaterol
NCT02296138,Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Jun-18,Boehringer Ingelheim,Drug: tiotropium
NCT02294474,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,18-Jan-18,Sanofi,Drug: SAR342434
NCT02294474,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,18-Jan-18,Sanofi,Drug: Humalog
NCT02294474,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,18-Jan-18,Sanofi,Drug: insulin glargine HOE901
NCT02294227,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","Arthritis, Psoriatic",Interventional,2-Jul-19,Novartis Pharmaceuticals,Biological: Secukinumab
NCT02294227,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","Arthritis, Psoriatic",Interventional,2-Jul-19,Novartis Pharmaceuticals,Other: Placebo
NCT02294227,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","Arthritis, Psoriatic",Interventional,2-Jul-19,Novartis,Biological: Secukinumab
NCT02294227,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis","Arthritis, Psoriatic",Interventional,2-Jul-19,Novartis,Other: Placebo
NCT02294019,Actual Use Trial of Ibuprofen 400 mg,Patient Compliance,Interventional,30-May-16,Pfizer,Drug: Ibuprofen 400 mg caplet
NCT02291861,Addressing Involuntary Movements in Tardive Dyskinesia,Tardive Dyskinesia,Interventional,11-Apr-18,"Auspex Pharmaceuticals, Inc.",Drug: SD-809
NCT02291861,Addressing Involuntary Movements in Tardive Dyskinesia,Tardive Dyskinesia,Interventional,11-Apr-18,"Auspex Pharmaceuticals, Inc.",Drug: Placebo
NCT02291861,Addressing Involuntary Movements in Tardive Dyskinesia,Tardive Dyskinesia,Interventional,11-Apr-18,Teva Pharmaceutical Industries,Drug: SD-809
NCT02291861,Addressing Involuntary Movements in Tardive Dyskinesia,Tardive Dyskinesia,Interventional,11-Apr-18,Teva Pharmaceutical Industries,Drug: Placebo
NCT02291549,S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps,Chronic Sinusitis|Nasal Polyposis,Interventional,9-Jul-18,Intersect ENT,Drug: S8 Sinus Implant
NCT02291549,S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps,Chronic Sinusitis|Nasal Polyposis,Interventional,9-Jul-18,Intersect ENT,Drug: Mometasone furoate nasal spray
NCT02291549,S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps,Chronic Sinusitis|Nasal Polyposis,Interventional,9-Jul-18,Intersect ENT,Procedure: Sham
NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),Spinal Muscular Atrophy,Interventional,21-Feb-18,Biogen,Drug: Nusinersen
NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),Spinal Muscular Atrophy,Interventional,21-Feb-18,Biogen,Procedure: Sham procedure
NCT02285998,Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age,Influenza,Interventional,4-Oct-16,Protein Sciences Corporation,Biological: Flublok Quadrivalent Influenza Vaccine
NCT02285998,Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age,Influenza,Interventional,4-Oct-16,Protein Sciences Corporation,Biological: Inactivated Influenza Vaccine
NCT02284893,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,Type 2 Diabetes,Interventional,1-Jun-18,AstraZeneca,Drug: Saxagliptin
NCT02284893,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,Type 2 Diabetes,Interventional,1-Jun-18,AstraZeneca,Drug: Dapagliflozin
NCT02284893,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,Type 2 Diabetes,Interventional,1-Jun-18,AstraZeneca,Drug: Sitagliptin
NCT02284893,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,Type 2 Diabetes,Interventional,1-Jun-18,AstraZeneca,Drug: Placebo matching with Saxagliptin
NCT02284893,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,Type 2 Diabetes,Interventional,1-Jun-18,AstraZeneca,Drug: Placebo matching with Dapagliflozin
NCT02284893,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,Type 2 Diabetes,Interventional,1-Jun-18,AstraZeneca,Drug: Placebo matching with Sitagliptin
NCT02284516,A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3),Dry Eye Disease,Interventional,15-Mar-17,Shire,Drug: Lifitegrast
NCT02284516,A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3),Dry Eye Disease,Interventional,15-Mar-17,Shire,Drug: Placebo
NCT02283268,Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery,Von Willebrand Disease,Interventional,31-Aug-17,Baxalta now part of Shire,Biological: Recombinant von Willebrand Factor (rVWF)
NCT02283268,Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery,Von Willebrand Disease,Interventional,31-Aug-17,Shire,Biological: Recombinant von Willebrand Factor (rVWF)
NCT02290821,Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries,Acute Blunt Soft Tissue Injuries/Contusions,Interventional,19-Apr-17,Novartis,Drug: placebo
NCT02290821,Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries,Acute Blunt Soft Tissue Injuries/Contusions,Interventional,19-Apr-17,Novartis,Drug: Placebos
NCT02290509,Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age,Influenza,Interventional,22-Sep-16,Protein Sciences Corporation,Biological: Flublok Quadrivalent
NCT02290509,Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age,Influenza,Interventional,22-Sep-16,Protein Sciences Corporation,Biological: Inactivated Influenza Vaccine (IIV4)
NCT02290509,Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age,Influenza,Interventional,22-Sep-16,Syneos Health,Biological: Flublok Quadrivalent
NCT02290509,Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age,Influenza,Interventional,22-Sep-16,Syneos Health,Biological: Inactivated Influenza Vaccine (IIV4)
NCT02290509,Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age,Influenza,Interventional,22-Sep-16,Department of Health and Human Services,Biological: Flublok Quadrivalent
NCT02290509,Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age,Influenza,Interventional,22-Sep-16,Department of Health and Human Services,Biological: Inactivated Influenza Vaccine (IIV4)
NCT02281318,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control,Asthma,Interventional,4-May-17,GlaxoSmithKline,Biological: Mepolizumab
NCT02281318,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control,Asthma,Interventional,4-May-17,GlaxoSmithKline,Drug: Placebo
NCT02281318,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control,Asthma,Interventional,4-May-17,GlaxoSmithKline,Drug: SOC
NCT02281357,Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma,Asthma,Interventional,16-May-18,AstraZeneca,Biological: Tralokinumab
NCT02281357,Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma,Asthma,Interventional,16-May-18,AstraZeneca,Other: Placebo
NCT02279498,SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,Interventional,14-Aug-18,Anthera Pharmaceuticals,Drug: Liprotamase
NCT02279498,SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,Interventional,14-Aug-18,Anthera Pharmaceuticals,Drug: porcine (pig) PERT
NCT02279082,DFN-02 Open Label Safety Study in Patients With Acute Migraine,Acute Migraine,Interventional,28-Aug-17,Dr. Reddy's Laboratories Limited,Drug: DFN-02
NCT02276222,A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD,Chronic Obstructive Pulmonary Disease (COPD),Interventional,13-Mar-18,Sunovion Respiratory Development Inc.,Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer
NCT02276222,A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD,Chronic Obstructive Pulmonary Disease (COPD),Interventional,13-Mar-18,Sunovion Respiratory Development Inc.,Drug: Spiriva® 18 mcg QD Handihaler
NCT02274766,Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia,Dyskinesia|Levodopa-Induced Dyskinesia (LID)|Parkinson's Disease (PD),Interventional,10-Jan-18,"Adamas Pharmaceuticals, Inc.",Drug: ADS-5102
NCT02274766,Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia,Dyskinesia|Levodopa-Induced Dyskinesia (LID)|Parkinson's Disease (PD),Interventional,10-Jan-18,"Adamas Pharmaceuticals, Inc.",Other: Placebo
NCT02274558,A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Tardive Dyskinesia,Interventional,11-Jul-17,Neurocrine Biosciences,Drug: NBI-98854
NCT02274558,A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Tardive Dyskinesia,Interventional,11-Jul-17,Neurocrine Biosciences,Drug: Placebo
NCT02273180,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,Type 1 Diabetes Mellitus,Interventional,18-Jan-18,Sanofi,Drug: SAR342434
NCT02273180,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,Type 1 Diabetes Mellitus,Interventional,18-Jan-18,Sanofi,Drug: Humalog
NCT02273180,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,Type 1 Diabetes Mellitus,Interventional,18-Jan-18,Sanofi,Drug: Insulin glargine HOE901
NCT02271217,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,Post-Ischemic Stroke,Interventional,4-Dec-17,Acorda Therapeutics,Drug: Placebo
NCT02271217,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,Post-Ischemic Stroke,Interventional,4-Dec-17,Acorda Therapeutics,Drug: dalfampridine-ER 7.5mg
NCT02271217,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,Post-Ischemic Stroke,Interventional,4-Dec-17,Acorda Therapeutics,Drug: dalfampridine-ER 10mg
NCT02280473,A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease,Dry Eye Syndromes,Interventional,7-Jun-17,Allergan,Drug: Refresh Optive® Gel Drops
NCT02280473,A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease,Dry Eye Syndromes,Interventional,7-Jun-17,Allergan,Drug: REFRESH LIQUIGEL®
NCT02268994,KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD,Anemia of Chronic Kidney Disease,Interventional,21-Feb-18,Keryx Biopharmaceuticals,Drug: ferric citrate
NCT02268994,KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD,Anemia of Chronic Kidney Disease,Interventional,21-Feb-18,Keryx Biopharmaceuticals,Drug: Placebo
NCT02656069,Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics,"Hypoglycemia|Diabetes Mellitus, Type 1",Interventional,28-Sep-18,Xeris Pharmaceuticals,Drug: G-Pen (glucagon injection)
NCT02656069,Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics,"Hypoglycemia|Diabetes Mellitus, Type 1",Interventional,28-Sep-18,Xeris Pharmaceuticals,Drug: Lilly Glucagon (glucagon injection [rDNA origin])
NCT02267135,Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis,Chronic Scalp Psoriasis,Interventional,28-Feb-18,Novartis Pharmaceuticals,Biological: Secukinumab 300 mg
NCT02267135,Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis,Chronic Scalp Psoriasis,Interventional,28-Feb-18,Novartis Pharmaceuticals,Biological: Placebo
NCT02267135,Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis,Chronic Scalp Psoriasis,Interventional,28-Feb-18,Novartis,Biological: Secukinumab 300 mg
NCT02267135,Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis,Chronic Scalp Psoriasis,Interventional,28-Feb-18,Novartis,Biological: Placebo
NCT02326298,An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,13-Aug-18,UCB Biopharma S.P.R.L.,Biological: Certolizumab Pegol
NCT02326298,An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,13-Aug-18,UCB Biopharma S.P.R.L.,Other: Placebo
NCT02326298,An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,13-Aug-18,UCB Pharma,Biological: Certolizumab Pegol
NCT02326298,An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Psoriasis|Plaque Psoriasis,Interventional,13-Aug-18,UCB Pharma,Other: Placebo
NCT02260791,A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients,"Arthritis, Rheumatoid",Interventional,20-Sep-17,"Fujifilm Kyowa Kirin Biologics Co., Ltd.",Drug: FKB327
NCT02260791,A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients,"Arthritis, Rheumatoid",Interventional,20-Sep-17,"Fujifilm Kyowa Kirin Biologics Co., Ltd.",Drug: Humira®
NCT02268396,Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD,COPD,Interventional,23-Dec-16,"Pearl Therapeutics, Inc.",Drug: Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
NCT02258542,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Interventional,6-Feb-19,AstraZeneca,Biological: Benralizumab
NCT02266810,Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus,Chronic Sinusitis,Interventional,6-Oct-17,Intersect ENT,Device: PROPEL Mini Sinus Implant.
NCT02266810,Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus,Chronic Sinusitis,Interventional,6-Oct-17,Intersect ENT,Procedure: Sinus Surgery alone
NCT02266810,Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus,Chronic Sinusitis,Interventional,6-Oct-17,Intersect ENT,Device: Propel Nova Sinus Implant
NCT02266810,Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus,Chronic Sinusitis,Interventional,6-Oct-17,Advance Research Associates,Device: PROPEL Mini Sinus Implant.
NCT02266810,Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus,Chronic Sinusitis,Interventional,6-Oct-17,Advance Research Associates,Procedure: Sinus Surgery alone
NCT02266810,Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus,Chronic Sinusitis,Interventional,6-Oct-17,Advance Research Associates,Device: Propel Nova Sinus Implant
NCT02256488,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Prophylaxis: Influenza,Interventional,7-Aug-15,Novartis Vaccines,Biological: TIVc_LOT A
NCT02256488,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Prophylaxis: Influenza,Interventional,7-Aug-15,Novartis Vaccines,Biological: TIVc_LOT B
NCT02256488,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Prophylaxis: Influenza,Interventional,7-Aug-15,Novartis Vaccines,Biological: TIVc_LOT C
NCT02256488,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Prophylaxis: Influenza,Interventional,7-Aug-15,Novartis Vaccines,Biological: TIVf
NCT02256488,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Prophylaxis: Influenza,Interventional,7-Aug-15,Novartis,Biological: TIVc_LOT A
NCT02256488,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Prophylaxis: Influenza,Interventional,7-Aug-15,Novartis,Biological: TIVc_LOT B
NCT02256488,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Prophylaxis: Influenza,Interventional,7-Aug-15,Novartis,Biological: TIVc_LOT C
NCT02256488,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Prophylaxis: Influenza,Interventional,7-Aug-15,Novartis,Biological: TIVf
NCT02253173,Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women,Vulvovaginal Atrophy|Menopause|Dyspareunia|Painful Intercourse,Interventional,25-May-17,TherapeuticsMD,Drug: Estradiol
NCT02253173,Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women,Vulvovaginal Atrophy|Menopause|Dyspareunia|Painful Intercourse,Interventional,25-May-17,TherapeuticsMD,Drug: Placebo
NCT02254486,"Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults",Colon Cancer|Colorectal Carcinoma|Colon Cleansing,Interventional,23-May-17,Norgine,Drug: NER1006
NCT02254486,"Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults",Colon Cancer|Colorectal Carcinoma|Colon Cleansing,Interventional,23-May-17,Norgine,Drug: Trisulfate solution
NCT02261493,A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides,Facial Rhytides|Glabellar Rhytides,Interventional,25-Jul-17,Allergan,Biological: OnabotulinumtoxinA
NCT02261493,A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides,Facial Rhytides|Glabellar Rhytides,Interventional,25-Jul-17,Allergan,Drug: Normal Saline
NCT02246439,BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis,Gastroenteritis|Gastritis,Interventional,20-Feb-19,RedHill Biopharma Limited,Drug: RHB-102
NCT02246439,BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis,Gastroenteritis|Gastritis,Interventional,20-Feb-19,RedHill Biopharma Limited,Drug: Placebo Oral Tablet
NCT02242643,Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age,Influenza,Interventional,12-Apr-16,GlaxoSmithKline,Biological: FluLaval™ Quadrivalent
NCT02242643,Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age,Influenza,Interventional,12-Apr-16,GlaxoSmithKline,Biological: Fluzone® Quadrivalent
NCT02240030,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Idiopathic Parkinson's Disease,Interventional,17-Apr-18,Acorda Therapeutics,Drug: CVT-301 Low Dose
NCT02240030,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Idiopathic Parkinson's Disease,Interventional,17-Apr-18,Acorda Therapeutics,Drug: CVT-301 High Dose
NCT02240030,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Idiopathic Parkinson's Disease,Interventional,17-Apr-18,Acorda Therapeutics,Other: Placebo
NCT02237950,Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV),Bacterial Vaginosis,Interventional,9-Jul-19,Starpharma Pty Ltd,Drug: Metronidazole oral tablets 500mg
NCT02237950,Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV),Bacterial Vaginosis,Interventional,9-Jul-19,Starpharma Pty Ltd,Drug: 1% SPL7013 Gel
NCT02237950,Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV),Bacterial Vaginosis,Interventional,9-Jul-19,Starpharma Pty Ltd,Drug: Placebo gel
NCT02261467,A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides,Forehead Rhytides|Glabellar Rhytides,Interventional,23-Jun-17,Allergan,Biological: OnabotulinumtoxinA
NCT02261467,A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides,Forehead Rhytides|Glabellar Rhytides,Interventional,23-Jun-17,Allergan,Drug: Normal Saline
NCT02229396,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,Diabetes Mellitus,Interventional,8-Sep-17,AstraZeneca,Drug: Exantide with Dapagliflozin
NCT02229396,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,Diabetes Mellitus,Interventional,8-Sep-17,AstraZeneca,Drug: Exentide
NCT02229396,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,Diabetes Mellitus,Interventional,8-Sep-17,AstraZeneca,Drug: Dapagliflozin
NCT02229383,Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus,Diabetes Mellitus,Interventional,18-Sep-17,AstraZeneca,Drug: Exenatide
NCT02229383,Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus,Diabetes Mellitus,Interventional,18-Sep-17,AstraZeneca,Drug: Exenatide matching placebo
NCT02226120,Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction,Chronic Heart Failure With Reduced Ejection Fraction,Interventional,20-Feb-19,Novartis Pharmaceuticals,Drug: LCZ696
NCT02226120,Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction,Chronic Heart Failure With Reduced Ejection Fraction,Interventional,20-Feb-19,Novartis,Drug: LCZ696
NCT02224690,A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,Epilepsy|Lennox-Gastaut Syndrome,Interventional,27-Jul-18,GW Research Ltd,Drug: GWP42003-P 20 mg/kg/day Dose
NCT02224690,A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,Epilepsy|Lennox-Gastaut Syndrome,Interventional,27-Jul-18,GW Research Ltd,Drug: Placebo
NCT02224560,Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,Epilepsy|Lennox Gastaut Syndrome,Interventional,27-Jul-18,GW Research Ltd,Drug: GWP42003-P
NCT02224560,Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,Epilepsy|Lennox Gastaut Syndrome,Interventional,27-Jul-18,GW Research Ltd,Drug: Placebo control
NCT02222493,A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).,Rheumatoid Arthritis,Interventional,11-Sep-17,Pfizer,Biological: PF-06438179
NCT02222493,A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).,Rheumatoid Arthritis,Interventional,11-Sep-17,Pfizer,Biological: Infliximab
NCT02221869,A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy,Narcolepsy With Cataplexy,Interventional,30-Apr-19,Jazz Pharmaceuticals,Drug: Xyrem
NCT02220998,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection,Hepatitis C Virus Infection,Interventional,15-Nov-16,Gilead Sciences,Drug: SOF/VEL
NCT02220998,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection,Hepatitis C Virus Infection,Interventional,15-Nov-16,Gilead Sciences,Drug: SOF
NCT02220998,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection,Hepatitis C Virus Infection,Interventional,15-Nov-16,Gilead Sciences,Drug: RBV
NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,Multiple Sclerosis,Interventional,27-Mar-17,Biogen,Drug: fampridine
NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,Multiple Sclerosis,Interventional,27-Mar-17,Biogen,Drug: Placebo
NCT02218008,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study,Major Depressive Disorder,Interventional,27-Mar-19,"Alkermes, Inc.",Drug: ALKS 5461
NCT02218008,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study,Major Depressive Disorder,Interventional,27-Mar-19,"Alkermes, Inc.",Drug: Placebo
NCT02214225,A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.,"Influenza, Human",Interventional,23-Feb-16,Seqirus,Biological: Quadrivalent Influenza Vaccine (QIV)
NCT02214225,A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.,"Influenza, Human",Interventional,23-Feb-16,Seqirus,Biological: Trivalent Influenza Vaccine (TIV-1)
NCT02214225,A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.,"Influenza, Human",Interventional,23-Feb-16,Seqirus,Biological: Trivalent Influenza Vaccine (TIV-2)
NCT02213263,"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)",Follicular Lymphoma,Interventional,30-Oct-18,Pfizer,Biological: PF-05280586
NCT02213263,"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)",Follicular Lymphoma,Interventional,30-Oct-18,Pfizer,Biological: MabThera®
NCT02210091,BAX 855 Pediatric Study,Hemophilia A,Interventional,27-Jan-17,Baxalta now part of Shire,Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
NCT02210091,BAX 855 Pediatric Study,Hemophilia A,Interventional,27-Jan-17,Baxalta now part of Shire,Biological: PEGylated Recombinant Factor VIII
NCT02210091,BAX 855 Pediatric Study,Hemophilia A,Interventional,27-Jan-17,Shire,Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
NCT02210091,BAX 855 Pediatric Study,Hemophilia A,Interventional,27-Jan-17,Shire,Biological: PEGylated Recombinant Factor VIII
NCT02207634,Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects,Dyslipidemia,Interventional,16-Jan-18,Amgen,Biological: Evolocumab
NCT02207634,Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects,Dyslipidemia,Interventional,16-Jan-18,Amgen,Drug: Placebo
NCT02207634,Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects,Dyslipidemia,Interventional,16-Jan-18,Amgen,Drug: Background Statin Therapy
NCT02203838,Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia,Schizophrenia,Interventional,28-Sep-18,Indivior Inc.,Drug: RBP-7000
NCT02203032,A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab,Psoriasis,Interventional,17-Jul-17,"Janssen Research & Development, LLC",Drug: Ustekinumab
NCT02203032,A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab,Psoriasis,Interventional,17-Jul-17,"Janssen Research & Development, LLC",Drug: Guselkumab
NCT02203032,A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab,Psoriasis,Interventional,17-Jul-17,"Janssen Research & Development, LLC",Drug: Placebo for ustekinumab
NCT02203032,A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab,Psoriasis,Interventional,17-Jul-17,"Janssen Research & Development, LLC",Drug: Placebo for guselkumab
NCT02201953,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection,Hepatitis C Virus Infection,Interventional,26-Oct-16,Gilead Sciences,Drug: SOF/VEL
NCT02201953,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection,Hepatitis C Virus Infection,Interventional,26-Oct-16,Gilead Sciences,Drug: SOF
NCT02201953,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection,Hepatitis C Virus Infection,Interventional,26-Oct-16,Gilead Sciences,Drug: RBV
NCT02201940,Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection,Hepatitis C Virus Infection,Interventional,16-Sep-16,Gilead Sciences,Drug: SOF/VEL
NCT02201940,Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection,Hepatitis C Virus Infection,Interventional,16-Sep-16,Gilead Sciences,Drug: Placebo
NCT02201901,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis,Hepatitis C Virus Infection,Interventional,14-Dec-16,Gilead Sciences,Drug: SOF/VEL
NCT02201901,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis,Hepatitis C Virus Infection,Interventional,14-Dec-16,Gilead Sciences,Drug: RBV
NCT02194699,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Interventional,21-Mar-18,AstraZeneca,Biological: Experimental: Tralokinumab
NCT02194699,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Interventional,21-Mar-18,AstraZeneca,Other: Placebo
NCT02184572,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Measles; Mumps; Rubella,Interventional,3-Jul-18,GlaxoSmithKline,Biological: Priorix
NCT02184572,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Measles; Mumps; Rubella,Interventional,3-Jul-18,GlaxoSmithKline,Biological: M-M-R II
NCT02184572,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Measles; Mumps; Rubella,Interventional,3-Jul-18,GlaxoSmithKline,Biological: Varivax
NCT02184572,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Measles; Mumps; Rubella,Interventional,3-Jul-18,GlaxoSmithKline,Biological: Havrix
NCT02184572,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Measles; Mumps; Rubella,Interventional,3-Jul-18,GlaxoSmithKline,Biological: Prevnar 13
NCT02186873,A Study of Golimumab in Participants With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,13-Nov-17,"Janssen Research & Development, LLC",Drug: Placebo
NCT02186873,A Study of Golimumab in Participants With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,13-Nov-17,"Janssen Research & Development, LLC",Drug: Golimumab
NCT02181673,A Study of Golimumab in Participants With Active Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,21-Dec-17,"Janssen Research & Development, LLC",Drug: Placebo
NCT02181673,A Study of Golimumab in Participants With Active Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,21-Dec-17,"Janssen Research & Development, LLC",Drug: Golimumab
NCT02234115,"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",Prostatic Neoplasms,Interventional,13-Apr-18,"Foresee Pharmaceuticals Co., Ltd.",Drug: Leuprolide Mesylate
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Fp MDPI
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: FS MDPI
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: FLOVENT HFA
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: ADVAIR DISKUS
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: albuterol/salbutamol HFA
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,Teva Pharmaceutical Industries,Drug: Fp MDPI
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,Teva Pharmaceutical Industries,Drug: FS MDPI
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,Teva Pharmaceutical Industries,Drug: FLOVENT HFA
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,Teva Pharmaceutical Industries,Drug: ADVAIR DISKUS
NCT02175771,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Persistent Asthma,Interventional,14-Apr-17,Teva Pharmaceutical Industries,Drug: albuterol/salbutamol HFA
NCT02168946,"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection,Interventional,11-Dec-18,"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",Drug: Vabomere
NCT02168946,"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection,Interventional,11-Dec-18,"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",Drug: Best Available Therapy
NCT02168946,"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection,Interventional,11-Dec-18,Department of Health and Human Services,Drug: Vabomere
NCT02168946,"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection,Interventional,11-Dec-18,Department of Health and Human Services,Drug: Best Available Therapy
NCT02168946,"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection,Interventional,11-Dec-18,"Melinta Therapeutics, Inc.",Drug: Vabomere
NCT02168946,"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection,Interventional,11-Dec-18,"Melinta Therapeutics, Inc.",Drug: Best Available Therapy
NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Dabigatran Etexilate 110mg
NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Warfarin 3mg
NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Aspirin
NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Dabigatran Etexilate 150mg
NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Clopidogrel or Ticagrelor
NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Warfarin 5mg
NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation|Percutaneous Coronary Intervention,Interventional,31-Jul-18,Boehringer Ingelheim,Drug: Warfarin 1mg
NCT02164513,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,10-Oct-18,GlaxoSmithKline,Drug: fluticasone furoate (FF)
NCT02164513,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,10-Oct-18,GlaxoSmithKline,Drug: vilanterol (VI)
NCT02164513,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,10-Oct-18,GlaxoSmithKline,Drug: umeclidinium bromide (UMEC)
NCT02163499,Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months,Hyperkalemia,Interventional,27-Jun-18,"ZS Pharma, Inc.",Drug: Sodium Zirconium Cyclosilicate
NCT02161757,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Interventional,17-Apr-18,AstraZeneca,Biological: Tralokinumab
NCT02161757,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Interventional,17-Apr-18,AstraZeneca,Other: Placebo
NCT02160145,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease|Autosomal Dominant Polycystic Kidney Disease,Interventional,8-Aug-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Tolvaptan (OPC-41061)
NCT02160145,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Chronic Kidney Disease|Autosomal Dominant Polycystic Kidney Disease,Interventional,8-Aug-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT02159469,Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism,Hypogonadism,Interventional,9-Jan-18,Antares Pharma Inc.,Combination Product: Testosterone enanthate auto-injector
NCT02158546,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study,Major Depressive Disorder,Interventional,25-Jun-19,"Alkermes, Inc.",Drug: ALKS 5461
NCT02158546,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study,Major Depressive Disorder,Interventional,25-Jun-19,"Alkermes, Inc.",Drug: Placebo
NCT02158533,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study,Major Depressive Disorder,Interventional,27-Mar-19,"Alkermes, Inc.",Drug: High Dose ALKS 5461
NCT02158533,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study,Major Depressive Disorder,Interventional,27-Mar-19,"Alkermes, Inc.",Drug: Low Dose ALKS 5461
NCT02158533,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study,Major Depressive Disorder,Interventional,27-Mar-19,"Alkermes, Inc.",Drug: Placebo
NCT02157935,Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease,COPD Patients,Interventional,12-Jun-17,AstraZeneca,Drug: Symbicort
NCT02157935,Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease,COPD Patients,Interventional,12-Jun-17,AstraZeneca,Drug: Formoterol turbohaler
NCT02157935,Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease,COPD Patients,Interventional,12-Jun-17,AstraZeneca,Other: Placebo for Symbicort pMDI
NCT02157935,Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease,COPD Patients,Interventional,12-Jun-17,AstraZeneca,Other: Placebo for Formoterol Turbohaler
NCT02159053,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","Spondylitis, Ankylosing",Interventional,10-Apr-19,Novartis Pharmaceuticals,Biological: Secukinumab
NCT02159053,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","Spondylitis, Ankylosing",Interventional,10-Apr-19,Novartis Pharmaceuticals,Biological: Placebo
NCT02159053,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","Spondylitis, Ankylosing",Interventional,10-Apr-19,Novartis,Biological: Secukinumab
NCT02159053,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","Spondylitis, Ankylosing",Interventional,10-Apr-19,Novartis,Biological: Placebo
NCT02152371,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,"Diabetes Mellitus, Type 2",Interventional,7-Dec-16,Eli Lilly and Company,Drug: Dulaglutide
NCT02152371,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,"Diabetes Mellitus, Type 2",Interventional,7-Dec-16,Eli Lilly and Company,Drug: Placebo
NCT02152371,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,"Diabetes Mellitus, Type 2",Interventional,7-Dec-16,Eli Lilly and Company,Drug: Insulin Glargine
NCT02152371,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,"Diabetes Mellitus, Type 2",Interventional,7-Dec-16,Eli Lilly and Company,Drug: Metformin
NCT02149264,A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males,Adult Male Hypogonadism,Interventional,28-Jul-17,Ferring Pharmaceuticals,Drug: Testosterone gel (FE 999303)
NCT02149108,Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1),Colorectal Neoplasms,Interventional,21-Jul-17,Boehringer Ingelheim,Drug: Nintedanib (BIBF 1120)
NCT02149108,Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1),Colorectal Neoplasms,Interventional,21-Jul-17,Boehringer Ingelheim,Drug: Placebo
NCT02149108,Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1),Colorectal Neoplasms,Interventional,21-Jul-17,Boehringer Ingelheim,Drug: BSC
NCT02152605,A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,25-Feb-16,GlaxoSmithKline,Drug: UMEC/VI
NCT02152605,A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,25-Feb-16,GlaxoSmithKline,Drug: Placebo
NCT02157948,A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,16-Aug-17,Amgen,Drug: Denosumab (CP2)
NCT02157948,A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,16-Aug-17,Amgen,Drug: Denosumab (CP4)
NCT02147197,A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas,Leiomyoma|Uterine Hemorrhage,Interventional,5-Apr-19,Allergan,Drug: Ulipristal acetate (UPA)
NCT02147197,A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas,Leiomyoma|Uterine Hemorrhage,Interventional,5-Apr-19,Allergan,Drug: Placebo
NCT02147158,A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas,Leiomyoma|Uterine Hemorrhage,Interventional,4-Jun-19,Allergan,Drug: Ulipristal acetate (UPA)
NCT02147158,A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas,Leiomyoma|Uterine Hemorrhage,Interventional,4-Jun-19,Allergan,Drug: Placebo
NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Interventional,2-Jun-17,GlaxoSmithKline,Drug: Losmapimod 7.5 mg twice daily
NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Interventional,2-Jun-17,GlaxoSmithKline,Drug: Placebo twice daily
NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Interventional,2-Jun-17,GlaxoSmithKline,Drug: Standard therapy
NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Interventional,2-Jun-17,The TIMI Study Group,Drug: Losmapimod 7.5 mg twice daily
NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Interventional,2-Jun-17,The TIMI Study Group,Drug: Placebo twice daily
NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Acute Coronary Syndrome,Interventional,2-Jun-17,The TIMI Study Group,Drug: Standard therapy
NCT02141854,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: FS MDPI
NCT02141854,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Fp MDPI
NCT02141854,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo MDPI
NCT02141854,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Albuterol/salmeterol HFA MDI
NCT02141854,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: FS MDPI
NCT02141854,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: Fp MDPI
NCT02141854,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: Placebo MDPI
NCT02141854,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: Albuterol/salmeterol HFA MDI
NCT02141399,A Long-Term Safety Study of ALKS 5461,Major Depressive Disorder,Interventional,14-Dec-18,"Alkermes, Inc.",Drug: ALKS 5461
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: FS MDPI
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Fp MDPI
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo MDPI
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: albuterol/salbutamol
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: FS MDPI
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: Fp MDPI
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: Placebo MDPI
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: albuterol/salbutamol
NCT02139644,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Asthma,Interventional,12-Apr-17,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate
NCT02139046,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Interventional,3-Nov-16,Takeda,Drug: Febuxostat IR
NCT02139046,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Interventional,3-Nov-16,Takeda,Drug: Febuxostat XR
NCT02139046,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Interventional,3-Nov-16,Takeda,Drug: Febuxostat placebo
NCT02139046,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Interventional,3-Nov-16,Takeda,Drug: Colchicine
NCT02139046,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Interventional,3-Nov-16,Takeda,Drug: Naproxen
NCT02139046,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Interventional,3-Nov-16,Takeda,Drug: Lansoprazole
NCT02137785,Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities,Actinic Keratosis,Interventional,16-Sep-15,"DUSA Pharmaceuticals, Inc.",Drug: Aminolevulinic Acid (ALA)
NCT02137785,Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities,Actinic Keratosis,Interventional,16-Sep-15,"DUSA Pharmaceuticals, Inc.",Drug: Topical Solution Vehicle
NCT02137785,Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities,Actinic Keratosis,Interventional,16-Sep-15,"DUSA Pharmaceuticals, Inc.",Device: Blue Light Photodynamic Therapy Illuminator (BLU-U)
NCT02137226,BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,8-Dec-17,Boehringer Ingelheim,Drug: BI 695501
NCT02137226,BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,8-Dec-17,Boehringer Ingelheim,Drug: US-licensed Humira®
NCT02136914,ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study),Dyskinesia|Levodopa Induced Dyskinesia (LID)|Parkinson's Disease,Interventional,6-Feb-18,"Adamas Pharmaceuticals, Inc.",Drug: ADS-5102
NCT02136914,ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study),Dyskinesia|Levodopa Induced Dyskinesia (LID)|Parkinson's Disease,Interventional,6-Feb-18,"Adamas Pharmaceuticals, Inc.",Other: Placebo
NCT02135692,"A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects",Asthma,Interventional,2-May-18,GlaxoSmithKline,Biological: Mepolizumab
NCT02135692,"A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects",Asthma,Interventional,2-May-18,GlaxoSmithKline,Drug: SOC
NCT02135029,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins,Hyperlipidemia,Interventional,14-Dec-17,Pfizer,Drug: Bococizumab (PF-04950615;RN316)
NCT02135029,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins,Hyperlipidemia,Interventional,14-Dec-17,Pfizer,Drug: Atorvastatin
NCT02135029,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins,Hyperlipidemia,Interventional,14-Dec-17,Pfizer,Other: Placebo for Bococizumab (PF-04950615;RN316)
NCT02135029,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins,Hyperlipidemia,Interventional,14-Dec-17,Pfizer,Other: Placebo for atorvastatin
NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Breast Neoplasms,Interventional,8-Jun-17,Hoffmann-La Roche,Drug: Carboplatin
NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Breast Neoplasms,Interventional,8-Jun-17,Hoffmann-La Roche,Drug: Docetaxel
NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Breast Neoplasms,Interventional,8-Jun-17,Hoffmann-La Roche,Drug: Pertuzumab
NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Breast Neoplasms,Interventional,8-Jun-17,Hoffmann-La Roche,Drug: Trastuzumab
NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Breast Neoplasms,Interventional,8-Jun-17,Hoffmann-La Roche,Drug: Trastuzumab Emtansine
NCT02128932,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,8-Mar-18,Novo Nordisk A/S,Drug: semaglutide
NCT02128932,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,8-Mar-18,Novo Nordisk A/S,Drug: insulin glargine
NCT02127970,Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Interventional,14-Aug-18,"Durata Therapeutics Inc., an affiliate of Allergan plc",Drug: Dalbavancin
NCT02127970,Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Interventional,14-Aug-18,"Durata Therapeutics Inc., an affiliate of Allergan plc",Drug: Dalbavancin-matching Placebo
NCT02126839,A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics,Asthma,Interventional,5-Feb-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Albuterol MDPI
NCT02126839,A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics,Asthma,Interventional,5-Feb-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT02126839,A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics,Asthma,Interventional,5-Feb-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: ProAir HFA inhaler
NCT02126839,A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics,Asthma,Interventional,5-Feb-16,Teva Pharmaceutical Industries,Drug: Albuterol MDPI
NCT02126839,A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics,Asthma,Interventional,5-Feb-16,Teva Pharmaceutical Industries,Drug: Placebo
NCT02126839,A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics,Asthma,Interventional,5-Feb-16,Teva Pharmaceutical Industries,Drug: ProAir HFA inhaler
NCT02122471,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Interventional,14-Mar-19,"Bausch Health Americas, Inc.",Drug: Plecanatide
NCT02122471,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Interventional,14-Mar-19,"Bausch Health Americas, Inc.",Drug: Placebo
NCT02121795,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,HIV-1 Infection,Interventional,30-Nov-16,Gilead Sciences,Drug: FTC/TDF
NCT02121795,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,HIV-1 Infection,Interventional,30-Nov-16,Gilead Sciences,Drug: F/TAF
NCT02121795,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,HIV-1 Infection,Interventional,30-Nov-16,Gilead Sciences,Drug: Allowed third antiretroviral agent
NCT02121795,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,HIV-1 Infection,Interventional,30-Nov-16,Gilead Sciences,Drug: FTC/TDF Placebo
NCT02121795,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,HIV-1 Infection,Interventional,30-Nov-16,Gilead Sciences,Drug: F/TAF Placebo
NCT02117934,"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine",Healthy,Interventional,10-Jan-18,Dynavax Technologies Corporation,Biological: HEPLISAV
NCT02117934,"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine",Healthy,Interventional,10-Jan-18,Dynavax Technologies Corporation,Biological: Engerix-B
NCT02119286,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","Pulmonary Disease, Chronic Obstructive",Interventional,12-Dec-14,GlaxoSmithKline,Drug: FF
NCT02119286,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","Pulmonary Disease, Chronic Obstructive",Interventional,12-Dec-14,GlaxoSmithKline,Drug: VI
NCT02119286,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","Pulmonary Disease, Chronic Obstructive",Interventional,12-Dec-14,GlaxoSmithKline,Drug: UMEC
NCT02119286,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","Pulmonary Disease, Chronic Obstructive",Interventional,12-Dec-14,GlaxoSmithKline,Drug: Placebo
NCT02114931,Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,24-Apr-17,Amgen,Biological: ABP 501
NCT02114177,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis,Hepatitis C Virus Infection,Interventional,12-Apr-16,Janssen Infectious Diseases BVBA,Drug: Simeprevir
NCT02114177,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis,Hepatitis C Virus Infection,Interventional,12-Apr-16,Janssen Infectious Diseases BVBA,Drug: Sofosbuvir
NCT02114151,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis,Hepatitis C Virus Infection,Interventional,4-Apr-16,Janssen Infectious Diseases BVBA,Drug: Simeprevir
NCT02114151,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis,Hepatitis C Virus Infection,Interventional,4-Apr-16,Janssen Infectious Diseases BVBA,Drug: Sofosbuvir
NCT02110901,A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1),Chronic Kidney Disease,Interventional,9-Jul-19,Proteon Therapeutics,Drug: PRT-201
NCT02110901,A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1),Chronic Kidney Disease,Interventional,9-Jul-19,Proteon Therapeutics,Drug: Placebo
NCT02109562,"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients",Schizophrenia,Interventional,26-Oct-18,Indivior Inc.,Drug: RBP-7000
NCT02109562,"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients",Schizophrenia,Interventional,26-Oct-18,Indivior Inc.,Drug: Placebo
NCT02109562,"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients",Schizophrenia,Interventional,26-Oct-18,Indivior Inc.,Drug: Risperidone
NCT02166476,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Urinary Tract Infection Complicated|Acute Pyelonephritis,Interventional,26-Oct-17,"Melinta Therapeutics, Inc.",Drug: Meropenem-Vaborbactam
NCT02166476,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Urinary Tract Infection Complicated|Acute Pyelonephritis,Interventional,26-Oct-17,"Melinta Therapeutics, Inc.",Drug: Piperacillin-Tazobactam
NCT02166476,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Urinary Tract Infection Complicated|Acute Pyelonephritis,Interventional,26-Oct-17,"Melinta Therapeutics, Inc.",Drug: Levofloxacin
NCT02166476,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Urinary Tract Infection Complicated|Acute Pyelonephritis,Interventional,26-Oct-17,"Melinta Therapeutics, Inc.",Drug: Saline
NCT02166476,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Urinary Tract Infection Complicated|Acute Pyelonephritis,Interventional,26-Oct-17,Department of Health and Human Services,Drug: Meropenem-Vaborbactam
NCT02166476,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Urinary Tract Infection Complicated|Acute Pyelonephritis,Interventional,26-Oct-17,Department of Health and Human Services,Drug: Piperacillin-Tazobactam
NCT02166476,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Urinary Tract Infection Complicated|Acute Pyelonephritis,Interventional,26-Oct-17,Department of Health and Human Services,Drug: Levofloxacin
NCT02166476,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Urinary Tract Infection Complicated|Acute Pyelonephritis,Interventional,26-Oct-17,Department of Health and Human Services,Drug: Saline
NCT02107196,12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D),Irritable Bowel Syndrome With Diarrhea,Interventional,27-Sep-16,Menarini Group,Drug: Ibodutant 10 mg
NCT02107196,12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D),Irritable Bowel Syndrome With Diarrhea,Interventional,27-Sep-16,Menarini Group,Drug: Placebo
NCT02107092,Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.,Hyperkalemia,Interventional,15-Aug-18,"ZS Pharma, Inc.",Drug: Sodium Zirconium Cyclosilicate
NCT02105974,Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,13-Apr-16,GlaxoSmithKline,Drug: Fluticasone Furoate/Vilanterol
NCT02105974,Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,13-Apr-16,GlaxoSmithKline,Drug: Vilanterol
NCT02105961,Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,6-Apr-18,GlaxoSmithKline,Drug: Mepolizumab
NCT02105961,Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,6-Apr-18,GlaxoSmithKline,Drug: Placebo
NCT02105948,Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,6-Apr-18,GlaxoSmithKline,Drug: Mepolizumab
NCT02105948,Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,6-Apr-18,GlaxoSmithKline,Drug: Placebo
NCT02104947,Reversal of Dabigatran Anticoagulant Effect With Idarucizumab,Hemorrhage,Interventional,18-Aug-17,Boehringer Ingelheim,Drug: idarucizumab
NCT02102204,Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",Interventional,17-Nov-17,Amgen,Drug: Etelcalcetide
NCT02100514,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Interventional,21-Jul-17,Pfizer,Drug: Bococizumab (PF-04950615; RN316)
NCT02100514,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Interventional,21-Jul-17,Pfizer,Other: Placebo
NCT02098395,The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,3-Jun-16,Novo Nordisk A/S,Drug: liraglutide
NCT02098395,The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,3-Jun-16,Novo Nordisk A/S,Drug: placebo
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: Infanrix hexa
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: Pediarix
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: ActHIB
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: Pentacel
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: Engerix-B
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: Infanrix
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: Hiberix
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: Prevnar13
NCT02096263,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Interventional,1-Aug-18,GlaxoSmithKline,Biological: Rotarix
NCT02091986,"A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg",Asthma,Interventional,10-Apr-17,AstraZeneca,Drug: Symbicort pMDI
NCT02091986,"A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg",Asthma,Interventional,10-Apr-17,AstraZeneca,Other: Budesonide pMDI
NCT02091375,Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1),Epilepsy|Dravet Syndrome,Interventional,20-Jul-18,GW Research Ltd,Drug: GWP42003-P 20 mg/kg/day Dose
NCT02091375,Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1),Epilepsy|Dravet Syndrome,Interventional,20-Jul-18,GW Research Ltd,Drug: Placebo control
NCT02088073,Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.,Hyperkalemia,Interventional,7-Dec-18,"ZS Pharma, Inc.",Drug: Sodium zirconium cyclosilicate
NCT02088073,Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.,Hyperkalemia,Interventional,7-Dec-18,"ZS Pharma, Inc.",Drug: Placebo
NCT02079246,Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,10-Aug-18,H. Lundbeck A/S,Drug: Idalopirdine 60 mg
NCT02075255,Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy,Asthma,Interventional,17-Oct-17,AstraZeneca,Biological: Benralizumab
NCT02075255,Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy,Asthma,Interventional,17-Oct-17,AstraZeneca,Biological: Placebo
NCT02074982,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,Chronic Plaque Type Psoriasis,Interventional,21-Jul-17,Novartis Pharmaceuticals,Drug: AIN457 300 mg
NCT02074982,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,Chronic Plaque Type Psoriasis,Interventional,21-Jul-17,Novartis Pharmaceuticals,Drug: ustekinumab 45/90 mg
NCT02074982,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,Chronic Plaque Type Psoriasis,Interventional,21-Jul-17,Novartis Pharmaceuticals,Drug: placebo secukinumab
NCT02074982,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,Chronic Plaque Type Psoriasis,Interventional,21-Jul-17,Novartis,Drug: AIN457 300 mg
NCT02074982,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,Chronic Plaque Type Psoriasis,Interventional,21-Jul-17,Novartis,Drug: ustekinumab 45/90 mg
NCT02074982,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,Chronic Plaque Type Psoriasis,Interventional,21-Jul-17,Novartis,Drug: placebo secukinumab
NCT02076399,A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura,Interventional,11-Jan-19,Rigel Pharmaceuticals,Drug: Fostamatinib disodium
NCT02076399,A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura,Interventional,11-Jan-19,Rigel Pharmaceuticals,Drug: Placebo
NCT02073656,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection,Hepatitis C Virus|HIV,Interventional,21-Oct-16,Gilead Sciences,Drug: LDV/SOF
NCT02073656,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection,Hepatitis C Virus|HIV,Interventional,21-Oct-16,Gilead Sciences,Drug: RBV
NCT02072434,Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF),Atrial Fibrillation,Interventional,13-Mar-19,"Daiichi Sankyo, Inc.",Drug: Edoxaban
NCT02072434,Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF),Atrial Fibrillation,Interventional,13-Mar-19,"Daiichi Sankyo, Inc.",Drug: Warfarin
NCT02072434,Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF),Atrial Fibrillation,Interventional,13-Mar-19,"Daiichi Sankyo, Inc.",Drug: Enoxaparin
NCT02071082,Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults,HIV|HBV,Interventional,4-Apr-16,Gilead Sciences,Drug: E/C/F/TAF
NCT02059135,"Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia",Preeclampsia,Interventional,9-Aug-17,rEVO Biologics,Biological: Recombinant human antithrombin (ATryn)
NCT02059135,"Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia",Preeclampsia,Interventional,9-Aug-17,rEVO Biologics,Other: Normal Saline 0.9%
NCT02058160,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,10-Feb-17,Sanofi,Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)
NCT02058160,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,10-Feb-17,Sanofi,Drug: Insulin glargine (HOE901)
NCT02058160,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,Type 2 Diabetes,Interventional,10-Feb-17,Sanofi,Drug: Metformin (Background Drug)
NCT02058147,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,Type 2 Diabetes,Interventional,10-Feb-17,Sanofi,Drug: Insulin glargine/lixisenatide Fixed Ratio Combination
NCT02058147,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,Type 2 Diabetes,Interventional,10-Feb-17,Sanofi,Drug: Insulin glargine (HOE901)
NCT02058147,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,Type 2 Diabetes,Interventional,10-Feb-17,Sanofi,Drug: Lixisenatide (AVE0010)
NCT02058147,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,Type 2 Diabetes,Interventional,10-Feb-17,Sanofi,Drug: Metformin
NCT02054897,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,23-Jan-18,Novo Nordisk A/S,Drug: semaglutide
NCT02054897,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,23-Jan-18,Novo Nordisk A/S,Drug: placebo
NCT02052596,"Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older",Herpes Zoster,Interventional,24-Apr-18,GlaxoSmithKline,Biological: Herpes Zoster vaccine GSK 1437173A
NCT02052596,"Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older",Herpes Zoster,Interventional,24-Apr-18,GlaxoSmithKline,Biological: Boostrix
NCT02046369,Lurasidone Pediatric Bipolar Study,Bipolar I Depression,Interventional,20-Dec-17,Sunovion,Drug: Lurasidone
NCT02046369,Lurasidone Pediatric Bipolar Study,Bipolar I Depression,Interventional,20-Dec-17,Sunovion,Drug: Placebo
NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Interventional,6-Jun-18,Astellas Pharma Europe B.V.,Drug: Solifenacin succinate
NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Interventional,6-Jun-18,Astellas Pharma Europe B.V.,Drug: Mirabegron
NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Interventional,6-Jun-18,Astellas Pharma Europe B.V.,Drug: Placebo to match solifenacin
NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Interventional,6-Jun-18,Astellas Pharma Europe B.V.,Drug: Placebo to match mirabegron
NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Interventional,6-Jun-18,Astellas Pharma Inc,Drug: Solifenacin succinate
NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Interventional,6-Jun-18,Astellas Pharma Inc,Drug: Mirabegron
NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Interventional,6-Jun-18,Astellas Pharma Inc,Drug: Placebo to match solifenacin
NCT02045862,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Interventional,6-Jun-18,Astellas Pharma Inc,Drug: Placebo to match mirabegron
NCT02040779,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,Persistent Asthma,Interventional,11-Dec-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate breath-actuated inhaler
NCT02040779,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,Persistent Asthma,Interventional,11-Dec-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo breath-actuated inhaler
NCT02040779,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,Persistent Asthma,Interventional,11-Dec-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: albuterol/salbutamol
NCT02040779,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,Persistent Asthma,Interventional,11-Dec-17,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate breath-actuated inhaler
NCT02040779,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,Persistent Asthma,Interventional,11-Dec-17,Teva Pharmaceutical Industries,Drug: Placebo breath-actuated inhaler
NCT02040779,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,Persistent Asthma,Interventional,11-Dec-17,Teva Pharmaceutical Industries,Drug: albuterol/salbutamol
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate BAI
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo BAI
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: albuterol/salbutamol 90 mcg
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate MDI
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo MDI
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate BAI
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,Teva Pharmaceutical Industries,Drug: Placebo BAI
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,Teva Pharmaceutical Industries,Drug: albuterol/salbutamol 90 mcg
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate MDI
NCT02040766,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Asthma,Interventional,12-Feb-18,Teva Pharmaceutical Industries,Drug: Placebo MDI
NCT02034513,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes","Diabetes|Diabetes Mellitus, Type 1",Interventional,15-May-17,Novo Nordisk A/S,Drug: insulin degludec
NCT02034513,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes","Diabetes|Diabetes Mellitus, Type 1",Interventional,15-May-17,Novo Nordisk A/S,Drug: insulin glargine
NCT02034513,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes","Diabetes|Diabetes Mellitus, Type 1",Interventional,15-May-17,Novo Nordisk A/S,Drug: insulin aspart
NCT02032901,Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV,Hepatitis C,Interventional,14-Sep-15,Bristol-Myers Squibb,Drug: Daclatasvir
NCT02032901,Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV,Hepatitis C,Interventional,14-Sep-15,Bristol-Myers Squibb,Drug: Sofosbuvir
NCT02032888,A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.,Hepatitis C,Interventional,27-Oct-15,Bristol-Myers Squibb,Drug: Daclatasvir
NCT02032888,A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.,Hepatitis C,Interventional,27-Oct-15,Bristol-Myers Squibb,Drug: Sofosbuvir
NCT02031640,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Asthma,Interventional,5-Jan-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate
NCT02031640,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Asthma,Interventional,5-Jan-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT02031640,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Asthma,Interventional,5-Jan-18,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Albuterol/salbutamol
NCT02031640,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Asthma,Interventional,5-Jan-18,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate
NCT02031640,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Asthma,Interventional,5-Jan-18,Teva Pharmaceutical Industries,Drug: Placebo
NCT02031640,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Asthma,Interventional,5-Jan-18,Teva Pharmaceutical Industries,Drug: Albuterol/salbutamol
NCT02030600,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,30-Jan-17,Novo Nordisk A/S,Drug: insulin degludec
NCT02030600,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,30-Jan-17,Novo Nordisk A/S,Drug: insulin glargine
NCT02025621,Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass,Coronary Artery Bypass Grafting|Mitral Valve Surgery|Low Cardiac Output Syndrome,Interventional,22-May-18,"Tenax Therapeutics, Inc.",Drug: Levosimendan
NCT02025621,Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass,Coronary Artery Bypass Grafting|Mitral Valve Surgery|Low Cardiac Output Syndrome,Interventional,22-May-18,"Tenax Therapeutics, Inc.",Drug: Placebo
NCT02085135,A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD),Major Depressive Disorder,Interventional,27-Mar-19,"Alkermes, Inc.",Drug: ALKS 5461
NCT02040428,The Fibrin Pad CV Phase III Study,Cardiovascular Disease,Interventional,15-Aug-17,"Ethicon, Inc.",Biological: EVARREST™ Fibrin Sealant Patch
NCT02040428,The Fibrin Pad CV Phase III Study,Cardiovascular Disease,Interventional,15-Aug-17,"Ethicon, Inc.",Biological: Topical hemostat
NCT02015234,12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients,Primary Fibromyalgia,Interventional,7-Jul-17,"Tonix Pharmaceuticals, Inc.",Drug: TNX-102 SL
NCT02013544,Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause,Vaginal Atrophy,Interventional,1-Jun-17,EndoCeutics Inc.,Drug: Placebo
NCT02013544,Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause,Vaginal Atrophy,Interventional,1-Jun-17,EndoCeutics Inc.,Drug: Prasterone (DHEA)
NCT02009865,Epanova® for Lowering Very High Triglycerides II (EVOLVE II),Hypertriglyceridemia,Interventional,15-Jan-16,AstraZeneca,Drug: Epanova
NCT02009865,Epanova® for Lowering Very High Triglycerides II (EVOLVE II),Hypertriglyceridemia,Interventional,15-Jan-16,AstraZeneca,Drug: Olive Oil
NCT02009163,Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Binge Eating Disorder,Interventional,1-Apr-16,Shire,Drug: Lisdexamfetamine dimesylate
NCT02009163,Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Binge Eating Disorder,Interventional,1-Apr-16,Shire,Other: Placebo
NCT02008227,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,Non-Squamous Non-Small Cell Lung Cancer,Interventional,2-Jul-17,Hoffmann-La Roche,Drug: Atezolizumab
NCT02008227,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,Non-Squamous Non-Small Cell Lung Cancer,Interventional,2-Jul-17,Hoffmann-La Roche,Drug: Docetaxel
NCT02008916,"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients","Spondylitis, Ankylosing",Interventional,12-Dec-18,Novartis Pharmaceuticals,Drug: Secukinumab
NCT02008916,"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients","Spondylitis, Ankylosing",Interventional,12-Dec-18,Novartis Pharmaceuticals,Drug: Placebo secukinumab
NCT02008916,"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients","Spondylitis, Ankylosing",Interventional,12-Dec-18,Novartis,Drug: Secukinumab
NCT02008916,"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients","Spondylitis, Ankylosing",Interventional,12-Dec-18,Novartis,Drug: Placebo secukinumab
NCT02006732,Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2),"Pulmonary Disease, Chronic Obstructive",Interventional,20-Jan-16,Boehringer Ingelheim,Drug: olodaterol
NCT02006732,Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2),"Pulmonary Disease, Chronic Obstructive",Interventional,20-Jan-16,Boehringer Ingelheim,Drug: tiotropium
NCT02006732,Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2),"Pulmonary Disease, Chronic Obstructive",Interventional,20-Jan-16,Boehringer Ingelheim,Drug: placebo
NCT02063659,Telotristat Etiprate for Carcinoid Syndrome Therapy,Carcinoid Syndrome,Interventional,25-Sep-17,Lexicon Pharmaceuticals,Drug: Telotristat etiprate
NCT02063659,Telotristat Etiprate for Carcinoid Syndrome Therapy,Carcinoid Syndrome,Interventional,25-Sep-17,Lexicon Pharmaceuticals,Drug: Placebo
NCT01999777,Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU,Epilepsy,Interventional,27-Nov-18,"Proximagen, LLC",Drug: USL261
NCT01999777,Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU,Epilepsy,Interventional,27-Nov-18,"Proximagen, LLC",Drug: Placebo
NCT01997229,Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study),Refractory Generalized Myasthenia Gravis,Interventional,7-Feb-18,Alexion Pharmaceuticals,Biological: Eculizumab
NCT01997229,Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study),Refractory Generalized Myasthenia Gravis,Interventional,7-Feb-18,Alexion Pharmaceuticals,Drug: Placebo
NCT01994889,Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy,Transthyretin (TTR) Amyloid Cardiomyopathy,Interventional,3-Apr-19,Pfizer,Drug: Tafamidis
NCT01994889,Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy,Transthyretin (TTR) Amyloid Cardiomyopathy,Interventional,3-Apr-19,Pfizer,Drug: Placebo
NCT01994720,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],Acute Ischaemic Stroke|Transient Ischaemic Attack,Interventional,12-Jun-17,AstraZeneca,Drug: ticagrelor
NCT01994720,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],Acute Ischaemic Stroke|Transient Ischaemic Attack,Interventional,12-Jun-17,AstraZeneca,Drug: Acetylsalicylic acid (ASA)
NCT01993940,Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation,Opioid-induced Constipation,Interventional,30-May-17,Shionogi,Drug: Naldemedine
NCT01993940,Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation,Opioid-induced Constipation,Interventional,30-May-17,Shionogi,Drug: Placebo
NCT01993940,Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation,Opioid-induced Constipation,Interventional,30-May-17,Shionogi Inc.,Drug: Naldemedine
NCT01993940,Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation,Opioid-induced Constipation,Interventional,30-May-17,Shionogi Inc.,Drug: Placebo
NCT01992107,Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old,Influenza,Interventional,8-Dec-15,Novartis Vaccines,Biological: QIVc
NCT01992107,Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old,Influenza,Interventional,8-Dec-15,Novartis Vaccines,Biological: TIV1c
NCT01992107,Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old,Influenza,Interventional,8-Dec-15,Novartis Vaccines,Biological: TIV2c
NCT01992107,Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old,Influenza,Interventional,8-Dec-15,Novartis,Biological: QIVc
NCT01992107,Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old,Influenza,Interventional,8-Dec-15,Novartis,Biological: TIV1c
NCT01992107,Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old,Influenza,Interventional,8-Dec-15,Novartis,Biological: TIV2c
NCT01992094,Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older,Influenza,Interventional,10-Dec-15,Novartis Vaccines,Biological: QIVc
NCT01992094,Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older,Influenza,Interventional,10-Dec-15,Novartis Vaccines,Biological: TIV1c
NCT01992094,Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older,Influenza,Interventional,10-Dec-15,Novartis Vaccines,Biological: TIV2c
NCT01992094,Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older,Influenza,Interventional,10-Dec-15,Novartis,Biological: QIVc
NCT01992094,Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older,Influenza,Interventional,10-Dec-15,Novartis,Biological: TIV1c
NCT01992094,Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older,Influenza,Interventional,10-Dec-15,Novartis,Biological: TIV2c
NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,Clostridium Difficile Infection,Interventional,4-May-18,Actelion,Drug: Cadazolid
NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,Clostridium Difficile Infection,Interventional,4-May-18,Actelion,Drug: Vancomycin
NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,Clostridium Difficile Infection,Interventional,4-May-18,Actelion,Drug: Cadazolid-matching placebo
NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,Clostridium Difficile Infection,Interventional,4-May-18,Actelion,Drug: Vancomycin-matching placebo
NCT01989468,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,16-Apr-19,Novartis Pharmaceuticals,Biological: Secukinumab
NCT01989468,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,16-Apr-19,Novartis Pharmaceuticals,Biological: Placebo
NCT01989468,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,16-Apr-19,Novartis,Biological: Secukinumab
NCT01989468,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,16-Apr-19,Novartis,Biological: Placebo
NCT01984684,Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections|Skin Structures and Soft Tissue Infections,Interventional,28-Aug-17,"Melinta Therapeutics, Inc.",Drug: delafloxacin
NCT01984684,Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections|Skin Structures and Soft Tissue Infections,Interventional,28-Aug-17,"Melinta Therapeutics, Inc.",Drug: vancomycin
NCT01984684,Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections|Skin Structures and Soft Tissue Infections,Interventional,28-Aug-17,"Melinta Therapeutics, Inc.",Drug: aztreonam
NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,Hyperlipidemia,Interventional,13-Mar-18,Amgen,Drug: Atorvastatin
NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,Hyperlipidemia,Interventional,13-Mar-18,Amgen,Drug: Placebo to Atorvastatin
NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,Hyperlipidemia,Interventional,13-Mar-18,Amgen,Other: Placebo to Ezetimibe
NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,Hyperlipidemia,Interventional,13-Mar-18,Amgen,Drug: Ezetimibe
NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,Hyperlipidemia,Interventional,13-Mar-18,Amgen,Other: Placebo to Evolocumab
NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,Hyperlipidemia,Interventional,13-Mar-18,Amgen,Drug: Evolocumab
NCT01983683,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,Clostridium Difficile Infection,Interventional,13-Apr-18,Actelion,Drug: Cadazolid
NCT01983683,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,Clostridium Difficile Infection,Interventional,13-Apr-18,Actelion,Drug: Vancomycin
NCT01983683,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,Clostridium Difficile Infection,Interventional,13-Apr-18,Actelion,Drug: Cadazolid-matching placebo
NCT01983683,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,Clostridium Difficile Infection,Interventional,13-Apr-18,Actelion,Drug: Vancomycin-matching placebo
NCT01982240,12-Week Study of Plecanatide for CIC (The CIC3 Study),Chronic Idiopathic Constipation,Interventional,21-Mar-19,Synergy Pharmaceuticals Inc.,Drug: Plecanatide
NCT01982240,12-Week Study of Plecanatide for CIC (The CIC3 Study),Chronic Idiopathic Constipation,Interventional,21-Mar-19,Synergy Pharmaceuticals Inc.,Drug: Placebo
NCT01982240,12-Week Study of Plecanatide for CIC (The CIC3 Study),Chronic Idiopathic Constipation,Interventional,21-Mar-19,Synergy Pharmaceuticals Inc.,Drug: Bisacodyl
NCT01993888,The EVARREST® Fibrin Sealant Patch Liver Study,Hemorrhage,Interventional,11-Jul-16,"Ethicon, Inc.",Biological: EVARREST® Fibrin Sealant Patch
NCT01993888,The EVARREST® Fibrin Sealant Patch Liver Study,Hemorrhage,Interventional,11-Jul-16,"Ethicon, Inc.",Other: Standard of Care (SoC)
NCT01978093,"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",Neisseria Meningitidis|Haemophilus Influenzae Type b,Interventional,25-Jun-18,GlaxoSmithKline,Biological: Hib-MenCY-TT (MenHibrix®)
NCT01978093,"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",Neisseria Meningitidis|Haemophilus Influenzae Type b,Interventional,25-Jun-18,GlaxoSmithKline,Biological: Pediarix®
NCT01978093,"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",Neisseria Meningitidis|Haemophilus Influenzae Type b,Interventional,25-Jun-18,GlaxoSmithKline,Biological: Rotarix®
NCT01978093,"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",Neisseria Meningitidis|Haemophilus Influenzae Type b,Interventional,25-Jun-18,GlaxoSmithKline,Biological: Prevnar 13®
NCT01978093,"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",Neisseria Meningitidis|Haemophilus Influenzae Type b,Interventional,25-Jun-18,GlaxoSmithKline,Biological: PedvaxHIB®
NCT01978093,"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",Neisseria Meningitidis|Haemophilus Influenzae Type b,Interventional,25-Jun-18,GlaxoSmithKline,Biological: Havrix®
NCT01980095,ERADICATE Hp - Treating Helicobacter Pylori With RHB-105,Dyspepsia|Helicobacter Pylori Infection,Interventional,10-Jan-17,RedHill Biopharma Limited,Drug: RHB-105
NCT01980095,ERADICATE Hp - Treating Helicobacter Pylori With RHB-105,Dyspepsia|Helicobacter Pylori Infection,Interventional,10-Jan-17,RedHill Biopharma Limited,Drug: Placebo
NCT01976104,Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure,Thrombocytopenia Associated With Liver Disease,Interventional,27-Feb-18,Eisai Inc.,Drug: avatrombopag (lower baseline platelet count)
NCT01976104,Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure,Thrombocytopenia Associated With Liver Disease,Interventional,27-Feb-18,Eisai Inc.,Drug: placebo (lower baseline platelet count)
NCT01976104,Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure,Thrombocytopenia Associated With Liver Disease,Interventional,27-Feb-18,Eisai Inc.,Drug: avatrombopag (higher baseline platelet count)
NCT01976104,Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure,Thrombocytopenia Associated With Liver Disease,Interventional,27-Feb-18,Eisai Inc.,Drug: placebo (higher baseline platelet count)
NCT01979952,Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Interventional,17-Apr-18,Boehringer Ingelheim,Drug: Matching Placebo
NCT01979952,Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Interventional,17-Apr-18,Boehringer Ingelheim,Drug: Nintedanib
NCT01973205,Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine,Acute Migraine,Interventional,11-Jun-15,Novartis,Drug: Acetaminophen 250 mg and Aspirin 250 mg
NCT01973205,Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine,Acute Migraine,Interventional,11-Jun-15,Novartis,Drug: Placebo
NCT01972841,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Interventional,12-Jun-18,Astellas Pharma Europe B.V.,Drug: Solifenacin succinate
NCT01972841,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Interventional,12-Jun-18,Astellas Pharma Europe B.V.,Drug: Mirabegron
NCT01972841,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Interventional,12-Jun-18,Astellas Pharma Europe B.V.,Drug: Placebo to match solifenacin succinate
NCT01972841,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Interventional,12-Jun-18,Astellas Pharma Europe B.V.,Drug: Placebo to match mirabegron
NCT01972841,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Interventional,12-Jun-18,Astellas Pharma Inc,Drug: Solifenacin succinate
NCT01972841,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Interventional,12-Jun-18,Astellas Pharma Inc,Drug: Mirabegron
NCT01972841,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Interventional,12-Jun-18,Astellas Pharma Inc,Drug: Placebo to match solifenacin succinate
NCT01972841,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Interventional,12-Jun-18,Astellas Pharma Inc,Drug: Placebo to match mirabegron
NCT01972529,Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure,Thrombocytopenia Associated With Liver Disease,Interventional,27-Feb-18,Eisai Inc.,Drug: avatrombopag (lower baseline platelet count)
NCT01972529,Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure,Thrombocytopenia Associated With Liver Disease,Interventional,27-Feb-18,Eisai Inc.,Drug: placebo (lower baseline platelet count)
NCT01972529,Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure,Thrombocytopenia Associated With Liver Disease,Interventional,27-Feb-18,Eisai Inc.,Drug: avatrombopag (higher baseline platelet count)
NCT01972529,Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure,Thrombocytopenia Associated With Liver Disease,Interventional,27-Feb-18,Eisai Inc.,Drug: placebo (higher baseline platelet count)
NCT01970878,"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,6-Feb-17,"Pearl Therapeutics, Inc.",Drug: GFF MDI (PT 003)
NCT01970878,"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,6-Feb-17,"Pearl Therapeutics, Inc.",Drug: GP MDI (PT001)
NCT01970878,"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,6-Feb-17,"Pearl Therapeutics, Inc.",Drug: FF MDI (PT005)
NCT01970878,"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,6-Feb-17,"Pearl Therapeutics, Inc.",Drug: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
NCT01968980,A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia,Heterozygous Familial Hypercholesterolemia,Interventional,19-May-17,Pfizer,Drug: Bococizumab (PF-04950615;RN316)
NCT01968980,A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia,Heterozygous Familial Hypercholesterolemia,Interventional,19-May-17,Pfizer,Other: Placebo
NCT01968967,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Interventional,24-Jul-17,Pfizer,Drug: Bococizumab (PF-04950615; RN316)
NCT01968967,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Interventional,24-Jul-17,Pfizer,Other: Placebo
NCT01968954,Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Interventional,17-May-17,Pfizer,Drug: Bococizumab (PF-04950615;RN316)
NCT01968954,Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Interventional,17-May-17,Pfizer,Other: Placebo
NCT01968551,Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults,HIV-1|HIV Infections|Acquired Immunodeficiency Syndrome,Interventional,1-Nov-16,Gilead Sciences,Drug: E/C/F/TAF
NCT01968551,Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults,HIV-1|HIV Infections|Acquired Immunodeficiency Syndrome,Interventional,1-Nov-16,Gilead Sciences,Drug: DRV
NCT01968551,Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults,HIV-1|HIV Infections|Acquired Immunodeficiency Syndrome,Interventional,1-Nov-16,Gilead Sciences,Drug: Baseline DRV- containing ARV regimen
NCT01967069,A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis,Psoriasis,Interventional,13-Mar-17,"Promius Pharma, LLC",Drug: DFD01 Spray
NCT01967069,A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis,Psoriasis,Interventional,13-Mar-17,"Promius Pharma, LLC",Drug: Vehicle Spray
NCT01965652,Long Term Safety of Naldemedine,Opioid-induced Constipation,Interventional,30-May-17,Shionogi,Drug: Naldemedine
NCT01965652,Long Term Safety of Naldemedine,Opioid-induced Constipation,Interventional,30-May-17,Shionogi,Drug: Placebo
NCT01965652,Long Term Safety of Naldemedine,Opioid-induced Constipation,Interventional,30-May-17,Shionogi Inc.,Drug: Naldemedine
NCT01965652,Long Term Safety of Naldemedine,Opioid-induced Constipation,Interventional,30-May-17,Shionogi Inc.,Drug: Placebo
NCT01965158,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,Opioid-induced Constipation,Interventional,30-May-17,Shionogi,Drug: Naldemedine
NCT01965158,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,Opioid-induced Constipation,Interventional,30-May-17,Shionogi,Drug: Placebo
NCT01965158,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,Opioid-induced Constipation,Interventional,30-May-17,Shionogi Inc.,Drug: Naldemedine
NCT01965158,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,Opioid-induced Constipation,Interventional,30-May-17,Shionogi Inc.,Drug: Placebo
NCT01964352,Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1),"Pulmonary Disease, Chronic Obstructive",Interventional,25-Nov-15,Boehringer Ingelheim,Drug: tiotropium
NCT01964352,Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1),"Pulmonary Disease, Chronic Obstructive",Interventional,25-Nov-15,Boehringer Ingelheim,Drug: placebo
NCT01964352,Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1),"Pulmonary Disease, Chronic Obstructive",Interventional,25-Nov-15,Boehringer Ingelheim,Drug: olodaterol
NCT01964326,Actual Use Trial of Atorvastatin Calcium 10 mg,Hypercholesterolemia,Interventional,27-Jan-16,Pfizer,Drug: Atorvastatin calcium 10 mg
NCT02020889,A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis,Churg-Strauss Syndrome,Interventional,26-Jan-18,GlaxoSmithKline,Biological: Mepolizumab
NCT02020889,A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis,Churg-Strauss Syndrome,Interventional,26-Jan-18,GlaxoSmithKline,Drug: Placebo
NCT02020889,A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis,Churg-Strauss Syndrome,Interventional,26-Jan-18,National Institute of Allergy and Infectious Diseases (NIAID),Biological: Mepolizumab
NCT02020889,A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis,Churg-Strauss Syndrome,Interventional,26-Jan-18,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Placebo
NCT01962441,SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection,Hepatitis C,Interventional,5-Feb-16,Gilead Sciences,Drug: SOF
NCT01962441,SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection,Hepatitis C,Interventional,5-Feb-16,Gilead Sciences,Drug: RBV
NCT01962441,SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection,Hepatitis C,Interventional,5-Feb-16,Gilead Sciences,Drug: Peg-IFN
NCT01959529,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Nov-17,Novo Nordisk A/S,Drug: insulin degludec
NCT01959529,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Nov-17,Novo Nordisk A/S,Drug: insulin glargine
NCT01960348,"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis","TTR-mediated Amyloidosis|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Familial Amyloid Polyneuropathies|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related",Interventional,6-Sep-18,Alnylam Pharmaceuticals,Drug: patisiran (ALN-TTR02)
NCT01960348,"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis","TTR-mediated Amyloidosis|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Familial Amyloid Polyneuropathies|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related",Interventional,6-Sep-18,Alnylam Pharmaceuticals,Drug: Sterile Normal Saline (0.9% NaCl)
NCT02106494,"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",Chemotherapy-induced Nausea and Vomiting,Interventional,28-Dec-16,Heron Therapeutics,Drug: APF530
NCT02106494,"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",Chemotherapy-induced Nausea and Vomiting,Interventional,28-Dec-16,Heron Therapeutics,Drug: Ondansetron
NCT02106494,"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",Chemotherapy-induced Nausea and Vomiting,Interventional,28-Dec-16,Heron Therapeutics,Drug: Ondansetron placebo
NCT02106494,"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",Chemotherapy-induced Nausea and Vomiting,Interventional,28-Dec-16,Heron Therapeutics,Drug: APF530 placebo
NCT02106494,"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",Chemotherapy-induced Nausea and Vomiting,Interventional,28-Dec-16,Heron Therapeutics,Drug: Fosaprepitant
NCT02106494,"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",Chemotherapy-induced Nausea and Vomiting,Interventional,28-Dec-16,Heron Therapeutics,Drug: Dexamethasone
NCT01957163,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,25-Nov-14,GlaxoSmithKline,Drug: FF
NCT01957163,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,25-Nov-14,GlaxoSmithKline,Drug: VI
NCT01957163,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,25-Nov-14,GlaxoSmithKline,Drug: UMEC
NCT01957163,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,25-Nov-14,GlaxoSmithKline,Drug: Placebo
NCT01952145,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Jan-17,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT01952145,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Jan-17,Novo Nordisk A/S,Drug: insulin glargine
NCT01952080,"A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome",Short Bowel Syndrome,Interventional,14-Sep-15,Shire,Drug: teduglutide
NCT02100475,"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Jan-17,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT02100475,"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Jan-17,Novo Nordisk A/S,Drug: insulin aspart
NCT01947491,"A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis",Psoriasis,Interventional,6-Oct-16,"Promius Pharma, LLC",Drug: DFD01 Spray
NCT01947491,"A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis",Psoriasis,Interventional,6-Oct-16,"Promius Pharma, LLC",Drug: Comp01 Lotion
NCT01947491,"A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis",Psoriasis,Interventional,6-Oct-16,"Promius Pharma, LLC",Drug: Vehicle Lotion
NCT01947491,"A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis",Psoriasis,Interventional,6-Oct-16,"Promius Pharma, LLC",Drug: Vehicle Spray
NCT01945034,5% Topical Ibuprofen (IBU) for Ankle Sprain,Ankle Injuries,Interventional,26-May-16,Pfizer,Drug: Topical IBU twice daily
NCT01945034,5% Topical Ibuprofen (IBU) for Ankle Sprain,Ankle Injuries,Interventional,26-May-16,Pfizer,Drug: Placebo twice daily
NCT01945034,5% Topical Ibuprofen (IBU) for Ankle Sprain,Ankle Injuries,Interventional,26-May-16,Pfizer,Drug: Topical IBU three times daily
NCT01945034,5% Topical Ibuprofen (IBU) for Ankle Sprain,Ankle Injuries,Interventional,26-May-16,Pfizer,Drug: Placebo three times daily
NCT01946412,Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation,Cystic Fibrosis,Interventional,1-Feb-17,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01946412,Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation,Cystic Fibrosis,Interventional,1-Feb-17,Cystic Fibrosis Foundation,Drug: Ivacaftor
NCT01942668,A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms,Menopause,Interventional,6-May-19,TherapeuticsMD,Drug: Estradiol
NCT01942668,A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms,Menopause,Interventional,6-May-19,TherapeuticsMD,Drug: Progesterone
NCT01942668,A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms,Menopause,Interventional,6-May-19,TherapeuticsMD,Drug: Placebo
NCT01942785,Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy,Major Depressive Disorder|Irritability,Interventional,15-Mar-16,H. Lundbeck A/S,Drug: Brexpiprazole
NCT01939002,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),Relapsing Multiple Sclerosis,Interventional,25-Jan-17,Biogen,Drug: BIIB017
NCT01939002,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),Relapsing Multiple Sclerosis,Interventional,25-Jan-17,Biogen,Drug: naproxen
NCT02302807,A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211],Bladder Cancer,Interventional,11-Apr-18,Hoffmann-La Roche,"Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody"
NCT02302807,A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211],Bladder Cancer,Interventional,11-Apr-18,Hoffmann-La Roche,Drug: Docetaxel
NCT02302807,A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211],Bladder Cancer,Interventional,11-Apr-18,Hoffmann-La Roche,Drug: Paclitaxel
NCT02302807,A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211],Bladder Cancer,Interventional,11-Apr-18,Hoffmann-La Roche,Drug: Vinflunine
NCT01932970,Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide,"Hyperparathyroidism, Secondary",Interventional,4-Apr-17,Amgen,Drug: Etelcalcetide
NCT01931839,A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis,"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",Interventional,12-May-17,Vertex Pharmaceuticals Incorporated,Drug: Lumacaftor Plus Ivacaftor Combination
NCT01931839,A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis,"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",Interventional,12-May-17,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01928771,Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma,Asthma,Interventional,3-May-17,AstraZeneca,Biological: Benralizumab
NCT01928771,Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma,Asthma,Interventional,3-May-17,AstraZeneca,Biological: Placebo
NCT01925768,Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis,Psoriatic Arthritis,Interventional,13-Jun-16,Celgene,Drug: Apremilast 30 mg
NCT01925768,Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis,Psoriatic Arthritis,Interventional,13-Jun-16,Celgene,Drug: Placebo
NCT01922739,"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets",Low Back Pain,Interventional,2-Jun-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Hydrocodone ER
NCT01922739,"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets",Low Back Pain,Interventional,2-Jun-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT01922739,"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets",Low Back Pain,Interventional,2-Jun-17,Teva Pharmaceutical Industries,Drug: Hydrocodone ER
NCT01922739,"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets",Low Back Pain,Interventional,2-Jun-17,Teva Pharmaceutical Industries,Drug: Placebo
NCT01921205,Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures,Epilepsy,Interventional,19-Mar-18,UCB Pharma,Drug: Lacosamide
NCT01921205,Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures,Epilepsy,Interventional,19-Mar-18,UCB Pharma,Other: Placebo
NCT01919697,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Interventional,2-Jul-19,"Bausch Health Americas, Inc.",Drug: Plecanatide
NCT01919697,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Interventional,2-Jul-19,Syneos Health,Drug: Plecanatide
NCT01915823,Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,29-Jun-15,Meda Pharmaceuticals,Drug: azelastine hydrochloride and fluticasone propionate
NCT01915823,Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,29-Jun-15,Meda Pharmaceuticals,Drug: Dymista vehicle
NCT01914757,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,Asthma,Interventional,25-Jan-17,AstraZeneca,Biological: Benralizumab
NCT01914757,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,Asthma,Interventional,25-Jan-17,AstraZeneca,Biological: Placebo
NCT01911442,Lurasidone Pediatric Autism Study,Autism,Interventional,25-Feb-16,Sunovion,Drug: Lurasidone 20 mg daily
NCT01911442,Lurasidone Pediatric Autism Study,Autism,Interventional,25-Feb-16,Sunovion,Drug: Lurasidone
NCT01911442,Lurasidone Pediatric Autism Study,Autism,Interventional,25-Feb-16,Sunovion,Drug: Placebo
NCT01911429,Pediatric Schizophrenia Efficacy and Safety Study,Schizophrenia,Interventional,22-Mar-17,Sunovion,Drug: Lurasidone 40 mg
NCT01911429,Pediatric Schizophrenia Efficacy and Safety Study,Schizophrenia,Interventional,22-Mar-17,Sunovion,Drug: Lurasidone 80 mg
NCT01911429,Pediatric Schizophrenia Efficacy and Safety Study,Schizophrenia,Interventional,22-Mar-17,Sunovion,Drug: Placebo 40 or 80 mg
NCT01908842,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,"Opioid Dependence, on Agonist Therapy",Interventional,22-May-15,Orexo AB,Drug: BNX sublingual tablets
NCT01908842,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,"Opioid Dependence, on Agonist Therapy",Interventional,22-May-15,Orexo AB,Drug: BNX sublingual film
NCT01908842,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,"Opioid Dependence, on Agonist Therapy",Interventional,22-May-15,Orexo AB,Drug: Buprenorphine
NCT01908842,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,"Opioid Dependence, on Agonist Therapy",Interventional,22-May-15,Worldwide Clinical Trials,Drug: BNX sublingual tablets
NCT01908842,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,"Opioid Dependence, on Agonist Therapy",Interventional,22-May-15,Worldwide Clinical Trials,Drug: BNX sublingual film
NCT01908842,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,"Opioid Dependence, on Agonist Therapy",Interventional,22-May-15,Worldwide Clinical Trials,Drug: Buprenorphine
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Europe Ltd.,Drug: mirabegron 25 mg
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Europe Ltd.,Drug: mirabegron 50 mg
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Europe Ltd.,Drug: solifenacin 5 mg
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Europe Ltd.,Drug: solifenacin 10 mg
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Europe Ltd.,Drug: mirabegron 25 mg matching placebo
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Europe Ltd.,Drug: mirabegron 50 mg matching placebo
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Europe Ltd.,Drug: solifenacin 5 mg matching placebo
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Europe Ltd.,Drug: solifenacin 10 mg matching placebo
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Inc,Drug: mirabegron 25 mg
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Inc,Drug: mirabegron 50 mg
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Inc,Drug: solifenacin 5 mg
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Inc,Drug: solifenacin 10 mg
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Inc,Drug: mirabegron 25 mg matching placebo
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Inc,Drug: mirabegron 50 mg matching placebo
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Inc,Drug: solifenacin 5 mg matching placebo
NCT01908829,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Interventional,9-Oct-17,Astellas Pharma Inc,Drug: solifenacin 10 mg matching placebo
NCT01906866,Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities,Sleep Disorders,Interventional,30-Oct-18,Neurim Pharmaceuticals Ltd.,Drug: Circadin 2/5/10 mg
NCT01906866,Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities,Sleep Disorders,Interventional,30-Oct-18,Neurim Pharmaceuticals Ltd.,Drug: Placebo
NCT01901185,Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept,Rheumatoid Arthritis|Psoriatic Arthritis,Interventional,21-Nov-14,Amgen,Drug: Etanercept / Autoinjector A
NCT01897896,Alternatives for Reducing Chorea in Huntington Disease,Chorea Associated With Huntington Disease,Interventional,16-Apr-19,"Auspex Pharmaceuticals, Inc.",Drug: SD-809
NCT01897896,Alternatives for Reducing Chorea in Huntington Disease,Chorea Associated With Huntington Disease,Interventional,16-Apr-19,Teva Pharmaceutical Industries,Drug: SD-809
NCT01897233,"Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,5-Dec-16,Vertex Pharmaceuticals Incorporated,Drug: Lumacaftor
NCT01897233,"Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Interventional,5-Dec-16,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01896232,Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Secondary Hyperparathyroidism|Chronic Kidney Disease,Interventional,27-Mar-17,Amgen,Drug: Etelcalcetide
NCT01896232,Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Secondary Hyperparathyroidism|Chronic Kidney Disease,Interventional,27-Mar-17,Amgen,Drug: Cinacalcet
NCT01896232,Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Secondary Hyperparathyroidism|Chronic Kidney Disease,Interventional,27-Mar-17,Amgen,Drug: Oral Placebo
NCT01896232,Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Secondary Hyperparathyroidism|Chronic Kidney Disease,Interventional,27-Mar-17,Amgen,Drug: Intravenous Placebo
NCT01895543,Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Interventional,9-May-16,Ferring Pharmaceuticals,Drug: Elobixibat 10 mg
NCT01895452,An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070),Schizophrenia,Interventional,25-Aug-17,"Alkermes, Inc.","Drug: ALKS 9072, Low Dose"
NCT01895452,An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070),Schizophrenia,Interventional,25-Aug-17,"Alkermes, Inc.","Drug: ALKS 9072, High Dose"
NCT01892436,Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis,Psoriatic Arthritis,Interventional,12-Jun-19,Novartis Pharmaceuticals,Drug: Secukinumab
NCT01892436,Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis,Psoriatic Arthritis,Interventional,12-Jun-19,Novartis Pharmaceuticals,Drug: Placebo
NCT01892436,Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis,Psoriatic Arthritis,Interventional,12-Jun-19,Novartis,Drug: Secukinumab
NCT01892436,Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis,Psoriatic Arthritis,Interventional,12-Jun-19,Novartis,Drug: Placebo
NCT01889862,Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU,Phenylketonuria (PKU),Interventional,12-Jul-19,BioMarin Pharmaceutical,Drug: BMN165 20mg/day
NCT01889862,Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU,Phenylketonuria (PKU),Interventional,12-Jul-19,BioMarin Pharmaceutical,Drug: BMN165 40mg/day
NCT01889862,Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU,Phenylketonuria (PKU),Interventional,12-Jul-19,BioMarin Pharmaceutical,Drug: Placebo
NCT01890434,Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),Coronary Artery Disease,Interventional,16-May-18,Bayer,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)"
NCT01887678,Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee,"Osteoarthritis, Knee",Interventional,20-Mar-15,Biologische Heilmittel Heel GmbH,Drug: Traumeel® / Zeel® Injectable Solution
NCT01887678,Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee,"Osteoarthritis, Knee",Interventional,20-Mar-15,Biologische Heilmittel Heel GmbH,Drug: Placebo
NCT01885208,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,30-Mar-18,Novo Nordisk A/S,Drug: semaglutide
NCT01885208,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,30-Mar-18,Novo Nordisk A/S,Drug: exenatide
NCT01882439,Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors,Psoriatic Arthritis,Interventional,15-Sep-17,Pfizer,Drug: Tofacitinib
NCT01882439,Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors,Psoriatic Arthritis,Interventional,15-Sep-17,Pfizer,Other: Placebo
NCT01880320,"Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris",Acne Vulgaris,Interventional,9-Sep-16,Galderma R&D,Drug: CD0271 0.3% / CD1579 2.5%
NCT01880320,"Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris",Acne Vulgaris,Interventional,9-Sep-16,Galderma R&D,Drug: CD0271 0.1% / CD1579 2.5%
NCT01880320,"Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris",Acne Vulgaris,Interventional,9-Sep-16,Galderma R&D,Drug: Topical Gel Vehicle
NCT01879319,Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen,Primary Hypercholesterolemia|Mixed Dyslipidemia,Interventional,23-Dec-15,Amgen,Biological: Evolocumab AMD
NCT01879319,Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen,Primary Hypercholesterolemia|Mixed Dyslipidemia,Interventional,23-Dec-15,Amgen,Biological: Evolocumab AI/pen
NCT01882647,A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305),Plaque Psoriasis,Interventional,13-Feb-17,"Therapeutics, Inc.",Drug: 000-0551 Lotion
NCT01882647,A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305),Plaque Psoriasis,Interventional,13-Feb-17,"Therapeutics, Inc.",Drug: Vehicle Lotion
NCT01879410,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-14,GlaxoSmithKline,Drug: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI
NCT01879410,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-14,GlaxoSmithKline,Drug: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
NCT01879410,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-14,GlaxoSmithKline,Drug: Placebo DISKUS
NCT01879410,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-14,GlaxoSmithKline,Drug: Placebo NDPI
NCT01877668,Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study,Psoriatic Arthritis,Interventional,6-Jul-17,Pfizer,Drug: Tofacitinib 5 mg BID
NCT01877668,Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study,Psoriatic Arthritis,Interventional,6-Jul-17,Pfizer,Drug: Tofacitinib 10 mg BID
NCT01877668,Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study,Psoriatic Arthritis,Interventional,6-Jul-17,Pfizer,Drug: Adalimumab
NCT01877668,Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study,Psoriatic Arthritis,Interventional,6-Jul-17,Pfizer,Drug: Placebo
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Hypertension,Interventional,7-Dec-15,Novartis Pharmaceuticals,Drug: LCZ696
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Hypertension,Interventional,7-Dec-15,Novartis Pharmaceuticals,Drug: Olmesartan
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Hypertension,Interventional,7-Dec-15,Novartis Pharmaceuticals,Drug: Placebo of LCZ696
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Hypertension,Interventional,7-Dec-15,Novartis Pharmaceuticals,Drug: Placebo of Olmesartan
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Hypertension,Interventional,7-Dec-15,Novartis,Drug: LCZ696
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Hypertension,Interventional,7-Dec-15,Novartis,Drug: Olmesartan
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Hypertension,Interventional,7-Dec-15,Novartis,Drug: Placebo of LCZ696
NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Hypertension,Interventional,7-Dec-15,Novartis,Drug: Placebo of Olmesartan
NCT01874145,Safety and Tolerability of Glatiramer Acetate,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Jan-16,Teva Pharmaceutical Industries,Drug: GA 20 mg/mL
NCT01874145,Safety and Tolerability of Glatiramer Acetate,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Jan-16,Teva Pharmaceutical Industries,Drug: GA 40 mg/mL
NCT01870778,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Interventional,30-Mar-18,Novartis Pharmaceuticals,Drug: RLX030
NCT01870778,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Interventional,30-Mar-18,Novartis Pharmaceuticals,Drug: Placebo
NCT01870778,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Interventional,30-Mar-18,Novartis,Drug: RLX030
NCT01870778,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Interventional,30-Mar-18,Novartis,Drug: Placebo
NCT01868009,DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,4-Mar-14,GlaxoSmithKline,Device: ELLIPTA
NCT01868009,DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,4-Mar-14,GlaxoSmithKline,Device: DISKUS
NCT01888432,Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants,Liver Transplantation,Interventional,12-Nov-18,Novartis Pharmaceuticals,Drug: Everolimus + reduced tacrolimus
NCT01888432,Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants,Liver Transplantation,Interventional,12-Nov-18,Novartis Pharmaceuticals,Drug: Standard tacrolimus
NCT01888432,Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants,Liver Transplantation,Interventional,12-Nov-18,Novartis,Drug: Everolimus + reduced tacrolimus
NCT01888432,Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants,Liver Transplantation,Interventional,12-Nov-18,Novartis,Drug: Standard tacrolimus
NCT01871402,A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304),Plaque Psoriasis,Interventional,11-Apr-16,"Therapeutics, Inc.",Drug: 000-0551 Lotion
NCT01871402,A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304),Plaque Psoriasis,Interventional,11-Apr-16,"Therapeutics, Inc.",Drug: Vehicle Lotion
NCT01913405,Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures,Hemophilia A,Interventional,14-May-18,Baxalta now part of Shire,Biological: PEGylated Recombinant factor VIII (rFVIII)
NCT01913405,Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures,Hemophilia A,Interventional,14-May-18,Shire,Biological: PEGylated Recombinant factor VIII (rFVIII)
NCT01857323,Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI),Asthma|Chronic Obstructive Pulmonary Disease (COPD),Interventional,8-Jun-15,Teva Pharmaceutical Industries,Drug: Albuterol Spiromax®
NCT01857206,Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age,Influenza|Fever,Interventional,3-Nov-14,Novartis Vaccines,Biological: Mammalian cell based flu vaccine
NCT01857206,Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age,Influenza|Fever,Interventional,3-Nov-14,Novartis Vaccines,Biological: Egg based flu vaccine
NCT01857206,Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age,Influenza|Fever,Interventional,3-Nov-14,Novartis,Biological: Mammalian cell based flu vaccine
NCT01857206,Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age,Influenza|Fever,Interventional,3-Nov-14,Novartis,Biological: Egg based flu vaccine
NCT01855789,A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX,Rheumatoid Arthritis,Interventional,26-Dec-17,Hoffmann-La Roche,Drug: Tocilizumab (TCZ)
NCT01855789,A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX,Rheumatoid Arthritis,Interventional,26-Dec-17,Hoffmann-La Roche,Drug: Methotrexate (MTX)
NCT01855789,A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX,Rheumatoid Arthritis,Interventional,26-Dec-17,Hoffmann-La Roche,Drug: Placebo (PBO)
NCT01854918,Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia,Hyperlipidemia and Mixed Dyslipidemia,Interventional,11-Jun-19,Amgen,Biological: Evolocumab
NCT01854918,Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia,Hyperlipidemia and Mixed Dyslipidemia,Interventional,11-Jun-19,Amgen,Drug: Standard of Care
NCT01854658,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: GFF MDI (PT003)
NCT01854658,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: GP MDI (PT001)
NCT01854658,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: FF MDI (PT005)
NCT01854658,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: Placebo
NCT01854645,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",Chronic Obstructive Pulmonary Disease,Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: GFF MDI
NCT01854645,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",Chronic Obstructive Pulmonary Disease,Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: GP MDI
NCT01854645,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",Chronic Obstructive Pulmonary Disease,Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: FF MDI
NCT01854645,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",Chronic Obstructive Pulmonary Disease,Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
NCT01854645,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",Chronic Obstructive Pulmonary Disease,Interventional,28-Mar-17,"Pearl Therapeutics, Inc.",Drug: Placebo MDI
NCT01853254,A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials,"Hepatitis C, Chronic",Interventional,4-Sep-13,Hoffmann-La Roche,Drug: Peginterferon alfa-2a
NCT01853254,A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials,"Hepatitis C, Chronic",Interventional,4-Sep-13,Hoffmann-La Roche,Drug: Ribavirin
NCT01851330,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3),Chronic Hepatitis C Virus,Interventional,30-Dec-14,Gilead Sciences,Drug: LDV/SOF
NCT01851330,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3),Chronic Hepatitis C Virus,Interventional,30-Dec-14,Gilead Sciences,Drug: RBV
NCT01850615,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Jan-18,Novo Nordisk A/S,Drug: Faster-acting insulin aspart
NCT01850615,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Jan-18,Novo Nordisk A/S,Drug: basal insulin
NCT01849497,Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen,Primary Hypercholesterolemia|Mixed Dyslipidemia,Interventional,9-Oct-15,Amgen,Biological: Evolocumab Pre-filled Syringe
NCT01849497,Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen,Primary Hypercholesterolemia|Mixed Dyslipidemia,Interventional,9-Oct-15,Amgen,Biological: Evolocumab AI/pen
NCT01849289,A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,14-Jan-16,Novo Nordisk A/S,Drug: Insulin Degludec
NCT01849289,A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,14-Jan-16,Novo Nordisk A/S,Drug: Insulin Glargine
NCT01974752,Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),Metastatic|Uveal Melanoma,Interventional,28-Sep-16,AstraZeneca,Drug: 75mg selumetinib
NCT01974752,Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),Metastatic|Uveal Melanoma,Interventional,28-Sep-16,AstraZeneca,Drug: placebo
NCT01974752,Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),Metastatic|Uveal Melanoma,Interventional,28-Sep-16,AstraZeneca,Drug: Dacarbazine
NCT01848054,Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence,Opioid-Related Disorders|Opiate Dependence,Interventional,24-Jun-15,Orexo AB,Drug: Buprenorphine/naloxone sublingual tablets
NCT01848054,Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence,Opioid-Related Disorders|Opiate Dependence,Interventional,24-Jun-15,Orexo AB,Drug: Buprenorphine
NCT01848054,Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence,Opioid-Related Disorders|Opiate Dependence,Interventional,24-Jun-15,Worldwide Clinical Trials,Drug: Buprenorphine/naloxone sublingual tablets
NCT01848054,Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence,Opioid-Related Disorders|Opiate Dependence,Interventional,24-Jun-15,Worldwide Clinical Trials,Drug: Buprenorphine
NCT01844856,Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections,Complicated Intra-abdominal Infections,Interventional,21-Mar-16,"Tetraphase Pharmaceuticals, Inc.",Drug: Eravacycline
NCT01844856,Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections,Complicated Intra-abdominal Infections,Interventional,21-Mar-16,"Tetraphase Pharmaceuticals, Inc.",Drug: Ertapenem
NCT01844856,Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections,Complicated Intra-abdominal Infections,Interventional,21-Mar-16,"Tetraphase Pharmaceuticals, Inc.",Drug: Placebo
NCT01843062,Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,Interventional,22-Apr-19,AstraZeneca,Drug: Selumetinib
NCT01843062,Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,Interventional,22-Apr-19,AstraZeneca,Drug: Placebo
NCT01843062,Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,Interventional,22-Apr-19,AstraZeneca,Drug: Radioactive Iodine Therapy
NCT01842607,A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects,Asthma,Interventional,3-Mar-16,GlaxoSmithKline,Biological: Mepolizumab
NCT01841762,Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument,Pulmonary Arterial Hypertension,Interventional,31-Oct-18,Actelion,Drug: Macitentan
NCT01836523,The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,6-Mar-17,Novo Nordisk A/S,Drug: liraglutide
NCT01836523,The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,6-Mar-17,Novo Nordisk A/S,Drug: placebo
NCT01835431,A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 1",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin degludec/insulin aspart
NCT01835431,A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 1",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin aspart
NCT01835431,A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 1",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin detemir
NCT01831765,Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,23-Jan-18,Novo Nordisk A/S,Drug: Faster-acting insulin aspart
NCT01831765,Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,23-Jan-18,Novo Nordisk A/S,Drug: insulin detemir
NCT01831765,Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,23-Jan-18,Novo Nordisk A/S,Drug: insulin aspart
NCT01830855,"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years",Meningococcal Vaccine,Interventional,14-Jun-16,Pfizer,Biological: rLP2086
NCT01830855,"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years",Meningococcal Vaccine,Interventional,14-Jun-16,Pfizer,Biological: Havrix (HAV)
NCT01830855,"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years",Meningococcal Vaccine,Interventional,14-Jun-16,Pfizer,Biological: Saline
NCT01825200,"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age",Influenza,Interventional,18-Feb-15,Protein Sciences Corporation,Biological: Flublok
NCT01825200,"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age",Influenza,Interventional,18-Feb-15,Protein Sciences Corporation,Biological: Afluria
NCT01821378,Lurasidone Low-Dose - High-Dose Study Study,Schizophrenia,Interventional,8-Jan-16,Sunovion,Drug: Lurasidone
NCT01821378,Lurasidone Low-Dose - High-Dose Study Study,Schizophrenia,Interventional,8-Jan-16,Sunovion,Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
NCT01821378,Lurasidone Low-Dose - High-Dose Study Study,Schizophrenia,Interventional,8-Jan-16,Sunovion,Drug: Placebo
NCT01819727,An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165,Phenylketonuria,Interventional,10-Sep-18,BioMarin Pharmaceutical,Drug: BMN 165
NCT01819129,Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,5-Dec-17,Novo Nordisk A/S,Drug: Faster-acting insulin aspart
NCT01819129,Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,5-Dec-17,Novo Nordisk A/S,Drug: Insulin aspart
NCT01819129,Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,5-Dec-17,Novo Nordisk A/S,Drug: Insulin glargine
NCT01818596,Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment,HIV|HIV Infections,Interventional,18-Feb-16,Gilead Sciences,Drug: E/C/F/TAF
NCT01818752,"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",Multiple Myeloma,Interventional,1-Aug-17,Amgen,Drug: Carfilzomib
NCT01818752,"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",Multiple Myeloma,Interventional,1-Aug-17,Amgen,Drug: Bortezomib
NCT01818752,"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",Multiple Myeloma,Interventional,1-Aug-17,Amgen,Drug: Melphalan
NCT01818752,"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",Multiple Myeloma,Interventional,1-Aug-17,Amgen,Drug: Prednisone
NCT01818336,Evaluation of Skin Testing Reagents for Penicillin Allergy,History of IgE Dependent Reaction to a Penicillin Product,Interventional,4-Jan-17,AllerQuest LLC,Drug: Penicillin skin test kit
NCT01816295,"A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy",Hypogonadism,Interventional,2-Oct-15,Eli Lilly and Company,Drug: Testosterone Solution
NCT01816295,"A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy",Hypogonadism,Interventional,2-Oct-15,Eli Lilly and Company,Drug: Placebo Solution
NCT01814137,A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin degludec/insulin aspart
NCT01814137,A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01814137,A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin aspart
NCT01813422,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,Hypercholesterolemia,Interventional,4-Jan-18,Amgen,Biological: Evolocumab
NCT01813422,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,Hypercholesterolemia,Interventional,4-Jan-18,Amgen,Drug: Placebo
NCT01814553,ADAM-Afatinib Diarrhea Assessment and Management,"Carcinoma, Non-Small-Cell Lung",Interventional,31-Oct-16,Boehringer Ingelheim,Drug: afatinib
NCT01814553,ADAM-Afatinib Diarrhea Assessment and Management,"Carcinoma, Non-Small-Cell Lung",Interventional,31-Oct-16,Boehringer Ingelheim,Drug: loperamide
NCT01811732,Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections,Interventional,24-Aug-17,"Melinta Therapeutics, Inc.",Drug: Delafloxacin
NCT01811732,Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections,Interventional,24-Aug-17,"Melinta Therapeutics, Inc.",Drug: Vancomycin
NCT01811732,Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections,Interventional,24-Aug-17,"Melinta Therapeutics, Inc.",Drug: Aztreonam
NCT01811732,Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections,Interventional,24-Aug-17,"Melinta Therapeutics, Inc.",Drug: Placebo
NCT01810939,"A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)",Chronic Kidney Disease (CKD)|Hyperkalemia (HK),Interventional,15-Dec-15,"Relypsa, Inc.",Drug: Patiromer
NCT01810939,"A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)",Chronic Kidney Disease (CKD)|Hyperkalemia (HK),Interventional,15-Dec-15,"Relypsa, Inc.",Drug: Placebo
NCT01829711,Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia,"Leukemia, Hairy Cell",Interventional,27-Aug-18,MedImmune LLC,Drug: Moxetumomab pasudotox
NCT01829711,Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia,"Leukemia, Hairy Cell",Interventional,27-Aug-18,MedImmune LLC,Drug: IV Bag Protectant for Moxetumomab pasudotox
NCT01809327,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","Diabetes Mellitus, Type 2",Interventional,6-Jan-16,"Janssen Research & Development, LLC",Drug: Canagliflozin 100 mg
NCT01809327,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","Diabetes Mellitus, Type 2",Interventional,6-Jan-16,"Janssen Research & Development, LLC",Drug: Canagliflozin 300 mg
NCT01809327,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","Diabetes Mellitus, Type 2",Interventional,6-Jan-16,"Janssen Research & Development, LLC",Drug: Metformin XR
NCT01808144,Lesinurad and Febuxostat Combination Extension Study in Gout,Gout,Interventional,30-Jan-18,"Ardea Biosciences, Inc.",Drug: lesinurad
NCT01808144,Lesinurad and Febuxostat Combination Extension Study in Gout,Gout,Interventional,30-Jan-18,"Ardea Biosciences, Inc.",Drug: febuxostat
NCT01807949,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Interventional,1-Sep-15,Vertex Pharmaceuticals Incorporated,Drug: Placebo
NCT01807949,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Interventional,1-Sep-15,Vertex Pharmaceuticals Incorporated,Drug: Lumacaftor Plus Ivacaftor Combination
NCT01807949,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Interventional,1-Sep-15,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01807923,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Interventional,31-Aug-15,Vertex Pharmaceuticals Incorporated,Drug: Lumacaftor Plus Ivacaftor Combination
NCT01807923,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Interventional,31-Aug-15,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01807923,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Interventional,31-Aug-15,Vertex Pharmaceuticals Incorporated,Drug: Placebo
NCT02729025,Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)),"Subjects With Hyperlipidemia, Dyslipidemia",Interventional,23-Apr-19,Amgen,Drug: Evolocumab
NCT02729025,Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)),"Subjects With Hyperlipidemia, Dyslipidemia",Interventional,23-Apr-19,Amgen,Drug: Placebo
NCT01801735,Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip,Osteoarthritis,Interventional,12-May-15,"Iroko Pharmaceuticals, LLC",Drug: Meloxicam Test Capsules
NCT01798706,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,Type 2 Diabetes,Interventional,14-Oct-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT01798706,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,Type 2 Diabetes,Interventional,14-Oct-16,Sanofi,Drug: Placebo
NCT01798706,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,Type 2 Diabetes,Interventional,14-Oct-16,Sanofi,Drug: Antidiabetic background therapy
NCT01817764,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,29-May-14,GlaxoSmithKline,Drug: Umeclidinium/vilanterol
NCT01817764,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,29-May-14,GlaxoSmithKline,Drug: Fluticasone propionate/salmeterol
NCT01817764,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,29-May-14,GlaxoSmithKline,Drug: Placebo
NCT01797445,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,8-Jan-16,Gilead Sciences,Drug: E/C/F/TAF
NCT01797445,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,8-Jan-16,Gilead Sciences,Drug: E/C/F/TDF
NCT01797445,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,8-Jan-16,Gilead Sciences,Drug: E/C/F/TDF Placebo
NCT01797445,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,8-Jan-16,Gilead Sciences,Drug: E/C/F/TAF Placebo
NCT01797185,Safety Study of SPARC1104,Spasticity,Interventional,12-Mar-19,Sun Pharma Advanced Research Company Limited,Drug: SPARC1104 modified dose regimen I
NCT01797185,Safety Study of SPARC1104,Spasticity,Interventional,12-Mar-19,Sun Pharma Advanced Research Company Limited,Drug: SPARC1104 modified dose regimen II
NCT01797185,Safety Study of SPARC1104,Spasticity,Interventional,12-Mar-19,Sun Pharma Advanced Research Company Limited,Drug: SPARC1104 modified dose regimen III
NCT01795859,First Time Use of SD-809 in Huntington Disease,Chorea,Interventional,11-Aug-17,Teva Pharmaceutical Industries,Drug: SD-809
NCT01795859,First Time Use of SD-809 in Huntington Disease,Chorea,Interventional,11-Aug-17,Teva Pharmaceutical Industries,Drug: Placebo
NCT01814800,"Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)",Primary Immune Deficiency Disorder,Interventional,5-Oct-16,"ADMA Biologics, Inc.",Biological: RI-002
NCT01794741,3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis,Allergic Rhinitis,Interventional,31-Mar-15,Meda Pharmaceuticals,Drug: Dymista Nasal Spray
NCT01794741,3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis,Allergic Rhinitis,Interventional,31-Mar-15,Meda Pharmaceuticals,Drug: Fluticasone propionate nasal spray
NCT01792284,A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Interventional,20-Apr-18,Eli Lilly and Company,Drug: LY2605541
NCT01792284,A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Interventional,20-Apr-18,Eli Lilly and Company,Drug: Insulin Lispro
NCT01791153,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),Giant Cell Arteritis,Interventional,18-May-17,Hoffmann-La Roche,Drug: Tocilizumab
NCT01791153,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),Giant Cell Arteritis,Interventional,18-May-17,Hoffmann-La Roche,Drug: Prednisone
NCT01791153,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),Giant Cell Arteritis,Interventional,18-May-17,Hoffmann-La Roche,Drug: Tocilizumab Placebo
NCT01791153,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),Giant Cell Arteritis,Interventional,18-May-17,Hoffmann-La Roche,Drug: Prednisone Placebo
NCT01791153,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),Giant Cell Arteritis,Interventional,18-May-17,Hoffmann-La Roche,Drug: Corticosteroids
NCT01791153,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),Giant Cell Arteritis,Interventional,18-May-17,Hoffmann-La Roche,Drug: Methotrexate
NCT01790438,A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,3-May-18,Eli Lilly and Company,Drug: LY2605541
NCT01790438,A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,3-May-18,Eli Lilly and Company,Drug: Human Insulin NPH
NCT01790438,A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,3-May-18,Eli Lilly and Company,Drug: Oral Antihyperglycemic Medications (OAM)
NCT01789970,Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain,Low Back Pain,Interventional,5-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Hydrocodone ER
NCT01789970,Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain,Low Back Pain,Interventional,5-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT01789970,Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain,Low Back Pain,Interventional,5-Apr-17,Teva Pharmaceutical Industries,Drug: Hydrocodone ER
NCT01789970,Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain,Low Back Pain,Interventional,5-Apr-17,Teva Pharmaceutical Industries,Drug: Placebo
NCT01789606,Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet,Analgesia,Interventional,28-Aug-17,Pfizer,Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
NCT01788358,Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension,Hypertension,Interventional,17-Aug-15,Bayer,Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
NCT01788046,Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",Interventional,27-Mar-17,Amgen,Drug: Etelcalcetide
NCT01788046,Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",Interventional,27-Mar-17,Amgen,Drug: Placebo
NCT01787188,Study of Meloxicam Capsules to Treat Osteoarthritis Pain,Osteoarthritis,Interventional,11-Mar-15,"Iroko Pharmaceuticals, LLC",Drug: Meloxicam Test Capsules
NCT01787188,Study of Meloxicam Capsules to Treat Osteoarthritis Pain,Osteoarthritis,Interventional,11-Mar-15,"Iroko Pharmaceuticals, LLC",Drug: Placebo Capsules
NCT01786993,MultiPoint Pacing IDE Study,Heart Failure,Interventional,30-Sep-16,Abbott Medical Devices,Device: MultiPoint Pacing
NCT01786993,MultiPoint Pacing IDE Study,Heart Failure,Interventional,30-Sep-16,Abbott Medical Devices,Device: Traditional Biventricular Pacing
NCT01785875,Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",Interventional,27-Mar-17,Amgen,Drug: Etelcalcetide
NCT01785849,Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",Interventional,27-Mar-17,Amgen,Drug: Etelcalcetide
NCT01785849,Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",Interventional,27-Mar-17,Amgen,Drug: Placebo
NCT01807520,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis",Moderate to Severe Nail Psoriasis,Interventional,13-Mar-18,Novartis Pharmaceuticals,Biological: Secukinumab
NCT01807520,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis",Moderate to Severe Nail Psoriasis,Interventional,13-Mar-18,Novartis Pharmaceuticals,Biological: Placebo
NCT01807520,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis",Moderate to Severe Nail Psoriasis,Interventional,13-Mar-18,Novartis,Biological: Secukinumab
NCT01807520,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis",Moderate to Severe Nail Psoriasis,Interventional,13-Mar-18,Novartis,Biological: Placebo
NCT01783548,Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR),Allergic Rhinitis,Interventional,12-Oct-15,Teva Pharmaceutical Industries,Drug: BDP Nasal Aerosol
NCT01783548,Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR),Allergic Rhinitis,Interventional,12-Oct-15,Teva Pharmaceutical Industries,Drug: Placebo
NCT01780506,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,8-Jan-16,Gilead Sciences,Drug: E/C/F/TAF
NCT01780506,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,8-Jan-16,Gilead Sciences,Drug: E/C/F/TDF
NCT01780506,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,8-Jan-16,Gilead Sciences,Drug: E/C/F/TDF Placebo
NCT01780506,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,8-Jan-16,Gilead Sciences,Drug: E/C/F/TAF Placebo
NCT01777334,The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,5-Jun-14,GlaxoSmithKline,Drug: Umeclidinium/Vilanterol 62.5/25 mcg
NCT01777334,The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,5-Jun-14,GlaxoSmithKline,Drug: Tiotropium 18 mcg
NCT01777191,Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Interventional,26-May-16,Eli Lilly and Company,Drug: Ixekizumab Auto-Injector
NCT01777191,Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Interventional,26-May-16,Eli Lilly and Company,Drug: Ixekizumab Prefilled Syringe
NCT01772147,Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.,"Pulmonary Disease, Chronic Obstructive",Interventional,21-Apr-14,GlaxoSmithKline,Drug: Umeclidinium bromide 62.5mcg
NCT01772147,Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.,"Pulmonary Disease, Chronic Obstructive",Interventional,21-Apr-14,GlaxoSmithKline,Drug: Umeclidinium bromide 125mcg
NCT01772147,Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.,"Pulmonary Disease, Chronic Obstructive",Interventional,21-Apr-14,GlaxoSmithKline,Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg
NCT01772134,Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Apr-14,GlaxoSmithKline,Drug: Umeclidinium bromide 62.5mcg
NCT01772134,Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Apr-14,GlaxoSmithKline,Drug: Umeclidinium bromide 125mcg
NCT01772134,Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Apr-14,GlaxoSmithKline,Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg
NCT01772134,Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Apr-14,GlaxoSmithKline,Drug: Placebo
NCT01768559,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,Type 2 Diabetes,Interventional,4-Jan-17,Sanofi,Drug: Lixisenatide (AVE0010)
NCT01768559,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,Type 2 Diabetes,Interventional,4-Jan-17,Sanofi,Drug: Insulin glulisine QD
NCT01768559,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,Type 2 Diabetes,Interventional,4-Jan-17,Sanofi,Drug: Insulin glulisine TID
NCT01768559,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,Type 2 Diabetes,Interventional,4-Jan-17,Sanofi,Drug: Insulin Glargine (Mandatory background drug)
NCT01768559,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,Type 2 Diabetes,Interventional,4-Jan-17,Sanofi,Drug: Metformin (Background drug)
NCT01768286,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection,Chronic Hepatitis C Virus,Interventional,26-Nov-14,Gilead Sciences,Drug: LDV/SOF
NCT01768286,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection,Chronic Hepatitis C Virus,Interventional,26-Nov-14,Gilead Sciences,Drug: RBV
NCT01767155,Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer,Endometrial Cancer,Interventional,31-Jul-18,AEterna Zentaris,Drug: AEZS-108 / zoptarelin doxorubicin
NCT01767155,Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer,Endometrial Cancer,Interventional,31-Jul-18,AEterna Zentaris,Drug: doxorubicin
NCT01765179,Safety and Efficacy Trial of Testosterone Undecanoate,Male Hypogonadism,Interventional,21-Sep-17,"Clarus Therapeutics, Inc.",Drug: Oral testosterone undecanoate
NCT01765179,Safety and Efficacy Trial of Testosterone Undecanoate,Male Hypogonadism,Interventional,21-Sep-17,inVentiv Health Clinical,Drug: Oral testosterone undecanoate
NCT01764633,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Interventional,15-Feb-18,Amgen,Biological: Evolocumab
NCT01764633,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Interventional,15-Feb-18,Amgen,Drug: Placebo
NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Biological: Evolocumab
NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Placebo to Evolocumab
NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Ezetimibe
NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Placebo to Ezetimibe
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Biological: Evolocumab
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Ezetimibe
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Placebo to Evolocumab
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Placebo to Ezetimibe
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Atorvastatin
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Rosuvastatin
NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Simvastatin
NCT01763827,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,Hyperlipidemia,Interventional,30-Dec-15,Amgen,Biological: Evolocumab
NCT01763827,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,Hyperlipidemia,Interventional,30-Dec-15,Amgen,Drug: Ezetimibe
NCT01763827,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,Hyperlipidemia,Interventional,30-Dec-15,Amgen,Biological: Placebo to Evolocumab
NCT01763827,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,Hyperlipidemia,Interventional,30-Dec-15,Amgen,Other: Placebo to Ezetimibe
NCT01764386,Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects,Obesity|Overweight,Interventional,26-Nov-15,"Orexigen Therapeutics, Inc",Drug: NB
NCT01764386,Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects,Obesity|Overweight,Interventional,26-Nov-15,"Orexigen Therapeutics, Inc",Behavioral: CLI
NCT01764386,Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects,Obesity|Overweight,Interventional,26-Nov-15,"Orexigen Therapeutics, Inc",Behavioral: Usual Care
NCT01806597,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",Moderate to Severe Palmoplantar Psoriasis,Interventional,21-Feb-18,Novartis Pharmaceuticals,Biological: secukinumab 150 mg
NCT01806597,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",Moderate to Severe Palmoplantar Psoriasis,Interventional,21-Feb-18,Novartis Pharmaceuticals,Biological: secukinumab 300 mg
NCT01806597,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",Moderate to Severe Palmoplantar Psoriasis,Interventional,21-Feb-18,Novartis Pharmaceuticals,Biological: Placebo
NCT01806597,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",Moderate to Severe Palmoplantar Psoriasis,Interventional,21-Feb-18,Novartis,Biological: secukinumab 150 mg
NCT01806597,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",Moderate to Severe Palmoplantar Psoriasis,Interventional,21-Feb-18,Novartis,Biological: secukinumab 300 mg
NCT01806597,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",Moderate to Severe Palmoplantar Psoriasis,Interventional,21-Feb-18,Novartis,Biological: Placebo
NCT01755546,Long-term Open-Label Safety Study to Evaluate EN3409,Low Back Pain|Osteoarthritis|Neuropathic Pain,Interventional,12-Sep-18,BioDelivery Sciences International,Drug: EN3409
NCT01754480,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries,Parenchymous Tissue Surgical Bleeding,Interventional,8-Feb-17,"Instituto Grifols, S.A.",Biological: Fibrin Sealant Grifols
NCT01754480,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries,Parenchymous Tissue Surgical Bleeding,Interventional,8-Feb-17,"Instituto Grifols, S.A.",Device: Surgicel®
NCT01754480,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries,Parenchymous Tissue Surgical Bleeding,Interventional,8-Feb-17,"Grifols Biologicals, LLC",Biological: Fibrin Sealant Grifols
NCT01754480,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries,Parenchymous Tissue Surgical Bleeding,Interventional,8-Feb-17,"Grifols Biologicals, LLC",Device: Surgicel®
NCT01753336,Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia,Cervical Dystonia,Interventional,4-May-17,Ipsen,Drug: Dysport®
NCT01753310,Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.,Cervical Dystonia,Interventional,16-Mar-17,Ipsen,Drug: Dysport®
NCT01753310,Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.,Cervical Dystonia,Interventional,16-Mar-17,Ipsen,Drug: Placebo
NCT01747629,Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics,Asthma,Interventional,21-May-15,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo MDPI
NCT01747629,Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics,Asthma,Interventional,21-May-15,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Albuterol MDPI
NCT01747629,Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics,Asthma,Interventional,21-May-15,Teva Pharmaceutical Industries,Drug: Placebo MDPI
NCT01747629,Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics,Asthma,Interventional,21-May-15,Teva Pharmaceutical Industries,Drug: Albuterol MDPI
NCT01743729,A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye,Dry Eye Disease,Interventional,24-Feb-17,Shire,Drug: Lifitegrast
NCT01743729,A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye,Dry Eye Disease,Interventional,24-Feb-17,Shire,Drug: Placebo
NCT01739595,Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism,Secondary Hypogonadism,Interventional,27-May-15,Repros Therapeutics Inc.,Drug: enclomiphene citrate
NCT01739595,Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism,Secondary Hypogonadism,Interventional,27-May-15,Repros Therapeutics Inc.,Drug: Placebo
NCT01738477,Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults,Tetanus|Acellular Pertussis|Diphtheria,Interventional,27-Dec-17,GlaxoSmithKline,Biological: Boostrix
NCT01737762,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2,Venous Leg Ulcers,Interventional,26-Jul-17,Healthpoint,Biological: HP802-247
NCT01737762,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2,Venous Leg Ulcers,Interventional,26-Jul-17,Healthpoint,Biological: Vehicle
NCT01737697,Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia,Hyperkalemia,Interventional,12-Oct-18,"ZS Pharma, Inc.",Drug: Zirconium silicate (acute phase)
NCT01737697,Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia,Hyperkalemia,Interventional,12-Oct-18,"ZS Pharma, Inc.",Drug: Zirconium silicate (subacute phase)
NCT01737697,Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia,Hyperkalemia,Interventional,12-Oct-18,"ZS Pharma, Inc.",Drug: Placebo (acute phase)
NCT01737697,Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia,Hyperkalemia,Interventional,12-Oct-18,"ZS Pharma, Inc.",Drug: Placebo ( subacute phase)
NCT01732822,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,Interventional,30-Oct-17,AstraZeneca,Drug: Ticagrelor
NCT01732822,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,Interventional,30-Oct-17,AstraZeneca,Drug: Clopidogrel
NCT01732796,IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1,"Hepatitis C, Chronic",Interventional,18-Apr-16,Boehringer Ingelheim,Drug: Ribavirin (RBV)
NCT01732796,IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1,"Hepatitis C, Chronic",Interventional,18-Apr-16,Boehringer Ingelheim,Drug: BI 201335 (Faldaprevir)
NCT01732796,IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1,"Hepatitis C, Chronic",Interventional,18-Apr-16,Boehringer Ingelheim,Drug: BI 207127
NCT01732796,IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1,"Hepatitis C, Chronic",Interventional,18-Apr-16,Boehringer Ingelheim,Drug: Faldaprevir (BI 201335)
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: BI 207127-placebo: 8-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: Ribavirin: 24-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: BI 207127: 24-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: Faldaprevir: 24-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: Ribavirin-placebo: 8-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: Faldaprevir-placebo: 8-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: Faldaprevir: 16-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: Ribavirin: 16-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: RBV: 24-week treatment
NCT01728324,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Hepatitis C, Chronic",Interventional,12-Feb-16,Boehringer Ingelheim,Drug: BI 207127: 16-week treatment
NCT01727726,"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,8-Jun-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Brexpiprazole
NCT01727726,"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,8-Jun-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Seroquel XR
NCT01727726,"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,8-Jun-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT01727713,Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder,Tourette's Disorder|Tic Disorder,Interventional,16-Oct-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT01727700,Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder,Tourette's Disorder|Tic Disorder,Interventional,13-Feb-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT01727700,Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder,Tourette's Disorder|Tic Disorder,Interventional,13-Feb-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT01727141,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Chronic Obstructive Pulmonary Disease (COPD),Interventional,9-Jun-15,Novartis Pharmaceuticals,Drug: QVA149
NCT01727141,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Chronic Obstructive Pulmonary Disease (COPD),Interventional,9-Jun-15,Novartis Pharmaceuticals,Drug: QAB149
NCT01727141,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Chronic Obstructive Pulmonary Disease (COPD),Interventional,9-Jun-15,Novartis Pharmaceuticals,Drug: NVA237
NCT01727141,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Chronic Obstructive Pulmonary Disease (COPD),Interventional,9-Jun-15,Novartis Pharmaceuticals,Drug: Placebo
NCT01727141,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Chronic Obstructive Pulmonary Disease (COPD),Interventional,9-Jun-15,Novartis,Drug: QVA149
NCT01727141,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Chronic Obstructive Pulmonary Disease (COPD),Interventional,9-Jun-15,Novartis,Drug: QAB149
NCT01727141,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Chronic Obstructive Pulmonary Disease (COPD),Interventional,9-Jun-15,Novartis,Drug: NVA237
NCT01727141,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Chronic Obstructive Pulmonary Disease (COPD),Interventional,9-Jun-15,Novartis,Drug: Placebo
NCT01721057,A Study in Moderate to Severe Rheumatoid Arthritis Participants,Rheumatoid Arthritis,Interventional,12-Jun-17,Eli Lilly and Company,Drug: Placebo
NCT01721057,A Study in Moderate to Severe Rheumatoid Arthritis Participants,Rheumatoid Arthritis,Interventional,12-Jun-17,Eli Lilly and Company,Drug: Baricitinib
NCT01721057,A Study in Moderate to Severe Rheumatoid Arthritis Participants,Rheumatoid Arthritis,Interventional,12-Jun-17,Eli Lilly and Company,Drug: cDMARD
NCT01721044,A Moderate to Severe Rheumatoid Arthritis Study,Rheumatoid Arthritis,Interventional,18-Jan-18,Eli Lilly and Company,Drug: Placebo
NCT01721044,A Moderate to Severe Rheumatoid Arthritis Study,Rheumatoid Arthritis,Interventional,18-Jan-18,Eli Lilly and Company,Drug: Baricitinib
NCT01721044,A Moderate to Severe Rheumatoid Arthritis Study,Rheumatoid Arthritis,Interventional,18-Jan-18,Eli Lilly and Company,Drug: cDMARD
NCT01720446,Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,15-Mar-18,Novo Nordisk A/S,Drug: semaglutide
NCT01720446,Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,15-Mar-18,Novo Nordisk A/S,Drug: placebo
NCT01767467,Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers,Herpes Zoster,Interventional,25-May-17,GlaxoSmithKline,Biological: Herpes zoster vaccine (GSK 1437173A)
NCT01767467,Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers,Herpes Zoster,Interventional,25-May-17,GlaxoSmithKline,Drug: Placebo
NCT01718509,SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Binge Eating Disorder,Interventional,21-Aug-14,Shire,Drug: SPD489 (Lisdexamfetamine dimesylate)
NCT01718509,SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Binge Eating Disorder,Interventional,21-Aug-14,Shire,Drug: Placebo
NCT01718483,SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Binge Eating Disorder,Interventional,21-Jul-14,Shire,Drug: SPD489 (Lisdexamfetamine dimesylate)
NCT01718483,SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Binge Eating Disorder,Interventional,21-Jul-14,Shire,Drug: Placebo
NCT01715298,NVA237 BID Versus Placebo Twelve-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Interventional,11-Mar-15,Novartis Pharmaceuticals,Drug: NVA237
NCT01715298,NVA237 BID Versus Placebo Twelve-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Interventional,11-Mar-15,Novartis Pharmaceuticals,Drug: Placebo
NCT01715298,NVA237 BID Versus Placebo Twelve-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Interventional,11-Mar-15,Novartis,Drug: NVA237
NCT01715298,NVA237 BID Versus Placebo Twelve-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Interventional,11-Mar-15,Novartis,Drug: Placebo
NCT01714817,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,Lupus Nephritis,Interventional,21-Dec-17,Bristol-Myers Squibb,Biological: BMS-188667
NCT01714817,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,Lupus Nephritis,Interventional,21-Dec-17,Bristol-Myers Squibb,Drug: Mycophenolate mofetil
NCT01714817,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,Lupus Nephritis,Interventional,21-Dec-17,Bristol-Myers Squibb,Drug: Prednisone
NCT01714817,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,Lupus Nephritis,Interventional,21-Dec-17,Bristol-Myers Squibb,Biological: Placebo matching with BMS-188667
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Tuberous Sclerosis Complex-associated Refractory Seizures,Interventional,7-Nov-18,Novartis Pharmaceuticals,Drug: RAD001
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Tuberous Sclerosis Complex-associated Refractory Seizures,Interventional,7-Nov-18,Novartis Pharmaceuticals,Drug: Placebo
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Tuberous Sclerosis Complex-associated Refractory Seizures,Interventional,7-Nov-18,Novartis Pharmaceuticals,Drug: Antiepileptic drug (1 to 3 only)
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Tuberous Sclerosis Complex-associated Refractory Seizures,Interventional,7-Nov-18,Novartis Pharmaceuticals,Drug: open label RAD001 (only used for post-extension phase)
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Tuberous Sclerosis Complex-associated Refractory Seizures,Interventional,7-Nov-18,Novartis,Drug: RAD001
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Tuberous Sclerosis Complex-associated Refractory Seizures,Interventional,7-Nov-18,Novartis,Drug: Placebo
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Tuberous Sclerosis Complex-associated Refractory Seizures,Interventional,7-Nov-18,Novartis,Drug: Antiepileptic drug (1 to 3 only)
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Tuberous Sclerosis Complex-associated Refractory Seizures,Interventional,7-Nov-18,Novartis,Drug: open label RAD001 (only used for post-extension phase)
NCT01713530,A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin degludec/insulin aspart
NCT01713530,A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01713530,A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin aspart
NCT01712984,Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years,Influenza,Interventional,10-Feb-14,"Sanofi Pasteur, a Sanofi Company","Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation"
NCT01712984,Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years,Influenza,Interventional,10-Feb-14,"Sanofi Pasteur, a Sanofi Company",Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal
NCT01712984,Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years,Influenza,Interventional,10-Feb-14,"Sanofi Pasteur, a Sanofi Company",Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
NCT01712984,Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years,Influenza,Interventional,10-Feb-14,Sanofi,"Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation"
NCT01712984,Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years,Influenza,Interventional,10-Feb-14,Sanofi,Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal
NCT01712984,Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years,Influenza,Interventional,10-Feb-14,Sanofi,Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
NCT01712516,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Interventional,15-Jul-15,Novartis Pharmaceuticals,Drug: QVA149
NCT01712516,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Interventional,15-Jul-15,Novartis Pharmaceuticals,Drug: QAB149
NCT01712516,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Interventional,15-Jul-15,Novartis Pharmaceuticals,Drug: NVA237
NCT01712516,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Interventional,15-Jul-15,Novartis Pharmaceuticals,Drug: Placebo
NCT01712516,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Interventional,15-Jul-15,Novartis,Drug: QVA149
NCT01712516,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Interventional,15-Jul-15,Novartis,Drug: QAB149
NCT01712516,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Interventional,15-Jul-15,Novartis,Drug: NVA237
NCT01712516,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Interventional,15-Jul-15,Novartis,Drug: Placebo
NCT01711359,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Baricitinib
NCT01711359,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Methotrexate
NCT01711359,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Baricitinib Placebo
NCT01711359,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: MTX Placebo
NCT01711359,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Folic Acid
NCT01710358,A Study in Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Adalimumab
NCT01710358,A Study in Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Baricitinib
NCT01710358,A Study in Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Methotrexate
NCT01710358,A Study in Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Adalimumab Placebo
NCT01710358,A Study in Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,15-Aug-17,Eli Lilly and Company,Drug: Baricitinib Placebo
NCT01709864,NVA237 Versus Placebo 12-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Interventional,12-Feb-15,Novartis Pharmaceuticals,Drug: NVA237
NCT01709864,NVA237 Versus Placebo 12-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Interventional,12-Feb-15,Novartis Pharmaceuticals,Drug: Placebo
NCT01709864,NVA237 Versus Placebo 12-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Interventional,12-Feb-15,Novartis,Drug: NVA237
NCT01709864,NVA237 Versus Placebo 12-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Interventional,12-Feb-15,Novartis,Drug: Placebo
NCT01707992,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",Multiple Sclerosis,Interventional,13-Mar-19,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Laquinimod
NCT01707992,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",Multiple Sclerosis,Interventional,13-Mar-19,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT01707992,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",Multiple Sclerosis,Interventional,13-Mar-19,Teva Pharmaceutical Industries,Drug: Laquinimod
NCT01707992,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",Multiple Sclerosis,Interventional,13-Mar-19,Teva Pharmaceutical Industries,Drug: Placebo
NCT01707290,Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation,Cystic Fibrosis,Interventional,12-May-17,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01707290,Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation,Cystic Fibrosis,Interventional,12-May-17,Cystic Fibrosis Foundation,Drug: Ivacaftor
NCT01706328,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,5-Mar-14,GlaxoSmithKline,Drug: FF/VI 100/25 Inhalation Powder NDPI
NCT01706328,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,5-Mar-14,GlaxoSmithKline,Drug: Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS
NCT01706328,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,5-Mar-14,GlaxoSmithKline,Drug: Placebo Inhalation Powder NDPI
NCT01706328,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,5-Mar-14,GlaxoSmithKline,Drug: Placebo Inhalation Powder ACCUHALER/DISKUS
NCT01706328,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,5-Mar-14,GlaxoSmithKline,Drug: Salbutamol as needed
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: E/C/F/TDF
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: RTV
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: ATV
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: FTC/TDF
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: E/C/F/TDF Placebo
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: RTV Placebo
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: ATV Placebo
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: FTC/TDF Placebo
NCT01705574,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Mar-16,Gilead Sciences,Drug: E/C/F/TAF
NCT01705145,Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation,Cystic Fibrosis,Interventional,24-Apr-15,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01705145,Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation,Cystic Fibrosis,Interventional,24-Apr-15,Cystic Fibrosis Foundation,Drug: Ivacaftor
NCT01703741,A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel,Adult Male Hypogonadism,Interventional,6-Oct-17,Ferring Pharmaceuticals,Drug: Testosterone Gel (FE 999093)
NCT01702428,"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",Rubella|Measles|Mumps,Interventional,28-Jun-18,GlaxoSmithKline,Biological: Priorix
NCT01702428,"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",Rubella|Measles|Mumps,Interventional,28-Jun-18,GlaxoSmithKline,Biological: M-M-R II
NCT01702428,"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",Rubella|Measles|Mumps,Interventional,28-Jun-18,GlaxoSmithKline,Biological: Varivax
NCT01702428,"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",Rubella|Measles|Mumps,Interventional,28-Jun-18,GlaxoSmithKline,Biological: Havrix
NCT01702428,"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",Rubella|Measles|Mumps,Interventional,28-Jun-18,GlaxoSmithKline,Biological: Prevnar 13
NCT01701401,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV,Chronic Hepatitis C Virus,Interventional,27-Mar-15,Gilead Sciences,Drug: LDV/SOF
NCT01701401,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV,Chronic Hepatitis C Virus,Interventional,27-Mar-15,Gilead Sciences,Drug: RBV
NCT01701362,Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain,Neuropathic Pain,Interventional,7-Jun-17,Pfizer,Drug: pregabalin
NCT01701362,Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain,Neuropathic Pain,Interventional,7-Jun-17,Pfizer,Drug: placebo
NCT01699178,"Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men",Male Hypogonadism,Interventional,30-Oct-18,"Clarus Therapeutics, Inc.",Drug: Oral testosterone undecanoate
NCT01699178,"Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men",Male Hypogonadism,Interventional,30-Oct-18,"Clarus Therapeutics, Inc.",Drug: Transdermal testosterone gel (AndroGel)
NCT01698320,Safety Study of Albuterol Spiromax® in Subjects With Asthma,Asthma,Interventional,19-Aug-15,Teva Pharmaceutical Industries,Drug: Placebo MDPI
NCT01698320,Safety Study of Albuterol Spiromax® in Subjects With Asthma,Asthma,Interventional,19-Aug-15,Teva Pharmaceutical Industries,Drug: Albuterol MDPI
NCT01697696,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Interventional,16-Mar-16,Novartis Pharmaceuticals,Drug: NVA237
NCT01697696,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Interventional,16-Mar-16,Novartis Pharmaceuticals,Drug: Long-acting beta 2-agonist (LABA)
NCT01697696,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Interventional,16-Mar-16,Novartis Pharmaceuticals,Drug: Placebo
NCT01697696,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Interventional,16-Mar-16,Novartis,Drug: NVA237
NCT01697696,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Interventional,16-Mar-16,Novartis,Drug: Long-acting beta 2-agonist (LABA)
NCT01697696,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Interventional,16-Mar-16,Novartis,Drug: Placebo
NCT01696058,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Nov-14,Boehringer Ingelheim,Drug: Tiotropium
NCT01696058,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Nov-14,Boehringer Ingelheim,Drug: Placebo matching Olodaterol
NCT01696058,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Nov-14,Boehringer Ingelheim,Drug: Olodaterol
NCT01695239,A Study of Ixekizumab in Participants With Active Psoriatic Arthritis,"Psoriasis, Arthritic",Interventional,27-Oct-16,Eli Lilly and Company,Drug: Ixekizumab
NCT01695239,A Study of Ixekizumab in Participants With Active Psoriatic Arthritis,"Psoriasis, Arthritic",Interventional,27-Oct-16,Eli Lilly and Company,Drug: Placebo
NCT01695239,A Study of Ixekizumab in Participants With Active Psoriatic Arthritis,"Psoriasis, Arthritic",Interventional,27-Oct-16,Eli Lilly and Company,Drug: Adalimumab
NCT01694771,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Sep-14,Boehringer Ingelheim,Drug: Tiotropium
NCT01694771,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Sep-14,Boehringer Ingelheim,Drug: Placebo matching Olodaterol
NCT01694771,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Sep-14,Boehringer Ingelheim,Drug: Olodaterol
NCT01693029,Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa,Anemia|Chronic Kidney Disease (CKD),Interventional,12-May-17,Sandoz,Drug: HX575 epoetin alfa
NCT01693029,Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa,Anemia|Chronic Kidney Disease (CKD),Interventional,12-May-17,Sandoz,Drug: US-licensed epoetin alfa
NCT01691521,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,Asthma,Interventional,26-Jan-16,GlaxoSmithKline,Drug: Mepolizumab IV
NCT01691521,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,Asthma,Interventional,26-Jan-16,GlaxoSmithKline,Drug: Mepolizumab SC
NCT01691521,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,Asthma,Interventional,26-Jan-16,GlaxoSmithKline,Drug: IV Placebo
NCT01691521,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,Asthma,Interventional,26-Jan-16,GlaxoSmithKline,Drug: SC Placebo
NCT01691859,MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects,Asthma,Interventional,22-May-18,GlaxoSmithKline,Drug: Mepolizumab
NCT01690299,Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis,Psoriasis|Psoriatic Arthritis,Interventional,4-Aug-15,Celgene,Drug: Apremilast
NCT01690299,Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis,Psoriasis|Psoriatic Arthritis,Interventional,4-Aug-15,Celgene,Drug: Etanercept
NCT01690299,Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis,Psoriasis|Psoriatic Arthritis,Interventional,4-Aug-15,Celgene,Drug: Placebo tablet
NCT01690299,Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis,Psoriasis|Psoriatic Arthritis,Interventional,4-Aug-15,Celgene,Drug: Placebo injection
NCT01687712,Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF,Infertility,Interventional,18-Oct-17,Fertility Biotech AG,Drug: AFOLIA
NCT01687712,Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF,Infertility,Interventional,18-Oct-17,Fertility Biotech AG,Drug: Gonal-f® RFF
NCT01686633,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.",Asthma,Interventional,6-Jun-14,GlaxoSmithKline,Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg
NCT01686633,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.",Asthma,Interventional,6-Jun-14,GlaxoSmithKline,Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg
NCT01686633,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.",Asthma,Interventional,6-Jun-14,GlaxoSmithKline,Drug: Fluticasone Furoate 100 mcg
NCT01685684,Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Feb-17,"Collegium Pharmaceutical, Inc.",Drug: Oxycodone DETERx
NCT01685684,Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Feb-17,"Collegium Pharmaceutical, Inc.",Drug: Placebo
NCT01685567,Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure,Carotid Artery Disease,Interventional,6-Mar-17,Silk Road Medical,Device: MICHI NPS+f
NCT01683838,Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury,Spinal Cord Injury|Muscle Spasticity,Interventional,5-Feb-14,Acorda Therapeutics,Drug: Fampridine-SR
NCT01683838,Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury,Spinal Cord Injury|Muscle Spasticity,Interventional,5-Feb-14,Acorda Therapeutics,Drug: Placebo
NCT01683266,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Interventional,23-Apr-15,Sanofi,Drug: HOE901-U300 (Insulin glargine new formulation)
NCT01683266,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Interventional,23-Apr-15,Sanofi,Drug: Lantus (Insulin glargine)
NCT01682876,"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","Meningococcal Disease|Infections, Meningococcal",Interventional,6-Oct-14,GlaxoSmithKline,Biological: MenACWY-CRM
NCT01682863,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,Chronic Obstructive Pulmonary Disease (COPD),Interventional,30-Mar-16,Novartis Pharmaceuticals,Drug: QVA149
NCT01682863,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,Chronic Obstructive Pulmonary Disease (COPD),Interventional,30-Mar-16,Novartis Pharmaceuticals,Drug: QAB149
NCT01682863,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,Chronic Obstructive Pulmonary Disease (COPD),Interventional,30-Mar-16,Novartis Pharmaceuticals,Drug: Placebo
NCT01682863,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,Chronic Obstructive Pulmonary Disease (COPD),Interventional,30-Mar-16,Novartis,Drug: QVA149
NCT01682863,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,Chronic Obstructive Pulmonary Disease (COPD),Interventional,30-Mar-16,Novartis,Drug: QAB149
NCT01682863,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,Chronic Obstructive Pulmonary Disease (COPD),Interventional,30-Mar-16,Novartis,Drug: Placebo
NCT01681992,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life,Measles|Mumps|Rubella,Interventional,17-Aug-18,GlaxoSmithKline,Biological: Priorix
NCT01681992,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life,Measles|Mumps|Rubella,Interventional,17-Aug-18,GlaxoSmithKline,Biological: M-M-R II
NCT01681992,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life,Measles|Mumps|Rubella,Interventional,17-Aug-18,GlaxoSmithKline,Biological: Varivax
NCT01681992,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life,Measles|Mumps|Rubella,Interventional,17-Aug-18,GlaxoSmithKline,Biological: Havrix
NCT01681992,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life,Measles|Mumps|Rubella,Interventional,17-Aug-18,GlaxoSmithKline,Biological: Prevnar 13
NCT01680341,Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin degludec/insulin aspart
NCT01677910,TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome),Carcinoid Syndrome,Interventional,18-Sep-17,Lexicon Pharmaceuticals,Drug: Telotristat etiprate
NCT01677910,TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome),Carcinoid Syndrome,Interventional,18-Sep-17,Lexicon Pharmaceuticals,Drug: Placebo-matching telotristat etiprate
NCT01676220,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy,Type 2 Diabetes Mellitus,Interventional,23-Apr-15,Sanofi,Drug: HOE901-U300 (new formulation of insulin glargine)
NCT01676220,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy,Type 2 Diabetes Mellitus,Interventional,23-Apr-15,Sanofi,Drug: Lantus (insulin glargine)
NCT01676116,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,"Diabetes|Diabetes Mellitus, Type 2",Interventional,9-Jul-18,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT01676116,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,"Diabetes|Diabetes Mellitus, Type 2",Interventional,9-Jul-18,Novo Nordisk A/S,Drug: liraglutide
NCT01676116,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,"Diabetes|Diabetes Mellitus, Type 2",Interventional,9-Jul-18,Novo Nordisk A/S,Drug: exenatide
NCT01675167,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects,Low Back Pain,Interventional,3-Feb-16,BioDelivery Sciences International,Drug: Buprenorphine
NCT01675167,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects,Low Back Pain,Interventional,3-Feb-16,BioDelivery Sciences International,Drug: Placebo
NCT01674634,Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures,Dupuytren's Contracture,Interventional,20-Feb-15,Endo Pharmaceuticals,Biological: XIAFLEX / XIAPEX
NCT02558829,Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency,Growth Hormone Deficiency With Pituitary Anomalies,Interventional,9-Feb-18,AEterna Zentaris,Drug: Macimorelin
NCT02558829,Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency,Growth Hormone Deficiency With Pituitary Anomalies,Interventional,9-Feb-18,AEterna Zentaris,Drug: Insulin
NCT01667731,"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults",Hepatitis C|Human Immunodeficiency Virus,Interventional,21-Nov-14,Gilead Sciences,Drug: SOF
NCT01667731,"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults",Hepatitis C|Human Immunodeficiency Virus,Interventional,21-Nov-14,Gilead Sciences,Drug: RBV
NCT01667419,A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma,Melanoma,Interventional,17-Oct-18,Hoffmann-La Roche,Drug: Vemurafenib
NCT01667419,A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma,Melanoma,Interventional,17-Oct-18,Hoffmann-La Roche,Drug: Placebo
NCT01667679,Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura,Migraine|Headaches,Interventional,14-Mar-17,Avanir Pharmaceuticals,Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
NCT01667679,Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura,Migraine|Headaches,Interventional,14-Mar-17,Avanir Pharmaceuticals,Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
NCT01978938,Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections,cUTI,Interventional,11-Dec-18,"Tetraphase Pharmaceuticals, Inc.",Drug: Eravacycline
NCT01978938,Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections,cUTI,Interventional,11-Dec-18,"Tetraphase Pharmaceuticals, Inc.",Drug: Levofloxacin
NCT01665599,A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel,Adult Male Hypogonadism,Interventional,20-Sep-17,Ferring Pharmaceuticals,Drug: Testosterone gel (FE 999303)
NCT01665053,The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s),Coronary Artery Disease,Interventional,7-Jan-16,Boston Scientific Corporation,Device: PROMUS Element Plus
NCT01665053,The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s),Coronary Artery Disease,Interventional,7-Jan-16,Boston Scientific Corporation,Device: SYNERGY
NCT01664247,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,"Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Apr-16,Novo Nordisk A/S,Drug: insulin degludec
NCT01664247,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,"Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Apr-16,Novo Nordisk A/S,Drug: placebo
NCT01664247,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,"Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Apr-16,Novo Nordisk A/S,Drug: liraglutide
NCT01663727,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",Metastatic Breast Cancer,Interventional,10-Feb-16,Hoffmann-La Roche,Drug: Bevacizumab [Avastin]
NCT01663727,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",Metastatic Breast Cancer,Interventional,10-Feb-16,Hoffmann-La Roche,Drug: Paclitaxel
NCT01663727,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",Metastatic Breast Cancer,Interventional,10-Feb-16,Hoffmann-La Roche,Drug: Placebo
NCT01662856,Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery,Vascular Surgical Bleeding,Interventional,6-Apr-17,"Instituto Grifols, S.A.",Biological: Fibrin Sealant Grifols
NCT01662856,Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery,Vascular Surgical Bleeding,Interventional,6-Apr-17,"Instituto Grifols, S.A.",Procedure: Manual Compression
NCT01662856,Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery,Vascular Surgical Bleeding,Interventional,6-Apr-17,"Grifols Biologicals, LLC",Biological: Fibrin Sealant Grifols
NCT01662856,Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery,Vascular Surgical Bleeding,Interventional,6-Apr-17,"Grifols Biologicals, LLC",Procedure: Manual Compression
NCT01662492,A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine,Migraine Disorders,Interventional,5-Sep-17,Allergan,Biological: Botulinum toxin type A Dose 1
NCT01662492,A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine,Migraine Disorders,Interventional,5-Sep-17,Allergan,Biological: Botulinum toxin type A Dose 2
NCT01662492,A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine,Migraine Disorders,Interventional,5-Sep-17,Allergan,Drug: Placebo (Normal Saline)
NCT01662063,A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,12-Oct-16,"Genentech, Inc.",Drug: Tocilizumab
NCT01659021,Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Interventional,31-Mar-17,Gilead Sciences,Drug: Idelalisib
NCT01659021,Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Interventional,31-Mar-17,Gilead Sciences,Drug: Ofatumumab
NCT01657019,Open Label Extension in Adults With Binge Eating Disorder (BED),Binge Eating Disorder,Interventional,15-Dec-15,Shire,Drug: Lisdexamfetamine dimesylate
NCT01652872,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Anemia in Chronic Kidney Disease Patients Not on Dialysis,Interventional,8-Nov-18,Amgen,Biological: Darbepoetin alfa
NCT01652872,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Anemia in Chronic Kidney Disease Patients Not on Dialysis,Interventional,8-Nov-18,Amgen,Other: Placebo
NCT01652729,"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",Diabetes Type 2,Interventional,23-Apr-15,AstraZeneca,Drug: Exenatide once weekly suspension
NCT01652729,"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",Diabetes Type 2,Interventional,23-Apr-15,AstraZeneca,Drug: Sitagliptin
NCT01652729,"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",Diabetes Type 2,Interventional,23-Apr-15,AstraZeneca,Drug: Placebo
NCT01652716,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Sep-15,AstraZeneca,Drug: Exenatide once weekly suspension
NCT01652716,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Sep-15,AstraZeneca,Drug: Exenatide twice daily
NCT01650246,Open-Label Lesinurad Monotherapy Extension Study in Gout,Gout,Interventional,26-May-16,"Ardea Biosciences, Inc.",Drug: lesinurad
NCT01646320,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,11-Apr-16,AstraZeneca,Drug: Dapagliflozin
NCT01646320,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,11-Apr-16,AstraZeneca,Drug: Placebo matching with Dapagliflozin
NCT01646320,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,11-Apr-16,AstraZeneca,Drug: Saxagliptin
NCT01646320,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,11-Apr-16,AstraZeneca,Drug: Metformin immediate release (IR)
NCT01641822,Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF,Cystic Fibrosis,Interventional,9-May-16,Gilead Sciences,Drug: AZLI
NCT01641822,Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF,Cystic Fibrosis,Interventional,9-May-16,Gilead Sciences,Drug: Placebo to match AZLI
NCT01641822,Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF,Cystic Fibrosis,Interventional,9-May-16,Gilead Sciences,Drug: Tobramycin inhalation solution
NCT01641640,"Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection",Chronic Hepatitis C,Interventional,8-May-14,Gilead Sciences,Drug: Sofosbuvir
NCT01641640,"Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection",Chronic Hepatitis C,Interventional,8-May-14,Gilead Sciences,Drug: RBV
NCT01641640,"Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection",Chronic Hepatitis C,Interventional,8-May-14,Gilead Sciences,Drug: PEG
NCT01691508,Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma,Asthma,Interventional,26-Jan-16,GlaxoSmithKline,Drug: Mepolizumab
NCT01691508,Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma,Asthma,Interventional,26-Jan-16,GlaxoSmithKline,Drug: Placebo
NCT01691508,Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma,Asthma,Interventional,26-Jan-16,GlaxoSmithKline,Drug: OCS (prednisone/prednisolone)
NCT01640951,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis,Moderate to Severe Chronic Plaque-Type Psoriasis,Interventional,25-May-18,Novartis Pharmaceuticals,Drug: AIN457 150 mg
NCT01640951,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis,Moderate to Severe Chronic Plaque-Type Psoriasis,Interventional,25-May-18,Novartis Pharmaceuticals,Drug: AIN457 300 mg
NCT01640951,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis,Moderate to Severe Chronic Plaque-Type Psoriasis,Interventional,25-May-18,Novartis Pharmaceuticals,Drug: Placebo
NCT01640951,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis,Moderate to Severe Chronic Plaque-Type Psoriasis,Interventional,25-May-18,Novartis,Drug: AIN457 150 mg
NCT01640951,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis,Moderate to Severe Chronic Plaque-Type Psoriasis,Interventional,25-May-18,Novartis,Drug: AIN457 300 mg
NCT01640951,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis,Moderate to Severe Chronic Plaque-Type Psoriasis,Interventional,25-May-18,Novartis,Drug: Placebo
NCT01641042,Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects,"Infections, Meningococcal",Interventional,18-Oct-17,GlaxoSmithKline,Biological: Meningococcal vaccine GSK134612
NCT01639495,THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS,Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation,Interventional,15-May-18,"Biosense Webster, Inc.",Device: THERMOCOOL® SMARTTOUCH™ Catheter
NCT01636206,Safety Study of Lifitegrast to Treat Dry Eye,Dry Eye Disease,Interventional,3-Oct-16,Shire,Drug: Lifitegrast
NCT01636206,Safety Study of Lifitegrast to Treat Dry Eye,Dry Eye Disease,Interventional,3-Oct-16,Shire,Drug: Placebo
NCT01636687,Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE),Plaque-type Psoriasis,Interventional,27-Sep-18,Novartis Pharmaceuticals,Drug: Placebo
NCT01636687,Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE),Plaque-type Psoriasis,Interventional,27-Sep-18,Novartis Pharmaceuticals,Drug: Secukinumab 150mg
NCT01636687,Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE),Plaque-type Psoriasis,Interventional,27-Sep-18,Novartis Pharmaceuticals,Drug: Secukinumab 300mg
NCT01636687,Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE),Plaque-type Psoriasis,Interventional,27-Sep-18,Novartis,Drug: Placebo
NCT01636687,Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE),Plaque-type Psoriasis,Interventional,27-Sep-18,Novartis,Drug: Secukinumab 150mg
NCT01636687,Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE),Plaque-type Psoriasis,Interventional,27-Sep-18,Novartis,Drug: Secukinumab 300mg
NCT01633944,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects,Low Back Pain,Interventional,3-Feb-16,BioDelivery Sciences International,Drug: Buprenorphine
NCT01633944,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects,Low Back Pain,Interventional,3-Feb-16,BioDelivery Sciences International,Drug: Placebo
NCT01632904,Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study,Polycythemia Vera,Interventional,7-Apr-15,Incyte Corporation,Drug: Ruxolitinib
NCT01632904,Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study,Polycythemia Vera,Interventional,7-Apr-15,Incyte Corporation,Drug: Hydroxyurea (HU)
NCT01632904,Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study,Polycythemia Vera,Interventional,7-Apr-15,Incyte Corporation,Drug: HU-placebo
NCT01632904,Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study,Polycythemia Vera,Interventional,7-Apr-15,Incyte Corporation,Drug: Ruxolitinib-placebo
NCT01654250,NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder,Interventional,3-Feb-16,Pfizer,Drug: NWP09
NCT01654250,NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder,Interventional,3-Feb-16,Pfizer,Drug: Placebo
NCT01631214,Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis,Postmenopausal Women With Osteoporosis,Interventional,12-Dec-18,Amgen,Biological: Romosozumab
NCT01631214,Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis,Postmenopausal Women With Osteoporosis,Interventional,12-Dec-18,Amgen,Drug: Alendronate
NCT01631214,Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis,Postmenopausal Women With Osteoporosis,Interventional,12-Dec-18,Amgen,Drug: Placebo to Romosozumab
NCT01631214,Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis,Postmenopausal Women With Osteoporosis,Interventional,12-Dec-18,Amgen,Drug: Placebo to Alendronate
NCT01628120,"A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin",Chronic Renal Failure Requiring Hemodialysis,Interventional,19-Jul-18,Pfizer,Biological: Epoetin Hospira
NCT01628107,"A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin",Chronic Renal Failure Requiring Hemodialysis,Interventional,19-Jul-18,Pfizer,Biological: Epoetin Hospira
NCT01626456,A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070),Schizophrenia,Interventional,27-Oct-16,"Alkermes, Inc.","Drug: ALKS 9072, Low"
NCT01626456,A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070),Schizophrenia,Interventional,27-Oct-16,"Alkermes, Inc.","Drug: ALKS 9072, High"
NCT01625338,Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies,Chronic Hepatitis C,Interventional,9-Nov-15,Gilead Sciences,Drug: SOF
NCT01625338,Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies,Chronic Hepatitis C,Interventional,9-Nov-15,Gilead Sciences,Drug: RBV
NCT01625338,Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies,Chronic Hepatitis C,Interventional,9-Nov-15,Gilead Sciences,Drug: Peg-IFN
NCT01624259,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,Type 2 Diabetes,Interventional,9-Oct-14,Eli Lilly and Company,Drug: LY2189265
NCT01624259,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,Type 2 Diabetes,Interventional,9-Oct-14,Eli Lilly and Company,Drug: Liraglutide
NCT01624259,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,Type 2 Diabetes,Interventional,9-Oct-14,Eli Lilly and Company,Drug: Metformin
NCT01627327,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-Nov-13,GlaxoSmithKline,Drug: fluticasone furoate/vilanterol 100/25mcg
NCT01627327,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-Nov-13,GlaxoSmithKline,Drug: tiotropium bromide 18mcg
NCT01623323,Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps,Chronic Sinusitis With or Without Nasal Polyps,Interventional,1-Mar-16,Optinose US Inc.,Drug: Fluticasone Propionate
NCT01623310,12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device,Nasal Polyps,Interventional,24-Jan-18,Optinose US Inc.,Drug: Fluticasone Propionate
NCT01622569,"Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety",Bilateral Nasal Polyposis,Interventional,5-Dec-18,Optinose US Inc.,Drug: Fluticasone Propionate
NCT01621802,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age,Rubella|Mumps|Measles,Interventional,13-Sep-17,GlaxoSmithKline,Biological: Priorix
NCT01621802,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age,Rubella|Mumps|Measles,Interventional,13-Sep-17,GlaxoSmithKline,Biological: M-M-R II
NCT01621802,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age,Rubella|Mumps|Measles,Interventional,13-Sep-17,GlaxoSmithKline,Biological: Kinrix
NCT01621802,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age,Rubella|Mumps|Measles,Interventional,13-Sep-17,GlaxoSmithKline,Biological: ProQuad
NCT01621178,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Type 2 Diabetes|Chronic Kidney Disease,Interventional,24-Jul-17,Eli Lilly and Company,Drug: Dulaglutide
NCT01621178,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Type 2 Diabetes|Chronic Kidney Disease,Interventional,24-Jul-17,Eli Lilly and Company,Drug: Insulin glargine
NCT01621178,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Type 2 Diabetes|Chronic Kidney Disease,Interventional,24-Jul-17,Eli Lilly and Company,Drug: Insulin lispro
NCT01620489,Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment,"Diabetes|Diabetes Mellitus, Type 2",Interventional,30-Oct-14,Novo Nordisk A/S,Drug: liraglutide
NCT01620489,Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment,"Diabetes|Diabetes Mellitus, Type 2",Interventional,30-Oct-14,Novo Nordisk A/S,Drug: placebo
NCT01619059,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Mar-16,AstraZeneca,Drug: Saxagliptin
NCT01619059,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Mar-16,AstraZeneca,Drug: Dapagliflozin
NCT01619059,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Mar-16,AstraZeneca,Drug: Metformin IR
NCT01619059,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,17-Mar-16,AstraZeneca,Drug: Placebo matching with Saxagliptin
NCT01743001,Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome,Pulmonary Arterial Hypertension,Interventional,30-Jan-18,Actelion,Drug: Macitentan 10 mg
NCT01743001,Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome,Pulmonary Arterial Hypertension,Interventional,30-Jan-18,Actelion,Drug: Placebo
NCT01618669,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),Coronary Artery Disease (CAD),Interventional,8-Feb-16,"Astellas Pharma Global Development, Inc.",Drug: Regadenoson
NCT01618669,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),Coronary Artery Disease (CAD),Interventional,8-Feb-16,"Astellas Pharma Global Development, Inc.",Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
NCT01618669,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),Coronary Artery Disease (CAD),Interventional,8-Feb-16,Astellas Pharma Inc,Drug: Regadenoson
NCT01618669,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),Coronary Artery Disease (CAD),Interventional,8-Feb-16,Astellas Pharma Inc,Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
NCT01618162,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Feb-17,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT01618162,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Feb-17,Novo Nordisk A/S,Drug: placebo
NCT01617434,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,28-Oct-14,Novo Nordisk A/S,Drug: liraglutide
NCT01617434,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,28-Oct-14,Novo Nordisk A/S,Drug: placebo
NCT01624662,"Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device",Bilateral Nasal Polyposis,Interventional,5-Dec-18,Optinose US Inc.,Drug: Fluticasone propionate
NCT01614457,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT),Cystic Fibrosis,Interventional,12-Feb-15,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01614457,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT),Cystic Fibrosis,Interventional,12-Feb-15,Vertex Pharmaceuticals Incorporated,Drug: Placebo
NCT01614457,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT),Cystic Fibrosis,Interventional,12-Feb-15,Cystic Fibrosis Foundation,Drug: Ivacaftor
NCT01614457,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT),Cystic Fibrosis,Interventional,12-Feb-15,Cystic Fibrosis Foundation,Drug: Placebo
NCT01610414,"Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A",Herpes Zoster,Interventional,23-Jan-18,GlaxoSmithKline,Biological: Herpes Zoster vaccine GSK1437173A
NCT01610414,"Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A",Herpes Zoster,Interventional,23-Jan-18,GlaxoSmithKline,Biological: Placebo
NCT01607957,Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies,Colorectal Cancer,Interventional,21-May-19,"Taiho Oncology, Inc.",Drug: TAS-102
NCT01607957,Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies,Colorectal Cancer,Interventional,21-May-19,"Taiho Oncology, Inc.",Drug: Placebo
NCT01608100,Evaluation of a New Cardiac Biomarker Assay,Acute Coronary Syndrome|Acute Myocardial Infarction,Interventional,17-Mar-15,Abbott Diagnostics Division,Device: ARCHITECT STAT High Sensitive Troponin I Assay
NCT01606007,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,20-Oct-15,AstraZeneca,Drug: Saxagliptin
NCT01606007,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,20-Oct-15,AstraZeneca,Drug: Metformin XR
NCT01606007,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,20-Oct-15,AstraZeneca,Drug: Dapagliflozin
NCT01606007,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,20-Oct-15,AstraZeneca,Drug: Placebo matching with Dapagliflozin
NCT01606007,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,20-Oct-15,AstraZeneca,Drug: Placebo matching with Saxagliptin
NCT01605227,Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100,Prostate Cancer|Castration Resistant Prostate Cancer|Pain|Prostatic Neoplasms,Interventional,14-Mar-18,Exelixis,Drug: cabozantinib
NCT01605227,Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100,Prostate Cancer|Castration Resistant Prostate Cancer|Pain|Prostatic Neoplasms,Interventional,14-Mar-18,Exelixis,Drug: prednisone
NCT01604850,Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION),Chronic Hepatitis C,Interventional,1-May-14,Gilead Sciences,Drug: SOF
NCT01604850,Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION),Chronic Hepatitis C,Interventional,1-May-14,Gilead Sciences,Drug: RBV
NCT01604850,Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION),Chronic Hepatitis C,Interventional,1-May-14,Gilead Sciences,Drug: Placebo to match SOF
NCT01604850,Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION),Chronic Hepatitis C,Interventional,1-May-14,Gilead Sciences,Drug: Placebo to match RBV
NCT01603628,BOTOX® Treatment in Pediatric Lower Limb Spasticity,Pediatrics|Muscle Spasticity|Cerebral Palsy,Interventional,14-Aug-18,Allergan,Biological: botulinum toxin Type A
NCT01603628,BOTOX® Treatment in Pediatric Lower Limb Spasticity,Pediatrics|Muscle Spasticity|Cerebral Palsy,Interventional,14-Aug-18,Allergan,Drug: Normal Saline (Placebo)
NCT01603602,BOTOX® Treatment in Pediatric Upper Limb Spasticity,Pediatrics|Muscle Spasticity|Cerebral Palsy|Stroke,Interventional,14-Aug-18,Allergan,Biological: botulinum toxin Type A
NCT01603602,BOTOX® Treatment in Pediatric Upper Limb Spasticity,Pediatrics|Muscle Spasticity|Cerebral Palsy|Stroke,Interventional,14-Aug-18,Allergan,Drug: Normal Saline (Placebo)
NCT01598090,Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir,Hepatitis C Virus,Interventional,21-May-19,Bristol-Myers Squibb,Biological: Peginterferon Lambda-1a
NCT01598090,Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir,Hepatitis C Virus,Interventional,21-May-19,Bristol-Myers Squibb,Biological: Peginterferon Alfa-2a
NCT01598090,Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir,Hepatitis C Virus,Interventional,21-May-19,Bristol-Myers Squibb,Drug: Ribavirin
NCT01598090,Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir,Hepatitis C Virus,Interventional,21-May-19,Bristol-Myers Squibb,Drug: Telaprevir
NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,Melanoma,Interventional,4-Dec-14,Novartis Pharmaceuticals,Drug: Dabrafenib
NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,Melanoma,Interventional,4-Dec-14,Novartis Pharmaceuticals,Drug: Vemurafenib
NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,Melanoma,Interventional,4-Dec-14,Novartis Pharmaceuticals,Drug: Trametinib
NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,Melanoma,Interventional,4-Dec-14,Novartis,Drug: Dabrafenib
NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,Melanoma,Interventional,4-Dec-14,Novartis,Drug: Vemurafenib
NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,Melanoma,Interventional,4-Dec-14,Novartis,Drug: Trametinib
NCT01594762,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Diabetic Foot Infection,Interventional,14-Jun-17,"Dipexium Pharmaceuticals, Inc.",Drug: Topical pexiganan cream 0.8%
NCT01594762,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Diabetic Foot Infection,Interventional,14-Jun-17,"Dipexium Pharmaceuticals, Inc.",Drug: Topical placebo cream
NCT01594762,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Diabetic Foot Infection,Interventional,14-Jun-17,"Dipexium Pharmaceuticals, Inc.",Other: Standard wound care
NCT01590758,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Diabetic Foot Infection,Interventional,14-Jun-17,"Dipexium Pharmaceuticals, Inc.",Drug: Topical pexiganan cream 0.8%
NCT01590758,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Diabetic Foot Infection,Interventional,14-Jun-17,"Dipexium Pharmaceuticals, Inc.",Drug: Topical placebo cream
NCT01590758,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Diabetic Foot Infection,Interventional,14-Jun-17,"Dipexium Pharmaceuticals, Inc.",Other: Standard wound care
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,Melanoma,Interventional,15-Aug-14,Novartis Pharmaceuticals,Drug: dabrafenib
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,Melanoma,Interventional,15-Aug-14,Novartis Pharmaceuticals,Drug: dabrafenib plus trametinib placebo
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,Melanoma,Interventional,15-Aug-14,Novartis Pharmaceuticals,Drug: Trametinib
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,Melanoma,Interventional,15-Aug-14,Novartis,Drug: dabrafenib
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,Melanoma,Interventional,15-Aug-14,Novartis,Drug: dabrafenib plus trametinib placebo
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,Melanoma,Interventional,15-Aug-14,Novartis,Drug: Trametinib
NCT01583374,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Ankylosing Spondyloarthritis,Interventional,17-Mar-15,Celgene,Drug: Apremilast tablet 20 mg
NCT01583374,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Ankylosing Spondyloarthritis,Interventional,17-Mar-15,Celgene,Drug: Apremilast tablet 30 mg BID
NCT01583374,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Ankylosing Spondyloarthritis,Interventional,17-Mar-15,Celgene,Drug: Placebo
NCT01583218,Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study),Venous Thromboembolism (VTE),Interventional,20-Sep-17,Portola Pharmaceuticals,Drug: Betrixaban
NCT01583218,Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study),Venous Thromboembolism (VTE),Interventional,20-Sep-17,Portola Pharmaceuticals,Drug: Enoxaparin
NCT01582451,A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,20-Apr-18,Eli Lilly and Company,Drug: LY2605541
NCT01582451,A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,20-Apr-18,Eli Lilly and Company,Drug: Insulin glargine
NCT01582061,"An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.",Cushing's Disease,Interventional,19-Jun-18,Novartis Pharmaceuticals,Drug: Pasireotide sub-cutaneous
NCT01582061,"An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.",Cushing's Disease,Interventional,19-Jun-18,Novartis,Drug: Pasireotide sub-cutaneous
NCT01598987,"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.",Renal Function|Liver Transplant,Interventional,24-Jan-17,Novartis Pharmaceuticals,"Drug: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation."
NCT01598987,"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.",Renal Function|Liver Transplant,Interventional,24-Jan-17,Novartis,"Drug: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation."
NCT01579565,"Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification",Intraocular Lens Replacement,Interventional,22-Aug-14,Omeros Corporation,Drug: OMS302
NCT01579565,"Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification",Intraocular Lens Replacement,Interventional,22-Aug-14,Omeros Corporation,Drug: Placebo
NCT01575873,Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids,"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor",Interventional,27-Jul-18,Amgen,Drug: Denosumab
NCT01575873,Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids,"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor",Interventional,27-Jul-18,Amgen,Drug: Placebo for risendronate
NCT01575873,Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids,"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor",Interventional,27-Jul-18,Amgen,Drug: Risendronate
NCT01575873,Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids,"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor",Interventional,27-Jul-18,Amgen,Drug: Placebo for denosumab
NCT01575834,Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Romosozumab
NCT01575834,Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Placebo
NCT01575834,Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Denosumab
NCT01575561,"This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296",Bipolar I Disorder,Interventional,22-Aug-16,Sunovion,Drug: Lurasidone
NCT01694966,The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy,Colorectal Cancer,Interventional,6-Nov-17,Cosmo Technologies Ltd,Drug: Methylene Blue MMX®
NCT01694966,The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy,Colorectal Cancer,Interventional,6-Nov-17,Cosmo Technologies Ltd,Drug: Placebo
NCT01572792,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,21-Apr-17,AstraZeneca,Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
NCT01572792,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,21-Apr-17,AstraZeneca,Drug: Aclidinium bromide
NCT01572792,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,21-Apr-17,AstraZeneca,Drug: Formoterol Fumarate
NCT01572792,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,21-Apr-17,AstraZeneca,Drug: Placebo
NCT01571362,A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain,Chronic Pain|Low Back Pain|Analgesia,Interventional,4-Apr-17,Pfizer,Drug: ALO-02
NCT01571362,A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain,Chronic Pain|Low Back Pain|Analgesia,Interventional,4-Apr-17,Pfizer,Drug: Placebo
NCT01570751,"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin","Diabetes|Diabetes Mellitus, Type 2",Interventional,18-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01570751,"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin","Diabetes|Diabetes Mellitus, Type 2",Interventional,18-Nov-15,Novo Nordisk A/S,Drug: insulin glargine
NCT01569464,Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS),Restless Legs Syndrome,Interventional,26-Aug-14,UCB Pharma,Drug: Rotigotine
NCT01569464,Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS),Restless Legs Syndrome,Interventional,26-Aug-14,UCB Pharma,Other: Placebo
NCT01569295,"A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Chronic Lymphocytic Leukemia,Interventional,27-Feb-18,Gilead Sciences,Drug: Idelalisib
NCT01569295,"A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Chronic Lymphocytic Leukemia,Interventional,27-Feb-18,Gilead Sciences,Drug: Rituximab
NCT01569295,"A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Chronic Lymphocytic Leukemia,Interventional,27-Feb-18,Gilead Sciences,Drug: Bendamustine
NCT01569295,"A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Chronic Lymphocytic Leukemia,Interventional,27-Feb-18,Gilead Sciences,Drug: Placebo to match idelalisib
NCT01568866,Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,Multiple Myeloma,Interventional,11-Dec-15,Amgen,Drug: Carfilzomib
NCT01568866,Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,Multiple Myeloma,Interventional,11-Dec-15,Amgen,Drug: Bortezomib
NCT01568866,Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,Multiple Myeloma,Interventional,11-Dec-15,Amgen,Drug: Dexamethasone
NCT01614470,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation,Cystic Fibrosis,Interventional,29-Oct-14,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01614470,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation,Cystic Fibrosis,Interventional,29-Oct-14,Vertex Pharmaceuticals Incorporated,Drug: Placebo
NCT01614470,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation,Cystic Fibrosis,Interventional,29-Oct-14,Cystic Fibrosis Foundation,Drug: Ivacaftor
NCT01614470,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation,Cystic Fibrosis,Interventional,29-Oct-14,Cystic Fibrosis Foundation,Drug: Placebo
NCT01566162,"A Twelve Week, Open Label Extension Study in Patients With Schizophrenia",Schizophrenia,Interventional,20-Nov-14,Sunovion,Drug: Lurasidone
NCT01557166,Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea,Metabolism and Nutrition Disorder|Obesity|Obstructive Sleep Apnoea,Interventional,9-Feb-15,Novo Nordisk A/S,Drug: liraglutide
NCT01557166,Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea,Metabolism and Nutrition Disorder|Obesity|Obstructive Sleep Apnoea,Interventional,9-Feb-15,Novo Nordisk A/S,Drug: placebo
NCT01556997,Perindopril Amlodipine for the Treatment of Hypertension,Essential Hypertension,Interventional,25-Aug-15,Symplmed Pharmaceuticals LLC,Drug: XOMA 985
NCT01556997,Perindopril Amlodipine for the Treatment of Hypertension,Essential Hypertension,Interventional,25-Aug-15,Symplmed Pharmaceuticals LLC,Drug: Amlodipine Besylate
NCT01556997,Perindopril Amlodipine for the Treatment of Hypertension,Essential Hypertension,Interventional,25-Aug-15,Symplmed Pharmaceuticals LLC,Drug: Perindopril Erbumine
NCT01555463,"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea",Papulopustular Rosacea,Interventional,27-Jan-15,Bayer,"Drug: Azelaic acid foam, 15% (BAY39-6251)"
NCT01555463,"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea",Papulopustular Rosacea,Interventional,27-Jan-15,Bayer,Drug: Vehicle foam
NCT01555164,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,Type 2 Diabetes Mellitus,Interventional,23-Sep-14,Gilead Sciences,Drug: Ranolazine
NCT01555164,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,Type 2 Diabetes Mellitus,Interventional,23-Sep-14,Gilead Sciences,Drug: Placebo to match ranolazine
NCT01555164,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,Type 2 Diabetes Mellitus,Interventional,23-Sep-14,Gilead Sciences,Drug: Metformin
NCT01555164,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,Type 2 Diabetes Mellitus,Interventional,23-Sep-14,Gilead Sciences,Drug: Placebo to match metformin
NCT01555164,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,Type 2 Diabetes Mellitus,Interventional,23-Sep-14,Gilead Sciences,Behavioral: Diet
NCT01555164,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,Type 2 Diabetes Mellitus,Interventional,23-Sep-14,Gilead Sciences,Behavioral: Exercise
NCT01555125,First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks,Moderate to Severe Plaque-type Psoriasis,Interventional,8-Aug-18,Novartis Pharmaceuticals,Drug: secukinumab 150 mg
NCT01555125,First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks,Moderate to Severe Plaque-type Psoriasis,Interventional,8-Aug-18,Novartis Pharmaceuticals,Drug: secukinumab 300 mg
NCT01555125,First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks,Moderate to Severe Plaque-type Psoriasis,Interventional,8-Aug-18,Novartis Pharmaceuticals,Drug: placebo
NCT01555125,First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks,Moderate to Severe Plaque-type Psoriasis,Interventional,8-Aug-18,Novartis,Drug: secukinumab 150 mg
NCT01555125,First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks,Moderate to Severe Plaque-type Psoriasis,Interventional,8-Aug-18,Novartis,Drug: secukinumab 300 mg
NCT01555125,First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks,Moderate to Severe Plaque-type Psoriasis,Interventional,8-Aug-18,Novartis,Drug: placebo
NCT01554982,A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis,End Stage Renal Disease|Kidney Failure|Renal Failure|Hyperphosphatemia|ESRD,Interventional,13-Jul-16,Keryx Biopharmaceuticals,Drug: ferric citrate
NCT01553747,"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",Irritable Bowel Syndrome,Interventional,30-Jul-18,"Furiex Pharmaceuticals, Inc",Drug: Eluxadoline
NCT01553747,"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",Irritable Bowel Syndrome,Interventional,30-Jul-18,"Furiex Pharmaceuticals, Inc",Drug: Placebo
NCT01553591,"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",Irritable Bowel Syndrome,Interventional,3-Sep-18,"Furiex Pharmaceuticals, Inc",Drug: Eluxadoline
NCT01553591,"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",Irritable Bowel Syndrome,Interventional,3-Sep-18,"Furiex Pharmaceuticals, Inc",Drug: Placebo
NCT01550744,"A Study of Ustekinumab to Evaluate a ""Subject-tailored"" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis",Psoriasis,Interventional,7-Nov-16,"Janssen Biotech, Inc.",Drug: Ustekinumab 45 mg
NCT01550744,"A Study of Ustekinumab to Evaluate a ""Subject-tailored"" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis",Psoriasis,Interventional,7-Nov-16,"Janssen Biotech, Inc.",Drug: Ustekinumab 90 mg
NCT01550744,"A Study of Ustekinumab to Evaluate a ""Subject-tailored"" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis",Psoriasis,Interventional,7-Nov-16,"Janssen Biotech, Inc.",Drug: Placebo
NCT01546142,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,Moderate or Severe Submental Fullness,Interventional,15-Jun-15,Kythera Biopharmaceuticals,Drug: Deoxycholic acid injection
NCT01546142,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,Moderate or Severe Submental Fullness,Interventional,15-Jun-15,Kythera Biopharmaceuticals,Drug: Placebo
NCT01544595,Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab,Moderate to Severe Plaque-type Psoriasis,Interventional,20-Dec-18,Novartis Pharmaceuticals,Drug: Secukinumab (AIN457)
NCT01544595,Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab,Moderate to Severe Plaque-type Psoriasis,Interventional,20-Dec-18,Novartis Pharmaceuticals,Drug: Placebo
NCT01544595,Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab,Moderate to Severe Plaque-type Psoriasis,Interventional,20-Dec-18,Novartis,Drug: Secukinumab (AIN457)
NCT01544595,Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab,Moderate to Severe Plaque-type Psoriasis,Interventional,20-Dec-18,Novartis,Drug: Placebo
NCT01543178,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Interventional,8-Jul-15,"Bausch Health Americas, Inc.",Drug: open-label rifaximin
NCT01543178,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Interventional,8-Jul-15,"Bausch Health Americas, Inc.",Drug: double-blind placebo
NCT01543178,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Interventional,8-Jul-15,"Bausch Health Americas, Inc.",Drug: double-blind rifaximin
NCT01542788,"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",Chronic Hepatitis C,Interventional,17-Feb-14,Gilead Sciences,Drug: SOF
NCT01542788,"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",Chronic Hepatitis C,Interventional,17-Feb-14,Gilead Sciences,Drug: RBV
NCT01542788,"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",Chronic Hepatitis C,Interventional,17-Feb-14,Gilead Sciences,Drug: Placebo to match SOF
NCT01542788,"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",Chronic Hepatitis C,Interventional,17-Feb-14,Gilead Sciences,Drug: Placebo to match RBV
NCT01552343,Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary,Nocturia,Interventional,5-May-17,Ferring Pharmaceuticals,Drug: Desmopressin
NCT01552343,Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary,Nocturia,Interventional,5-May-17,Ferring Pharmaceuticals,Drug: Placebo
NCT01542034,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,Moderate or Severe Submental Fullness,Interventional,15-Jun-15,Kythera Biopharmaceuticals,Drug: Deoxycholic acid injection
NCT01542034,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,Moderate or Severe Submental Fullness,Interventional,15-Jun-15,Kythera Biopharmaceuticals,Drug: Placebo
NCT01541553,A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp,Actinic Keratosis,Interventional,28-Mar-14,LEO Pharma,Procedure: Cryotherapy
NCT01541553,A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp,Actinic Keratosis,Interventional,28-Mar-14,LEO Pharma,Drug: Vehicle
NCT01541553,A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp,Actinic Keratosis,Interventional,28-Mar-14,LEO Pharma,Drug: Ingenol metabute
NCT01541215,"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,11-Dec-18,Novo Nordisk A/S,Drug: liraglutide
NCT01541215,"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,11-Dec-18,Novo Nordisk A/S,Drug: placebo
NCT01541215,"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,11-Dec-18,Novo Nordisk A/S,Drug: metformin
NCT01539538,"A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain",Post-Operative Pain,Interventional,27-Mar-14,"AcelRx Pharmaceuticals, Inc.",Drug: Sufentanil NanoTab PCA System/15 mcg
NCT01539538,"A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain",Post-Operative Pain,Interventional,27-Mar-14,"AcelRx Pharmaceuticals, Inc.",Drug: morphine IV PCA
NCT01539512,"A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Chronic Lymphocytic Leukemia,Interventional,16-Oct-14,Gilead Sciences,Drug: Idelalisib
NCT01539512,"A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Chronic Lymphocytic Leukemia,Interventional,16-Oct-14,Gilead Sciences,Drug: Rituximab
NCT01539512,"A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Chronic Lymphocytic Leukemia,Interventional,16-Oct-14,Gilead Sciences,Drug: Placebo to match idelalisib
NCT01539642,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery",Post-Operative Pain,Interventional,3-Feb-14,"AcelRx Pharmaceuticals, Inc.",Drug: Sufentanil NanoTab PCA System/15 mcg
NCT01539642,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery",Post-Operative Pain,Interventional,3-Feb-14,"AcelRx Pharmaceuticals, Inc.",Drug: Placebo Sufentanil NanoTab PCA System
NCT01534208,Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism,Secondary Hypogonadism,Interventional,24-Jul-14,Repros Therapeutics Inc.,Drug: Androxal
NCT01533428,A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN),Diabetic Peripheral Neuropathy|Pain,Interventional,13-Mar-15,Astellas Pharma Inc,Drug: Capsaicin 8%
NCT01533428,A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN),Diabetic Peripheral Neuropathy|Pain,Interventional,13-Mar-15,Astellas Pharma Inc,Drug: Placebo
NCT01532869,A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis,"Sclerosis, Systemic",Interventional,5-Nov-15,Hoffmann-La Roche,Drug: Placebo
NCT01532869,A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis,"Sclerosis, Systemic",Interventional,5-Nov-15,Hoffmann-La Roche,Drug: tocilizumab [RoActemra/Actemra]
NCT01532414,Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism,Secondary Hypogonadism,Interventional,27-May-15,Repros Therapeutics Inc.,Drug: Androxal
NCT01532414,Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism,Secondary Hypogonadism,Interventional,27-May-15,Repros Therapeutics Inc.,Drug: Placebo
NCT01533935,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: Placebo
NCT01533935,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: Tiotropium + Olodaterol
NCT01533935,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: tiotropium + Olodaterol
NCT01533935,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: Tiotropium
NCT01533935,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: Olodaterol
NCT01533935,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Device: Respimat
NCT01529515,A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,18-Jun-15,"Janssen Research & Development, LLC",Drug: PP3M 175 mg eq.
NCT01529515,A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,18-Jun-15,"Janssen Research & Development, LLC",Drug: PP3M 263 mg eq.
NCT01529515,A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,18-Jun-15,"Janssen Research & Development, LLC",Drug: PP3M 350 mg eq.
NCT01529515,A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,18-Jun-15,"Janssen Research & Development, LLC",Drug: PP3M 525 mg eq.
NCT01529515,A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,18-Jun-15,"Janssen Research & Development, LLC",Drug: Placebo (20% Intralipid emulsion)
NCT01525615,A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Device: Respimat inhaler
NCT01525615,A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: tiotropium+olodaterol (low dose)
NCT01525615,A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: tiotropium + olodaterol (high dose)
NCT01525615,A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: placebo to tiotropium+olodaterol
NCT01523587,LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy,"Carcinoma, Non-Small-Cell Lung",Interventional,21-Nov-14,Boehringer Ingelheim,Drug: afatinib
NCT01523587,LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy,"Carcinoma, Non-Small-Cell Lung",Interventional,21-Nov-14,Boehringer Ingelheim,Drug: erlotinib
NCT01521923,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,10-Jan-17,UCB Pharma,Biological: Certolizumab Pegol + Methotrexate (MTX)
NCT01521923,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,10-Jan-17,UCB Pharma,Biological: Placebo + Methotrexate (MTX)
NCT01519791,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,22-Sep-15,UCB Pharma SA,Biological: Certolizumab Pegol
NCT01519791,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,22-Sep-15,UCB Pharma SA,Other: Placebo
NCT01519791,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,22-Sep-15,UCB Pharma SA,Biological: Methotrexate
NCT01519791,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,22-Sep-15,UCB Pharma,Biological: Certolizumab Pegol
NCT01519791,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,22-Sep-15,UCB Pharma,Other: Placebo
NCT01519791,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,22-Sep-15,UCB Pharma,Biological: Methotrexate
NCT01517412,Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin,Type 2 Diabetes Mellitus,Interventional,14-Oct-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT01517412,Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin,Type 2 Diabetes Mellitus,Interventional,14-Oct-16,Sanofi,Device: Self-injector pen device (OptiClik®)
NCT01517412,Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin,Type 2 Diabetes Mellitus,Interventional,14-Oct-16,Sanofi,Drug: Metformin
NCT01516879,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,Hypercholesterolemia,Interventional,29-Sep-15,Amgen,Biological: Evolocumab
NCT01516879,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,Hypercholesterolemia,Interventional,29-Sep-15,Amgen,Biological: Placebo
NCT01516879,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,Hypercholesterolemia,Interventional,29-Sep-15,Amgen,Drug: Atorvastatin
NCT01516879,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,Hypercholesterolemia,Interventional,29-Sep-15,Amgen,Drug: Ezetimibe
NCT01516879,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,Hypercholesterolemia,Interventional,29-Sep-15,Amgen,Other: Diet Only
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: PP3M 175 mg eq.
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: PP3M 263 mg eq.
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: PP3M 350 mg eq.
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: PP3M 525 mg eq.
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: Placebo (20% Intralipid)
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: PP1M 50 mg eq.
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: PP1M 75 mg eq.
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: PP1M 100 mg eq.
NCT01515423,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Schizophrenia,Interventional,2-May-16,"Janssen Research & Development, LLC",Drug: PP1M 150 mg eq.
NCT01513759,Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy,Pulmonary Embolism|Acute Pulmonary Embolism|Sub-massive Pulmonary Embolism|Massive Pulmonary Embolism|Pulmonary Thromboembolism,Interventional,3-Jul-19,EKOS Corporation,Drug: recombinant tissue plasminogen activator
NCT01513759,Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy,Pulmonary Embolism|Acute Pulmonary Embolism|Sub-massive Pulmonary Embolism|Massive Pulmonary Embolism|Pulmonary Thromboembolism,Interventional,3-Jul-19,EKOS Corporation,Device: EKOS EkoSonic Endovascular System
NCT01513473,A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 1",Interventional,12-Jan-16,Novo Nordisk A/S,Drug: insulin degludec
NCT01513473,A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 1",Interventional,12-Jan-16,Novo Nordisk A/S,Drug: insulin detemir
NCT01513473,A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 1",Interventional,12-Jan-16,Novo Nordisk A/S,Drug: insulin aspart
NCT01515189,Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab,Melanoma,Interventional,24-Mar-17,Bristol-Myers Squibb,Biological: Ipilimumab
NCT01533259,"Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,26-Jan-15,Gilead Sciences,Drug: Stribild
NCT01510912,Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain,Osteoarthritis,Interventional,9-May-14,"Iroko Pharmaceuticals, LLC",Drug: Diclofenac
NCT01510769,Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat,Tophaceous Gout,Interventional,26-May-16,"Ardea Biosciences, Inc.",Drug: Lesinurad
NCT01510769,Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat,Tophaceous Gout,Interventional,26-May-16,"Ardea Biosciences, Inc.",Drug: Placebo
NCT01510769,Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat,Tophaceous Gout,Interventional,26-May-16,"Ardea Biosciences, Inc.",Drug: Febuxostat
NCT01510158,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Interventional,18-Aug-16,"Ardea Biosciences, Inc.",Drug: Lesinurad
NCT01510158,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Interventional,18-Aug-16,"Ardea Biosciences, Inc.",Drug: Placebo
NCT01510158,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Interventional,18-Aug-16,"Ardea Biosciences, Inc.",Drug: Allopurinol
NCT01508936,Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Reslizumab
NCT01508936,Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT01508936,Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,Teva Pharmaceutical Industries,Drug: Reslizumab
NCT01508936,Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,Teva Pharmaceutical Industries,Drug: Placebo
NCT01508910,Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina,Chronic Myocardial Ischemia|Refractory Angina Pectoris|Advanced Coronary Heart Disease,Interventional,15-Feb-17,"Caladrius Biosciences, Inc.",Biological: Auto-CD34+ cells
NCT01508910,Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina,Chronic Myocardial Ischemia|Refractory Angina Pectoris|Advanced Coronary Heart Disease,Interventional,15-Feb-17,"Caladrius Biosciences, Inc.",Biological: Placebo: Diluent used to suspend Auto-CD34+ cells
NCT01508910,Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina,Chronic Myocardial Ischemia|Refractory Angina Pectoris|Advanced Coronary Heart Disease,Interventional,15-Feb-17,"Caladrius Biosciences, Inc.",Other: Standard of care
NCT01508702,Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors,Gout,Interventional,12-Feb-16,"Ardea Biosciences, Inc.",Drug: lesinurad
NCT01508702,Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors,Gout,Interventional,12-Feb-16,"Ardea Biosciences, Inc.",Drug: Placebo
NCT01503021,Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis,End Stage Renal Disease|Chronic Kidney Disease,Interventional,21-Apr-15,"Rockwell Medical Technologies, Inc.",Drug: SFP
NCT01503021,Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis,End Stage Renal Disease|Chronic Kidney Disease,Interventional,21-Apr-15,"Rockwell Medical Technologies, Inc.",Other: Placebo
NCT01500434,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL),Coronary Artery Disease,Interventional,14-Feb-12,Boston Scientific Corporation,Device: PROMUS Element Coronary Stent System
NCT01500434,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL),Coronary Artery Disease,Interventional,14-Feb-12,Boston Scientific Corporation,Drug: Aspirin
NCT01500434,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL),Coronary Artery Disease,Interventional,14-Feb-12,Boston Scientific Corporation,Drug: Thienopyridine
NCT01499095,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy,Type 2 Diabetes Mellitus,Interventional,23-Apr-15,Sanofi,Drug: Lantus (Insulin glargine)
NCT01499095,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy,Type 2 Diabetes Mellitus,Interventional,23-Apr-15,Sanofi,Drug: HOE901-U300 (new formulation of insulin glargine)
NCT01499082,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin,Type 2 Diabetes Mellitus,Interventional,23-Apr-15,Sanofi,Drug: HOE901-U300 (new formulation of insulin glargine)
NCT01499082,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin,Type 2 Diabetes Mellitus,Interventional,23-Apr-15,Sanofi,Drug: Lantus (insulin glargine)
NCT01497938,Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature,Type 1 Diabetes,Interventional,17-Mar-14,Medtronic Diabetes,Device: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature
NCT01497938,Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature,Type 1 Diabetes,Interventional,17-Mar-14,Medtronic Diabetes,Device: Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
NCT01497366,Phase 3 Study of Sofosbuvir and Ribavirin,Hepatitis C,Interventional,2-Apr-14,Gilead Sciences,Drug: Sofosbuvir
NCT01497366,Phase 3 Study of Sofosbuvir and Ribavirin,Hepatitis C,Interventional,2-Apr-14,Gilead Sciences,Drug: PEG
NCT01497366,Phase 3 Study of Sofosbuvir and Ribavirin,Hepatitis C,Interventional,2-Apr-14,Gilead Sciences,Drug: RBV
NCT01495702,"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,26-Jan-15,Gilead Sciences,Drug: NNRTI
NCT01495702,"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,26-Jan-15,Gilead Sciences,Drug: FTC/TDF
NCT01495702,"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,26-Jan-15,Gilead Sciences,Drug: Stribild
NCT01494987,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,1-Sep-14,Gilead Sciences,Drug: Ranolazine
NCT01494987,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,1-Sep-14,Gilead Sciences,Drug: Placebo
NCT01494987,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,1-Sep-14,Gilead Sciences,Drug: Glimepiride
NCT01494987,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,1-Sep-14,Gilead Sciences,Behavioral: Diet
NCT01494987,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,1-Sep-14,Gilead Sciences,Behavioral: Exercise
NCT01494506,"Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer",Metastatic Pancreatic Cancer,Interventional,12-Feb-16,Merrimack Pharmaceuticals,Drug: MM-398
NCT01494506,"Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer",Metastatic Pancreatic Cancer,Interventional,12-Feb-16,Merrimack Pharmaceuticals,Drug: 5 Fluorouracil
NCT01494506,"Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer",Metastatic Pancreatic Cancer,Interventional,12-Feb-16,Merrimack Pharmaceuticals,Drug: Leucovorin
NCT01494467,Phase 3 Papulopustular Rosacea Study,Papulopustular Rosacea,Interventional,16-Jan-15,Galderma,Drug: CD5024
NCT01494467,Phase 3 Papulopustular Rosacea Study,Papulopustular Rosacea,Interventional,16-Jan-15,Galderma,Drug: Azelaic acid 15% Gel
NCT01493778,Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A,Congenital Bleeding Disorder|Haemophilia A,Interventional,30-Oct-18,Novo Nordisk A/S,Drug: turoctocog alfa
NCT01493687,Phase 3 Papulopustular Rosacea Study,Papulopustular Rosacea (PPR),Interventional,16-Jan-15,Galderma,Drug: CD5024
NCT01493687,Phase 3 Papulopustular Rosacea Study,Papulopustular Rosacea (PPR),Interventional,16-Jan-15,Galderma,Drug: Azelaic acid 15% Gel
NCT01493531,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Interventional,26-May-16,"Ardea Biosciences, Inc.",Drug: Lesinurad
NCT01493531,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Interventional,26-May-16,"Ardea Biosciences, Inc.",Drug: Placebo
NCT01493531,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Interventional,26-May-16,"Ardea Biosciences, Inc.",Drug: Allopurinol
NCT01492426,Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection,Hepatitis C,Interventional,3-Jun-16,Bristol-Myers Squibb,Drug: Daclatasvir
NCT01492426,Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection,Hepatitis C,Interventional,3-Jun-16,Bristol-Myers Squibb,Drug: Telaprevir
NCT01492426,Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection,Hepatitis C,Interventional,3-Jun-16,Bristol-Myers Squibb,Drug: Peginterferon alfa-2a
NCT01492426,Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection,Hepatitis C,Interventional,3-Jun-16,Bristol-Myers Squibb,Drug: Ribavirin
NCT01533922,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: Placebo
NCT01533922,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: Tiotropium
NCT01533922,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: Olodaterol
NCT01533922,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: tiotropium + olodaterol
NCT01533922,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Drug: Tiotropium + Olodaterol
NCT01533922,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,15-Sep-15,Boehringer Ingelheim,Device: Respimat
NCT01485991,"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy",Hepatitis C,Interventional,10-Apr-15,Janssen R&D Ireland,Drug: TMC435
NCT01485991,"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy",Hepatitis C,Interventional,10-Apr-15,Janssen R&D Ireland,Drug: TVR
NCT01484977,eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam,Epilepsy,Interventional,26-Nov-14,UCB Pharma,Drug: Lacosamide
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Interventional,31-Jul-18,"Millennium Pharmaceuticals, Inc.",Drug: Alisertib
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Interventional,31-Jul-18,"Millennium Pharmaceuticals, Inc.",Drug: Pralatrexate
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Interventional,31-Jul-18,"Millennium Pharmaceuticals, Inc.",Drug: Gemcitabine
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Interventional,31-Jul-18,"Millennium Pharmaceuticals, Inc.",Drug: Romidepsin
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Interventional,31-Jul-18,Takeda,Drug: Alisertib
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Interventional,31-Jul-18,Takeda,Drug: Pralatrexate
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Interventional,31-Jul-18,Takeda,Drug: Gemcitabine
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Interventional,31-Jul-18,Takeda,Drug: Romidepsin
NCT01481779,A Study in Participants With Type 1 Diabetes Mellitus,"Diabetes Mellitus, Type 1",Interventional,17-Apr-18,Eli Lilly and Company,Drug: Glargine
NCT01481779,A Study in Participants With Type 1 Diabetes Mellitus,"Diabetes Mellitus, Type 1",Interventional,17-Apr-18,Eli Lilly and Company,Drug: LY2605541
NCT01481779,A Study in Participants With Type 1 Diabetes Mellitus,"Diabetes Mellitus, Type 1",Interventional,17-Apr-18,Eli Lilly and Company,Drug: Insulin Lispro
NCT01475838,"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,26-Jan-15,Gilead Sciences,Drug: PI
NCT01475838,"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,26-Jan-15,Gilead Sciences,Drug: RTV
NCT01475838,"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,26-Jan-15,Gilead Sciences,Drug: FTC/TDF
NCT01475838,"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,26-Jan-15,Gilead Sciences,Drug: Stribild
NCT01475825,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,Hypercholesterolemia|Heterozygous Familial,Interventional,14-Mar-19,"Kastle Therapeutics, LLC",Drug: mipomersen sodium 200 mg
NCT01475825,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,Hypercholesterolemia|Heterozygous Familial,Interventional,14-Mar-19,"Kastle Therapeutics, LLC",Drug: Placebo
NCT01475825,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,Hypercholesterolemia|Heterozygous Familial,Interventional,14-Mar-19,"Kastle Therapeutics, LLC",Drug: mipomersen sodium 70 mg
NCT01474772,Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN),Diabetic Peripheral Neuropathy,Interventional,18-Nov-14,Pfizer,Drug: Pregabalin
NCT01474772,Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN),Diabetic Peripheral Neuropathy,Interventional,18-Nov-14,Pfizer,Other: placebo
NCT01474512,A Phase 3 Study in Participants With Moderate to Severe Psoriasis,Psoriasis,Interventional,27-May-16,Eli Lilly and Company,"Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3"
NCT01474512,A Phase 3 Study in Participants With Moderate to Severe Psoriasis,Psoriasis,Interventional,27-May-16,Eli Lilly and Company,Drug: Placebo
NCT01474109,Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients,Systemic Sclerosis|Ulcers,Interventional,6-Jan-15,Actelion,Drug: macitentan 3mg
NCT01474109,Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients,Systemic Sclerosis|Ulcers,Interventional,6-Jan-15,Actelion,Drug: macitentan 10mg
NCT01474109,Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients,Systemic Sclerosis|Ulcers,Interventional,6-Jan-15,Actelion,Drug: placebo
NCT01473602,Second Study of the Effect of Teriparatide on Hip Fracture Healing,Femur Neck Fracture,Interventional,17-Nov-14,Eli Lilly and Company,Drug: Teriparatide
NCT01473602,Second Study of the Effect of Teriparatide on Hip Fracture Healing,Femur Neck Fracture,Interventional,17-Nov-14,Eli Lilly and Company,Drug: Placebo
NCT01473602,Second Study of the Effect of Teriparatide on Hip Fracture Healing,Femur Neck Fracture,Interventional,17-Nov-14,Eli Lilly and Company,Dietary Supplement: Calcium supplementation
NCT01473602,Second Study of the Effect of Teriparatide on Hip Fracture Healing,Femur Neck Fracture,Interventional,17-Nov-14,Eli Lilly and Company,Dietary Supplement: Vitamin D supplementation
NCT01473589,Effect of Teriparatide on Hip Fracture Healing,Femur Neck Fracture,Interventional,17-Nov-14,Eli Lilly and Company,Drug: Teriparatide
NCT01473589,Effect of Teriparatide on Hip Fracture Healing,Femur Neck Fracture,Interventional,17-Nov-14,Eli Lilly and Company,Drug: Placebo
NCT01473589,Effect of Teriparatide on Hip Fracture Healing,Femur Neck Fracture,Interventional,17-Nov-14,Eli Lilly and Company,Dietary Supplement: Calcium supplementation
NCT01473589,Effect of Teriparatide on Hip Fracture Healing,Femur Neck Fracture,Interventional,17-Nov-14,Eli Lilly and Company,Dietary Supplement: Vitamin D supplementation
NCT01473524,Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis,Primary Biliary Cirrhosis,Interventional,13-Feb-17,Intercept Pharmaceuticals,Drug: Obeticholic Acid (OCA)
NCT01473524,Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis,Primary Biliary Cirrhosis,Interventional,13-Feb-17,Intercept Pharmaceuticals,Drug: Placebo
NCT01474538,Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,Eli Lilly and Company,Drug: Insulin Lispro
NCT01474538,Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy,Type 2 Diabetes Mellitus,Interventional,20-Mar-14,Eli Lilly and Company,Drug: Insulin Aspart
NCT01472185,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,15-Oct-14,Gilead Sciences,Drug: Ranolazine
NCT01472185,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,15-Oct-14,Gilead Sciences,Drug: Placebo
NCT01472185,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,15-Oct-14,Gilead Sciences,Behavioral: Diet
NCT01472185,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,15-Oct-14,Gilead Sciences,Behavioral: Exercise
NCT01479868,"A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1",Hepatitis C Virus Genotype-1,Interventional,29-Oct-14,Janssen R&D Ireland,Drug: TMC435
NCT01479868,"A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1",Hepatitis C Virus Genotype-1,Interventional,29-Oct-14,Janssen R&D Ireland,Drug: Pegylated interferon alpha-2a
NCT01479868,"A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1",Hepatitis C Virus Genotype-1,Interventional,29-Oct-14,Janssen R&D Ireland,Drug: Ribavirin
NCT01471574,Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus,"Hepatitis C, Genotype 1",Interventional,17-Dec-15,Bristol-Myers Squibb,Drug: Daclatasvir
NCT01471574,Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus,"Hepatitis C, Genotype 1",Interventional,17-Dec-15,Bristol-Myers Squibb,Drug: Ribavirin
NCT01471574,Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus,"Hepatitis C, Genotype 1",Interventional,17-Dec-15,Bristol-Myers Squibb,Drug: PEG-Interferon alfa 2a
NCT01471028,Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure,Acute Alcoholic Hepatitis,Interventional,15-Feb-19,"Vital Therapies, Inc.",Biological: ELAD treatment
NCT01471028,Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure,Acute Alcoholic Hepatitis,Interventional,15-Feb-19,"Vital Therapies, Inc.",Other: Standard of care (Control)
NCT01469039,"A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia",Schizophrenia,Interventional,22-Jan-16,"Alkermes, Inc.",Drug: ALKS 9072
NCT01469039,"A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia",Schizophrenia,Interventional,22-Jan-16,"Alkermes, Inc.",Drug: Placebo
NCT01468987,A Study in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,17-Apr-18,Eli Lilly and Company,Drug: LY2605541
NCT01468987,A Study in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,17-Apr-18,Eli Lilly and Company,Drug: Insulin Glargine
NCT01468987,A Study in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,17-Apr-18,Eli Lilly and Company,Drug: Insulin Lispro
NCT01465763,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis",Ulcerative Colitis,Interventional,7-Jun-16,Pfizer,Drug: tofacitinib
NCT01465763,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis",Ulcerative Colitis,Interventional,7-Jun-16,Pfizer,Drug: Placebo
NCT01467882,"Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty",Central Precocious Puberty,Interventional,4-Sep-15,Debiopharm International SA,Drug: Triptorelin
NCT01464307,Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke,Post-stroke Spasticity of the Lower Limb,Interventional,7-Nov-16,Merz Pharmaceuticals GmbH,Drug: IncobotulinumtoxinA (400 Units)
NCT01464307,Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke,Post-stroke Spasticity of the Lower Limb,Interventional,7-Nov-16,Merz Pharmaceuticals GmbH,Drug: Placebo Comparator
NCT01769378,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),Type 2 Diabetes Mellitus,Interventional,14-Oct-15,Eli Lilly and Company,Drug: Placebo
NCT01769378,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),Type 2 Diabetes Mellitus,Interventional,14-Oct-15,Eli Lilly and Company,Drug: Dulaglutide
NCT01769378,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),Type 2 Diabetes Mellitus,Interventional,14-Oct-15,Eli Lilly and Company,Drug: Glimepiride
NCT01462812,Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine,Migraine Headache,Interventional,6-May-15,Optinose US Inc.,Drug: Sumatriptan
NCT01462812,Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine,Migraine Headache,Interventional,6-May-15,Optinose US Inc.,Drug: Placebo
NCT01461369,Study of Diclofenac Capsules to Treat Osteoarthritis Pain,Osteoarthritis,Interventional,26-May-14,"Iroko Pharmaceuticals, LLC",Drug: Diclofenac
NCT01461369,Study of Diclofenac Capsules to Treat Osteoarthritis Pain,Osteoarthritis,Interventional,26-May-14,"Iroko Pharmaceuticals, LLC",Drug: Placebo
NCT01458951,"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis",Ulcerative Colitis,Interventional,1-Jun-16,Pfizer,Drug: tofacitinib
NCT01458951,"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis",Ulcerative Colitis,Interventional,1-Jun-16,Pfizer,Drug: Placebo
NCT01458574,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,Interventional,18-May-17,Pfizer,Drug: Placebo
NCT01458574,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,Interventional,18-May-17,Pfizer,"Drug: CP690,550"
NCT01458574,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,Interventional,18-May-17,Pfizer,"Drug: CP-690,550"
NCT01458275,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,15-May-14,Sunovion,Drug: Ciclesonide nasal aerosol 37 mcg
NCT01458275,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,15-May-14,Sunovion,Drug: ciclesonide nasal aerosol 74 mcg
NCT01458275,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Interventional,15-May-14,Sunovion,Drug: Placebo
NCT01457352,Efficacy and Safety of SPARC0921 in Subjects With Spasticity,Spasticity,Interventional,18-Jun-19,Sun Pharma Advanced Research Company Limited,Drug: SPARC0921
NCT01457352,Efficacy and Safety of SPARC0921 in Subjects With Spasticity,Spasticity,Interventional,18-Jun-19,Sun Pharma Advanced Research Company Limited,Drug: Placebo0921
NCT01456195,Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,5-Apr-16,Takeda,Drug: Placebo
NCT01456195,Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,5-Apr-16,Takeda,Drug: Fasiglifam
NCT01456000,HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF),Paroxysmal Atrial Fibrillation,Interventional,8-Sep-16,CardioFocus,Device: EAS-AC (HeartLight)
NCT01456000,HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF),Paroxysmal Atrial Fibrillation,Interventional,8-Sep-16,CardioFocus,Procedure: Control Arm Ablation
NCT01455415,Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain,Painful Diabetic Peripheral Neuropathy,Interventional,23-Apr-15,Pfizer,Drug: pregabalin
NCT01455415,Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain,Painful Diabetic Peripheral Neuropathy,Interventional,23-Apr-15,Pfizer,Drug: placebo
NCT01454739,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,Hemophilia A,Interventional,22-Nov-18,Bioverativ Therapeutics Inc.,Drug: rFVIIIFc
NCT01454934,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Interventional,1-Mar-17,Eisai Inc.,Drug: Eribulin
NCT01454934,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Interventional,1-Mar-17,Eisai Inc.,"Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed"
NCT01454284,A Study in Participants With Type I Diabetes Mellitus,"Diabetes Mellitus, Type 1",Interventional,17-Apr-18,Eli Lilly and Company,Drug: Glargine
NCT01454284,A Study in Participants With Type I Diabetes Mellitus,"Diabetes Mellitus, Type 1",Interventional,17-Apr-18,Eli Lilly and Company,Drug: LY2605541
NCT01454284,A Study in Participants With Type I Diabetes Mellitus,"Diabetes Mellitus, Type 1",Interventional,17-Apr-18,Eli Lilly and Company,Drug: Insulin Lispro
NCT01454063,Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification,Intraocular Lens Replacement,Interventional,21-Aug-14,Omeros Corporation,Drug: OMS302
NCT01454063,Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification,Intraocular Lens Replacement,Interventional,21-Aug-14,Omeros Corporation,Drug: Placebo
NCT01452529,Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain,Chronic Low Back Pain,Interventional,4-Dec-14,Purdue Pharma LP,Drug: Hydrocodone bitartrate q24h film-coated tablets
NCT01452529,Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain,Chronic Low Back Pain,Interventional,4-Dec-14,Purdue Pharma LP,Drug: Placebo to match hydrocodone bitartrate q24h tablets
NCT01451541,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).,Perennial Allergic Rhinitis|PAR,Interventional,6-May-14,Sunovion,Drug: Ciclesonide nasal aerosol 37 mcg
NCT01451541,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).,Perennial Allergic Rhinitis|PAR,Interventional,6-May-14,Sunovion,Drug: ciclesonide nasal aerosol 74 mcg
NCT01451541,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).,Perennial Allergic Rhinitis|PAR,Interventional,6-May-14,Sunovion,Drug: Placebo
NCT01451398,Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes,Interventional,17-Oct-14,Mannkind Corporation,Drug: Technosphere® Insulin
NCT01451398,Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus,Type 2 Diabetes,Interventional,17-Oct-14,Mannkind Corporation,Drug: Technosphere Powder
NCT01450761,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,Small Cell Lung Carcinoma,Interventional,18-Jul-16,Bristol-Myers Squibb,Biological: Ipilimumab
NCT01450761,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,Small Cell Lung Carcinoma,Interventional,18-Jul-16,Bristol-Myers Squibb,Biological: Placebo matching Ipilimumab
NCT01450761,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,Small Cell Lung Carcinoma,Interventional,18-Jul-16,Bristol-Myers Squibb,Drug: Etoposide
NCT01450761,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,Small Cell Lung Carcinoma,Interventional,18-Jul-16,Bristol-Myers Squibb,Drug: Cisplatin
NCT01450761,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,Small Cell Lung Carcinoma,Interventional,18-Jul-16,Bristol-Myers Squibb,Drug: Carboplatin
NCT01447719,Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07,Alzheimer's Disease,Interventional,7-May-12,Avid Radiopharmaceuticals,Drug: florbetapir F 18
NCT01446042,Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism,Male Hypogonadism,Interventional,13-Jun-18,Acerus Pharmaceuticals Corporation,Drug: Testosterone
NCT01445951,Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period,Type 1 Diabetes Mellitus,Interventional,22-Oct-14,Mannkind Corporation,Drug: Technosphere® Insulin with MedTone C Inhaler
NCT01445951,Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period,Type 1 Diabetes Mellitus,Interventional,22-Oct-14,Mannkind Corporation,Drug: Technosphere ®Insulin with Gen2 Inhaler
NCT01445951,Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period,Type 1 Diabetes Mellitus,Interventional,22-Oct-14,Mannkind Corporation,Drug: Insulin Aspart in combination with a basal insulin
NCT01444430,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,Asthma,Interventional,15-Dec-16,AstraZeneca,Drug: Symbicort pMDI
NCT01444430,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,Asthma,Interventional,15-Dec-16,AstraZeneca,Drug: budesonide pMDI
NCT01444417,Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients,Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenic Purpura|Immune Thrombocytopenia,Interventional,19-Jan-17,Amgen,Drug: Romiplostim
NCT01444417,Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients,Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenic Purpura|Immune Thrombocytopenia,Interventional,19-Jan-17,Amgen,Drug: Placebo
NCT01442038,Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI),Coronary Artery Disease|Angina Pectoris,Interventional,15-Jul-16,Gilead Sciences,Drug: Ranolazine
NCT01442038,Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI),Coronary Artery Disease|Angina Pectoris,Interventional,15-Jul-16,Gilead Sciences,Drug: Placebo
NCT01442376,Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients,Chemotherapy-Induced Nausea and Vomiting,Interventional,28-Jul-14,Helsinn Healthcare SA,Drug: Palonosetron
NCT01442376,Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients,Chemotherapy-Induced Nausea and Vomiting,Interventional,28-Jul-14,Helsinn Healthcare SA,Drug: Ondansetron
NCT01442376,Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients,Chemotherapy-Induced Nausea and Vomiting,Interventional,28-Jul-14,Helsinn Healthcare SA,Drug: Placebo to Ondansetron
NCT01442376,Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients,Chemotherapy-Induced Nausea and Vomiting,Interventional,28-Jul-14,Helsinn Healthcare SA,Drug: Placebo to Palonosetron
NCT01444092,Safety Study of Entocort for Children With Crohn's Disease,Crohn's Disease,Interventional,11-Aug-16,Perrigo Company,Drug: Entocort
NCT01437540,Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease,Interventional,11-May-17,AstraZeneca,Drug: Aclidinium Bromide/Formoterol Fumarate
NCT01437540,Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease,Interventional,11-May-17,AstraZeneca,Drug: Formoterol Fumarate
NCT01437397,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,23-Mar-17,AstraZeneca,Drug: Aclidinium Bromide/Formoterol Fumarate
NCT01437397,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,23-Mar-17,AstraZeneca,Drug: Aclidinium Bromide
NCT01437397,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,23-Mar-17,AstraZeneca,Drug: Formoterol Fumarate
NCT01437397,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,23-Mar-17,AstraZeneca,Drug: Placebo
NCT01436162,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,7-Nov-14,Shire,Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
NCT01436162,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,7-Nov-14,Shire,Drug: Antidepressant + Placebo
NCT01436149,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,19-Nov-14,Shire,Drug: SPD489 (Lisdexamfetamine dimesylate )
NCT01436149,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,19-Nov-14,Shire,Drug: Placebo
NCT01436110,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma,Asthma,Interventional,3-Sep-14,GlaxoSmithKline,Drug: Fluticasone furoate 50mcg
NCT01436110,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma,Asthma,Interventional,3-Sep-14,GlaxoSmithKline,Drug: Fluticasone propionate 100mcg
NCT01436110,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma,Asthma,Interventional,3-Sep-14,GlaxoSmithKline,Drug: Placebo
NCT01435928,PEARL Schizophrenia Maintenance,Schizophrenia,Interventional,25-Sep-14,Sunovion,Drug: Lurasidone
NCT01435928,PEARL Schizophrenia Maintenance,Schizophrenia,Interventional,25-Sep-14,Sunovion,Drug: Matching Placebo
NCT01435616,A Study in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,13-Apr-18,Eli Lilly and Company,Drug: Glargine
NCT01435616,A Study in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,13-Apr-18,Eli Lilly and Company,Drug: LY2605541
NCT01432444,Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole,Schizophrenia,Interventional,27-Mar-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole (Abilify®) IM Depot Injection
NCT01438710,Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO),Renal Failure|Tremors,Interventional,8-May-15,Veloxis Pharmaceuticals,Drug: Prograf
NCT01438710,Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO),Renal Failure|Tremors,Interventional,8-May-15,Veloxis Pharmaceuticals,Drug: LCP-Tacro
NCT01432236,A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression,Fibromyalgia,Interventional,22-Oct-14,Pfizer,Drug: Pregabalin
NCT01432236,A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression,Fibromyalgia,Interventional,22-Oct-14,Pfizer,Drug: placebo
NCT01431950,Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents,Asthma,Interventional,3-Sep-14,GlaxoSmithKline,Drug: fluticasone furoate
NCT01431950,Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents,Asthma,Interventional,3-Sep-14,GlaxoSmithKline,Drug: albuterol/salbutamol
NCT01431339,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Interventional,12-Feb-14,"Durata Therapeutics Inc., an affiliate of Allergan plc",Drug: IV Dalbavancin
NCT01431339,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Interventional,12-Feb-14,"Durata Therapeutics Inc., an affiliate of Allergan plc",Drug: Vancomycin/Linezolid
NCT01431287,Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: tiotropium + olodaterol
NCT01431287,Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: tiotropium
NCT01431287,Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: olodaterol
NCT01431287,Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Device: Respimat
NCT01431274,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: tiotropium + olodaterol
NCT01431274,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: tiotropium
NCT01431274,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: olodaterol
NCT01431274,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Device: Respimat
NCT01430754,Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder,Non-24-Hour Sleep-Wake Disorder,Interventional,10-Oct-14,Vanda Pharmaceuticals,Drug: tasimelteon
NCT01430754,Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder,Non-24-Hour Sleep-Wake Disorder,Interventional,10-Oct-14,Vanda Pharmaceuticals,Drug: Placebo
NCT01436071,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma,Asthma,Interventional,3-Sep-14,GlaxoSmithKline,Drug: Fluticasone furoate 50mcg
NCT01436071,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma,Asthma,Interventional,3-Sep-14,GlaxoSmithKline,Drug: Placebo
NCT01429441,Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole,Vitreomacular Adhesion Including Macular Hole,Interventional,11-Jan-16,ThromboGenics,Drug: Ocriplasmin
NCT01429441,Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole,Vitreomacular Adhesion Including Macular Hole,Interventional,11-Jan-16,ThromboGenics,Other: Sham injection
NCT01428583,Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain,Chronic Noncancer Pain,Interventional,21-Nov-16,Pfizer,Drug: oxycodone HCl and naltrexone HCl extended-release capsules
NCT01728077,"Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy",Epilepsy,Interventional,2-Aug-17,UCB Pharma SA,Drug: Brivaracetam
NCT01728077,"Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy",Epilepsy,Interventional,2-Aug-17,UCB Pharma,Drug: Brivaracetam
NCT01427803,Actual Use Trial of Naproxen Sodium,Pain,Interventional,20-May-13,Bayer,Drug: Naproxen Sodium ER (BAYH6689)
NCT01426425,Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia,AtrioVentricular Nodal Reentrant Tachycardia|Supraventricular Tachycardia|Heart Disease,Interventional,31-Mar-17,Medtronic Cardiac Rhythm and Heart Failure,Device: Freezor Xtra Cryoablation Catheter
NCT01426373,Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area,Moderate or Severe Submental Fullness,Interventional,14-Jan-16,Kythera Biopharmaceuticals,Drug: Deoxycholic acid injection
NCT01424813,A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma,Asthma,Interventional,20-May-15,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo MDPI
NCT01424813,A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma,Asthma,Interventional,20-May-15,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Albuterol MDPI
NCT01424813,A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma,Asthma,Interventional,20-May-15,Teva Pharmaceutical Industries,Drug: Placebo MDPI
NCT01424813,A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma,Asthma,Interventional,20-May-15,Teva Pharmaceutical Industries,Drug: Albuterol MDPI
NCT01423253,Major Depressive Disorder With Mixed Features - Extension,Major Depressive Disorder,Interventional,14-Oct-15,Sunovion,Drug: Lurasidone
NCT01421511,TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections,Interventional,8-Sep-14,Trius Therapeutics LLC,Drug: TR-701 FA
NCT01421511,TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Skin and Subcutaneous Tissue Bacterial Infections,Interventional,8-Sep-14,Trius Therapeutics LLC,Drug: Linezolid
NCT01421134,Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose,Major Depressive Disorder With Mixed Features,Interventional,9-Oct-15,Sunovion,Drug: Lurasidone
NCT01421134,Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose,Major Depressive Disorder With Mixed Features,Interventional,9-Oct-15,Sunovion,Drug: Placebo
NCT01421498,Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1),Keratoconjunctivitis Sicca|Dry Eye Disease,Interventional,24-Feb-17,Shire,Drug: Lifitegrast
NCT01421498,Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1),Keratoconjunctivitis Sicca|Dry Eye Disease,Interventional,24-Feb-17,Shire,Drug: Placebo
NCT01425723,Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B,Severe Hemophilia B,Interventional,22-Nov-18,Bioverativ Therapeutics Inc.,Biological: rFIXFc
NCT01419197,A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy,Breast Cancer,Interventional,5-May-14,Hoffmann-La Roche,Drug: Trastuzumab emtansine
NCT01419197,A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy,Breast Cancer,Interventional,5-May-14,Hoffmann-La Roche,Drug: Treatment of physician's choice
NCT01415960,Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer,Prostate Cancer,Interventional,18-Jan-17,GP-Pharm,"Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA"
NCT01408576,Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,3-Oct-18,UCB Pharma,Drug: Epratuzumab
NCT01415427,Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),Mucopolysaccharidosis IV A|Morquio A Syndrome|MPS IVA,Interventional,19-May-17,BioMarin Pharmaceutical,Drug: BMN 110 - Weekly
NCT01415427,Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),Mucopolysaccharidosis IV A|Morquio A Syndrome|MPS IVA,Interventional,19-May-17,BioMarin Pharmaceutical,Drug: BMN 110 - Every Other Week
NCT01406938,Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens,Moderate to Severe Plaque-type Psoriasis,Interventional,19-May-15,Novartis Pharmaceuticals,Drug: AIN457 150mg
NCT01406938,Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens,Moderate to Severe Plaque-type Psoriasis,Interventional,19-May-15,Novartis Pharmaceuticals,Drug: AIN457 300mg
NCT01406938,Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens,Moderate to Severe Plaque-type Psoriasis,Interventional,19-May-15,Novartis,Drug: AIN457 150mg
NCT01406938,Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens,Moderate to Severe Plaque-type Psoriasis,Interventional,19-May-15,Novartis,Drug: AIN457 300mg
NCT01410227,"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",Von Willebrand Disease,Interventional,21-Apr-16,Baxalta now part of Shire,Biological: Recombinant von Willebrand factor (rVWF)
NCT01410227,"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",Von Willebrand Disease,Interventional,21-Apr-16,Baxalta now part of Shire,Drug: Placebo
NCT01410227,"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",Von Willebrand Disease,Interventional,21-Apr-16,Baxalta now part of Shire,Biological: Recombinant factor VIIII (rFVIII)
NCT01410227,"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",Von Willebrand Disease,Interventional,21-Apr-16,Shire,Biological: Recombinant von Willebrand factor (rVWF)
NCT01410227,"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",Von Willebrand Disease,Interventional,21-Apr-16,Shire,Drug: Placebo
NCT01410227,"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",Von Willebrand Disease,Interventional,21-Apr-16,Shire,Biological: Recombinant factor VIIII (rFVIII)
NCT01401361,Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System,Typical Atrial Flutter,Interventional,23-Dec-13,Abbott Medical Devices,Device: Treatment Arm
NCT01401465,"Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray",Perennial Allergic Rhinitis,Interventional,30-Apr-13,Sunovion,Drug: ciclesonide
NCT01401465,"Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray",Perennial Allergic Rhinitis,Interventional,30-Apr-13,Sunovion,Drug: mometasone
NCT01400425,Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline,Progressive Cognitive Decline,Interventional,22-Mar-13,Avid Radiopharmaceuticals,Drug: florbetapir F 18
NCT01400139,Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.,Chronic Nonmalignant and Nonneuropathic Pain,Interventional,4-Dec-14,Purdue Pharma LP,Drug: Hydrocodone bitartrate q24h film-coated tablets
NCT01399619,Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4),"Hepatitis C, Chronic",Interventional,4-Sep-15,Boehringer Ingelheim,Drug: PegIFN/RBV
NCT01399619,Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4),"Hepatitis C, Chronic",Interventional,4-Sep-15,Boehringer Ingelheim,Drug: BI201335
NCT01399619,Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4),"Hepatitis C, Chronic",Interventional,4-Sep-15,Boehringer Ingelheim,Drug: BI201335 24W
NCT01399619,Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4),"Hepatitis C, Chronic",Interventional,4-Sep-15,Boehringer Ingelheim,Drug: Bi 201335
NCT01397786,Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia,Schizophrenia,Interventional,27-Mar-17,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: OPC-34712
NCT01404234,Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways,Cystic Fibrosis|Pseudomonas Aeruginosa,Interventional,1-May-14,Gilead Sciences,Drug: AZLI
NCT01396421,Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia,Acute Schizophrenia,Interventional,29-Oct-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: OPC-34712 [Brexpiprazole] High Dose
NCT01396421,Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia,Acute Schizophrenia,Interventional,29-Oct-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Experimental: OPC-34712 [Brexpiprazole] Middle Dose
NCT01396421,Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia,Acute Schizophrenia,Interventional,29-Oct-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Experimental: OPC-34712 [Brexpiprazole] Low Dose
NCT01396421,Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia,Acute Schizophrenia,Interventional,29-Oct-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT01395914,Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3),Cachexia|Non-Small Cell Lung Cancer,Interventional,11-Jul-17,"Helsinn Therapeutics (U.S.), Inc",Drug: Anamorelin HCl
NCT01395914,Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3),Cachexia|Non-Small Cell Lung Cancer,Interventional,11-Jul-17,"Helsinn Therapeutics (U.S.), Inc",Drug: Placebo
NCT01395810,Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773,Congenital Bleeding Disorder|Haemophilia B,Interventional,9-May-18,Novo Nordisk A/S,Drug: nonacog beta pegol
NCT01395524,A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Interventional,17-Jun-15,AstraZeneca,Drug: NKTR-118
NCT01395524,A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Interventional,17-Jun-15,AstraZeneca,Drug: Placebo
NCT01395901,Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients,Postoperative Nausea and Vomiting,Interventional,30-Jul-14,Helsinn Healthcare SA,Drug: Palonosetron
NCT01395901,Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients,Postoperative Nausea and Vomiting,Interventional,30-Jul-14,Helsinn Healthcare SA,Drug: Ondansetron
NCT01395901,Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients,Postoperative Nausea and Vomiting,Interventional,30-Jul-14,Helsinn Healthcare SA,Drug: Placebo to Ondansetron
NCT01395901,Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients,Postoperative Nausea and Vomiting,Interventional,30-Jul-14,Helsinn Healthcare SA,Drug: Placebo to Palonosetron
NCT01393613,Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia,Acute Schizophrenia,Interventional,26-Nov-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: OPC-34712
NCT01393613,Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia,Acute Schizophrenia,Interventional,26-Nov-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo
NCT01392573,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Jan-17,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT01392573,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Jan-17,Novo Nordisk A/S,Drug: insulin degludec
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",Psoriatic Arthritis,Interventional,4-Feb-16,Novartis Pharmaceuticals,Drug: Secukinumab (75 mg)
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",Psoriatic Arthritis,Interventional,4-Feb-16,Novartis Pharmaceuticals,Drug: Secukinumab (150 mg)
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",Psoriatic Arthritis,Interventional,4-Feb-16,Novartis Pharmaceuticals,Drug: Placebo Comparator
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",Psoriatic Arthritis,Interventional,4-Feb-16,Novartis,Drug: Secukinumab (75 mg)
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",Psoriatic Arthritis,Interventional,4-Feb-16,Novartis,Drug: Secukinumab (150 mg)
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",Psoriatic Arthritis,Interventional,4-Feb-16,Novartis,Drug: Placebo Comparator
NCT01392547,Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors,Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors,Interventional,6-Dec-13,Novo Nordisk A/S,Drug: vatreptacog alfa (activated)
NCT01392547,Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors,Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors,Interventional,6-Dec-13,Novo Nordisk A/S,Drug: eptacog alfa (activated)
NCT01392300,Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke,Post-stroke Spasticity of the Upper Limb,Interventional,11-Feb-16,Merz Pharmaceuticals GmbH,Drug: IncobotulinumtoxinA (400 Units)
NCT01392300,Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke,Post-stroke Spasticity of the Upper Limb,Interventional,11-Feb-16,Merz Pharmaceuticals GmbH,Drug: Placebo Comparator
NCT01389596,A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years,"Epilepsy, Partial Seizures",Interventional,21-Mar-17,Pfizer,Drug: Pregabalin add-on therapy
NCT01389323,"BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C",Hepatitis C,Interventional,16-Sep-15,Bristol-Myers Squibb,Drug: Daclatasvir
NCT01389323,"BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C",Hepatitis C,Interventional,16-Sep-15,Bristol-Myers Squibb,Drug: Peg-Interferon Alfa-2a
NCT01389323,"BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C",Hepatitis C,Interventional,16-Sep-15,Bristol-Myers Squibb,Drug: Ribavirin
NCT01390038,Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty,"Primary Generalized (Osteo)Arthritis|Post-traumatic Arthrosis of Other Joints, Upper Arm",Interventional,14-Apr-16,"Tornier, Inc.",Device: Simpliciti™ Shoulder System
NCT01389102,Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms,Hot Flashes,Interventional,11-Jun-12,"Lumara Health, Inc.",Drug: Estradiol transdermal one 90 μL spray
NCT01389102,Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms,Hot Flashes,Interventional,11-Jun-12,"Lumara Health, Inc.","Drug: Estradiol transdermal spray, two 90 μL sprays"
NCT01389102,Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms,Hot Flashes,Interventional,11-Jun-12,"Lumara Health, Inc.",Drug: Estradiol transdermal three 90 μL sprays
NCT01389102,Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms,Hot Flashes,Interventional,11-Jun-12,"Lumara Health, Inc.",Drug: Placebo transdermal two 90 μL sprays
NCT01389102,Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms,Hot Flashes,Interventional,11-Jun-12,"Lumara Health, Inc.",Drug: Placebo transdermal three 90 μL sprays
NCT01389102,Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms,Hot Flashes,Interventional,11-Jun-12,"Lumara Health, Inc.",Drug: Placebo transdermal one 90 μL spray
NCT01388361,Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin,"Diabetes|Diabetes Mellitus, Type 2",Interventional,26-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01388361,Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin,"Diabetes|Diabetes Mellitus, Type 2",Interventional,26-Nov-15,Novo Nordisk A/S,Drug: insulin aspart
NCT01388361,Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin,"Diabetes|Diabetes Mellitus, Type 2",Interventional,26-Nov-15,Novo Nordisk A/S,Drug: liraglutide
NCT01387282,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2),Cachexia|Non-Small Cell Lung Cancer,Interventional,11-Jul-17,"Helsinn Therapeutics (U.S.), Inc",Drug: Anamorelin HCl
NCT01387282,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2),Cachexia|Non-Small Cell Lung Cancer,Interventional,11-Jul-17,"Helsinn Therapeutics (U.S.), Inc",Drug: Placebo
NCT01387269,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1),Cachexia|Non-Small Cell Lung Cancer,Interventional,11-Jul-17,"Helsinn Therapeutics (U.S.), Inc",Drug: Anamorelin HCl
NCT01387269,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1),Cachexia|Non-Small Cell Lung Cancer,Interventional,11-Jul-17,"Helsinn Therapeutics (U.S.), Inc",Drug: Placebo
NCT01385202,THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation,Heart Diseases|Arrhythmia|Atrial Fibrillation,Interventional,26-Jan-15,"Biosense Webster, Inc.",Device: THERMOCOOL® SMARTTOUCH™ Catheter
NCT01386658,"A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema",Hereditary Angioedema (HAE),Interventional,25-Mar-19,Shire,Drug: icatibant
NCT01377194,Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder,Major Depressive Disorder,Interventional,29-Oct-13,Forest Laboratories,Drug: Levomilnacipran ER
NCT01377194,Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder,Major Depressive Disorder,Interventional,29-Oct-13,Forest Laboratories,Drug: Placebo
NCT01377012,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents",Rheumatoid Arthritis,Interventional,29-Mar-17,Novartis Pharmaceuticals,Biological: Secukinumab (AIN457)
NCT01377012,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents",Rheumatoid Arthritis,Interventional,29-Mar-17,Novartis Pharmaceuticals,Biological: Placebo
NCT01377012,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents",Rheumatoid Arthritis,Interventional,29-Mar-17,Novartis,Biological: Secukinumab (AIN457)
NCT01377012,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents",Rheumatoid Arthritis,Interventional,29-Mar-17,Novartis,Biological: Placebo
NCT01489254,Efficacy and Safety of GTR in Comparison to Copaxone®,Multiple Sclerosis,Interventional,31-Oct-16,Synthon BV,Drug: Glatiramer Acetate (GTR)
NCT01489254,Efficacy and Safety of GTR in Comparison to Copaxone®,Multiple Sclerosis,Interventional,31-Oct-16,Synthon BV,Drug: Glatiramer Acetate (Copaxone®)
NCT01489254,Efficacy and Safety of GTR in Comparison to Copaxone®,Multiple Sclerosis,Interventional,31-Oct-16,Synthon BV,Drug: Placebo
NCT01383486,Self Selection Trial of Naproxen Sodium,Pain,Interventional,29-Nov-12,Bayer,Drug: Naproxen sodium ER (BAYH6689)
NCT01383486,Self Selection Trial of Naproxen Sodium,Pain,Interventional,29-Nov-12,Bayer,Drug: Advil
NCT01374906,Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease,Cushing's Disease,Interventional,11-Apr-18,Novartis Pharmaceuticals,Drug: pasireotide LAR
NCT01374906,Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease,Cushing's Disease,Interventional,11-Apr-18,Novartis Pharmaceuticals,Drug: SOM230 LAR 30 mg
NCT01374906,Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease,Cushing's Disease,Interventional,11-Apr-18,Novartis Pharmaceuticals,Drug: SOM230 LAR 10 mg
NCT01374906,Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease,Cushing's Disease,Interventional,11-Apr-18,Novartis,Drug: pasireotide LAR
NCT01374906,Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease,Cushing's Disease,Interventional,11-Apr-18,Novartis,Drug: SOM230 LAR 30 mg
NCT01374906,Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease,Cushing's Disease,Interventional,11-Apr-18,Novartis,Drug: SOM230 LAR 10 mg
NCT01372150,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Major Depressive Disorder,Interventional,20-Nov-15,Pfizer,Drug: desvenlafaxine succinate sustained release
NCT01372150,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Major Depressive Disorder,Interventional,20-Nov-15,Pfizer,Drug: fluoxetine
NCT01372150,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Major Depressive Disorder,Interventional,20-Nov-15,Pfizer,Drug: placebo
NCT01371734,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Major Depressive Disorder,Interventional,20-Mar-17,Pfizer,Drug: Desvenlafaxine Succinate Sustained-Release
NCT01371734,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Major Depressive Disorder,Interventional,20-Mar-17,Pfizer,Drug: Placebo
NCT01371721,"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD",Major Depressive Disorder,Interventional,8-Feb-17,Pfizer,Drug: DVS SR
NCT01371708,"A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD",Major Depressive Disorder,Interventional,8-Dec-16,Pfizer,Drug: DVS SR
NCT01370733,Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder,Major Depressive Disorder,Interventional,14-Jul-15,"NeoSync, Inc.",Device: NEST-1 (NeoSync EEG Synchronized TMS)
NCT01370733,Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder,Major Depressive Disorder,Interventional,14-Jul-15,"NeoSync, Inc.",Device: SHAM
NCT01369615,Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001,Pain,Interventional,15-Jan-15,Purdue Pharma LP,Drug: Oxycodone hydrochloride controlled-release tablets
NCT01369342,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2),Crohn's Disease|Inflammatory Bowel Disease|IBD|Colitis,Interventional,6-Jan-17,"Janssen Research & Development, LLC",Drug: Group 1: Placebo
NCT01369342,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2),Crohn's Disease|Inflammatory Bowel Disease|IBD|Colitis,Interventional,6-Jan-17,"Janssen Research & Development, LLC",Drug: Group 2 ustekinumab 130 mg
NCT01369342,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2),Crohn's Disease|Inflammatory Bowel Disease|IBD|Colitis,Interventional,6-Jan-17,"Janssen Research & Development, LLC",Drug: Group 3: ustekinumab approximately 6 mg/kg
NCT01369329,A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1),Crohn's Disease|IBD|Colitis|Inflammatory Bowel Disease,Interventional,7-Dec-16,"Janssen Research & Development, LLC",Drug: Group 2 ustekinumab 130 mg
NCT01369329,A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1),Crohn's Disease|IBD|Colitis|Inflammatory Bowel Disease,Interventional,7-Dec-16,"Janssen Research & Development, LLC",Drug: Group 3: ustekinumab approximately 6 mg/kg
NCT01369329,A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1),Crohn's Disease|IBD|Colitis|Inflammatory Bowel Disease,Interventional,7-Dec-16,"Janssen Research & Development, LLC",Drug: Group 1: Placebo
NCT01365507,Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens,"Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Nov-15,Novo Nordisk A/S,Drug: insulin degludec/insulin aspart
NCT01365455,Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year,Moderate to Severe Plaque-type Psoriasis,Interventional,29-May-15,Novartis Pharmaceuticals,Drug: secukinumab 150 mg
NCT01365455,Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year,Moderate to Severe Plaque-type Psoriasis,Interventional,29-May-15,Novartis Pharmaceuticals,Drug: placebo to secukinumab 150 mg
NCT01365455,Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year,Moderate to Severe Plaque-type Psoriasis,Interventional,29-May-15,Novartis,Drug: secukinumab 150 mg
NCT01365455,Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year,Moderate to Severe Plaque-type Psoriasis,Interventional,29-May-15,Novartis,Drug: placebo to secukinumab 150 mg
NCT01365052,Safety Trial of Naproxen Sodium/ Diphenhydramine,Pain,Interventional,16-Jun-14,Bayer,Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)
NCT01365052,Safety Trial of Naproxen Sodium/ Diphenhydramine,Pain,Interventional,16-Jun-14,Bayer,Drug: Placebo
NCT01364649,Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction,Treatment Outcome,Interventional,9-Oct-14,Takeda,Drug: Vortioxetine
NCT01364649,Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction,Treatment Outcome,Interventional,9-Oct-14,Takeda,Drug: Escitalopram
NCT01364649,Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction,Treatment Outcome,Interventional,9-Oct-14,Takeda,Drug: Placebo
NCT01364428,Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,18-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01363011,Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,31-Oct-14,Gilead Sciences,Drug: E/C/F/TDF
NCT01363011,Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,31-Oct-14,Gilead Sciences,Drug: COBI
NCT01363011,Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,31-Oct-14,Gilead Sciences,Drug: ATV
NCT01363011,Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,31-Oct-14,Gilead Sciences,Drug: DRV
NCT01363011,Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,31-Oct-14,Gilead Sciences,Drug: NRTI
NCT01370538,Efficacy of Esomeprazole in Patients With Frequent Heartburn,Heartburn,Interventional,11-Apr-13,AstraZeneca,Drug: Esomeprazole
NCT01370525,Efficacy of Esomeprazole in Patients With Frequent Heartburn,Heartburn,Interventional,14-Mar-13,AstraZeneca,Drug: Esomeprazole
NCT01411137,Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study,Parkinson's Disease,Interventional,18-Apr-17,"Impax Laboratories, LLC",Drug: IPX066
NCT01411137,Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study,Parkinson's Disease,Interventional,18-Apr-17,Michael J. Fox Foundation for Parkinson's Research,Drug: IPX066
NCT01361308,Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS),Postmenopausal Symptoms,Interventional,20-May-14,Noven Therapeutics,Drug: Brisdelle (paroxetine mesylate)
NCT01361308,Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS),Postmenopausal Symptoms,Interventional,20-May-14,Noven Therapeutics,Drug: Placebo capsules
NCT01360866,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,17-Sep-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: OPC-34712
NCT01360866,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,17-Sep-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Escitalopram
NCT01360866,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,17-Sep-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Fluoxetine
NCT01360866,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,17-Sep-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Paroxetine CR
NCT01360866,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,17-Sep-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Sertraline
NCT01360866,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,17-Sep-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Duloxetine
NCT01360866,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,17-Sep-18,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Venlafaxine XR
NCT01360645,Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,26-Nov-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: OPC-34712 + ADT
NCT01360645,Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,26-Nov-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo + ADT
NCT01360632,Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,1-Jan-16,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: OPC-34712 + ADT
NCT01360632,Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial),"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Interventional,1-Jan-16,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo + ADT
NCT01360554,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,24-May-17,Pfizer,Drug: Dacomitinib (PF-00299804)
NCT01360554,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,24-May-17,Pfizer,Drug: Active Comparator (erlotinib)
NCT01360554,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,24-May-17,Pfizer,Drug: Placebo erlotinib
NCT01360554,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,24-May-17,Pfizer,Drug: Placebo PF00299804
NCT01360021,New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day,Asthma,Interventional,11-Mar-14,AstraZeneca,Drug: Symbicort
NCT01360021,New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day,Asthma,Interventional,11-Mar-14,AstraZeneca,Drug: Budesonide
NCT01358864,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3),"Hepatitis C, Chronic",Interventional,28-Oct-15,Boehringer Ingelheim,Drug: BI 201335
NCT01358864,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3),"Hepatitis C, Chronic",Interventional,28-Oct-15,Boehringer Ingelheim,Drug: Pegylated Interferon-alpha (IFN)
NCT01358864,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3),"Hepatitis C, Chronic",Interventional,28-Oct-15,Boehringer Ingelheim,Drug: Ribavirin (RBV)
NCT01358864,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3),"Hepatitis C, Chronic",Interventional,28-Oct-15,Boehringer Ingelheim,Drug: Placebo
NCT01358760,Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy,Vaginal Atrophy,Interventional,12-Jun-17,EndoCeutics Inc.,Drug: Placebo
NCT01358760,Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy,Vaginal Atrophy,Interventional,12-Jun-17,EndoCeutics Inc.,Drug: DHEA
NCT01358526,Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,Low Back Pain,Interventional,3-Sep-14,Purdue Pharma LP,Drug: Oxycodone/Naloxone Controlled-release
NCT01358526,Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,Low Back Pain,Interventional,3-Sep-14,Purdue Pharma LP,Drug: Placebo
NCT01358357,Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex,Bipolar I Disorder,Interventional,26-Jul-16,Sunovion,Drug: Lurasidone
NCT01358357,Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex,Bipolar I Disorder,Interventional,26-Jul-16,Sunovion,Drug: Placebo
NCT01358266,Study Assessing Double-masked Uveitis Treatment,"Uveitis; Posterior, Disorder",Interventional,16-Jul-19,Santen Inc.,Drug: DE-109 44 ug
NCT01358266,Study Assessing Double-masked Uveitis Treatment,"Uveitis; Posterior, Disorder",Interventional,16-Jul-19,Santen Inc.,Drug: DE-109 440 ug
NCT01358266,Study Assessing Double-masked Uveitis Treatment,"Uveitis; Posterior, Disorder",Interventional,16-Jul-19,Santen Inc.,Drug: DE-109 880 ug
NCT01358578,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",Chronic Plaque Psoriasis,Interventional,23-Sep-15,Novartis Pharmaceuticals,Drug: Placebo
NCT01358578,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",Chronic Plaque Psoriasis,Interventional,23-Sep-15,Novartis Pharmaceuticals,Drug: secukinumab (AIN457)
NCT01358578,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",Chronic Plaque Psoriasis,Interventional,23-Sep-15,Novartis Pharmaceuticals,Drug: etanercept
NCT01358578,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",Chronic Plaque Psoriasis,Interventional,23-Sep-15,Novartis,Drug: Placebo
NCT01358578,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",Chronic Plaque Psoriasis,Interventional,23-Sep-15,Novartis,Drug: secukinumab (AIN457)
NCT01358578,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",Chronic Plaque Psoriasis,Interventional,23-Sep-15,Novartis,Drug: etanercept
NCT01356602,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Interventional,29-Jan-14,Novartis Pharmaceuticals,Drug: Canakinumab pre-filled syringe
NCT01356602,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Interventional,29-Jan-14,Novartis Pharmaceuticals,Drug: Canakinumab lyophilized powder
NCT01356602,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Interventional,29-Jan-14,Novartis Pharmaceuticals,Drug: Triamcinolone Acetonide
NCT01356602,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Interventional,29-Jan-14,Novartis Pharmaceuticals,Drug: Placebo
NCT01356602,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Interventional,29-Jan-14,Novartis,Drug: Canakinumab pre-filled syringe
NCT01356602,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Interventional,29-Jan-14,Novartis,Drug: Canakinumab lyophilized powder
NCT01356602,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Interventional,29-Jan-14,Novartis,Drug: Triamcinolone Acetonide
NCT01356602,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Interventional,29-Jan-14,Novartis,Drug: Placebo
NCT01356498,Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout,Gout,Interventional,2-Dec-11,Savient Pharmaceuticals,Biological: pegloticase
NCT01405508,Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy,Epilepsy,Interventional,13-Apr-16,UCB Pharma,Drug: Brivaracetam tablets
NCT01405508,Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy,Epilepsy,Interventional,13-Apr-16,UCB Pharma,Drug: Brivaracetam bolus
NCT01405508,Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy,Epilepsy,Interventional,13-Apr-16,UCB Pharma,Drug: Brivaracetam infusion
NCT01405508,Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy,Epilepsy,Interventional,13-Apr-16,UCB Pharma,Other: Placebo
NCT01355484,Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC),Muscle Wasting|Non Small Cell Lung Cancer,Interventional,3-Mar-16,GTx,Drug: GTx-024
NCT01355484,Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC),Muscle Wasting|Non Small Cell Lung Cancer,Interventional,3-Mar-16,GTx,Drug: placebo
NCT01355471,Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Rosacea,Interventional,21-Nov-13,Galderma,Drug: CD07805/47 Gel
NCT01355471,Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Rosacea,Interventional,21-Nov-13,Galderma,Drug: Placebo
NCT01355458,Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Rosacea,Interventional,21-Nov-13,Galderma,Drug: CD07805/47 gel
NCT01355458,Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Rosacea,Interventional,21-Nov-13,Galderma,Drug: Placebo
NCT01653262,Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV),Epilepsy,Interventional,15-Aug-16,UCB Pharma SA,Drug: Brivaracetam
NCT01653262,Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV),Epilepsy,Interventional,15-Aug-16,UCB Pharma,Drug: Brivaracetam
NCT01352845,"A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.",Healthy,Interventional,23-Feb-16,Pfizer,Biological: rLP2086
NCT01352845,"A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.",Healthy,Interventional,23-Feb-16,Pfizer,Other: Placebo
NCT01352793,A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years,"Meningitis, Meningococcal",Interventional,11-Mar-15,Pfizer,Biological: rLP2086 vaccine
NCT01352793,A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years,"Meningitis, Meningococcal",Interventional,11-Mar-15,Pfizer,Biological: control
NCT01358175,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,27-Jan-17,Novartis Pharmaceuticals,Drug: Secukinumab (75 mg)
NCT01358175,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,27-Jan-17,Novartis Pharmaceuticals,Drug: Secukinumab (150 mg)
NCT01358175,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,27-Jan-17,Novartis Pharmaceuticals,Drug: Placebo
NCT01358175,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,27-Jan-17,Novartis,Drug: Secukinumab (75 mg)
NCT01358175,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,27-Jan-17,Novartis,Drug: Secukinumab (150 mg)
NCT01358175,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,27-Jan-17,Novartis,Drug: Placebo
NCT01351415,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),Non-Squamous Non-Small Cell Lung Cancer,Interventional,18-Sep-17,Hoffmann-La Roche,Drug: Bevacizumab
NCT01351415,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),Non-Squamous Non-Small Cell Lung Cancer,Interventional,18-Sep-17,Hoffmann-La Roche,Drug: Docetaxel
NCT01351415,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),Non-Squamous Non-Small Cell Lung Cancer,Interventional,18-Sep-17,Hoffmann-La Roche,Drug: Erlotinib
NCT01351415,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),Non-Squamous Non-Small Cell Lung Cancer,Interventional,18-Sep-17,Hoffmann-La Roche,Drug: Pemetrexed
NCT01350804,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",Rheumatoid Arthritis,Interventional,23-May-16,Novartis Pharmaceuticals,Biological: AIN457
NCT01350804,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",Rheumatoid Arthritis,Interventional,23-May-16,Novartis Pharmaceuticals,Biological: Placebo
NCT01350804,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",Rheumatoid Arthritis,Interventional,23-May-16,Novartis Pharmaceuticals,Biological: Abatacept
NCT01350804,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",Rheumatoid Arthritis,Interventional,23-May-16,Novartis,Biological: AIN457
NCT01350804,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",Rheumatoid Arthritis,Interventional,23-May-16,Novartis,Biological: Placebo
NCT01350804,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",Rheumatoid Arthritis,Interventional,23-May-16,Novartis,Biological: Abatacept
NCT01368276,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,Melanoma,Interventional,18-Dec-15,BioVex Limited,Biological: Talimogene Laherparepvec
NCT01368276,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,Melanoma,Interventional,18-Dec-15,BioVex Limited,Drug: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Mar-17,Biogen,Drug: Midazolam
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Mar-17,Biogen,Other: Caffeine
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Mar-17,Biogen,Drug: S-warfarin
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Mar-17,Biogen,Other: Vitamin K
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Mar-17,Biogen,Drug: Omeprazole
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Mar-17,Biogen,Drug: Dextromethorphan
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,14-Mar-17,Biogen,Biological: BIIB019 (Daclizumab)
NCT01349465,3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection,Hepatitis C,Interventional,16-Feb-17,Janssen R&D Ireland,Drug: No treatment
NCT01347710,A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.,Coronary Artery Disease,Interventional,5-Apr-16,Lantheus Medical Imaging,Drug: Flurpiridaz F18
NCT01347710,A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.,Coronary Artery Disease,Interventional,5-Apr-16,Lantheus Medical Imaging,Drug: 99mTechnicium (sestamibi or tetrofosmin)
NCT01346293,Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age,Tetanus|Diphtheria|Pertussis|Measles|Polio,Interventional,29-May-15,"Sanofi Pasteur, a Sanofi Company","Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus"
NCT01346293,Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age,Tetanus|Diphtheria|Pertussis|Measles|Polio,Interventional,29-May-15,"Sanofi Pasteur, a Sanofi Company",Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
NCT01346293,Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age,Tetanus|Diphtheria|Pertussis|Measles|Polio,Interventional,29-May-15,Sanofi,"Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus"
NCT01346293,Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age,Tetanus|Diphtheria|Pertussis|Measles|Polio,Interventional,29-May-15,Sanofi,Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
NCT01344460,Gadobutrol Enhanced MRA of the Renal Arteries,Renal Artery Obstruction,Interventional,26-Aug-15,Bayer,"Drug: Gadobutrol (Gadovist, BAY86-4875)"
NCT01344447,Gadobutrol Enhanced MRA of the Supra-aortic Vessels,Carotid Stenosis,Interventional,26-Aug-15,Bayer,"Drug: Gadobutrol (Gadovist, BAY86-4875)"
NCT01453946,Safety and Maintenance Study of Entocort for Children With Crohn's Disease,Crohn's Disease,Interventional,19-Jun-15,Perrigo Company,Drug: Entocort
NCT01339091,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Interventional,25-Dec-13,"Durata Therapeutics Inc., an affiliate of Allergan plc",Drug: Dalbavancin
NCT01339091,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Interventional,25-Dec-13,"Durata Therapeutics Inc., an affiliate of Allergan plc",Drug: Vancomycin / Linezolid
NCT01338818,Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder,Attention Deficit/Hyperactivity Disorder,Interventional,26-May-14,Novartis Pharmaceuticals,Drug: Ritalin LA (methylphenidate hydrochloride extended release)
NCT01338818,Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder,Attention Deficit/Hyperactivity Disorder,Interventional,26-May-14,Novartis,Drug: Ritalin LA (methylphenidate hydrochloride extended release)
NCT01336608,A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Jul-15,GlaxoSmithKline,Drug: Fluticasone Furoate/Vilanterol
NCT01336608,A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Jul-15,GlaxoSmithKline,Drug: Vilanterol
NCT01336608,A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Jul-15,GlaxoSmithKline,Drug: Placebo
NCT01336205,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Interventional,20-Oct-14,AstraZeneca,Drug: NKTR-118
NCT01336205,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Interventional,20-Oct-14,AstraZeneca,Drug: Usual care
NCT01336023,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,2-Jun-17,Novo Nordisk A/S,Drug: insulin degludec/liraglutide
NCT01336023,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,2-Jun-17,Novo Nordisk A/S,Drug: insulin degludec
NCT01336023,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,2-Jun-17,Novo Nordisk A/S,Drug: liraglutide
NCT01335477,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II,Pulmonary Fibrosis,Interventional,13-Feb-15,Boehringer Ingelheim,Drug: placebo
NCT01335477,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II,Pulmonary Fibrosis,Interventional,13-Feb-15,Boehringer Ingelheim,Drug: BIBF 1120
NCT01335464,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients,Pulmonary Fibrosis,Interventional,13-Feb-15,Boehringer Ingelheim,Drug: placebo
NCT01335464,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients,Pulmonary Fibrosis,Interventional,13-Feb-15,Boehringer Ingelheim,Drug: BIBF 1120
NCT01333111,Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients,Congenital Bleeding Disorder|Haemophilia B,Interventional,28-Jul-17,Novo Nordisk A/S,Drug: nonacog beta pegol
NCT01330316,A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients,Hepatitis C,Interventional,31-Jul-15,Boehringer Ingelheim,Drug: BI 201335
NCT01330316,A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients,Hepatitis C,Interventional,31-Jul-15,Boehringer Ingelheim,Drug: PegIFN/RBV
NCT01328379,Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis,Multiple Sclerosis,Interventional,13-Aug-13,Acorda Therapeutics,Drug: Dalfampridine-ER 5mg
NCT01328379,Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis,Multiple Sclerosis,Interventional,13-Aug-13,Acorda Therapeutics,Drug: Dalfampridine-ER 10mg
NCT01328379,Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis,Multiple Sclerosis,Interventional,13-Aug-13,Acorda Therapeutics,Other: Placebo
NCT01327885,Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma,Soft Tissue Sarcoma,Interventional,28-Feb-17,Eisai Inc.,Drug: Eribulin mesylate 1.4 mg/m^2 intravenous
NCT01327885,Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma,Soft Tissue Sarcoma,Interventional,28-Feb-17,Eisai Inc.,"Drug: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV"
NCT01326026,Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus,"Diabetes|Diabetes Mellitus, Type 2",Interventional,17-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GSK 573719 +GW642444 125/25
NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GSK573719 + GW642444 62.5/25
NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GSK 573719 125
NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GSK 573719 62.5
NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GW642444 25
NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: Plb
NCT01324570,"Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children",Pain,Interventional,6-Jul-17,Purdue Pharma LP,Drug: Buprenorphine transdermal system
NCT01323790,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Interventional,2-Jun-15,AstraZeneca,Drug: NKTR-118
NCT01323790,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Interventional,2-Jun-15,AstraZeneca,Drug: Placebo
NCT01323660,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,"Pulmonary Disease, Chronic Obstructive",Interventional,11-Apr-14,GlaxoSmithKline,Drug: GSK573719/GW642444 125/25
NCT01323660,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,"Pulmonary Disease, Chronic Obstructive",Interventional,11-Apr-14,GlaxoSmithKline,Drug: GSK573719/GW642444 62.5/25
NCT01323660,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,"Pulmonary Disease, Chronic Obstructive",Interventional,11-Apr-14,GlaxoSmithKline,Drug: GSK573719 125
NCT01323660,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,"Pulmonary Disease, Chronic Obstructive",Interventional,11-Apr-14,GlaxoSmithKline,Drug: GSK573719 62.5
NCT01323660,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,"Pulmonary Disease, Chronic Obstructive",Interventional,11-Apr-14,GlaxoSmithKline,Drug: GW642444 25
NCT01323660,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,"Pulmonary Disease, Chronic Obstructive",Interventional,11-Apr-14,GlaxoSmithKline,Device: placebo
NCT01323621,Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,6-Feb-14,GlaxoSmithKline,Drug: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg
NCT01323621,Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,6-Feb-14,GlaxoSmithKline,Drug: Fluticasone Propionate 250mcg / salmeterol 50mcg
NCT01323621,Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,6-Feb-14,GlaxoSmithKline,Drug: Double-dummy placebo
NCT01323621,Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,6-Feb-14,GlaxoSmithKline,Drug: Salbutamol as needed
NCT01322347,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2),Renal Failure Chronic Requiring Hemodialysis,Interventional,24-Apr-15,"Rockwell Medical Technologies, Inc.",Drug: Soluble Ferric Pyrophosphate (SFP)
NCT01322347,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2),Renal Failure Chronic Requiring Hemodialysis,Interventional,24-Apr-15,"Rockwell Medical Technologies, Inc.",Device: Standard dialysate
NCT01323634,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,30-Jul-13,GlaxoSmithKline,Drug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg
NCT01323634,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,30-Jul-13,GlaxoSmithKline,Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcg
NCT01321554,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",Thyroid Cancer,Interventional,12-Dec-16,Eisai Inc.,Drug: Lenvatinib
NCT01321554,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",Thyroid Cancer,Interventional,12-Dec-16,Eisai Inc.,Drug: Placebo
NCT01320202,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients,Renal Failure Chronic Requiring Hemodialysis,Interventional,28-Apr-15,"Rockwell Medical Technologies, Inc.",Drug: Soluble Ferric Pyrophosphate (SFP)
NCT01320202,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients,Renal Failure Chronic Requiring Hemodialysis,Interventional,28-Apr-15,"Rockwell Medical Technologies, Inc.",Device: Standard dialysate
NCT01318733,Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Rosacea,Interventional,8-Jan-14,Galderma,Drug: CD07805/47 gel 0.5%
NCT01318694,Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants,Hepatitis C,Interventional,30-Sep-16,Debiopharm International SA,Drug: Alisporivir
NCT01318694,Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants,Hepatitis C,Interventional,30-Sep-16,Debiopharm International SA,Drug: Peginterferon alfa-2a
NCT01318694,Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants,Hepatitis C,Interventional,30-Sep-16,Debiopharm International SA,Drug: Ribavirin
NCT01318694,Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants,Hepatitis C,Interventional,30-Sep-16,Debiopharm International SA,Drug: ALV Placebo
NCT01316913,24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,24-Feb-14,GlaxoSmithKline,Drug: GSK573719/GW642444 125/25
NCT01316913,24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,24-Feb-14,GlaxoSmithKline,Drug: GSK573719/GW642444 62.5/25
NCT01316913,24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,24-Feb-14,GlaxoSmithKline,Drug: GSK573719
NCT01316913,24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,24-Feb-14,GlaxoSmithKline,Drug: tiotropium bromide
NCT01316900,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GSK573719/GW642444 125/25
NCT01316900,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GSK573719/GW642444 62.5/25
NCT01316900,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GW642444
NCT01316900,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: tiotropium bromide
NCT01316887,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,20-Mar-14,GlaxoSmithKline,Drug: 125/25 mcg once-daily GSK573719/GW642444
NCT01316887,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,20-Mar-14,GlaxoSmithKline,Drug: 125mcg once-daily GSK573719
NCT01316887,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Interventional,20-Mar-14,GlaxoSmithKline,Drug: Placebo once-daily
NCT01314716,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,Bronchiectasis,Interventional,16-Apr-14,Gilead Sciences,Drug: AZLI
NCT01314716,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,Bronchiectasis,Interventional,16-Apr-14,Gilead Sciences,Drug: Placebo
NCT01313676,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,9-Aug-16,GlaxoSmithKline,Drug: fluticasone furoate/vilanterol
NCT01313676,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,9-Aug-16,GlaxoSmithKline,Drug: fluticasone furoate
NCT01313676,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,9-Aug-16,GlaxoSmithKline,Drug: vilanterol
NCT01313676,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,9-Aug-16,GlaxoSmithKline,Other: Placebo
NCT01313650,A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Mar-14,GlaxoSmithKline,Drug: 62.5/25mcg
NCT01313650,A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Mar-14,GlaxoSmithKline,Drug: 62.5mcg
NCT01313650,A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Mar-14,GlaxoSmithKline,Drug: 25mcg
NCT01313650,A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,4-Mar-14,GlaxoSmithKline,Drug: Placebo
NCT01313637,A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GSK573719/GW642444 125/25mcg
NCT01313637,A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GSK573719 125mcg
NCT01313637,A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: GW642444 25mcg
NCT01313637,A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,10-Feb-14,GlaxoSmithKline,Drug: Placebo only
NCT01313624,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,Bronchiectasis,Interventional,16-Apr-14,Gilead Sciences,Drug: AZLI
NCT01313624,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,Bronchiectasis,Interventional,16-Apr-14,Gilead Sciences,Drug: Placebo
NCT01313299,Dysport® Adult Upper Limb Spasticity,Nervous System Disorders,Interventional,23-Oct-15,Ipsen,Drug: Botulinum type A toxin (Dysport®)
NCT01313299,Dysport® Adult Upper Limb Spasticity,Nervous System Disorders,Interventional,23-Oct-15,Ipsen,Drug: Placebo
NCT01603459,Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm,Spasticity of the Upper and Lower Limb Due to Cerebral Causes,Interventional,3-Feb-17,Merz Pharmaceuticals GmbH,Drug: IncobotulinumtoxinA
NCT01313312,Dysport® Adult Upper Limb Spasticity Extension Study,Nervous System Disorders,Interventional,7-Jun-17,Ipsen,Drug: Dysport®
NCT01328951,A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy,Non-Squamous Non-Small Cell Lung Cancer,Interventional,29-Feb-16,Hoffmann-La Roche,Drug: Placebo
NCT01328951,A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy,Non-Squamous Non-Small Cell Lung Cancer,Interventional,29-Feb-16,Hoffmann-La Roche,Drug: Erlotinib
NCT01328951,A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy,Non-Squamous Non-Small Cell Lung Cancer,Interventional,29-Feb-16,Hoffmann-La Roche,Drug: Second-Line Chemotherapy
NCT01309841,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Interventional,1-Jun-15,AstraZeneca,Drug: NKTR-118
NCT01309841,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Interventional,1-Jun-15,AstraZeneca,Drug: Placebo
NCT01309737,"A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,Interventional,19-Sep-14,Pfizer,"Drug: CP-690,550"
NCT01309737,"A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,Interventional,19-Sep-14,Pfizer,"Drug: Placebo/CP-690,550"
NCT01309243,"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV-1 Infection,Interventional,27-Nov-13,Gilead Sciences,Drug: FTC/RPV/TDF
NCT01309243,"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV-1 Infection,Interventional,27-Nov-13,Gilead Sciences,Drug: EFV/FTC/TDF
NCT01308580,Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer,Prostate Cancer,Interventional,11-Oct-16,Sanofi,Drug: Cabazitaxel (XRP6258)
NCT01308580,Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer,Prostate Cancer,Interventional,11-Oct-16,Sanofi,Drug: Prednisone (or Prednisolone)
NCT01308567,Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer,Prostate Cancer,Interventional,3-Mar-17,Sanofi,Drug: Cabazitaxel (XRP6258)
NCT01308567,Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer,Prostate Cancer,Interventional,3-Mar-17,Sanofi,Drug: Docetaxel (XRP6976)
NCT01308567,Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer,Prostate Cancer,Interventional,3-Mar-17,Sanofi,Drug: Prednisone
NCT01310413,Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age,Influenza,Interventional,31-Mar-14,GlaxoSmithKline,Biological: Influenza A (H5N1) Virus monovalent vaccine
NCT01310413,Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age,Influenza,Interventional,31-Mar-14,GlaxoSmithKline,Biological: Saline placebo
NCT01307423,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA),Psoriatic Arthritis,Interventional,15-Aug-14,Celgene,Drug: Apremilast 20mg
NCT01307423,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA),Psoriatic Arthritis,Interventional,15-Aug-14,Celgene,Drug: Apremilast 30mg
NCT01307423,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA),Psoriatic Arthritis,Interventional,15-Aug-14,Celgene,Drug: Placebo
NCT01307319,Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies,Seasonal Allergic Rhinitis|SAR,Interventional,20-Feb-15,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: BDP HFA
NCT01307319,Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies,Seasonal Allergic Rhinitis|SAR,Interventional,20-Feb-15,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo nasal aerosol
NCT01307319,Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies,Seasonal Allergic Rhinitis|SAR,Interventional,20-Feb-15,Teva Pharmaceutical Industries,Drug: BDP HFA
NCT01307319,Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies,Seasonal Allergic Rhinitis|SAR,Interventional,20-Feb-15,Teva Pharmaceutical Industries,Drug: Placebo nasal aerosol
NCT01305408,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Cephalon,Drug: Armodafinil
NCT01305408,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Cephalon,Drug: Placebo
NCT01305408,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Teva Pharmaceutical Industries,Drug: Armodafinil
NCT01305408,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Teva Pharmaceutical Industries,Drug: Placebo
NCT01347073,"Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)",Urea Cycle Disorders,Interventional,28-May-15,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: HPN-100
NCT01302119,Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail,Onychomycosis of Toenails,Interventional,15-Aug-14,Pfizer,"Drug: AN2690 Topical Solution, 5%"
NCT01302119,Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail,Onychomycosis of Toenails,Interventional,15-Aug-14,Pfizer,Drug: Solution Vehicle
NCT01345682,LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,"Head and Neck Neoplasms|Carcinoma, Squamous Cell",Interventional,14-Apr-15,Boehringer Ingelheim,Drug: Afatinib
NCT01345682,LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,"Head and Neck Neoplasms|Carcinoma, Squamous Cell",Interventional,14-Apr-15,Boehringer Ingelheim,Drug: Methotrexate
NCT01299272,A Study in Prevention of Re-emergence of Depression Symptoms,Major Depressive Disorder,Interventional,17-Apr-18,Eli Lilly and Company,Drug: LY2216684
NCT01299272,A Study in Prevention of Re-emergence of Depression Symptoms,Major Depressive Disorder,Interventional,17-Apr-18,Eli Lilly and Company,Drug: Placebo
NCT01299272,A Study in Prevention of Re-emergence of Depression Symptoms,Major Depressive Disorder,Interventional,17-Apr-18,Eli Lilly and Company,Drug: SSRI
NCT01298765,Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain,Pain|Low Back Pain|Osteoarthritis|Neuropathic Pain,Interventional,7-Aug-18,BioDelivery Sciences International,Drug: BEMA Buprenorphine
NCT01297270,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2),Hepatitis C,Interventional,18-Sep-15,Boehringer Ingelheim,Drug: BI201335
NCT01297270,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2),Hepatitis C,Interventional,18-Sep-15,Boehringer Ingelheim,Drug: PegIFN/RBV
NCT01297270,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2),Hepatitis C,Interventional,18-Sep-15,Boehringer Ingelheim,Drug: Placebo
NCT01295710,Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD),GVHD|Adult Acute Myeloid Leukemia|Adult Acute Lymphoid Leukemia|Myelodysplastic Syndrome,Interventional,20-Mar-19,Neovii Biotech,Biological: US-ATG-F
NCT01295710,Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD),GVHD|Adult Acute Myeloid Leukemia|Adult Acute Lymphoid Leukemia|Myelodysplastic Syndrome,Interventional,20-Mar-19,Neovii Biotech,Biological: Placebo
NCT01292473,"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",Chronic Idiopathic Urticaria,Interventional,2-Sep-13,"Genentech, Inc.",Drug: Placebo
NCT01292473,"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",Chronic Idiopathic Urticaria,Interventional,2-Sep-13,"Genentech, Inc.",Drug: Omalizumab
NCT02072824,"A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.",Partial Onset Seizures,Interventional,9-Oct-18,Pfizer,Drug: Pregabalin Dose Level 1
NCT02072824,"A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.",Partial Onset Seizures,Interventional,9-Oct-18,Pfizer,Drug: Pregabalin Dose Level 2
NCT02072824,"A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.",Partial Onset Seizures,Interventional,9-Oct-18,Pfizer,Drug: Placebo
NCT01290341,Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis,Tinea Pedis,Interventional,26-Sep-13,"Merz North America, Inc.",Drug: NAFT-600 (naftin 2 % gel)
NCT01290341,Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis,Tinea Pedis,Interventional,26-Sep-13,"Merz North America, Inc.",Drug: Placebo
NCT01289782,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients",Hepatitis C,Interventional,4-Jun-14,Janssen R&D Ireland,Drug: Placebo
NCT01289782,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients",Hepatitis C,Interventional,4-Jun-14,Janssen R&D Ireland,Drug: TMC435
NCT01289782,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients",Hepatitis C,Interventional,4-Jun-14,Janssen R&D Ireland,Drug: Peginterferon alpha-2a (PegIFN alpha-2a)
NCT01289782,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients",Hepatitis C,Interventional,4-Jun-14,Janssen R&D Ireland,Drug: Ribavirin (RBV)
NCT01289015,Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis,Tinea Pedis,Interventional,26-Sep-13,"Merz North America, Inc.",Drug: NAFT-600 ( naftin 2 % gel )
NCT01289015,Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis,Tinea Pedis,Interventional,26-Sep-13,"Merz North America, Inc.",Drug: Placebo
NCT01290679,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants",Hepatitis C,Interventional,13-Jun-14,Janssen R&D Ireland,Drug: Placebo
NCT01290679,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants",Hepatitis C,Interventional,13-Jun-14,Janssen R&D Ireland,Drug: TMC435
NCT01290679,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants",Hepatitis C,Interventional,13-Jun-14,Janssen R&D Ireland,Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)
NCT01290679,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants",Hepatitis C,Interventional,13-Jun-14,Janssen R&D Ireland,Drug: Ribavirin (RBV)
NCT01287117,A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment,Chronic Idiopathic Urticaria,Interventional,18-Oct-13,"Genentech, Inc.",Drug: Omalizumab
NCT01287117,A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment,Chronic Idiopathic Urticaria,Interventional,18-Oct-13,"Genentech, Inc.",Drug: Placebo
NCT01287039,A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Reslizumab
NCT01287039,A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT01287039,A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,Teva Pharmaceutical Industries,Drug: Reslizumab
NCT01287039,A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,Teva Pharmaceutical Industries,Drug: Placebo
NCT01285609,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin,Lung Cancer - Non Small Cell Squamous,Interventional,23-Jun-16,Bristol-Myers Squibb,Drug: Ipilimumab
NCT01285609,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin,Lung Cancer - Non Small Cell Squamous,Interventional,23-Jun-16,Bristol-Myers Squibb,Drug: Placebo
NCT01285609,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin,Lung Cancer - Non Small Cell Squamous,Interventional,23-Jun-16,Bristol-Myers Squibb,Drug: Paclitaxel
NCT01285609,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin,Lung Cancer - Non Small Cell Squamous,Interventional,23-Jun-16,Bristol-Myers Squibb,Drug: Carboplatin
NCT01285323,A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Reslizumab
NCT01285323,A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT01285323,A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,Teva Pharmaceutical Industries,Drug: Reslizumab
NCT01285323,A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,27-Jun-16,Teva Pharmaceutical Industries,Drug: Placebo
NCT01284517,Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression,Bipolar Depression,Interventional,14-Oct-13,Sunovion,Drug: Lurasidone
NCT01284517,Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression,Bipolar Depression,Interventional,14-Oct-13,Sunovion,Drug: Placebo
NCT01281839,"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy",Hepatitis C,Interventional,23-Apr-14,Janssen R&D Ireland,Drug: TMC435
NCT01281839,"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy",Hepatitis C,Interventional,23-Apr-14,Janssen R&D Ireland,Drug: Placebo
NCT01281839,"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy",Hepatitis C,Interventional,23-Apr-14,Janssen R&D Ireland,Drug: Peginterferon alpha-2a (PegIFN alpha-2a)
NCT01281839,"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy",Hepatitis C,Interventional,23-Apr-14,Janssen R&D Ireland,Drug: Ribavirin (RBV)
NCT01277666,A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease,Crohn's Disease,Interventional,19-Sep-17,GlaxoSmithKline,Drug: GSK1605786A
NCT01277666,A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease,Crohn's Disease,Interventional,19-Sep-17,GlaxoSmithKline,Drug: Placebo
NCT01276639,"A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,Interventional,19-Sep-14,Pfizer,"Drug: CP-690,550"
NCT01276639,"A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,Interventional,19-Sep-14,Pfizer,"Drug: Placebo/CP-690,550"
NCT01386528,Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B,Congenital Bleeding Disorder|Haemophilia B,Interventional,24-Jul-17,Novo Nordisk A/S,Drug: nonacog beta pegol
NCT01272232,Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes,Metabolism and Nutrition Disorder|Obesity,Interventional,9-Feb-15,Novo Nordisk A/S,Drug: liraglutide
NCT01272232,Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes,Metabolism and Nutrition Disorder|Obesity,Interventional,9-Feb-15,Novo Nordisk A/S,Drug: placebo
NCT01272219,Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes,Metabolism and Nutrition Disorder|Obesity,Interventional,9-Feb-15,Novo Nordisk A/S,Drug: liraglutide
NCT01272219,Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes,Metabolism and Nutrition Disorder|Obesity,Interventional,9-Feb-15,Novo Nordisk A/S,Drug: placebo
NCT01271933,Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients,Fibromyalgia,Interventional,14-Sep-18,Pfizer,Drug: pregabalin
NCT01271933,Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients,Fibromyalgia,Interventional,14-Sep-18,Pfizer,Drug: placebo
NCT01270971,Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail,Onychomycosis of Toenails,Interventional,15-Aug-14,Pfizer,"Drug: AN2690 Topical Solution, 5%"
NCT01270971,Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail,Onychomycosis of Toenails,Interventional,15-Aug-14,Pfizer,Drug: Solution Vehicle
NCT01270828,Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia,Post Herpetic Neuralgia,Interventional,13-Jan-16,Pfizer,Drug: Pregabalin
NCT01270828,Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia,Post Herpetic Neuralgia,Interventional,13-Jan-16,Pfizer,Drug: placebo
NCT01270464,A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,6-Jun-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Reslizumab
NCT01270464,A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,6-Jun-16,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT01270464,A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,6-Jun-16,Teva Pharmaceutical Industries,Drug: Reslizumab
NCT01270464,A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma,Eosinophilic Asthma,Interventional,6-Jun-16,Teva Pharmaceutical Industries,Drug: Placebo
NCT01378429,Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis,Perennial Allergic Rhinitis|PAR,Interventional,26-May-14,Sunovion,Drug: ciclesonide nasal aerosol
NCT01378429,Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis,Perennial Allergic Rhinitis|PAR,Interventional,26-May-14,Sunovion,Drug: Placebo
NCT01268098,Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY),Hypoparathyroidism,Interventional,6-Mar-15,Shire,Drug: NPSP558
NCT01264939,"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",Chronic Idiopathic Urticaria,Interventional,26-Nov-13,"Genentech, Inc.",Drug: Omalizumab
NCT01264939,"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",Chronic Idiopathic Urticaria,Interventional,26-Nov-13,"Genentech, Inc.",Drug: Placebo
NCT01264939,"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",Chronic Idiopathic Urticaria,Interventional,26-Nov-13,"Genentech, Inc.","Drug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist"
NCT01264939,"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",Chronic Idiopathic Urticaria,Interventional,26-Nov-13,"Genentech, Inc.",Drug: Diphenhydramine
NCT01262677,Once-A-Day Pregabalin For Partial Seizures,"Partial Seizures|Epilepsies, Partial",Interventional,5-Jun-18,Pfizer,Drug: pregabalin
NCT01262677,Once-A-Day Pregabalin For Partial Seizures,"Partial Seizures|Epilepsies, Partial",Interventional,5-Jun-18,Pfizer,Drug: placebo
NCT01262456,Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients,Nocturia,Interventional,15-Oct-15,Ferring Pharmaceuticals,Drug: Desmopressin
NCT01262456,Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients,Nocturia,Interventional,15-Oct-15,Ferring Pharmaceuticals,Drug: Placebo
NCT01262365,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,29-Jun-18,UCB Pharma,Drug: Epratuzumab
NCT01262365,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Interventional,29-Jun-18,UCB Pharma,Drug: Placebo
NCT01261793,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Interventional,29-Jun-18,UCB Pharma,Drug: Placebo
NCT01261793,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Interventional,29-Jun-18,UCB Pharma,Drug: Epratuzumab
NCT01261325,Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures,Epilepsy,Interventional,15-Aug-16,UCB Pharma,Drug: Placebo
NCT01261325,Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures,Epilepsy,Interventional,15-Aug-16,UCB Pharma,Drug: Brivaracetam
NCT01261325,Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures,Epilepsy,Interventional,15-Aug-16,UCB Pharma,Drug: Antiepileptic drugs with market authorization available per country
NCT02027701,Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",Interventional,2-Oct-18,CSL Behring,Biological: IgPro20
NCT01259492,Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD),Attention Deficit/Hyperactivity Disorder,Interventional,29-Apr-14,Novartis Pharmaceuticals,Drug: Placebo
NCT01259492,Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD),Attention Deficit/Hyperactivity Disorder,Interventional,29-Apr-14,Novartis Pharmaceuticals,Drug: Ritalin LA 20 mg
NCT01259492,Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD),Attention Deficit/Hyperactivity Disorder,Interventional,29-Apr-14,Novartis Pharmaceuticals,Drug: Ritalin LA 30 mg
NCT01259492,Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD),Attention Deficit/Hyperactivity Disorder,Interventional,29-Apr-14,Novartis,Drug: Placebo
NCT01259492,Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD),Attention Deficit/Hyperactivity Disorder,Interventional,29-Apr-14,Novartis,Drug: Ritalin LA 20 mg
NCT01259492,Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD),Attention Deficit/Hyperactivity Disorder,Interventional,29-Apr-14,Novartis,Drug: Ritalin LA 30 mg
NCT01271712,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),Gastrointestinal Stromal Tumors,Interventional,25-Oct-13,Bayer,"Drug: Regorafenib (Stivarga, BAY73-4506)"
NCT01271712,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),Gastrointestinal Stromal Tumors,Interventional,25-Oct-13,Bayer,Drug: Placebo
NCT01271712,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),Gastrointestinal Stromal Tumors,Interventional,25-Oct-13,Bayer,Drug: Best supportive care
NCT01256684,DHEA Against Vaginal Atrophy - 3-Month Efficacy Study,Vaginal Atrophy,Interventional,25-Apr-17,EndoCeutics Inc.,Drug: Placebo
NCT01256684,DHEA Against Vaginal Atrophy - 3-Month Efficacy Study,Vaginal Atrophy,Interventional,25-Apr-17,EndoCeutics Inc.,Drug: DHEA
NCT01256671,DHEA Against Vaginal Atrophy - Safety Study of 12 Months,Vaginal Atrophy,Interventional,18-Oct-17,EndoCeutics Inc.,Drug: DHEA
NCT01256450,Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain,Pain|Low Back Pain,Interventional,8-Dec-15,BioDelivery Sciences International,Drug: Buprenorphine
NCT01256450,Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain,Pain|Low Back Pain,Interventional,8-Dec-15,BioDelivery Sciences International,Drug: Placebo
NCT01537042,A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis,Restless Legs Syndrome|End-Stage Renal Disease,Interventional,3-Nov-14,UCB BIOSCIENCES GmbH,Drug: Rotigotine
NCT01537042,A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis,Restless Legs Syndrome|End-Stage Renal Disease,Interventional,3-Nov-14,UCB BIOSCIENCES GmbH,Drug: Placebo
NCT01537042,A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis,Restless Legs Syndrome|End-Stage Renal Disease,Interventional,3-Nov-14,UCB Pharma,Drug: Rotigotine
NCT01537042,A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis,Restless Legs Syndrome|End-Stage Renal Disease,Interventional,3-Nov-14,UCB Pharma,Drug: Placebo
NCT01254292,LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study,Contraception,Interventional,7-Apr-14,Bayer,"Drug: Levonorgestrel IUD (LCS, BAY86-5028)"
NCT01254292,LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study,Contraception,Interventional,7-Apr-14,Bayer,"Drug: Yasmin (EE30/DRSP, BAY86-5131)"
NCT01252940,Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF,HIV-1 Infection,Interventional,19-Apr-13,Gilead Sciences,Drug: FTC/RPV/TDF
NCT01252940,Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF,HIV-1 Infection,Interventional,19-Apr-13,Gilead Sciences,Drug: PI
NCT01252940,Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF,HIV-1 Infection,Interventional,19-Apr-13,Gilead Sciences,Drug: RTV
NCT01252940,Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF,HIV-1 Infection,Interventional,19-Apr-13,Gilead Sciences,Drug: NRTIs
NCT01251367,Dysport® Adult Lower Limb Spasticity Follow-on Study,Post-stroke Spasticity|Spasticity Post-Traumatic Brain Injury,Interventional,9-Nov-17,Ipsen,Drug: Dysport®
NCT01253577,A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis,Chronic Sinusitis,Interventional,13-Apr-15,Intersect ENT,Device: Sinus Stent with drug coating
NCT01253577,A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis,Chronic Sinusitis,Interventional,13-Apr-15,Intersect ENT,Device: Non Coated Sinus Stent
NCT01249404,Dysport® Adult Lower Limb Spasticity Study,Leg Spasticity,Interventional,17-Oct-17,Ipsen,Drug: Botulinum type A toxin (Dysport®)
NCT01249404,Dysport® Adult Lower Limb Spasticity Study,Leg Spasticity,Interventional,17-Oct-17,Ipsen,Drug: Placebo
NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,Melanoma,Interventional,15-Mar-13,GlaxoSmithKline,Drug: GSK1120212
NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,Melanoma,Interventional,15-Mar-13,GlaxoSmithKline,Drug: Chemotherapy
NCT01243411,A Study of AA4500 in Men With Peyronie's Disease,Peyronie's Disease,Interventional,15-Apr-15,Endo Pharmaceuticals,Biological: AA4500
NCT01244490,Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder,Interventional,14-Jul-14,Shire,Drug: Extended-release Guanfacine Hydrochloride
NCT01244490,Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder,Interventional,14-Jul-14,Shire,Drug: Atomoxetine Hydrochloride
NCT01244490,Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder,Interventional,14-Jul-14,Shire,Drug: Placebo Comparator
NCT01240863,Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time,Chronic Pain,Interventional,5-Jun-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Hydrocodone ER
NCT01240863,Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time,Chronic Pain,Interventional,5-Jun-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT01240863,Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time,Chronic Pain,Interventional,5-Jun-17,Teva Pharmaceutical Industries,Drug: Hydrocodone ER
NCT01240863,Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time,Chronic Pain,Interventional,5-Jun-17,Teva Pharmaceutical Industries,Drug: Placebo
NCT01240746,Study of Quadrivalent Influenza Vaccine Among Children,Influenza,Interventional,14-Jan-14,"Sanofi Pasteur, a Sanofi Company","Biological: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative"
NCT01240746,Study of Quadrivalent Influenza Vaccine Among Children,Influenza,Interventional,14-Jan-14,"Sanofi Pasteur, a Sanofi Company","Biological: Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative"
NCT01240746,Study of Quadrivalent Influenza Vaccine Among Children,Influenza,Interventional,14-Jan-14,"Sanofi Pasteur, a Sanofi Company","Biological: Quadrivalent Influenza Vaccine, No Preservative"
NCT01240746,Study of Quadrivalent Influenza Vaccine Among Children,Influenza,Interventional,14-Jan-14,Sanofi,"Biological: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative"
NCT01240746,Study of Quadrivalent Influenza Vaccine Among Children,Influenza,Interventional,14-Jan-14,Sanofi,"Biological: Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative"
NCT01240746,Study of Quadrivalent Influenza Vaccine Among Children,Influenza,Interventional,14-Jan-14,Sanofi,"Biological: Quadrivalent Influenza Vaccine, No Preservative"
NCT01237587,A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome,Fibromyalgia,Interventional,14-Aug-18,Eli Lilly and Company,Drug: Duloxetine
NCT01237587,A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome,Fibromyalgia,Interventional,14-Aug-18,Eli Lilly and Company,Drug: Placebo
NCT01236768,"Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm",Contraception,Interventional,15-Sep-17,Agile Therapeutics,Drug: AG200-15
NCT01236768,"Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm",Contraception,Interventional,15-Sep-17,Agile Therapeutics,Drug: Levora
NCT01255423,Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain,Ankle Sprain,Interventional,4-Oct-12,Novartis,Drug: Diclofenac sodium topical gel 1%
NCT01255423,Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain,Ankle Sprain,Interventional,4-Oct-12,Novartis,Drug: Placebo
NCT01232569,A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,23-Oct-13,Hoffmann-La Roche,Drug: Tocilizumab 162 mg
NCT01232569,A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,23-Oct-13,Hoffmann-La Roche,Drug: Placebo
NCT01232283,Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.,Plaque Psoriasis,Interventional,5-Nov-14,Celgene,Drug: Apremilast
NCT01232283,Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.,Plaque Psoriasis,Interventional,5-Nov-14,Celgene,Drug: Placebo
NCT01232283,Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.,Plaque Psoriasis,Interventional,5-Nov-14,Celgene,Other: Topical or Phototherapy Therapy
NCT01231620,A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza,"Influenza, Human",Interventional,20-Nov-17,GlaxoSmithKline,Drug: Zanamivir
NCT01231620,A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza,"Influenza, Human",Interventional,20-Nov-17,GlaxoSmithKline,Drug: Placebo to match zanamivir
NCT01231620,A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza,"Influenza, Human",Interventional,20-Nov-17,GlaxoSmithKline,Drug: Oseltamivir
NCT01231620,A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza,"Influenza, Human",Interventional,20-Nov-17,GlaxoSmithKline,Drug: Placebo to match oseltamivir
NCT01226511,A Study in Pediatric Participants With Generalized Anxiety Disorder,"Anxiety Neuroses|Anxiety States, Neurotic|Neuroses, Anxiety",Interventional,5-Mar-14,Eli Lilly and Company,Drug: Duloxetine
NCT01226511,A Study in Pediatric Participants With Generalized Anxiety Disorder,"Anxiety Neuroses|Anxiety States, Neurotic|Neuroses, Anxiety",Interventional,5-Mar-14,Eli Lilly and Company,Drug: Placebo
NCT01225562,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",Myocardial Infarction|Cardiovascular Death|Atherothrombosis|Stroke,Interventional,9-Dec-15,AstraZeneca,Drug: Ticagrelor 90 mg
NCT01225562,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",Myocardial Infarction|Cardiovascular Death|Atherothrombosis|Stroke,Interventional,9-Dec-15,AstraZeneca,Drug: Ticagrelor 60 mg
NCT01225562,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",Myocardial Infarction|Cardiovascular Death|Atherothrombosis|Stroke,Interventional,9-Dec-15,AstraZeneca,Drug: Ticagrelor Placebo
NCT01227889,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,Cancer,Interventional,16-May-14,GlaxoSmithKline,Drug: GSK2118436
NCT01227889,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,Cancer,Interventional,16-May-14,GlaxoSmithKline,Drug: Dacarbazine (DTIC)
NCT01224171,Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease,Crohn's Disease,Interventional,21-Jul-14,"Millennium Pharmaceuticals, Inc.",Drug: vedolizumab
NCT01224171,Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease,Crohn's Disease,Interventional,21-Jul-14,"Millennium Pharmaceuticals, Inc.",Other: Placebo
NCT01223937,Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients,Nocturia,Interventional,15-Oct-15,Ferring Pharmaceuticals,Drug: Desmopressin
NCT01223937,Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients,Nocturia,Interventional,15-Oct-15,Ferring Pharmaceuticals,Drug: Placebo
NCT01223365,Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time,Chronic Pain,Interventional,5-Apr-17,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Hydrocodone ER
NCT01223365,Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time,Chronic Pain,Interventional,5-Apr-17,Teva Pharmaceutical Industries,Drug: Hydrocodone ER
NCT01223027,Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma,Metastatic Renal Cell Carcinoma,Interventional,6-Nov-15,Novartis Pharmaceuticals,Drug: Dovitinib
NCT01223027,Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma,Metastatic Renal Cell Carcinoma,Interventional,6-Nov-15,Novartis Pharmaceuticals,Drug: Sorafenib
NCT01223027,Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma,Metastatic Renal Cell Carcinoma,Interventional,6-Nov-15,Novartis,Drug: Dovitinib
NCT01223027,Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma,Metastatic Renal Cell Carcinoma,Interventional,6-Nov-15,Novartis,Drug: Sorafenib
NCT01221623,Study of AA4500 in the Treatment of Peyronie's Disease,Peyronie's Disease,Interventional,7-Apr-15,Endo Pharmaceuticals,Biological: AA4500
NCT01221623,Study of AA4500 in the Treatment of Peyronie's Disease,Peyronie's Disease,Interventional,7-Apr-15,Endo Pharmaceuticals,Biological: Placebo
NCT01221597,Study of AA4500 in the Treatment of Peyronie's Disease,Peyronie's Disease,Interventional,7-Apr-15,Endo Pharmaceuticals,Biological: AA4500
NCT01221597,Study of AA4500 in the Treatment of Peyronie's Disease,Peyronie's Disease,Interventional,7-Apr-15,Endo Pharmaceuticals,Biological: Placebo
NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Relapsing Multiple Sclerosis,Interventional,13-Jan-17,Biogen,Drug: peginterferon beta-1a
NCT01218646,Study of Quadrivalent Influenza Vaccine Among Adults,Influenza,Interventional,12-Sep-13,"Sanofi Pasteur, a Sanofi Company","Biological: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative"
NCT01218646,Study of Quadrivalent Influenza Vaccine Among Adults,Influenza,Interventional,12-Sep-13,"Sanofi Pasteur, a Sanofi Company","Biological: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative"
NCT01218646,Study of Quadrivalent Influenza Vaccine Among Adults,Influenza,Interventional,12-Sep-13,"Sanofi Pasteur, a Sanofi Company","Biological: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative"
NCT01218646,Study of Quadrivalent Influenza Vaccine Among Adults,Influenza,Interventional,12-Sep-13,Sanofi,"Biological: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative"
NCT01218646,Study of Quadrivalent Influenza Vaccine Among Adults,Influenza,Interventional,12-Sep-13,Sanofi,"Biological: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative"
NCT01218646,Study of Quadrivalent Influenza Vaccine Among Adults,Influenza,Interventional,12-Sep-13,Sanofi,"Biological: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative"
NCT01970475,Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,13-Dec-16,Amgen,Biological: ABP 501
NCT01970475,Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis,"Arthritis, Rheumatoid",Interventional,13-Dec-16,Amgen,Biological: Adalimumab
NCT01214837,Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life,Meningococcal Disease|Meningococcal Meningitis,Interventional,2-Oct-14,Novartis Vaccines,Biological: MenACWY-CRM
NCT01214837,Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life,Meningococcal Disease|Meningococcal Meningitis,Interventional,2-Oct-14,Novartis Vaccines,Biological: Routine Vaccines
NCT01214837,Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life,Meningococcal Disease|Meningococcal Meningitis,Interventional,2-Oct-14,Novartis,Biological: MenACWY-CRM
NCT01214837,Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life,Meningococcal Disease|Meningococcal Meningitis,Interventional,2-Oct-14,Novartis,Biological: Routine Vaccines
NCT01967940,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",HIV|HIV Infections|Acquired Immunodeficiency Syndrome,Interventional,12-Jun-17,Gilead Sciences,Drug: TAF
NCT01967940,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",HIV|HIV Infections|Acquired Immunodeficiency Syndrome,Interventional,12-Jun-17,Gilead Sciences,Drug: Placebo
NCT01967940,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",HIV|HIV Infections|Acquired Immunodeficiency Syndrome,Interventional,12-Jun-17,Gilead Sciences,Drug: E/C/F/TAF
NCT01967940,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",HIV|HIV Infections|Acquired Immunodeficiency Syndrome,Interventional,12-Jun-17,Gilead Sciences,Drug: Current failing ARV regimen
NCT01967940,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",HIV|HIV Infections|Acquired Immunodeficiency Syndrome,Interventional,12-Jun-17,Gilead Sciences,Drug: ATV
NCT01212770,PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,20-May-14,Celgene,Drug: Apremilast 20mg
NCT01212770,PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,20-May-14,Celgene,Drug: Apremilast 30mg
NCT01212770,PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,20-May-14,Celgene,Drug: Placebo
NCT01212757,PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,19-May-14,Celgene,Drug: Apremilast 20mg
NCT01212757,PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,19-May-14,Celgene,Drug: Apremilast 30mg
NCT01212757,PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,19-May-14,Celgene,Drug: Placebo + 20 mg Apremilast
NCT01212757,PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,19-May-14,Celgene,Drug: Placebo + 30 mg Apremilast
NCT01211873,Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions,Diagnostic Self Evaluation|Central Nervous System Diseases,Interventional,29-May-14,Guerbet,Drug: Dotarem (gadoterate meglumine)
NCT01211873,Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions,Diagnostic Self Evaluation|Central Nervous System Diseases,Interventional,29-May-14,Guerbet,Drug: Magnevist (gadopentetate dimeglumine)
NCT01251380,Dysport® Pediatric Lower Limb Spasticity Follow-on Study,Cerebral Palsy|Muscle Spasticity|Children,Interventional,1-Jun-17,Ipsen,Drug: Botulinum type A toxin (Dysport®)
NCT01205438,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Interventional,19-Jun-18,Eli Lilly and Company,Drug: LY2127399
NCT01205438,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Interventional,19-Jun-18,Eli Lilly and Company,Drug: Placebo every 2 weeks
NCT01205438,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Interventional,19-Jun-18,Eli Lilly and Company,Drug: Placebo every 4 weeks
NCT01249417,Dysport® Pediatric Lower Limb Spasticity Study,Cerebral Palsy|Muscle Spasticity|Children,Interventional,3-Feb-17,Ipsen,Drug: Botulinum type A toxin (Dysport®)
NCT01249417,Dysport® Pediatric Lower Limb Spasticity Study,Cerebral Palsy|Muscle Spasticity|Children,Interventional,3-Feb-17,Ipsen,Drug: Placebo
NCT01202760,A Rheumatoid Arthritis Study in Participants,Rheumatoid Arthritis,Interventional,25-Apr-18,Eli Lilly and Company,Drug: LY2127399
NCT01202760,A Rheumatoid Arthritis Study in Participants,Rheumatoid Arthritis,Interventional,25-Apr-18,Eli Lilly and Company,Drug: Placebo
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis Pharmaceuticals,Drug: indacaterol and glycopyrronium (QVA149)
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis Pharmaceuticals,Drug: glycopyrronium (NVA237)
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis Pharmaceuticals,Drug: indacaterol (QAB149)
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis Pharmaceuticals,Drug: tiotropium
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis Pharmaceuticals,Drug: placebo
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis,Drug: indacaterol and glycopyrronium (QVA149)
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis,Drug: glycopyrronium (NVA237)
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis,Drug: indacaterol (QAB149)
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis,Drug: tiotropium
NCT01202188,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease (COPD),Interventional,3-May-13,Novartis,Drug: placebo
NCT01198756,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children,Influenza,Interventional,12-Mar-13,GlaxoSmithKline,Biological: Quadrivalent seasonal influenza vaccine GSK2282512A
NCT01198756,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children,Influenza,Interventional,12-Mar-13,GlaxoSmithKline,Biological: Fluarix™ VB
NCT01198756,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children,Influenza,Interventional,12-Mar-13,GlaxoSmithKline,Biological: Fluarix™ YB
NCT01197755,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist,Rheumatoid Arthritis,Interventional,7-Apr-14,AstraZeneca,Drug: fostamatinib
NCT01197755,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist,Rheumatoid Arthritis,Interventional,7-Apr-14,AstraZeneca,Drug: placebo
NCT01197534,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.,Rheumatoid Arthritis,Interventional,17-Apr-14,AstraZeneca,Drug: fostamatinib
NCT01197534,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.,Rheumatoid Arthritis,Interventional,17-Apr-14,AstraZeneca,"Drug: placebo, fostamatinib"
NCT01197521,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.,Rheumatoid Arthritis,Interventional,7-Apr-14,AstraZeneca,Drug: fostamatinib
NCT01197521,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.,Rheumatoid Arthritis,Interventional,7-Apr-14,AstraZeneca,"Drug: placebo, fostamatinib"
NCT01196988,Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children,Influenza,Interventional,19-Mar-13,GlaxoSmithKline,Biological: Influenza vaccine GSK2321138A
NCT01196988,Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children,Influenza,Interventional,19-Mar-13,GlaxoSmithKline,Biological: FluarixTM
NCT01196988,Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children,Influenza,Interventional,19-Mar-13,GlaxoSmithKline,Biological: Influenza vaccine GSK2604409A
NCT01196091,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Interventional,12-Jun-18,Eli Lilly and Company,Drug: LY2127399
NCT01196091,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Interventional,12-Jun-18,Eli Lilly and Company,Drug: Placebo every 2 weeks
NCT01196091,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Interventional,12-Jun-18,Eli Lilly and Company,Drug: Placebo every 4 weeks
NCT01196091,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Interventional,12-Jun-18,Eli Lilly and Company,Drug: Standard of Care
NCT01204671,Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A),Influenza,Interventional,17-Jun-13,GlaxoSmithKline,Biological: Influenza vaccine GSK2321138A
NCT01204671,Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A),Influenza,Interventional,17-Jun-13,GlaxoSmithKline,Biological: FluarixTM
NCT01204671,Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A),Influenza,Interventional,17-Jun-13,GlaxoSmithKline,Biological: Influenza vaccine GSK2604409A
NCT01194414,A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Feb-13,Hoffmann-La Roche,Drug: tocilizumab SC
NCT01194414,A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Feb-13,Hoffmann-La Roche,Drug: tocilizumab IV
NCT01194414,A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Feb-13,Hoffmann-La Roche,Drug: placebo to tocilizumab SC
NCT01194414,A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Feb-13,Hoffmann-La Roche,Drug: placebo to tocilizumab IV
NCT01194414,A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Feb-13,Hoffmann-La Roche,Drug: Disease-modifying antirheumatic drugs (DMARDs)
NCT01193257,Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.,Prostate Cancer,Interventional,18-Dec-18,"Millennium Pharmaceuticals, Inc.",Drug: Orteronel
NCT01193257,Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.,Prostate Cancer,Interventional,18-Dec-18,"Millennium Pharmaceuticals, Inc.",Drug: Prednisone
NCT01193257,Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.,Prostate Cancer,Interventional,18-Dec-18,"Millennium Pharmaceuticals, Inc.",Drug: Orteronel Placebo
NCT01193257,Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.,Prostate Cancer,Interventional,18-Dec-18,Takeda,Drug: Orteronel
NCT01193257,Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.,Prostate Cancer,Interventional,18-Dec-18,Takeda,Drug: Prednisone
NCT01193257,Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.,Prostate Cancer,Interventional,18-Dec-18,Takeda,Drug: Orteronel Placebo
NCT01193244,Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,17-May-17,"Millennium Pharmaceuticals, Inc.",Drug: Orteronel
NCT01193244,Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,17-May-17,"Millennium Pharmaceuticals, Inc.",Drug: Placebo
NCT01193244,Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,17-May-17,"Millennium Pharmaceuticals, Inc.",Drug: Prednisone
NCT01193244,Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,17-May-17,Takeda,Drug: Orteronel
NCT01193244,Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,17-May-17,Takeda,Drug: Placebo
NCT01193244,Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,17-May-17,Takeda,Drug: Prednisone
NCT01193153,A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder,Schizoaffective Disorder,Interventional,5-Jan-15,"Janssen Scientific Affairs, LLC",Drug: Placebo
NCT01193153,A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder,Schizoaffective Disorder,Interventional,5-Jan-15,"Janssen Scientific Affairs, LLC",Drug: paliperidone palmitate
NCT01192295,Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids,Pain,Interventional,6-Feb-15,Purdue Pharma LP,Drug: Oxycodone HCl controlled-release tablets
NCT01192022,TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery,Hemorrhage,Interventional,25-Nov-15,Takeda,Biological: TachoSil®
NCT01192022,TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery,Hemorrhage,Interventional,25-Nov-15,Takeda,Device: Surgicel® Original
NCT01191801,Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML,Acute Myeloid Leukemia,Interventional,9-May-17,Sunesis Pharmaceuticals,Drug: vosaroxin + cytarabine
NCT01191801,Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML,Acute Myeloid Leukemia,Interventional,9-May-17,Sunesis Pharmaceuticals,Drug: placebo + cytarabine
NCT01191268,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),"Diabetes Mellitus, Type 2",Interventional,8-Oct-14,Eli Lilly and Company,Drug: Insulin Glargine
NCT01191268,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),"Diabetes Mellitus, Type 2",Interventional,8-Oct-14,Eli Lilly and Company,Drug: LY2189265
NCT01191268,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),"Diabetes Mellitus, Type 2",Interventional,8-Oct-14,Eli Lilly and Company,Drug: Insulin Lispro
NCT01191255,A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis,Hyperphosphatemia|Kidney Failure,Interventional,10-Dec-14,Keryx Biopharmaceuticals,"Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo"
NCT01191086,Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures,Epilepsy,Interventional,23-Feb-15,Upsher-Smith Laboratories,Drug: USL255
NCT01190189,Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study,"Infections, Papillomavirus",Interventional,17-Dec-18,GlaxoSmithKline,Biological: GSK580299 (Cervarix)
NCT01188928,LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs),Psoriasis Vulgaris,Interventional,9-Apr-13,LEO Pharma,Drug: Calcipotriol plus betamethasone
NCT01188928,LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs),Psoriasis Vulgaris,Interventional,9-Apr-13,LEO Pharma,"Drug: Betamethasone-17,21-dipropionate"
NCT01188928,LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs),Psoriasis Vulgaris,Interventional,9-Apr-13,LEO Pharma,Drug: Calcipotriene
NCT01188928,LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs),Psoriasis Vulgaris,Interventional,9-Apr-13,LEO Pharma,Drug: Topical suspension vehicle
NCT01188564,"Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks",Hereditary Angioedema,Interventional,7-Aug-15,Pharming Technologies B.V.,Drug: rhC1INH
NCT01188564,"Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks",Hereditary Angioedema,Interventional,7-Aug-15,Pharming Technologies B.V.,Drug: Placebo (Saline)
NCT01187953,"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx",Renal Failure,Interventional,29-May-15,Veloxis Pharmaceuticals,Drug: Prograf (tacrolimus)
NCT01187953,"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx",Renal Failure,Interventional,29-May-15,Veloxis Pharmaceuticals,Drug: LCP-Tacro
NCT01187407,A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment,Major Depressive Disorder (MDD),Interventional,24-Apr-18,Eli Lilly and Company,Drug: LY2216684
NCT01187407,A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment,Major Depressive Disorder (MDD),Interventional,24-Apr-18,Eli Lilly and Company,Drug: Placebo
NCT01187407,A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment,Major Depressive Disorder (MDD),Interventional,24-Apr-18,Eli Lilly and Company,Drug: SSRI
NCT01186744,"A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis",Psoriasis,Interventional,4-Jun-14,Pfizer,"Drug: CP-690,550"
NCT01204775,"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",Type 2 Diabetes,Interventional,18-Apr-17,AstraZeneca,Drug: Saxagliptin
NCT01204775,"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",Type 2 Diabetes,Interventional,18-Apr-17,AstraZeneca,Drug: Placebo (Saxagliptin)
NCT01204775,"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",Type 2 Diabetes,Interventional,18-Apr-17,AstraZeneca,Drug: Metformin IR
NCT01204775,"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",Type 2 Diabetes,Interventional,18-Apr-17,AstraZeneca,Drug: Placebo (Metformin)
NCT01204775,"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",Type 2 Diabetes,Interventional,18-Apr-17,AstraZeneca,Drug: Metformin (Active Rescue)
NCT01185340,A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor,Major Depressive Disorder,Interventional,27-Apr-18,Eli Lilly and Company,Drug: LY2216684
NCT01185340,A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor,Major Depressive Disorder,Interventional,27-Apr-18,Eli Lilly and Company,Drug: Placebo
NCT01185340,A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor,Major Depressive Disorder,Interventional,27-Apr-18,Eli Lilly and Company,Drug: SSRI
NCT01185301,Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA),Early Rheumatoid Arthritis,Interventional,15-Nov-13,"AbbVie (prior sponsor, Abbott)",Biological: adalimumab
NCT01185301,Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA),Early Rheumatoid Arthritis,Interventional,15-Nov-13,"AbbVie (prior sponsor, Abbott)",Drug: methotrexate
NCT01185301,Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA),Early Rheumatoid Arthritis,Interventional,15-Nov-13,AbbVie,Biological: adalimumab
NCT01185301,Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA),Early Rheumatoid Arthritis,Interventional,15-Nov-13,AbbVie,Drug: methotrexate
NCT01228071,"Time to Eugonadal Range, Time to Steady State and Drying Time",Male Hypogonadism,Interventional,22-Jul-13,Endo Pharmaceuticals,Drug: testosterone gel 2%
NCT01182441,Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy,Atrial Fibrillation|Stroke,Interventional,26-Jul-18,Boston Scientific Corporation,Device: WATCHMAN Device
NCT01182441,Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy,Atrial Fibrillation|Stroke,Interventional,26-Jul-18,Boston Scientific Corporation,Drug: Warfarin
NCT01181479,Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System,Contraception,Interventional,3-Jul-18,Agile Therapeutics,Drug: AG200-15 (cycles 1-13)
NCT01181479,Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System,Contraception,Interventional,3-Jul-18,Agile Therapeutics,Drug: Lessina crossover to AG200-15
NCT01179516,Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,18-Dec-13,Takeda,Drug: Vortioxetine
NCT01179516,Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,18-Dec-13,Takeda,Drug: Placebo
NCT01179217,A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia,Sickle Cell Anemia|Sickle ß0-Thalassemia,Interventional,10-Aug-17,"Emmaus Medical, Inc.",Drug: L-glutamine
NCT01179217,A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia,Sickle Cell Anemia|Sickle ß0-Thalassemia,Interventional,10-Aug-17,"Emmaus Medical, Inc.",Drug: Placebo
NCT01179347,Tiotropium Bromide in Cystic Fibrosis,Cystic Fibrosis,Interventional,26-Mar-13,Boehringer Ingelheim,Drug: tiotropium Respimat® inhaler
NCT01179347,Tiotropium Bromide in Cystic Fibrosis,Cystic Fibrosis,Interventional,26-Mar-13,Boehringer Ingelheim,Drug: Placebo Respimat® inhaler
NCT01179048,Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,"Diabetes|Diabetes Mellitus, Type 2",Interventional,1-Mar-17,Novo Nordisk A/S,Drug: liraglutide
NCT01179048,Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,"Diabetes|Diabetes Mellitus, Type 2",Interventional,1-Mar-17,Novo Nordisk A/S,Drug: placebo
NCT01178281,Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence,Primary Myelofibrosis|MPN-associated Myelofibrosis,Interventional,14-Mar-14,Celgene,Drug: Pomalidomide 0.5 mg
NCT01178281,Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence,Primary Myelofibrosis|MPN-associated Myelofibrosis,Interventional,14-Mar-14,Celgene,Drug: Placebo
NCT01178281,Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence,Primary Myelofibrosis|MPN-associated Myelofibrosis,Interventional,14-Mar-14,Celgene,Drug: Pomalidomide
NCT01181895,Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma,Asthma,Interventional,26-Aug-13,GlaxoSmithKline,Drug: Vilanterol
NCT01181895,Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma,Asthma,Interventional,26-Aug-13,GlaxoSmithKline,Drug: Salmeterol Inhalation Powder
NCT01181895,Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma,Asthma,Interventional,26-Aug-13,GlaxoSmithKline,Drug: Placebo Inhalation Powder NDPI
NCT01181895,Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma,Asthma,Interventional,26-Aug-13,GlaxoSmithKline,Drug: Placebo Inhalation Powder Diskus
NCT01178125,A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy,Contraception|Female Contraception,Interventional,11-Dec-13,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: DR-102
NCT01178125,A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy,Contraception|Female Contraception,Interventional,11-Dec-13,Teva Pharmaceutical Industries,Drug: DR-102
NCT01176240,A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease,Orthostatic Hypotension|Parkinson's Disease,Interventional,20-May-14,Chelsea Therapeutics,Drug: Droxidopa
NCT01176240,A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease,Orthostatic Hypotension|Parkinson's Disease,Interventional,20-May-14,Chelsea Therapeutics,Other: Placebo
NCT01218659,Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease,Fabry Disease,Interventional,1-Nov-18,Amicus Therapeutics,Drug: migalastat hydrochloride
NCT01218659,Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease,Fabry Disease,Interventional,1-Nov-18,Amicus Therapeutics,Biological: agalsidase
NCT01174004,A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis,Parkinson's Disease Psychosis,Interventional,26-Mar-14,ACADIA Pharmaceuticals Inc.,Drug: pimavanserin tartrate
NCT01174004,A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis,Parkinson's Disease Psychosis,Interventional,26-Mar-14,ACADIA Pharmaceuticals Inc.,Drug: placebo
NCT01173601,A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,17-Apr-18,Eli Lilly and Company,Drug: LY2216684
NCT01173601,A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,17-Apr-18,Eli Lilly and Company,Drug: Placebo
NCT01173601,A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder,Major Depressive Disorder,Interventional,17-Apr-18,Eli Lilly and Company,Drug: SSRI
NCT01172938,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,20-May-14,Celgene,Drug: Apremilast 20mg
NCT01172938,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,20-May-14,Celgene,Drug: Apremilast 30mg
NCT01172938,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,20-May-14,Celgene,Drug: Placebo + 20 mg Apremilast
NCT01172938,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Psoriatic Arthritis,Interventional,20-May-14,Celgene,Drug: Placebo + 30 mg Apremilast
NCT01175213,Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID,Primary Immunodeficiency Diseases (PID),Interventional,26-May-16,Baxalta now part of Shire,"Biological: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)"
NCT01175213,Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID,Primary Immunodeficiency Diseases (PID),Interventional,26-May-16,Baxalta now part of Shire,"Biological: SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)"
NCT01175213,Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID,Primary Immunodeficiency Diseases (PID),Interventional,26-May-16,Baxalta now part of Shire,"Biological: IV treatment with IGSC, 10%"
NCT01175213,Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID,Primary Immunodeficiency Diseases (PID),Interventional,26-May-16,Shire,"Biological: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)"
NCT01175213,Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID,Primary Immunodeficiency Diseases (PID),Interventional,26-May-16,Shire,"Biological: SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)"
NCT01175213,Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID,Primary Immunodeficiency Diseases (PID),Interventional,26-May-16,Shire,"Biological: IV treatment with IGSC, 10%"
NCT01170221,TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.,Skin and Subcutaneous Tissue Bacterial Infections,Interventional,3-Sep-14,Trius Therapeutics LLC,Drug: TR-701 FA
NCT01170221,TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.,Skin and Subcutaneous Tissue Bacterial Infections,Interventional,3-Sep-14,Trius Therapeutics LLC,Drug: Linezolid
NCT01170663,A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma,Gastric Cancer,Interventional,31-Jul-14,Eli Lilly and Company,Biological: Ramucirumab (IMC-1211B) DP
NCT01170663,A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma,Gastric Cancer,Interventional,31-Jul-14,Eli Lilly and Company,Drug: Placebo
NCT01170663,A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma,Gastric Cancer,Interventional,31-Jul-14,Eli Lilly and Company,Drug: Paclitaxel
NCT01210352,"Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects",Post Operative Pain,Interventional,7-May-19,Endo Pharmaceuticals,Drug: oxymorphone HCl
NCT01165229,"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older",Herpes Zoster,Interventional,20-Nov-17,GlaxoSmithKline,Biological: Herpes Zoster Vaccine GSK1437173A
NCT01165229,"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older",Herpes Zoster,Interventional,20-Nov-17,GlaxoSmithKline,Biological: Placebo
NCT01165177,"Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older",Herpes Zoster,Interventional,1-May-17,GlaxoSmithKline,Biological: Herpes Zoster Vaccine GSK1437173A
NCT01165177,"Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older",Herpes Zoster,Interventional,1-May-17,GlaxoSmithKline,Biological: Placebo
NCT01165138,Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Asthma,Interventional,30-Jul-13,GlaxoSmithKline,Drug: Fluticasone furoate/Vilanterol Inhalation Powder
NCT01165138,Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Asthma,Interventional,30-Jul-13,GlaxoSmithKline,Drug: Fluticasone Furoate Inhalation Powder
NCT01165138,Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Asthma,Interventional,30-Jul-13,GlaxoSmithKline,Drug: Placebo Inhaltion Powder
NCT01163266,Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,18-Dec-13,Takeda,Drug: Vortioxetine
NCT01163266,Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,18-Dec-13,Takeda,Drug: Placebo
NCT01163032,Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder,Non-24-Hour Sleep-Wake Disorder,Interventional,16-Oct-14,Vanda Pharmaceuticals,Drug: tasimelteon
NCT01163032,Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder,Non-24-Hour Sleep-Wake Disorder,Interventional,16-Oct-14,Vanda Pharmaceuticals,Drug: Placebo
NCT01162122,Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects,Influenza,Interventional,12-Jun-14,Novartis Vaccines,Biological: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)
NCT01162122,Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects,Influenza,Interventional,12-Jun-14,Novartis Vaccines,Biological: Non-adjuvanted trivalent subunit influenza vaccine (TIV)
NCT01162122,Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects,Influenza,Interventional,12-Jun-14,Novartis,Biological: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)
NCT01162122,Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects,Influenza,Interventional,12-Jun-14,Novartis,Biological: Non-adjuvanted trivalent subunit influenza vaccine (TIV)
NCT01161420,Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com),Obstructive Sleep Apnea,Interventional,15-Dec-14,"Inspire Medical Systems, Inc.",Device: Inspire Upper Airway Stimulation System
NCT01159912,Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Fluticasone propionate
NCT01159912,Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Fluticasone furoate
NCT01159912,Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Placebo
NCT01158378,Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures,Elective Cranial Procedures With Dural Incision,Interventional,8-Apr-14,"HyperBranch Medical Technology, Inc",Device: Adherus Dural Sealant
NCT01155661,A Safety Study in Participants With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,17-Apr-18,Eli Lilly and Company,Drug: LY2216684 (edivoxetine)
NCT01155661,A Safety Study in Participants With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,17-Apr-18,Eli Lilly and Company,Drug: SSRI
NCT01154140,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,Non Squamous Lung Cancer,Interventional,5-Jan-15,Pfizer,Drug: treatment
NCT01153009,Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,18-Dec-13,Takeda,Drug: Vortioxetine
NCT01153009,Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,18-Dec-13,Takeda,Drug: Duloxetine
NCT01153009,Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,18-Dec-13,Takeda,Drug: Placebo
NCT01151410,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",Hypertension,Interventional,7-Mar-16,Novartis Pharmaceuticals,Drug: Aliskiren
NCT01151410,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",Hypertension,Interventional,7-Mar-16,Novartis Pharmaceuticals,Drug: Enalapril
NCT01151410,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",Hypertension,Interventional,7-Mar-16,Novartis,Drug: Aliskiren
NCT01151410,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",Hypertension,Interventional,7-Mar-16,Novartis,Drug: Enalapril
NCT01151098,Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study,Chronic Nonmalignant Pain,Interventional,23-Sep-10,Purdue Pharma LP,Drug: Buprenorphine transdermal patch
NCT01150357,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,Hypertension,Interventional,15-Oct-15,Novartis Pharmaceuticals,Drug: Aliskiren (6.25/12.5/25 mg)
NCT01150357,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,Hypertension,Interventional,15-Oct-15,Novartis Pharmaceuticals,Drug: Aliskiren (37.5/75/150 mg)
NCT01150357,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,Hypertension,Interventional,15-Oct-15,Novartis Pharmaceuticals,Drug: Aliskiren (150/300/600 mg)
NCT01150357,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,Hypertension,Interventional,15-Oct-15,Novartis,Drug: Aliskiren (6.25/12.5/25 mg)
NCT01150357,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,Hypertension,Interventional,15-Oct-15,Novartis,Drug: Aliskiren (37.5/75/150 mg)
NCT01150357,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,Hypertension,Interventional,15-Oct-15,Novartis,Drug: Aliskiren (150/300/600 mg)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis Pharmaceuticals,Drug: Tacrolimus (reduced tacrolimus)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis Pharmaceuticals,Drug: Everolimus (reduced tacrolimus)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis Pharmaceuticals,Drug: Tacrolimus (tacrolimus elimination)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis Pharmaceuticals,Drug: Everolimus (tacrolimus elimination)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis Pharmaceuticals,Drug: Tacrolimus (tacrolimus control)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis Pharmaceuticals,Drug: Corticosteroids
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis,Drug: Tacrolimus (reduced tacrolimus)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis,Drug: Everolimus (reduced tacrolimus)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis,Drug: Tacrolimus (tacrolimus elimination)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis,Drug: Everolimus (tacrolimus elimination)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis,Drug: Tacrolimus (tacrolimus control)
NCT01150097,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Liver Transplant Recipient,Interventional,30-May-14,Novartis,Drug: Corticosteroids
NCT01147848,HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents,Asthma,Interventional,5-Sep-13,GlaxoSmithKline,Drug: Fluticasone furoate/Vilanterol Inhalation Powder
NCT01147848,HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents,Asthma,Interventional,5-Sep-13,GlaxoSmithKline,Drug: Fluticasone propionate/salmeterol Inhalation Powder
NCT01147848,HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents,Asthma,Interventional,5-Sep-13,GlaxoSmithKline,Drug: Placebo (1)
NCT01147848,HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents,Asthma,Interventional,5-Sep-13,GlaxoSmithKline,Drug: Placebo (2)
NCT01147250,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),Acute Coronary Syndrome,Interventional,14-Oct-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT01147250,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),Acute Coronary Syndrome,Interventional,14-Oct-16,Sanofi,Drug: Placebo
NCT01144637,"A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects",Smallpox,Interventional,3-Jan-19,Bavarian Nordic,Biological: IMVAMUNE®
NCT01144637,"A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects",Smallpox,Interventional,3-Jan-19,Bavarian Nordic,Other: Placebo
NCT01144338,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,8-Aug-18,AstraZeneca,Drug: Exenatide Once Weekly
NCT01144338,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,8-Aug-18,AstraZeneca,Drug: Placebo
NCT01143090,A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder,Schizophrenia|Schizoaffective Disorder,Interventional,17-Dec-12,Sunovion,Drug: Lurasidone HCl
NCT01143077,A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents,Schizophrenia|Schizoaffective Disorder,Interventional,16-Aug-12,Sunovion,Drug: Lurasidone HCl
NCT01142193,Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures,Epilepsy,Interventional,7-May-14,Upsher-Smith Laboratories,Drug: USL255
NCT01142193,Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures,Epilepsy,Interventional,7-May-14,Upsher-Smith Laboratories,Drug: Placebo
NCT01142726,Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,17-Oct-14,Bristol-Myers Squibb,Drug: Abatacept
NCT01142726,Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,17-Oct-14,Bristol-Myers Squibb,Drug: Methotrexate
NCT01142726,Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,17-Oct-14,Bristol-Myers Squibb,Drug: Abatacept placebo
NCT01142726,Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,17-Oct-14,Bristol-Myers Squibb,Drug: Methotrexate placebo
NCT01141283,Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase,Osteoarthritis,Interventional,21-Sep-10,Purdue Pharma LP,Drug: Buprenorphine transdermal patch
NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,Hepatocellular Carcinoma,Interventional,26-Mar-15,Eli Lilly and Company,Biological: Placebo
NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,Hepatocellular Carcinoma,Interventional,26-Mar-15,Eli Lilly and Company,Biological: Ramucirumab DP (IMC-1121B)
NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,Hepatocellular Carcinoma,Interventional,26-Mar-15,Eli Lilly and Company,Other: BSC
NCT01138501,Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A,Congenital Bleeding Disorder|Haemophilia A,Interventional,11-Jun-14,Novo Nordisk A/S,Drug: turoctocog alfa
NCT01137812,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),"Diabetes Mellitus, Type 2",Interventional,17-May-13,"Janssen Research & Development, LLC",Drug: Sitagliptin 100 mg
NCT01137812,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),"Diabetes Mellitus, Type 2",Interventional,17-May-13,"Janssen Research & Development, LLC",Drug: Canagliflozin 300 mg
NCT01137812,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),"Diabetes Mellitus, Type 2",Interventional,17-May-13,"Janssen Research & Development, LLC",Drug: Metformin
NCT01137812,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),"Diabetes Mellitus, Type 2",Interventional,17-May-13,"Janssen Research & Development, LLC",Drug: Sulphonylurea
NCT01135992,Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™),"Diabetes|Diabetes Mellitus, Type 2",Interventional,22-Jan-16,Novo Nordisk A/S,Drug: insulin degludec
NCT01135992,Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™),"Diabetes|Diabetes Mellitus, Type 2",Interventional,22-Jan-16,Novo Nordisk A/S,Drug: insulin glargine
NCT01134705,Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis),"Rhinitis, Allergic, Perennial",Interventional,23-May-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
NCT01134705,Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis),"Rhinitis, Allergic, Perennial",Interventional,23-May-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo Nasal Aerosol
NCT01134705,Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis),"Rhinitis, Allergic, Perennial",Interventional,23-May-12,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
NCT01134705,Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis),"Rhinitis, Allergic, Perennial",Interventional,23-May-12,Teva Pharmaceutical Industries,Drug: Placebo Nasal Aerosol
NCT01134042,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Fluticasone Furoate/Vilanterol Inhalation Powder
NCT01134042,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Fluticasone Furoate Inhalation Powder
NCT01134042,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Fluticasone Propionate Inhalation Powder
NCT01134042,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Other: Placebo Inhalation Powder 1
NCT01134042,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Other: Placebo Inhalation Powder 2
NCT01139762,A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms,Benign Prostatic Hyperplasia|Enlarged Prostate,Interventional,27-Feb-13,Eli Lilly and Company,Drug: Tadalafil
NCT01139762,A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms,Benign Prostatic Hyperplasia|Enlarged Prostate,Interventional,27-Feb-13,Eli Lilly and Company,Drug: Placebo
NCT01139762,A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms,Benign Prostatic Hyperplasia|Enlarged Prostate,Interventional,27-Feb-13,Eli Lilly and Company,Drug: Finasteride
NCT01130493,A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066,Parkinson's Disease,Interventional,13-Sep-17,"Impax Laboratories, LLC",Drug: IPX066
NCT01130493,A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066,Parkinson's Disease,Interventional,13-Sep-17,"Impax Laboratories, LLC",Drug: CLE
NCT01412944,Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis,Plaque-type Psoriasis,Interventional,18-Mar-15,Novartis Pharmaceuticals,Drug: secukinumab 150mg
NCT01412944,Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis,Plaque-type Psoriasis,Interventional,18-Mar-15,Novartis Pharmaceuticals,Drug: secukinumab 10mg/kg i.v. regimen
NCT01412944,Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis,Plaque-type Psoriasis,Interventional,18-Mar-15,Novartis,Drug: secukinumab 150mg
NCT01412944,Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis,Plaque-type Psoriasis,Interventional,18-Mar-15,Novartis,Drug: secukinumab 10mg/kg i.v. regimen
NCT01128894,A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.,"Diabetes Mellitus, Type 2",Interventional,20-May-14,GlaxoSmithKline,Biological: albiglutide
NCT01128894,A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.,"Diabetes Mellitus, Type 2",Interventional,20-May-14,GlaxoSmithKline,Drug: liraglutide
NCT01127581,Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery,Reducing Time to Vaginal Delivery|Cervical Ripening|Induction of Labor,Interventional,7-Mar-14,Ferring Pharmaceuticals,Drug: MVI 200
NCT01127581,Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery,Reducing Time to Vaginal Delivery|Cervical Ripening|Induction of Labor,Interventional,7-Mar-14,Ferring Pharmaceuticals,Drug: Dinoprostone Vaginal Insert (DVI)
NCT01126580,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),"Diabetes Mellitus, Type 2",Interventional,16-Jan-15,Eli Lilly and Company,Drug: Metformin
NCT01126580,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),"Diabetes Mellitus, Type 2",Interventional,16-Jan-15,Eli Lilly and Company,Drug: LY2189265
NCT01126580,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),"Diabetes Mellitus, Type 2",Interventional,16-Jan-15,Eli Lilly and Company,Drug: Placebo (oral)
NCT01126580,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),"Diabetes Mellitus, Type 2",Interventional,16-Jan-15,Eli Lilly and Company,Drug: Placebo (subcutaneous)
NCT01126437,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,20-Jun-14,Boehringer Ingelheim,Drug: tiotropium 18 mcg
NCT01126437,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,20-Jun-14,Boehringer Ingelheim,Drug: tiotropium 1.25 mcg (2 actuations/day)
NCT01126437,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,20-Jun-14,Boehringer Ingelheim,Drug: tiotropium 2.5 mcg (2 actuations/day)
NCT01125566,LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment,Breast Neoplasms,Interventional,21-Aug-14,Boehringer Ingelheim,Drug: BIBW 2992
NCT01125566,LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment,Breast Neoplasms,Interventional,21-Aug-14,Boehringer Ingelheim,Drug: trastuzumab
NCT01125566,LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment,Breast Neoplasms,Interventional,21-Aug-14,Boehringer Ingelheim,Drug: vinorelbine
NCT01123512,The Kiva® System as a Vertebral Augmentation Treatment,"Spinal Fractures|Fractures, Compression|Back Injuries",Interventional,21-Aug-14,"Benvenue Medical, Inc.",Device: Vertebral augmentation
NCT01120691,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Chronic Obstructive Pulmonary Disease,Interventional,30-Sep-13,Novartis Pharmaceuticals,Drug: QVA149
NCT01120691,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Chronic Obstructive Pulmonary Disease,Interventional,30-Sep-13,Novartis Pharmaceuticals,Drug: NVA237
NCT01120691,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Chronic Obstructive Pulmonary Disease,Interventional,30-Sep-13,Novartis Pharmaceuticals,Drug: tiotropium
NCT01120691,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Chronic Obstructive Pulmonary Disease,Interventional,30-Sep-13,Novartis Pharmaceuticals,Drug: Salbutamol/albuterol
NCT01120691,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Chronic Obstructive Pulmonary Disease,Interventional,30-Sep-13,Novartis,Drug: QVA149
NCT01120691,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Chronic Obstructive Pulmonary Disease,Interventional,30-Sep-13,Novartis,Drug: NVA237
NCT01120691,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Chronic Obstructive Pulmonary Disease,Interventional,30-Sep-13,Novartis,Drug: tiotropium
NCT01120691,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Chronic Obstructive Pulmonary Disease,Interventional,30-Sep-13,Novartis,Drug: Salbutamol/albuterol
NCT01117012,Rollover Study of VX-770 in Cystic Fibrosis Subjects,Cystic Fibrosis,Interventional,7-Jul-15,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT01117012,Rollover Study of VX-770 in Cystic Fibrosis Subjects,Cystic Fibrosis,Interventional,7-Jul-15,Cystic Fibrosis Foundation,Drug: Ivacaftor
NCT01115569,Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain,Chronic Pain,Interventional,25-Apr-14,"Zogenix, Inc.",Drug: Hydrocodone Bitartrate
NCT01114737,Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients,Phenylketonuria,Interventional,1-Feb-16,BioMarin Pharmaceutical,Drug: Sapropterin dihydrochloride
NCT01114737,Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients,Phenylketonuria,Interventional,1-Feb-16,BioMarin Pharmaceutical,Drug: Placebo
NCT01114217,A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia,Iron Deficiency Anemia,Interventional,11-Jun-18,"AMAG Pharmaceuticals, Inc.",Drug: Ferumoxytol
NCT01114139,A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia,Iron Deficiency Anemia,Interventional,11-Jun-18,"AMAG Pharmaceuticals, Inc.",Drug: Ferumoxytol
NCT01114139,A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia,Iron Deficiency Anemia,Interventional,11-Jun-18,"AMAG Pharmaceuticals, Inc.",Other: Placebo
NCT01113931,Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin,Urogential Chlamydia Trachomatis Infection,Interventional,27-Jan-12,Warner Chilcott,Drug: Doxycyline Hyclate tablet
NCT01113931,Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin,Urogential Chlamydia Trachomatis Infection,Interventional,27-Jan-12,Warner Chilcott,Drug: Vibramycin (doxycyline hyclate) capsule
NCT01108510,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: COBI
NCT01108510,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: RTV
NCT01108510,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: ATV
NCT01108510,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: FTC/TDF
NCT01108510,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: COBI placebo
NCT01108510,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,28-Oct-14,Gilead Sciences,Drug: RTV placebo
NCT01106690,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),"Diabetes Mellitus, Type 2",Interventional,21-May-13,"Janssen Research & Development, LLC",Drug: Placebo
NCT01106690,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),"Diabetes Mellitus, Type 2",Interventional,21-May-13,"Janssen Research & Development, LLC",Drug: Canagliflozin
NCT01106690,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),"Diabetes Mellitus, Type 2",Interventional,21-May-13,"Janssen Research & Development, LLC",Drug: Sitagliptin
NCT01106690,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),"Diabetes Mellitus, Type 2",Interventional,21-May-13,"Janssen Research & Development, LLC",Drug: Metformin
NCT01106690,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),"Diabetes Mellitus, Type 2",Interventional,21-May-13,"Janssen Research & Development, LLC",Drug: Pioglitazone
NCT01106677,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),"Diabetes Mellitus, Type 2",Interventional,30-Jul-13,"Janssen Research & Development, LLC",Drug: Placebo
NCT01106677,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),"Diabetes Mellitus, Type 2",Interventional,30-Jul-13,"Janssen Research & Development, LLC",Drug: Canagliflozin
NCT01106677,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),"Diabetes Mellitus, Type 2",Interventional,30-Jul-13,"Janssen Research & Development, LLC",Drug: Sitagliptin
NCT01106677,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),"Diabetes Mellitus, Type 2",Interventional,30-Jul-13,"Janssen Research & Development, LLC",Drug: Metformin immediate release
NCT01106651,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,29-May-13,"Janssen Research & Development, LLC",Drug: Canagliflozin 100 mg
NCT01106651,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,29-May-13,"Janssen Research & Development, LLC",Drug: Canagliflozin 300 mg
NCT01106651,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,29-May-13,"Janssen Research & Development, LLC",Drug: Antihyperglycemic agent(s)
NCT01106651,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,29-May-13,"Janssen Research & Development, LLC",Drug: Placebo
NCT01106625,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),"Diabetes Mellitus, Type 2",Interventional,29-May-13,"Janssen Research & Development, LLC",Drug: Canagliflozin
NCT01106625,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),"Diabetes Mellitus, Type 2",Interventional,29-May-13,"Janssen Research & Development, LLC",Drug: Placebo
NCT01106625,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),"Diabetes Mellitus, Type 2",Interventional,29-May-13,"Janssen Research & Development, LLC",Drug: Metformin
NCT01106625,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),"Diabetes Mellitus, Type 2",Interventional,29-May-13,"Janssen Research & Development, LLC",Drug: Sulphonylruea
NCT01106586,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: Stribild
NCT01106586,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: ATV
NCT01106586,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: Ritonavir
NCT01106586,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: FTC/TDF
NCT01106586,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: Stribild Placebo
NCT01106586,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: ATV Placebo
NCT01106586,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: RTV Placebo
NCT01106586,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: FTC/TDF Placebo
NCT01109316,Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use,"Diabetes Mellitus, Type 1",Interventional,30-Oct-12,Eli Lilly and Company,Drug: Insulin lispro 2 day reservoir in-use
NCT01109316,Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use,"Diabetes Mellitus, Type 1",Interventional,30-Oct-12,Eli Lilly and Company,Drug: Insulin lispro 6 day reservoir in-use
NCT01109316,Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use,"Diabetes Mellitus, Type 1",Interventional,30-Oct-12,Eli Lilly and Company,Drug: Insulin aspart 6 day reservoir in-use
NCT01106430,Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate,Attention-Deficit/Hyperactivity Disorder,Interventional,24-Jun-13,Shire,Drug: Lisdexamfetamine Dimesylate
NCT01106430,Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate,Attention-Deficit/Hyperactivity Disorder,Interventional,24-Jun-13,Shire,Drug: Atomoxetine Hydrochloride
NCT01106014,Selexipag (ACT-293987) in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,1-Mar-16,Actelion,Drug: Selexipag
NCT01106014,Selexipag (ACT-293987) in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,1-Mar-16,Actelion,Drug: Placebo
NCT01103323,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,Metastatic Colorectal Cancer,Interventional,19-Nov-12,Bayer,"Drug: Regorafenib (Stivarga, BAY73-4506)"
NCT01103323,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,Metastatic Colorectal Cancer,Interventional,19-Nov-12,Bayer,Drug: Placebo
NCT01103323,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,Metastatic Colorectal Cancer,Interventional,19-Nov-12,Bayer,Other: Best Supportive Care (BSC)
NCT01103284,Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults,Type 1 Diabetes Mellitus,Interventional,26-May-16,Andromeda Biotech Ltd.,Drug: DiaPep277
NCT01103284,Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults,Type 1 Diabetes Mellitus,Interventional,26-May-16,Andromeda Biotech Ltd.,Drug: Placebo
NCT01149655,Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia,Schizophrenia,Interventional,2-Apr-15,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT01101841,24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms,Hot Flashes,Interventional,21-Apr-14,Noven Therapeutics,Drug: Brisdelle (paroxetine mesylate)
NCT01101841,24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms,Hot Flashes,Interventional,21-Apr-14,Noven Therapeutics,Drug: Placebo capsules
NCT01101035,Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES),Cardiovascular Disease,Interventional,14-Jun-18,Takeda,Drug: Febuxostat
NCT01101035,Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES),Cardiovascular Disease,Interventional,14-Jun-18,Takeda,Drug: Allopurinol
NCT01377922,A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS),Lambert Eaton Myasthenic Syndrome,Interventional,4-Jan-18,"Catalyst Pharmaceuticals, Inc.",Drug: Amifampridine Phosphate
NCT01377922,A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS),Lambert Eaton Myasthenic Syndrome,Interventional,4-Jan-18,"Catalyst Pharmaceuticals, Inc.",Drug: Placebo
NCT01145625,Clinical Trial in Females With Female Pattern Hair Loss,Alopecia,Interventional,25-Apr-14,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",Drug: 5% Minoxidil
NCT01145625,Clinical Trial in Females With Female Pattern Hair Loss,Alopecia,Interventional,25-Apr-14,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",Drug: 2% Minoxidil
NCT01145625,Clinical Trial in Females With Female Pattern Hair Loss,Alopecia,Interventional,25-Apr-14,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: 5% Minoxidil
NCT01145625,Clinical Trial in Females With Female Pattern Hair Loss,Alopecia,Interventional,25-Apr-14,Johnson & Johnson Consumer and Personal Products Worldwide,Drug: 2% Minoxidil
NCT01098539,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Biological: albiglutide
NCT01098539,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Drug: sitagliptin
NCT01096186,An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,3-Mar-16,"Impax Laboratories, LLC",Drug: IPX066 95 mg
NCT01096186,An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,3-Mar-16,"Impax Laboratories, LLC",Drug: IPX066 145 mg
NCT01096186,An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,3-Mar-16,"Impax Laboratories, LLC",Drug: IPX066 195 mg
NCT01096186,An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,3-Mar-16,"Impax Laboratories, LLC",Drug: IPX066 245 mg
NCT01095796,"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: Stribild
NCT01095796,"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: Atripla
NCT01095796,"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: Stribild Placebo
NCT01095796,"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",HIV|HIV Infections,Interventional,22-Oct-12,Gilead Sciences,Drug: Atripla Placebo
NCT01091662,Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic,Epilepsy,Interventional,21-Dec-15,Sunovion,Drug: Eslicarbazepine acetate 1600 mg
NCT01091662,Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic,Epilepsy,Interventional,21-Dec-15,Sunovion,Drug: Eslicarbazepine acetate 1200 mg
NCT01091246,A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children,Healthy or Stable Chronic Illness,Interventional,22-Sep-11,MedImmune LLC,Biological: Q/LAIV (MEDI3250)
NCT01091246,A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children,Healthy or Stable Chronic Illness,Interventional,22-Sep-11,MedImmune LLC,Biological: FluMist/B/Yamagata
NCT01091246,A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children,Healthy or Stable Chronic Illness,Interventional,22-Sep-11,MedImmune LLC,Biological: FluMist/B/Victoria
NCT01104584,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI),Breast Cancer,Interventional,11-Nov-14,Bayer,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)"
NCT01089127,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Indacaterol
NCT01089127,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Salmeterol 50 μg
NCT01089127,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to indacaterol
NCT01089127,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to salmeterol
NCT01089127,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Indacaterol
NCT01089127,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Salmeterol 50 μg
NCT01089127,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT01089127,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Placebo to salmeterol
NCT01087788,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,25-Feb-14,UCB BIOSCIENCES GmbH,Biological: CZP 200 mg Q2W
NCT01087788,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,25-Feb-14,UCB BIOSCIENCES GmbH,Biological: CZP 400 mg Q4W
NCT01087788,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,25-Feb-14,UCB BIOSCIENCES GmbH,Other: Placebo
NCT01087788,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,25-Feb-14,UCB Pharma,Biological: CZP 200 mg Q2W
NCT01087788,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,25-Feb-14,UCB Pharma,Biological: CZP 400 mg Q4W
NCT01087788,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,25-Feb-14,UCB Pharma,Other: Placebo
NCT01087762,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Spondyloarthropathies,Interventional,25-Dec-13,UCB BIOSCIENCES GmbH,Biological: CZP 200 mg Q2W
NCT01087762,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Spondyloarthropathies,Interventional,25-Dec-13,UCB BIOSCIENCES GmbH,Biological: CZP 400 mg Q4W
NCT01087762,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Spondyloarthropathies,Interventional,25-Dec-13,UCB BIOSCIENCES GmbH,Other: Placebo
NCT01087762,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Spondyloarthropathies,Interventional,25-Dec-13,UCB Pharma,Biological: CZP 200 mg Q2W
NCT01087762,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Spondyloarthropathies,Interventional,25-Dec-13,UCB Pharma,Biological: CZP 400 mg Q4W
NCT01087762,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Spondyloarthropathies,Interventional,25-Dec-13,UCB Pharma,Other: Placebo
NCT01086384,Asthma Exacerbation Study,Asthma,Interventional,11-Sep-13,GlaxoSmithKline,Drug: Fluticasone Furoate/GW642444
NCT01086384,Asthma Exacerbation Study,Asthma,Interventional,11-Sep-13,GlaxoSmithKline,Drug: Fluticasone furoate
NCT01081912,Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain,Back Pain Lower Back Chronic,Interventional,21-Apr-14,"Zogenix, Inc.",Drug: Placebo
NCT01081912,Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain,Back Pain Lower Back Chronic,Interventional,21-Apr-14,"Zogenix, Inc.",Drug: Hydrocodone bitartrate
NCT01081834,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,"Diabetes Mellitus, Type 2",Interventional,3-Jun-13,"Janssen Research & Development, LLC",Drug: Canagliflozin
NCT01081834,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,"Diabetes Mellitus, Type 2",Interventional,3-Jun-13,"Janssen Research & Development, LLC",Drug: Placebo
NCT01081834,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,"Diabetes Mellitus, Type 2",Interventional,3-Jun-13,"Janssen Research & Development, LLC",Drug: Sitagliptin
NCT01081145,Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD),Attention-deficit/Hyperactivity Disorder,Interventional,9-Jun-14,Shire,Drug: Extended-release Guanfacine Hydrochloride
NCT01081145,Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD),Attention-deficit/Hyperactivity Disorder,Interventional,9-Jun-14,Shire,Other: Placebo
NCT01081132,Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl,Attention-Deficit/Hyperactivity Disorder,Interventional,23-May-14,Shire,Drug: Extended-release Guanfacine Hydrochloride
NCT01081132,Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl,Attention-Deficit/Hyperactivity Disorder,Interventional,23-May-14,Shire,Other: Placebo
NCT01080391,"Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",Relapsed Multiple Myeloma,Interventional,8-Jul-15,Amgen,Drug: Dexamethasone
NCT01080391,"Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",Relapsed Multiple Myeloma,Interventional,8-Jul-15,Amgen,Drug: Lenalidomide
NCT01080391,"Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",Relapsed Multiple Myeloma,Interventional,8-Jul-15,Amgen,Drug: Carfilzomib
NCT01080300,Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women,Hot Flashes,Interventional,26-Mar-14,Depomed,Drug: Gabapentin Extended Release
NCT01080300,Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women,Hot Flashes,Interventional,26-Mar-14,Depomed,Drug: Placebo
NCT01080131,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Acute Gout,Interventional,26-Dec-11,Novartis Pharmaceuticals,Drug: Canakinumab 150 mg
NCT01080131,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Acute Gout,Interventional,26-Dec-11,Novartis Pharmaceuticals,Drug: Triamcinolone acetonide 40 mg
NCT01080131,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Acute Gout,Interventional,26-Dec-11,Novartis Pharmaceuticals,Drug: Placebo to canakinumab
NCT01080131,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Acute Gout,Interventional,26-Dec-11,Novartis Pharmaceuticals,Drug: Placebo to triamcinolone acetonide
NCT01080131,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Acute Gout,Interventional,26-Dec-11,Novartis,Drug: Canakinumab 150 mg
NCT01080131,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Acute Gout,Interventional,26-Dec-11,Novartis,Drug: Triamcinolone acetonide 40 mg
NCT01080131,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Acute Gout,Interventional,26-Dec-11,Novartis,Drug: Placebo to canakinumab
NCT01080131,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Acute Gout,Interventional,26-Dec-11,Novartis,Drug: Placebo to triamcinolone acetonide
NCT01079234,Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,31-Dec-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01079234,Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,31-Dec-15,Novo Nordisk A/S,Drug: insulin glargine
NCT01079234,Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,31-Dec-15,Novo Nordisk A/S,Drug: insulin aspart
NCT01079806,A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection,"Chronic Hepatitis B Virus, Pediatric",Interventional,21-Apr-14,Bristol-Myers Squibb,Drug: Entecavir
NCT01079806,A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection,"Chronic Hepatitis B Virus, Pediatric",Interventional,21-Apr-14,Bristol-Myers Squibb,Drug: Placebo
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,Asthma,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Indacaterol
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,Asthma,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Salmeterol
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,Asthma,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to Indacaterol
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,Asthma,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to Salmeterol
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,Asthma,Interventional,19-Aug-11,Novartis,Drug: Indacaterol
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,Asthma,Interventional,19-Aug-11,Novartis,Drug: Salmeterol
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,Asthma,Interventional,19-Aug-11,Novartis,Drug: Placebo to Indacaterol
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,Asthma,Interventional,19-Aug-11,Novartis,Drug: Placebo to Salmeterol
NCT01077960,Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome,Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome,Interventional,23-Jun-10,EMD Serono,Biological: Serostim
NCT01077362,A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents,"Arthritis, Psoriatic",Interventional,27-Feb-14,"Janssen Research & Development, LLC",Drug: placebo
NCT01077362,A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents,"Arthritis, Psoriatic",Interventional,27-Feb-14,"Janssen Research & Development, LLC",Drug: ustekinumab 45 mg
NCT01077362,A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents,"Arthritis, Psoriatic",Interventional,27-Feb-14,"Janssen Research & Development, LLC",Drug: ustekinumab 90 mg
NCT01076647,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,10-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01076647,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,10-Nov-15,Novo Nordisk A/S,Drug: insulin glargine
NCT01074125,A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease,Hyperphosphatemia|End-Stage Renal Disease,Interventional,4-Dec-14,Keryx Biopharmaceuticals,Drug: ferric citrate
NCT01074125,A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease,Hyperphosphatemia|End-Stage Renal Disease,Interventional,4-Dec-14,Collaborative Study Group (CSG),Drug: ferric citrate
NCT01073163,Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL),Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,4-Apr-14,Cephalon,Drug: Bendamustine
NCT01073163,Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL),Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,4-Apr-14,Cephalon,Drug: Rituximab
NCT01073163,Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL),Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,4-Apr-14,Teva Pharmaceutical Industries,Drug: Bendamustine
NCT01073163,Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL),Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,4-Apr-14,Teva Pharmaceutical Industries,Drug: Rituximab
NCT01072929,A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Cephalon,Drug: Armodafinil
NCT01072929,A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Cephalon,Drug: Placebo
NCT01072929,A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Teva Pharmaceutical Industries,Drug: Armodafinil
NCT01072929,A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Teva Pharmaceutical Industries,Drug: Placebo
NCT01072630,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Cephalon,Drug: Armodafinil
NCT01072630,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Cephalon,Drug: Placebo
NCT01072630,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Teva Pharmaceutical Industries,Drug: Armodafinil
NCT01072630,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Depression,Interventional,26-Jan-15,Teva Pharmaceutical Industries,Drug: Placebo
NCT01072448,12-week Efficacy of Indacaterol,Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Indacaterol 75 μg
NCT01072448,12-week Efficacy of Indacaterol,Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT01071954,A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura,Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP,Interventional,29-Jan-19,Amgen,Biological: Romiplostim
NCT01070979,Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.,Hormone Replacement Therapy,Interventional,8-Apr-11,Warner Chilcott,Drug: Estradiol acetate
NCT01070979,Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.,Hormone Replacement Therapy,Interventional,8-Apr-11,Warner Chilcott,Drug: Estradiol
NCT01070979,Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.,Hormone Replacement Therapy,Interventional,8-Apr-11,Warner Chilcott,Drug: Conjugated equine estrogens
NCT01070303,"Remission in Subjects With Crohn's Disease, Open Label Extension",Crohn's Disease,Interventional,7-May-10,Abbott,Biological: Adalimumab 40 mg eow or ew
NCT01073943,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep,Bowel Preparation,Interventional,11-Sep-12,Ferring Pharmaceuticals,Drug: PicoPrep
NCT01073943,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep,Bowel Preparation,Interventional,11-Sep-12,Ferring Pharmaceuticals,Drug: HalfLytely
NCT01073943,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep,Bowel Preparation,Interventional,11-Sep-12,Ferring Pharmaceuticals,Drug: bisacodyl
NCT01068678,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,28-Dec-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01068678,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,28-Dec-15,Novo Nordisk A/S,Drug: insulin glargine
NCT01068665,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01068665,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin glargine
NCT01068600,Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks,Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Indacaterol
NCT01068600,Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks,Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT01074944,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE),Gaucher Disease,Interventional,2-Dec-16,"Genzyme, a Sanofi Company",Drug: Eliglustat tartrate
NCT01074944,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE),Gaucher Disease,Interventional,2-Dec-16,Sanofi,Drug: Eliglustat tartrate
NCT01067521,"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",Relapsing Remitting Multiple Sclerosis,Interventional,9-Oct-18,"Teva Pharmaceutical Industries, Ltd.",Drug: Glatiramer acetate (GA)
NCT01067521,"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",Relapsing Remitting Multiple Sclerosis,Interventional,9-Oct-18,"Teva Pharmaceutical Industries, Ltd.",Drug: Placebo
NCT01067521,"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",Relapsing Remitting Multiple Sclerosis,Interventional,9-Oct-18,Teva Pharmaceutical Industries,Drug: Glatiramer acetate (GA)
NCT01067521,"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",Relapsing Remitting Multiple Sclerosis,Interventional,9-Oct-18,Teva Pharmaceutical Industries,Drug: Placebo
NCT01067105,A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,Perennial Allergic Rhinitis,Interventional,11-Jun-12,Sunovion,Drug: ciclesonide HFA 160 μg
NCT01106040,Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes,Breast Cancer|Melanoma,Interventional,3-Jun-13,Navidea Biopharmaceuticals,Drug: Lymphoseek
NCT01796301,An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Romozosumab
NCT01796301,An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Teriparatide
NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,26-Jan-15,Eli Lilly and Company,Drug: LY2189265
NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,26-Jan-15,Eli Lilly and Company,Drug: Exenatide
NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,26-Jan-15,Eli Lilly and Company,Drug: Placebo
NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,26-Jan-15,Eli Lilly and Company,Drug: Metformin
NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,26-Jan-15,Eli Lilly and Company,Drug: Pioglitazone
NCT01064414,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","Diabetes Mellitus, Type 2|Renal Insufficiency",Interventional,27-May-13,"Janssen Research & Development, LLC",Drug: Canagliflozin
NCT01064414,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","Diabetes Mellitus, Type 2|Renal Insufficiency",Interventional,27-May-13,"Janssen Research & Development, LLC",Drug: Placebo
NCT01063855,Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction,Erectile Dysfunction|Sexual Dysfunction,Interventional,5-Nov-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT01063855,Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction,Erectile Dysfunction|Sexual Dysfunction,Interventional,5-Nov-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Dapoxetine
NCT01063855,Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction,Erectile Dysfunction|Sexual Dysfunction,Interventional,5-Nov-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: PDE5I (phosphodiesterase-5 inhibitor)
NCT01059565,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection,Cystic Fibrosis|Burkholderia Infections,Interventional,11-Mar-14,Gilead Sciences,Drug: AZLI
NCT01059565,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection,Cystic Fibrosis|Burkholderia Infections,Interventional,11-Mar-14,Gilead Sciences,Drug: Placebo
NCT01057810,Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer,Prostate Cancer,Interventional,18-Aug-16,Bristol-Myers Squibb,Drug: Ipilimumab
NCT01057810,Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer,Prostate Cancer,Interventional,18-Aug-16,Bristol-Myers Squibb,Drug: Placebo
NCT01057693,Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy,"Diabetic Neuropathy, Painful",Interventional,22-Feb-13,Pfizer,Drug: pregabalin (Lyrica)
NCT01057693,Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy,"Diabetic Neuropathy, Painful",Interventional,22-Feb-13,Pfizer,Drug: Placebo
NCT01073930,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep,Bowel Preparation,Interventional,11-Sep-12,Ferring Pharmaceuticals,Drug: PicoPrep
NCT01073930,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep,Bowel Preparation,Interventional,11-Sep-12,Ferring Pharmaceuticals,Drug: HalfLytely
NCT01073930,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep,Bowel Preparation,Interventional,11-Sep-12,Ferring Pharmaceuticals,Drug: bisacodyl
NCT01054885,Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-13,GlaxoSmithKline,Drug: FF Inhalation Powder
NCT01054885,Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-13,GlaxoSmithKline,Drug: FF/GW642444 Inhalation Powder
NCT01054885,Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-13,GlaxoSmithKline,Drug: GW642444 Inhalation Powder
NCT01054885,Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-13,GlaxoSmithKline,Drug: Placebo
NCT01053988,A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-13,GlaxoSmithKline,Drug: FF/GW642444 Inhalation Powder
NCT01053988,A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-13,GlaxoSmithKline,Drug: FF Inhalation Powder
NCT01053988,A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-13,GlaxoSmithKline,Drug: GW642444 Inhalation Powder
NCT01053988,A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,15-Aug-13,GlaxoSmithKline,Drug: Placebo
NCT01050257,A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza,Influenza,Interventional,1-Nov-13,Hoffmann-La Roche,Drug: Oseltamivir IV
NCT01050257,A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza,Influenza,Interventional,1-Nov-13,Hoffmann-La Roche,Drug: Oseltamivir Oral
NCT01046110,Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin,"Diabetes|Diabetes Mellitus, Type 2",Interventional,18-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT01046110,Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin,"Diabetes|Diabetes Mellitus, Type 2",Interventional,18-Nov-15,Novo Nordisk A/S,Drug: sitagliptin
NCT01045707,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Nov-15,Novo Nordisk A/S,Drug: insulin degludec/insulin aspart
NCT01045707,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,20-Nov-15,Novo Nordisk A/S,Drug: insulin glargine
NCT01045447,"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,18-Nov-15,Novo Nordisk A/S,Drug: insulin degludec/insulin aspart
NCT01045447,"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2",Interventional,18-Nov-15,Novo Nordisk A/S,Drug: insulin glargine
NCT01323153,A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE),Coronary Heart Disease,Interventional,6-Aug-18,Hoffmann-La Roche,Drug: dalcetrapib
NCT01323153,A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE),Coronary Heart Disease,Interventional,6-Aug-18,Hoffmann-La Roche,Drug: placebo
NCT01045161,"Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)",Chronic Obstructive Pulmonary Disease,Interventional,9-Dec-15,AstraZeneca,Drug: Aclidinium bromide
NCT01045161,"Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)",Chronic Obstructive Pulmonary Disease,Interventional,9-Dec-15,AstraZeneca,Drug: Placebo
NCT01044459,"Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)",Chronic Obstructive Pulmonary Disease,Interventional,13-Sep-12,AstraZeneca,Drug: Aclidinium Bromide 200 µg
NCT01044459,"Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)",Chronic Obstructive Pulmonary Disease,Interventional,13-Sep-12,AstraZeneca,Drug: Aclidinium Bromide 400 µg
NCT01039688,"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX","Arthritis, Rheumatoid",Interventional,6-Apr-18,Pfizer,"Drug: CP-690,550"
NCT01039688,"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX","Arthritis, Rheumatoid",Interventional,6-Apr-18,Pfizer,Drug: Disease-modifying antirheumatic drug
NCT01037244,Treatment of Erectile Dysfunction I,Erectile Dysfunction,Interventional,22-Dec-11,Warner Chilcott,Drug: Udenafil
NCT01037244,Treatment of Erectile Dysfunction I,Erectile Dysfunction,Interventional,22-Dec-11,Warner Chilcott,Drug: Placebo
NCT01037218,Treatment of Erectile Dysfunction II,Erectile Dysfunction,Interventional,22-Dec-11,Warner Chilcott,Drug: Udenafil
NCT01037218,Treatment of Erectile Dysfunction II,Erectile Dysfunction,Interventional,22-Dec-11,Warner Chilcott,Drug: Placebo
NCT01035229,Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.,Carcinoma,Interventional,27-Oct-14,Novartis Pharmaceuticals,Drug: Everolimus
NCT01035229,Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.,Carcinoma,Interventional,27-Oct-14,Novartis Pharmaceuticals,Drug: Everolimus Placebo
NCT01035229,Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.,Carcinoma,Interventional,27-Oct-14,Novartis Pharmaceuticals,Other: Best Supportive Care (BSC)
NCT01035229,Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.,Carcinoma,Interventional,27-Oct-14,Novartis,Drug: Everolimus
NCT01035229,Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.,Carcinoma,Interventional,27-Oct-14,Novartis,Drug: Everolimus Placebo
NCT01035229,Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.,Carcinoma,Interventional,27-Oct-14,Novartis,Other: Best Supportive Care (BSC)
NCT01035138,A Study of Semagacestat for Alzheimer's Patients,Alzheimer's Disease,Interventional,25-Sep-14,Eli Lilly and Company,Drug: semagacestat
NCT01034462,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Major Depressive Disorder,Interventional,25-Oct-13,Forest Laboratories,Drug: Levomilnacipran ER
NCT01034462,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Major Depressive Disorder,Interventional,25-Oct-13,Forest Laboratories,Drug: Placebo
NCT01034163,"A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)",Hodgkin's Lymphoma,Interventional,7-Jul-16,Novartis Pharmaceuticals,Drug: Panobinostat
NCT01034163,"A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)",Hodgkin's Lymphoma,Interventional,7-Jul-16,Novartis Pharmaceuticals,Drug: Placebo
NCT01034163,"A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)",Hodgkin's Lymphoma,Interventional,7-Jul-16,Novartis,Drug: Panobinostat
NCT01034163,"A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)",Hodgkin's Lymphoma,Interventional,7-Jul-16,Novartis,Drug: Placebo
NCT01033071,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.,Essential Hypertension,Interventional,7-Feb-12,Takeda,Drug: Azilsartan medoxomil and chlorthalidone
NCT01033071,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.,Essential Hypertension,Interventional,7-Feb-12,Takeda,Drug: Olmesartan medoxomil and hydrochlorothiazide
NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Interventional,7-Dec-18,"Janssen Research & Development, LLC",Drug: Placebo
NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Interventional,7-Dec-18,"Janssen Research & Development, LLC",Drug: Canagliflozin (JNJ-28431754) 100 mg
NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Interventional,7-Dec-18,"Janssen Research & Development, LLC",Drug: Canagliflozin (JNJ-28431754) 300 mg
NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Interventional,7-Dec-18,"The George Institute for Global Health, Australia",Drug: Placebo
NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Interventional,7-Dec-18,"The George Institute for Global Health, Australia",Drug: Canagliflozin (JNJ-28431754) 100 mg
NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Interventional,7-Dec-18,"The George Institute for Global Health, Australia",Drug: Canagliflozin (JNJ-28431754) 300 mg
NCT01072149,"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo","Pulmonary Disease, Chronic Obstructive",Interventional,25-Dec-13,GlaxoSmithKline,Drug: Fluticasone Furoate (FF)/GW642444 Inhalation Powder
NCT01072149,"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo","Pulmonary Disease, Chronic Obstructive",Interventional,25-Dec-13,GlaxoSmithKline,Device: placebo
NCT01025817,Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients,Kidney Transplant,Interventional,6-Jun-14,Novartis Pharmaceuticals,Drug: Everolimus and tacrolimus
NCT01025817,Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients,Kidney Transplant,Interventional,6-Jun-14,Novartis Pharmaceuticals,Drug: mycophenolate mofetil and tacrolimus
NCT01025817,Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients,Kidney Transplant,Interventional,6-Jun-14,Novartis,Drug: Everolimus and tacrolimus
NCT01025817,Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients,Kidney Transplant,Interventional,6-Jun-14,Novartis,Drug: mycophenolate mofetil and tacrolimus
NCT01025336,Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated,Healthy,Interventional,20-Jun-12,Pfizer,Other: Blood draw
NCT01023581,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,26-Mar-13,Takeda,Drug: Alogliptin
NCT01023581,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,26-Mar-13,Takeda,Drug: Metformin
NCT01023581,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,26-Mar-13,Takeda,Drug: Alogliptin Placebo
NCT01023581,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,26-Mar-13,Takeda,Drug: Metformin Placebo
NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,Multiple Myeloma,Interventional,23-Oct-15,Novartis Pharmaceuticals,Drug: Panobinostat
NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,Multiple Myeloma,Interventional,23-Oct-15,Novartis Pharmaceuticals,Drug: Bortezomib
NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,Multiple Myeloma,Interventional,23-Oct-15,Novartis Pharmaceuticals,Drug: Placebo
NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,Multiple Myeloma,Interventional,23-Oct-15,Novartis,Drug: Panobinostat
NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,Multiple Myeloma,Interventional,23-Oct-15,Novartis,Drug: Bortezomib
NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,Multiple Myeloma,Interventional,23-Oct-15,Novartis,Drug: Placebo
NCT01066585,A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation,Head Lice,Interventional,4-Apr-12,Topaz Pharmaceuticals Inc,Drug: Ivermectin Cream
NCT01066585,A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation,Head Lice,Interventional,4-Apr-12,Topaz Pharmaceuticals Inc,Drug: vehicle control
NCT01019694,Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-May-12,Boehringer Ingelheim,Drug: Combivent CFC-MDI
NCT01019694,Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-May-12,Boehringer Ingelheim,Drug: Combivent Respimat 20/100 mcg
NCT01019694,Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-May-12,Boehringer Ingelheim,Drug: Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
NCT01018862,A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis,Perennial Allergic Rhinitis,Interventional,11-Jun-12,Meda Pharmaceuticals,Drug: Azelastine hydrochloride nasal spray 0.15%
NCT01018862,A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis,Perennial Allergic Rhinitis,Interventional,11-Jun-12,Meda Pharmaceuticals,Drug: Azelastine hydrochloride nasal spray 0.10%
NCT01018862,A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis,Perennial Allergic Rhinitis,Interventional,11-Jun-12,Meda Pharmaceuticals,Drug: Placebo
NCT01018680,A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis,Osteoarthritis Knee Pain,Interventional,5-Oct-12,Eli Lilly and Company,Drug: Duloxetine
NCT01018680,A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis,Osteoarthritis Knee Pain,Interventional,5-Oct-12,Eli Lilly and Company,Drug: Placebo
NCT01741545,Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia,Hepatitis C Virus,Interventional,24-Jun-19,Bristol-Myers Squibb,Biological: Pegylated-Interferon-lambda
NCT01741545,Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia,Hepatitis C Virus,Interventional,24-Jun-19,Bristol-Myers Squibb,Drug: Ribavirin
NCT01741545,Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia,Hepatitis C Virus,Interventional,24-Jun-19,Bristol-Myers Squibb,Drug: Daclatasvir
NCT01018186,Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study,Asthma,Interventional,29-Oct-13,GlaxoSmithKline,Drug: Fluticasone Furoate/GW642444
NCT01018186,Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study,Asthma,Interventional,29-Oct-13,GlaxoSmithKline,Drug: Fluticasone propionate
NCT01017952,A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,19-Aug-13,GlaxoSmithKline,Drug: FF/GW642444 Inhalation Powder
NCT01017952,A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,19-Aug-13,GlaxoSmithKline,Drug: GW642444 Inhalation Powder
NCT01015118,LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer,Ovarian Neoplasms|Peritoneal Neoplasms,Interventional,15-Jan-15,Boehringer Ingelheim,Drug: Placebo
NCT01015118,LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer,Ovarian Neoplasms|Peritoneal Neoplasms,Interventional,15-Jan-15,Boehringer Ingelheim,Drug: Paclitaxel
NCT01015118,LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer,Ovarian Neoplasms|Peritoneal Neoplasms,Interventional,15-Jan-15,Boehringer Ingelheim,Drug: BIBF 1120
NCT01015118,LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer,Ovarian Neoplasms|Peritoneal Neoplasms,Interventional,15-Jan-15,Boehringer Ingelheim,Drug: Carboplatin
NCT01733316,"Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis",Cystinosis,Interventional,24-May-17,"Horizon Pharma USA, Inc.",Drug: RP103
NCT01733316,"Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis",Cystinosis,Interventional,24-May-17,"Horizon Pharma USA, Inc.",Drug: Cystagon®
NCT01014208,Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma,"Lymphoma, Large-Cell, Diffuse",Interventional,16-Oct-14,GlaxoSmithKline,Drug: OFATUMUMAB + DHAP
NCT01014208,Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma,"Lymphoma, Large-Cell, Diffuse",Interventional,16-Oct-14,GlaxoSmithKline,Drug: RITUXIMAB + DHAP
NCT01027884,Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD),"Muscular Dystrophy, Duchenne|Ambulatory Care",Interventional,19-Oct-15,Santhera Pharmaceuticals,Drug: Placebo
NCT01027884,Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD),"Muscular Dystrophy, Duchenne|Ambulatory Care",Interventional,19-Oct-15,Santhera Pharmaceuticals,Drug: Idebenone
NCT01009463,A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,19-Aug-13,GlaxoSmithKline,Drug: FF/GW642444 Inhalation Powder
NCT01009463,A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,19-Aug-13,GlaxoSmithKline,Drug: GW642444 Inhalation Powder
NCT01009086,A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,13-Mar-14,"Janssen Research & Development, LLC",Drug: Placebo
NCT01009086,A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,13-Mar-14,"Janssen Research & Development, LLC",Drug: Ustekinumab 45 mg
NCT01009086,A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis,"Arthritis, Psoriatic",Interventional,13-Mar-14,"Janssen Research & Development, LLC",Drug: Ustekinumab 90 mg
NCT01007942,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Interventional,5-Apr-17,Novartis Pharmaceuticals,Drug: everolimus
NCT01007942,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Interventional,5-Apr-17,Novartis Pharmaceuticals,Drug: Placebo
NCT01007942,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Interventional,5-Apr-17,Novartis Pharmaceuticals,Drug: vinorelbine
NCT01007942,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Interventional,5-Apr-17,Novartis Pharmaceuticals,Drug: trastuzumab
NCT01007942,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Interventional,5-Apr-17,Novartis,Drug: everolimus
NCT01007942,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Interventional,5-Apr-17,Novartis,Drug: Placebo
NCT01007942,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Interventional,5-Apr-17,Novartis,Drug: vinorelbine
NCT01007942,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Interventional,5-Apr-17,Novartis,Drug: trastuzumab
NCT01007435,A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Jul-13,Hoffmann-La Roche,Drug: Tocilizumab
NCT01007435,A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Jul-13,Hoffmann-La Roche,Drug: Placebo to tocilizumab
NCT01007435,A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Jul-13,Hoffmann-La Roche,Drug: Methotrexate
NCT01007435,A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,12-Jul-13,Hoffmann-La Roche,Drug: Placebo to methotrexate
NCT01006980,A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3),Malignant Melanoma,Interventional,16-Nov-11,Hoffmann-La Roche,Drug: Vemurafenib
NCT01006980,A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3),Malignant Melanoma,Interventional,16-Nov-11,Hoffmann-La Roche,Drug: Dacarbazine
NCT01005901,"A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo",Chronic Obstructive Pulmonary Disease,Interventional,12-Apr-12,Novartis,Drug: Glycopyrronium bromide
NCT01005901,"A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo",Chronic Obstructive Pulmonary Disease,Interventional,12-Apr-12,Novartis,Drug: Placebo
NCT01005888,C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,Hereditary Angioedema,Interventional,3-Jun-10,Shire,Biological: C1 esterase inhibitor [human] (C1INH-nf)
NCT01005888,C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,Hereditary Angioedema,Interventional,3-Jun-10,Shire,Drug: Placebo (saline)
NCT01005407,"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine",Healthy,Interventional,11-Jan-18,Dynavax Technologies Corporation,Biological: HEPLISAV and/or Placebo
NCT01005407,"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine",Healthy,Interventional,11-Jan-18,Dynavax Technologies Corporation,Biological: Engerix-B
NCT01003990,Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access,HIV,Interventional,11-May-17,Bristol-Myers Squibb,Drug: Atazanavir
NCT01003990,Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access,HIV,Interventional,11-May-17,Bristol-Myers Squibb,Drug: Atazanavir/Ritonavir
NCT01003990,Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access,HIV,Interventional,11-May-17,Bristol-Myers Squibb,Drug: Tenofovir/Emtricitabine
NCT01003990,Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access,HIV,Interventional,11-May-17,Bristol-Myers Squibb,Drug: Lopinavir/ritonavir
NCT01002573,"Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients",Fever,Interventional,7-Nov-16,Cumberland Pharmaceuticals,Drug: ibuprofen
NCT01002573,"Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients",Fever,Interventional,7-Nov-16,Cumberland Pharmaceuticals,Drug: acetaminophen
NCT01275066,A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),MPS IV A,Interventional,15-Apr-14,BioMarin Pharmaceutical,Drug: BMN 110 Weekly
NCT01275066,A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),MPS IV A,Interventional,15-Apr-14,BioMarin Pharmaceutical,Drug: Placebo
NCT01275066,A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),MPS IV A,Interventional,15-Apr-14,BioMarin Pharmaceutical,Drug: BMN 110 Every Other Week
NCT01000974,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Interventional,19-Aug-13,GlaxoSmithKline,Biological: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)
NCT01000974,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Interventional,19-Aug-13,GlaxoSmithKline,Biological: ActHIB™
NCT01000974,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Interventional,19-Aug-13,GlaxoSmithKline,Biological: Pentacel™
NCT01000974,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Interventional,19-Aug-13,GlaxoSmithKline,Biological: Pediarix™
NCT01000974,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Interventional,19-Aug-13,GlaxoSmithKline,Biological: Prevnar 13™
NCT01000974,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Interventional,19-Aug-13,GlaxoSmithKline,Biological: Rotarix™
NCT01000974,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Interventional,19-Aug-13,GlaxoSmithKline,Biological: Engerix™-B
NCT01000974,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Interventional,19-Aug-13,GlaxoSmithKline,Biological: Infanrix™
NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Interventional,10-Aug-17,GlaxoSmithKline,Drug: Darapladib 160 mg
NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Interventional,10-Aug-17,GlaxoSmithKline,Drug: Placebo
NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Interventional,10-Aug-17,GlaxoSmithKline,Other: Standard Therapy
NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Interventional,10-Aug-17,The TIMI Study Group,Drug: Darapladib 160 mg
NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Interventional,10-Aug-17,The TIMI Study Group,Drug: Placebo
NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Interventional,10-Aug-17,The TIMI Study Group,Other: Standard Therapy
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis Vaccines,Biological: MenACWY-CRM
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis Vaccines,Biological: DTaP-IPV/Hib
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis Vaccines,Biological: HBV
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis Vaccines,Biological: PCV
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis Vaccines,Biological: MMR
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis,Biological: MenACWY-CRM
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis,Biological: DTaP-IPV/Hib
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis,Biological: HBV
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis,Biological: PCV
NCT01000311,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Meningococcal Disease,Interventional,26-Mar-14,Novartis,Biological: MMR
NCT00997984,Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study),Attention-Deficit/Hyperactivity Disorder,Interventional,26-Oct-11,Shire,Drug: extended-release guanfacine hydrochloride (SPD503)
NCT00997984,Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study),Attention-Deficit/Hyperactivity Disorder,Interventional,26-Oct-11,Shire,Drug: placebo
NCT00997984,Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study),Attention-Deficit/Hyperactivity Disorder,Interventional,26-Oct-11,Shire,Drug: extended-release guanfacine hydrochloride
NCT00996580,A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy,Pregnancy Prevention,Interventional,14-Jun-13,Teva Women's Health,Drug: DR-103
NCT00996580,A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy,Pregnancy Prevention,Interventional,14-Jun-13,Teva Pharmaceutical Industries,Drug: DR-103
NCT00996372,Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women,"Sexual Dysfunctions, Psychological",Interventional,12-Jun-14,"Sprout Pharmaceuticals, Inc",Drug: flibanserin
NCT00996372,Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women,"Sexual Dysfunctions, Psychological",Interventional,12-Jun-14,"Sprout Pharmaceuticals, Inc",Drug: placebo
NCT00996164,Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,"Sexual Dysfunctions, Psychological",Interventional,19-May-14,"Sprout Pharmaceuticals, Inc",Drug: Flibanserin
NCT00996164,Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,"Sexual Dysfunctions, Psychological",Interventional,19-May-14,"Sprout Pharmaceuticals, Inc",Drug: Placebo
NCT00992459,Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders,Urea Cycle Disorders,Interventional,12-Aug-13,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: HPN-100
NCT00992459,Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders,Urea Cycle Disorders,Interventional,12-Aug-13,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: Buphenyl (NaPBA)
NCT00991276,Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance,Restless Legs Syndrome,Interventional,8-Oct-12,Pfizer,Drug: pregabalin
NCT00991276,Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance,Restless Legs Syndrome,Interventional,8-Oct-12,Pfizer,Drug: placebo
NCT00991276,Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance,Restless Legs Syndrome,Interventional,8-Oct-12,Pfizer,Drug: pramipexole
NCT00988247,Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis,"Rhinitis, Allergic, Perennial",Interventional,23-May-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Beclomethasone dipropionate
NCT00988247,Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis,"Rhinitis, Allergic, Perennial",Interventional,23-May-12,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo Nasal Aerosol
NCT00988247,Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis,"Rhinitis, Allergic, Perennial",Interventional,23-May-12,Teva Pharmaceutical Industries,Drug: Beclomethasone dipropionate
NCT00988247,Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis,"Rhinitis, Allergic, Perennial",Interventional,23-May-12,Teva Pharmaceutical Industries,Drug: Placebo Nasal Aerosol
NCT00988208,Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,Prostate Cancer,Interventional,5-Sep-13,Celgene,Drug: Lenalidomide
NCT00988208,Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,Prostate Cancer,Interventional,5-Sep-13,Celgene,Drug: Docetaxel
NCT00988208,Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,Prostate Cancer,Interventional,5-Sep-13,Celgene,Drug: Prednisone
NCT00988208,Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,Prostate Cancer,Interventional,5-Sep-13,Celgene,Drug: Placebo
NCT00988091,Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee,Osteoarthritis of the Knee,Interventional,4-Jun-12,Ferring Pharmaceuticals,Device: 1.2% Sodium Hyaluronate
NCT00988091,Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee,Osteoarthritis of the Knee,Interventional,4-Jun-12,Ferring Pharmaceuticals,Device: Buffered Saline
NCT00986154,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,Venous Thromboembolism|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Thromboembolism|Venous Thrombosis,Interventional,25-Feb-15,"Daiichi Sankyo, Inc.",Drug: edoxaban tosylate(DU-176b)
NCT00986154,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,Venous Thromboembolism|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Thromboembolism|Venous Thrombosis,Interventional,25-Feb-15,"Daiichi Sankyo, Inc.",Drug: low molecular weight heparin/unfractionated heparin
NCT00986154,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,Venous Thromboembolism|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Thromboembolism|Venous Thrombosis,Interventional,25-Feb-15,"Daiichi Sankyo, Inc.",Drug: warfarin
NCT00984204,Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL),Typical Atrial Flutter,Interventional,20-Dec-13,Abbott Medical Devices,Device: Therapy Cool Path Duo
NCT00984126,"Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015",Congenital Bleeding Disorder|Haemophilia A,Interventional,27-Jul-17,Novo Nordisk A/S,Drug: turoctocog alfa
NCT00982644,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT00982644,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin glargine
NCT00982228,Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,29-Dec-15,Novo Nordisk A/S,Drug: insulin degludec
NCT00982228,Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,29-Dec-15,Novo Nordisk A/S,Drug: insulin glargine
NCT00982228,Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,29-Dec-15,Novo Nordisk A/S,Drug: insulin aspart
NCT00988221,A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis,Juvenile Idiopathic Arthritis,Interventional,1-Nov-12,Hoffmann-La Roche,Drug: Tocilizumab
NCT00988221,A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis,Juvenile Idiopathic Arthritis,Interventional,1-Nov-12,Hoffmann-La Roche,Drug: Placebo
NCT00981214,Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Interventional,4-Apr-14,Forest Laboratories,Drug: EUR-1008 (APT-1008)
NCT00980005,Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children,Influenza,Interventional,15-Feb-12,GlaxoSmithKline,Biological: GSK investigational vaccine GSK1557482A
NCT00980005,Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children,Influenza,Interventional,15-Feb-12,GlaxoSmithKline,Biological: Fluzone®
NCT00979602,"Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older",Influenza,Interventional,21-Sep-17,GlaxoSmithKline,Biological: GSK2340274A
NCT00979602,"Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older",Influenza,Interventional,21-Sep-17,GlaxoSmithKline,Biological: GSK2340273A
NCT01020838,Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology,Alzheimer Disease,Interventional,25-Mar-15,Life Molecular Imaging SA,Drug: Florbetaben (BAY94-9172)
NCT00978627,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,20-Nov-15,Novo Nordisk A/S,Drug: insulin degludec/insulin aspart
NCT00978627,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,20-Nov-15,Novo Nordisk A/S,Drug: insulin detemir
NCT00978627,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,"Diabetes|Diabetes Mellitus, Type 1",Interventional,20-Nov-15,Novo Nordisk A/S,Drug: insulin aspart
NCT00976937,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00976937,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Lixisenatide Placebo
NCT00976937,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Device: Pen auto-injector
NCT00976937,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Sitagliptin
NCT00976937,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Sitagliptin Placebo
NCT00976937,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Metformin
NCT00978380,Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Interventional,13-Dec-16,Novo Nordisk A/S,Drug: catridecacog
NCT00976391,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,"Diabetes Mellitus, Type 2",Interventional,16-Jul-14,GlaxoSmithKline,Biological: albiglutide + insulin glargine
NCT00976391,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,"Diabetes Mellitus, Type 2",Interventional,16-Jul-14,GlaxoSmithKline,Drug: insulin glargine + preprandial lispro insulin
NCT00975286,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00975286,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Placebo
NCT00975286,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Insulin glargine
NCT00975286,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Device: Pen auto-injector
NCT00975286,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Metformin
NCT00975286,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,Type 2 Diabetes Mellitus,Interventional,11-Oct-16,Sanofi,Drug: Thiazolidinedione (TZD)
NCT00975221,Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,"Hyperparathyroidism, Primary|Hypercalcemia",Interventional,25-Jan-16,Amgen,Drug: Cinacalcet
NCT00975221,Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,"Hyperparathyroidism, Primary|Hypercalcemia",Interventional,25-Jan-16,Amgen,Drug: Placebo
NCT00975143,Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne,Severe Nodular Acne,Interventional,4-Jul-14,Cipher Pharmaceuticals Inc.,Drug: CIP-Isotretinoin
NCT00975143,Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne,Severe Nodular Acne,Interventional,4-Jul-14,Cipher Pharmaceuticals Inc.,Drug: Isotretinoin
NCT00974974,A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).,Parkinson's Disease,Interventional,14-Jan-16,"Impax Laboratories, LLC",Drug: IPX066
NCT00974974,A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).,Parkinson's Disease,Interventional,14-Jan-16,"Impax Laboratories, LLC",Drug: IR CD-LD
NCT00975000,Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients,Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation,Interventional,29-Jan-16,Amgen,Drug: Cinacalcet
NCT00975000,Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients,Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation,Interventional,29-Jan-16,Amgen,Drug: Placebo
NCT00973362,Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System,Human Papillomavirus Infection,Interventional,6-Jan-17,"Gen-Probe, Incorporated",Device: APTIMA HPV Assay
NCT00973362,Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System,Human Papillomavirus Infection,Interventional,6-Jan-17,"Gen-Probe, Incorporated",Device: FDA-Approved HPV DNA Test
NCT03187678,Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,21-May-19,Actelion,Drug: i.v. selexipag
NCT03187678,Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,21-May-19,Actelion,Drug: oral selexipag (Uptravi)
NCT00972283,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin degludec
NCT00972283,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin glargine
NCT00972283,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-Nov-15,Novo Nordisk A/S,Drug: insulin aspart
NCT00970268,"Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)",Chronic Obstructive Pulmonary Disease,Interventional,14-Sep-12,AstraZeneca,Drug: Aclidinium bromide
NCT00969709,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Major Depressive Disorder,Interventional,25-Oct-13,Forest Laboratories,Drug: Levomilnacipran ER
NCT00969709,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Major Depressive Disorder,Interventional,25-Oct-13,Forest Laboratories,Drug: Placebo
NCT00969150,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Major Depressive Disorder,Interventional,25-Oct-13,Forest Laboratories,Drug: Levomilnacipran ER
NCT00969150,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Major Depressive Disorder,Interventional,25-Oct-13,Forest Laboratories,Drug: Placebo
NCT00968812,CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride,"Diabetes Mellitus, Type 2",Interventional,4-Jun-13,"Janssen Research & Development, LLC",Drug: Glimepiride
NCT00968812,CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride,"Diabetes Mellitus, Type 2",Interventional,4-Jun-13,"Janssen Research & Development, LLC",Drug: Canagliflozin (JNJ-28431754)
NCT00968812,CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride,"Diabetes Mellitus, Type 2",Interventional,4-Jun-13,"Janssen Research & Development, LLC",Drug: Metformin
NCT00968708,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"Diabetes Mellitus, Type 2|Acute Coronary Syndrome",Interventional,15-Apr-14,Takeda,Drug: Alogliptin
NCT00968708,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"Diabetes Mellitus, Type 2|Acute Coronary Syndrome",Interventional,15-Apr-14,Takeda,Drug: Placebo
NCT00965484,Genotropin Study Assessing Use of Injection Pen,Growth Hormone Deficiency|Idiopathic Short Stature,Interventional,23-Dec-10,Pfizer,Device: New Genotropin Pen
NCT00980655,Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients,"Vaccines, Pneumococcal Conjugate Vaccine",Interventional,21-Apr-14,Pfizer,Biological: 13vPnC
NCT00980655,Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients,"Vaccines, Pneumococcal Conjugate Vaccine",Interventional,21-Apr-14,Pfizer,Biological: 23vPS
NCT00963235,Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS,HIV Infections|Pneumococcal Infections,Interventional,10-Jun-13,Pfizer,Biological: 13-valent pneumococcal conjugate vaccine
NCT00963235,Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS,HIV Infections|Pneumococcal Infections,Interventional,10-Jun-13,Pfizer,Procedure: Blood draw
NCT01068158,A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects,Head Lice,Interventional,4-Apr-12,Topaz Pharmaceuticals Inc,Drug: 0.5% Ivermectin Cream
NCT01068158,A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects,Head Lice,Interventional,4-Apr-12,Topaz Pharmaceuticals Inc,Drug: Placebo control
NCT01067976,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI,Breast Cancer|Diagnostic Imaging,Interventional,11-Nov-14,Bayer,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)"
NCT00960440,"Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors","Arthritis, Rheumatoid",Interventional,10-Jan-13,Pfizer,"Drug: CP-690,550"
NCT00960440,"Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors","Arthritis, Rheumatoid",Interventional,10-Jan-13,Pfizer,Drug: Placebo
NCT00959049,A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population,Influenza,Interventional,29-Jul-11,Seqirus,Biological: CSL's Influenza Virus Vaccine (Afluria)
NCT00959049,A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population,Influenza,Interventional,29-Jul-11,Seqirus,Biological: Influenza Virus Vaccine (Fluzone)
NCT00958568,A Study in Relapse Prevention of Treatment-Resistant Depression,Treatment Resistant Depression,Interventional,1-Apr-14,Eli Lilly and Company,Drug: Olanzapine and Fluoxetine combination (OFC)
NCT00958568,A Study in Relapse Prevention of Treatment-Resistant Depression,Treatment Resistant Depression,Interventional,1-Apr-14,Eli Lilly and Company,Drug: Fluoxetine
NCT00957996,Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza,Seasonal Influenza|Cough|Sore Throat|Nasal Congestion|Myalgia|Headache|Fatigue,Interventional,12-Feb-15,BioCryst Pharmaceuticals,Drug: Peramivir
NCT00957996,Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza,Seasonal Influenza|Cough|Sore Throat|Nasal Congestion|Myalgia|Headache|Fatigue,Interventional,12-Feb-15,Department of Health and Human Services,Drug: Peramivir
NCT00955825,Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis,Allergic Rhinitis Due to Grass Pollens,Interventional,19-May-16,Stallergenes Greer,Drug: 300 IR
NCT00955825,Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis,Allergic Rhinitis Due to Grass Pollens,Interventional,19-May-16,Stallergenes Greer,Drug: Placebo
NCT00955747,Naturlose (D-Tagatose) Efficacy Evaluation Trial,Type 2 Diabetes,Interventional,19-Nov-14,Robert Lodder,Drug: Tagatose
NCT00955747,Naturlose (D-Tagatose) Efficacy Evaluation Trial,Type 2 Diabetes,Interventional,19-Nov-14,Robert Lodder,Drug: Sugar Substitute Splenda
NCT00955747,Naturlose (D-Tagatose) Efficacy Evaluation Trial,Type 2 Diabetes,Interventional,19-Nov-14,University of Kentucky,Drug: Tagatose
NCT00955747,Naturlose (D-Tagatose) Efficacy Evaluation Trial,Type 2 Diabetes,Interventional,19-Nov-14,University of Kentucky,Drug: Sugar Substitute Splenda
NCT00955747,Naturlose (D-Tagatose) Efficacy Evaluation Trial,Type 2 Diabetes,Interventional,19-Nov-14,Spherix Incorporated,Drug: Tagatose
NCT00955747,Naturlose (D-Tagatose) Efficacy Evaluation Trial,Type 2 Diabetes,Interventional,19-Nov-14,Spherix Incorporated,Drug: Sugar Substitute Splenda
NCT00953147,A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,Allergic Rhinitis|Perennial Allergic Rhinitis,Interventional,7-Jun-12,Sunovion,Drug: Ciclesonide HFA 80 mcg
NCT00953147,A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,Allergic Rhinitis|Perennial Allergic Rhinitis,Interventional,7-Jun-12,Sunovion,Drug: Ciclesonide HFA 160 mcg
NCT00953147,A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,Allergic Rhinitis|Perennial Allergic Rhinitis,Interventional,7-Jun-12,Sunovion,Drug: Placebo
NCT00952705,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age,Healthy or Stable Underlying Chronic Medical Condition,Interventional,13-Jan-12,MedImmune LLC,Biological: Q/LAIV-BFS (MEDI8662)
NCT00952705,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age,Healthy or Stable Underlying Chronic Medical Condition,Interventional,13-Jan-12,MedImmune LLC,Biological: FluMist/B/Yamagata
NCT00952705,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age,Healthy or Stable Underlying Chronic Medical Condition,Interventional,13-Jan-12,MedImmune LLC,Biological: FluMist/B/Victoria
NCT00952289,COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial,MPN (Myeloproliferative Neoplasms),Interventional,24-Jan-12,Incyte Corporation,Drug: Ruxolitinib
NCT00952289,COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial,MPN (Myeloproliferative Neoplasms),Interventional,24-Jan-12,Incyte Corporation,Drug: Placebo
NCT00993473,6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,22-Jun-12,Sanofi,Drug: Insulin glargine (HOE901)
NCT00993473,6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,22-Jun-12,Sanofi,Drug: Neutral Protamine Hagedorn (NPH) insulin
NCT00993473,6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes,Type 1 Diabetes Mellitus,Interventional,22-Jun-12,Sanofi,Drug: Insulin lispro
NCT00947297,Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD),Urea Cycle Disorders,Interventional,15-Aug-13,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: HPN-100
NCT00946920,A Trial of Degarelix in Patients With Prostate Cancer,Prostate Cancer,Interventional,2-Jun-14,Ferring Pharmaceuticals,Drug: Degarelix
NCT00946920,A Trial of Degarelix in Patients With Prostate Cancer,Prostate Cancer,Interventional,2-Jun-14,Ferring Pharmaceuticals,Drug: Goserelin acetate
NCT00945906,An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency,Factor XIII Deficiency,Interventional,12-Oct-12,CSL Behring,Biological: FXIII Concentrate (Human) (FXIII)
NCT00943111,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE),"Gaucher Disease, Type 1",Interventional,4-Sep-14,"Genzyme, a Sanofi Company",Drug: Eliglustat tartrate
NCT00943111,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE),"Gaucher Disease, Type 1",Interventional,4-Sep-14,"Genzyme, a Sanofi Company",Drug: Imiglucerase
NCT00943111,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE),"Gaucher Disease, Type 1",Interventional,4-Sep-14,Sanofi,Drug: Eliglustat tartrate
NCT00943111,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE),"Gaucher Disease, Type 1",Interventional,4-Sep-14,Sanofi,Drug: Imiglucerase
NCT00942604,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Actinic Keratoses,Interventional,19-Mar-12,Peplin,Drug: PEP005 (ingenol mebutate) Gel
NCT00942604,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Actinic Keratoses,Interventional,19-Mar-12,Peplin,Drug: Vehicle gel
NCT00961051,Evaluation of an Investigational Multi-Purpose Solution (MPS),Study Focus is Healthy Contact Lens Wearers,Interventional,7-Jan-14,Abbott Medical Optics,Device: Investigational MPS
NCT00961051,Evaluation of an Investigational Multi-Purpose Solution (MPS),Study Focus is Healthy Contact Lens Wearers,Interventional,7-Jan-14,Abbott Medical Optics,Device: Opti-Free
NCT00959764,A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women,"Osteoporosis, Postmenopausal",Interventional,19-Nov-13,"Tarsa Therapeutics, Inc.",Drug: Oral Calcitonin Tablets
NCT00959764,A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women,"Osteoporosis, Postmenopausal",Interventional,19-Nov-13,"Tarsa Therapeutics, Inc.",Drug: Intranasal Calcitonin
NCT00959764,A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women,"Osteoporosis, Postmenopausal",Interventional,19-Nov-13,"Tarsa Therapeutics, Inc.",Drug: Placebo tablets and placebo intranasal spray
NCT00945945,A Study of Duloxetine in Patients With Osteoarthritis Knee Pain,Osteoarthritis Knee Pain,Interventional,8-Mar-11,Eli Lilly and Company,Drug: Duloxetine (DLX)
NCT00945945,A Study of Duloxetine in Patients With Osteoarthritis Knee Pain,Osteoarthritis Knee Pain,Interventional,8-Mar-11,Eli Lilly and Company,Drug: Placebo (PLA)
NCT00937950,Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects,"Infections, Papillomavirus",Interventional,15-Jan-15,GlaxoSmithKline,Procedure: Gynaecological follow-up
NCT00936741,An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome,Cushing's Syndrome,Interventional,2-Apr-14,Corcept Therapeutics,Drug: mifepristone
NCT00933933,Evaluation of Diagnostic HIV Ag/Ab Combo Assay,Human Immunodeficiency Viruses,Interventional,19-Aug-10,Abbott Diagnostics Division,Device: ARCHITECT HIV Ag/Ab Combo
NCT00932893,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Carcinoma, Non-Small-Cell Lung",Interventional,6-Jun-13,Pfizer,Drug: PF-02341066
NCT00932893,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Carcinoma, Non-Small-Cell Lung",Interventional,6-Jun-13,Pfizer,Drug: Pemetrexed
NCT00932893,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Carcinoma, Non-Small-Cell Lung",Interventional,6-Jun-13,Pfizer,Drug: Docetaxel
NCT00932321,Study of Safety and Efficacy of an Oral Contraceptive,Prevention of Pregnancy,Interventional,22-Mar-11,Warner Chilcott,Drug: Norethindrone Acetate/Ethinyl Estradiol 24 Days
NCT00932321,Study of Safety and Efficacy of an Oral Contraceptive,Prevention of Pregnancy,Interventional,22-Mar-11,Warner Chilcott,Drug: Norethindrone Acetate /Ethinyl Estradiol 21 Days
NCT00932646,Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,27-Jun-14,Boehringer Ingelheim,Drug: BI 1744 (Olodaterol) Low Dose
NCT00932646,Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,27-Jun-14,Boehringer Ingelheim,Drug: BI 1744 (Olodaterol) Medium Dose
NCT00932646,Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,27-Jun-14,Boehringer Ingelheim,Drug: Placebo
NCT00932646,Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,27-Jun-14,Boehringer Ingelheim,Drug: Foradil
NCT00931632,Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants,Bronchopulmonary Dysplasia,Interventional,11-Aug-15,Mallinckrodt,Drug: Inhaled Nitric Oxide
NCT00931632,Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants,Bronchopulmonary Dysplasia,Interventional,11-Aug-15,Mallinckrodt,Drug: Placebo
NCT00929864,Abatacept Versus Adalimumab Head-to-Head,Rheumatoid Arthritis,Interventional,3-Jan-14,Bristol-Myers Squibb,Drug: Abatacept
NCT00929864,Abatacept Versus Adalimumab Head-to-Head,Rheumatoid Arthritis,Interventional,3-Jan-14,Bristol-Myers Squibb,Drug: Adalimumab
NCT00931385,Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-Jul-14,Boehringer Ingelheim,Drug: BI 1744
NCT00931385,Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-Jul-14,Boehringer Ingelheim,Drug: bi1744
NCT00931385,Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-Jul-14,Boehringer Ingelheim,Drug: Placebo
NCT00931385,Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,1-Jul-14,Boehringer Ingelheim,Drug: Foradil
NCT00929110,"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,27-Jul-12,Novartis,Drug: Glycopyrronium bromide
NCT00929110,"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,27-Jul-12,Novartis,Drug: Placebo to glycopyrronium bromide
NCT00929110,"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Interventional,27-Jul-12,Novartis,Drug: Tiotropium
NCT00928434,A Study of Degarelix in Patients With Prostate Cancer,Prostate Cancer,Interventional,13-Dec-16,Ferring Pharmaceuticals,Drug: Degarelix
NCT00928434,A Study of Degarelix in Patients With Prostate Cancer,Prostate Cancer,Interventional,13-Dec-16,Ferring Pharmaceuticals,Drug: Leuprolide
NCT01196975,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults,Influenza,Interventional,24-Dec-12,GlaxoSmithKline,Biological: Quadrivalent seasonal influenza vaccine GSK2282512A
NCT01196975,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults,Influenza,Interventional,24-Dec-12,GlaxoSmithKline,Biological: FluLavalTM-VB
NCT01196975,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults,Influenza,Interventional,24-Dec-12,GlaxoSmithKline,Biological: FluLavalTM-YB
NCT00943826,A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma,Glioblastoma,Interventional,20-May-13,Hoffmann-La Roche,Drug: Bevacizumab
NCT00943826,A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma,Glioblastoma,Interventional,20-May-13,Hoffmann-La Roche,Drug: Temozolomide
NCT00943826,A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma,Glioblastoma,Interventional,20-May-13,Hoffmann-La Roche,Radiation: Radiation therapy
NCT00943826,A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma,Glioblastoma,Interventional,20-May-13,Hoffmann-La Roche,Drug: Placebo
NCT00925600,Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss,Cancer|Cataract|Low Bone Mineral Density|Osteopenia|Osteoporosis|Prostate Cancer,Interventional,30-May-17,Amgen,Biological: Denosumab
NCT00925600,Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss,Cancer|Cataract|Low Bone Mineral Density|Osteopenia|Osteoporosis|Prostate Cancer,Interventional,30-May-17,Amgen,Biological: Placebo
NCT00925301,Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease,Fabry Disease,Interventional,30-Oct-18,Amicus Therapeutics,Drug: migalastat hydrochloride
NCT00925301,Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease,Fabry Disease,Interventional,30-Oct-18,Amicus Therapeutics,Drug: Placebo
NCT01029340,Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A,Blood Coagulation Disorders|Hemophilia A,Interventional,18-Nov-13,Bayer,Biological: Recombinant Factor VIII (BAY81-8973)
NCT01029340,Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A,Blood Coagulation Disorders|Hemophilia A,Interventional,18-Nov-13,Bayer,"Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)"
NCT01029262,A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q,Anemia,Interventional,18-Jun-15,Celgene,Drug: Lenalidomide
NCT01029262,A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q,Anemia,Interventional,18-Jun-15,Celgene,Other: Placebo
NCT00939003,Study of Adalimumab in Patients With Axial Spondyloarthritis,Axial Spondyloarthritis,Interventional,6-Mar-12,"AbbVie (prior sponsor, Abbott)",Biological: Adalimumab
NCT00939003,Study of Adalimumab in Patients With Axial Spondyloarthritis,Axial Spondyloarthritis,Interventional,6-Mar-12,"AbbVie (prior sponsor, Abbott)",Biological: Placebo
NCT00939003,Study of Adalimumab in Patients With Axial Spondyloarthritis,Axial Spondyloarthritis,Interventional,6-Mar-12,"AbbVie (prior sponsor, Abbott)",Biological: Open-label Adalimumab
NCT00939003,Study of Adalimumab in Patients With Axial Spondyloarthritis,Axial Spondyloarthritis,Interventional,6-Mar-12,AbbVie,Biological: Adalimumab
NCT00939003,Study of Adalimumab in Patients With Axial Spondyloarthritis,Axial Spondyloarthritis,Interventional,6-Mar-12,AbbVie,Biological: Placebo
NCT00939003,Study of Adalimumab in Patients With Axial Spondyloarthritis,Axial Spondyloarthritis,Interventional,6-Mar-12,AbbVie,Biological: Open-label Adalimumab
NCT00937391,Contrast-enhanced MRI in Children 2 Months to <2 Years,Magnetic Resonance Imaging,Interventional,13-Oct-11,Bayer,"Drug: Gadopentetate dimeglumine (Magnevist, BAY86-6661)"
NCT00918138,Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg,Type 2 Diabetes,Interventional,6-Oct-11,AstraZeneca,Drug: Saxagliptin
NCT00918138,Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg,Type 2 Diabetes,Interventional,6-Oct-11,AstraZeneca,Drug: Metformin XR
NCT00918138,Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg,Type 2 Diabetes,Interventional,6-Oct-11,AstraZeneca,Drug: Placebo matching Metformin XR
NCT00918138,Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg,Type 2 Diabetes,Interventional,6-Oct-11,AstraZeneca,Drug: Placebo matching Saxagliptin
NCT00917384,Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma,Gastric Cancer|Adenocarcinoma,Interventional,16-Oct-14,Eli Lilly and Company,Biological: ramucirumab
NCT00917384,Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma,Gastric Cancer|Adenocarcinoma,Interventional,16-Oct-14,Eli Lilly and Company,Drug: Placebo
NCT00917384,Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma,Gastric Cancer|Adenocarcinoma,Interventional,16-Oct-14,Eli Lilly and Company,Other: Best Supportive Care (BSC)
NCT00916370,SPIRIT PRIME Clinical Trial,Myocardial Ischemia|Coronary Artery Stenosis|Coronary Disease|Coronary Artery Disease|Coronary Restenosis,Interventional,1-Jun-12,Abbott Medical Devices,Device: Core size Xience Prime
NCT00916370,SPIRIT PRIME Clinical Trial,Myocardial Ischemia|Coronary Artery Stenosis|Coronary Disease|Coronary Artery Disease|Coronary Restenosis,Interventional,1-Jun-12,Abbott Medical Devices,Device: Xience Prime Long Lesion (LL)
NCT00916006,"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Actinic Keratosis,Interventional,21-Mar-12,Peplin,Drug: PEP005 Gel
NCT00916006,"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Actinic Keratosis,Interventional,21-Mar-12,Peplin,Drug: Vehicle gel
NCT00915551,"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Actinic Keratosis,Interventional,16-Mar-12,Peplin,"Drug: PEP005 (Ingenol Mebutate) gel, 0.015%"
NCT00915551,"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Actinic Keratosis,Interventional,16-Mar-12,Peplin,Drug: Vehicle Gel
NCT00912964,A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"Urinary Bladder, Overactive",Interventional,17-Oct-12,Astellas Pharma Inc,Drug: Mirabegron
NCT00912964,A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"Urinary Bladder, Overactive",Interventional,17-Oct-12,Astellas Pharma Inc,Drug: Placebo
NCT00912093,A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3),Hereditary Angioedema,Interventional,6-Aug-14,Shire,Drug: Icatibant
NCT00912093,A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3),Hereditary Angioedema,Interventional,6-Aug-14,Shire,Drug: Placebo
NCT00911534,"Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)",Symptomatic Gastroesophageal Reflux Disease (sGERD),Interventional,2-Feb-16,Eisai Inc.,Drug: rabeprazole sodium
NCT00911534,"Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)",Symptomatic Gastroesophageal Reflux Disease (sGERD),Interventional,2-Feb-16,Eisai Inc.,Drug: Placebo
NCT00911170,PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study,Cancer|Colon Cancer|Colorectal Cancer|Fever|Locally Advanced|Metastatic Colorectal Cancer|Neutropenia|Rectal Cancer,Interventional,7-Jan-14,Amgen,Drug: Pegfilgrastim
NCT00911170,PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study,Cancer|Colon Cancer|Colorectal Cancer|Fever|Locally Advanced|Metastatic Colorectal Cancer|Neutropenia|Rectal Cancer,Interventional,7-Jan-14,Amgen,Drug: Placebo
NCT00911170,PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study,Cancer|Colon Cancer|Colorectal Cancer|Fever|Locally Advanced|Metastatic Colorectal Cancer|Neutropenia|Rectal Cancer,Interventional,7-Jan-14,Amgen,Biological: Bevacizumab
NCT00911170,PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study,Cancer|Colon Cancer|Colorectal Cancer|Fever|Locally Advanced|Metastatic Colorectal Cancer|Neutropenia|Rectal Cancer,Interventional,7-Jan-14,Amgen,Drug: Standard Chemotherapy
NCT00910910,Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial),B-Cell Chronic Lymphocytic Leukemia,Interventional,21-Dec-16,Celgene,Drug: Lenalidomide
NCT00910910,Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial),B-Cell Chronic Lymphocytic Leukemia,Interventional,21-Dec-16,Celgene,Drug: Chlorambucil
NCT00910247,Eslicarbazepine Acetate Monotherapy Long Term Study,Epilepsy,Interventional,17-Jul-18,Sunovion,Drug: Eslicarbazepine acetate
NCT00909870,Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers,Venous Leg Ulcer,Interventional,4-Feb-13,Organogenesis,Device: Dermagraft(R)
NCT00909870,Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers,Venous Leg Ulcer,Interventional,4-Feb-13,Organogenesis,Device: Profore
NCT00909779,Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects,Chronic Obstructive Pulmonary Disease,Interventional,11-Nov-13,Sunovion,Drug: Arformoterol
NCT00909779,Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects,Chronic Obstructive Pulmonary Disease,Interventional,11-Nov-13,Sunovion,Drug: Placebo
NCT00909727,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation,Cystic Fibrosis,Interventional,21-Aug-12,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT00909727,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation,Cystic Fibrosis,Interventional,21-Aug-12,Vertex Pharmaceuticals Incorporated,Drug: Placebo
NCT00909727,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation,Cystic Fibrosis,Interventional,21-Aug-12,Cystic Fibrosis Foundation,Drug: Ivacaftor
NCT00909727,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation,Cystic Fibrosis,Interventional,21-Aug-12,Cystic Fibrosis Foundation,Drug: Placebo
NCT00909532,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation,Cystic Fibrosis,Interventional,21-Aug-12,Vertex Pharmaceuticals Incorporated,Drug: Ivacaftor
NCT00909532,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation,Cystic Fibrosis,Interventional,21-Aug-12,Vertex Pharmaceuticals Incorporated,Drug: Placebo
NCT00909532,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation,Cystic Fibrosis,Interventional,21-Aug-12,Cystic Fibrosis Foundation,Drug: Ivacaftor
NCT00909532,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation,Cystic Fibrosis,Interventional,21-Aug-12,Cystic Fibrosis Foundation,Drug: Placebo
NCT00909181,Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence,Urge Urinary Incontinence|Urinary Frequency,Interventional,19-Jan-11,Antares Pharma Inc.,Drug: Oxybutynin
NCT00909181,Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence,Urge Urinary Incontinence|Urinary Frequency,Interventional,19-Jan-11,Antares Pharma Inc.,Drug: Placebo
NCT00908349,Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy,Partial Epilepsy,Interventional,31-May-17,"Supernus Pharmaceuticals, Inc.",Drug: Oxcarbazepine XR
NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis,Interventional,19-Sep-14,Biogen,Drug: BIIB017 (peginterferon beta-1a)
NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis,Interventional,19-Sep-14,Biogen,Drug: Placebo
NCT00909857,Effect on Primary Dysmenorrhea,Primary Dysmenorrhea,Interventional,27-Feb-12,Bayer,"Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)"
NCT00909857,Effect on Primary Dysmenorrhea,Primary Dysmenorrhea,Interventional,27-Feb-12,Bayer,"Drug: Ethinyl estradiol, Levonorgestrel (Miranova)"
NCT00909857,Effect on Primary Dysmenorrhea,Primary Dysmenorrhea,Interventional,27-Feb-12,Bayer,Drug: Placebo Match to SH T00658ID
NCT00909857,Effect on Primary Dysmenorrhea,Primary Dysmenorrhea,Interventional,27-Feb-12,Bayer,Drug: Placebo Match to SH D593B
NCT01010971,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older,Seasonal Allergic Rhinitis,Interventional,8-Jun-12,Sunovion,Drug: Ciclesonide HFA 160 μg
NCT01010971,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older,Seasonal Allergic Rhinitis,Interventional,8-Jun-12,Sunovion,Drug: Ciclesonide HFA 80 μg
NCT01010971,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older,Seasonal Allergic Rhinitis,Interventional,8-Jun-12,Sunovion,Drug: Placebo
NCT00903409,"Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects",Hypertriglyceridemia,Interventional,4-Aug-09,GlaxoSmithKline,Drug: Simvastatin + Lovaza® (omega-3-acid ethyl esters)
NCT00902174,Imatinib (QTI571) in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,16-Jul-13,Novartis Pharmaceuticals,Drug: imatinib mesylate
NCT00902174,Imatinib (QTI571) in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,16-Jul-13,Novartis Pharmaceuticals,Drug: Placebo
NCT00902174,Imatinib (QTI571) in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,16-Jul-13,Novartis,Drug: imatinib mesylate
NCT00902174,Imatinib (QTI571) in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,16-Jul-13,Novartis,Drug: Placebo
NCT00901901,Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma,"Carcinoma, Hepatocellular",Interventional,30-Sep-13,Bayer,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00901901,Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma,"Carcinoma, Hepatocellular",Interventional,30-Sep-13,Bayer,Drug: Erlotinib (Tarceva)
NCT00901901,Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma,"Carcinoma, Hepatocellular",Interventional,30-Sep-13,Bayer,Drug: Placebo
NCT00900731,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Indacaterol 150 μg
NCT00900731,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Tiotropium 18 μg
NCT00900731,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to indacaterol
NCT00900731,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to tiotropium
NCT00900731,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Indacaterol 150 μg
NCT00900731,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Tiotropium 18 μg
NCT00900731,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT00900731,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,19-Aug-11,Novartis,Drug: Placebo to tiotropium
NCT00896337,EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries,Iliac Artery Stenosis,Interventional,3-Jul-12,Boston Scientific Corporation,Device: Epic™ Nitinol Stent System
NCT00896337,EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries,Iliac Artery Stenosis,Interventional,3-Jul-12,Boston Scientific Corporation,Drug: Anti-platelet therapy
NCT00896337,EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries,Iliac Artery Stenosis,Interventional,3-Jul-12,Boston Scientific Corporation,Drug: Anti-coagulation therapy
NCT00895011,Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy,Erectile Dysfunction,Interventional,28-Jun-12,"VIVUS, Inc.",Drug: Placebo
NCT00895011,Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy,Erectile Dysfunction,Interventional,28-Jun-12,"VIVUS, Inc.",Drug: Avanafil
NCT00894387,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",Acute Decompensated Heart Failure|Congestive Heart Failure,Interventional,10-Oct-13,Novartis Pharmaceuticals,Drug: Aliskiren
NCT00894387,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",Acute Decompensated Heart Failure|Congestive Heart Failure,Interventional,10-Oct-13,Novartis Pharmaceuticals,Drug: Placebo
NCT00894387,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",Acute Decompensated Heart Failure|Congestive Heart Failure,Interventional,10-Oct-13,Novartis,Drug: Aliskiren
NCT00894387,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",Acute Decompensated Heart Failure|Congestive Heart Failure,Interventional,10-Oct-13,Novartis,Drug: Placebo
NCT00894647,Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery,Actinic Keratosis,Interventional,23-Aug-10,"Graceway Pharmaceuticals, LLC",Drug: imiquimod cream
NCT00894647,Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery,Actinic Keratosis,Interventional,23-Aug-10,"Graceway Pharmaceuticals, LLC",Drug: placebo cream
NCT00892957,FS VH S/D 500 S-apr in Vascular Surgery,Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses,Interventional,27-Nov-12,Baxter Healthcare Corporation,"Biological: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)"
NCT00892957,FS VH S/D 500 S-apr in Vascular Surgery,Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses,Interventional,27-Nov-12,Baxter Healthcare Corporation,Other: Surgical gauze pads
NCT00891735,A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR),Age-related Macular Degeneration,Interventional,18-Jan-13,"Genentech, Inc.",Drug: Ranibizumab
NCT00891462,Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33),Chronic Obstructive Pulmonary Disease,Interventional,13-Sep-12,AstraZeneca,Drug: Aclidinium bromide
NCT00891462,Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33),Chronic Obstructive Pulmonary Disease,Interventional,13-Sep-12,AstraZeneca,Drug: Placebo
NCT00891020,A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs),Rheumatoid Arthritis,Interventional,17-Apr-12,Hoffmann-La Roche,Drug: tocilizumab [RoActemra/Actemra]
NCT00891020,A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs),Rheumatoid Arthritis,Interventional,17-Apr-12,Hoffmann-La Roche,Drug: Nonbiologic DMARDs of investigator's choice
NCT00889863,Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Systemic Juvenile Idiopathic Arthritis With Active Flare,Interventional,16-Oct-12,Novartis Pharmaceuticals,Drug: canakinumab
NCT00889863,Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Systemic Juvenile Idiopathic Arthritis With Active Flare,Interventional,16-Oct-12,Novartis Pharmaceuticals,Drug: placebo
NCT00889863,Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Systemic Juvenile Idiopathic Arthritis With Active Flare,Interventional,16-Oct-12,Pediatric Rheumatology International Trials Organization,Drug: canakinumab
NCT00889863,Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Systemic Juvenile Idiopathic Arthritis With Active Flare,Interventional,16-Oct-12,Pediatric Rheumatology International Trials Organization,Drug: placebo
NCT00889863,Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Systemic Juvenile Idiopathic Arthritis With Active Flare,Interventional,16-Oct-12,Novartis,Drug: canakinumab
NCT00889863,Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Systemic Juvenile Idiopathic Arthritis With Active Flare,Interventional,16-Oct-12,Novartis,Drug: placebo
NCT00887978,Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension,Pulmonary Hypertension,Interventional,15-Jan-13,United Therapeutics,Drug: UT-15C SR
NCT00887978,Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension,Pulmonary Hypertension,Interventional,15-Jan-13,United Therapeutics,Drug: Placebo
NCT00887224,Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder,Major Depressive Disorder,Interventional,27-Jun-12,Pfizer,Drug: Desvenlafaxine succinate sustained release 50 mg
NCT00887224,Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder,Major Depressive Disorder,Interventional,27-Jun-12,Pfizer,Drug: Desvenlafaxine succinate sustained release 25 mg
NCT00887224,Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder,Major Depressive Disorder,Interventional,27-Jun-12,Pfizer,Drug: Placebo
NCT00887198,Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,9-Apr-15,"Janssen Research & Development, LLC",Drug: Abiraterone acetate
NCT00887198,Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,9-Apr-15,"Janssen Research & Development, LLC",Drug: Placebo
NCT00887198,Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Interventional,9-Apr-15,"Janssen Research & Development, LLC",Drug: Prednisone
NCT00885742,A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency,Factor XIII Deficiency,Interventional,4-Jul-12,CSL Behring,Biological: FXIII Concentrate (Human)
NCT00885378,Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,16-Dec-11,AstraZeneca,Drug: Saxagliptin plus metformin IR
NCT00885378,Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,16-Dec-11,AstraZeneca,Drug: Placebo plus metformin IR
NCT00883740,Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia,Fibromyalgia|Sleep Disorders,Interventional,10-Aug-11,Pfizer,Drug: Pregabalin
NCT00883740,Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia,Fibromyalgia|Sleep Disorders,Interventional,10-Aug-11,Pfizer,Drug: Placebo
NCT00883168,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,7-Sep-12,Meda Pharmaceuticals,Drug: Placebo
NCT00883168,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,7-Sep-12,Meda Pharmaceuticals,Drug: azelastineHcl
NCT00883168,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,7-Sep-12,Meda Pharmaceuticals,Drug: fluticasone propionate
NCT00883168,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,7-Sep-12,Meda Pharmaceuticals,Drug: azelastine Hcl/fluticasone propionate
NCT03021304,Study of Mepolizumab Safety Syringe in Asthmatics,Asthma,Interventional,31-Jan-18,GlaxoSmithKline,Drug: Mepolizumab
NCT00880620,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,22-Feb-16,"Impax Laboratories, LLC",Drug: Placebo
NCT00880620,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,22-Feb-16,"Impax Laboratories, LLC",Drug: IPX066 95 mg LD
NCT00880620,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,22-Feb-16,"Impax Laboratories, LLC",Drug: IPX066 145 mg LD
NCT00880620,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,22-Feb-16,"Impax Laboratories, LLC",Drug: IPX066 195 mg LD
NCT00880620,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,Parkinson's Disease,Interventional,22-Feb-16,"Impax Laboratories, LLC",Drug: IPX066 245 mg LD
NCT00880100,Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF),Cystic Fibrosis|Pancreatic Insufficiency,Interventional,19-Feb-15,Forest Laboratories,Drug: Ultrase® MT12
NCT00877929,Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus,Hypertension,Interventional,7-Jun-11,Boehringer Ingelheim,Drug: Telmisartan 80
NCT00877929,Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus,Hypertension,Interventional,7-Jun-11,Boehringer Ingelheim,Drug: Amlodipine 10
NCT00877383,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Indacaterol 150 μg
NCT00877383,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Tiotropium 18 μg
NCT00877383,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to indacaterol
NCT00877383,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-Aug-11,Novartis,Drug: Indacaterol 150 μg
NCT00877383,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-Aug-11,Novartis,Drug: Tiotropium 18 μg
NCT00877383,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: bendamustine
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: rituximab
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: vincristine
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: prednisone
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: cyclophosphamide
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: doxorubicin
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,Teva Pharmaceutical Industries,Drug: bendamustine
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,Teva Pharmaceutical Industries,Drug: rituximab
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,Teva Pharmaceutical Industries,Drug: vincristine
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,Teva Pharmaceutical Industries,Drug: prednisone
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,Teva Pharmaceutical Industries,Drug: cyclophosphamide
NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Interventional,28-Apr-14,Teva Pharmaceutical Industries,Drug: doxorubicin
NCT00876395,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,19-Dec-18,Novartis Pharmaceuticals,Drug: Everolimus
NCT00876395,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,19-Dec-18,Novartis Pharmaceuticals,Drug: Placebo
NCT00876395,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,19-Dec-18,Novartis Pharmaceuticals,Drug: Trastuzumab
NCT00876395,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,19-Dec-18,Novartis Pharmaceuticals,Drug: Paclitaxel
NCT00876395,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,19-Dec-18,Novartis,Drug: Everolimus
NCT00876395,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,19-Dec-18,Novartis,Drug: Placebo
NCT00876395,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,19-Dec-18,Novartis,Drug: Trastuzumab
NCT00876395,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,19-Dec-18,Novartis,Drug: Paclitaxel
NCT00875550,Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects,Sedation,Interventional,30-Oct-14,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Dexmedetomidine
NCT00875550,Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects,Sedation,Interventional,30-Oct-14,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Midazolam
NCT00875550,Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects,Sedation,Interventional,30-Oct-14,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Fentanyl
NCT00875550,Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects,Sedation,Interventional,30-Oct-14,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Morphine
NCT00868959,Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression,Bipolar Depression,Interventional,1-Apr-14,Sunovion,Drug: lurasidone
NCT00868699,Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy),Bipolar Depression,Interventional,2-Jul-13,Sunovion,Drug: lurasidone
NCT00868699,Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy),Bipolar Depression,Interventional,2-Jul-13,Sunovion,Drug: Placebo
NCT00868452,Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on),Bipolar Depression,Interventional,2-Apr-13,Sunovion,Drug: lurasidone + (lithium or divalproex)
NCT00868452,Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on),Bipolar Depression,Interventional,2-Apr-13,Sunovion,Drug: Placebo + (lithium or divalproex)
NCT00871117,Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years,Tetanus|Acellular Pertussis|Diphtheria,Interventional,10-Feb-11,GlaxoSmithKline,Biological: GSK Biologicals'Kinrix®
NCT00871117,Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years,Tetanus|Acellular Pertussis|Diphtheria,Interventional,10-Feb-11,GlaxoSmithKline,Biological: Merck and Company's MMRII
NCT00871117,Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years,Tetanus|Acellular Pertussis|Diphtheria,Interventional,10-Feb-11,GlaxoSmithKline,Biological: Merck and Company's Varivax
NCT00868296,Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,7-Jan-10,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: pantoprazole
NCT00866775,Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs,Epilepsy With Simple or Complex Partial Onset Seizures,Interventional,4-Feb-16,Sunovion,Drug: Eslicarbazepine acetate
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,Malignant Melanoma,Interventional,5-Jun-14,Celgene,Drug: ABI-007
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,Malignant Melanoma,Interventional,5-Jun-14,Celgene,Drug: Dacarbazine
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,Malignant Melanoma,Interventional,5-Jun-14,University of Arizona,Drug: ABI-007
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,Malignant Melanoma,Interventional,5-Jun-14,University of Arizona,Drug: Dacarbazine
NCT00863655,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,Breast Cancer,Interventional,31-Aug-12,Novartis Pharmaceuticals,Drug: Everolimus
NCT00863655,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,Breast Cancer,Interventional,31-Aug-12,Novartis Pharmaceuticals,Drug: Exemestane
NCT00863655,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,Breast Cancer,Interventional,31-Aug-12,Novartis Pharmaceuticals,Drug: Everolimus Placebo
NCT00863655,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,Breast Cancer,Interventional,31-Aug-12,Novartis,Drug: Everolimus
NCT00863655,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,Breast Cancer,Interventional,31-Aug-12,Novartis,Drug: Exemestane
NCT00863655,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,Breast Cancer,Interventional,31-Aug-12,Novartis,Drug: Everolimus Placebo
NCT00861614,Study of Immunotherapy to Treat Advanced Prostate Cancer,Prostate Cancer,Interventional,16-Mar-16,Bristol-Myers Squibb,Drug: Ipilimumab
NCT00861614,Study of Immunotherapy to Treat Advanced Prostate Cancer,Prostate Cancer,Interventional,16-Mar-16,Bristol-Myers Squibb,Drug: Placebo
NCT00860262,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,Hypertension,Interventional,4-Jan-11,Boehringer Ingelheim,Drug: amlodipine
NCT00860262,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,Hypertension,Interventional,4-Jan-11,Boehringer Ingelheim,Drug: telmisartan
NCT00860262,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,Hypertension,Interventional,4-Jan-11,Boehringer Ingelheim,Drug: telmisartan and amlodipine
NCT00857415,Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain,Alzheimer's Disease,Interventional,7-May-12,Avid Radiopharmaceuticals,Drug: florbetapir F 18
NCT00857220,Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia,Insomnia|Attention Deficit Hyperactivity Disorder,Interventional,22-Jul-13,Sunovion,Drug: eszopiclone
NCT00856986,The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-May-11,Novo Nordisk A/S,Drug: liraglutide
NCT00856986,The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-May-11,Novo Nordisk A/S,Drug: insulin detemir
NCT00856986,The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,13-May-11,Novo Nordisk A/S,Drug: metformin
NCT00856973,Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia,Insomnia|Attention Deficit Hyperactivity Disorder,Interventional,10-Apr-13,Sunovion,Drug: eszopiclone
NCT00856973,Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia,Insomnia|Attention Deficit Hyperactivity Disorder,Interventional,10-Apr-13,Sunovion,Drug: Placebo
NCT00856544,"A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications","Arthritis, Rheumatoid",Interventional,10-Jan-13,Pfizer,"Drug: CP-690,550"
NCT00856544,"A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications","Arthritis, Rheumatoid",Interventional,10-Jan-13,Pfizer,Drug: Placebo
NCT00856284,Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,3-Dec-13,Takeda,Drug: Alogliptin
NCT00856284,Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,3-Dec-13,Takeda,Drug: Metformin
NCT00856284,Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,3-Dec-13,Takeda,Drug: Glipizide
NCT00856206,Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE),Gout,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Biological: Rilonacept
NCT00856206,Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE),Gout,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Other: Placebo
NCT00855920,Study Utilizing Rilonacept in Gout Exacerbations,Acute Gout Flare,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Drug: Rilonacept
NCT00855920,Study Utilizing Rilonacept in Gout Exacerbations,Acute Gout Flare,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Drug: Indomethacin
NCT00855920,Study Utilizing Rilonacept in Gout Exacerbations,Acute Gout Flare,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Other: Placebo (for Indomethacin)
NCT00855920,Study Utilizing Rilonacept in Gout Exacerbations,Acute Gout Flare,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Other: Placebo (for Rilonacept)
NCT00855582,A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia,Erectile Dysfunction|Benign Prostatic Hyperplasia,Interventional,30-Jun-11,Eli Lilly and Company,Drug: Tadalafil
NCT00855582,A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia,Erectile Dysfunction|Benign Prostatic Hyperplasia,Interventional,30-Jun-11,Eli Lilly and Company,Drug: Placebo
NCT00855465,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.,Pulmonary Hypertension,Interventional,11-Mar-14,Bayer,"Drug: Riociguat (Adempas, BAY63-2521)"
NCT00855465,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.,Pulmonary Hypertension,Interventional,11-Mar-14,Bayer,Drug: Placebo
NCT00855335,"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",HIV|HIV Infections|Pregnancy,Interventional,15-Sep-17,"Janssen Scientific Affairs, LLC",Drug: Darunavir
NCT00855335,"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",HIV|HIV Infections|Pregnancy,Interventional,15-Sep-17,"Janssen Scientific Affairs, LLC",Drug: Ritonavir
NCT00855335,"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",HIV|HIV Infections|Pregnancy,Interventional,15-Sep-17,"Janssen Scientific Affairs, LLC",Drug: Etravirine
NCT00855335,"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",HIV|HIV Infections|Pregnancy,Interventional,15-Sep-17,"Janssen Scientific Affairs, LLC",Drug: Rilpivirine
NCT00855335,"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",HIV|HIV Infections|Pregnancy,Interventional,15-Sep-17,"Janssen Scientific Affairs, LLC",Drug: Darunavir/Cobicistat (FDC)
NCT00857454,A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations,Hypogonadism,Interventional,5-Jan-11,Eli Lilly and Company,Drug: Testosterone MD-Lotion
NCT00963508,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",Pediculosis,Interventional,13-Jun-14,Taro Pharmaceuticals USA,Drug: Malathion gel 0.5%
NCT00963508,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",Pediculosis,Interventional,13-Jun-14,Taro Pharmaceuticals USA,Drug: Permethrin 1% rinse (Nix Crème)
NCT00853827,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,Coronary Artery Disease (CAD)|Coronary Atherosclerosis,Interventional,7-May-14,Novartis Pharmaceuticals,Drug: Placebo
NCT00853827,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,Coronary Artery Disease (CAD)|Coronary Atherosclerosis,Interventional,7-May-14,Novartis Pharmaceuticals,Drug: Aliskiren
NCT00853827,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,Coronary Artery Disease (CAD)|Coronary Atherosclerosis,Interventional,7-May-14,The Cleveland Clinic,Drug: Placebo
NCT00853827,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,Coronary Artery Disease (CAD)|Coronary Atherosclerosis,Interventional,7-May-14,The Cleveland Clinic,Drug: Aliskiren
NCT00853827,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,Coronary Artery Disease (CAD)|Coronary Atherosclerosis,Interventional,7-May-14,Novartis,Drug: Placebo
NCT00853827,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,Coronary Artery Disease (CAD)|Coronary Atherosclerosis,Interventional,7-May-14,Novartis,Drug: Aliskiren
NCT00853658,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,Chronic Heart Failure,Interventional,25-Nov-16,Novartis Pharmaceuticals,Drug: Enalapril
NCT00853658,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,Chronic Heart Failure,Interventional,25-Nov-16,Novartis Pharmaceuticals,Drug: Aliskiren
NCT00853658,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,Chronic Heart Failure,Interventional,25-Nov-16,Novartis,Drug: Enalapril
NCT00853658,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,Chronic Heart Failure,Interventional,25-Nov-16,Novartis,Drug: Aliskiren
NCT00853606,Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction,Erectile Dysfunction,Interventional,28-Jun-12,"VIVUS, Inc.",Drug: avanafil
NCT00853385,"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,9-Jan-13,Pfizer,"Drug: CP 690,550"
NCT00853385,"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,9-Jan-13,Pfizer,"Drug: CP-690,550"
NCT00853385,"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,9-Jan-13,Pfizer,Other: Placebo
NCT00853385,"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis",Rheumatoid Arthritis,Interventional,9-Jan-13,Pfizer,Biological: Biologic TNFi
NCT00849901,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-Mar-12,Eli Lilly and Company,Drug: duloxetine
NCT00849901,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-Mar-12,Eli Lilly and Company,Drug: Placebo
NCT00849901,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-Mar-12,Eli Lilly and Company,Drug: fluoxetine
NCT00849693,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Major Depressive Disorder,Interventional,19-Apr-12,Eli Lilly and Company,Drug: Placebo
NCT00849693,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Major Depressive Disorder,Interventional,19-Apr-12,Eli Lilly and Company,Drug: fluoxetine
NCT00849693,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Major Depressive Disorder,Interventional,19-Apr-12,Eli Lilly and Company,Drug: duloxetine
NCT00849056,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,1-Jul-14,GlaxoSmithKline,Biological: albiglutide
NCT00849056,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,1-Jul-14,GlaxoSmithKline,Drug: placebo
NCT00849017,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,5-Jun-14,GlaxoSmithKline,Biological: albiglutide
NCT00849017,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,5-Jun-14,GlaxoSmithKline,Biological: albiglutide uptitration
NCT00849017,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,5-Jun-14,GlaxoSmithKline,Biological: placebo
NCT00848081,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers,Benign Prostatic Hyperplasia,Interventional,14-Sep-10,Eli Lilly and Company,Drug: Tadalafil
NCT00848081,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers,Benign Prostatic Hyperplasia,Interventional,14-Sep-10,Eli Lilly and Company,Drug: Placebo
NCT00847808,Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy,Gastroesophageal Reflux,Interventional,29-Apr-11,Takeda,Drug: Dexlansoprazole MR QD
NCT00847626,Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension,Hypertension,Interventional,7-Feb-12,Takeda,Drug: Azilsartan medoxomil and chlorthalidone
NCT00847626,Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension,Hypertension,Interventional,7-Feb-12,Takeda,Drug: Chlorthalidone
NCT00847626,Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension,Hypertension,Interventional,7-Feb-12,Takeda,Drug: Azilsartan medoxomil
NCT00847613,"A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate","Arthritis, Rheumatoid",Interventional,9-Jan-13,Pfizer,"Drug: CP-690,550"
NCT00847613,"A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate","Arthritis, Rheumatoid",Interventional,9-Jan-13,Pfizer,Drug: Placebo
NCT00846586,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Indacaterol 150 μg
NCT00846586,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Tiotropium 18 μg
NCT00846586,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to indacaterol
NCT00846586,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis,Drug: Indacaterol 150 μg
NCT00846586,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis,Drug: Tiotropium 18 μg
NCT00846586,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT00846365,Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension,Essential Hypertension,Interventional,13-Mar-12,Takeda,Drug: Azilsartan medoxomil and chlorthalidone
NCT00846365,Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension,Essential Hypertension,Interventional,13-Mar-12,Takeda,Drug: Olmesartan medoxomil-hydrochlorothiazide
NCT00844649,Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas,Metastatic Pancreatic Cancer,Interventional,11-Dec-13,Celgene,Drug: Albumin-bound paclitaxel (ABI-007)
NCT00844649,Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas,Metastatic Pancreatic Cancer,Interventional,11-Dec-13,Celgene,Drug: Gemcitabine
NCT00843024,Migraine Study in Adolescent Patients,Migraine Disorders,Interventional,9-May-11,GlaxoSmithKline,Drug: Sumatriptan and Naproxen Sodium
NCT00843024,Migraine Study in Adolescent Patients,Migraine Disorders,Interventional,9-May-11,GlaxoSmithKline,Drug: Placebo
NCT00840086,Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects,Congenital Bleeding Disorder|Haemophilia A,Interventional,4-Sep-14,Novo Nordisk A/S,Drug: turoctocog alfa
NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,1-Jul-14,GlaxoSmithKline,Drug: placebo to match albiglutide
NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,1-Jul-14,GlaxoSmithKline,Biological: albiglutide
NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,1-Jul-14,GlaxoSmithKline,Drug: metformin
NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,1-Jul-14,GlaxoSmithKline,Drug: glimepiride
NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,1-Jul-14,GlaxoSmithKline,Drug: pioglitazone
NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,1-Jul-14,GlaxoSmithKline,Drug: placebo to match pioglitazone
NCT00838916,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Jun-14,GlaxoSmithKline,Biological: albiglutide
NCT00838916,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,4-Jun-14,GlaxoSmithKline,Drug: insulin glargine
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Biological: albiglutide
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Drug: sitagliptin
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Drug: glimepiride
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Drug: metformin
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Biological: placebo albiglutide
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Drug: placebo sitagliptin
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-May-14,GlaxoSmithKline,Drug: placebo glimepiride
NCT00949650,BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",Interventional,19-Nov-13,Boehringer Ingelheim,Drug: Pemetrexed
NCT00949650,BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",Interventional,19-Nov-13,Boehringer Ingelheim,Drug: BIBW 2992
NCT00949650,BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",Interventional,19-Nov-13,Boehringer Ingelheim,Drug: Cisplatin
NCT00838201,Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer,Cancer|Carcinoma|Castrate-Resistant Prostate Cancer|Prostate Cancer|Tumors,Interventional,24-Sep-13,Amgen,Drug: Denosumab
NCT00835237,Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.,Tetanus|Acellular Pertussis|Diphtheria,Interventional,5-Aug-10,GlaxoSmithKline,Biological: Boostrix®
NCT00835237,Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.,Tetanus|Acellular Pertussis|Diphtheria,Interventional,5-Aug-10,GlaxoSmithKline,Biological: Decavac™
NCT00879333,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),Advanced Gastric Cancer,Interventional,6-Apr-15,Novartis Pharmaceuticals,Drug: Everolimus
NCT00879333,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),Advanced Gastric Cancer,Interventional,6-Apr-15,Novartis Pharmaceuticals,Drug: Everolimus placebo
NCT00879333,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),Advanced Gastric Cancer,Interventional,6-Apr-15,Novartis Pharmaceuticals,Drug: Best Supportive Care (BSC)
NCT00879333,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),Advanced Gastric Cancer,Interventional,6-Apr-15,Novartis,Drug: Everolimus
NCT00879333,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),Advanced Gastric Cancer,Interventional,6-Apr-15,Novartis,Drug: Everolimus placebo
NCT00879333,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),Advanced Gastric Cancer,Interventional,6-Apr-15,Novartis,Drug: Best Supportive Care (BSC)
NCT00833248,Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer,Prostate Cancer,Interventional,27-Sep-12,Ferring Pharmaceuticals,Drug: Degarelix
NCT00833248,Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer,Prostate Cancer,Interventional,27-Sep-12,Ferring Pharmaceuticals,Drug: Goserelin
NCT00833248,Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer,Prostate Cancer,Interventional,27-Sep-12,Ferring Pharmaceuticals,Drug: Bicalutamide
NCT00834080,ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals,Opiate Dependence,Interventional,29-Jul-13,"Alkermes, Inc.",Drug: Medisorb naltrexone 380 mg
NCT00829829,PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1,Intercritical Gout,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Other: Placebo
NCT00829829,PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1,Intercritical Gout,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Drug: Rilonacept 80 mg
NCT00829829,PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1,Intercritical Gout,Interventional,28-Apr-17,Regeneron Pharmaceuticals,Drug: Rilonacept 160 mg
NCT00829166,A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,23-Apr-13,Hoffmann-La Roche,Drug: Trastuzumab emtansine
NCT00829166,A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,23-Apr-13,Hoffmann-La Roche,Drug: Lapatinib
NCT00829166,A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Interventional,23-Apr-13,Hoffmann-La Roche,Drug: Capecitabine
NCT00828204,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,Multiple Sclerosis,Interventional,9-Aug-11,Biogen,Device: single-use autoinjector with a prefilled liquid Avonex syringe
NCT00828204,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,Multiple Sclerosis,Interventional,9-Aug-11,Biogen,Device: Avonex prefilled syringe via manual IM injection
NCT00828204,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,Multiple Sclerosis,Interventional,9-Aug-11,Biogen,Drug: BG9418 (interferon beta-1a)
NCT00826280,Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI),Coronary Artery Disease (CAD),Interventional,21-Oct-11,Astellas Pharma Inc,Drug: regadenoson
NCT00826280,Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI),Coronary Artery Disease (CAD),Interventional,21-Oct-11,Astellas Pharma Inc,Drug: overencapsulated caffeine
NCT00826280,Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI),Coronary Artery Disease (CAD),Interventional,21-Oct-11,Astellas Pharma Inc,Radiation: technetium
NCT00826280,Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI),Coronary Artery Disease (CAD),Interventional,21-Oct-11,Astellas Pharma Inc,Drug: placebo
NCT00827242,Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily,Benign Prostatic Hyperplasia,Interventional,17-Nov-10,Eli Lilly and Company,Drug: Placebo
NCT00827242,Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily,Benign Prostatic Hyperplasia,Interventional,17-Nov-10,Eli Lilly and Company,Drug: tadalafil
NCT00823212,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions,Coronary Artery Disease,Interventional,27-Jan-12,Boston Scientific Corporation,Device: PROMUS Coronary Stent System
NCT00823212,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions,Coronary Artery Disease,Interventional,27-Jan-12,Boston Scientific Corporation,Device: PROMUS Element Coronary Stent System
NCT00823212,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions,Coronary Artery Disease,Interventional,27-Jan-12,Boston Scientific Corporation,Drug: Aspirin
NCT00823212,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions,Coronary Artery Disease,Interventional,27-Jan-12,Boston Scientific Corporation,Drug: Thienopyridine
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Indacaterol 150 µg
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Salmeterol 50 µg
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to indacaterol
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to salmeterol
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis,Drug: Indacaterol 150 µg
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis,Drug: Salmeterol 50 µg
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,18-Aug-11,Novartis,Drug: Placebo to salmeterol
NCT00820222,Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer,"Metastases, Brain",Interventional,15-Mar-13,Novartis Pharmaceuticals,Drug: capecitabine
NCT00820222,Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer,"Metastases, Brain",Interventional,15-Mar-13,Novartis Pharmaceuticals,Drug: lapatinib
NCT00820222,Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer,"Metastases, Brain",Interventional,15-Mar-13,Novartis Pharmaceuticals,Drug: trastuzumab
NCT00820222,Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer,"Metastases, Brain",Interventional,15-Mar-13,Novartis,Drug: capecitabine
NCT00820222,Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer,"Metastases, Brain",Interventional,15-Mar-13,Novartis,Drug: lapatinib
NCT00820222,Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer,"Metastases, Brain",Interventional,15-Mar-13,Novartis,Drug: trastuzumab
NCT00818883,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension,Essential Hypertension,Interventional,7-Feb-12,Takeda,Drug: Azilsartan medoxomil and chlorthalidone
NCT00818883,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension,Essential Hypertension,Interventional,7-Feb-12,Takeda,Drug: Azilsartan medoxomil and hydrochlorothiazide
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Baxalta now part of Shire,"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg"
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Baxalta now part of Shire,"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg"
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Baxalta now part of Shire,Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Baxalta now part of Shire,Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Alzheimer's Disease Cooperative Study (ADCS),"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg"
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Alzheimer's Disease Cooperative Study (ADCS),"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg"
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Alzheimer's Disease Cooperative Study (ADCS),Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Alzheimer's Disease Cooperative Study (ADCS),Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Shire,"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg"
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Shire,"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg"
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Shire,Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Alzheimer´s Disease,Interventional,28-Oct-14,Shire,Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
NCT00819091,"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug","Diabetes Mellitus, Type 2",Interventional,1-Aug-11,Boehringer Ingelheim,Drug: BI 1356
NCT00819091,"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug","Diabetes Mellitus, Type 2",Interventional,1-Aug-11,Boehringer Ingelheim,Drug: Placebo
NCT00928746,Actuation Indicator Trial in Patients With COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,28-Sep-10,Boehringer Ingelheim,Device: Ipratropium bromide
NCT00819052,Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients,HIV Infections,Interventional,24-Feb-12,Boehringer Ingelheim,Drug: Nevirapine XR
NCT00819052,Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients,HIV Infections,Interventional,24-Feb-12,Boehringer Ingelheim,Drug: Nevirapine IR
NCT00814307,"A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis","Arthritis, Rheumatoid",Interventional,11-Jan-13,Pfizer,"Drug: CP-690,550"
NCT00814307,"A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis","Arthritis, Rheumatoid",Interventional,11-Jan-13,Pfizer,Drug: Placebo
NCT00814320,Gammagard Liquid and rHuPH20 in PID,Primary Immunodeficiency Diseases (PID),Interventional,3-Dec-15,Baxalta now part of Shire,Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
NCT00814320,Gammagard Liquid and rHuPH20 in PID,Primary Immunodeficiency Diseases (PID),Interventional,3-Dec-15,Shire,Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
NCT00813488,Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain,Chronic Pain,Interventional,31-Dec-10,Cephalon,Drug: Fentanyl Buccal Tablet
NCT00813488,Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain,Chronic Pain,Interventional,31-Dec-10,Cephalon,Drug: Immediate release oxycodone
NCT00813488,Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain,Chronic Pain,Interventional,31-Dec-10,Teva Pharmaceutical Industries,Drug: Fentanyl Buccal Tablet
NCT00813488,Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain,Chronic Pain,Interventional,31-Dec-10,Teva Pharmaceutical Industries,Drug: Immediate release oxycodone
NCT00812955,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides","Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",Interventional,1-Aug-12,AstraZeneca,Drug: ABT-143
NCT00812955,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides","Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",Interventional,1-Aug-12,AstraZeneca,Drug: simvastatin
NCT00811473,Pediatric Bipolar Depression,Bipolar Depression,Interventional,1-Dec-11,AstraZeneca,Drug: Quetiapine XR
NCT00811473,Pediatric Bipolar Depression,Bipolar Depression,Interventional,1-Dec-11,AstraZeneca,Drug: Placebo
NCT00810693,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),Pulmonary Hypertension,Interventional,26-Feb-14,Bayer,"Drug: Riociguat (Adempas, BAY63-2521)"
NCT00810693,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),Pulmonary Hypertension,Interventional,26-Feb-14,Bayer,Drug: Placebo
NCT00810199,A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment,Rheumatoid Arthritis,Interventional,18-Jul-14,Hoffmann-La Roche,Drug: tocilizumab [RoActemra/Actemra]
NCT00810199,A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment,Rheumatoid Arthritis,Interventional,18-Jul-14,Hoffmann-La Roche,Drug: methotrexate
NCT00810199,A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment,Rheumatoid Arthritis,Interventional,18-Jul-14,Hoffmann-La Roche,Drug: placebo
NCT00809757,"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma",Asthma,Interventional,28-Jul-14,Sunovion,Drug: Levalbuterol
NCT00809757,"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma",Asthma,Interventional,28-Jul-14,Sunovion,Drug: Levalbuterol UDV TID
NCT00809757,"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma",Asthma,Interventional,28-Jul-14,Sunovion,Drug: Placebo
NCT00809471,Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D),Erectile Dysfunction,Interventional,28-Jun-12,"VIVUS, Inc.",Drug: placebo
NCT00809471,Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D),Erectile Dysfunction,Interventional,28-Jun-12,"VIVUS, Inc.",Drug: avanafil
NCT00808132,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause|Osteoporosis,Interventional,20-Dec-13,Pfizer,Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
NCT00808132,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause|Osteoporosis,Interventional,20-Dec-13,Pfizer,Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
NCT00808132,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause|Osteoporosis,Interventional,20-Dec-13,Pfizer,Drug: bazedoxifene 20 mg
NCT00808132,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause|Osteoporosis,Interventional,20-Dec-13,Pfizer,Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
NCT00808132,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause|Osteoporosis,Interventional,20-Dec-13,Pfizer,Drug: Placebo
NCT00808067,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,Atrial Fibrillation,Interventional,8-Apr-14,Boehringer Ingelheim,Drug: dabigatran dose 1
NCT00808067,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,Atrial Fibrillation,Interventional,8-Apr-14,Boehringer Ingelheim,Drug: dabigatran dose 2
NCT00806819,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,"Carcinoma, Non-Small-Cell Lung",Interventional,20-Nov-14,Boehringer Ingelheim,Drug: Nintedanib (BIBF1120)
NCT00806819,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,"Carcinoma, Non-Small-Cell Lung",Interventional,20-Nov-14,Boehringer Ingelheim,Drug: Pemetrexed
NCT00806819,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,"Carcinoma, Non-Small-Cell Lung",Interventional,20-Nov-14,Boehringer Ingelheim,Drug: pemetrexed
NCT00806819,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,"Carcinoma, Non-Small-Cell Lung",Interventional,20-Nov-14,Boehringer Ingelheim,Drug: B12
NCT00806819,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,"Carcinoma, Non-Small-Cell Lung",Interventional,20-Nov-14,Boehringer Ingelheim,Drug: dexamethasone (or corticosteroid equivalent)
NCT00806819,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,"Carcinoma, Non-Small-Cell Lung",Interventional,20-Nov-14,Boehringer Ingelheim,Drug: placebo
NCT00806819,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,"Carcinoma, Non-Small-Cell Lung",Interventional,20-Nov-14,Boehringer Ingelheim,Drug: Folic Acid
NCT00806546,An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months,Migraine Disorders,Interventional,20-Mar-13,NuPathe Inc.,Drug: NP101
NCT00806546,An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months,Migraine Disorders,Interventional,20-Mar-13,Teva Pharmaceutical Industries,Drug: NP101
NCT00806026,Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients,Idiopathic Restless Legs Syndrome,Interventional,27-Sep-12,Pfizer,Drug: placebo and pregabalin
NCT00806026,Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients,Idiopathic Restless Legs Syndrome,Interventional,27-Sep-12,Pfizer,Drug: pramipexol
NCT00806026,Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients,Idiopathic Restless Legs Syndrome,Interventional,27-Sep-12,Pfizer,Drug: Pregabalin
NCT00803101,"An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure",Reversal of Coagulopathy,Interventional,25-Feb-14,CSL Behring,Biological: Beriplex® P/N (Kcentra)
NCT00803101,"An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure",Reversal of Coagulopathy,Interventional,25-Feb-14,CSL Behring,Biological: Fresh frozen plasma
NCT00803023,Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia,Fibromyalgia,Interventional,16-Aug-11,Jazz Pharmaceuticals,Drug: Sodium Oxybate
NCT00803023,Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia,Fibromyalgia,Interventional,16-Aug-11,Jazz Pharmaceuticals,Drug: Sodium Oxybate & 6 Tablets
NCT00803023,Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia,Fibromyalgia,Interventional,16-Aug-11,Jazz Pharmaceuticals,Drug: Sodium Oxybate & 8 Tablets
NCT00803023,Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia,Fibromyalgia,Interventional,16-Aug-11,Jazz Pharmaceuticals,Drug: Sodium Oxybate Oral Solution (6 grams)
NCT00800683,"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive","Diabetes Mellitus, Type 2",Interventional,1-Feb-12,Boehringer Ingelheim,Drug: BI 1356
NCT00800683,"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive","Diabetes Mellitus, Type 2",Interventional,1-Feb-12,Boehringer Ingelheim,Drug: placebo
NCT00799903,The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial,Atherosclerosis,Interventional,10-Aug-17,GlaxoSmithKline,Drug: Darapladib
NCT00799903,The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial,Atherosclerosis,Interventional,10-Aug-17,GlaxoSmithKline,Drug: Placebo
NCT00799825,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US,"Infections, Papillomavirus",Interventional,20-Sep-13,GlaxoSmithKline,Biological: GSK Biological's HPV vaccine GSK580299 (Cervarix™)
NCT00801398,Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.,Postoperative Pain,Interventional,27-Feb-19,Endo Pharmaceuticals,Drug: Oxymorphone IR
NCT00800735,A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols,"Hepatitis C, Chronic",Interventional,13-Sep-13,Hoffmann-La Roche,Drug: Pegylated-interferon alfa-2a
NCT00800735,A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols,"Hepatitis C, Chronic",Interventional,13-Sep-13,Hoffmann-La Roche,Drug: Ribavirin
NCT00798707,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder,Major Depressive Disorder,Interventional,6-Jun-11,Pfizer,Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
NCT00798707,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder,Major Depressive Disorder,Interventional,6-Jun-11,Pfizer,Drug: placebo
NCT00798317,Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.,Vitreomacular Adhesion,Interventional,30-Jan-13,ThromboGenics,Drug: Ocriplasmin 125µg
NCT00798317,Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.,Vitreomacular Adhesion,Interventional,30-Jan-13,ThromboGenics,Drug: Placebo
NCT00797797,Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia,Fibromyalgia,Interventional,16-Feb-11,Forest Laboratories,Drug: No Treatment Added
NCT00797797,Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia,Fibromyalgia,Interventional,16-Feb-11,Forest Laboratories,Drug: Milnacipran Added
NCT00792103,An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months,Migraine Disorders,Interventional,7-May-13,NuPathe Inc.,Drug: NP101
NCT00792103,An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months,Migraine Disorders,Interventional,7-May-13,Teva Pharmaceutical Industries,Drug: NP101
NCT00790933,An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease,Ulcerative Colitis|Crohn's Disease,Interventional,12-Mar-19,Takeda,Drug: Vedolizumab
NCT00790751,Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED,Erectile Dysfunction,Interventional,28-Jun-12,"VIVUS, Inc.",Drug: placebo
NCT00790751,Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED,Erectile Dysfunction,Interventional,28-Jun-12,"VIVUS, Inc.",Drug: avanafil
NCT00790192,Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.,Schizophrenia,Interventional,6-Oct-11,Sunovion,Drug: Lurasidone
NCT00790192,Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.,Schizophrenia,Interventional,6-Oct-11,Sunovion,Drug: Quetiapine XR
NCT00790192,Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.,Schizophrenia,Interventional,6-Oct-11,Sunovion,Drug: Placebo
NCT00790036,Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy,Diffuse Large B-cell Lymphoma,Interventional,12-Jul-17,Novartis Pharmaceuticals,Drug: Everolimus
NCT00790036,Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy,Diffuse Large B-cell Lymphoma,Interventional,12-Jul-17,Novartis Pharmaceuticals,Drug: Everolimus Placebo
NCT00790036,Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy,Diffuse Large B-cell Lymphoma,Interventional,12-Jul-17,Novartis,Drug: Everolimus
NCT00790036,Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy,Diffuse Large B-cell Lymphoma,Interventional,12-Jul-17,Novartis,Drug: Everolimus Placebo
NCT00789750,Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,26-Jun-17,"Daiichi Sankyo, Inc.",Drug: Colesevelam
NCT00789750,Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,26-Jun-17,"Daiichi Sankyo, Inc.",Drug: Placebo
NCT00789750,Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,26-Jun-17,"Daiichi Sankyo, Inc.",Drug: Pioglitazone
NCT00789737,Welchol as Monotherapy for Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,22-Jan-14,"Daiichi Sankyo, Inc.",Drug: Welchol
NCT00789737,Welchol as Monotherapy for Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Interventional,22-Jan-14,"Daiichi Sankyo, Inc.",Drug: Placebo
NCT00789698,Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia,Chronic Schizophrenia,Interventional,21-Aug-12,Sunovion,Drug: Lurasidone HC1
NCT00789698,Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia,Chronic Schizophrenia,Interventional,21-Aug-12,Sunovion,Drug: Quetiapine XR
NCT00828191,Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF),In Vitro Fertilization,Interventional,26-Dec-12,IBSA Institut Biochimique SA,Drug: Progesterone
NCT00827606,Atorvastatin Three Year Pediatric Study,Familial Hypercholesterolemia,Interventional,2-Jun-15,Pfizer,Drug: atorvastatin
NCT00789828,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Interventional,1-May-12,Novartis Pharmaceuticals,Drug: Everolimus
NCT00789828,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Interventional,1-May-12,Novartis Pharmaceuticals,Drug: Placebo
NCT00789828,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Interventional,1-May-12,Novartis,Drug: Everolimus
NCT00789828,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Interventional,1-May-12,Novartis,Drug: Placebo
NCT00803634,Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO),Hypertension|Heart Failure,Interventional,19-Aug-14,The Medicines Company,Drug: Clevidipine
NCT00803634,Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO),Hypertension|Heart Failure,Interventional,19-Aug-14,The Medicines Company,Drug: Standard of Care IV antihypertensive
NCT00785785,A Study of Nilotinib Versus Imatinib in GIST Patients,Gastrointestinal Stromal Tumor (GIST),Interventional,7-Apr-16,Novartis Pharmaceuticals,Drug: Nilotinib (AMN107)
NCT00785785,A Study of Nilotinib Versus Imatinib in GIST Patients,Gastrointestinal Stromal Tumor (GIST),Interventional,7-Apr-16,Novartis Pharmaceuticals,Drug: imatinib (STI571)
NCT00785785,A Study of Nilotinib Versus Imatinib in GIST Patients,Gastrointestinal Stromal Tumor (GIST),Interventional,7-Apr-16,Novartis,Drug: Nilotinib (AMN107)
NCT00785785,A Study of Nilotinib Versus Imatinib in GIST Patients,Gastrointestinal Stromal Tumor (GIST),Interventional,7-Apr-16,Novartis,Drug: imatinib (STI571)
NCT00783718,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis,Ulcerative Colitis,Interventional,18-Jul-14,"Millennium Pharmaceuticals, Inc.",Drug: vedolizumab
NCT00783718,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis,Ulcerative Colitis,Interventional,18-Jul-14,"Millennium Pharmaceuticals, Inc.",Other: Placebo
NCT00783692,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease,Crohn's Disease,Interventional,21-Jul-14,"Millennium Pharmaceuticals, Inc.",Drug: vedolizumab
NCT00783692,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease,Crohn's Disease,Interventional,21-Jul-14,"Millennium Pharmaceuticals, Inc.",Other: Placebo
NCT00782509,12 / 48 wk Pivotal PFT vs PBO in COPD II,"Pulmonary Disease, Chronic Obstructive",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: Olodaterol (BI 1744)
NCT00782509,12 / 48 wk Pivotal PFT vs PBO in COPD II,"Pulmonary Disease, Chronic Obstructive",Interventional,17-Jun-14,Boehringer Ingelheim,Drug: Placebo
NCT00782210,12 / 48 Week Pivotal PFT vs PBO in COPD I,"Pulmonary Disease, Chronic Obstructive",Interventional,30-Apr-14,Boehringer Ingelheim,Drug: Olodaterol (BI1744)
NCT00782210,12 / 48 Week Pivotal PFT vs PBO in COPD I,"Pulmonary Disease, Chronic Obstructive",Interventional,30-Apr-14,Boehringer Ingelheim,Drug: placebo
NCT00789191,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,10-Dec-10,Novo Nordisk A/S,Drug: insulin detemir
NCT00789191,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,10-Dec-10,Novo Nordisk A/S,Drug: sitagliptin
NCT00789191,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,10-Dec-10,Novo Nordisk A/S,Drug: metformin
NCT00789191,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,10-Dec-10,Novo Nordisk A/S,Drug: sulphonylurea
NCT00781937,Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance,Metabolism and Nutrition Disorder|Obesity,Interventional,28-Nov-11,Novo Nordisk A/S,Drug: liraglutide
NCT00781937,Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance,Metabolism and Nutrition Disorder|Obesity,Interventional,28-Nov-11,Novo Nordisk A/S,Drug: placebo
NCT00781859,Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.,Vitreomacular Adhesion,Interventional,28-Jan-13,ThromboGenics,Drug: 125 µg Ocriplasmin
NCT00781859,Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.,Vitreomacular Adhesion,Interventional,28-Jan-13,ThromboGenics,Drug: Placebo
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,"Daiichi Sankyo, Inc.",Drug: warfarin tablets
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,"Daiichi Sankyo, Inc.",Drug: Edoxaban tablets (high dose regimen-60mg)
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,"Daiichi Sankyo, Inc.",Drug: Edoxaban tablets (low dose regimen-30mg)
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,"Daiichi Sankyo, Inc.",Drug: placebo warfarin
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,"Daiichi Sankyo, Inc.",Drug: placebo edoxaban
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,The TIMI Study Group,Drug: warfarin tablets
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,The TIMI Study Group,Drug: Edoxaban tablets (high dose regimen-60mg)
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,The TIMI Study Group,Drug: Edoxaban tablets (low dose regimen-30mg)
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,The TIMI Study Group,Drug: placebo warfarin
NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke|Atrial Fibrillation|Embolism,Interventional,25-Mar-15,The TIMI Study Group,Drug: placebo edoxaban
NCT00779402,PROvenge Treatment and Early Cancer Treatment,Prostate Cancer,Interventional,29-Jan-18,Dendreon,Other: Control
NCT00779402,PROvenge Treatment and Early Cancer Treatment,Prostate Cancer,Interventional,29-Jan-18,Dendreon,Biological: Sipuleucel-T
NCT00777153,Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma,Recurrent Glioblastoma,Interventional,21-Dec-12,AstraZeneca,Drug: Cediranib
NCT00777153,Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma,Recurrent Glioblastoma,Interventional,21-Dec-12,AstraZeneca,Drug: Lomustine Chemotherapy
NCT00777153,Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma,Recurrent Glioblastoma,Interventional,21-Dec-12,AstraZeneca,Drug: Placebo Cediranib
NCT00777023,Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.,Hot Flashes,Interventional,17-Feb-12,Depomed,Drug: Gabapentin Extended-Release (G-ER) 1200 mg
NCT00777023,Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.,Hot Flashes,Interventional,17-Feb-12,Depomed,Drug: Gabapentin Extended-Release (G-ER) 1800 mg
NCT00777023,Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.,Hot Flashes,Interventional,17-Feb-12,Depomed,Drug: Placebo
NCT00775203,"A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.",Major Depressive Disorder,Interventional,7-Apr-10,Labopharm Inc.,Drug: Trazodone Hydrochloride (HCl) Extended-Release Tablets
NCT00775203,"A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.",Major Depressive Disorder,Interventional,7-Apr-10,Labopharm Inc.,Drug: Placebo
NCT00774930,An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome,Carcinoid Syndrome,Interventional,9-Feb-16,Ipsen,Drug: Lanreotide
NCT00774930,An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome,Carcinoid Syndrome,Interventional,9-Feb-16,Ipsen,Drug: Placebo
NCT00775528,Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis,Cystic Fibrosis|Pancreatic Exocrine Insufficiency,Interventional,1-Oct-10,Solvay Pharmaceuticals,Drug: Pancrelipase Delayed Release
NCT00773279,"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Interventional,27-Mar-17,Novo Nordisk A/S,Device: FlexTouch®
NCT00773279,"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Interventional,27-Mar-17,Novo Nordisk A/S,Device: FlexPen®
NCT00772928,Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™,Diphtheria|Tetanus|Haemophilus Infection|Pertussis|Polio,Interventional,12-Feb-10,Sanofi,Biological: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
NCT00772382,Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia,Chronic Kidney Disease|Dialysis|Hyperphosphatemia,Interventional,12-May-14,Mitsubishi Tanabe Pharma Corporation,Drug: MCI-196
NCT00772109,Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults,Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Interventional,10-Aug-11,"Sanofi Pasteur, a Sanofi Company",Biological: Influenza Virus Vaccine USP Trivalent Types A and B
NCT00772109,Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults,Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Interventional,10-Aug-11,Sanofi,Biological: Influenza Virus Vaccine USP Trivalent Types A and B
NCT00788593,"A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)",Chronic Pancreatitis|Exocrine Pancreatic Insufficiency,Interventional,12-Mar-14,Forest Laboratories,Drug: Placebo
NCT00788593,"A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)",Chronic Pancreatitis|Exocrine Pancreatic Insufficiency,Interventional,12-Mar-14,Forest Laboratories,Drug: EUR-1008 (APT-1008) High Dose
NCT00788593,"A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)",Chronic Pancreatitis|Exocrine Pancreatic Insufficiency,Interventional,12-Mar-14,Forest Laboratories,Drug: EUR-1008 (APT-1008) Low Dose
NCT00764868,Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study,ADHD,Interventional,28-Mar-11,Shire,Drug: Lisdexamfetamine Dimesylate (LDX)
NCT00764790,Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children,Influenza,Interventional,27-Jul-10,GlaxoSmithKline,Biological: Fluarix
NCT00764790,Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children,Influenza,Interventional,27-Jul-10,GlaxoSmithKline,Biological: Fluzone
NCT00764504,Reverse Shoulder Prosthesis Study,Rotator Cuff Arthropathy|Failed Total Shoulder|Failed Hemi-arthroplasty,Interventional,19-Apr-11,"Encore Medical, L.P.",Device: Reverse Shoulder Prosthesis
NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",Diabetes Mellitus Type 2,Interventional,11-Oct-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",Diabetes Mellitus Type 2,Interventional,11-Oct-16,Sanofi,Drug: Placebo
NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",Diabetes Mellitus Type 2,Interventional,11-Oct-16,Sanofi,Device: Pen auto-injector
NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",Diabetes Mellitus Type 2,Interventional,11-Oct-16,Sanofi,Drug: Pioglitazone
NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",Diabetes Mellitus Type 2,Interventional,11-Oct-16,Sanofi,Drug: Metformin
NCT00763321,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Dec-13,"AbbVie (prior sponsor, Abbott)",Drug: ABT-712
NCT00763321,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Dec-13,"AbbVie (prior sponsor, Abbott)",Drug: Placebo
NCT00763321,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Dec-13,AbbVie,Drug: ABT-712
NCT00763321,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Dec-13,AbbVie,Drug: Placebo
NCT00762411,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo",Alzheimer's Disease,Interventional,25-Sep-14,Eli Lilly and Company,Drug: LY450139
NCT00762411,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo",Alzheimer's Disease,Interventional,25-Sep-14,Eli Lilly and Company,Drug: Placebo
NCT00762034,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,Interventional,28-Nov-13,Eli Lilly and Company,Drug: Pemetrexed
NCT00762034,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,Interventional,28-Nov-13,Eli Lilly and Company,Drug: Paclitaxel
NCT00762034,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,Interventional,28-Nov-13,Eli Lilly and Company,Drug: Carboplatin
NCT00762034,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,Interventional,28-Nov-13,Eli Lilly and Company,Biological: Bevacizumab
NCT00761774,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam",Epilepsy,Interventional,23-Apr-18,UCB Pharma,Drug: Brivaracetam
NCT00769314,Phase 3 Clinical Study for the Treatment of Cold Sore,Herpes Labialis,Interventional,21-Dec-12,Onxeo,Drug: Acyclovir Lauriad
NCT00769314,Phase 3 Clinical Study for the Treatment of Cold Sore,Herpes Labialis,Interventional,21-Dec-12,Onxeo,Drug: Placebo
NCT00761631,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years,Healthy Subjects,Interventional,10-Aug-11,Pfizer,Biological: 13 valent pneumococcal conjugate vaccine
NCT00761462,BAY 0 9867 Cipro Pediatric Use Study (QUIP),Infectious Diseases,Interventional,14-Apr-09,Bayer,Drug: Ciprofloxacin
NCT00761462,BAY 0 9867 Cipro Pediatric Use Study (QUIP),Infectious Diseases,Interventional,14-Apr-09,Bayer,Drug: Non-quinolone antibiotic
NCT00761267,"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis",Candidemia,Interventional,14-Sep-18,Pfizer,Drug: Anidulafungin
NCT00761267,"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis",Candidemia,Interventional,14-Sep-18,Pfizer,Drug: Fluconazole
NCT00761150,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Dec-13,"AbbVie (prior sponsor, Abbott)",Drug: ABT-712
NCT00761150,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Dec-13,"AbbVie (prior sponsor, Abbott)",Drug: Placebo
NCT00761150,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Dec-13,AbbVie,Drug: ABT-712
NCT00761150,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Chronic Low Back Pain,Interventional,23-Dec-13,AbbVie,Drug: Placebo
NCT00758758,Performance of the Hedrocel(R) Cervical Fusion Device,Symptomatic Cervical Disc Disease,Interventional,12-Aug-13,Zimmer Biomet,Device: Anterior Cervical Discectomy and Fusion
NCT00757588,Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin,Type 2 Diabetes,Interventional,13-Dec-11,AstraZeneca,"Drug: Saxagliptin, 5 mg + insulin"
NCT00757588,Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin,Type 2 Diabetes,Interventional,13-Dec-11,AstraZeneca,Drug: Placebo + insulin
NCT00755807,Duloxetine for Multiple Sclerosis Pain,Multiple Sclerosis,Interventional,9-Dec-11,Eli Lilly and Company,Drug: Duloxetine Hydrochloride (HCI)
NCT00755807,Duloxetine for Multiple Sclerosis Pain,Multiple Sclerosis,Interventional,9-Dec-11,Eli Lilly and Company,Drug: Placebo
NCT00755417,Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women,Hot Flashes,Interventional,7-Mar-12,Depomed,Drug: Gabapentin Extended-Release (G-ER) 1200 mg
NCT00755417,Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women,Hot Flashes,Interventional,7-Mar-12,Depomed,Drug: Gabapentin Extended-Release (G-ER) 1800 mg
NCT00755417,Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women,Hot Flashes,Interventional,7-Mar-12,Depomed,Drug: Placebo
NCT00756977,BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy,Colon Cancer,Interventional,9-Aug-13,Braintree Laboratories,Drug: BLI850
NCT00756977,BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy,Colon Cancer,Interventional,9-Aug-13,Braintree Laboratories,Drug: polyethylene glycol 3350 based bowel preparation
NCT00756548,BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy,Colon Cancer,Interventional,27-Dec-13,Braintree Laboratories,Drug: BLI850
NCT00756548,BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy,Colon Cancer,Interventional,27-Dec-13,Braintree Laboratories,Drug: polyethylene glycol 3350 based bowel preparation
NCT00754065,To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada),Contraception,Interventional,28-Aug-12,Bayer,"Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)"
NCT00754065,To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada),Contraception,Interventional,28-Aug-12,Bayer,Drug: Ortho Tri Cyclen Lo
NCT00753454,Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,14-Jun-12,UCB Pharma,Drug: Certolizumab pegol
NCT00753272,Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older,Influenza,Interventional,19-Jun-12,GlaxoSmithKline,Biological: GSK Bio's influenza vaccine GSK2186877A
NCT00753272,Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older,Influenza,Interventional,19-Jun-12,GlaxoSmithKline,Biological: Fluarix TM
NCT00772889,Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly,Influenza,Interventional,24-Apr-12,GlaxoSmithKline,Biological: Influenza vaccine GSK2186877A
NCT00772889,Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly,Influenza,Interventional,24-Apr-12,GlaxoSmithKline,Biological: GSK Biologicals' Fluarix™
NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Multiple Sclerosis,Interventional,26-Jun-13,Sanofi,Drug: Placebo
NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Multiple Sclerosis,Interventional,26-Jun-13,Sanofi,Drug: Teriflunomide
NCT00750139,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis,Tinea Pedis|Athlete's Foot,Interventional,29-Jan-13,"Merz North America, Inc.",Drug: NAFT-500
NCT00750139,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis,Tinea Pedis|Athlete's Foot,Interventional,29-Jan-13,"Merz North America, Inc.",Drug: Placebo 2-weeks
NCT00750139,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis,Tinea Pedis|Athlete's Foot,Interventional,29-Jan-13,"Merz North America, Inc.",Drug: Naftin 1%
NCT00750139,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis,Tinea Pedis|Athlete's Foot,Interventional,29-Jan-13,"Merz North America, Inc.",Drug: Placebo 4-weeks
NCT00750152,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris,Tinea Cruris|Jock Itch,Interventional,13-Mar-12,"Merz North America, Inc.",Drug: NAFT-500
NCT00750152,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris,Tinea Cruris|Jock Itch,Interventional,13-Mar-12,"Merz North America, Inc.",Drug: Placebo
NCT00748098,Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance,Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,18-May-11,"XenoPort, Inc.",Drug: GSK1838262 Extended Release Tablets
NCT00748098,Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance,Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,18-May-11,"XenoPort, Inc.",Drug: Placebo
NCT00753688,Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy,"Sarcoma, Soft Tissue",Interventional,21-Dec-11,GlaxoSmithKline,Drug: PAZOPANIB
NCT00753688,Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy,"Sarcoma, Soft Tissue",Interventional,21-Dec-11,GlaxoSmithKline,Drug: Placebo
NCT00745290,A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty,Postoperative Pain,Interventional,6-Aug-13,"Pacira Pharmaceuticals, Inc",Drug: Bupivacaine HCl
NCT00745290,A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty,Postoperative Pain,Interventional,6-Aug-13,"Pacira Pharmaceuticals, Inc",Drug: SKY0402
NCT00747227,Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL),Cataract,Interventional,11-Nov-11,Abbott Medical Optics,Device: modified light transmission intraocular lens
NCT00747227,Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL),Cataract,Interventional,11-Nov-11,Abbott Medical Optics,Device: monofocal acrylic intraocular lens
NCT00744848,Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy,Hemorrhoids,Interventional,6-Aug-13,"Pacira Pharmaceuticals, Inc",Drug: Bupivacaine HCl
NCT00744848,Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy,Hemorrhoids,Interventional,6-Aug-13,"Pacira Pharmaceuticals, Inc",Drug: SKY0402
NCT00744497,Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer,Prostatic Neoplasms,Interventional,6-Feb-14,Bristol-Myers Squibb,Drug: Placebo
NCT00744497,Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer,Prostatic Neoplasms,Interventional,6-Feb-14,Bristol-Myers Squibb,Drug: Dasatinib
NCT00744497,Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer,Prostatic Neoplasms,Interventional,6-Feb-14,Bristol-Myers Squibb,Drug: Docetaxel
NCT00744497,Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer,Prostatic Neoplasms,Interventional,6-Feb-14,Bristol-Myers Squibb,Drug: Prednisone
NCT00743652,Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.,Pneumococcal Disease|13-valent Pneumococcal Vaccine,Interventional,10-Feb-12,Pfizer,Biological: 13-valent Pneumococcal Conjugate Vaccine
NCT00742391,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Actinic Keratoses,Interventional,21-Mar-12,Peplin,Drug: PEP005 (ingenol mebutate) Gel
NCT00742391,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Actinic Keratoses,Interventional,21-Mar-12,Peplin,Drug: Vehicle gel
NCT00740792,A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,7-Sep-12,Meda Pharmaceuticals,Drug: azelastine HCl/fluticasone propionate
NCT00740792,A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,7-Sep-12,Meda Pharmaceuticals,Drug: azelastine Hcl
NCT00740792,A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,7-Sep-12,Meda Pharmaceuticals,Drug: fluticasone propionate
NCT00740792,A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,7-Sep-12,Meda Pharmaceuticals,Drug: placebo
NCT00740051,"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","Diabetes Mellitus, Type 2",Interventional,26-Oct-11,Boehringer Ingelheim,Drug: Linagliptin
NCT00740051,"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","Diabetes Mellitus, Type 2",Interventional,26-Oct-11,Boehringer Ingelheim,Drug: Linagliptin Placebo
NCT00740051,"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","Diabetes Mellitus, Type 2",Interventional,26-Oct-11,Boehringer Ingelheim,Drug: Glimepiride
NCT01009047,An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia,Schizophrenia,Interventional,21-Jun-13,"Janssen Research & Development, LLC",Drug: Paliperidone extended release (ER)
NCT01009047,An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia,Schizophrenia,Interventional,21-Jun-13,"Janssen Research & Development, LLC",Drug: Aripiprazole
NCT00738062,Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Neurogenic Orthostatic Hypotension|Non-Diabetic Autonomic Neuropathy|Multiple System Atrophy|Dopamine Beta Hydroxylase Deficiency,Interventional,16-May-14,Chelsea Therapeutics,Drug: Droxidopa
NCT00738062,Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Neurogenic Orthostatic Hypotension|Non-Diabetic Autonomic Neuropathy|Multiple System Atrophy|Dopamine Beta Hydroxylase Deficiency,Interventional,16-May-14,Chelsea Therapeutics,Drug: Placebo
NCT00737672,GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis,Renal Failure|Hemodialysis,Interventional,21-Oct-14,W.L.Gore & Associates,Device: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface
NCT00737672,GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis,Renal Failure|Hemodialysis,Interventional,21-Oct-14,W.L.Gore & Associates,Procedure: Percutaneous Transluminal Angioplasty
NCT00735462,Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts,Genital Warts,Interventional,20-Jul-11,"Graceway Pharmaceuticals, LLC",Drug: 2.5% imiquimod cream
NCT00735462,Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts,Genital Warts,Interventional,20-Jul-11,"Graceway Pharmaceuticals, LLC",Drug: 3.75% imiquimod cream
NCT00735462,Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts,Genital Warts,Interventional,20-Jul-11,"Graceway Pharmaceuticals, LLC",Drug: Placebo cream
NCT00736099,Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM,"Diabetes Mellitus, Type 2",Interventional,8-Mar-12,Boehringer Ingelheim,Drug: linagliptine 5 mg
NCT00736099,Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM,"Diabetes Mellitus, Type 2",Interventional,8-Mar-12,Boehringer Ingelheim,Drug: linagliptine 5 mg and pioglitazone 30 mg
NCT00735397,Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Epilepsy,Interventional,26-Jan-16,Eisai Inc.,Drug: perampanel
NCT00735371,Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,23-Feb-10,Shire,Drug: LDX 30 mg
NCT00735371,Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,23-Feb-10,Shire,Drug: LDX 50 mg
NCT00735371,Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,23-Feb-10,Shire,Drug: LDX 70 mg
NCT00735371,Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder (ADHD),Interventional,23-Feb-10,Shire,Drug: Placebo
NCT00734578,Efficacy and Safety of SPD503 in Combination With Psychostimulants,ADHD,Interventional,23-Nov-10,Shire,Drug: SPD503-AM
NCT00734578,Efficacy and Safety of SPD503 in Combination With Psychostimulants,ADHD,Interventional,23-Nov-10,Shire,Drug: SPD503-PM
NCT00734578,Efficacy and Safety of SPD503 in Combination With Psychostimulants,ADHD,Interventional,23-Nov-10,Shire,Drug: Placebo
NCT00732615,Use of NPSP558 in the Treatment of Hypoparathyroidism,Hypoparathyroidism,Interventional,6-Mar-15,Shire,Drug: Placebo
NCT00732615,Use of NPSP558 in the Treatment of Hypoparathyroidism,Hypoparathyroidism,Interventional,6-Mar-15,Shire,Drug: NPSP558
NCT00731679,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),Non-Constipation Irritable Bowel Syndrome,Interventional,28-Jul-14,"Bausch Health Americas, Inc.",Drug: Rifaximin
NCT00731679,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),Non-Constipation Irritable Bowel Syndrome,Interventional,28-Jul-14,"Bausch Health Americas, Inc.",Drug: Placebo
NCT00727857,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,Diabetes Mellitus,Interventional,9-Mar-10,Takeda,Drug: Pioglitazone and metformin
NCT00727857,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,Diabetes Mellitus,Interventional,9-Mar-10,Takeda,Drug: Pioglitazone
NCT00727857,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,Diabetes Mellitus,Interventional,9-Mar-10,Takeda,Drug: Metformin
NCT00996216,Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390,Hepatitis C,Interventional,6-Dec-13,GlaxoSmithKline,Drug: Eltrombopag
NCT00996216,Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390,Hepatitis C,Interventional,6-Dec-13,GlaxoSmithKline,Drug: Antiviral therapy
NCT00770211,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines,Moderate to Severe Glabellar Frown Lines,Interventional,13-Sep-11,Merz Pharmaceuticals GmbH,Drug: IncobotulinumtoxinA (Xeomin) (20 Units)
NCT00770211,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines,Moderate to Severe Glabellar Frown Lines,Interventional,13-Sep-11,Merz Pharmaceuticals GmbH,Drug: Placebo
NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),Multiple Sclerosis,Interventional,10-Oct-13,EMD Serono,Drug: Cladribine
NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),Multiple Sclerosis,Interventional,10-Oct-13,EMD Serono,Drug: Placebo
NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),Multiple Sclerosis,Interventional,10-Oct-13,EMD Serono,Drug: Rebif® new formulation (RNF)
NCT00724815,The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine,Migraine Disorders,Interventional,7-May-13,NuPathe Inc.,Drug: NP101 - Sumatriptan iontophoretic transdermal patch
NCT00724815,The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine,Migraine Disorders,Interventional,7-May-13,NuPathe Inc.,Drug: Placebo
NCT00724815,The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine,Migraine Disorders,Interventional,7-May-13,Teva Pharmaceutical Industries,Drug: NP101 - Sumatriptan iontophoretic transdermal patch
NCT00724815,The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine,Migraine Disorders,Interventional,7-May-13,Teva Pharmaceutical Industries,Drug: Placebo
NCT00724126,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),Non-Constipation Irritable Bowel Syndrome,Interventional,28-Jul-14,"Bausch Health Americas, Inc.",Drug: Rifaximin
NCT00724126,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),Non-Constipation Irritable Bowel Syndrome,Interventional,28-Jul-14,"Bausch Health Americas, Inc.",Drug: Placebo
NCT00723450,Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients,Bipolar Disorder,Interventional,4-Jun-14,GlaxoSmithKline,Drug: lamictal
NCT00723190,"Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)",Attention Deficit Hyperactivity Disorder,Interventional,27-Feb-12,Shionogi,Drug: CLONICEL (Clonidine HCl sustained release)
NCT00723190,"Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)",Attention Deficit Hyperactivity Disorder,Interventional,27-Feb-12,Shionogi Inc.,Drug: CLONICEL (Clonidine HCl sustained release)
NCT00765362,Mobile - Bearing Knee Study,Inflammatory Tissue Disorder|Osteoarthritis|Avascular Necrosis|Post-traumatic Arthritis|Secondary Arthritis,Interventional,19-Apr-11,"Encore Medical, L.P.",Device: Encore Mobile-Bearing Knee
NCT00720798,An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies,Rheumatoid Arthritis,Interventional,30-Sep-14,Hoffmann-La Roche,Drug: Tocilizumab
NCT00720798,An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies,Rheumatoid Arthritis,Interventional,30-Sep-14,Hoffmann-La Roche,Drug: Disease-modifying anti-rheumatic drugs
NCT00720798,An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies,Rheumatoid Arthritis,Interventional,30-Sep-14,Hoffmann-La Roche,Drug: Non-steroidal anti-inflammatory drugs
NCT00720798,An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies,Rheumatoid Arthritis,Interventional,30-Sep-14,Hoffmann-La Roche,Drug: Oral corticosteroids
NCT00824473,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,28-Jan-10,Meda Pharmaceuticals,Drug: Placebo
NCT00824473,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,28-Jan-10,Meda Pharmaceuticals,Drug: 0.15% azelastine hydrochloride
NCT00720382,A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis,Perennial Allergic Rhinitis,Interventional,15-Jan-10,Meda Pharmaceuticals,Drug: 0.15% azelastine hydrochloride
NCT00720382,A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis,Perennial Allergic Rhinitis,Interventional,15-Jan-10,Meda Pharmaceuticals,Drug: Mometasone furoate
NCT00720278,A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,27-Oct-09,Meda Pharmaceuticals,Drug: 0.15% azelastine hydrochloride 1644 mcg daily
NCT00720278,A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,27-Oct-09,Meda Pharmaceuticals,Drug: 0.1% azelastine hydrochloride 1096 mcg daily
NCT00720278,A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,27-Oct-09,Meda Pharmaceuticals,Drug: Placebo
NCT00719862,A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,28-Jan-10,Meda Pharmaceuticals,Drug: Placebo nasal spray
NCT00719862,A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,28-Jan-10,Meda Pharmaceuticals,Drug: 0.15% azelastine hydrochloride Nasal Spray
NCT00717236,Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,6-May-11,UCB Pharma,Drug: Certolizumab pegol (CZP)
NCT00717236,Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,6-May-11,UCB Pharma,Other: Placebo
NCT00713310,Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis,Ulcerative Colitis,Interventional,4-Apr-12,Warner Chilcott,Drug: Asacol 400 mg
NCT00712920,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies,Perennial Allergic Rhinitis,Interventional,15-Jan-10,Meda Pharmaceuticals,Drug: 0.15% azelastine hydrochloride
NCT00712920,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies,Perennial Allergic Rhinitis,Interventional,15-Jan-10,Meda Pharmaceuticals,Drug: 0.1% azelastine hydrochloride
NCT00712920,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies,Perennial Allergic Rhinitis,Interventional,15-Jan-10,Meda Pharmaceuticals,Drug: Placebo
NCT00718861,3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs,Post-menopausal Osteoporosis,Interventional,30-Dec-13,Novartis Pharmaceuticals,Drug: Placebo
NCT00718861,3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs,Post-menopausal Osteoporosis,Interventional,30-Dec-13,Novartis Pharmaceuticals,Drug: Zoledronic acid
NCT00718861,3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs,Post-menopausal Osteoporosis,Interventional,30-Dec-13,Novartis,Drug: Placebo
NCT00718861,3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs,Post-menopausal Osteoporosis,Interventional,30-Dec-13,Novartis,Drug: Zoledronic acid
NCT00712166,"Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa",Cystic Fibrosis|Lung Infection|Pseudomonas Aeruginosa,Interventional,20-Dec-10,Gilead Sciences,Drug: AZLI 75 mg three times daily (TID)
NCT00712166,"Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa",Cystic Fibrosis|Lung Infection|Pseudomonas Aeruginosa,Interventional,20-Dec-10,Gilead Sciences,Drug: Placebo three times daily (TID)
NCT00713648,Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Interventional,14-Jul-14,Novo Nordisk A/S,Drug: catridecacog
NCT00709956,Iloprost Power 15 in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,26-Oct-12,Actelion,Drug: iloprost (5 µg)
NCT00709956,Iloprost Power 15 in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,26-Oct-12,Actelion,Drug: placebo
NCT00709852,Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging,Diagnostic Imaging|Central Nervous System Diseases,Interventional,6-Mar-12,Bayer,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)"
NCT00709852,Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging,Diagnostic Imaging|Central Nervous System Diseases,Interventional,6-Mar-12,Bayer,Drug: Gadoteridol (ProHance)
NCT00709098,Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,29-Oct-12,Actelion,Drug: iloprost
NCT00708435,Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy,Blood Coagulation Disorders|Acute Major Bleeding,Interventional,13-Aug-13,CSL Behring,Biological: Beriplex® P/N (Kcentra)
NCT00708435,Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy,Blood Coagulation Disorders|Acute Major Bleeding,Interventional,13-Aug-13,CSL Behring,Biological: Fresh frozen plasma
NCT00708162,"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",HIV Infection,Interventional,6-Nov-14,Gilead Sciences,Drug: Elvitegravir
NCT00708162,"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",HIV Infection,Interventional,6-Nov-14,Gilead Sciences,Drug: Raltegravir
NCT00708162,"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",HIV Infection,Interventional,6-Nov-14,Gilead Sciences,Drug: EVG placebo
NCT00708162,"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",HIV Infection,Interventional,6-Nov-14,Gilead Sciences,Drug: RAL placebo
NCT00708162,"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",HIV Infection,Interventional,6-Nov-14,Gilead Sciences,Drug: Background regimen
NCT00707993,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,Diabetes Mellitus,Interventional,24-May-13,Takeda,Drug: Alogliptin
NCT00707993,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,Diabetes Mellitus,Interventional,24-May-13,Takeda,Drug: Glipizide
NCT00706654,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,14-Aug-13,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole depot 300 or 400 mg
NCT00706654,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,14-Aug-13,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole 10-30 mg orally
NCT00706654,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,14-Aug-13,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole depot 25 or 50 mg
NCT00706654,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,14-Aug-13,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo depot
NCT00706654,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,14-Aug-13,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo tablets
NCT00705783,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,19-Jul-13,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole depot
NCT00705783,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Schizophrenia,Interventional,19-Jul-13,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo depot
NCT00700817,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","Diabetes|Diabetes Mellitus, Type 2",Interventional,4-Aug-10,Novo Nordisk A/S,Drug: liraglutide
NCT00700817,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","Diabetes|Diabetes Mellitus, Type 2",Interventional,4-Aug-10,Novo Nordisk A/S,Drug: sitagliptin
NCT00700817,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","Diabetes|Diabetes Mellitus, Type 2",Interventional,4-Aug-10,Novo Nordisk A/S,Drug: metformin
NCT00702650,A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations,Hypogonadism,Interventional,5-Jan-11,Eli Lilly and Company,Drug: Testosterone MD-Lotion
NCT00699972,Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Refractory Partial Seizures,Interventional,5-Feb-13,Eisai Inc.,Drug: E2007 (perampanel)
NCT00699972,Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Refractory Partial Seizures,Interventional,5-Feb-13,Eisai Inc.,Drug: Placebo
NCT00699582,To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Refractory Partial Seizures,Interventional,22-Nov-12,Eisai Inc.,Drug: E2007 (perampanel)
NCT00699582,To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Refractory Partial Seizures,Interventional,22-Nov-12,Eisai Inc.,Drug: Placebo
NCT00696436,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Azilsartan medoxomil
NCT00696436,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Valsartan
NCT00696436,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Olmesartan
NCT00696436,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Placebo
NCT00696384,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Hypertension,Interventional,4-Jan-12,Takeda,Drug: Azilsartan medoxomil
NCT00696384,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Hypertension,Interventional,4-Jan-12,Takeda,"Drug: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications."
NCT00696384,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Hypertension,Interventional,4-Jan-12,Takeda,Drug: Placebo
NCT00696241,Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Azilsartan medoxomil and olmesartan
NCT00696241,Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Olmesartan
NCT00696241,Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Placebo
NCT00695955,One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Azilsartan medoxomil with or without add-on chlorthalidone
NCT00695955,One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide
NCT00736840,BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis,Chronic Liver Disease,Interventional,16-Mar-12,Exalenz Bioscience LTD.,Device: c13 methacetin solution with breath analyzer
NCT00692770,Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM),"Carcinoma, Hepatocellular",Interventional,1-Dec-14,Bayer,"Drug: Nexavar (Sorafenib, BAY43-9006)"
NCT00692770,Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM),"Carcinoma, Hepatocellular",Interventional,1-Dec-14,Bayer,Drug: Placebo
NCT00689936,"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma",Multiple Myeloma,Interventional,11-Aug-17,Celgene,Drug: Lenalidomide and low-dose dexamethasone
NCT00689936,"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma",Multiple Myeloma,Interventional,11-Aug-17,Celgene,Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
NCT00689936,"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma",Multiple Myeloma,Interventional,11-Aug-17,Celgene,"Drug: Melphalan, Prednisone and Thalidomide"
NCT00688688,Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"Urinary Bladder, Overactive",Interventional,19-Oct-12,Astellas Pharma Inc,Drug: Mirabegron
NCT00688688,Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"Urinary Bladder, Overactive",Interventional,19-Oct-12,Astellas Pharma Inc,Drug: Tolterodine
NCT00688688,Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"Urinary Bladder, Overactive",Interventional,19-Oct-12,Astellas Pharma Inc,Drug: Placebo to Mirabegron
NCT00688688,Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"Urinary Bladder, Overactive",Interventional,19-Oct-12,Astellas Pharma Inc,Drug: Placebo to Tolterodine
NCT00688064,Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris,Severe Acne Vulgaris,Interventional,31-Mar-10,Galderma,Drug: Adapalene BPO Gel associated with Doxycyline Hyclate
NCT00688064,Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris,Severe Acne Vulgaris,Interventional,31-Mar-10,Galderma,Drug: Vehicle Gel associated with Doxycycline Hyclate
NCT00687908,Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance,Acne,Interventional,24-Sep-10,Galderma,Drug: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
NCT00687908,Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance,Acne,Interventional,24-Sep-10,Galderma,Drug: Vehicle Gel
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,26-Nov-15,Eli Lilly and Company,Drug: Pemetrexed
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,26-Nov-15,Eli Lilly and Company,Drug: Cisplatin
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,26-Nov-15,Eli Lilly and Company,Drug: Etoposide
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,26-Nov-15,Eli Lilly and Company,Drug: Vinorelbine
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,26-Nov-15,Eli Lilly and Company,Drug: Paclitaxel
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,26-Nov-15,Eli Lilly and Company,Drug: Carboplatin
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Interventional,26-Nov-15,Eli Lilly and Company,Radiation: Thoracic Radiation Therapy (TRT)
NCT00684177,Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL),"Skin Infections, Bacterial",Interventional,4-Aug-10,GlaxoSmithKline,"Drug: Retapamulin Ointment, 1%"
NCT00684177,Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL),"Skin Infections, Bacterial",Interventional,4-Aug-10,GlaxoSmithKline,Drug: Placebo ointment
NCT00683878,Add-on to Thiazolidinedione (TZD) Failures,Type 2 Diabetes,Interventional,23-Feb-17,AstraZeneca,Drug: Dapagliflozin
NCT00683878,Add-on to Thiazolidinedione (TZD) Failures,Type 2 Diabetes,Interventional,23-Feb-17,AstraZeneca,Drug: Placebo matching Dapagliflozin
NCT00683878,Add-on to Thiazolidinedione (TZD) Failures,Type 2 Diabetes,Interventional,23-Feb-17,AstraZeneca,Drug: Thiazolidinedione (Pioglitazone)
NCT00683878,Add-on to Thiazolidinedione (TZD) Failures,Type 2 Diabetes,Interventional,23-Feb-17,"Astra Zeneca, Bristol-Myers Squibb",Drug: Dapagliflozin
NCT00683878,Add-on to Thiazolidinedione (TZD) Failures,Type 2 Diabetes,Interventional,23-Feb-17,"Astra Zeneca, Bristol-Myers Squibb",Drug: Placebo matching Dapagliflozin
NCT00683878,Add-on to Thiazolidinedione (TZD) Failures,Type 2 Diabetes,Interventional,23-Feb-17,"Astra Zeneca, Bristol-Myers Squibb",Drug: Thiazolidinedione (Pioglitazone)
NCT00690820,Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF),Cystic Fibrosis|Pancreatic Exocrine Insufficiency,Interventional,10-Mar-10,Solvay Pharmaceuticals,Drug: Pancrelipase Delayed Release
NCT00690820,Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF),Cystic Fibrosis|Pancreatic Exocrine Insufficiency,Interventional,10-Mar-10,Solvay Pharmaceuticals,Drug: Placebo Comparator
NCT00683800,Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women,Vasomotor Symptoms,Interventional,17-Aug-11,Pfizer,Drug: desvenlafaxine succinate (DVS) SR
NCT00683800,Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women,Vasomotor Symptoms,Interventional,17-Aug-11,Pfizer,Drug: Placebo
NCT00683657,Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone,Type 2 Diabetes,Interventional,10-Mar-10,AstraZeneca,Drug: Saxagliptin
NCT00683657,Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone,Type 2 Diabetes,Interventional,10-Mar-10,AstraZeneca,Drug: Placebo
NCT00690430,Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease,Symptomatic Refractory Resistant Carcinoid Disease,Interventional,30-Jul-13,Novartis Pharmaceuticals,Drug: Pasireotide
NCT00690430,Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease,Symptomatic Refractory Resistant Carcinoid Disease,Interventional,30-Jul-13,Novartis Pharmaceuticals,Drug: Octreotide
NCT00690430,Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease,Symptomatic Refractory Resistant Carcinoid Disease,Interventional,30-Jul-13,Novartis,Drug: Pasireotide
NCT00690430,Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease,Symptomatic Refractory Resistant Carcinoid Disease,Interventional,30-Jul-13,Novartis,Drug: Octreotide
NCT00680017,30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease,Dyslipidemia|Kidney Disease,Interventional,16-Jul-12,AstraZeneca,Drug: ABT-335 plus rosuvastatin
NCT00680017,30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease,Dyslipidemia|Kidney Disease,Interventional,16-Jul-12,AstraZeneca,Drug: Rosuvastatin
NCT00679432,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,Ulcerative Colitis,Interventional,1-Aug-14,"Bausch Health Americas, Inc.","Procedure: Blood sampling, endoscopy"
NCT00679432,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,Ulcerative Colitis,Interventional,1-Aug-14,"Bausch Health Americas, Inc.",Drug: budesonide-MMX® 6 mg
NCT00679432,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,Ulcerative Colitis,Interventional,1-Aug-14,"Bausch Health Americas, Inc.",Drug: budesonide-MMX® 9 mg
NCT00679432,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,Ulcerative Colitis,Interventional,1-Aug-14,"Bausch Health Americas, Inc.",Drug: Placebo
NCT00679432,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,Ulcerative Colitis,Interventional,1-Aug-14,"Bausch Health Americas, Inc.",Drug: Asacol® 400 mg
NCT00678886,Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1,"Diabetes Mellitus, Type 1",Interventional,3-Oct-17,GlaxoSmithKline,Biological: otelixizumab infusion plus physician determined standard of care
NCT00678886,Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1,"Diabetes Mellitus, Type 1",Interventional,3-Oct-17,GlaxoSmithKline,Biological: placebo infusion plus physician determined standard of care
NCT00678886,Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1,"Diabetes Mellitus, Type 1",Interventional,3-Oct-17,Juvenile Diabetes Research Foundation,Biological: otelixizumab infusion plus physician determined standard of care
NCT00678886,Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1,"Diabetes Mellitus, Type 1",Interventional,3-Oct-17,Juvenile Diabetes Research Foundation,Biological: placebo infusion plus physician determined standard of care
NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Interventional,27-Mar-12,Pfizer,Drug: Axitinib (AG-013736)
NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Interventional,27-Mar-12,Pfizer,Drug: Sorafenib
NCT00677807,"Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",COPD,Interventional,18-Aug-11,Novartis,Drug: Indacaterol
NCT00677807,"Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",COPD,Interventional,18-Aug-11,Novartis,Drug: Placebo
NCT00680186,Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE),Thromboembolism,Interventional,14-Jun-12,Boehringer Ingelheim,Drug: Warfarin
NCT00680186,Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE),Thromboembolism,Interventional,14-Jun-12,Boehringer Ingelheim,Drug: Dabigatran etexilate
NCT00674739,Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts,Genital Warts,Interventional,18-May-11,"Graceway Pharmaceuticals, LLC",Drug: Imiquimod
NCT00674739,Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts,Genital Warts,Interventional,18-May-11,"Graceway Pharmaceuticals, LLC",Drug: 3.75% imiquimod cream
NCT00674739,Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts,Genital Warts,Interventional,18-May-11,"Graceway Pharmaceuticals, LLC",Drug: placebo cream
NCT00671879,Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Lower Back Pain,Interventional,21-Nov-12,Meda Pharmaceuticals,Drug: Carisoprodol SR 700 mg
NCT00671879,Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Lower Back Pain,Interventional,21-Nov-12,Meda Pharmaceuticals,Drug: Carisoprodol SR 500 mg
NCT00671879,Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Lower Back Pain,Interventional,21-Nov-12,Meda Pharmaceuticals,Drug: Placebo
NCT00671502,A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Lower Back Pain,Interventional,9-Nov-11,Meda Pharmaceuticals,Drug: Carisoprodol SR
NCT00671502,A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Lower Back Pain,Interventional,9-Nov-11,Meda Pharmaceuticals,Drug: Placebo
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,Breast Cancer|Melanoma,Interventional,3-Jun-13,Navidea Biopharmaceuticals,Drug: Lymphoseek
NCT00670306,Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH),Benign Prostatic Hypertrophy,Interventional,19-Jan-11,AEterna Zentaris,Drug: Cetrorelix Pamoate
NCT00669331,Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis,Bronchiectasis,Interventional,29-Apr-16,Pharmaxis,Drug: Inhaled mannitol
NCT00669331,Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis,Bronchiectasis,Interventional,29-Apr-16,Pharmaxis,Drug: Matched control
NCT00668525,Escitalopram in Adult Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-May-10,Forest Laboratories,Drug: Escitalopram
NCT00668525,Escitalopram in Adult Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,6-May-10,Forest Laboratories,Drug: Placebo
NCT00674661,Corneal Collagen Cross-Linking for Ectasia (CXL),Ectasia,Interventional,27-Jan-17,"Avedro, Inc.",Drug: riboflavin ophthalmic solution
NCT00674661,Corneal Collagen Cross-Linking for Ectasia (CXL),Ectasia,Interventional,27-Jan-17,"Avedro, Inc.",Device: UVA Irradiation
NCT00683592,"Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)",Major Depressive Disorder,Interventional,27-Oct-10,Forest Laboratories,Drug: vilazodone
NCT00683592,"Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)",Major Depressive Disorder,Interventional,27-Oct-10,Forest Laboratories,Drug: placebo
NCT00667459,Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD,Cervical Degenerative Disc Disease,Interventional,22-Sep-14,Medtronic Spinal and Biologics,Device: PRESTIGE® LP Cervical Disc
NCT00667459,Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD,Cervical Degenerative Disc Disease,Interventional,22-Sep-14,Medtronic Spinal and Biologics,Device: ATLANTIS Anterior Cervical Plate
NCT00667446,Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty,Precocious|Leuprolide Acetate|Luteinizing Hormone (LH)|Gonadotrophin-releasing Hormone Agonist (GnRHa)|Tanner Staging|Depot Formulation|Suppression of LH|Central Precocious Puberty (CPP)|Gonadotrophin-releasing Hormone (GnRH)|Lupron|GnRH Analog|Pediatrics Central Precocious Puberty,Interventional,10-Dec-13,"AbbVie (prior sponsor, Abbott)",Drug: Leuprolide Acetate 3 Month Depot
NCT00667446,Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty,Precocious|Leuprolide Acetate|Luteinizing Hormone (LH)|Gonadotrophin-releasing Hormone Agonist (GnRHa)|Tanner Staging|Depot Formulation|Suppression of LH|Central Precocious Puberty (CPP)|Gonadotrophin-releasing Hormone (GnRH)|Lupron|GnRH Analog|Pediatrics Central Precocious Puberty,Interventional,10-Dec-13,AbbVie,Drug: Leuprolide Acetate 3 Month Depot
NCT00666328,Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE),Hypertension|Hemorrhage,Interventional,8-Apr-13,The Medicines Company,Drug: clevidipine
NCT00666263,Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy,Multifocal Motor Neuropathy,Interventional,13-Mar-13,Baxalta now part of Shire,"Biological: Immune Globulin Intravenous (human), 10%"
NCT00666263,Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy,Multifocal Motor Neuropathy,Interventional,13-Mar-13,Baxalta now part of Shire,Biological: 0.25% human albumin solution (Placebo)
NCT00666263,Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy,Multifocal Motor Neuropathy,Interventional,13-Mar-13,Shire,"Biological: Immune Globulin Intravenous (human), 10%"
NCT00666263,Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy,Multifocal Motor Neuropathy,Interventional,13-Mar-13,Shire,Biological: 0.25% human albumin solution (Placebo)
NCT00663702,Phase IIIB Switching From Intravenous to Subcutaneous Study,"Arthritis, Rheumatoid",Interventional,26-Mar-12,Bristol-Myers Squibb,Drug: Abatacept
NCT01345929,"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis",Complicated Urinary Tract Infection|Pyelonephritis,Interventional,15-Jan-15,Cubist Pharmaceuticals LLC,Drug: CXA-201
NCT01345929,"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis",Complicated Urinary Tract Infection|Pyelonephritis,Interventional,15-Jan-15,Cubist Pharmaceuticals LLC,Drug: Levofloxacin
NCT00662909,A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"Urinary Bladder, Overactive",Interventional,17-Oct-12,Astellas Pharma Inc,Drug: Mirabegron
NCT00662909,A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,"Urinary Bladder, Overactive",Interventional,17-Oct-12,Astellas Pharma Inc,Drug: Placebo
NCT00662558,A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain,Low Back Pain,Interventional,23-Nov-09,Pfizer,Drug: celecoxib
NCT00662558,A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain,Low Back Pain,Interventional,23-Nov-09,Pfizer,Drug: tramadol HCL
NCT00660179,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,5-May-14,Actelion,Drug: macitentan (ACT-064992)
NCT00660179,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,5-May-14,Actelion,Drug: placebo
NCT01343004,Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women,Osteoporosis|Postmenopausal Osteoporosis,Interventional,1-Mar-17,"Radius Health, Inc.",Drug: Placebo
NCT01343004,Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women,Osteoporosis|Postmenopausal Osteoporosis,Interventional,1-Mar-17,"Radius Health, Inc.",Drug: BA058 80 mcg
NCT01343004,Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women,Osteoporosis|Postmenopausal Osteoporosis,Interventional,1-Mar-17,"Radius Health, Inc.",Drug: teriparatide
NCT00767806,A Study for Patient With Chronic Low Back Pain,Chronic Low Back Pain,Interventional,18-Oct-10,Eli Lilly and Company,Drug: Duloxetine
NCT00767806,A Study for Patient With Chronic Low Back Pain,Chronic Low Back Pain,Interventional,18-Oct-10,Eli Lilly and Company,Drug: Placebo
NCT00658632,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,23-Jun-15,Eisai Inc.,Drug: Rabeprazole sodium
NCT00658632,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,23-Jun-15,Eisai Inc.,Drug: Esomeprazole
NCT00658567,A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Parkinson's Disease Psychosis,Interventional,9-Sep-14,ACADIA Pharmaceuticals Inc.,Drug: Pimavanserin tartrate (ACP-103)
NCT00657540,Black Widow Spider Antivenin for Patients With Systemic Latrodectism,Latrodectism,Interventional,18-Sep-17,Instituto Bioclon S.A. de C.V.,Drug: Analatro
NCT00657540,Black Widow Spider Antivenin for Patients With Systemic Latrodectism,Latrodectism,Interventional,18-Sep-17,Instituto Bioclon S.A. de C.V.,Drug: Saline
NCT00657540,Black Widow Spider Antivenin for Patients With Systemic Latrodectism,Latrodectism,Interventional,18-Sep-17,Rare Disease Therapeutics Inc.,Drug: Analatro
NCT00657540,Black Widow Spider Antivenin for Patients With Systemic Latrodectism,Latrodectism,Interventional,18-Sep-17,Rare Disease Therapeutics Inc.,Drug: Saline
NCT00658788,"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis",Psoriasis,Interventional,27-Aug-14,"Galderma Laboratories, L.P.",Drug: clobetasol propionate spray 0.05%
NCT00658788,"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis",Psoriasis,Interventional,27-Aug-14,"Galderma Laboratories, L.P.",Drug: calcitriol ointment
NCT00656136,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),"Carcinoma, Non-Small-Cell Lung",Interventional,27-Nov-13,Boehringer Ingelheim,Drug: placebo
NCT00656136,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),"Carcinoma, Non-Small-Cell Lung",Interventional,27-Nov-13,Boehringer Ingelheim,Drug: BIBW 2992
NCT02646566,Study of APD421 as PONV Treatment (Prior Prophylaxis),Postoperative Nausea and Vomiting,Interventional,18-Dec-18,Acacia Pharma Ltd,Drug: APD421
NCT02646566,Study of APD421 as PONV Treatment (Prior Prophylaxis),Postoperative Nausea and Vomiting,Interventional,18-Dec-18,Acacia Pharma Ltd,Drug: Placebo
NCT00662675,A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency,Exocrine Pancreatic Insufficiency|Steatorrhea|Malabsorption Syndromes|Cystic Fibrosis,Interventional,17-Mar-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Drug: Pancrease MT 10.5, or MT 21"
NCT00662675,A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency,Exocrine Pancreatic Insufficiency|Steatorrhea|Malabsorption Syndromes|Cystic Fibrosis,Interventional,17-Mar-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo for Pancrease MT 10.5 or MT 21
NCT00654927,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis",Multiple Sclerosis,Interventional,29-Feb-12,Acorda Therapeutics,Drug: Fampridine-SR b.i.d. (Twice Daily)
NCT01338415,FUTURE 3 Study Extension,Pulmonary Arterial Hypertension,Interventional,11-Dec-17,Actelion,Drug: Bosentan
NCT00657150,Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty,Venous Thromboembolism,Interventional,17-Dec-10,Boehringer Ingelheim,Drug: Enoxaparin
NCT00657150,Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty,Venous Thromboembolism,Interventional,17-Dec-10,Boehringer Ingelheim,Drug: Dabigatran etexilate
NCT00651118,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,26-Sep-12,Meda Pharmaceuticals,Drug: Placebo
NCT00651118,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,26-Sep-12,Meda Pharmaceuticals,Drug: azelastine Hcl
NCT00651118,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,26-Sep-12,Meda Pharmaceuticals,Drug: azelastineHcl / fluticasone propionate
NCT00651118,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,26-Sep-12,Meda Pharmaceuticals,Drug: fluticasone propionate
NCT00650078,Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,13-Dec-12,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: MR prednisone
NCT00650078,Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,13-Dec-12,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Drug: Placebo
NCT00649792,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial",Multiple Sclerosis,Interventional,27-Feb-12,Acorda Therapeutics,Drug: Fampridine-SR
NCT00649389,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Interventional,1-Sep-10,"Daiichi Sankyo, Inc.",Drug: Olmesartan medoxomil
NCT00649389,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Interventional,1-Sep-10,"Daiichi Sankyo, Inc.",Drug: Amlodipine
NCT00649389,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Interventional,1-Sep-10,"Daiichi Sankyo, Inc.",Drug: Hydrochlorothiazide
NCT00648908,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial",Multiple Sclerosis,Interventional,27-Feb-12,Acorda Therapeutics,Drug: Fampridine-SR
NCT00647270,"Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing",Rheumatoid Arthritis,Interventional,10-May-10,Abbott,Drug: adalimumab
NCT00647270,"Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing",Rheumatoid Arthritis,Interventional,10-May-10,Abbott,Drug: Placebo
NCT00644358,A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD),Major Depressive Disorder,Interventional,25-Sep-17,Forest Laboratories,Drug: vilazodone
NCT00643851,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,Type 2 Diabetes,Interventional,23-Feb-17,AstraZeneca,Drug: Dapagliflozin
NCT00643851,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,Type 2 Diabetes,Interventional,23-Feb-17,AstraZeneca,Drug: Metformin XR
NCT00643851,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,Type 2 Diabetes,Interventional,23-Feb-17,"Astra Zeneca, Bristol-Myers Squibb",Drug: Dapagliflozin
NCT00643851,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,Type 2 Diabetes,Interventional,23-Feb-17,"Astra Zeneca, Bristol-Myers Squibb",Drug: Metformin XR
NCT00642460,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA),Juvenile Idiopathic Arthritis,Interventional,26-Oct-11,Hoffmann-La Roche,Drug: tocilizumab [RoActemra/Actemra]
NCT00642460,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA),Juvenile Idiopathic Arthritis,Interventional,26-Oct-11,Hoffmann-La Roche,Drug: Placebo
NCT00642460,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA),Juvenile Idiopathic Arthritis,Interventional,26-Oct-11,Hoffmann-La Roche,Drug: Non-steroidal anti-inflammatory drugs (NSAIDs)
NCT00642460,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA),Juvenile Idiopathic Arthritis,Interventional,26-Oct-11,Hoffmann-La Roche,Drug: methotrexate
NCT00642460,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA),Juvenile Idiopathic Arthritis,Interventional,26-Oct-11,Hoffmann-La Roche,Drug: corticosteroids
NCT00641745,Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia,Schizophrenia|Schizoaffective Disorder,Interventional,6-Oct-11,Sunovion,Drug: Lurasidone HCl
NCT00641745,Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia,Schizophrenia|Schizoaffective Disorder,Interventional,6-Oct-11,Sunovion,Drug: Risperidone
NCT00641537,CLARITY Extension Study,Relapsing-Remitting Multiple Sclerosis,Interventional,2-Dec-13,EMD Serono,Drug: Cladribine
NCT00641537,CLARITY Extension Study,Relapsing-Remitting Multiple Sclerosis,Interventional,2-Dec-13,EMD Serono,Drug: Placebo
NCT00660010,Study of Lupron Depot In The Treatment of Central Precocious Puberty,"Puberty, Precocious",Interventional,20-Jul-10,Abbott,Drug: Lupron (leuprolide acetate)
NCT00650104,Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164,Parkinson Disease,Interventional,21-Apr-10,GlaxoSmithKline,Drug: Ropinirole XL (formerly CR)
NCT00647699,Corneal Collagen Cross-linking for Progressive Keratoconus,Progressive Keratoconus,Interventional,7-Jul-16,"Avedro, Inc.",Drug: riboflavin ophthalmic solution
NCT00647699,Corneal Collagen Cross-linking for Progressive Keratoconus,Progressive Keratoconus,Interventional,7-Jul-16,"Avedro, Inc.",Device: UVA Irradiation
NCT00639158,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipidemia,Interventional,5-Nov-09,Abbott,Drug: ABT-335
NCT00639158,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipidemia,Interventional,5-Nov-09,Abbott,Drug: placebo
NCT00639158,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipidemia,Interventional,5-Nov-09,Abbott,Drug: atorvastatin
NCT00639158,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipidemia,Interventional,5-Nov-09,Abbott,Drug: ezetimibe
NCT00638690,Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy,Prostatic Neoplasms,Interventional,16-May-13,"Cougar Biotechnology, Inc.",Drug: Placebo
NCT00638690,Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy,Prostatic Neoplasms,Interventional,16-May-13,"Cougar Biotechnology, Inc.",Drug: Abiraterone acetate
NCT00638690,Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy,Prostatic Neoplasms,Interventional,16-May-13,"Cougar Biotechnology, Inc.",Drug: Prednisone/prednisolone
NCT00636636,Safety and Efficacy of Gabapentin in Postherpetic Neuralgia,"Neuralgia,Postherpetic",Interventional,13-Jan-12,Depomed,Drug: Gabapentin Extended Release tablets
NCT00636636,Safety and Efficacy of Gabapentin in Postherpetic Neuralgia,"Neuralgia,Postherpetic",Interventional,13-Jan-12,Depomed,Drug: Placebo
NCT00635817,A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty,"Puberty, Precocious",Interventional,9-Feb-11,Abbott,Drug: Leuprolide acetate 11.25 mg
NCT00635817,A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty,"Puberty, Precocious",Interventional,9-Feb-11,Abbott,Drug: Leuprolide acetate 30 mg
NCT00632736,An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease,Parkinson Disease|Parkinson's Disease,Interventional,24-Dec-10,GlaxoSmithKline,Drug: Ropinirole XL (formerly CR)
NCT00631475,Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443,Idiopathic Pulmonary Fibrosis,Interventional,3-Aug-12,Actelion,Drug: Bosentan
NCT00631371,Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects,Renal Cell Carcinoma,Interventional,4-Jun-13,Pfizer,Drug: Bevacizumab
NCT00631371,Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects,Renal Cell Carcinoma,Interventional,4-Jun-13,Pfizer,Drug: Temsirolimus
NCT00631371,Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects,Renal Cell Carcinoma,Interventional,4-Jun-13,Pfizer,Drug: Interferon-Alfa 9MU
NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,Dyslipidemia,Interventional,9-Oct-09,Abbott,Drug: Niacin extended-release (NER)
NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,Dyslipidemia,Interventional,9-Oct-09,Abbott,Drug: Niacin extended-release (NER) placebo
NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,Dyslipidemia,Interventional,9-Oct-09,Abbott,Drug: Aspirin (ASA)
NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,Dyslipidemia,Interventional,9-Oct-09,Abbott,Drug: Aspirin (ASA) placebo
NCT00630331,Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects,Influenza,Interventional,16-Jan-13,Novartis Vaccines,Biological: Cell culture-derived influenza vaccine
NCT00630331,Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects,Influenza,Interventional,16-Jan-13,Novartis Vaccines,Biological: Egg-derived influenza virus vaccine
NCT00630331,Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects,Influenza,Interventional,16-Jan-13,Novartis Vaccines,Biological: Placebo
NCT00630331,Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects,Influenza,Interventional,16-Jan-13,Novartis,Biological: Cell culture-derived influenza vaccine
NCT00630331,Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects,Influenza,Interventional,16-Jan-13,Novartis,Biological: Egg-derived influenza virus vaccine
NCT00630331,Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects,Influenza,Interventional,16-Jan-13,Novartis,Biological: Placebo
NCT00628498,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Hepatic Veno-Occlusive Disease,Interventional,30-Nov-17,Jazz Pharmaceuticals,Drug: Defibrotide
NCT00628108,Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months,Allergic Rhinitis|Chronic Urticaria,Interventional,14-Oct-09,UCB Pharma,Drug: Levocetirizine 1.25 mg
NCT00628108,Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months,Allergic Rhinitis|Chronic Urticaria,Interventional,14-Oct-09,UCB Pharma,Other: Placebo
NCT00635427,An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease,"Gaucher Disease, Type 1",Interventional,28-Jan-14,Shire,Biological: VPRIV®
NCT00644969,Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder,Smoking Cessation,Interventional,15-Apr-11,Pfizer,Drug: placebo
NCT00644969,Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder,Smoking Cessation,Interventional,15-Apr-11,Pfizer,"Drug: varenicline (CP-526,555)"
NCT00627016,A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn,Gastroesophageal Reflux,Interventional,6-May-10,Takeda,Drug: Dexlansoprazole
NCT00627016,A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn,Gastroesophageal Reflux,Interventional,6-May-10,Takeda,Drug: Placebo
NCT00626431,A Study of Leuprolide to Treat Prostate Cancer,Prostate Cancer,Interventional,1-Nov-10,Abbott,Drug: Leuprolide acetate - Formulation A
NCT00626431,A Study of Leuprolide to Treat Prostate Cancer,Prostate Cancer,Interventional,1-Nov-10,Abbott,Drug: Leuprolide acetate - Formulation B
NCT00626392,Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia,Dyslipidemia,Interventional,25-Aug-09,Abbott,Drug: niacin extended-release (NER)
NCT00626392,Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia,Dyslipidemia,Interventional,25-Aug-09,Abbott,Drug: aspirin (ASA)
NCT00626392,Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia,Dyslipidemia,Interventional,25-Aug-09,Abbott,Drug: aspirin placebo (ASA Pbo)
NCT00626327,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Meningococcal Infections,Interventional,15-Mar-13,Novartis Vaccines,Biological: MenACWY-CRM + MMRV
NCT00626327,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Meningococcal Infections,Interventional,15-Mar-13,Novartis Vaccines,Biological: MMRV
NCT00626327,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Meningococcal Infections,Interventional,15-Mar-13,Novartis Vaccines,Biological: MenACWY-CRM
NCT00626327,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Meningococcal Infections,Interventional,15-Mar-13,Novartis,Biological: MenACWY-CRM + MMRV
NCT00626327,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Meningococcal Infections,Interventional,15-Mar-13,Novartis,Biological: MMRV
NCT00626327,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Meningococcal Infections,Interventional,15-Mar-13,Novartis,Biological: MenACWY-CRM
NCT00624286,Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,18-Aug-11,Novartis,Drug: Indacaterol 150 μg
NCT00624286,Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,18-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT00734604,A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.,Erectile Dysfunction,Interventional,18-Nov-10,Eli Lilly and Company,Drug: tadalafil once a day [T(OaD)]
NCT00734604,A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.,Erectile Dysfunction,Interventional,18-Nov-10,Eli Lilly and Company,Drug: sildenafil citrate as needed [S(PRN)]
NCT00734604,A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.,Erectile Dysfunction,Interventional,18-Nov-10,Eli Lilly and Company,Drug: tadalafil as needed [T(PRN)]
NCT00624065,Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure,Hypertension,Interventional,3-Aug-09,GlaxoSmithKline,Drug: carvedilol controlled release/lisinopril
NCT00624065,Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure,Hypertension,Interventional,3-Aug-09,GlaxoSmithKline,Drug: lisinopril + placebo
NCT00623480,Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment,Hemophilia A,Interventional,7-Aug-13,Bayer,"Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)"
NCT00623467,Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging,Central Nervous System Diseases,Interventional,6-Oct-11,Bayer,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)"
NCT00623428,A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response,"Hepatitis C, Chronic",Interventional,24-Jun-13,Hoffmann-La Roche,Drug: peginterferon alfa-2a
NCT00623428,A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response,"Hepatitis C, Chronic",Interventional,24-Jun-13,Hoffmann-La Roche,Drug: Ribavirin
NCT00623103,Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD),Parkinson's Disease Dementia,Interventional,28-Nov-11,Novartis,Drug: Rivastigmine capsule
NCT00623103,Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD),Parkinson's Disease Dementia,Interventional,28-Nov-11,Novartis,Drug: Rivastigmine transdermal patch
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis Pharmaceuticals,Drug: Tacrolimus (reduced tacrolimus)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis Pharmaceuticals,Drug: Tacrolimus (tacrolimus elimination)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis Pharmaceuticals,Drug: Tacrolimus (tacrolimus control)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis Pharmaceuticals,Drug: Everolimus (reduced tacrolimus)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis Pharmaceuticals,Drug: Everolimus (tacrolimus elimination)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis Pharmaceuticals,Drug: Corticosteroids
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis,Drug: Tacrolimus (reduced tacrolimus)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis,Drug: Tacrolimus (tacrolimus elimination)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis,Drug: Tacrolimus (tacrolimus control)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis,Drug: Everolimus (reduced tacrolimus)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis,Drug: Everolimus (tacrolimus elimination)
NCT00622869,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Liver Transplantation,Interventional,20-May-13,Novartis,Drug: Corticosteroids
NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Multiple Sclerosis,Interventional,19-Dec-14,Sanofi,Drug: Teriflunomide
NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Multiple Sclerosis,Interventional,19-Dec-14,Sanofi,Drug: Placebo
NCT00622284,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,20-Feb-12,Boehringer Ingelheim,Drug: Placebo identical to BI 1356 5mg
NCT00622284,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,20-Feb-12,Boehringer Ingelheim,Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg
NCT00622284,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,20-Feb-12,Boehringer Ingelheim,Drug: BI 1356
NCT00622284,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,20-Feb-12,Boehringer Ingelheim,Drug: Glimepiride
NCT00891202,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE),"Gaucher Disease, Type 1",Interventional,3-Sep-14,"Genzyme, a Sanofi Company",Drug: Eliglustat tartrate
NCT00891202,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE),"Gaucher Disease, Type 1",Interventional,3-Sep-14,"Genzyme, a Sanofi Company",Drug: Placebo
NCT00891202,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE),"Gaucher Disease, Type 1",Interventional,3-Sep-14,Sanofi,Drug: Eliglustat tartrate
NCT00891202,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE),"Gaucher Disease, Type 1",Interventional,3-Sep-14,Sanofi,Drug: Placebo
NCT00620542,CRESTOR Athero Imaging Head to Head IVUS Study,Coronary Atherosclerosis,Interventional,25-Jun-12,AstraZeneca,Drug: Rosuvastatin
NCT00620542,CRESTOR Athero Imaging Head to Head IVUS Study,Coronary Atherosclerosis,Interventional,25-Jun-12,AstraZeneca,Drug: Atorvastatin
NCT00620542,CRESTOR Athero Imaging Head to Head IVUS Study,Coronary Atherosclerosis,Interventional,25-Jun-12,The Cleveland Clinic,Drug: Rosuvastatin
NCT00620542,CRESTOR Athero Imaging Head to Head IVUS Study,Coronary Atherosclerosis,Interventional,25-Jun-12,The Cleveland Clinic,Drug: Atorvastatin
NCT00619801,Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin,Allergic Rhinitis|Chronic Urticaria,Interventional,4-Sep-09,UCB Pharma,Drug: Levocetirizine
NCT00619801,Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin,Allergic Rhinitis|Chronic Urticaria,Interventional,4-Sep-09,UCB Pharma,Drug: Placebo
NCT00621504,Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia,Bacterial Pneumonia,Interventional,10-Nov-10,Forest Laboratories,Drug: Ceftaroline fosamil for Injection
NCT00621504,Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia,Bacterial Pneumonia,Interventional,10-Nov-10,Forest Laboratories,Drug: IV Ceftriaxone
NCT00621504,Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia,Bacterial Pneumonia,Interventional,10-Nov-10,Forest Laboratories,Drug: Placebo
NCT00621504,Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia,Bacterial Pneumonia,Interventional,10-Nov-10,Forest Laboratories,Drug: Clarithromycin
NCT00891046,An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.,Systemic Juvenile Idiopathic Arthritis,Interventional,10-Mar-17,Novartis Pharmaceuticals,Drug: Canakinumab
NCT00891046,An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.,Systemic Juvenile Idiopathic Arthritis,Interventional,10-Mar-17,Pediatric Rheumatology International Trials Organization,Drug: Canakinumab
NCT00891046,An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.,Systemic Juvenile Idiopathic Arthritis,Interventional,10-Mar-17,Novartis,Drug: Canakinumab
NCT00617669,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer,Prostate Cancer,Interventional,31-May-12,AstraZeneca,Drug: Docetaxel
NCT00617669,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer,Prostate Cancer,Interventional,31-May-12,AstraZeneca,Drug: ZD4054
NCT00617669,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer,Prostate Cancer,Interventional,31-May-12,AstraZeneca,Drug: Placebo
NCT00616928,Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years,Influenza,Interventional,7-Feb-14,GlaxoSmithKline,"Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted"
NCT00616928,Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years,Influenza,Interventional,7-Feb-14,GlaxoSmithKline,Biological: Placebo
NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Interventional,20-Jan-14,"AbbVie (prior sponsor, Abbott)",Drug: ABT-335
NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Interventional,20-Jan-14,"AbbVie (prior sponsor, Abbott)",Drug: Placebo
NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Interventional,20-Jan-14,"AbbVie (prior sponsor, Abbott)",Other: Atorvastatin
NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Interventional,20-Jan-14,AbbVie,Drug: ABT-335
NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Interventional,20-Jan-14,AbbVie,Drug: Placebo
NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Interventional,20-Jan-14,AbbVie,Other: Atorvastatin
NCT00616421,Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children,Meningococcal Infections,Interventional,9-Jun-11,Novartis Vaccines,Biological: MenACWY-CRM
NCT00616421,Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children,Meningococcal Infections,Interventional,9-Jun-11,Novartis Vaccines,Biological: Licensed meningococcal ACWY vaccine
NCT00616421,Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children,Meningococcal Infections,Interventional,9-Jun-11,Novartis,Biological: MenACWY-CRM
NCT00616421,Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children,Meningococcal Infections,Interventional,9-Jun-11,Novartis,Biological: Licensed meningococcal ACWY vaccine
NCT00615836,"An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (""Melt"") Formulation of Desmopressin for the Treatment of Nocturia in Adults",Nocturia,Interventional,15-Dec-15,Ferring Pharmaceuticals,Drug: Desmopressin Melt
NCT00615550,PREGNANT Short Cervix Trial,Preterm Delivery|Short Cervix|Short Uterine Cervical Length,Interventional,13-Mar-12,"Juniper Pharmaceuticals, Inc.",Drug: progesterone
NCT00615550,PREGNANT Short Cervix Trial,Preterm Delivery|Short Cervix|Short Uterine Cervical Length,Interventional,13-Mar-12,"Juniper Pharmaceuticals, Inc.",Drug: placebo
NCT00615550,PREGNANT Short Cervix Trial,Preterm Delivery|Short Cervix|Short Uterine Cervical Length,Interventional,13-Mar-12,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Drug: progesterone
NCT00615550,PREGNANT Short Cervix Trial,Preterm Delivery|Short Cervix|Short Uterine Cervical Length,Interventional,13-Mar-12,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Drug: placebo
NCT00615433,Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia,Schizophrenia,Interventional,14-Feb-11,Sunovion,Drug: Lurasidone
NCT00615433,Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia,Schizophrenia,Interventional,14-Feb-11,Sunovion,Drug: Olanzapine
NCT00615433,Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia,Schizophrenia,Interventional,14-Feb-11,Sunovion,Drug: Placebo comparator
NCT00615433,Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia,Schizophrenia,Interventional,14-Feb-11,Sunovion,Drug: Lurasidone 40 mg tablets
NCT00614614,"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","Infections, Meningococcal",Interventional,20-Jul-12,GlaxoSmithKline,Biological: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)
NCT00614614,"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","Infections, Meningococcal",Interventional,20-Jul-12,GlaxoSmithKline,Biological: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)
NCT00614614,"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","Infections, Meningococcal",Interventional,20-Jul-12,GlaxoSmithKline,Biological: Infanrix®
NCT00614614,"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","Infections, Meningococcal",Interventional,20-Jul-12,GlaxoSmithKline,Biological: ActHIB®
NCT00614614,"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","Infections, Meningococcal",Interventional,20-Jul-12,GlaxoSmithKline,Biological: Pediarix®
NCT00611026,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.,Overactive Bladder,Interventional,12-Jan-11,Pfizer,Drug: Tolterodine ER
NCT00611026,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.,Overactive Bladder,Interventional,12-Jan-11,Pfizer,Drug: Placebo
NCT00611026,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.,Overactive Bladder,Interventional,12-Jan-11,Pfizer,Drug: Fesoterodine
NCT00608023,TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy,Lipodystrophy|HIV Infections,Interventional,15-Jan-14,Theratechnologies,Drug: Tesamorelin
NCT00608023,TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy,Lipodystrophy|HIV Infections,Interventional,15-Jan-14,Theratechnologies,Drug: Placebo for Tesamorelin
NCT02585895,Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment,Hypercholesterolemia,Interventional,19-Sep-17,Amgen,Biological: Evolocumab
NCT02585895,Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment,Hypercholesterolemia,Interventional,19-Sep-17,Amgen,Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
NCT00606632,Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody,Renal Cell Carcinoma|Kidney Cancer,Interventional,14-Apr-14,Wilex,Drug: 124-Iodine-cG250 (124I-cG250)
NCT00606632,Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody,Renal Cell Carcinoma|Kidney Cancer,Interventional,14-Apr-14,Wilex,Procedure: CT
NCT00605176,Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs),Actinic Keratoses,Interventional,22-Jun-10,"Graceway Pharmaceuticals, LLC",Drug: imiquimod cream
NCT00605176,Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs),Actinic Keratoses,Interventional,22-Jun-10,"Graceway Pharmaceuticals, LLC",Drug: Placebo
NCT00604214,Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock,Sepsis,Interventional,18-Sep-12,Eli Lilly and Company,Drug: Drotrecogin alfa (activated)
NCT00604214,Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock,Sepsis,Interventional,18-Sep-12,Eli Lilly and Company,Drug: Placebo
NCT00603798,Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs),Actinic Keratosis,Interventional,22-Jun-10,"Graceway Pharmaceuticals, LLC",Drug: Imiquimod cream
NCT00603798,Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs),Actinic Keratosis,Interventional,22-Jun-10,"Graceway Pharmaceuticals, LLC",Drug: Placebo cream
NCT00716859,"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.",Glaucoma,Interventional,2-Dec-10,Pfizer,Drug: Timolol
NCT00716859,"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.",Glaucoma,Interventional,2-Dec-10,Pfizer,Drug: latanoprost
NCT00601250,Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,7-Jun-11,Boehringer Ingelheim,Drug: linagliptin
NCT00601172,A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.,"Nausea and Vomiting, Chemotherapy-Induced",Interventional,17-Jan-18,GlaxoSmithKline,Drug: Casopitant
NCT00601172,A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.,"Nausea and Vomiting, Chemotherapy-Induced",Interventional,17-Jan-18,GlaxoSmithKline,Drug: Dexamethasone
NCT00601172,A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.,"Nausea and Vomiting, Chemotherapy-Induced",Interventional,17-Jan-18,GlaxoSmithKline,Drug: Placebo
NCT00601172,A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.,"Nausea and Vomiting, Chemotherapy-Induced",Interventional,17-Jan-18,GlaxoSmithKline,Drug: Ondansetron
NCT00600886,Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly,Acromegaly,Interventional,30-Jan-15,Novartis Pharmaceuticals,Drug: Pasireotide
NCT00600886,Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly,Acromegaly,Interventional,30-Jan-15,Novartis Pharmaceuticals,Drug: Octreotide
NCT00600886,Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly,Acromegaly,Interventional,30-Jan-15,Novartis,Drug: Pasireotide
NCT00600886,Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly,Acromegaly,Interventional,30-Jan-15,Novartis,Drug: Octreotide
NCT00599872,Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies,Allergic Rhinitis,Interventional,14-Jan-15,Greer Laboratories,Biological: Standardized Ragweed Allergenic Extract
NCT00599872,Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies,Allergic Rhinitis,Interventional,14-Jan-15,Greer Laboratories,Biological: Placebo
NCT00599521,"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",Acne Vulgaris,Interventional,19-Apr-11,Galderma,Drug: Adapalene lotion 0.1%
NCT00599521,"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",Acne Vulgaris,Interventional,19-Apr-11,Galderma,Drug: Adapalene Lotion Vehicle
NCT00598832,"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",Acne Vulgaris,Interventional,19-Apr-11,Galderma,Drug: Adapalene lotion 0.1%
NCT00598832,"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",Acne Vulgaris,Interventional,19-Apr-11,Galderma,Drug: Adapalene Lotion Vehicle
NCT00598806,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612),Bladder Cancer,Interventional,15-Aug-17,"Spectrum Pharmaceuticals, Inc",Drug: Apaziquone
NCT00598806,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612),Bladder Cancer,Interventional,15-Aug-17,"Spectrum Pharmaceuticals, Inc",Drug: Placebo
NCT00598806,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612),Bladder Cancer,Interventional,15-Aug-17,"Spectrum Pharmaceuticals, Inc",Procedure: TURBT
NCT00617981,Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC),Hepatocellular Carcinoma,Interventional,24-Mar-17,Celsion,Drug: ThermoDox
NCT00617981,Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC),Hepatocellular Carcinoma,Interventional,24-Mar-17,Celsion,Drug: 5% Dextrose Solution
NCT00598702,Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients,Pain|Fever,Interventional,6-Jan-11,Mallinckrodt,Drug: IV Acetaminophen
NCT00598559,Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients,Acute Pain|Fever,Interventional,10-Dec-10,Mallinckrodt,Drug: IV Acetaminophen
NCT00596466,Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures,Epilepsy,Interventional,11-Sep-12,Pfizer,Drug: pregabalin
NCT00601523,Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).,Parkinson Disease,Interventional,25-Aug-11,Boehringer Ingelheim,Drug: Placebo
NCT00601523,Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).,Parkinson Disease,Interventional,25-Aug-11,Boehringer Ingelheim,Drug: Pramipexole
NCT00594568,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Alzheimer's Disease,Interventional,25-Sep-14,Eli Lilly and Company,Drug: LY450139
NCT00594568,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Alzheimer's Disease,Interventional,25-Sep-14,Eli Lilly and Company,Drug: Placebo
NCT00594386,An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease,Parkinson's Disease,Interventional,18-Dec-09,UCB Pharma,Drug: Rotigotine
NCT00594165,An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.,Early-Stage Parkinson's Disease,Interventional,25-Feb-10,UCB Pharma,Drug: Rotigotine
NCT00591773,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Azilsartan medoxomil and chlorthalidone
NCT00591773,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Chlorthalidone
NCT00591578,Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Azilsartan Medoxomil
NCT00591578,Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Valsartan
NCT00591266,"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension",Hypertension,Interventional,19-Apr-11,Takeda,Drug: Azilsartan Medoxomil and amlodipine
NCT00591266,"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension",Hypertension,Interventional,19-Apr-11,Takeda,Drug: Amlodipine
NCT00591253,Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Azilsartan medoxomil
NCT00591253,Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension,Hypertension,Interventional,19-Apr-11,Takeda,Drug: Placebo
NCT00590577,"Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia",Schizophrenia,Interventional,5-Oct-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Paliperidone palmitate 25 mg eq.
NCT00590577,"Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia",Schizophrenia,Interventional,5-Oct-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Paliperidone palmitate 150 mg eq.
NCT00590577,"Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia",Schizophrenia,Interventional,5-Oct-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00590577,"Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia",Schizophrenia,Interventional,5-Oct-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Paliperidone palmitate 100 mg eq.
NCT00589914,Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia,Schizophrenia,Interventional,4-Oct-11,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: RISPERDAL CONSTA
NCT00589914,Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia,Schizophrenia,Interventional,4-Oct-11,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Paliperidone palmitate
NCT00699751,A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases,Hormone Refractory Prostate Cancer|Bone Metastases,Interventional,7-May-14,Bayer,"Drug: Radium-223 dichloride (Xofigo, BAY88-8223)"
NCT00699751,A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases,Hormone Refractory Prostate Cancer|Bone Metastases,Interventional,7-May-14,Bayer,Drug: Placebo
NCT00699751,A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases,Hormone Refractory Prostate Cancer|Bone Metastases,Interventional,7-May-14,Bayer,Drug: Best standard of care (BSoC)
NCT00579982,An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder,Mood Disorders,Interventional,3-Aug-09,GlaxoSmithKline,Drug: Lamotrigine
NCT00626028,Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing,Idiopathic Pulmonary Arterial Hypertension|Congenital Heart Disease With Pulmonary Hypertension|Cardiomyopathy,Interventional,16-Sep-10,Mallinckrodt,Drug: Nitric Oxide for inhalation
NCT00626028,Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing,Idiopathic Pulmonary Arterial Hypertension|Congenital Heart Disease With Pulmonary Hypertension|Cardiomyopathy,Interventional,16-Sep-10,Mallinckrodt,Drug: Oxygen
NCT00626028,Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing,Idiopathic Pulmonary Arterial Hypertension|Congenital Heart Disease With Pulmonary Hypertension|Cardiomyopathy,Interventional,16-Sep-10,Mallinckrodt,Drug: Nitric Oxide plus Oxygen
NCT00578812,PCM Cervical Disc System,Radiculopathy|Myelopathy,Interventional,12-Feb-13,NuVasive,Device: Anterior Cervical Discectomy and Fusion (ACDF)
NCT00578812,PCM Cervical Disc System,Radiculopathy|Myelopathy,Interventional,12-Feb-13,NuVasive,Device: PCM Cervical Disc
NCT00577863,Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy,Osteoporosis,Interventional,24-Jun-09,Eli Lilly and Company,Drug: teriparatide
NCT00577473,Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I),Ulcerative Colitis,Interventional,22-Jun-11,Warner Chilcott,Drug: mesalamine
NCT00577655,Albuterol HFA MDI in Pediatric Participants With Asthma,Asthma,Interventional,3-Dec-09,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Albuterol
NCT00577655,Albuterol HFA MDI in Pediatric Participants With Asthma,Asthma,Interventional,3-Dec-09,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Placebo
NCT00577655,Albuterol HFA MDI in Pediatric Participants With Asthma,Asthma,Interventional,3-Dec-09,"Teva Branded Pharmaceutical Products, R&D Inc.",Drug: Proventil® HFA
NCT00577655,Albuterol HFA MDI in Pediatric Participants With Asthma,Asthma,Interventional,3-Dec-09,Teva Pharmaceutical Industries,Drug: Albuterol
NCT00577655,Albuterol HFA MDI in Pediatric Participants With Asthma,Asthma,Interventional,3-Dec-09,Teva Pharmaceutical Industries,Drug: Placebo
NCT00577655,Albuterol HFA MDI in Pediatric Participants With Asthma,Asthma,Interventional,3-Dec-09,Teva Pharmaceutical Industries,Drug: Proventil® HFA
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Pseudobulbar Affect (PBA),Interventional,10-Jul-13,Avanir Pharmaceuticals,Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Pseudobulbar Affect (PBA),Interventional,10-Jul-13,Avanir Pharmaceuticals,Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Pseudobulbar Affect (PBA),Interventional,10-Jul-13,Avanir Pharmaceuticals,Drug: Placebo
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Pseudobulbar Affect (PBA),Interventional,10-Jul-13,Syneos Health,Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Pseudobulbar Affect (PBA),Interventional,10-Jul-13,Syneos Health,Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Pseudobulbar Affect (PBA),Interventional,10-Jul-13,Syneos Health,Drug: Placebo
NCT00573170,TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults,"Migraine Disorders|Migraine, Acute",Interventional,29-Dec-10,GlaxoSmithKline,Drug: TREXIMET®
NCT00573170,TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults,"Migraine Disorders|Migraine, Acute",Interventional,29-Dec-10,GlaxoSmithKline,Drug: Butalbital-containing Combination Medications (BCM)
NCT00573170,TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults,"Migraine Disorders|Migraine, Acute",Interventional,29-Dec-10,GlaxoSmithKline,Drug: placebo
NCT00570739,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes,Interventional,13-Jul-10,"Daiichi Sankyo, Inc.",Drug: Metformin HCl and Colesevelam Placebo
NCT00570739,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes,Interventional,13-Jul-10,"Daiichi Sankyo, Inc.",Drug: Metformin HCl tablets and Colesevelam tablets
NCT00570739,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes,Interventional,13-Jul-10,"Daiichi Sankyo, Inc.",Drug: Colesevelam placebo
NCT00570739,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes,Interventional,13-Jul-10,"Daiichi Sankyo, Inc.",Drug: Colesevelam
NCT00686205,Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay,Healthy Donors|HIV Positive,Interventional,5-Jul-10,Abbott Diagnostics Division,Device: collection of follow-up sample based on PRISM HIV O Plus result
NCT00569582,A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome,Cushing's Syndrome,Interventional,28-May-12,Corcept Therapeutics,Drug: mifepristone
NCT00567255,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day
NCT00567255,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Placebo
NCT00567255,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Behavioral: Ancillary therapy
NCT00567164,Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ,"Contraception|Ovulation Inhibition|Contraceptives, Oral",Interventional,12-Mar-14,Bayer,Drug: EE20/DRSP (BAY86-5300)
NCT00567164,Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ,"Contraception|Ovulation Inhibition|Contraceptives, Oral",Interventional,12-Mar-14,Bayer,"Drug: EE20/DRSP (YAZ, BAY86-5300)"
NCT00566722,Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy,Psoriasis,Interventional,28-May-10,Abbott,Biological: adalimumab
NCT00564486,Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain,Pain,Interventional,30-Nov-10,Mallinckrodt,Drug: IV Placebo
NCT00564486,Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain,Pain,Interventional,30-Nov-10,Mallinckrodt,Drug: IV Acetaminophen
NCT00562302,Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure,Pneumothorax,Interventional,27-Mar-13,Angiotech Pharmaceuticals,Device: Bio-Seal Plug
NCT00561925,VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients,HIV Infections,Interventional,19-Jan-12,Boehringer Ingelheim,Drug: nevirapine IR
NCT00561925,VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients,HIV Infections,Interventional,19-Jan-12,Boehringer Ingelheim,Drug: nevirapine XR
NCT00560417,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,"Diabetes Mellitus, Type 2",Interventional,14-Dec-10,Eli Lilly and Company,Drug: Insulin Lispro Protamine Suspension
NCT00560417,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,"Diabetes Mellitus, Type 2",Interventional,14-Dec-10,Eli Lilly and Company,Drug: Insulin Glargine
NCT00559585,Methotrexate-Inadequate Response Study,Rheumatoid Arthritis (RA),Interventional,6-Jul-11,Bristol-Myers Squibb,Drug: Subcutaneous (SC) Abatacept
NCT00559585,Methotrexate-Inadequate Response Study,Rheumatoid Arthritis (RA),Interventional,6-Jul-11,Bristol-Myers Squibb,Drug: Intravenous (IV) Abatacept
NCT00558259,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,Venous Thromboembolism,Interventional,2-Mar-12,Boehringer Ingelheim,Drug: dabigatran etexilate 150 mg twice daily (BID)
NCT00558259,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,Venous Thromboembolism,Interventional,2-Mar-12,Boehringer Ingelheim,Drug: matching placebo twice daily (BID)
NCT00824265,Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia,"Leukaemia, Lymphocytic, Chronic",Interventional,25-Jul-16,Novartis Pharmaceuticals,Drug: OFC Infusion
NCT00824265,Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia,"Leukaemia, Lymphocytic, Chronic",Interventional,25-Jul-16,Novartis Pharmaceuticals,Drug: FC infusion
NCT00824265,Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia,"Leukaemia, Lymphocytic, Chronic",Interventional,25-Jul-16,Novartis,Drug: OFC Infusion
NCT00824265,Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia,"Leukaemia, Lymphocytic, Chronic",Interventional,25-Jul-16,Novartis,Drug: FC infusion
NCT00554229,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases,Prostate Cancer,Interventional,31-May-12,AstraZeneca,Drug: ZD4054
NCT00554229,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases,Prostate Cancer,Interventional,31-May-12,AstraZeneca,Drug: Placebo
NCT00552058,Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease,Crohn Disease,Interventional,30-Dec-10,UCB Pharma,"Biological: certolizumab pegol (CDP870, CZP)"
NCT00552058,Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease,Crohn Disease,Interventional,30-Dec-10,UCB Pharma,Other: Placebo
NCT00551135,Surgical Pain After Inguinal Hernia Repair (SPAIHR),"Pain, Postoperative|Hernia, Inguinal",Interventional,15-Jul-10,Pfizer,Drug: Pregabalin
NCT00551135,Surgical Pain After Inguinal Hernia Repair (SPAIHR),"Pain, Postoperative|Hernia, Inguinal",Interventional,15-Jul-10,Pfizer,Drug: placebo
NCT00550238,A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Parkinson's Disease Psychosis,Interventional,24-Jun-19,ACADIA Pharmaceuticals Inc.,Drug: Pimavanserin tartrate (ACP-103)
NCT00660517,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,23-Jul-12,Meda Pharmaceuticals,Drug: MP29-02
NCT00660517,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,23-Jul-12,Meda Pharmaceuticals,Drug: azelastine Hcl
NCT00660517,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,23-Jul-12,Meda Pharmaceuticals,Drug: fluticasone propionate
NCT00660517,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Seasonal Allergic Rhinitis,Interventional,23-Jul-12,Meda Pharmaceuticals,Drug: placebo
NCT00549718,Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia,Schizophrenia,Interventional,14-Dec-10,Sunovion,Drug: Lurasidone HCl
NCT00549549,Celebrex In Acute Gouty Arthritis Study,"Arthritis, Gouty",Interventional,24-Feb-11,Pfizer,Drug: Indomethacin
NCT00549549,Celebrex In Acute Gouty Arthritis Study,"Arthritis, Gouty",Interventional,24-Feb-11,Pfizer,Drug: Celecoxib
NCT00560885,AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation,Atrial Fibrillation,Interventional,14-Mar-13,"AtriCure, Inc.",Device: AtriCure Bipolar System
NCT00548340,VEC-162 Study in Adult Patients With Primary Insomnia,Primary Insomnia,Interventional,15-Oct-14,Vanda Pharmaceuticals,Drug: VEC-162 20 mg
NCT00548340,VEC-162 Study in Adult Patients With Primary Insomnia,Primary Insomnia,Interventional,15-Oct-14,Vanda Pharmaceuticals,Drug: Placebo
NCT00548340,VEC-162 Study in Adult Patients With Primary Insomnia,Primary Insomnia,Interventional,15-Oct-14,Vanda Pharmaceuticals,Drug: VEC-162 50 mg
NCT00547521,Phase IIIB Subcutaneous Abatacept Monotherapy Study,Rheumatoid Arthritis (RA),Interventional,24-Jan-11,Bristol-Myers Squibb,Drug: abatacept
NCT00547521,Phase IIIB Subcutaneous Abatacept Monotherapy Study,Rheumatoid Arthritis (RA),Interventional,24-Jan-11,Bristol-Myers Squibb,Drug: Methotrexate (MTX)
NCT00655551,Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures,Partial Epilepsies|Partial Onset Seizures,Interventional,20-Oct-10,"UCB BIOSCIENCES, Inc.",Drug: lacosamide
NCT00655551,Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures,Partial Epilepsies|Partial Onset Seizures,Interventional,20-Oct-10,UCB Pharma,Drug: lacosamide
NCT00655486,Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures,Partial Epilepsies|Partial Onset Seizures,Interventional,15-Jul-11,"UCB BIOSCIENCES, Inc.",Drug: lacosamide
NCT00655486,Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures,Partial Epilepsies|Partial Onset Seizures,Interventional,15-Jul-11,UCB Pharma,Drug: lacosamide
NCT00546637,"Fesoterodine ""add-on"" Male Overactive Bladder Study",Overactive Bladder Syndrome,Interventional,22-Nov-10,Pfizer,Drug: Fesoterodine
NCT00546637,"Fesoterodine ""add-on"" Male Overactive Bladder Study",Overactive Bladder Syndrome,Interventional,22-Nov-10,Pfizer,Drug: Placebo
NCT00546572,"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Pneumococcal Infections,Interventional,30-May-11,Wyeth is now a wholly owned subsidiary of Pfizer,Biological: 13 valent Pneumococcal Conjugate Vaccine
NCT00546572,"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Pneumococcal Infections,Interventional,30-May-11,Wyeth is now a wholly owned subsidiary of Pfizer,Biological: 23vPS
NCT00545740,Prevention of Recurrence of Diverticulitis,Diverticulitis,Interventional,25-Jan-13,Shire,Drug: SPD476 (1.2g)
NCT00545740,Prevention of Recurrence of Diverticulitis,Diverticulitis,Interventional,25-Jan-13,Shire,Drug: SPD476 (2.4 g)
NCT00545740,Prevention of Recurrence of Diverticulitis,Diverticulitis,Interventional,25-Jan-13,Shire,Drug: SPD476 (4.8 g)
NCT00545740,Prevention of Recurrence of Diverticulitis,Diverticulitis,Interventional,25-Jan-13,Shire,Drug: Placebo
NCT00545532,A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.,"Influenza, Human",Interventional,12-Jul-18,Hoffmann-La Roche,Drug: oseltamivir
NCT00545532,A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.,"Influenza, Human",Interventional,12-Jul-18,Hoffmann-La Roche,Other: placebo
NCT00545103,Prevention of Recurrence of Diverticulitis,Diverticulitis,Interventional,19-Dec-12,Shire,"Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet"
NCT00545103,Prevention of Recurrence of Diverticulitis,Diverticulitis,Interventional,19-Dec-12,Shire,Drug: Placebo
NCT00543725,TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors,HIV Infections|HIV-1,Interventional,12-Jul-11,"Tibotec Pharmaceuticals, Ireland",Drug: TMC278
NCT00543725,TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors,HIV Infections|HIV-1,Interventional,12-Jul-11,"Tibotec Pharmaceuticals, Ireland",Drug: efavirenz
NCT01223352,Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,29-Jun-17,Actelion,Drug: bosentan
NCT00649428,Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles,Bilateral Nasolabial Fold Wrinkles,Interventional,13-Mar-12,"Fibrocell Technologies, Inc.",Biological: Autologous Human Fibroblast (azficel-T)
NCT00649428,Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles,Bilateral Nasolabial Fold Wrinkles,Interventional,13-Mar-12,"Fibrocell Technologies, Inc.",Biological: Placebo
NCT00541658,A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis,Postmenopausal Osteoporosis,Interventional,21-Jun-11,Warner Chilcott,Drug: risedronate
NCT00540514,Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Interventional,19-Aug-13,Celgene,Drug: Albumin-bound paclitaxel
NCT00540514,Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Interventional,19-Aug-13,Celgene,Drug: Paclitaxel
NCT00540514,Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Interventional,19-Aug-13,Celgene,Drug: Carboplatin
NCT00540449,TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.,HIV Infections|HIV-1|Human Immunodeficiency Virus Type 1,Interventional,11-Jul-11,"Tibotec Pharmaceuticals, Ireland",Drug: TMC278
NCT00540449,TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.,HIV Infections|HIV-1|Human Immunodeficiency Virus Type 1,Interventional,11-Jul-11,"Tibotec Pharmaceuticals, Ireland",Drug: Efavirenz
NCT00538915,"Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)",Primary Immune Deficiency Disorders (PIDD),Interventional,26-Mar-12,Biotest Pharmaceuticals Corporation,Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
NCT00538863,Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain,Cancer|Pain,Interventional,11-Oct-13,INSYS Therapeutics Inc,Drug: Fentanyl sublingual spray
NCT00536744,Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers,Diabetic Foot Ulcers,Interventional,14-Apr-14,"SANUWAVE, Inc.",Device: acoustical pulse energy (extracorporeal shockwave)
NCT00536744,Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers,Diabetic Foot Ulcers,Interventional,14-Apr-14,"SANUWAVE, Inc.",Other: Sham
NCT00536484,Fesoterodine Flexible Dose Study,Overactive Bladder,Interventional,11-Sep-09,Pfizer,Drug: Fesoterodine
NCT00536484,Fesoterodine Flexible Dose Study,Overactive Bladder,Interventional,11-Sep-09,Pfizer,Drug: Placebo
NCT00535782,A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,14-Nov-12,Hoffmann-La Roche,Drug: Tocilizumab
NCT00535782,A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,14-Nov-12,Hoffmann-La Roche,Drug: Placebo
NCT00535782,A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,14-Nov-12,Hoffmann-La Roche,Drug: Methotrexate
NCT00534599,Generalized Anxiety Disorder Adjunct Study,Anxiety|Anxiety Disorders|Anxiety Neuroses|Anxiety States,Interventional,5-Apr-11,AstraZeneca,Drug: Placebo
NCT00534599,Generalized Anxiety Disorder Adjunct Study,Anxiety|Anxiety Disorders|Anxiety Neuroses|Anxiety States,Interventional,5-Apr-11,AstraZeneca,Drug: quetiapine fumarate XR
NCT00533897,Phase IIIB Subcutaneous Missed Dose Study,Rheumatoid Arthritis,Interventional,3-Jun-11,Bristol-Myers Squibb,Drug: Abatacept
NCT00533897,Phase IIIB Subcutaneous Missed Dose Study,Rheumatoid Arthritis,Interventional,3-Jun-11,Bristol-Myers Squibb,Drug: Placebo
NCT00532779,A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day
NCT00532779,A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day
NCT00532779,A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Placebo
NCT00532779,A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Behavioral: Ancillary therapy
NCT00531817,A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,4-Aug-10,Hoffmann-La Roche,Drug: Tocilizumab
NCT00531817,A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,4-Aug-10,Hoffmann-La Roche,Drug: Placebo
NCT00531817,A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,4-Aug-10,Hoffmann-La Roche,Drug: Permitted DMARDs
NCT00531479,Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis,Aspergillosis,Interventional,30-Apr-12,Pfizer,Drug: voriconazole
NCT00531479,Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis,Aspergillosis,Interventional,30-Apr-12,Pfizer,Drug: anidulafungin
NCT00531427,Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee,Chronic Pain|Osteoarthritis of the Knee,Interventional,21-Sep-10,Purdue Pharma LP,Drug: Buprenorphine
NCT00531427,Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee,Chronic Pain|Osteoarthritis of the Knee,Interventional,21-Sep-10,Purdue Pharma LP,Drug: Placebo
NCT00530855,Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures,Epilepsy,Interventional,3-Jun-15,UCB Pharma,Drug: Lacosamide
NCT00529568,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease,"Hepatitis C, Chronic",Interventional,17-May-12,GlaxoSmithKline,Drug: eltrombopag
NCT00529568,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease,"Hepatitis C, Chronic",Interventional,17-May-12,GlaxoSmithKline,Drug: placebo
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Asthma,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Indacaterol 300 μg
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Asthma,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Salmeterol 50 μg
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Asthma,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to indacaterol
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Asthma,Interventional,19-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to salmeterol
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Asthma,Interventional,19-Aug-11,Novartis,Drug: Indacaterol 300 μg
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Asthma,Interventional,19-Aug-11,Novartis,Drug: Salmeterol 50 μg
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Asthma,Interventional,19-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Asthma,Interventional,19-Aug-11,Novartis,Drug: Placebo to salmeterol
NCT00528567,BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer,Breast Cancer,Interventional,10-Sep-13,Hoffmann-La Roche,Drug: Bevacizumab
NCT00528567,BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer,Breast Cancer,Interventional,10-Sep-13,Hoffmann-La Roche,Drug: Standard adjuvant chemotherapy
NCT00528112,Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study,Contraception,Interventional,24-Sep-12,Bayer,Drug: LCS12
NCT00528112,Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study,Contraception,Interventional,24-Sep-12,Bayer,Drug: LCS16
NCT00528606,"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture",Dupuytren's Contracture,Interventional,22-Oct-10,Endo Pharmaceuticals,Biological: collagenase clostridium histolyticum
NCT00528606,"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture",Dupuytren's Contracture,Interventional,22-Oct-10,Endo Pharmaceuticals,Biological: Placebo
NCT00528424,"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",Advanced Dupuytren's Disease,Interventional,22-Oct-10,Endo Pharmaceuticals,Biological: AA4500
NCT00528840,"Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",Advanced Dupuytren's Disease,Interventional,22-Oct-10,Endo Pharmaceuticals,Biological: collagenase clostridium histolyticum
NCT00527514,Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension,Hypertension,Interventional,23-Sep-09,"Daiichi Sankyo, Inc.",Drug: Amlodipine
NCT00527514,Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension,Hypertension,Interventional,23-Sep-09,"Daiichi Sankyo, Inc.",Drug: Olmesartan medoxomil plus amlodipine
NCT00524368,A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN),Human Immunodeficiency Virus - Type 1,Interventional,22-Sep-10,"Tibotec Pharmaceuticals, Ireland",Drug: Darunavir (DRV)
NCT00524368,A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN),Human Immunodeficiency Virus - Type 1,Interventional,22-Sep-10,"Tibotec Pharmaceuticals, Ireland",Drug: Ritonavir (rtv)
NCT00790400,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),Interventional,28-Aug-12,Novartis Pharmaceuticals,Drug: Everolimus (RAD001)
NCT00790400,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),Interventional,28-Aug-12,Novartis Pharmaceuticals,Drug: Everolimus Placebo
NCT00790400,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),Interventional,28-Aug-12,Novartis,Drug: Everolimus (RAD001)
NCT00790400,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),Interventional,28-Aug-12,Novartis,Drug: Everolimus Placebo
NCT00529555,Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis,Adult Periodontitis,Interventional,9-May-14,Sunstar Americas,Drug: minocycline HCl 2.1%
NCT00529555,Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis,Adult Periodontitis,Interventional,9-May-14,Sunstar Americas,Procedure: Scaling and root planing
NCT01197378,Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103),Cystinosis,Interventional,24-Jul-18,"Horizon Pharma USA, Inc.",Drug: Cysteamine Bitartrate Delayed-release Capsules
NCT00522873,Endometrial Safety Study,Postmenopause,Interventional,28-Jun-12,Bayer,Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
NCT00522873,Endometrial Safety Study,Postmenopause,Interventional,28-Jun-12,Bayer,Drug: 0.5mg NETA / 1.0mg E2 (Activella)
NCT00522873,Endometrial Safety Study,Postmenopause,Interventional,28-Jun-12,Laboratorium für Klinische Forschung,Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
NCT00522873,Endometrial Safety Study,Postmenopause,Interventional,28-Jun-12,Laboratorium für Klinische Forschung,Drug: 0.5mg NETA / 1.0mg E2 (Activella)
NCT00522873,Endometrial Safety Study,Postmenopause,Interventional,28-Jun-12,Diagnostic Cytology Laboratory,Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
NCT00522873,Endometrial Safety Study,Postmenopause,Interventional,28-Jun-12,Diagnostic Cytology Laboratory,Drug: 0.5mg NETA / 1.0mg E2 (Activella)
NCT00522873,Endometrial Safety Study,Postmenopause,Interventional,28-Jun-12,"University of California, San Francisco",Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
NCT00522873,Endometrial Safety Study,Postmenopause,Interventional,28-Jun-12,"University of California, San Francisco",Drug: 0.5mg NETA / 1.0mg E2 (Activella)
NCT00522379,Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch,Parkinson's Disease,Interventional,10-Dec-12,UCB Pharma,Drug: Rotigotine
NCT00522379,Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch,Parkinson's Disease,Interventional,10-Dec-12,UCB Pharma,Other: Placebo
NCT00522275,Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures,Partial Epilepsies,Interventional,22-Nov-10,"UCB BIOSCIENCES, Inc.",Drug: lacosamide
NCT00522275,Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures,Partial Epilepsies,Interventional,22-Nov-10,UCB Pharma,Drug: lacosamide
NCT00622635,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Indacaterol 300 μg
NCT00622635,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Placebo to indacaterol
NCT00622635,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,18-Aug-11,Novartis Pharmaceuticals,Drug: Salmeterol 50 μg
NCT00622635,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,18-Aug-11,Novartis,Drug: Indacaterol 300 μg
NCT00622635,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,18-Aug-11,Novartis,Drug: Placebo to indacaterol
NCT00622635,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,18-Aug-11,Novartis,Drug: Salmeterol 50 μg
NCT00521586,Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine,Influenza,Interventional,9-Apr-15,Pfizer,Biological: 13 valent pneumococcal conjugate vaccine
NCT00520741,Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures,Epilepsy,Interventional,23-Apr-14,"UCB BIOSCIENCES, Inc.",Drug: Lacosamide
NCT00520741,Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures,Epilepsy,Interventional,23-Apr-14,UCB Pharma,Drug: Lacosamide
NCT00518882,Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,23-Mar-10,Novo Nordisk A/S,Drug: liraglutide
NCT00518882,Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Interventional,23-Mar-10,Novo Nordisk A/S,Drug: exenatide
NCT00518713,Clobazam in Patients With Lennox-Gastaut Syndrome,"Epilepsy|Epilepsy, Generalized|Seizures",Interventional,9-Feb-12,Lundbeck LLC,Drug: Clobazam Low Dose
NCT00518713,Clobazam in Patients With Lennox-Gastaut Syndrome,"Epilepsy|Epilepsy, Generalized|Seizures",Interventional,9-Feb-12,Lundbeck LLC,Drug: Clobazam Medium Dose
NCT00518713,Clobazam in Patients With Lennox-Gastaut Syndrome,"Epilepsy|Epilepsy, Generalized|Seizures",Interventional,9-Feb-12,Lundbeck LLC,Drug: Clobazam High Dose
NCT00518713,Clobazam in Patients With Lennox-Gastaut Syndrome,"Epilepsy|Epilepsy, Generalized|Seizures",Interventional,9-Feb-12,Lundbeck LLC,Drug: Placebo
NCT00529516,Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults,Influenza,Interventional,30-May-12,GlaxoSmithKline,Biological: Fluarix
NCT00529516,Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults,Influenza,Interventional,30-May-12,GlaxoSmithKline,Biological: GSK Biologicals Influenza Vaccine GSK576389A
NCT00516321,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease,"Hepatitis C, Chronic",Interventional,30-Jul-12,GlaxoSmithKline,Drug: eltrombopag
NCT00516321,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease,"Hepatitis C, Chronic",Interventional,30-Jul-12,GlaxoSmithKline,Drug: placebo
NCT00516139,Lamotrigine Extended-Release In Elderly Patients With Epilepsy,Epilepsy,Interventional,13-Jan-12,GlaxoSmithKline,Drug: Lamotrigine
NCT00514735,Tailored Treatment of Permanent Atrial Fibrillation,Atrial Fibrillation,Interventional,9-May-12,Medtronic Cardiac Rhythm and Heart Failure,Procedure: Medtronic Cardiac Ablation System
NCT00514735,Tailored Treatment of Permanent Atrial Fibrillation,Atrial Fibrillation,Interventional,9-May-12,Medtronic Cardiac Rhythm and Heart Failure,Drug: Class I or III Antiarrhythmic Medications
NCT00518323,"A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients",Schizophrenia,Interventional,9-Jun-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Paliperidone ER
NCT00518323,"A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients",Schizophrenia,Interventional,9-Jun-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00510484,Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,Cystic Fibrosis,Interventional,20-Jul-09,Solvay Pharmaceuticals,Drug: Pancrelipase Delayed Release
NCT00510484,Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,Cystic Fibrosis,Interventional,20-Jul-09,Solvay Pharmaceuticals,Drug: Placebo Comparator
NCT00510068,Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors,Advanced Neuroendocrine Tumors of Pancreatic Origin,Interventional,15-Dec-11,Novartis Pharmaceuticals,Drug: Everolimus
NCT00510068,Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors,Advanced Neuroendocrine Tumors of Pancreatic Origin,Interventional,15-Dec-11,Novartis Pharmaceuticals,Drug: Everolimus Placebo
NCT00510068,Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors,Advanced Neuroendocrine Tumors of Pancreatic Origin,Interventional,15-Dec-11,Novartis,Drug: Everolimus
NCT00510068,Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors,Advanced Neuroendocrine Tumors of Pancreatic Origin,Interventional,15-Dec-11,Novartis,Drug: Everolimus Placebo
NCT00510952,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE),"Diabetes Mellitus, Type 2",Interventional,3-Nov-09,Eli Lilly and Company,Drug: Insulin Lispro Protamine Suspension
NCT00510952,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE),"Diabetes Mellitus, Type 2",Interventional,3-Nov-09,Eli Lilly and Company,Drug: Insulin Glargine
NCT00507416,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Interventional,1-May-14,"Millennium Pharmaceuticals, Inc.",Drug: Bortezomib
NCT00507416,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Interventional,1-May-14,"Millennium Pharmaceuticals, Inc.",Drug: Dexamethasone
NCT00507416,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Interventional,1-May-14,"Millennium Pharmaceuticals, Inc.",Drug: Melphalan
NCT00507416,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Interventional,1-May-14,"Millennium Pharmaceuticals, Inc.",Drug: Prednisone
NCT00507416,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Interventional,1-May-14,"Millennium Pharmaceuticals, Inc.",Drug: Thalidomide
NCT00506883,MPC-004 for the Treatment of an Acute Gout Flare,Gout,Interventional,22-Sep-09,Takeda,Drug: High Dose Colchicine (4.8 mg total dose)
NCT00506883,MPC-004 for the Treatment of an Acute Gout Flare,Gout,Interventional,22-Sep-09,Takeda,Drug: Low Dose Colchicine (1.8mg total dose)
NCT00506883,MPC-004 for the Treatment of an Acute Gout Flare,Gout,Interventional,22-Sep-09,Takeda,Other: Placebo Control
NCT00506441,"A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia",Chronic Kidney Disease|Dialysis|Hyperphosphatemia,Interventional,25-Jul-14,Mitsubishi Tanabe Pharma Corporation,Drug: MCI-196
NCT00506441,"A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia",Chronic Kidney Disease|Dialysis|Hyperphosphatemia,Interventional,25-Jul-14,Mitsubishi Tanabe Pharma Corporation,Drug: Placebo
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis Pharmaceuticals,Drug: Rivastigmine 5 cm^2
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis Pharmaceuticals,Drug: Rivastigmine 10 cm^2
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis Pharmaceuticals,Drug: Rivastigmine 15 cm^2
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis Pharmaceuticals,Drug: Placebo to 15 cm^2 patch
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis Pharmaceuticals,Drug: Placebo to 10 cm^2 patch
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis,Drug: Rivastigmine 5 cm^2
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis,Drug: Rivastigmine 10 cm^2
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis,Drug: Rivastigmine 15 cm^2
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis,Drug: Placebo to 15 cm^2 patch
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Alzheimer Disease,Interventional,19-Sep-12,Novartis,Drug: Placebo to 10 cm^2 patch
NCT00506493,Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent,Atrial Fibrillation,Interventional,16-Oct-13,Medtronic Cardiovascular,Device: Cardioblate Surgical Ablation System
NCT00506493,Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent,Atrial Fibrillation,Interventional,16-Oct-13,Medtronic Cardiovascular,Procedure: Surgical RF Ablation
NCT00505778,A Comparison of Once a Day Dose Compared to 2 Doses/Day,Ulcerative Colitis,Interventional,12-May-11,Warner Chilcott,Drug: Mesalamine Once-Daily
NCT00505778,A Comparison of Once a Day Dose Compared to 2 Doses/Day,Ulcerative Colitis,Interventional,12-May-11,Warner Chilcott,Drug: Mesalamine Twice-Daily
NCT00501293,Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,ADHD,Interventional,15-Jan-10,Noven Therapeutics,Drug: Methylphenidate Transdermal System
NCT00501059,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,Moderate Risk of CVD,Interventional,8-Jan-18,Bayer,"Drug: Aspirin (Acetylsalicylic acid, BAYE4465)"
NCT00501059,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,Moderate Risk of CVD,Interventional,8-Jan-18,Bayer,Drug: Placebo
NCT00500318,A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,17-Dec-12,AstraZeneca,Drug: Aclidinium Bromide
NCT00500318,A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,17-Dec-12,AstraZeneca,Drug: Placebo
NCT00499863,Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,ADHD,Interventional,11-Jun-09,Noven Therapeutics,Drug: methylphenidate transdermal system
NCT00499863,Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,ADHD,Interventional,11-Jun-09,Noven Therapeutics,Drug: Placebo
NCT00500266,Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects,Pneumococcal Infections,Interventional,16-Sep-11,Pfizer,Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
NCT00497796,Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients,Cytomegalovirus Infections,Interventional,4-Jun-15,Shire,Drug: maribavir
NCT00497796,Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients,Cytomegalovirus Infections,Interventional,4-Jun-15,Shire,Drug: ganciclovir
NCT00497146,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,Chronic Kidney Disease|Left Ventricular Hypertrophy,Interventional,23-Dec-11,"AbbVie (prior sponsor, Abbott)",Drug: paricalcitol
NCT00497146,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,Chronic Kidney Disease|Left Ventricular Hypertrophy,Interventional,23-Dec-11,"AbbVie (prior sponsor, Abbott)",Drug: placebo
NCT00497146,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,Chronic Kidney Disease|Left Ventricular Hypertrophy,Interventional,23-Dec-11,Massachusetts General Hospital,Drug: paricalcitol
NCT00497146,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,Chronic Kidney Disease|Left Ventricular Hypertrophy,Interventional,23-Dec-11,Massachusetts General Hospital,Drug: placebo
NCT00497146,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,Chronic Kidney Disease|Left Ventricular Hypertrophy,Interventional,23-Dec-11,AbbVie,Drug: paricalcitol
NCT00497146,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,Chronic Kidney Disease|Left Ventricular Hypertrophy,Interventional,23-Dec-11,AbbVie,Drug: placebo
NCT00494013,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY),Diabetes Mellitus Type 2,Interventional,4-Nov-09,Eli Lilly and Company,Drug: Insulin Lispro Protamine Suspension
NCT00494013,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY),Diabetes Mellitus Type 2,Interventional,4-Nov-09,Eli Lilly and Company,Drug: Detemir
NCT00492024,BAY12-8039: 5 Days for Sinusitis vs Placebo,Sinusitis,Interventional,2-Dec-09,Bayer,"Drug: Moxifloxacin (Avelox, BAY12-8039)"
NCT00492024,BAY12-8039: 5 Days for Sinusitis vs Placebo,Sinusitis,Interventional,2-Dec-09,Bayer,Drug: Placebo
NCT00505687,An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease,Idiopathic Parkinson's Disease,Interventional,12-Jan-10,UCB Pharma,Drug: Rotigotine
NCT00490971,A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder,Bipolar Disorder,Interventional,5-Mar-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Olanzapine
NCT00490971,A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder,Bipolar Disorder,Interventional,5-Mar-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Paliperidone ER
NCT00490971,A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder,Bipolar Disorder,Interventional,5-Mar-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00490919,Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain,Low Back Pain,Interventional,9-Sep-10,Purdue Pharma LP,Drug: Buprenorphine transdermal system
NCT00490919,Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain,Low Back Pain,Interventional,9-Sep-10,Purdue Pharma LP,Drug: Placebo
NCT00489970,"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9",Acellular Pertussis|Tetanus|Diphtheria,Interventional,11-Aug-10,GlaxoSmithKline,Procedure: Taking of blood samples
NCT00489970,"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9",Acellular Pertussis|Tetanus|Diphtheria,Interventional,11-Aug-10,GlaxoSmithKline,Biological: Boostrix
NCT00489970,"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9",Acellular Pertussis|Tetanus|Diphtheria,Interventional,11-Aug-10,GlaxoSmithKline,Biological: Adacel
NCT00489541,TAXUS PERSEUS Small Vessel,Coronary Artery Disease,Interventional,28-Jun-11,Boston Scientific Corporation,Device: Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
NCT00488514,Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents,Migraine Disorders,Interventional,6-Sep-10,GlaxoSmithKline,Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium)
NCT00488319,Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.,Schizophrenia|Schizophrenic Disorders|Psychotic Disorders|Dementia Praecox,Interventional,6-Jan-14,"Janssen Research & Development, LLC",Drug: Paliperidone ER
NCT02377921,"Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)","Hereditary Inclusion Body Myopathy|Distal Myopathy With Rimmed Vacuoles|Distal Myopathy, Nonaka Type|GNE Myopathy",Interventional,9-Jul-18,Ultragenyx Pharmaceutical Inc,Drug: aceneuramic acid extended-release (Ace-ER)
NCT02377921,"Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)","Hereditary Inclusion Body Myopathy|Distal Myopathy With Rimmed Vacuoles|Distal Myopathy, Nonaka Type|GNE Myopathy",Interventional,9-Jul-18,Ultragenyx Pharmaceutical Inc,Drug: Placebo
NCT00500149,A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD),ADHD,Interventional,5-Jun-09,Shire,Drug: Vyvanse (lisdexamfetamine dimesylate)
NCT00500149,A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD),ADHD,Interventional,5-Jun-09,Shire,Drug: Placebo
NCT00486031,"Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study",Inflammatory Bowel Disease|Ulcerative Colitis,Interventional,19-Jan-18,"Bausch Health Americas, Inc.",Drug: Balsalazide Disodium
NCT00484419,"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin",Type 2 Diabetes|Hyperlipidemia,Interventional,17-Jun-09,"Daiichi Sankyo, Inc.",Drug: Colesevelam HCl
NCT00484419,"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin",Type 2 Diabetes|Hyperlipidemia,Interventional,17-Jun-09,"Daiichi Sankyo, Inc.",Drug: rosiglitazone maleate
NCT00484419,"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin",Type 2 Diabetes|Hyperlipidemia,Interventional,17-Jun-09,"Daiichi Sankyo, Inc.",Drug: sitagliptin phosphate
NCT00484315,TAXUS PERSEUS Workhorse,Coronary Artery Disease,Interventional,28-Jun-11,Boston Scientific Corporation,Device: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
NCT00484315,TAXUS PERSEUS Workhorse,Coronary Artery Disease,Interventional,28-Jun-11,Boston Scientific Corporation,Device: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
NCT00483652,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,Multiple Sclerosis,Interventional,14-Apr-11,Acorda Therapeutics,Drug: Fampridine-SR
NCT00483652,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,Multiple Sclerosis,Interventional,14-Apr-11,Acorda Therapeutics,Drug: Placebo
NCT00483574,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,6-Jul-11,"Sanofi Pasteur, a Sanofi Company",Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
NCT00483574,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,6-Jul-11,"Sanofi Pasteur, a Sanofi Company",Biological: Measles-mumps-rubella-varicella vaccine
NCT00483574,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,6-Jul-11,"Sanofi Pasteur, a Sanofi Company",Biological: Routine paediatric vaccine - Pneumococcal conjugate (PCV)
NCT00483574,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,6-Jul-11,"Sanofi Pasteur, a Sanofi Company",Biological: Routine paediatric vaccine - Hepatitis A
NCT00483574,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,6-Jul-11,Sanofi,Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
NCT00483574,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,6-Jul-11,Sanofi,Biological: Measles-mumps-rubella-varicella vaccine
NCT00483574,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,6-Jul-11,Sanofi,Biological: Routine paediatric vaccine - Pneumococcal conjugate (PCV)
NCT00483574,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,6-Jul-11,Sanofi,Biological: Routine paediatric vaccine - Hepatitis A
NCT00483548,Adjunctive Ziprasidone in the Treatment of Bipolar I Depression,"Bipolar Disorder|Depression, Bipolar",Interventional,23-Feb-10,Pfizer,Drug: Ziprasidone
NCT00483548,Adjunctive Ziprasidone in the Treatment of Bipolar I Depression,"Bipolar Disorder|Depression, Bipolar",Interventional,23-Feb-10,Pfizer,Drug: Placebo
NCT00479401,"Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients",Early Parkinson Disease (Early PD),Interventional,15-Apr-10,Boehringer Ingelheim,Drug: Pramipexol Extended Release
NCT00479401,"Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients",Early Parkinson Disease (Early PD),Interventional,15-Apr-10,Boehringer Ingelheim,Drug: Pramipexol Immediate Release
NCT00479401,"Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients",Early Parkinson Disease (Early PD),Interventional,15-Apr-10,Boehringer Ingelheim,Drug: Placebo
NCT00478192,Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia,Hyponatremia,Interventional,21-Apr-10,Cumberland Pharmaceuticals,Drug: Conivaptan
NCT00478192,Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia,Hyponatremia,Interventional,21-Apr-10,Cumberland Pharmaceuticals,Drug: Placebo
NCT00477672,A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Parkinson's Disease Psychosis,Interventional,26-Mar-14,ACADIA Pharmaceuticals Inc.,Drug: Pimavanserin tartrate (ACP-103)
NCT00477672,A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Parkinson's Disease Psychosis,Interventional,26-Mar-14,ACADIA Pharmaceuticals Inc.,Drug: Placebo
NCT00477633,Study of Safety and Efficacy of an Oral Contraceptive,Contraception,Interventional,24-Jan-11,Warner Chilcott,Drug: Norethindrone/ethinyl estradiol
NCT00477490,Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia,Nocturia,Interventional,2-Nov-15,Ferring Pharmaceuticals,Drug: desmopressin acetate
NCT00477490,Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia,Nocturia,Interventional,2-Nov-15,Ferring Pharmaceuticals,Drug: Placebo
NCT00475852,A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure,Heart Decompensation,Interventional,10-May-12,"Scios, Inc.",Drug: Nesiritide
NCT00475852,A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure,Heart Decompensation,Interventional,10-May-12,"Scios, Inc.",Drug: Placebo
NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,Renal Cell Carcinoma,Interventional,7-Mar-13,Pfizer,Drug: Sorafenib
NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,Renal Cell Carcinoma,Interventional,7-Mar-13,Pfizer,Drug: temsirolimus (Torisel)
NCT00474630,A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes,"Obesity|Overweight|Diabetes Mellitus, Type 2",Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/ day
NCT00474630,A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes,"Obesity|Overweight|Diabetes Mellitus, Type 2",Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Placebo
NCT00474630,A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes,"Obesity|Overweight|Diabetes Mellitus, Type 2",Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Behavioral: Ancillary therapy
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis Vaccines,Biological: Meningococcal ACWY Conjugate Vaccine
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis Vaccines,Biological: DTaP-IPV-HBV
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis Vaccines,Biological: Hib
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis Vaccines,Biological: Rotavirus
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis Vaccines,Biological: Pneumococcal 7-valent Conjugate Vaccine
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis Vaccines,Biological: HAV
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis Vaccines,Biological: MMR-V
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis Vaccines,Biological: DTaP
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis,Biological: Meningococcal ACWY Conjugate Vaccine
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis,Biological: DTaP-IPV-HBV
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis,Biological: Hib
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis,Biological: Rotavirus
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis,Biological: Pneumococcal 7-valent Conjugate Vaccine
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis,Biological: HAV
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis,Biological: MMR-V
NCT00474526,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,"Meningitis, Meningococcal",Interventional,24-Mar-14,Novartis,Biological: DTaP
NCT00471146,Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.,"Carcinoma, Pancreatic Ductal",Interventional,16-Jul-12,Pfizer,Drug: AG-013736
NCT00471146,Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.,"Carcinoma, Pancreatic Ductal",Interventional,16-Jul-12,Pfizer,Drug: Gemcitabine
NCT00471146,Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.,"Carcinoma, Pancreatic Ductal",Interventional,16-Jul-12,Pfizer,Drug: placebo
NCT00471328,Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib,Gastrointestinal Stromal Tumors,Interventional,17-May-11,Novartis Pharmaceuticals,Drug: Nilotinib
NCT00471328,Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib,Gastrointestinal Stromal Tumors,Interventional,17-May-11,Novartis Pharmaceuticals,Other: Best Supportive Care (BSC) +/- imatinib or sunitinib
NCT00471328,Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib,Gastrointestinal Stromal Tumors,Interventional,17-May-11,Novartis,Drug: Nilotinib
NCT00471328,Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib,Gastrointestinal Stromal Tumors,Interventional,17-May-11,Novartis,Other: Best Supportive Care (BSC) +/- imatinib or sunitinib
NCT00468728,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),Clostridium Infections|Diarrhea,Interventional,29-Jul-11,Optimer Pharmaceuticals LLC,Drug: PAR-101/OPT-80
NCT00468728,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),Clostridium Infections|Diarrhea,Interventional,29-Jul-11,Optimer Pharmaceuticals LLC,Drug: Vancomycin
NCT00468845,Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy,"Pain, Postoperative",Interventional,26-May-11,Pfizer,Drug: pregabalin (Lyrica)
NCT00468845,Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy,"Pain, Postoperative",Interventional,26-May-11,Pfizer,Drug: matched placebo
NCT00468559,Phase 3/Safety & Efficacy of Esomeprazole in Infants,Gastroesophageal Reflux Disease (GERD),Interventional,2-Jun-14,AstraZeneca,Drug: Open Label Run In Esomeprazole
NCT00468559,Phase 3/Safety & Efficacy of Esomeprazole in Infants,Gastroesophageal Reflux Disease (GERD),Interventional,2-Jun-14,AstraZeneca,Drug: Double Blind Esomeprazole
NCT00468559,Phase 3/Safety & Efficacy of Esomeprazole in Infants,Gastroesophageal Reflux Disease (GERD),Interventional,2-Jun-14,AstraZeneca,Drug: Double Blind Placebo
NCT00467519,Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age,Tetanus|Diphtheria|Pertussis,Interventional,3-Dec-10,"Sanofi Pasteur, a Sanofi Company",Biological: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)
NCT00467519,Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age,Tetanus|Diphtheria|Pertussis,Interventional,3-Dec-10,"Sanofi Pasteur, a Sanofi Company",Biological: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
NCT00467519,Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age,Tetanus|Diphtheria|Pertussis,Interventional,3-Dec-10,Sanofi,Biological: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)
NCT00467519,Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age,Tetanus|Diphtheria|Pertussis,Interventional,3-Dec-10,Sanofi,Biological: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
NCT00467259,Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women,Hypoactive Sexual Desire Disorder,Interventional,15-Dec-11,Warner Chilcott,Drug: Testosterone Transdermal System
NCT00467259,Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women,Hypoactive Sexual Desire Disorder,Interventional,15-Dec-11,Warner Chilcott,Drug: Placebo patch
NCT00465088,An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME),Hyperlipidemia|Mixed Dyslipidemia,Interventional,13-May-09,Abbott,Drug: Niacin ER/Simvastatin Tablets
NCT00465088,An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME),Hyperlipidemia|Mixed Dyslipidemia,Interventional,13-May-09,Abbott,Drug: atorvastatin
NCT00464269,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",Epilepsy,Interventional,13-Apr-16,UCB Pharma,Other: Placebo
NCT00464269,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",Epilepsy,Interventional,13-Apr-16,UCB Pharma,Drug: Brivaracetam 2.5 mg
NCT00464269,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",Epilepsy,Interventional,13-Apr-16,UCB Pharma,Drug: Brivaracetam 10 mg
NCT00464269,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",Epilepsy,Interventional,13-Apr-16,UCB Pharma,Drug: Brivaracetam 25 mg
NCT00463606,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,Hypercholesterolemia|Dyslipidemia,Interventional,1-Aug-12,AstraZeneca,Drug: ABT-335 and rosuvastatin calcium
NCT00463606,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,Hypercholesterolemia|Dyslipidemia,Interventional,1-Aug-12,AstraZeneca,Drug: ABT-335
NCT00463606,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,Hypercholesterolemia|Dyslipidemia,Interventional,1-Aug-12,AstraZeneca,Drug: rosuvastatin calcium
NCT00463047,Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain,Chronic Pain,Interventional,14-Dec-10,Cephalon,Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
NCT00463047,Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain,Chronic Pain,Interventional,14-Dec-10,Teva Pharmaceutical Industries,Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
NCT00462709,Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,Hereditary Angioedema,Interventional,3-May-10,Shire,Biological: C1 esterase inhibitor [human] (C1INH-nf)
NCT00461591,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611),Bladder Cancer,Interventional,15-Aug-17,"Spectrum Pharmaceuticals, Inc",Drug: Apaziquone
NCT00461591,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611),Bladder Cancer,Interventional,15-Aug-17,"Spectrum Pharmaceuticals, Inc",Drug: Placebo
NCT00461591,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611),Bladder Cancer,Interventional,15-Aug-17,"Spectrum Pharmaceuticals, Inc",Procedure: TURBT
NCT00543439,"Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII",Hemophilia A,Interventional,11-Jan-19,Pfizer,Biological: Moroctocog alfa (AF-CC)
NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,"Multiple Sclerosis, Relapsing-Remitting",Interventional,17-Aug-09,Bayer,"Drug: Interferon beta-1b (Betaseron, BAY86-5046)"
NCT00457392,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,"Carcinoma, Non-Small Cell Lung",Interventional,2-Aug-11,Pfizer,Drug: erlotinib
NCT00457392,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,"Carcinoma, Non-Small Cell Lung",Interventional,2-Aug-11,Pfizer,Drug: sunitinib
NCT00457392,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,"Carcinoma, Non-Small Cell Lung",Interventional,2-Aug-11,Pfizer,Drug: placebo
NCT00457015,Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE),Hereditary Angioedema (HAE),Interventional,4-May-10,Shire,Drug: ecallantide
NCT00457015,Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE),Hereditary Angioedema (HAE),Interventional,4-May-10,Shire,"Drug: Phosphate Buffer Saline (PBS), pH 7.0"
NCT00457002,Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness,Venous Thrombosis|Pulmonary Embolism,Interventional,20-May-14,Bristol-Myers Squibb,Drug: Apixaban
NCT00457002,Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness,Venous Thrombosis|Pulmonary Embolism,Interventional,20-May-14,Bristol-Myers Squibb,Drug: Enoxaparin
NCT00456508,Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE),Hereditary Angioedema (HAE),Interventional,28-Dec-12,Shire,Drug: ecallantide
NCT00468481,Efficacy and Safety Study for an Oral Contraceptive Containing Folate,Neural Tube Defects|Contraception|Oral Contraceptives (OC),Interventional,25-Jan-11,Bayer,Drug: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate
NCT00468481,Efficacy and Safety Study for an Oral Contraceptive Containing Folate,Neural Tube Defects|Contraception|Oral Contraceptives (OC),Interventional,25-Jan-11,Bayer,Drug: Drospirenone/Ethinylestradiol (Yaz)
NCT00451958,A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy,Prostate Cancer,Interventional,21-Mar-13,Ferring Pharmaceuticals,Drug: Degarelix 80 mg / Degarelix 80 mg
NCT00451958,A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy,Prostate Cancer,Interventional,21-Mar-13,Ferring Pharmaceuticals,Drug: Degarelix 160 mg / Degarelix 160 mg
NCT00451958,A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy,Prostate Cancer,Interventional,21-Mar-13,Ferring Pharmaceuticals,Drug: Leuprolide 7.5 mg / Degarelix 80 mg
NCT00451958,A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy,Prostate Cancer,Interventional,21-Mar-13,Ferring Pharmaceuticals,Drug: Leuprolide 7.5 mg / Degarelix 160 mg
NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,2-Jun-14,Biogen,Drug: BG00012
NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,2-Jun-14,Biogen,Drug: Placebo
NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,2-Jun-14,Biogen,Drug: Glatiramer Acetate
NCT00450437,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults,Meningococcal Infections|Meningococcal Meningitis,Interventional,24-Sep-10,Novartis Vaccines,Biological: MenACWY CRM
NCT00450437,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults,Meningococcal Infections|Meningococcal Meningitis,Interventional,24-Sep-10,Novartis Vaccines,Biological: Meningococcal ACWY Conjugate vaccine
NCT00450437,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults,Meningococcal Infections|Meningococcal Meningitis,Interventional,24-Sep-10,Novartis,Biological: MenACWY CRM
NCT00450437,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults,Meningococcal Infections|Meningococcal Meningitis,Interventional,24-Sep-10,Novartis,Biological: Meningococcal ACWY Conjugate vaccine
NCT00449540,Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura,Migraine With Aura,Interventional,10-Aug-11,Neuralieve,Device: Active Transcranial Magnetic Stimulation (TMS) Device
NCT00449540,Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura,Migraine With Aura,Interventional,10-Aug-11,Neuralieve,Device: Sham TMS Device
NCT00448916,Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures,"Epilepsies, Partial",Interventional,2-Dec-14,Pfizer,Drug: Pregabalin
NCT00448539,Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures,Refractory Partial Onset Seizures,Interventional,10-Dec-12,Eisai Inc.,Drug: Rufinamide
NCT00448539,Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures,Refractory Partial Onset Seizures,Interventional,10-Dec-12,Eisai Inc.,Drug: Placebo
NCT00448747,"Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.",Diagnosis of Adult Growth Hormone Deficiency (AGDH),Interventional,23-Jul-19,AEterna Zentaris,Drug: AEZS-130 (formerly ARD-07)
NCT00448747,"Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.",Diagnosis of Adult Growth Hormone Deficiency (AGDH),Interventional,23-Jul-19,AEterna Zentaris,Drug: L-ARG+GHRH
NCT00685373,"Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease",Cryopyrin-Associated Periodic Syndromes|Familial Cold Autoinflammatory Syndrome|Muckle Wells Syndrome|Neonatal Onset Multisystem Inflammatory Disease,Interventional,27-May-11,Novartis,Drug: Canakinumab (ACZ885)
NCT00447499,Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel,Acromegaly,Interventional,20-Dec-10,Ipsen,Drug: Somatuline Autogel (lanreotide acetate)
NCT00447499,Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel,Acromegaly,Interventional,20-Dec-10,Ipsen,Behavioral: Home administration
NCT00446199,Low-dose Hormone Therapy for Relief of Vasomotor Symptoms,Vasomotor Symptoms|Hot Flashes,Interventional,18-Apr-12,Bayer,Drug: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)
NCT00446199,Low-dose Hormone Therapy for Relief of Vasomotor Symptoms,Vasomotor Symptoms|Hot Flashes,Interventional,18-Apr-12,Bayer,Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
NCT00446199,Low-dose Hormone Therapy for Relief of Vasomotor Symptoms,Vasomotor Symptoms|Hot Flashes,Interventional,18-Apr-12,Bayer,Drug: Estradiol (E2 0.3mg)
NCT00446199,Low-dose Hormone Therapy for Relief of Vasomotor Symptoms,Vasomotor Symptoms|Hot Flashes,Interventional,18-Apr-12,Bayer,Drug: Placebo
NCT00456521,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day
NCT00456521,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Drug: Placebo
NCT00456521,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program,Obesity|Overweight,Interventional,21-Nov-14,"Orexigen Therapeutics, Inc",Behavioral: Intensive group lifestyle modification counseling
NCT00444925,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB),Overactive Bladder,Interventional,3-Sep-09,Pfizer,Drug: fesoterodine fumarate
NCT00444925,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB),Overactive Bladder,Interventional,3-Sep-09,Pfizer,Drug: placebo
NCT00444925,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB),Overactive Bladder,Interventional,3-Sep-09,Pfizer,Drug: tolterodine tartrate
NCT00444457,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,"Vaccines, Pneumococcal",Interventional,14-Jul-10,Wyeth is now a wholly owned subsidiary of Pfizer,Biological: 13-valent Pneumococcal Conjugate Vaccine
NCT00444457,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,"Vaccines, Pneumococcal",Interventional,14-Jul-10,Wyeth is now a wholly owned subsidiary of Pfizer,Biological: 7vPnC
NCT00443898,"Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Onychomycosis,Interventional,20-Apr-11,Novartis Pharmaceuticals,Drug: terbinafine
NCT00443898,"Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Onychomycosis,Interventional,20-Apr-11,Novartis Pharmaceuticals,Drug: Placebo
NCT00443898,"Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Onychomycosis,Interventional,20-Apr-11,Novartis,Drug: terbinafine
NCT00443898,"Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Onychomycosis,Interventional,20-Apr-11,Novartis,Drug: Placebo
NCT00443820,"Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Onychomycosis,Interventional,19-Apr-11,Novartis Pharmaceuticals,Drug: terbinafine
NCT00443820,"Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Onychomycosis,Interventional,19-Apr-11,Novartis Pharmaceuticals,Drug: Placebo
NCT00443820,"Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Onychomycosis,Interventional,19-Apr-11,Novartis,Drug: terbinafine
NCT00443820,"Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Onychomycosis,Interventional,19-Apr-11,Novartis,Drug: Placebo
NCT00442546,Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement,Osteoarthritis|Postoperative Pain,Interventional,18-Aug-10,Pfizer,Drug: pregabalin
NCT00442546,Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement,Osteoarthritis|Postoperative Pain,Interventional,18-Aug-10,Pfizer,Drug: Placebo
NCT00441727,Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA),Gastric Ulcer|Duodenal Ulcer,Interventional,13-Feb-12,AstraZeneca,Drug: Esomeprazole 40 mg
NCT00441727,Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA),Gastric Ulcer|Duodenal Ulcer,Interventional,13-Feb-12,AstraZeneca,Drug: Esomeprazole 20 mg
NCT00441727,Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA),Gastric Ulcer|Duodenal Ulcer,Interventional,13-Feb-12,AstraZeneca,Drug: Placebo
NCT00441545,Head to Head Study Against Sevelamer Hydrochloride,"Chronic Kidney Disease, Stage 5",Interventional,13-Aug-09,Shire,Drug: Fosrenol (Lanthanum Carbonate)
NCT00441545,Head to Head Study Against Sevelamer Hydrochloride,"Chronic Kidney Disease, Stage 5",Interventional,13-Aug-09,Shire,Drug: Sevelamer hydrochloride
NCT00441441,A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma,Asthma,Interventional,23-Sep-10,GlaxoSmithKline,Drug: fluticasone propionate
NCT00441441,A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma,Asthma,Interventional,23-Sep-10,GlaxoSmithKline,Drug: fluticasone propionate/salmeterol
NCT00442702,"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.",Anemia,Interventional,3-Oct-11,Hoffmann-La Roche,Drug: Mircera
NCT00442702,"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.",Anemia,Interventional,3-Oct-11,Hoffmann-La Roche,Drug: Darbepoetin alfa
NCT00440557,An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease,Anemia,Interventional,8-Feb-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Epoetin alfa 3 times weekly /once weekly
NCT00440557,An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease,Anemia,Interventional,8-Feb-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Epoetin alfa once weekly
NCT00440557,An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease,Anemia,Interventional,8-Feb-10,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Epoetin alfa once every two weeks
NCT00440466,PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients,Anemia|Renal Diseases,Interventional,14-Apr-11,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: epoetin alfa
NCT00439244,Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis,Osteoporosis,Interventional,20-Apr-11,Novartis,Drug: Zoledronic acid
NCT00439244,Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis,Osteoporosis,Interventional,20-Apr-11,Novartis,Drug: Placebo
NCT00439244,Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis,Osteoporosis,Interventional,20-Apr-11,Novartis,Drug: Teriparatide
NCT00438815,Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks,Hereditary Angioedema,Interventional,9-Jun-10,Shire,Biological: C1 esterase inhibitor [human] (C1INH-nf)
NCT00436553,Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization,Macular Degeneration|Choroidal Neovascularization,Interventional,19-Apr-11,Novartis,Drug: Verteporfin Photodynamic Therapy
NCT00436553,Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization,Macular Degeneration|Choroidal Neovascularization,Interventional,19-Apr-11,Novartis,Drug: Ranibizumab
NCT00436553,Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization,Macular Degeneration|Choroidal Neovascularization,Interventional,19-Apr-11,Novartis,Drug: Verteporfin Placebo
NCT00436553,Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization,Macular Degeneration|Choroidal Neovascularization,Interventional,19-Apr-11,Novartis,Drug: Ranibizumab Placebo
NCT00436969,ORTHOVISC Shoulder Osteoarthritis Study,Glenohumeral Osteoarthritis,Interventional,11-Apr-14,DePuy Mitek,Device: Orthovisc
NCT00436969,ORTHOVISC Shoulder Osteoarthritis Study,Glenohumeral Osteoarthritis,Interventional,11-Apr-14,DePuy Mitek,Drug: Control
NCT00435409,A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer,Breast Neoplasms,Interventional,13-Jan-11,Pfizer,Drug: Sunitinib + Capecitabine
NCT00435409,A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer,Breast Neoplasms,Interventional,13-Jan-11,Pfizer,Drug: Capecitabine
NCT00432276,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,4-Apr-13,Takeda,Drug: Alogliptin
NCT00432276,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,4-Apr-13,Takeda,Drug: Pioglitazone
NCT00432276,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,4-Apr-13,Takeda,Drug: Metformin
NCT00432276,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,4-Apr-13,Takeda,Drug: Placebo
NCT00431834,Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study,Atrial Fibrillation,Interventional,16-Oct-13,Medtronic Cardiovascular,Device: Cardioblate System Surgical Ablation System
NCT00431834,Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study,Atrial Fibrillation,Interventional,16-Oct-13,Medtronic Cardiovascular,Procedure: Surgical RF Ablation
NCT00430248,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Gout,Interventional,16-Jul-09,Takeda,Drug: Febuxostat
NCT00430248,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Gout,Interventional,16-Jul-09,Takeda,Drug: Allopurinol
NCT00434148,"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease",Cushing's Disease,Interventional,6-Feb-13,Novartis Pharmaceuticals,Drug: Pasireotide
NCT00434148,"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease",Cushing's Disease,Interventional,6-Feb-13,Novartis,Drug: Pasireotide
NCT00433771,A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction,"Cholestasis, Extrahepatic",Interventional,9-Feb-10,Boston Scientific Corporation,Device: WallFlex™ Biliary Fully Covered Metal Stent placement
NCT00428389,Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease,Alzheimer's Disease,Interventional,27-Jun-11,Novartis,Drug: Rivastigmine 5 cm^2 transdermal patch
NCT00428389,Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease,Alzheimer's Disease,Interventional,27-Jun-11,Novartis,Drug: Rivastigmine 10 cm^2 transdermal patch
NCT00428090,Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,19-May-17,GlaxoSmithKline,Drug: Rosiglitazone
NCT00427895,Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pneumococcal Infections,Interventional,5-Sep-12,Pfizer,Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
NCT00427895,Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Pneumococcal Infections,Interventional,5-Sep-12,Pfizer,Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
NCT00426660,Expanded Access Program for Maraviroc At Multiple Centers,HIV Infections,Interventional,17-Oct-11,ViiV Healthcare,Drug: maraviroc
NCT00425100,A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients,Overactive Bladder,Interventional,10-Feb-09,Pfizer,Drug: fesoterodine fumarate
NCT00423813,A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.,Fibromyalgia,Interventional,10-Jan-12,Jazz Pharmaceuticals,Drug: placebo
NCT00423813,A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.,Fibromyalgia,Interventional,10-Jan-12,Jazz Pharmaceuticals,Drug: Xyrem®
NCT00423657,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,Bacterial Infections,Interventional,18-Nov-10,Forest Laboratories,Drug: ceftaroline
NCT00423657,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,Bacterial Infections,Interventional,18-Nov-10,Forest Laboratories,Drug: vancomycin plus aztreonam
NCT00423657,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,Bacterial Infections,Interventional,18-Nov-10,Forest Laboratories,Drug: Placebo
NCT00423605,Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.,Fibromyalgia,Interventional,20-Oct-11,Jazz Pharmaceuticals,Drug: Xyrem®
NCT00423319,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3),Deep Vein Thrombosis|Pulmonary Embolism,Interventional,14-May-14,Bristol-Myers Squibb,Drug: Enoxaparin
NCT00423319,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3),Deep Vein Thrombosis|Pulmonary Embolism,Interventional,14-May-14,Bristol-Myers Squibb,Drug: Apixaban
NCT00423319,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3),Deep Vein Thrombosis|Pulmonary Embolism,Interventional,14-May-14,Bristol-Myers Squibb,Drug: Enoxaparin-matching placebo
NCT00423319,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3),Deep Vein Thrombosis|Pulmonary Embolism,Interventional,14-May-14,Bristol-Myers Squibb,Drug: Apixaban-matching placebo
NCT00424190,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,Bacterial Infections,Interventional,8-Nov-10,Forest Laboratories,Drug: IV Vancomycin plus IV Aztreonam
NCT00424190,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,Bacterial Infections,Interventional,8-Nov-10,Forest Laboratories,Drug: Ceftaroline
NCT00423046,Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age,"Infections, Papillomavirus",Interventional,25-Aug-10,GlaxoSmithKline,Biological: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)
NCT00423046,Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age,"Infections, Papillomavirus",Interventional,25-Aug-10,GlaxoSmithKline,Biological: Gardasil ® (Merck & Co. Inc)
NCT00423046,Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age,"Infections, Papillomavirus",Interventional,25-Aug-10,GlaxoSmithKline,Biological: Placebo
NCT00422292,Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,2-Jun-11,"Sanofi Pasteur, a Sanofi Company",Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
NCT00422292,Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,2-Jun-11,"Sanofi Pasteur, a Sanofi Company","Biological: Measles, Mumps, Rubella and Varicella"
NCT00422292,Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,2-Jun-11,Sanofi,Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
NCT00422292,Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,2-Jun-11,Sanofi,"Biological: Measles, Mumps, Rubella and Varicella"
NCT00421993,A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,11-Mar-09,Galderma,Drug: Adapalene/Benzoyl Peroxide
NCT00421993,A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,11-Mar-09,Galderma,Drug: Adapalene
NCT00421993,A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,11-Mar-09,Galderma,Drug: Benzoyl Peroxide
NCT00421993,A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Interventional,11-Mar-09,Galderma,Drug: Topical Gel Vehicle
NCT00420992,"A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee",Osteoarthritis|Chronic Pain,Interventional,30-Oct-09,Pfizer,Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)
NCT00420992,"A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee",Osteoarthritis|Chronic Pain,Interventional,30-Oct-09,Pfizer,Drug: Placebo
NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,2-Jun-14,Biogen,Drug: BG00012
NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis,Interventional,2-Jun-14,Biogen,Drug: Placebo
NCT00419952,A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.,Asthma,Interventional,30-Oct-12,AstraZeneca,Drug: Budesonide/formoterol (SYMBICORT) pMDI
NCT00419952,A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.,Asthma,Interventional,30-Oct-12,AstraZeneca,Drug: Budesonide HFA pMDI
NCT00419757,"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma",Asthma,Interventional,27-Aug-12,AstraZeneca,Drug: Budesonide/formoterol (SYMBICORT) pMDI
NCT00419757,"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma",Asthma,Interventional,27-Aug-12,AstraZeneca,Drug: Budesonide HFA pMDI
NCT00419744,A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD,Chronic Obstructive Pulmonary Disease,Interventional,16-Sep-10,AstraZeneca,Drug: Budesonide/formoterol (SYMBICORT) pMDI
NCT00419744,A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD,Chronic Obstructive Pulmonary Disease,Interventional,16-Sep-10,AstraZeneca,Drug: Formoterol Turbuhaler
NCT00419393,Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures,Epilepsy,Interventional,13-Jul-11,UCB Pharma,Drug: Keppra XR (Levetiracetam XR)
NCT00419094,Conversion to Monotherapy Study With Keppra XR for Partial Seizures,Epilepsy,Interventional,20-Dec-10,UCB Pharma,Drug: Keppra XR
NCT00419341,Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy,Primary Immune Deficiency,Interventional,25-Jan-13,CSL Behring,Biological: Human Normal Immunoglobulin for Subcutaneous Administration
NCT00491894,Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions,Cerebral Palsy|Neurological Conditions|Mental Retardation|Sialorrhea,Interventional,9-Jul-12,Shionogi,Drug: Oral Glycopyrrolate Liquid
NCT00491894,Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions,Cerebral Palsy|Neurological Conditions|Mental Retardation|Sialorrhea,Interventional,9-Jul-12,Shionogi Inc.,Drug: Oral Glycopyrrolate Liquid
NCT00415597,"Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain",Pain,Interventional,29-Oct-09,Pfizer,Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
NCT00414908,A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy,Chronic Pancreatitis|Pancreatectomy|Pancreatic Exocrine Insufficiency,Interventional,16-Sep-09,Solvay Pharmaceuticals,Drug: Pancrelipase delayed release capsule
NCT00414908,A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy,Chronic Pancreatitis|Pancreatectomy|Pancreatic Exocrine Insufficiency,Interventional,16-Sep-09,Solvay Pharmaceuticals,Drug: Placebo Comparator
NCT00415194,A Study for Patients With Head and Neck Cancer,Head and Neck Neoplasms,Interventional,6-Apr-11,Eli Lilly and Company,Drug: pemetrexed
NCT00415194,A Study for Patients With Head and Neck Cancer,Head and Neck Neoplasms,Interventional,6-Apr-11,Eli Lilly and Company,Drug: cisplatin
NCT00415194,A Study for Patients With Head and Neck Cancer,Head and Neck Neoplasms,Interventional,6-Apr-11,Eli Lilly and Company,Drug: placebo
NCT00413699,"Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis","Arthritis, Rheumatoid",Interventional,27-Mar-18,Pfizer,"Drug: CP-690,550"
NCT00413010,Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).,Generalized Anxiety Disorder,Interventional,2-Dec-09,Pfizer,Drug: pregabalin
NCT00413010,Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).,Generalized Anxiety Disorder,Interventional,2-Dec-09,Pfizer,Drug: placebo
NCT00412984,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Atrial Fibrillation|Atrial Flutter,Interventional,29-Apr-13,Bristol-Myers Squibb,Drug: warfarin
NCT00412984,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Atrial Fibrillation|Atrial Flutter,Interventional,29-Apr-13,Bristol-Myers Squibb,Drug: apixaban
NCT00412061,Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor,Carcinoid Tumor|Malignant Carcinoid Syndrome,Interventional,12-Mar-12,Novartis Pharmaceuticals,Drug: Octreotide
NCT00412061,Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor,Carcinoid Tumor|Malignant Carcinoid Syndrome,Interventional,12-Mar-12,Novartis Pharmaceuticals,Drug: Placebo
NCT00412061,Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor,Carcinoid Tumor|Malignant Carcinoid Syndrome,Interventional,12-Mar-12,Novartis Pharmaceuticals,Drug: Everolimus
NCT00412061,Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor,Carcinoid Tumor|Malignant Carcinoid Syndrome,Interventional,12-Mar-12,Novartis,Drug: Octreotide
NCT00412061,Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor,Carcinoid Tumor|Malignant Carcinoid Syndrome,Interventional,12-Mar-12,Novartis,Drug: Placebo
NCT00412061,Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor,Carcinoid Tumor|Malignant Carcinoid Syndrome,Interventional,12-Mar-12,Novartis,Drug: Everolimus
NCT00411645,Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients,Cytomegalovirus Infections,Interventional,3-Jun-15,Shire,Drug: maribavir
NCT00411645,Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients,Cytomegalovirus Infections,Interventional,3-Jun-15,Shire,Other: placebo
NCT00410410,A Study of Abatacept in Patients With Active Ulcerative Colitis,Ulcerative Colitis,Interventional,2-Dec-10,Bristol-Myers Squibb,Drug: abatacept (ABA)
NCT00410410,A Study of Abatacept in Patients With Active Ulcerative Colitis,Ulcerative Colitis,Interventional,2-Dec-10,Bristol-Myers Squibb,Drug: placebo
NCT00410410,A Study of Abatacept in Patients With Active Ulcerative Colitis,Ulcerative Colitis,Interventional,2-Dec-10,Bristol-Myers Squibb,Drug: abatacept
NCT00410124,RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib,Metastatic Renal Cell Carcinoma,Interventional,15-Jan-13,Novartis Pharmaceuticals,Drug: RAD001
NCT00410124,RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib,Metastatic Renal Cell Carcinoma,Interventional,15-Jan-13,Novartis Pharmaceuticals,Drug: Placebo
NCT00410124,RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib,Metastatic Renal Cell Carcinoma,Interventional,15-Jan-13,Novartis,Drug: RAD001
NCT00410124,RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib,Metastatic Renal Cell Carcinoma,Interventional,15-Jan-13,Novartis,Drug: Placebo
NCT00410072,Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B,"Hepatitis B, Chronic",Interventional,3-Feb-12,Bristol-Myers Squibb,Drug: Entecavir
NCT00410072,Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B,"Hepatitis B, Chronic",Interventional,3-Feb-12,Bristol-Myers Squibb,Drug: Entecavir + Tenofovir
NCT00409682,Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease,Crohn's Disease,Interventional,4-Aug-11,Abbott,Biological: Adalimumab
NCT00408629,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis,Ulcerative Colitis,Interventional,31-Mar-11,Abbott,Biological: adalimumab
NCT00408629,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis,Ulcerative Colitis,Interventional,31-Mar-11,Abbott,Biological: placebo
NCT00408421,Duloxetine Versus Placebo for Osteoarthritis Knee Pain,Osteoarthritis Knee Pain,Interventional,19-Aug-09,Eli Lilly and Company,Drug: Duloxetine
NCT00408421,Duloxetine Versus Placebo for Osteoarthritis Knee Pain,Osteoarthritis Knee Pain,Interventional,19-Aug-09,Eli Lilly and Company,Drug: placebo
NCT00407745,A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury,Neuralgia|Spinal Cord Injuries,Interventional,8-Dec-11,Pfizer,Drug: placebo
NCT00407745,A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury,Neuralgia|Spinal Cord Injuries,Interventional,8-Dec-11,Pfizer,Drug: pregabalin
NCT00406640,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women,"Depression|Depressive Disorder|Depressive Disorder, Major",Interventional,29-Jun-10,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Desvenlafaxine succinate sustained-release (DVS SR)
NCT00406640,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women,"Depression|Depressive Disorder|Depressive Disorder, Major",Interventional,29-Jun-10,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Escitalopram
NCT00402363,"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","Fibrillation, Atrial",Interventional,15-Oct-10,GlaxoSmithKline,Drug: omega-3-acid ethyl esters
NCT00402363,"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","Fibrillation, Atrial",Interventional,15-Oct-10,GlaxoSmithKline,Drug: Placebo
NCT00401245,The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms,Vasomotor Symptoms,Interventional,12-Oct-11,Pfizer,Drug: desvenlafaxine succinate sustained release
NCT00401245,The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms,Vasomotor Symptoms,Interventional,12-Oct-11,Pfizer,Drug: Placebo
NCT00401193,Efficacy and Safety of XP12B in Women With Menorrhagia,Menorrhagia|Heavy Menstrual Bleeding,Interventional,24-Feb-10,Ferring Pharmaceuticals,Drug: Tranexamic acid tablets
NCT00401193,Efficacy and Safety of XP12B in Women With Menorrhagia,Menorrhagia|Heavy Menstrual Bleeding,Interventional,24-Feb-10,Ferring Pharmaceuticals,Drug: Placebo tablets
NCT02207413,A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children,Influenza,Interventional,20-Jun-16,GlaxoSmithKline,Biological: Influsplit Tetra™ vaccine produced by investigational process (IP)
NCT02207413,A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children,Influenza,Interventional,20-Jun-16,GlaxoSmithKline,Biological: Influsplit Tetra™ vaccine produced by licensed process (LP)
NCT00474058,Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine,Parkinson's Disease,Interventional,12-Apr-10,UCB Pharma,Drug: Rotigotine
NCT00474058,Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine,Parkinson's Disease,Interventional,12-Apr-10,UCB Pharma,Other: Placebo
NCT00400153,Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,1-Jun-09,Boehringer Ingelheim,Drug: Atrovent Respimat (20 mcg)
NCT00400153,Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,1-Jun-09,Boehringer Ingelheim,Drug: COMBIVENT MDI (36/206 mcg)
NCT00400153,Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,1-Jun-09,Boehringer Ingelheim,Drug: Combivent Respimat (20 mcg/100 mcg)
NCT00400153,Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Interventional,1-Jun-09,Boehringer Ingelheim,Drug: Placebo via corresponding inhaler for blinding purposes
NCT00399568,Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery,Postoperative Pain|Hysterectomy,Interventional,10-Dec-10,Mallinckrodt,Drug: IV Acetaminophen
NCT00399568,Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery,Postoperative Pain|Hysterectomy,Interventional,10-Dec-10,Mallinckrodt,Drug: IV Placebo 100 mL solution
NCT00398476,Fluticasone Nasal Spray Patient Preference Study,"Rhinitis, Allergic, Perennial",Interventional,29-Jan-18,GlaxoSmithKline,Drug: fluticasone propionate (FP)
NCT00398476,Fluticasone Nasal Spray Patient Preference Study,"Rhinitis, Allergic, Perennial",Interventional,29-Jan-18,GlaxoSmithKline,Drug: fluticasone furoate (FF)
NCT00396097,"Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,13-Nov-13,Pfizer,Drug: Genotropin
NCT00395512,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,27-Mar-13,Takeda,Drug: Alogliptin
NCT00395512,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,27-Mar-13,Takeda,Drug: Pioglitazone
NCT00395512,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,27-Mar-13,Takeda,Drug: Placebo
NCT02187744,A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),Early Breast Cancer,Interventional,7-Apr-17,Pfizer,Biological: PF-05280014
NCT02187744,A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),Early Breast Cancer,Interventional,7-Apr-17,Pfizer,Drug: Taxotere®
NCT02187744,A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),Early Breast Cancer,Interventional,7-Apr-17,Pfizer,Drug: Paraplatin®
NCT02187744,A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),Early Breast Cancer,Interventional,7-Apr-17,Pfizer,Biological: Trastuzumab-EU
NCT00391872,A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome,Interventional,13-Mar-12,AstraZeneca,Drug: Ticagrelor
NCT00391872,A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome,Interventional,13-Mar-12,AstraZeneca,Drug: Clopidogrel
NCT00391807,Study of Safety and Efficacy of an Oral Contraceptive,Contraception,Interventional,22-Dec-10,Warner Chilcott,Drug: Norethindrone acetate/ethinyl estradiol
NCT00391443,BUILD 3: Bosentan Use in Interstitial Lung Disease,Idiopathic Pulmonary Fibrosis,Interventional,25-May-12,Actelion,Drug: Bosentan
NCT00391443,BUILD 3: Bosentan Use in Interstitial Lung Disease,Idiopathic Pulmonary Fibrosis,Interventional,25-May-12,Actelion,Drug: Placebo
NCT00391053,"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly",Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Interventional,30-Apr-10,"Sanofi Pasteur, a Sanofi Company","Biological: High-Dose Inactivated, Split-Virion Influenza Vaccine"
NCT00391053,"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly",Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Interventional,30-Apr-10,"Sanofi Pasteur, a Sanofi Company","Biological: Inactivated, Split-Virion Influenza Vaccine"
NCT00391053,"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly",Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Interventional,30-Apr-10,Sanofi,"Biological: High-Dose Inactivated, Split-Virion Influenza Vaccine"
NCT00391053,"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly",Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Interventional,30-Apr-10,Sanofi,"Biological: Inactivated, Split-Virion Influenza Vaccine"
NCT00390806,Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer,"Lung Cancer, Non-Small Cell",Interventional,20-Jan-14,GlaxoSmithKline,"Drug: HYCAMTIN, oral capsules"
NCT00390806,Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer,"Lung Cancer, Non-Small Cell",Interventional,20-Jan-14,GlaxoSmithKline,Radiation: Radiation
NCT00390780,Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients,HIV Infections,Interventional,29-Aug-13,Onxeo,Drug: miconazole Lauriad
NCT00390780,Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients,HIV Infections,Interventional,29-Aug-13,Onxeo,Drug: Clotrimazole
NCT00389064,Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder,Anxiety Disorders,Interventional,23-Jun-09,AstraZeneca,Drug: Quetiapine XR
NCT00389064,Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder,Anxiety Disorders,Interventional,23-Jun-09,AstraZeneca,Drug: Placebo
NCT00388505,Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis,Cystic Fibrosis,Interventional,24-Jul-12,Novartis Pharmaceuticals,Drug: Tobramycin Inhalation Powder
NCT00388505,Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis,Cystic Fibrosis,Interventional,24-Jul-12,Novartis Pharmaceuticals,Drug: Tobramycin Solution for Inhalation
NCT00388505,Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis,Cystic Fibrosis,Interventional,24-Jul-12,Novartis,Drug: Tobramycin Inhalation Powder
NCT00388505,Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis,Cystic Fibrosis,Interventional,24-Jul-12,Novartis,Drug: Tobramycin Solution for Inhalation
NCT00388973,Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder,Major Depressive Disorder,Interventional,1-Apr-10,AstraZeneca,Drug: Quetiapine
NCT00387881,TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1),"Migraine, Without Aura",Interventional,10-Jul-09,GlaxoSmithKline,Drug: sumatriptan succinate / naproxen sodium
NCT00387881,TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1),"Migraine, Without Aura",Interventional,10-Jul-09,GlaxoSmithKline,Drug: Placebo
NCT00387088,Tiotropium / Respimat One Year Study in COPD.,"Pulmonary Disease, Chronic Obstructive",Interventional,22-Jan-10,Boehringer Ingelheim,Device: Respimat
NCT00387088,Tiotropium / Respimat One Year Study in COPD.,"Pulmonary Disease, Chronic Obstructive",Interventional,22-Jan-10,Boehringer Ingelheim,Drug: Tiotropium
NCT01001377,ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Interventional,24-Mar-14,Amgen,Drug: Cetuximab
NCT01001377,ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Interventional,24-Mar-14,Amgen,Drug: Panitumumab
NCT00386308,Efficacy and Safety Study of XP12B in Women With Menorrhagia,Menorrhagia|Heavy Menstrual Bleeding,Interventional,22-Feb-10,Ferring Pharmaceuticals,Drug: Tranexamic acid tablets
NCT00386308,Efficacy and Safety Study of XP12B in Women With Menorrhagia,Menorrhagia|Heavy Menstrual Bleeding,Interventional,22-Feb-10,Ferring Pharmaceuticals,Drug: Placebo tablets
NCT00385736,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis,Ulcerative Colitis,Interventional,27-May-10,Abbott,Biological: adalimumab
NCT00385736,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis,Ulcerative Colitis,Interventional,27-May-10,Abbott,Biological: placebo
NCT00384397,"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers",Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,2-Jun-11,"Sanofi Pasteur, a Sanofi Company",Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
NCT00384397,"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers",Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,2-Jun-11,"Sanofi Pasteur, a Sanofi Company",Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
NCT00384397,"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers",Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,2-Jun-11,Sanofi,Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
NCT00384397,"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers",Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Interventional,2-Jun-11,Sanofi,Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
NCT00385255,"Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults",Acellular Pertussis|Diphtheria|Tetanus,Interventional,17-Sep-18,GlaxoSmithKline,Biological: Fluarix®
NCT00385255,"Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults",Acellular Pertussis|Diphtheria|Tetanus,Interventional,17-Sep-18,GlaxoSmithKline,Biological: Boostrix®
NCT00395018,Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection,"Hepatitis B, Chronic",Interventional,31-May-12,Bristol-Myers Squibb,Drug: entecavir
NCT00384033,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder,"Depressive Disorder, Major",Interventional,15-Mar-12,Pfizer,Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
NCT00384033,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder,"Depressive Disorder, Major",Interventional,15-Mar-12,Pfizer,Drug: Placebo
NCT00384033,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder,"Depressive Disorder, Major",Interventional,15-Mar-12,Pfizer,Drug: Duloxetine 60 mg/day
NCT00383162,A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2),Migraine Disorders,Interventional,17-Feb-10,GlaxoSmithKline,Drug: Combination Product (sumatriptan succinate / naproxen sodium)
NCT00383162,A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2),Migraine Disorders,Interventional,17-Feb-10,GlaxoSmithKline,Drug: Placebo
NCT00383123,Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children,Influenza,Interventional,4-Dec-08,GlaxoSmithKline,Biological: Fluarix™
NCT00383123,Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children,Influenza,Interventional,4-Dec-08,GlaxoSmithKline,Biological: Fluzone
NCT00382993,A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2),Migraine Disorders,Interventional,20-Apr-10,GlaxoSmithKline,Drug: Placebo
NCT00382993,A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2),Migraine Disorders,Interventional,20-Apr-10,GlaxoSmithKline,Drug: Combination Product (sumatriptan succinate/naproxen sodium)
NCT00452426,Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy,"Colonoscopy|Endoscopy, Digestive System|Conscious Sedation",Interventional,25-Jan-11,Ethicon Endo-Surgery,Device: Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)
NCT00452426,Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy,"Colonoscopy|Endoscopy, Digestive System|Conscious Sedation",Interventional,25-Jan-11,Ethicon Endo-Surgery,Other: benzodiazepines and opioid sedation
NCT00380068,Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension,Pulmonary Hypertension,Interventional,19-Nov-10,Gilead Sciences,Drug: Ambrisentan
NCT00375674,A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer,Kidney Neoplasms,Interventional,18-Aug-17,Pfizer,Drug: Sunitinib malate
NCT00375674,A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer,Kidney Neoplasms,Interventional,18-Aug-17,Pfizer,Other: Placebo
NCT00374322,Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer,"Neoplasms, Breast",Interventional,18-Aug-14,GlaxoSmithKline,Drug: lapatinib
NCT00374322,Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer,"Neoplasms, Breast",Interventional,18-Aug-14,GlaxoSmithKline,Other: placebo
NCT00373958,Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,"Vaccines, Pneumococcal",Interventional,21-Feb-13,Pfizer,Biological: 13 valent pneumococcal conjugate vaccine
NCT00373958,Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,"Vaccines, Pneumococcal",Interventional,21-Feb-13,Pfizer,Biological: 7vPnc pneumococcal conjugate vaccine
NCT00373425,A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors,Non-small Cell Lung Cancer,Interventional,3-Jun-14,OSI Pharmaceuticals,Drug: Erlotinib
NCT00373425,A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors,Non-small Cell Lung Cancer,Interventional,3-Jun-14,OSI Pharmaceuticals,Drug: Placebo
NCT00373425,A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors,Non-small Cell Lung Cancer,Interventional,3-Jun-14,Astellas Pharma Inc,Drug: Erlotinib
NCT00373425,A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors,Non-small Cell Lung Cancer,Interventional,3-Jun-14,Astellas Pharma Inc,Drug: Placebo
NCT00373334,Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease|GERD|Heartburn,Interventional,17-Nov-09,Braintree Laboratories,Drug: nizatidine (axid)
NCT00373334,Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease|GERD|Heartburn,Interventional,17-Nov-09,Braintree Laboratories,Drug: placebo
NCT00373256,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Interventional,8-Oct-10,Pfizer,Drug: Sunitinib
NCT00373256,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Interventional,8-Oct-10,Pfizer,Drug: paclitaxel
NCT00373256,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Interventional,8-Oct-10,Pfizer,Drug: bevacizumab
NCT00371683,Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,Deep Vein Thrombosis|Pulmonary Embolism,Interventional,30-Dec-15,Bristol-Myers Squibb,Drug: Enoxaparin + Placebo
NCT00371683,Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,Deep Vein Thrombosis|Pulmonary Embolism,Interventional,30-Dec-15,Bristol-Myers Squibb,Drug: Apixaban + Placebo
NCT00371137,A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia,Fibromyalgia,Interventional,30-Nov-11,Jazz Pharmaceuticals,Drug: Xyrem®
NCT00371137,A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia,Fibromyalgia,Interventional,30-Nov-11,Jazz Pharmaceuticals,Drug: Placebo
NCT00370331,RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag,"Purpura, Thrombocytopaenic, Idiopathic",Interventional,23-Feb-10,GlaxoSmithKline,Drug: eltrombopag
NCT00370331,RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag,"Purpura, Thrombocytopaenic, Idiopathic",Interventional,23-Feb-10,GlaxoSmithKline,Drug: Placebo
NCT00369824,Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects,"Infections, Papillomavirus",Interventional,8-Oct-09,GlaxoSmithKline,Biological: Different formulations of GSK Biologicals' HPV vaccine (580299)
NCT00369824,Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects,"Infections, Papillomavirus",Interventional,8-Oct-09,GlaxoSmithKline,Biological: Menactra TM
NCT00369824,Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects,"Infections, Papillomavirus",Interventional,8-Oct-09,GlaxoSmithKline,Biological: Boostrix TM
NCT00369343,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women,"Depression|Depressive Disorder|Depressive Disorder, Major",Interventional,7-May-12,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
NCT00369343,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women,"Depression|Depressive Disorder|Depressive Disorder, Major",Interventional,7-May-12,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Placebo
NCT00368108,"Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",Parkinson's Disease,Interventional,5-Feb-13,Eisai Inc.,Drug: 2 mg perampanel
NCT00368108,"Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",Parkinson's Disease,Interventional,5-Feb-13,Eisai Inc.,Drug: 4 mg perampanel
NCT00368108,"Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",Parkinson's Disease,Interventional,5-Feb-13,Eisai Inc.,Drug: placebo comparator
NCT00367835,SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms,ADHD,Interventional,26-Nov-09,Shire,Drug: SPD503 (Guanfacine hydrochloride)
NCT00367835,SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms,ADHD,Interventional,26-Nov-09,Shire,Drug: Placebo
NCT00393939,Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Interventional,28-Feb-11,Pfizer,Drug: Sunitinib malate
NCT00393939,Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Interventional,28-Feb-11,Pfizer,Drug: Taxotere
NCT00366249,Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.,Bacterial Infections|Diabetic Foot|Osteomyelitis,Interventional,21-Aug-09,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Tigecycline
NCT00366249,Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.,Bacterial Infections|Diabetic Foot|Osteomyelitis,Interventional,21-Aug-09,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Ertapenem
NCT00365300,Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,7-Jan-10,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: pantoprazole
NCT00365300,Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux,Interventional,7-Jan-10,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: Placebo
NCT00364351,Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy,Non Small Cell Lung Cancer,Interventional,24-May-11,"Genzyme, a Sanofi Company",Drug: Vandetanib
NCT00364351,Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy,Non Small Cell Lung Cancer,Interventional,24-May-11,"Genzyme, a Sanofi Company",Drug: Erlotinib
NCT00364351,Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy,Non Small Cell Lung Cancer,Interventional,24-May-11,Sanofi,Drug: Vandetanib
NCT00364351,Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy,Non Small Cell Lung Cancer,Interventional,24-May-11,Sanofi,Drug: Erlotinib
NCT00363415,Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer,Small Cell Lung Cancer,Interventional,6-Oct-09,Eli Lilly and Company,Drug: pemetrexed
NCT00363415,Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer,Small Cell Lung Cancer,Interventional,6-Oct-09,Eli Lilly and Company,Drug: etoposide
NCT00363415,Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer,Small Cell Lung Cancer,Interventional,6-Oct-09,Eli Lilly and Company,Drug: carboplatin
NCT00363142,A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects,"HIV Infection|Infection, Human Immunodeficiency Virus",Interventional,24-Sep-09,GlaxoSmithKline,Drug: Half-boosted Fosamprenavir
NCT00363142,A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects,"HIV Infection|Infection, Human Immunodeficiency Virus",Interventional,24-Sep-09,GlaxoSmithKline,Drug: Full Boosted Fosamprenavir
NCT00362609,Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD,Gastroesophageal Reflux,Interventional,14-May-10,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: pantoprazole
NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,Venous Thromboembolism,Interventional,13-Jun-12,Bayer,"Drug: Rivaroxaban (Xarelto, BAY59-7939)"
NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,Venous Thromboembolism,Interventional,13-Jun-12,Bayer,Drug: Enoxaparin
NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,Venous Thromboembolism,Interventional,13-Jun-12,Bayer,Drug: Placebo: tablet of Rivaroxaban
NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,Venous Thromboembolism,Interventional,13-Jun-12,Bayer,Drug: Placebo: syringes of Enoxaparin
NCT00361569,"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy",Menopause,Interventional,14-Apr-09,Duramed Research,Drug: DR-2041a
NCT00361569,"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy",Menopause,Interventional,14-Apr-09,Duramed Research,Drug: DR-2041b
NCT00361569,"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy",Menopause,Interventional,14-Apr-09,Duramed Research,Other: Placebo
NCT00361569,"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy",Menopause,Interventional,14-Apr-09,Teva Pharmaceutical Industries,Drug: DR-2041a
NCT00361569,"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy",Menopause,Interventional,14-Apr-09,Teva Pharmaceutical Industries,Drug: DR-2041b
NCT00361569,"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy",Menopause,Interventional,14-Apr-09,Teva Pharmaceutical Industries,Other: Placebo
NCT00360555,Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,"Sexual Dysfunctions, Psychological",Interventional,27-Jun-16,"Sprout Pharmaceuticals, Inc",Drug: flibanserin
NCT00360555,Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,"Sexual Dysfunctions, Psychological",Interventional,27-Jun-16,"Sprout Pharmaceuticals, Inc",Drug: flibanserin 50mg
NCT00360555,Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,"Sexual Dysfunctions, Psychological",Interventional,27-Jun-16,"Sprout Pharmaceuticals, Inc",Drug: flibanserin 100mg
NCT00360555,Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,"Sexual Dysfunctions, Psychological",Interventional,27-Jun-16,"Sprout Pharmaceuticals, Inc",Drug: placebo
NCT00360529,24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder,"Sexual Dysfunctions, Psychological",Interventional,27-Jun-16,"Sprout Pharmaceuticals, Inc",Drug: flibanserin
NCT00360490,Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS),Menorrhagia,Interventional,19-Nov-09,Bayer,"Drug: Levonorgestrel IUS (Mirena, BAY86-5028)"
NCT00360490,Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS),Menorrhagia,Interventional,19-Nov-09,Bayer,Drug: Medroxyprogesterone acetate
NCT00360243,6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA,"Sexual Dysfunctions, Psychological",Interventional,27-Jun-16,"Sprout Pharmaceuticals, Inc",Drug: flibanserin
NCT00360243,6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA,"Sexual Dysfunctions, Psychological",Interventional,27-Jun-16,"Sprout Pharmaceuticals, Inc",Drug: placebo
NCT00359983,"Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB",Neisseria Meningitidis|Haemophilus Influenzae Type b,Interventional,20-Jul-12,GlaxoSmithKline,Biological: MenHibrix (Hib-MenCY-TT)
NCT00359983,"Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB",Neisseria Meningitidis|Haemophilus Influenzae Type b,Interventional,20-Jul-12,GlaxoSmithKline,Biological: Hib conjugate vaccine (ActHIB)
NCT00359021,An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).,HIV-1,Interventional,7-Mar-13,"Tibotec Pharmaceuticals, Ireland",Drug: TMC125
NCT00358501,Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients,Severe Hepatic Veno-Occlusive Disease,Interventional,30-Jan-17,Jazz Pharmaceuticals,Drug: Defibrotide
NCT00358501,Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients,Severe Hepatic Veno-Occlusive Disease,Interventional,30-Jan-17,FDA Office of Orphan Products Development,Drug: Defibrotide
NCT00358436,Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,1-Nov-12,AstraZeneca,Drug: Aclidinium bromide
NCT00358436,Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD),Chronic Obstructive Pulmonary Disease (COPD),Interventional,1-Nov-12,AstraZeneca,Drug: Placebo
NCT00358215,RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial,Heart Failure|Anemia|Cardiovascular Disease|Ventricular Dysfunction|Congestive Heart Failure,Interventional,13-Dec-13,Amgen,Drug: Darbepoetin alfa
NCT00358215,RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial,Heart Failure|Anemia|Cardiovascular Disease|Ventricular Dysfunction|Congestive Heart Failure,Interventional,13-Dec-13,Amgen,Drug: Placebo
NCT00356408,"Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease",Crohn's Disease,Interventional,25-May-11,UCB Pharma,Biological: Certolizumab pegol
NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Multiple Sclerosis,Interventional,26-Jun-12,Novartis,Drug: Fingolimod
NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Multiple Sclerosis,Interventional,26-Jun-12,Novartis,Drug: Placebo
NCT00355082,Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy,"Epilepsy, Partial",Interventional,25-Nov-09,GlaxoSmithKline,"Drug: lamotrigine, 300 mg/day"
NCT00355082,Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy,"Epilepsy, Partial",Interventional,25-Nov-09,GlaxoSmithKline,"Drug: lamotrigine, 250 mg/day"
NCT00351468,EXTEND (Eltrombopag Extended Dosing Study),"Purpura, Thrombocytopaenic, Idiopathic",Interventional,17-Apr-17,Novartis Pharmaceuticals,Drug: eltrombopag olamine (SB-497115-GR)
NCT00351468,EXTEND (Eltrombopag Extended Dosing Study),"Purpura, Thrombocytopaenic, Idiopathic",Interventional,17-Apr-17,Novartis,Drug: eltrombopag olamine (SB-497115-GR)
NCT00350636,A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo,Overactive Bladder,Interventional,10-May-10,Watson Pharmaceuticals,Drug: Oxybutynin topical gel
NCT00350636,A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo,Overactive Bladder,Interventional,10-May-10,Watson Pharmaceuticals,Other: Placebo topical gel
NCT00348374,Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes,Diabetes Mellitus,Interventional,16-Mar-10,Pfizer,Drug: Insulin Lispro
NCT00348374,Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes,Diabetes Mellitus,Interventional,16-Mar-10,Pfizer,Drug: Exubera
NCT00348140,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,5-Sep-17,GlaxoSmithKline,Drug: Rosiglitazone Extended Release 2mg
NCT00348140,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,5-Sep-17,GlaxoSmithKline,Drug: Rosiglitazone Extended Release 8mg
NCT00348140,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,Alzheimer's Disease,Interventional,5-Sep-17,GlaxoSmithKline,Other: Placebo
NCT00347360,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,Hypertension,Interventional,9-Nov-09,GlaxoSmithKline,Drug: lisinopril
NCT00347360,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,Hypertension,Interventional,9-Nov-09,GlaxoSmithKline,Drug: carvedilol controlled release formulation
NCT00346073,Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years,Acellular Pertussis|Diphtheria|Tetanus,Interventional,7-Aug-18,GlaxoSmithKline,Biological: Boostrix™
NCT00346073,Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years,Acellular Pertussis|Diphtheria|Tetanus,Interventional,7-Aug-18,GlaxoSmithKline,Biological: ADACEL®
NCT00345683,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.",Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,20-Jul-12,GlaxoSmithKline,Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)
NCT00345683,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.",Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,20-Jul-12,GlaxoSmithKline,Biological: PedvaxHIB
NCT00345683,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.",Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,20-Jul-12,GlaxoSmithKline,Biological: Prevnar
NCT00345683,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.",Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,20-Jul-12,GlaxoSmithKline,Biological: M-M-R II
NCT00345683,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.",Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,20-Jul-12,GlaxoSmithKline,Biological: Varivax
NCT00345631,Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device,"Angioplasty, Transluminal, Percutaneous Coronary|Coronary Arteriosclerosis|Peripheral Arteriosclerosis",Interventional,19-Mar-12,Cordis Corporation,Other: Manual Compression
NCT00345631,Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device,"Angioplasty, Transluminal, Percutaneous Coronary|Coronary Arteriosclerosis|Peripheral Arteriosclerosis",Interventional,19-Mar-12,Cordis Corporation,Device: Vascular Closure Device
NCT00345579,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age",Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,20-Jul-12,GlaxoSmithKline,Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014
NCT00345579,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age",Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,20-Jul-12,GlaxoSmithKline,Biological: ActHIB
NCT00345579,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age",Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,20-Jul-12,GlaxoSmithKline,Biological: Pediarix/Infanrix Penta
NCT00343460,APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer,"Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,28-Dec-16,Heron Therapeutics,Drug: APF530
NCT00343460,APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer,"Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,28-Dec-16,Heron Therapeutics,Drug: dexamethasone
NCT00343460,APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer,"Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,28-Dec-16,Heron Therapeutics,Drug: Palonosetron Hydrochloride
NCT00343460,APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer,"Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,28-Dec-16,Heron Therapeutics,Other: placebo
NCT00343252,Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis,"Osteoporosis, Postmenopausal|Back Pain|Spinal Fracture",Interventional,12-Jul-10,Eli Lilly and Company,Drug: teriparatide
NCT00343252,Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis,"Osteoporosis, Postmenopausal|Back Pain|Spinal Fracture",Interventional,12-Jul-10,Eli Lilly and Company,Drug: risedronate
NCT00343252,Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis,"Osteoporosis, Postmenopausal|Back Pain|Spinal Fracture",Interventional,12-Jul-10,Eli Lilly and Company,Drug: placebo
NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Multiple Sclerosis,Interventional,16-May-11,Novartis,Drug: Fingolimod 1.25 mg
NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Multiple Sclerosis,Interventional,16-May-11,Novartis,Drug: Fingolimod 0.5 mg
NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Multiple Sclerosis,Interventional,16-May-11,Novartis,Drug: Interferon β-1a 30 µg
NCT00528957,Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children,HIV Infections,Interventional,22-Mar-12,Gilead Sciences,Drug: Tenofovir DF
NCT00528957,Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children,HIV Infections,Interventional,22-Mar-12,Gilead Sciences,Drug: Zidovudine
NCT00528957,Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children,HIV Infections,Interventional,22-Mar-12,Gilead Sciences,Drug: Stavudine
NCT00338286,A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy,Breast Cancer|Neoplasm Metastasis,Interventional,24-Mar-16,"Janssen Research & Development, LLC",Other: Standard supportive care (packed RBC transfusion)
NCT00338286,A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy,Breast Cancer|Neoplasm Metastasis,Interventional,24-Mar-16,"Janssen Research & Development, LLC",Drug: epoetin alfa + packed RBC transfusion
NCT00337103,E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes,Metastatic Breast Cancer,Interventional,30-Sep-13,Eisai Inc.,Drug: Eribulin Mesylate
NCT00337103,E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes,Metastatic Breast Cancer,Interventional,30-Sep-13,Eisai Inc.,Drug: Capecitabine
NCT00336492,A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis,Ulcerative Colitis,Interventional,10-Aug-11,"Centocor, Inc.",Biological: infliximab
NCT00336544,Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia,Pneumonia,Interventional,26-Feb-10,"Advanced Life Sciences, Inc.",Drug: Cethromycin
NCT00336544,Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia,Pneumonia,Interventional,26-Feb-10,"Advanced Life Sciences, Inc.",Drug: Clarithromycin
NCT02073682,Cancer Venous Thromboembolism (VTE),Venous Thromboembolism (VTE)|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Cancer,Interventional,24-Oct-18,"Daiichi Sankyo, Inc.",Drug: Edoxaban
NCT02073682,Cancer Venous Thromboembolism (VTE),Venous Thromboembolism (VTE)|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Cancer,Interventional,24-Oct-18,"Daiichi Sankyo, Inc.",Drug: Dalteparin
NCT02073682,Cancer Venous Thromboembolism (VTE),Venous Thromboembolism (VTE)|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Cancer,Interventional,24-Oct-18,"Daiichi Sankyo, Inc.",Drug: Low molecular weight heparin
NCT00334958,Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures,Epilepsy,Interventional,5-Feb-13,Eisai Inc.,Drug: Placebo
NCT00334958,Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures,Epilepsy,Interventional,5-Feb-13,Eisai Inc.,Drug: Rufinamide
NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemia,Interventional,14-Oct-13,Novartis Pharmaceuticals,Drug: imatinib mesilate
NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemia,Interventional,14-Oct-13,Novartis Pharmaceuticals,Drug: interferon-alpha (INF-a)
NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemia,Interventional,14-Oct-13,Novartis Pharmaceuticals,Drug: cytarabine (ARA-C)
NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemia,Interventional,14-Oct-13,Novartis,Drug: imatinib mesilate
NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemia,Interventional,14-Oct-13,Novartis,Drug: interferon-alpha (INF-a)
NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemia,Interventional,14-Oct-13,Novartis,Drug: cytarabine (ARA-C)
NCT00333788,Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease,Crohn's Disease,Interventional,12-Jul-11,UCB Pharma,Biological: Certolizumab pegol (CDP870)
NCT00332488,Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Oct-14,Mannkind Corporation,Drug: Technosphere Insulin
NCT00332488,Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Oct-14,Mannkind Corporation,Drug: Metformin & Secretagogues
NCT00332488,Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Interventional,16-Oct-14,Mannkind Corporation,Drug: Technosphere Insulin & Metformin
NCT00332202,PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin,Non Hodgkin Lymphoma,Interventional,10-Sep-18,Eli Lilly and Company,Drug: enzastaurin
NCT00332202,PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin,Non Hodgkin Lymphoma,Interventional,10-Sep-18,Eli Lilly and Company,Drug: placebo
NCT00332189,Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006,Phenylketonuria,Interventional,16-Nov-12,BioMarin Pharmaceutical,Drug: sapropterin dihydrochloride
NCT00918580,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease,Pneumococcal Conjugate Vaccine,Interventional,21-Apr-14,Pfizer,Biological: 13-valent Pneumoccocal Conjugate Vaccine
NCT00329238,Secondary Prevention of Venous Thrombo Embolism (VTE).,Thromboembolism,Interventional,14-Sep-11,Boehringer Ingelheim,Drug: Dabigatran
NCT00329238,Secondary Prevention of Venous Thrombo Embolism (VTE).,Thromboembolism,Interventional,14-Sep-11,Boehringer Ingelheim,Drug: Warfarin
NCT00328627,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,Type 2 Diabetes Mellitus,Interventional,4-Apr-13,Takeda,Drug: Alogliptin
NCT00328627,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,Type 2 Diabetes Mellitus,Interventional,4-Apr-13,Takeda,Drug: Alogliptin placebo
NCT00328627,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,Type 2 Diabetes Mellitus,Interventional,4-Apr-13,Takeda,Drug: Pioglitazone
NCT00328627,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,Type 2 Diabetes Mellitus,Interventional,4-Apr-13,Takeda,Drug: Pioglitazone placebo
NCT00327015,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Saxagliptin
NCT00327015,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Metformin
NCT00327015,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Placebo
NCT00327015,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: pioglitazone
NCT00325442,FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH),Pulmonary Hypertension,Interventional,10-Jun-13,United Therapeutics,Drug: Oral treprostinil (UT-15C) sustained release tablets
NCT00325442,FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH),Pulmonary Hypertension,Interventional,10-Jun-13,United Therapeutics,Drug: Placebo
NCT00325403,FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH),Pulmonary Hypertension,Interventional,18-Mar-13,United Therapeutics,Drug: Oral treprostinil (UT-15C) Sustained Release Tablets
NCT00325403,FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH),Pulmonary Hypertension,Interventional,18-Mar-13,United Therapeutics,Other: Placebo
NCT00325195,Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout,Gout,Interventional,25-Feb-11,Savient Pharmaceuticals,Other: placebo
NCT00325195,Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout,Gout,Interventional,25-Feb-11,Savient Pharmaceuticals,Biological: pegloticase
NCT00323284,A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma,Open-Angle Glaucoma,Interventional,4-Oct-12,Glaukos Corporation,Device: iStent plus Cataract Surgery
NCT00323284,A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma,Open-Angle Glaucoma,Interventional,4-Oct-12,Glaukos Corporation,Procedure: Cataract surgery only
NCT00322153,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,Dementia of the Alzheimer's Type,Interventional,16-Sep-10,Forest Laboratories,Drug: memantine ER
NCT00322153,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,Dementia of the Alzheimer's Type,Interventional,16-Sep-10,Forest Laboratories,Drug: Placebo
NCT00353496,Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours,Endocrine Tumors,Interventional,18-Feb-15,Ipsen,Drug: lanreotide (Autogel formulation)
NCT00353496,Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours,Endocrine Tumors,Interventional,18-Feb-15,Ipsen,Drug: Placebo
NCT00321984,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease,Gastroesophageal Reflux Disease,Interventional,23-Mar-09,Takeda,Drug: Dexlansoprazole MR
NCT00321984,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease,Gastroesophageal Reflux Disease,Interventional,23-Mar-09,Takeda,Drug: Placebo
NCT00321737,Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,28-Aug-09,Takeda,Drug: Dexlansoprazole MR
NCT00321737,Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,28-Aug-09,Takeda,Drug: Placebo
NCT00320710,Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer,Breast Cancer,Interventional,4-Aug-14,Novartis Pharmaceuticals,Drug: Zoledronic acid
NCT00320710,Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer,Breast Cancer,Interventional,4-Aug-14,Novartis Pharmaceuticals,Drug: Placebo
NCT00320710,Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer,Breast Cancer,Interventional,4-Aug-14,Novartis,Drug: Zoledronic acid
NCT00320710,Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer,Breast Cancer,Interventional,4-Aug-14,Novartis,Drug: Placebo
NCT00320385,Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer,"Neoplasms, Breast",Interventional,30-Nov-11,GlaxoSmithKline,Drug: Lapatinib
NCT00320385,Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer,"Neoplasms, Breast",Interventional,30-Nov-11,GlaxoSmithKline,Biological: Trastuzumab
NCT00320489,Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia,Schizophrenia,Interventional,22-Oct-10,Eli Lilly and Company,Drug: olanzapine
NCT00320489,Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia,Schizophrenia,Interventional,22-Oct-10,Eli Lilly and Company,Drug: olanzapine pamoate depot
NCT00319696,Bosentan in Digital Ulcers,Digital Ulcers,Interventional,8-Aug-12,Actelion,Drug: Bosentan 62.5 mg
NCT00319696,Bosentan in Digital Ulcers,Digital Ulcers,Interventional,8-Aug-12,Actelion,Drug: Bosentan 125 mg
NCT00319501,Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.,"Seizures|Epilepsies, Partial|Epilepsy, Complex Partial|Epilepsy, Generalized|Epilepsy",Interventional,16-Aug-16,Pfizer,Drug: Placebo
NCT00319501,Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.,"Seizures|Epilepsies, Partial|Epilepsy, Complex Partial|Epilepsy, Generalized|Epilepsy",Interventional,16-Aug-16,Pfizer,Drug: Vanquix Auto-Injector (Diazepam Injection)
NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),Acute Myelogenous Leukemia,Interventional,15-Sep-11,"Genzyme, a Sanofi Company",Drug: clofarabine (IV formulation)
NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),Acute Myelogenous Leukemia,Interventional,15-Sep-11,"Genzyme, a Sanofi Company",Drug: placebo
NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),Acute Myelogenous Leukemia,Interventional,15-Sep-11,"Genzyme, a Sanofi Company",Drug: cytarabine
NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),Acute Myelogenous Leukemia,Interventional,15-Sep-11,Sanofi,Drug: clofarabine (IV formulation)
NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),Acute Myelogenous Leukemia,Interventional,15-Sep-11,Sanofi,Drug: placebo
NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),Acute Myelogenous Leukemia,Interventional,15-Sep-11,Sanofi,Drug: cytarabine
NCT00322556,Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID),Agammaglobulinemia|IgG Deficiency|Common Variable Immunodeficiency,Interventional,26-Oct-12,CSL Behring,Drug: Immunoglobulins Intravenous (Human)
NCT00316082,Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Saxagliptin
NCT00316082,Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Placebo
NCT00316082,Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: metformin
NCT00315445,The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.,Back Pain,Interventional,10-Aug-11,Purdue Pharma LP,Drug: Buprenorphine transdermal patch
NCT00315445,The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.,Back Pain,Interventional,10-Aug-11,Purdue Pharma LP,Drug: Placebo oxycodone/acetaminophen tablets
NCT00315445,The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.,Back Pain,Interventional,10-Aug-11,Purdue Pharma LP,Drug: OXY/APAP
NCT00315445,The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.,Back Pain,Interventional,10-Aug-11,Purdue Pharma LP,Drug: Placebo transdermal patch (TDS)
NCT00314132,Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.,Encephalitis|Japanese Encephalitis,Interventional,5-Dec-12,Sanofi,"Biological: ChimeriVax-JE, Japanese Encephalitis vaccine"
NCT00314132,Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.,Encephalitis|Japanese Encephalitis,Interventional,5-Dec-12,Sanofi,Biological: 0.9% Saline
NCT00313846,Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee,Osteoarthritis,Interventional,28-Sep-10,Purdue Pharma LP,Drug: Buprenorphine transdermal patch
NCT00313846,Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee,Osteoarthritis,Interventional,28-Sep-10,Purdue Pharma LP,Drug: Placebo
NCT00313313,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Saxagliptin
NCT00313313,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Glyburide
NCT00313313,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Placebo
NCT00313313,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,Diabetes,Interventional,25-Sep-09,AstraZeneca,Drug: Metformin
NCT00312572,Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain,Osteoarthritis,Interventional,23-Sep-10,Purdue Pharma LP,Drug: Buprenorphine transdermal patch
NCT00312494,3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects,Bipolar Disorder,Interventional,22-Jan-10,Pfizer,Drug: Placebo
NCT00312494,3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects,Bipolar Disorder,Interventional,22-Jan-10,Pfizer,Drug: Ziprasidone
NCT00312377,ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer,Non-small Cell Lung Cancer|Lung Cancer,Interventional,24-May-11,"Genzyme, a Sanofi Company",Drug: Docetaxel
NCT00312377,ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer,Non-small Cell Lung Cancer|Lung Cancer,Interventional,24-May-11,"Genzyme, a Sanofi Company",Drug: Vandetanib
NCT00312377,ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer,Non-small Cell Lung Cancer|Lung Cancer,Interventional,24-May-11,Sanofi,Drug: Docetaxel
NCT00312377,ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer,Non-small Cell Lung Cancer|Lung Cancer,Interventional,24-May-11,Sanofi,Drug: Vandetanib
NCT00310375,Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial,Epilepsy,Interventional,25-Nov-16,GlaxoSmithKline,Drug: Ezogabine: USAN Retigabine (International Nonproprietary Name)
NCT00309244,Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up,Diabetes Type 2,Interventional,16-Oct-14,Mannkind Corporation,Drug: Technosphere® Insulin Inhalation Powder
NCT00309244,Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up,Diabetes Type 2,Interventional,16-Oct-14,Mannkind Corporation,Drug: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
NCT00308737,Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes,"Diabetes, Type 1|Diabetes, Type 2",Interventional,16-Oct-14,Mannkind Corporation,Drug: Technosphere® Insulin Inhalation Powder
NCT00308737,Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes,"Diabetes, Type 1|Diabetes, Type 2",Interventional,16-Oct-14,Mannkind Corporation,Drug: Usual Care
NCT00308711,Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor,"Cervical Ripening|Labor, Induced",Interventional,19-Feb-10,Ferring Pharmaceuticals,Drug: Misoprostol vaginal insert 100 mcg
NCT00308711,Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor,"Cervical Ripening|Labor, Induced",Interventional,19-Feb-10,Ferring Pharmaceuticals,Drug: Misoprostol vaginal insert 50 mcg
NCT00308711,Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor,"Cervical Ripening|Labor, Induced",Interventional,19-Feb-10,Ferring Pharmaceuticals,Drug: Dinoprostone vaginal insert (Cervidil)
NCT00308581,Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab,Crohn's Disease,Interventional,17-Nov-09,UCB Pharma,Biological: Certolizumab pegol
NCT00308581,Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab,Crohn's Disease,Interventional,17-Nov-09,UCB Pharma,Other: Placebo
NCT00308308,Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes,"Diabetes, Type I",Interventional,16-Oct-14,Mannkind Corporation,Drug: Technosphere Insulin
NCT00308308,Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes,"Diabetes, Type I",Interventional,16-Oct-14,Mannkind Corporation,Drug: Active comparator
NCT00308139,Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1),Type 2 Diabetes Mellitus,Interventional,17-Aug-12,AstraZeneca,"Drug: exenatide, long acting release"
NCT00308139,Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1),Type 2 Diabetes Mellitus,Interventional,17-Aug-12,AstraZeneca,Drug: exenatide
NCT00307437,A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis,Psoriasis,Interventional,2-Nov-12,"Centocor Research & Development, Inc.",Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg
NCT00307437,A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis,Psoriasis,Interventional,2-Nov-12,"Centocor Research & Development, Inc.",Drug: Ustekinumab (CNTO 1275) 45 mg
NCT00307437,A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis,Psoriasis,Interventional,2-Nov-12,"Centocor Research & Development, Inc.",Drug: Ustekinumab (CNTO 1275) 90 mg
NCT00307047,SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System,Coronary Artery Disease,Interventional,21-Oct-10,Abbott Medical Devices,Device: XIENCE V® Everolimus Eluting Coronary Stent
NCT00307047,SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System,Coronary Artery Disease,Interventional,21-Oct-10,Abbott Medical Devices,Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
NCT00306787,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Genital Herpes,Interventional,17-Jun-11,Novartis Pharmaceuticals,Drug: Famciclovir
NCT00306787,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Genital Herpes,Interventional,17-Jun-11,Novartis Pharmaceuticals,Drug: Valacyclovir
NCT00306787,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Genital Herpes,Interventional,17-Jun-11,Novartis Pharmaceuticals,Drug: Placebo matching famciclovir
NCT00306787,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Genital Herpes,Interventional,17-Jun-11,Novartis Pharmaceuticals,Drug: Placebo matching valacyclovir
NCT00306787,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Genital Herpes,Interventional,17-Jun-11,Novartis,Drug: Famciclovir
NCT00306787,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Genital Herpes,Interventional,17-Jun-11,Novartis,Drug: Valacyclovir
NCT00306787,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Genital Herpes,Interventional,17-Jun-11,Novartis,Drug: Placebo matching famciclovir
NCT00306787,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Genital Herpes,Interventional,17-Jun-11,Novartis,Drug: Placebo matching valacyclovir
NCT00306384,Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,22-Mar-13,Takeda,Drug: Alogliptin
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Graft Rejection,Interventional,16-Aug-12,Novartis Pharmaceuticals,Drug: everolimus
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Graft Rejection,Interventional,16-Aug-12,Novartis Pharmaceuticals,Drug: mycophenolate mofetil
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Graft Rejection,Interventional,16-Aug-12,Novartis Pharmaceuticals,Drug: cyclosporine
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Graft Rejection,Interventional,16-Aug-12,Novartis Pharmaceuticals,Drug: corticosteroids
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Graft Rejection,Interventional,16-Aug-12,Novartis,Drug: everolimus
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Graft Rejection,Interventional,16-Aug-12,Novartis,Drug: mycophenolate mofetil
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Graft Rejection,Interventional,16-Aug-12,Novartis,Drug: cyclosporine
NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Graft Rejection,Interventional,16-Aug-12,Novartis,Drug: corticosteroids
NCT00297115,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125),Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-May-11,AstraZeneca,Drug: Roflumilast
NCT00297115,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125),Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-May-11,AstraZeneca,Drug: Placebo
NCT00297102,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124),Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-May-11,AstraZeneca,Drug: Roflumilast
NCT00297102,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124),Chronic Obstructive Pulmonary Disease (COPD),Interventional,19-May-11,AstraZeneca,Drug: Placebo
NCT00295750,The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer,Prostate Cancer,Interventional,16-Apr-09,Ferring Pharmaceuticals,Drug: Degarelix
NCT00295750,The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer,Prostate Cancer,Interventional,16-Apr-09,Ferring Pharmaceuticals,Drug: Leuprolide 7.5 mg
NCT00295633,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,"Diabetes Mellitus, Type 2",Interventional,25-Sep-09,AstraZeneca,Drug: Saxagliptin
NCT00295633,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,"Diabetes Mellitus, Type 2",Interventional,25-Sep-09,AstraZeneca,Drug: Placebo
NCT00295633,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,"Diabetes Mellitus, Type 2",Interventional,25-Sep-09,AstraZeneca,Drug: pioglitazone
NCT00295633,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,"Diabetes Mellitus, Type 2",Interventional,25-Sep-09,AstraZeneca,Drug: rosiglitazone
NCT00295633,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,"Diabetes Mellitus, Type 2",Interventional,25-Sep-09,AstraZeneca,Drug: metformin
NCT00294515,IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients,Cytomegalovirus Infections,Interventional,5-Jul-10,Hoffmann-La Roche,Drug: Valganciclovir
NCT00294047,Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older,"Infections, Papillomavirus",Interventional,27-Mar-12,GlaxoSmithKline,Biological: Cervarix
NCT00294047,Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older,"Infections, Papillomavirus",Interventional,27-Mar-12,GlaxoSmithKline,Biological: Placebo control
NCT00293059,Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding,Metrorrhagia,Interventional,6-Jun-11,Bayer,"Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)"
NCT00293059,Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding,Metrorrhagia,Interventional,6-Jun-11,Bayer,Drug: Placebo
NCT00292981,C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study),Hereditary Angioedema,Interventional,23-Jun-11,CSL Behring,Drug: C1 Esterase Inhibitor
NCT00291330,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,Thromboembolism,Interventional,11-Feb-11,Boehringer Ingelheim,Drug: dabigatran etexilate 150 mg
NCT00291330,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,Thromboembolism,Interventional,11-Feb-11,Boehringer Ingelheim,Drug: warfarin (INR 2-3)
NCT00291187,VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia,Insomnia,Interventional,15-Oct-14,Vanda Pharmaceuticals,Drug: 20 mg VEC-162
NCT00291187,VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia,Insomnia,Interventional,15-Oct-14,Vanda Pharmaceuticals,Drug: 50 mg VEC-162
NCT00291187,VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia,Insomnia,Interventional,15-Oct-14,Vanda Pharmaceuticals,Drug: 100 mg VEC-162
NCT00291187,VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia,Insomnia,Interventional,15-Oct-14,Vanda Pharmaceuticals,Drug: Placebo
NCT00289783,Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine,Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,6-Aug-12,GlaxoSmithKline,Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine
NCT00289783,Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine,Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,6-Aug-12,GlaxoSmithKline,Biological: ActHIB
NCT00289783,Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine,Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,6-Aug-12,GlaxoSmithKline,Biological: PedvaxHIB
NCT00289783,Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine,Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,6-Aug-12,GlaxoSmithKline,Biological: Pediarix
NCT00289783,Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine,Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,6-Aug-12,GlaxoSmithKline,Biological: Prevnar
NCT00289783,Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine,Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,6-Aug-12,GlaxoSmithKline,Biological: M-M-R II
NCT00289783,Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine,Haemophilus Influenzae Type b|Neisseria Meningitidis,Interventional,6-Aug-12,GlaxoSmithKline,Biological: Varivax
NCT00470600,Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients,Pain,Interventional,8-Dec-11,Cumberland Pharmaceuticals,Drug: Caldolor
NCT00470600,Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients,Pain,Interventional,8-Dec-11,Cumberland Pharmaceuticals,Other: Normal Saline
NCT00289211,C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks,Hereditary Angioedema,Interventional,2-Jun-10,Shire,Biological: C1 esterase inhibitor [human] (C1INH-nf)
NCT00289211,C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks,Hereditary Angioedema,Interventional,2-Jun-10,Shire,Drug: Placebo (saline)
NCT00288704,Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS),"Familial Cold Autoinflammatory Syndrome (FCAS)|Familial Cold Urticaria|Muckle-Wells Syndrome (MWS)|Genetic Diseases, Inborn",Interventional,13-Nov-09,Regeneron Pharmaceuticals,Drug: rilonacept 160 mg
NCT00288704,Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS),"Familial Cold Autoinflammatory Syndrome (FCAS)|Familial Cold Urticaria|Muckle-Wells Syndrome (MWS)|Genetic Diseases, Inborn",Interventional,13-Nov-09,Regeneron Pharmaceuticals,Drug: Placebo
NCT00288509,Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia,Cervical Dystonia,Interventional,2-Apr-10,Ipsen,Drug: abobotulinumtoxinA (Dysport) 250-1000 units
NCT00286494,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,27-Sep-11,Takeda,Drug: Alogliptin and pioglitazone
NCT00286494,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,27-Sep-11,Takeda,Drug: Pioglitazone
NCT00286468,Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.,Diabetes Mellitus,Interventional,25-Aug-11,Takeda,Drug: Alogliptin and glyburide
NCT00286468,Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.,Diabetes Mellitus,Interventional,25-Aug-11,Takeda,Drug: Glyburide
NCT00286455,Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes,Diabetes Mellitus,Interventional,29-Aug-11,Takeda,Drug: Alogliptin
NCT00286455,Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes,Diabetes Mellitus,Interventional,29-Aug-11,Takeda,Drug: Placebo
NCT00286442,Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,25-Aug-11,Takeda,Drug: Alogliptin and metformin
NCT00286442,Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,25-Aug-11,Takeda,Drug: Metformin
NCT00286429,Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.,Diabetes Mellitus,Interventional,12-Aug-11,Takeda,Drug: Alogliptin and insulin
NCT00286429,Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.,Diabetes Mellitus,Interventional,12-Aug-11,Takeda,Drug: Insulin
NCT00286078,Treatment for Migraines With an Implantable Device,Migraine,Interventional,9-Aug-16,Boston Scientific Corporation,Device: Precision
NCT00285012,Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).,Smoking Cessation,Interventional,3-Dec-09,Pfizer,Drug: placebo
NCT00285012,Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).,Smoking Cessation,Interventional,3-Dec-09,Pfizer,Drug: Varenicline Tartarate
NCT00282464,A Six-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.,Bipolar Disorder,Interventional,2-Jun-09,Pfizer,Drug: Placebo
NCT00282464,A Six-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.,Bipolar Disorder,Interventional,2-Jun-09,Pfizer,Drug: Geodon (Ziprasidone)
NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,Hypertension,Interventional,28-Apr-10,Boehringer Ingelheim,Drug: Amlodipine 5 mg
NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,Hypertension,Interventional,28-Apr-10,Boehringer Ingelheim,Drug: Placebo
NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,Hypertension,Interventional,28-Apr-10,Boehringer Ingelheim,Drug: Telmisartan 20 mg
NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,Hypertension,Interventional,28-Apr-10,Boehringer Ingelheim,Drug: Telmisartan 40 mg
NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,Hypertension,Interventional,28-Apr-10,Boehringer Ingelheim,Drug: Amlodipine 10 mg
NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,Hypertension,Interventional,28-Apr-10,Boehringer Ingelheim,Drug: Telmisartan 80 mg
NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,Hypertension,Interventional,28-Apr-10,Boehringer Ingelheim,Drug: Amlodipine 2.5 mg
NCT00280566,Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed),Bipolar Mania|Bipolar Disorder,Interventional,14-Dec-09,Pfizer,Drug: Placebo
NCT00280566,Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed),Bipolar Mania|Bipolar Disorder,Interventional,14-Dec-09,Pfizer,Drug: Ziprasidone Oral Capsule
NCT00273052,COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension,Hypertension,Interventional,1-Feb-10,GlaxoSmithKline,Drug: Carvedilol Phosphate modified release formulation
NCT00273052,COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension,Hypertension,Interventional,1-Feb-10,GlaxoSmithKline,Drug: metoprolol succinate
NCT00348283,Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon,Crohn's Disease,Interventional,11-Feb-10,Abbott,Biological: adalimumab
NCT00348283,Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon,Crohn's Disease,Interventional,11-Feb-10,Abbott,Biological: placebo
NCT00346775,Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q),"Rhinitis, Allergic, Perennial",Interventional,6-Dec-17,GlaxoSmithKline,Drug: Beclomethasone dipropionate
NCT00346775,Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q),"Rhinitis, Allergic, Perennial",Interventional,6-Dec-17,GlaxoSmithKline,Drug: Flunisolide
NCT00301366,The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency,Alpha 1-Antitrypsin Deficiency,Interventional,19-Aug-14,Grifols Therapeutics LLC,Drug: alpha-1 proteinase inhibitor (human)
NCT00267969,A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis,Psoriasis,Interventional,24-Aug-12,"Centocor Research & Development, Inc.",Drug: ustekinumab
NCT00267969,A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis,Psoriasis,Interventional,24-Aug-12,"Centocor Research & Development, Inc.",Drug: placebo
NCT00266695,Treatment for Completers of the Study B7A-MC-MBCM,Diabetic Retinopathy,Interventional,28-Jan-16,"Chromaderm, Inc.",Drug: Ruboxistaurin
NCT00265330,Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed),Bipolar Disorder,Interventional,3-Apr-09,Pfizer,Drug: Ziprasidone oral capsules
NCT00264875,Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy,Peripheral Neuropathy|HIV Infections,Interventional,23-Mar-09,Pfizer,Drug: pregabalin
NCT00264810,RNS® System Pivotal Study,Epilepsy,Interventional,28-Aug-13,NeuroPace,Procedure: RNS® System implantation
NCT00264810,RNS® System Pivotal Study,Epilepsy,Interventional,28-Aug-13,NeuroPace,Device: RNS® System responsive stimulation
NCT00295061,"Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults",Alpha 1-Antitrypsin Deficiency,Interventional,9-Sep-14,Grifols Therapeutics LLC,Drug: Alpha-1 MP
NCT00295061,"Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults",Alpha 1-Antitrypsin Deficiency,Interventional,9-Sep-14,Grifols Therapeutics LLC,Drug: alpha-1 proteinase inhibitor (human)
NCT00272792,Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet,Phenylketonurias,Interventional,9-Jul-09,BioMarin Pharmaceutical,Drug: Sapropterin Dihydrochloride
NCT00272792,Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet,Phenylketonurias,Interventional,9-Jul-09,BioMarin Pharmaceutical,Drug: Placebo
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Boehringer Ingelheim,Drug: warfarin
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Boehringer Ingelheim,Drug: Dabigatran dose 1
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Boehringer Ingelheim,Drug: Dabigatran dose 2
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Population Health Research Institute,Drug: warfarin
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Population Health Research Institute,Drug: Dabigatran dose 1
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Population Health Research Institute,Drug: Dabigatran dose 2
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Uppsala University,Drug: warfarin
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Uppsala University,Drug: Dabigatran dose 1
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation|Stroke,Interventional,10-Feb-11,Uppsala University,Drug: Dabigatran dose 2
NCT00262522,"Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects",Human Immunodeficiency Virus Infections,Interventional,20-Aug-09,Abbott,Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
NCT00260832,Trial of Decitabine in Patients With Acute Myeloid Leukemia,Acute Myeloid Leukemia,Interventional,21-Sep-11,Eisai Inc.,Drug: Cytarabine or Supportive Care
NCT00260832,Trial of Decitabine in Patients With Acute Myeloid Leukemia,Acute Myeloid Leukemia,Interventional,21-Sep-11,Eisai Inc.,Drug: Dacogen (decitabine) only
NCT00289198,Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR),"Rhinitis, Allergic, Perennial",Interventional,13-Apr-18,GlaxoSmithKline,Drug: FF
NCT00289198,Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR),"Rhinitis, Allergic, Perennial",Interventional,13-Apr-18,GlaxoSmithKline,Drug: Placebo
NCT00258895,Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®,Diphtheria|Tetanus|Pertussis,Interventional,28-Sep-09,"Sanofi Pasteur, a Sanofi Company",Biological: DAPTACEL®: DTaP
NCT00258895,Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®,Diphtheria|Tetanus|Pertussis,Interventional,28-Sep-09,Sanofi,Biological: DAPTACEL®: DTaP
NCT00257660,"Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia",Cervical Dystonia,Interventional,10-May-10,Ipsen,Drug: Botulinum type A toxin (Dysport®)
NCT00257660,"Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia",Cervical Dystonia,Interventional,10-May-10,Ipsen,Drug: Placebo
NCT00257608,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),Non-Small Cell Lung Cancer,Interventional,15-Mar-16,"Genentech, Inc.",Drug: bevacizumab
NCT00257608,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),Non-Small Cell Lung Cancer,Interventional,15-Mar-16,"Genentech, Inc.",Drug: placebo
NCT00257608,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),Non-Small Cell Lung Cancer,Interventional,15-Mar-16,"Genentech, Inc.",Drug: erlotinib HCl
NCT00257166,Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed),Bipolar Disorder,Interventional,19-Jul-13,Pfizer,Drug: Ziprasidone oral capsules
NCT00257166,Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed),Bipolar Disorder,Interventional,19-Jul-13,Pfizer,Drug: placebo oral capsules
NCT00256867,A Study In Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Interventional,23-Mar-18,GlaxoSmithKline,Drug: GSK523338
NCT00256854,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,15-Mar-19,GlaxoSmithKline,Drug: Ropinirole IR 1 mg
NCT00256854,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,15-Mar-19,GlaxoSmithKline,Drug: Ropinirole IR 2 mg
NCT00256854,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,15-Mar-19,GlaxoSmithKline,Drug: Ropinirole IR 1 mg Placebo
NCT00256854,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,15-Mar-19,GlaxoSmithKline,Drug: Ropinirole IR 2 mg Placebo
NCT00256854,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,15-Mar-19,GlaxoSmithKline,Drug: Ropinirole CR 2 mg
NCT00256854,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,15-Mar-19,GlaxoSmithKline,Drug: Ropinirole CR 3 mg
NCT00256854,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,15-Mar-19,GlaxoSmithKline,Drug: Ropinirole CR 2 mg Placebo
NCT00256854,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Restless Legs Syndrome|Restless Legs Syndrome (RLS),Interventional,15-Mar-19,GlaxoSmithKline,Drug: Ropinirole CR 3 mg Placebo
NCT00256750,Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT),Kidney Transplantation|Chronic Kidney Failure,Interventional,19-Aug-16,Bristol-Myers Squibb,Drug: Cyclosporine (CsA)
NCT00256750,Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT),Kidney Transplantation|Chronic Kidney Failure,Interventional,19-Aug-16,Bristol-Myers Squibb,Drug: Belatacept LI (less intensive)
NCT00256750,Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT),Kidney Transplantation|Chronic Kidney Failure,Interventional,19-Aug-16,Bristol-Myers Squibb,Drug: Belatacept MI (more intensive)
NCT00255190,Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Gastroesophageal Reflux Disease,Interventional,12-Aug-09,Takeda,Drug: Dexlansoprazole MR
NCT00255164,Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,28-Aug-09,Takeda,Drug: Dexlansoprazole MR
NCT00255164,Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,28-Aug-09,Takeda,Drug: Placebo
NCT00255151,Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,28-Aug-09,Takeda,Drug: Dexlansoprazole MR
NCT00255151,Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,28-Aug-09,Takeda,Drug: Placebo
NCT00255047,Safety and Immune Response of Different Pediatric Combination Vaccines.,Diphtheria|Polio|Pertussis,Interventional,10-Nov-10,"Sanofi Pasteur, a Sanofi Company","Biological: DAPTACEL®. (DTaP), IPOL®., and ActHIB®."
NCT00255047,Safety and Immune Response of Different Pediatric Combination Vaccines.,Diphtheria|Polio|Pertussis,Interventional,10-Nov-10,"Sanofi Pasteur, a Sanofi Company",Biological: Pentacel®: DTaP-IPV/Hib combined
NCT00255047,Safety and Immune Response of Different Pediatric Combination Vaccines.,Diphtheria|Polio|Pertussis,Interventional,10-Nov-10,"Sanofi Pasteur, a Sanofi Company",Biological: DTaP-IPV and ActHIB®
NCT00255047,Safety and Immune Response of Different Pediatric Combination Vaccines.,Diphtheria|Polio|Pertussis,Interventional,10-Nov-10,Sanofi,"Biological: DAPTACEL®. (DTaP), IPOL®., and ActHIB®."
NCT00255047,Safety and Immune Response of Different Pediatric Combination Vaccines.,Diphtheria|Polio|Pertussis,Interventional,10-Nov-10,Sanofi,Biological: Pentacel®: DTaP-IPV/Hib combined
NCT00255047,Safety and Immune Response of Different Pediatric Combination Vaccines.,Diphtheria|Polio|Pertussis,Interventional,10-Nov-10,Sanofi,Biological: DTaP-IPV and ActHIB®
NCT00251758,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Gastroesophageal Reflux Disease,Interventional,23-Mar-09,Takeda,Drug: Dexlansoprazole MR
NCT00251758,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Gastroesophageal Reflux Disease,Interventional,23-Mar-09,Takeda,Drug: Placebo
NCT00251745,Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Gastroesophageal Reflux Disease,Interventional,23-Mar-09,Takeda,Drug: Dexlansoprazole MR
NCT00251745,Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Gastroesophageal Reflux Disease,Interventional,23-Mar-09,Takeda,Drug: Placebo
NCT00251719,Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,23-Mar-09,Takeda,Drug: Dexlansoprazole MR
NCT00251719,Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,23-Mar-09,Takeda,Drug: Lansoprazole
NCT00251693,Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,23-Mar-09,Takeda,Drug: Dexlansoprazole MR
NCT00251693,Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis,"Esophagitis, Reflux|Esophagitis, Peptic",Interventional,23-Mar-09,Takeda,Drug: Lansoprazole
NCT00250679,Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease|Bronchitis|Emphysema,Interventional,19-Feb-09,Sunovion,Drug: Arformoterol tartrate inhalation solution
NCT00250679,Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease|Bronchitis|Emphysema,Interventional,19-Feb-09,Sunovion,Drug: Arformoterol 25 ųg BID
NCT00250679,Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease|Bronchitis|Emphysema,Interventional,19-Feb-09,Sunovion,Drug: Formoterol 12 ųg BID
NCT00250679,Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease|Bronchitis|Emphysema,Interventional,19-Feb-09,Sunovion,Drug: Placebo
NCT00248170,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,Breast Cancer,Interventional,9-Oct-15,Novartis Pharmaceuticals,Drug: Letrozole
NCT00248170,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,Breast Cancer,Interventional,9-Oct-15,Novartis Pharmaceuticals,Drug: Anastrozole
NCT00248170,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,Breast Cancer,Interventional,9-Oct-15,Novartis,Drug: Letrozole
NCT00248170,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,Breast Cancer,Interventional,9-Oct-15,Novartis,Drug: Anastrozole
NCT00244621,Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age,Hypertension,Interventional,15-Sep-09,AstraZeneca,Drug: candesartan cilexetil (Atacand)
NCT00272779,BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada,HIV Infections,Interventional,9-May-11,Bristol-Myers Squibb,Drug: ATV
NCT00272779,BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada,HIV Infections,Interventional,9-May-11,Bristol-Myers Squibb,Drug: RTV
NCT00272779,BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada,HIV Infections,Interventional,9-May-11,Bristol-Myers Squibb,Drug: Tenofovi-Emtricitabine (TDF/FTC) tablet
NCT00272779,BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada,HIV Infections,Interventional,9-May-11,Bristol-Myers Squibb,Drug: LPV
NCT00244140,Ultravist: Safety and Efficacy in Computed Tomography of Head and Body,Computed Tomography|Diagnostic Imaging,Interventional,20-Jul-09,Bayer,Drug: Iopromide 370 mg I/mL
NCT00244140,Ultravist: Safety and Efficacy in Computed Tomography of Head and Body,Computed Tomography|Diagnostic Imaging,Interventional,20-Jul-09,Bayer,Drug: Iopromide 300 mg I/mL
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Cephalon,Drug: PROVIGIL 200 mg
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Cephalon,Drug: Armodafinil 250 mg
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Cephalon,Drug: Armodafinil 200 mg
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Cephalon,Drug: Armodafinil 150 mg
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Cephalon,Drug: Placebo
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Teva Pharmaceutical Industries,Drug: PROVIGIL 200 mg
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Teva Pharmaceutical Industries,Drug: Armodafinil 250 mg
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Teva Pharmaceutical Industries,Drug: Armodafinil 200 mg
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Teva Pharmaceutical Industries,Drug: Armodafinil 150 mg
NCT00236080,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Chronic Shift Work Sleep Disorder,Interventional,3-Feb-10,Teva Pharmaceutical Industries,Drug: Placebo
NCT00235391,Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload,Thalassemia|Sickle Cell Disease|Diamond Blackfan Anemia|Myelofibrosis,Interventional,2-May-11,Novartis Pharmaceuticals,Drug: Deferasirox
NCT00235391,Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload,Thalassemia|Sickle Cell Disease|Diamond Blackfan Anemia|Myelofibrosis,Interventional,2-May-11,Novartis,Drug: Deferasirox
NCT00233402,Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy,Bladder Cancer,Interventional,11-Oct-13,Photocure,Drug: Hexvix
NCT00233402,Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy,Bladder Cancer,Interventional,11-Oct-13,Photocure,Procedure: Standard white light cystoscopy
NCT00232180,A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines,Heart Failure,Interventional,27-Jun-11,Pfizer,Drug: Eplerenone
NCT00232141,Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy,HIV Infections|Peripheral Neuropathy,Interventional,11-Aug-09,Pfizer,Drug: pregabalin
NCT00232141,Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy,HIV Infections|Peripheral Neuropathy,Interventional,11-Aug-09,Pfizer,Drug: Placebo
NCT00231153,Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters,Infection,Interventional,13-Aug-09,Mallinckrodt,Drug: Omiganan 1% gel
NCT00231153,Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters,Infection,Interventional,13-Aug-09,Mallinckrodt,Drug: Povidone-Iodine 10%
NCT00230178,Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome,Tumor Lysis Syndrome|Cancer|Hyperuricemia,Interventional,31-Dec-09,Sanofi,Drug: Rasburicase (SR29142)
NCT00230178,Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome,Tumor Lysis Syndrome|Cancer|Hyperuricemia,Interventional,31-Dec-09,Sanofi,Drug: Allopurinol
NCT00228566,Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome,Excessive Daytime Sleepiness|Narcolepsy|Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS),Interventional,25-Jun-10,Cephalon,Drug: Armodafinil
NCT00228566,Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome,Excessive Daytime Sleepiness|Narcolepsy|Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS),Interventional,25-Jun-10,Teva Pharmaceutical Industries,Drug: Armodafinil
NCT00228553,Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness,Excessive Daytime Sleepiness|Narcolepsy|Obstructive Sleep Apnea/Hypopnea Syndrome|Chronic Shift Work Sleep Disorder,Interventional,31-Mar-10,Cephalon,Drug: Armodafinil 100 to 250 mg/day
NCT00228553,Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness,Excessive Daytime Sleepiness|Narcolepsy|Obstructive Sleep Apnea/Hypopnea Syndrome|Chronic Shift Work Sleep Disorder,Interventional,31-Mar-10,Teva Pharmaceutical Industries,Drug: Armodafinil 100 to 250 mg/day
NCT00227305,Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder,Schizophrenia|Bipolar I Disorder,Interventional,5-Oct-12,AstraZeneca,Drug: quetiapine fumarate
NCT00225277,Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,10-Jun-09,Takeda,Drug: Pioglitazone
NCT00225277,Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus,Diabetes Mellitus,Interventional,10-Jun-09,Takeda,Drug: Glimepiride
NCT00224484,Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old,Herpes Simplex,Interventional,10-Apr-17,GlaxoSmithKline,Biological: GSK208141
NCT00224484,Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old,Herpes Simplex,Interventional,10-Apr-17,GlaxoSmithKline,Biological: Havrix (investigational formulation)
NCT00224484,Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old,Herpes Simplex,Interventional,10-Apr-17,GlaxoSmithKline,Biological: Placebo
NCT00225732,Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients,Pain,Interventional,15-Sep-11,Cumberland Pharmaceuticals,Other: Normal saline as placebo comparator
NCT00225732,Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients,Pain,Interventional,15-Sep-11,Cumberland Pharmaceuticals,Drug: Intravenous ibuprofen
NCT00242710,Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women,Endometrial Hyperplasia|Osteoporosis,Interventional,20-Dec-13,Pfizer,Drug: Bazedoxifene/Conjugated Estrogen
NCT00242710,Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women,Endometrial Hyperplasia|Osteoporosis,Interventional,20-Dec-13,Pfizer,Drug: CE 0.45 mg/MPA 1.5mg
NCT00242710,Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women,Endometrial Hyperplasia|Osteoporosis,Interventional,20-Dec-13,Pfizer,Other: Placebo
NCT00224133,The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months,Benign Prostatic Hyperplasia,Interventional,27-Apr-10,Watson Pharmaceuticals,Drug: Silodosin
NCT00224120,A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo,Benign Prostatic Hyperplasia,Interventional,3-Dec-09,Watson Pharmaceuticals,Drug: Silodosin
NCT00224120,A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo,Benign Prostatic Hyperplasia,Interventional,3-Dec-09,Watson Pharmaceuticals,Other: Placebo
NCT00224107,A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo,Benign Prostatic Hyperplasia (BPH),Interventional,3-Dec-09,Watson Pharmaceuticals,Drug: Silodosin
NCT00224107,A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo,Benign Prostatic Hyperplasia (BPH),Interventional,3-Dec-09,Watson Pharmaceuticals,Other: Placebo
NCT00770029,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2,Moderate to Severe Glabellar Frown Lines,Interventional,13-Sep-11,Merz Pharmaceuticals GmbH,Drug: IncobotulinumtoxinA (Xeomin) (20 Units)
NCT00770029,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2,Moderate to Severe Glabellar Frown Lines,Interventional,13-Sep-11,Merz Pharmaceuticals GmbH,Drug: Placebo
NCT00205777,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Interventional,10-Apr-13,Pfizer,Drug: Bazedoxifene Acetate
NCT00205777,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Interventional,10-Apr-13,Pfizer,Other: Placebo
NCT00197236,"Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months",Hepatitis A,Interventional,24-Jul-09,GlaxoSmithKline,Biological: Havrix™
NCT00197236,"Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months",Hepatitis A,Interventional,24-Jul-09,GlaxoSmithKline,Biological: Infanrix™
NCT00197236,"Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months",Hepatitis A,Interventional,24-Jul-09,GlaxoSmithKline,Biological: ActHIB™
NCT00197015,Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children,Hepatitis A,Interventional,1-Apr-10,GlaxoSmithKline,Biological: Havrix®
NCT00197015,Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children,Hepatitis A,Interventional,1-Apr-10,GlaxoSmithKline,Biological: M-M-R®II
NCT00197015,Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children,Hepatitis A,Interventional,1-Apr-10,GlaxoSmithKline,Biological: VARIVAX®
NCT00197002,Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age,Hepatitis A,Interventional,20-Feb-17,GlaxoSmithKline,Biological: GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)
NCT00197002,Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age,Hepatitis A,Interventional,20-Feb-17,GlaxoSmithKline,Biological: Prevnar™
NCT00196326,"Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive",Contraception,Interventional,15-Apr-09,Duramed Research,Drug: DR-1011
NCT00196326,"Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive",Contraception,Interventional,15-Apr-09,Teva Pharmaceutical Industries,Drug: DR-1011
NCT00195715,Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease,Crohn's Disease,Interventional,7-Jan-10,Abbott,Biological: Adalimumab
NCT00195702,Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.,Rheumatoid Arthritis,Interventional,1-Mar-10,Abbott,Biological: Adalimumab
NCT00195702,Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.,Rheumatoid Arthritis,Interventional,1-Mar-10,Abbott,Drug: Placebo
NCT00195676,Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis,Psoriasis,Interventional,19-Nov-10,Abbott,Drug: adalimumab
NCT00195663,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Early Rheumatoid Arthritis,Interventional,25-Feb-10,"AbbVie (prior sponsor, Abbott)",Biological: Adalimumab
NCT00195663,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Early Rheumatoid Arthritis,Interventional,25-Feb-10,"AbbVie (prior sponsor, Abbott)",Drug: Methotrexate
NCT00195663,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Early Rheumatoid Arthritis,Interventional,25-Feb-10,"AbbVie (prior sponsor, Abbott)",Biological: Adalimumab placebo
NCT00195663,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Early Rheumatoid Arthritis,Interventional,25-Feb-10,"AbbVie (prior sponsor, Abbott)",Drug: Methotrexate placebo
NCT00195663,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Early Rheumatoid Arthritis,Interventional,25-Feb-10,AbbVie,Biological: Adalimumab
NCT00195663,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Early Rheumatoid Arthritis,Interventional,25-Feb-10,AbbVie,Drug: Methotrexate
NCT00195663,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Early Rheumatoid Arthritis,Interventional,25-Feb-10,AbbVie,Biological: Adalimumab placebo
NCT00195663,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Early Rheumatoid Arthritis,Interventional,25-Feb-10,AbbVie,Drug: Methotrexate placebo
NCT00195650,Long Term Open Label Continuation Study,Rheumatoid Arthritis,Interventional,31-Jul-12,Abbott,Biological: Adalimumab
NCT00191646,"An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy","Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|Peritoneal Neoplasms",Interventional,9-Sep-10,Eli Lilly and Company,Drug: Gemcitabine
NCT00191646,"An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy","Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|Peritoneal Neoplasms",Interventional,9-Sep-10,Eli Lilly and Company,Drug: Paclitaxel
NCT00191646,"An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy","Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|Peritoneal Neoplasms",Interventional,9-Sep-10,Eli Lilly and Company,Drug: Carboplatin
NCT00191152,A Phase III Trial For Patients With Metastatic Breast Cancer,Breast Cancer|Breast Neoplasms|Cancer of the Breast,Interventional,8-Dec-09,Eli Lilly and Company,Drug: gemcitabine
NCT00191152,A Phase III Trial For Patients With Metastatic Breast Cancer,Breast Cancer|Breast Neoplasms|Cancer of the Breast,Interventional,8-Dec-09,Eli Lilly and Company,Drug: docetaxel
NCT00191152,A Phase III Trial For Patients With Metastatic Breast Cancer,Breast Cancer|Breast Neoplasms|Cancer of the Breast,Interventional,8-Dec-09,Eli Lilly and Company,Drug: capecitabine
NCT00190684,"Long-Term, Open Label Atomoxetine Study",Attention Deficit Hyperactivity Disorder,Interventional,17-Jan-11,Eli Lilly and Company,Drug: atomoxetine
NCT00180479,SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS),Stents|Coronary Artery Disease|Total Coronary Occlusion|Coronary Artery Restenosis|Stent Thrombosis|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis,Interventional,15-Dec-08,Abbott Medical Devices,Device: XIENCE V® Everolimus Eluting Coronary Stent
NCT00180479,SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS),Stents|Coronary Artery Disease|Total Coronary Occlusion|Coronary Artery Restenosis|Stent Thrombosis|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis,Interventional,15-Dec-08,Abbott Medical Devices,Device: TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
NCT00175877,A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,8-Mar-13,UCB Pharma,Biological: Certolizumab Pegol
NCT00168844,Tiotropium / Respimat One-Year Study,"Pulmonary Disease, Chronic Obstructive",Interventional,7-Oct-09,Boehringer Ingelheim,Drug: Tiotropium Inhalation Solution
NCT00168844,Tiotropium / Respimat One-Year Study,"Pulmonary Disease, Chronic Obstructive",Interventional,7-Oct-09,Boehringer Ingelheim,Other: Placebo
NCT00168831,Tiotropium / Respimat One-Year Study,"Pulmonary Disease, Chronic Obstructive",Interventional,7-Oct-09,Boehringer Ingelheim,Drug: Tiotropium Inhalation Solution
NCT00168831,Tiotropium / Respimat One-Year Study,"Pulmonary Disease, Chronic Obstructive",Interventional,7-Oct-09,Boehringer Ingelheim,Other: Placebo
NCT00162942,Study for the Treatment of Crohn's Disease With Adacolumn,Crohn's Disease,Interventional,7-Apr-09,Otsuka America Pharmaceutical,Device: Adacolumn
NCT00162942,Study for the Treatment of Crohn's Disease With Adacolumn,Crohn's Disease,Interventional,7-Apr-09,Otsuka America Pharmaceutical,Device: Sham
NCT00162032,A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease,Kawasaki Disease,Interventional,6-Dec-13,Lantheus Medical Imaging,Drug: Sestamibi
NCT00166205,Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity,"Obesity, Morbid",Interventional,11-Dec-08,Ethicon Endo-Surgery,Device: Swedish Adjustable Gastric Band
NCT00160706,A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease,Crohn's Disease,Interventional,4-Jul-13,UCB Pharma SA,Biological: Certolizumab Pegol (CDP870)
NCT00160706,A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease,Crohn's Disease,Interventional,4-Jul-13,UCB Pharma,Biological: Certolizumab Pegol (CDP870)
NCT00160693,Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,9-Jul-12,UCB Pharma,Biological: Certolizumab Pegol
NCT00160524,A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425],Crohn's Disease,Interventional,10-Oct-13,UCB Pharma SA,Biological: Certolizumab Pegol (CDP870)
NCT00160524,A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425],Crohn's Disease,Interventional,10-Oct-13,UCB Pharma,Biological: Certolizumab Pegol (CDP870)
NCT00159861,The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH,Pulmonary Hypertension,Interventional,12-Jan-11,Pfizer,Drug: Sildenafil citrate
NCT00157157,Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients,Hemophilia A,Interventional,15-Jul-11,Baxalta now part of Shire,Biological: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
NCT00157157,Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients,Hemophilia A,Interventional,15-Jul-11,Shire,Biological: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
NCT00152971,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,"Arthroplasty, Replacement, Knee|Thromboembolism",Interventional,17-Dec-10,Boehringer Ingelheim,Drug: Dabigatran Dose 1 - day 2 to completion
NCT00152971,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,"Arthroplasty, Replacement, Knee|Thromboembolism",Interventional,17-Dec-10,Boehringer Ingelheim,Drug: Dabigatran Dose 1 - day 1
NCT00152971,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,"Arthroplasty, Replacement, Knee|Thromboembolism",Interventional,17-Dec-10,Boehringer Ingelheim,Drug: Dabigatran Dose 2 - day 2 to completion
NCT00152971,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,"Arthroplasty, Replacement, Knee|Thromboembolism",Interventional,17-Dec-10,Boehringer Ingelheim,Drug: Dabigatran Dose 2 - day 1
NCT00152971,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,"Arthroplasty, Replacement, Knee|Thromboembolism",Interventional,17-Dec-10,Boehringer Ingelheim,Drug: Enoxaparin
NCT00152516,"Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures","Epilepsy, Partial",Interventional,13-Jan-10,UCB Pharma,Drug: levetiracetam (LEV)
NCT00151892,Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis,Ulcerative Colitis,Interventional,21-Sep-10,Shire,Drug: SPD476
NCT00151892,Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis,Ulcerative Colitis,Interventional,21-Sep-10,Shire,Drug: Asacol
NCT00160641,A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,7-Mar-13,UCB Pharma,Biological: Certolizumab Pegol
NCT00150800,"This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment",Epilepsy,Interventional,5-Dec-18,UCB PHARMA Inc. (US),Drug: Brivaracetam
NCT00150800,"This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment",Epilepsy,Interventional,5-Dec-18,UCB Pharma,Drug: Brivaracetam
NCT00159874,A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children,Pulmonary Arterial Hypertension,Interventional,11-Aug-14,Pfizer,Drug: Sildenafil citrate
NCT00147199,Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH),Pulmonary Hypertension,Interventional,12-Aug-13,United Therapeutics,Drug: Inhaled treprostinil
NCT00147199,Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH),Pulmonary Hypertension,Interventional,12-Aug-13,United Therapeutics,Drug: Placebo inhalation solution
NCT00145327,Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis),Osteoporosis,Interventional,20-Apr-11,Novartis,Drug: Zoledronic Acid
NCT00145327,Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis),Osteoporosis,Interventional,20-Apr-11,Novartis,Drug: Placebo
NCT00144339,Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,17-Aug-09,Boehringer Ingelheim,Drug: tiotropium
NCT00144339,Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients,"Pulmonary Disease, Chronic Obstructive",Interventional,17-Aug-09,Boehringer Ingelheim,Drug: placebo
NCT00141817,Study Evaluating Pantoprazole in Children With GERD,Gastroesophageal Reflux,Interventional,28-Dec-11,Wyeth is now a wholly owned subsidiary of Pfizer,Drug: pantoprazole for approximately 9 weeks.
NCT00141271,A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression,Bipolar Disorder,Interventional,24-Mar-09,Pfizer,Drug: Geodon (Ziprasidone)
NCT00141271,A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression,Bipolar Disorder,Interventional,24-Mar-09,Pfizer,Drug: Placebo
NCT00139659,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma,Asthma|Diabetes Mellitus,Interventional,12-May-10,Pfizer,Drug: Inhaled Insulin
NCT00139659,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma,Asthma|Diabetes Mellitus,Interventional,12-May-10,Pfizer,Drug: Subcutaneous Insulin
NCT00159913,"A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.","Pulmonary Arterial Hypertension, Children",Interventional,21-Jul-09,Pfizer,Drug: Sildenafil citrate
NCT00159913,"A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.","Pulmonary Arterial Hypertension, Children",Interventional,21-Jul-09,Pfizer,Drug: Placebo
NCT00205855,An Implantable Spinal Cord Stimulation Pain Management System,"Chronic Pain|Pain, Intractable|Pain|Back Pain|Failed Back Surgery Syndrome",Interventional,26-Oct-12,Boston Scientific Corporation,Device: Precision SCS
NCT00133952,Effect of Ruboxistaurin on Clinically Significant Macular Edema,Diabetic Macular Edema,Interventional,28-Jan-16,"Chromaderm, Inc.",Drug: Ruboxistaurin
NCT00133952,Effect of Ruboxistaurin on Clinically Significant Macular Edema,Diabetic Macular Edema,Interventional,28-Jan-16,"Chromaderm, Inc.",Drug: Placebo
NCT00132678,A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes,Bipolar Disorder,Interventional,27-Feb-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Risperdal Consta
NCT00132678,A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes,Bipolar Disorder,Interventional,27-Feb-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Placebo
NCT00172185,Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458),Short Bowel Syndrome,Interventional,23-Apr-13,Shire,Drug: teduglutide 0.05 mg/kg/d
NCT00172185,Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458),Short Bowel Syndrome,Interventional,23-Apr-13,Shire,Drug: teduglutide 0.10 mg/kg/d
NCT00131573,An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome,Overactive Bladder,Interventional,19-Nov-13,Boston Scientific Corporation,Device: bion
NCT00243659,"Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery",Hemophilia A,Interventional,20-Jul-09,Wyeth is now a wholly owned subsidiary of Pfizer,Biological: ReFacto AF
NCT00129766,Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children,Respiratory Syncytial Virus Infections,Interventional,28-Aug-13,MedImmune LLC,Biological: motavizumab (MEDI-524)
NCT00129766,Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children,Respiratory Syncytial Virus Infections,Interventional,28-Aug-13,MedImmune LLC,Biological: palivizumab
NCT00128492,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA),Cystic Fibrosis,Interventional,11-Mar-11,Gilead Sciences,Drug: AZLI 75 mg two times a day (BID)/ three times a day (TID)
NCT00127530,Study of Oral Fampridine-SR in Multiple Sclerosis,Multiple Sclerosis,Interventional,6-May-11,Acorda Therapeutics,Drug: Fampridine-SR
NCT00127530,Study of Oral Fampridine-SR in Multiple Sclerosis,Multiple Sclerosis,Interventional,6-May-11,Acorda Therapeutics,Drug: Placebo
NCT00124982,Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy,Rheumatoid Arthritis,Interventional,2-Jun-11,Bristol-Myers Squibb,Drug: Abatacept
NCT00124982,Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy,Rheumatoid Arthritis,Interventional,2-Jun-11,Bristol-Myers Squibb,Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
NCT00124982,Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy,Rheumatoid Arthritis,Interventional,2-Jun-11,Bristol-Myers Squibb,Drug: Anti-Tumor Necrosing Factor (TNF) Therapy
NCT00123487,Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML,"Myeloid Leukemia, Chronic, Accelerated Phase|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",Interventional,22-Oct-14,Bristol-Myers Squibb,Drug: dasatinib
NCT00123474,Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML,"Myeloid Leukemia, Chronic, Chronic-Phase",Interventional,26-Aug-15,Bristol-Myers Squibb,Drug: dasatinib
NCT00122681,Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18,"Infections, Papillomavirus",Interventional,20-Jan-10,GlaxoSmithKline,Biological: Cervarix™
NCT00122681,Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18,"Infections, Papillomavirus",Interventional,20-Jan-10,GlaxoSmithKline,Biological: Havrix™-based investigational formulation
NCT00122382,Remission and Joint Damage Progression in Early Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,13-Jul-10,Bristol-Myers Squibb,Drug: Abatacept
NCT00122382,Remission and Joint Damage Progression in Early Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,13-Jul-10,Bristol-Myers Squibb,Drug: placebo
NCT00122382,Remission and Joint Damage Progression in Early Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,13-Jul-10,Bristol-Myers Squibb,Drug: methotrexate
NCT00122317,Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH),"Paroxysmal Hemoglobinuria, Nocturnal",Interventional,5-Jun-17,Alexion Pharmaceuticals,Drug: eculizumab
NCT00121667,Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone,"Diabetes Mellitus, Type 2",Interventional,8-Apr-11,AstraZeneca,Drug: Saxagliptin + Metformin
NCT00121667,Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone,"Diabetes Mellitus, Type 2",Interventional,8-Apr-11,AstraZeneca,Drug: Placebo + Metformin
NCT00121667,Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone,"Diabetes Mellitus, Type 2",Interventional,8-Apr-11,AstraZeneca,Drug: Pioglitazone
NCT00121641,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"Diabetes Mellitus, Type 2",Interventional,11-May-11,AstraZeneca,Drug: Saxagliptin
NCT00121641,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"Diabetes Mellitus, Type 2",Interventional,11-May-11,AstraZeneca,Drug: Placebo matching Saxagliptin
NCT00121641,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"Diabetes Mellitus, Type 2",Interventional,11-May-11,AstraZeneca,Drug: Metformin
NCT00121641,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"Diabetes Mellitus, Type 2",Interventional,11-May-11,AstraZeneca,Drug: Placebo matching Metformin
NCT00120523,5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis,Atopic Dermatitis,Interventional,16-Jan-13,MEDA Pharma GmbH & Co. KG,Drug: Pimecrolimus
NCT00120523,5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis,Atopic Dermatitis,Interventional,16-Jan-13,MEDA Pharma GmbH & Co. KG,Drug: Topical corticosteroids
NCT00196196,A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.,Hydrocephalus|Normal Pressure Hydrocephalus,Interventional,5-Dec-08,Codman & Shurtleff,Device: Codman VPV System
NCT00118703,Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis,"Vasomotor Rhinitis|Rhinitis, Vasomotor",Interventional,2-May-17,GlaxoSmithKline,Drug: GW685698X
NCT00117676,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: TDF
NCT00117676,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: ADV
NCT00117676,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: TDF placebo
NCT00117676,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: ADV placebo
NCT00117676,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: FTC/TDF
NCT00117598,Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL),Lymphoma,Interventional,6-Mar-12,Pfizer,Drug: Temsirolimus (CCI-779)
NCT00117598,Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL),Lymphoma,Interventional,6-Mar-12,Pfizer,Drug: Investigator's choice
NCT00117325,Study Of Adults And Adolescents With Vasomotor Rhinitis,"Rhinitis, Vasomotor",Interventional,13-Mar-18,GlaxoSmithKline,Drug: GW685698X
NCT00116831,Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes,Atherosclerosis,Interventional,31-Mar-10,GlaxoSmithKline,Drug: Glipizide
NCT00116831,Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes,Atherosclerosis,Interventional,31-Mar-10,GlaxoSmithKline,Drug: rosiglitazone maleate
NCT00116805,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: TDF
NCT00116805,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: ADV
NCT00116805,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: TDF placebo
NCT00116805,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: ADV placebo
NCT00116805,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B,Chronic Hepatitis B,Interventional,19-May-10,Gilead Sciences,Drug: FTC/TDF
NCT00116428,NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation,Heart Diseases|Arrhythmia|Atrial Fibrillation,Interventional,14-Mar-13,"Biosense Webster, Inc.",Device: NAVISTAR® THERMOCOOL® Catheter
NCT00116428,NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation,Heart Diseases|Arrhythmia|Atrial Fibrillation,Interventional,14-Mar-13,"Biosense Webster, Inc.",Drug: Antiarrhythmic drug
NCT00114777,Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant,Renal Transplantation,Interventional,7-Jul-17,Bristol-Myers Squibb,Drug: Cyclosporin A
NCT00114777,Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant,Renal Transplantation,Interventional,7-Jul-17,Bristol-Myers Squibb,Drug: Belatacept Less Intensive Regimen (LI)
NCT00114777,Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant,Renal Transplantation,Interventional,7-Jul-17,Bristol-Myers Squibb,Drug: Belatacept More Intensive Regimen (MI)
NCT00113568,Safety Study of XP12B in Women With Menorrhagia,Menorrhagia|Heavy Menstrual Bleeding,Interventional,20-Jan-10,Ferring Pharmaceuticals,Drug: Tranexamic acid tablets (XP12B)
NCT00112359,International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa,Cystic Fibrosis,Interventional,21-Apr-11,Gilead Sciences,Drug: AZLI 75 mg three times a day (TID)
NCT00112359,International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa,Cystic Fibrosis,Interventional,21-Apr-11,Gilead Sciences,Drug: Placebo three times a day (TID)
NCT00110461,Aripiprazole in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Interventional,21-May-12,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT00110461,Aripiprazole in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Interventional,21-May-12,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: placebo
NCT00108082,The CLEVER Study - Coreg And Left Ventricular Mass Regression,"Hypertrophy, Left Ventricular",Interventional,9-Nov-09,GlaxoSmithKline,Drug: carvedilol MR
NCT00108082,The CLEVER Study - Coreg And Left Ventricular Mass Regression,"Hypertrophy, Left Ventricular",Interventional,9-Nov-09,GlaxoSmithKline,Drug: atenolol
NCT00108082,The CLEVER Study - Coreg And Left Ventricular Mass Regression,"Hypertrophy, Left Ventricular",Interventional,9-Nov-09,GlaxoSmithKline,Drug: lisinopril
NCT00669617,Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,17-Aug-11,Novartis,Drug: Indacaterol
NCT00669617,Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,17-Aug-11,Novartis,Drug: Salmeterol/fluticasone (50/500 μg)
NCT00669617,Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,17-Aug-11,Novartis,Drug: Salbutamol (200 µg)
NCT00669617,Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,17-Aug-11,Novartis,Drug: Placebo to Indacaterol
NCT00669617,Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,17-Aug-11,Novartis,Drug: Placebo to Salmeterol/fluticasone
NCT00669617,Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,17-Aug-11,Novartis,Drug: Placebo to salbutamol
NCT00109733,Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency,Childhood-onset Growth Hormone Deficiency|Pituitary Dwarfism,Interventional,22-Jun-10,EMD Serono,Biological: recombinant human growth hormone
NCT00107120,The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,4-Nov-09,Forest Laboratories,Drug: Escitalopram
NCT00107120,The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,4-Nov-09,Forest Laboratories,Drug: Placebo
NCT00106535,A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,7-Jun-11,Hoffmann-La Roche,Drug: tocilizumab [RoActemra/Actemra]
NCT00106535,A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,7-Jun-11,Hoffmann-La Roche,Drug: Placebo
NCT00106535,A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA),Rheumatoid Arthritis,Interventional,7-Jun-11,Hoffmann-La Roche,Drug: Methotrexate
NCT00105534,Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003),Bacterial Conjunctivitis,Interventional,27-Oct-11,Merck Sharp & Dohme Corp.,Drug: AzaSite
NCT00105534,Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003),Bacterial Conjunctivitis,Interventional,27-Oct-11,Merck Sharp & Dohme Corp.,Other: Vehicle
NCT00105521,Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia,Parkinson's Disease|Dyskinesia,Interventional,2-Apr-18,EMD Serono,Drug: Sarizotan
NCT00105521,Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia,Parkinson's Disease|Dyskinesia,Interventional,2-Apr-18,EMD Serono,Drug: Placebo
NCT00105508,Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia,Parkinson's Disease|Dyskinesia,Interventional,25-Jul-18,EMD Serono,Drug: Sarizotan
NCT00105508,Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia,Parkinson's Disease|Dyskinesia,Interventional,25-Jul-18,EMD Serono,Drug: Placebo
NCT00105469,Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004),Bacterial Conjunctivitis,Interventional,27-Oct-11,Merck Sharp & Dohme Corp.,Drug: AzaSite
NCT00105469,Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004),Bacterial Conjunctivitis,Interventional,27-Oct-11,Merck Sharp & Dohme Corp.,Drug: Tobramycin
NCT00105443,A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma,"Carcinoma, Hepatocellular",Interventional,27-Sep-10,Bayer,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00105443,A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma,"Carcinoma, Hepatocellular",Interventional,27-Sep-10,Bayer,Drug: Placebo
NCT00105183,EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection,Chronic Obstructive Pulmonary|Idiopathic Pulmonary Fibrosis|Cystic Fibrosis|Bronchiectasis|Pulmonary Vascular Disease,Interventional,8-Jun-12,Neovii Biotech,Biological: Placebo
NCT00105183,EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection,Chronic Obstructive Pulmonary|Idiopathic Pulmonary Fibrosis|Cystic Fibrosis|Bronchiectasis|Pulmonary Vascular Disease,Interventional,8-Jun-12,Neovii Biotech,Biological: EZ-2053
NCT00105183,EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection,Chronic Obstructive Pulmonary|Idiopathic Pulmonary Fibrosis|Cystic Fibrosis|Bronchiectasis|Pulmonary Vascular Disease,Interventional,8-Jun-12,Neovii Biotech,Biological: EZ-2053 5mg/kg
NCT00105079,GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection,HIV Infections,Interventional,2-Nov-11,Hoffmann-La Roche,Drug: saquinavir [Invirase]
NCT00105079,GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection,HIV Infections,Interventional,2-Nov-11,Hoffmann-La Roche,Drug: Lopinavir/ritonavir
NCT00105079,GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection,HIV Infections,Interventional,2-Nov-11,Hoffmann-La Roche,Drug: Emtricitabine/tenofovir disoproxil fumarate
NCT00105079,GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection,HIV Infections,Interventional,2-Nov-11,Hoffmann-La Roche,Drug: Ritonavir
NCT00104520,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa,Cystic Fibrosis,Interventional,11-Mar-11,Gilead Sciences,Drug: AZLI 75 mg two times a day (BID)/three times a day (TID)
NCT00104520,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa,Cystic Fibrosis,Interventional,11-Mar-11,Gilead Sciences,Drug: Placebo two times a day (BID)/three times a day (TID)
NCT00104416,Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures,"Epilepsy, Tonic-Clonic",Interventional,18-May-10,GlaxoSmithKline,Drug: lamotrigine (LAMICTAL) extended-release
NCT00104416,Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures,"Epilepsy, Tonic-Clonic",Interventional,18-May-10,GlaxoSmithKline,Drug: Placebo
NCT00104247,Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels,Phenylketonurias,Interventional,16-Apr-09,BioMarin Pharmaceutical,"Drug: sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin"
NCT00319046,"Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease",Gaucher Disease Type 1,Interventional,23-May-12,Actelion,Drug: Miglustat
NCT00103662,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients,Multiple Myeloma,Interventional,29-Sep-10,"Genzyme, a Sanofi Company",Drug: Granulocyte colony-stimulating factor plus plerixafor
NCT00103662,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients,Multiple Myeloma,Interventional,29-Sep-10,"Genzyme, a Sanofi Company",Drug: Granulocyte colony-stimulating factor plus placebo
NCT00103662,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients,Multiple Myeloma,Interventional,29-Sep-10,Sanofi,Drug: Granulocyte colony-stimulating factor plus plerixafor
NCT00103662,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients,Multiple Myeloma,Interventional,29-Sep-10,Sanofi,Drug: Granulocyte colony-stimulating factor plus placebo
NCT00103610,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients,"Lymphoma, Non-Hodgkin",Interventional,29-Sep-10,"Genzyme, a Sanofi Company",Drug: Granulocyte colony-stimulating factor plus plerixafor
NCT00103610,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients,"Lymphoma, Non-Hodgkin",Interventional,29-Sep-10,"Genzyme, a Sanofi Company",Drug: Granulocyte colony-stimulating factor plus placebo
NCT00103610,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients,"Lymphoma, Non-Hodgkin",Interventional,29-Sep-10,Sanofi,Drug: Granulocyte colony-stimulating factor plus plerixafor
NCT00103610,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients,"Lymphoma, Non-Hodgkin",Interventional,29-Sep-10,Sanofi,Drug: Granulocyte colony-stimulating factor plus placebo
NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,Multiple Myeloma,Interventional,25-May-15,"Janssen Research & Development, LLC",Drug: Bortezomib (VELCADE)
NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,Multiple Myeloma,Interventional,25-May-15,"Janssen Research & Development, LLC",Drug: Doxorubicin hydrochloride (DOXIL/CAELYX)
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis Pharmaceuticals,Drug: zoledronic acid
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis Pharmaceuticals,Drug: placebo to zoledronic acid
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis Pharmaceuticals,Drug: Risedronate
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis Pharmaceuticals,Drug: Placebo to risedronate
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis Pharmaceuticals,Drug: Calcium and vitamin D supplements
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis,Drug: zoledronic acid
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis,Drug: placebo to zoledronic acid
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis,Drug: Risedronate
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis,Drug: Placebo to risedronate
NCT00103740,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,2-May-12,Novartis,Drug: Calcium and vitamin D supplements
NCT00102518,"Aripiprazole Open-Label, Safety and Tolerability Study",Schizophrenia|Bipolar Disorder,Interventional,31-Aug-12,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Aripiprazole
NCT00102063,Aripiprazole in Adolescents With Schizophrenia,Schizophrenia,Interventional,1-Aug-12,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Drug: Aripiprazole tablet, 10 mg"
NCT00102063,Aripiprazole in Adolescents With Schizophrenia,Schizophrenia,Interventional,1-Aug-12,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Drug: Aripiprazole tablet, 30 mg"
NCT00102063,Aripiprazole in Adolescents With Schizophrenia,Schizophrenia,Interventional,1-Aug-12,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Drug: Placebo tablet
NCT00101686,Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.,Colorectal Neoplasms,Interventional,26-Nov-09,Pfizer,Drug: Modified Bolus 5-FU/LV with Irinotecan
NCT00101686,Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.,Colorectal Neoplasms,Interventional,26-Nov-09,Pfizer,Drug: FOLFIRI + bevacizumab
NCT00101686,Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.,Colorectal Neoplasms,Interventional,26-Nov-09,Pfizer,Drug: miFL + bevacizumab
NCT00101686,Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.,Colorectal Neoplasms,Interventional,26-Nov-09,Pfizer,Drug: Infusional 5-FU/LV with Irinotecan
NCT00101686,Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.,Colorectal Neoplasms,Interventional,26-Nov-09,Pfizer,Drug: Oral Capecitabine with Irinotecan
NCT00098059,Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection,Herpes Simplex,Interventional,6-May-09,Novartis Pharmaceuticals,Drug: Famciclovir
NCT00098059,Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection,Herpes Simplex,Interventional,6-May-09,Novartis,Drug: Famciclovir
NCT00097708,Experimental Medication For the Treatment of Generalized Anxiety Disorder,Anxiety Disorder,Interventional,3-Oct-14,Jazz Pharmaceuticals,Drug: experimental anti-anxiety drug
NCT00096785,Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection,Hepatitis B|Chronic Disease,Interventional,6-Jan-10,Bristol-Myers Squibb,Drug: entecavir
NCT00096785,Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection,Hepatitis B|Chronic Disease,Interventional,6-Jan-10,Bristol-Myers Squibb,Drug: adefovir
NCT00095147,Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,21-Jan-11,Bristol-Myers Squibb,"Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)"
NCT00095147,Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,21-Jan-11,Bristol-Myers Squibb,"Drug: Infliximab (INF) + MTX, DB"
NCT00095147,Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,21-Jan-11,Bristol-Myers Squibb,"Drug: Placebo (PLA) + MTX, DB"
NCT00095147,Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,21-Jan-11,Bristol-Myers Squibb,"Drug: PLA + MTX switched to ABA+ MTX, DB"
NCT00095147,Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,21-Jan-11,Bristol-Myers Squibb,"Drug: ABA, open-label (OL)"
NCT00094653,"MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma",Melanoma|Metastases,Interventional,23-Jun-11,Bristol-Myers Squibb,Drug: MDX-010 (anti-CTLA4) monoclonal antibody
NCT00094653,"MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma",Melanoma|Metastases,Interventional,23-Jun-11,Bristol-Myers Squibb,Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
NCT00095173,BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis,Juvenile Rheumatoid Arthritis,Interventional,18-Jan-17,Bristol-Myers Squibb,Drug: Abatacept
NCT00095173,BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis,Juvenile Rheumatoid Arthritis,Interventional,18-Jan-17,Bristol-Myers Squibb,Drug: Placebo
NCT00091442,A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer,Breast Cancer,Interventional,2-Oct-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: Docetaxel
NCT00091442,A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer,Breast Cancer,Interventional,2-Oct-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Drug: DOXIL
NCT00090753,"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia",Anemia,Interventional,5-Jan-12,Hoffmann-La Roche,Drug: Methoxy Polyethylene Glycol-Epoetin Beta
NCT00090753,"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia",Anemia,Interventional,5-Jan-12,Hoffmann-La Roche,Drug: Epoetin alfa
NCT00090753,"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia",Anemia,Interventional,5-Jan-12,Hoffmann-La Roche,Drug: Epoetin beta
NCT00090753,"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia",Anemia,Interventional,5-Jan-12,Hoffmann-La Roche,Drug: Darbepoetin alfa
NCT00090519,Reduction in the Occurrence of Center-Involved Diabetic Macular Edema,Diabetic Retinopathy,Interventional,16-May-16,"Chromaderm, Inc.",Drug: ruboxistaurin
NCT00090519,Reduction in the Occurrence of Center-Involved Diabetic Macular Edema,Diabetic Retinopathy,Interventional,16-May-16,"Chromaderm, Inc.",Drug: placebo
NCT00090103,Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment,Prostatic Hyperplasia,Interventional,16-Mar-10,GlaxoSmithKline,Drug: dutasteride 0.5mg once daily for 4 years
NCT00090103,Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment,Prostatic Hyperplasia,Interventional,16-Mar-10,GlaxoSmithKline,Drug: tamsulosin 0.4mg once daily for 4 years
NCT00088465,Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder,Schizophrenic Disorders|Schizoaffective Disorder,Interventional,11-Jan-12,Eli Lilly and Company,Drug: Intramuscular olanzapine depot
NCT00220740,Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",Interventional,10-Sep-15,Grifols Therapeutics LLC,"Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified"
NCT00220740,Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",Interventional,10-Sep-15,Grifols Therapeutics LLC,"Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)"
NCT00087022,Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer,Kidney Cancer,Interventional,12-Sep-18,Wilex,Biological: girentuximab
NCT00087022,Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer,Kidney Cancer,Interventional,12-Sep-18,Wilex,Other: placebo
NCT01559116,Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: tiotropium + olodaterol
NCT01559116,Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: tiotropium
NCT01559116,Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: olodaterol
NCT01559116,Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Drug: Placebo
NCT01559116,Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,16-Jul-15,Boehringer Ingelheim,Device: Respimat
NCT00171210,An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload,Transfusional Iron Overload in β-thalassemia,Interventional,2-May-11,Novartis Pharmaceuticals,Drug: Deferasirox
NCT00171210,An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload,Transfusional Iron Overload in β-thalassemia,Interventional,2-May-11,Novartis,Drug: Deferasirox
NCT00088530,"BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Non-Hodgkin",Interventional,1-Jun-17,CTI BioPharma,"Drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone"
NCT00088530,"BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Non-Hodgkin",Interventional,1-Jun-17,CTI BioPharma,"Drug: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab"
NCT00085644,Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,11-Mar-10,Abbott,Biological: adalimumab (D2E7)
NCT00085644,Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Interventional,11-Mar-10,Abbott,Biological: placebo
NCT00083889,SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma,"Carcinoma, Renal Cell",Interventional,10-Dec-09,Pfizer,Drug: Interferon-alfa
NCT00083889,SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma,"Carcinoma, Renal Cell",Interventional,10-Dec-09,Pfizer,Drug: SU011248
NCT01520909,"Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.",Idiopathic Thrombocytopenic Purpura,Interventional,29-Sep-14,GlaxoSmithKline,Drug: Eltrombopag
NCT01520909,"Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.",Idiopathic Thrombocytopenic Purpura,Interventional,29-Sep-14,GlaxoSmithKline,Drug: Placebo
NCT00082628,Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients,HIV Infections|Lipodystrophy,Interventional,20-Jul-18,EMD Serono,Drug: Placebo
NCT00082628,Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients,HIV Infections|Lipodystrophy,Interventional,20-Jul-18,EMD Serono,Drug: Serostim® 4 mg
NCT00082628,Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients,HIV Infections|Lipodystrophy,Interventional,20-Jul-18,EMD Serono,Drug: Serostim® 2 mg
NCT00082433,Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,Cancer|Breast Cancer,Interventional,17-Aug-09,R-Pharm,Drug: Ixabepilone + Capecitabine
NCT00082433,Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,Cancer|Breast Cancer,Interventional,17-Aug-09,R-Pharm,Drug: Capecitabine
NCT00081458,Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome,Short Bowel Syndrome,Interventional,15-Jul-13,Shire,Drug: Placebo
NCT00081458,Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome,Short Bowel Syndrome,Interventional,15-Jul-13,Shire,Drug: Teduglutide 0.05 mg/kg/d
NCT00081458,Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome,Short Bowel Syndrome,Interventional,15-Jul-13,Shire,Drug: Teduglutide 0.1 mg/kg/d
NCT00080470,An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence,Urinary Incontinence,Interventional,10-Oct-13,Boston Scientific Corporation,Device: bion
NCT00080301,Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,Breast Cancer|Metastases,Interventional,17-Aug-09,R-Pharm,Drug: Ixabepilone + Capecitabine
NCT00080301,Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,Breast Cancer|Metastases,Interventional,17-Aug-09,R-Pharm,Drug: Capecitabine
NCT00079937,"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",Asthma,Interventional,3-Aug-11,Novartis Pharmaceuticals,Drug: Omalizumab
NCT00079937,"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",Asthma,Interventional,3-Aug-11,Novartis Pharmaceuticals,Drug: Placebo
NCT00079937,"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",Asthma,Interventional,3-Aug-11,Novartis Pharmaceuticals,Drug: Fluticasone
NCT00079937,"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",Asthma,Interventional,3-Aug-11,Novartis,Drug: Omalizumab
NCT00079937,"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",Asthma,Interventional,3-Aug-11,Novartis,Drug: Placebo
NCT00079937,"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",Asthma,Interventional,3-Aug-11,Novartis,Drug: Fluticasone
NCT00009737,A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer,Colorectal Cancer,Interventional,22-Jun-16,Hoffmann-La Roche,Drug: 5-Fluorouracil
NCT00009737,A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer,Colorectal Cancer,Interventional,22-Jun-16,Hoffmann-La Roche,Drug: Leucovorin
NCT00009737,A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer,Colorectal Cancer,Interventional,22-Jun-16,Hoffmann-La Roche,Drug: Capecitabine [Xeloda]
NCT00005947,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,Prostate Cancer,Interventional,1-Nov-10,Dendreon,Biological: sipuleucel-T
NCT00005947,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,Prostate Cancer,Interventional,1-Nov-10,Dendreon,Biological: Placebo
NCT00078312,"Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder","Narcolepsy|Sleep Apnea, Obstructive|Sleep Apnea Syndromes|Shift-Work Sleep Disorder",Interventional,22-Feb-10,Cephalon,Drug: CEP-10953 (Armodafinil)
NCT00078312,"Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder","Narcolepsy|Sleep Apnea, Obstructive|Sleep Apnea Syndromes|Shift-Work Sleep Disorder",Interventional,22-Feb-10,Teva Pharmaceutical Industries,Drug: CEP-10953 (Armodafinil)
NCT00077623,A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.,Anemia,Interventional,26-Apr-16,Hoffmann-La Roche,Drug: epoetin alfa or beta
NCT00077623,A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.,Anemia,Interventional,26-Apr-16,Hoffmann-La Roche,Drug: methoxy polyethylene glycol-epoetin beta (Mircera)
NCT00077610,A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients,Anemia,Interventional,29-Feb-16,Hoffmann-La Roche,Drug: Epoetin alfa or beta
NCT00077610,A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients,Anemia,Interventional,29-Feb-16,Hoffmann-La Roche,Drug: RO0503821 (1x/2 Weeks)
NCT00077610,A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients,Anemia,Interventional,29-Feb-16,Hoffmann-La Roche,Drug: RO0503821 (1x/4 Weeks)
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,Integrative Medicine Institute,Drug: Zicam (Ionic zinc)
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,Integrative Medicine Institute,Drug: placebo
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,"Women's Health Services, Santa Fe, New Mexico",Drug: Zicam (Ionic zinc)
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,"Women's Health Services, Santa Fe, New Mexico",Drug: placebo
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,Southwest College of Naturopathic Medicine,Drug: Zicam (Ionic zinc)
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,Southwest College of Naturopathic Medicine,Drug: placebo
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,Beth Israel Medical Center,Drug: Zicam (Ionic zinc)
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,Beth Israel Medical Center,Drug: placebo
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,"Matrixx Initiatives, Inc.",Drug: Zicam (Ionic zinc)
NCT00809809,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Herpes Simplex Labialis,Interventional,8-Jan-14,"Matrixx Initiatives, Inc.",Drug: placebo
NCT01448044,Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C,Hepatitis C,Interventional,7-Sep-15,Bristol-Myers Squibb,Drug: BMS-790052 (NS5A Replication Complex Inhibitor)
NCT01448044,Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C,Hepatitis C,Interventional,7-Sep-15,Bristol-Myers Squibb,Drug: Placebo matching BMS-790052
NCT01448044,Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C,Hepatitis C,Interventional,7-Sep-15,Bristol-Myers Squibb,Drug: Pegylated-interferon alfa 2a
NCT01448044,Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C,Hepatitis C,Interventional,7-Sep-15,Bristol-Myers Squibb,Drug: Ribavirin
NCT01445678,Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections,Complicated Intra-abdominal Infection,Interventional,15-Jan-15,Cubist Pharmaceuticals LLC,Drug: CXA-201 and metronidazole
NCT01445678,Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections,Complicated Intra-abdominal Infection,Interventional,15-Jan-15,Cubist Pharmaceuticals LLC,Drug: Meropenem
NCT00075270,Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer,"Neoplasms, Breast",Interventional,31-Mar-14,GlaxoSmithKline,Drug: Paclitaxel
NCT00075270,Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer,"Neoplasms, Breast",Interventional,31-Mar-14,GlaxoSmithKline,Drug: GW572016 (Lapatinib)
NCT00075218,A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST),Gastrointestinal Stromal Tumor,Interventional,28-Sep-09,Pfizer,Drug: Placebo
NCT00075218,A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST),Gastrointestinal Stromal Tumor,Interventional,28-Sep-09,Pfizer,Drug: SU011248
NCT00424255,Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery,"Neoplasms, Head and Neck",Interventional,11-Feb-14,GlaxoSmithKline,Drug: Lapatinib
NCT00424255,Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery,"Neoplasms, Head and Neck",Interventional,11-Feb-14,GlaxoSmithKline,Radiation: Chemoradiation
NCT00424255,Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery,"Neoplasms, Head and Neck",Interventional,11-Feb-14,GlaxoSmithKline,Other: Placebo
NCT00073528,Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer,"Neoplasms, Breast",Interventional,17-May-12,Novartis Pharmaceuticals,Drug: Lapatinib (GW572016)
NCT00073528,Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer,"Neoplasms, Breast",Interventional,17-May-12,Novartis Pharmaceuticals,Drug: Letrozole
NCT00073528,Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer,"Neoplasms, Breast",Interventional,17-May-12,Novartis,Drug: Lapatinib (GW572016)
NCT00073528,Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer,"Neoplasms, Breast",Interventional,17-May-12,Novartis,Drug: Letrozole
NCT01407068,Administration of Two Injections for Multiple Dupuytren's Contractures,Dupuytren's Contracture,Interventional,20-Feb-15,Endo Pharmaceuticals,Biological: AA4500 collagenase clostridium histolyticum
NCT00073021,Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis,Ulcerative Colitis,Interventional,28-Jul-11,Warner Chilcott,Drug: Asacol 800 mg (mesalamine)
NCT00073021,Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis,Ulcerative Colitis,Interventional,28-Jul-11,Warner Chilcott,Drug: Asacol 400 mg (mesalamine)
NCT00102804,Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer,Interventional,29-Dec-14,Eli Lilly and Company,Drug: Pemetrexed
NCT00102804,Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer,Interventional,29-Dec-14,Eli Lilly and Company,Drug: Placebo
NCT00102804,Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer,Interventional,29-Dec-14,Eli Lilly and Company,Other: Best Supportive Care
NCT00076336,Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis,"Hepatitis|Hepatitis B, Chronic|Cirrhosis",Interventional,5-Sep-11,Novartis Pharmaceuticals,Drug: Telbivudine
NCT00076336,Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis,"Hepatitis|Hepatitis B, Chronic|Cirrhosis",Interventional,5-Sep-11,Novartis Pharmaceuticals,Drug: Lamivudine
NCT00076336,Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis,"Hepatitis|Hepatitis B, Chronic|Cirrhosis",Interventional,5-Sep-11,Novartis Pharmaceuticals,Drug: Placebo
NCT00076336,Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis,"Hepatitis|Hepatitis B, Chronic|Cirrhosis",Interventional,5-Sep-11,Novartis,Drug: Telbivudine
NCT00076336,Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis,"Hepatitis|Hepatitis B, Chronic|Cirrhosis",Interventional,5-Sep-11,Novartis,Drug: Lamivudine
NCT00076336,Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis,"Hepatitis|Hepatitis B, Chronic|Cirrhosis",Interventional,5-Sep-11,Novartis,Drug: Placebo
NCT00401973,Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine,Schizophrenia|Schizoaffective Disorders,Interventional,30-Sep-09,Eli Lilly and Company,Drug: olanzapine
NCT00401973,Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine,Schizophrenia|Schizoaffective Disorders,Interventional,30-Sep-09,Eli Lilly and Company,Drug: amantadine
NCT00401973,Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine,Schizophrenia|Schizoaffective Disorders,Interventional,30-Sep-09,Eli Lilly and Company,Drug: metformin
NCT00401973,Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine,Schizophrenia|Schizoaffective Disorders,Interventional,30-Sep-09,Eli Lilly and Company,Drug: zonisamide
NCT00401973,Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine,Schizophrenia|Schizoaffective Disorders,Interventional,30-Sep-09,Eli Lilly and Company,Behavioral: Wellness education
NCT01387230,Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,11-Feb-14,GlaxoSmithKline,Drug: GSK573719
NCT01387230,Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD,"Pulmonary Disease, Chronic Obstructive",Interventional,11-Feb-14,GlaxoSmithKline,Other: Placebo
NCT00069121,A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer,Colorectal Cancer,Interventional,29-Jul-11,Hoffmann-La Roche,Drug: capecitabine [Xeloda]
NCT00069121,A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer,Colorectal Cancer,Interventional,29-Jul-11,Hoffmann-La Roche,Drug: Oxaliplatin
NCT00069121,A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer,Colorectal Cancer,Interventional,29-Jul-11,Hoffmann-La Roche,Drug: Leucovorin
NCT00069121,A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer,Colorectal Cancer,Interventional,29-Jul-11,Hoffmann-La Roche,Drug: 5 FU
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Oxaliplatin 130 mg/m^2
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Capecitabine 1000 mg/m^2
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Bevacizumab 7.5 mg/kg
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Placebo for bevacizumab 7.5 mg/kg
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Oxaliplatin 85 mg/m^2
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Leucovorin 200 mg/m^2
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Fluorouracil 400 mg/m^2
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Bevacizumab 5 mg/kg
NCT00069095,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,22-Jan-16,Hoffmann-La Roche,Drug: Placebo for bevacizumab 5 mg/kg
NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,Myelodysplastic Syndromes,Interventional,5-Jul-10,Celgene Corporation,Drug: Azacitidine
NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,Myelodysplastic Syndromes,Interventional,5-Jul-10,Celgene Corporation,Other: Physician Choice
NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,Myelodysplastic Syndromes,Interventional,5-Jul-10,Celgene,Drug: Azacitidine
NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,Myelodysplastic Syndromes,Interventional,5-Jul-10,Celgene,Other: Physician Choice
NCT00066170,Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy,Narcolepsy,Interventional,30-Nov-11,Jazz Pharmaceuticals,Drug: Xyrem
NCT00066170,Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy,Narcolepsy,Interventional,30-Nov-11,Jazz Pharmaceuticals,Drug: Xyrem Placebo
NCT00066170,Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy,Narcolepsy,Interventional,30-Nov-11,Jazz Pharmaceuticals,Drug: Modafinil at established dose
NCT00066170,Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy,Narcolepsy,Interventional,30-Nov-11,Jazz Pharmaceuticals,Drug: Modafinil (Placebo)
NCT00065507,Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation,Hepatitis B,Interventional,2-Jul-10,Bristol-Myers Squibb,Drug: Entecavir (ETV)
NCT00065507,Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation,Hepatitis B,Interventional,2-Jul-10,Bristol-Myers Squibb,Drug: Adefovir (ADV)
NCT00065468,Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell|Kidney Neoplasms",Interventional,25-Oct-12,Pfizer,Drug: Interferon Alfa
NCT00065468,Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell|Kidney Neoplasms",Interventional,25-Oct-12,Pfizer,Drug: CCI-779
NCT00065468,Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell|Kidney Neoplasms",Interventional,25-Oct-12,Pfizer,Drug: Interferon Alfa and CCI-779
NCT00065442,Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy,Prostate Cancer,Interventional,6-Sep-10,Dendreon,Biological: Sipuleucel-T
NCT00065442,Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy,Prostate Cancer,Interventional,6-Sep-10,Dendreon,Biological: APC-Placebo
NCT00364182,Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B,Hemophilia B,Interventional,23-Aug-11,Pfizer,Drug: Recombinant Coagulation Factor IX (BeneFIX)
NCT00064701,Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients,Kidney Transplantation,Interventional,26-Sep-13,Astellas Pharma Inc,Drug: Tacrolimus Modified Release (MR)
NCT00064701,Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients,Kidney Transplantation,Interventional,26-Sep-13,Astellas Pharma Inc,Drug: Tacrolimus
NCT00064701,Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients,Kidney Transplantation,Interventional,26-Sep-13,Astellas Pharma Inc,Drug: cyclosporine microemulsion
NCT00064701,Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients,Kidney Transplantation,Interventional,26-Sep-13,Astellas Pharma Inc,Drug: mycophenolate mofetil
NCT00069108,A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,24-Feb-16,Hoffmann-La Roche,Drug: 5 FU
NCT00069108,A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,24-Feb-16,Hoffmann-La Roche,Drug: Leucovorin
NCT00069108,A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,24-Feb-16,Hoffmann-La Roche,Drug: Oxaliplatin
NCT00069108,A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Interventional,24-Feb-16,Hoffmann-La Roche,Drug: capecitabine [Xeloda]
NCT00057330,HerpeVac Trial for Young Women,Herpes Simplex Infection,Interventional,3-Nov-11,GlaxoSmithKline,"Biological: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine"
NCT00057330,HerpeVac Trial for Young Women,Herpes Simplex Infection,Interventional,3-Nov-11,GlaxoSmithKline,"Biological: Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine"
NCT00314145,A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX,Japanese Encephalitis,Interventional,5-Dec-12,Sanofi,Biological: ChimeriVax™-JE
NCT00314145,A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX,Japanese Encephalitis,Interventional,5-Dec-12,Sanofi,Biological: JE-VAX®
NCT00056407,"""REDUCE"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk","Neoplasms, Prostate",Interventional,5-Mar-10,GlaxoSmithKline,Drug: Dutasteride
NCT00056407,"""REDUCE"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk","Neoplasms, Prostate",Interventional,5-Mar-10,GlaxoSmithKline,Drug: Placebo
NCT00056160,CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma,Multiple Myeloma,Interventional,3-Mar-10,Celgene,Drug: CC-5013
NCT00056160,CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma,Multiple Myeloma,Interventional,3-Mar-10,Celgene,Drug: Dexamethasone
NCT00055497,"Remission in Subjects With Crohn's Disease, 1 Year Phase",Crohn's Disease,Interventional,18-May-10,Abbott,Biological: Double-blind (DB) adalimumab placebo
NCT00055497,"Remission in Subjects With Crohn's Disease, 1 Year Phase",Crohn's Disease,Interventional,18-May-10,Abbott,Biological: DB adalimumab 40 mg eow
NCT00055497,"Remission in Subjects With Crohn's Disease, 1 Year Phase",Crohn's Disease,Interventional,18-May-10,Abbott,Biological: DB adalimumab 40 mg ew
NCT00055497,"Remission in Subjects With Crohn's Disease, 1 Year Phase",Crohn's Disease,Interventional,18-May-10,Abbott,Biological: OL adalimumab 40 mg
NCT01230021,Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Interventional,12-Jun-14,Novo Nordisk A/S,Drug: catridecacog
NCT00054717,Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST),HIV Infections,Interventional,19-Nov-09,Boehringer Ingelheim,Drug: Tipranavir
NCT00054717,Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST),HIV Infections,Interventional,19-Nov-09,Boehringer Ingelheim,Drug: Ritonavir(r)
NCT00054717,Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST),HIV Infections,Interventional,19-Nov-09,Boehringer Ingelheim,Drug: Comparator Protease Inhibitor (CPI)
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis Pharmaceuticals,Drug: Zoledronic Acid
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis Pharmaceuticals,Drug: Risedronate
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis Pharmaceuticals,Drug: Placebo to Risedronate
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis Pharmaceuticals,Drug: Placebo to Zoledronic Acid
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis Pharmaceuticals,Dietary Supplement: Calcium and Vitamin D
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis,Drug: Zoledronic Acid
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis,Drug: Risedronate
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis,Drug: Placebo to Risedronate
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis,Drug: Placebo to Zoledronic Acid
NCT00051636,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Paget's Disease of Bone,Interventional,7-May-12,Novartis,Dietary Supplement: Calcium and Vitamin D
NCT00050960,"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",Non-small Cell Lung Cancer,Interventional,24-Aug-10,Eisai Inc.,Drug: bexarotene with carboplatin and paclitaxel
NCT00050960,"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",Non-small Cell Lung Cancer,Interventional,24-Aug-10,Eisai Inc.,Drug: carboplatin and paclitaxel
NCT00050011,Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy,Breast Neoplasms|Osteoporosis,Interventional,28-Jan-14,Novartis Pharmaceuticals,Drug: Zoledronic Acid
NCT00050011,Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy,Breast Neoplasms|Osteoporosis,Interventional,28-Jan-14,Novartis Pharmaceuticals,Drug: Letrozole
NCT00050011,Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy,Breast Neoplasms|Osteoporosis,Interventional,28-Jan-14,Novartis,Drug: Zoledronic Acid
NCT00050011,Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy,Breast Neoplasms|Osteoporosis,Interventional,28-Jan-14,Novartis,Drug: Letrozole
NCT00048932,A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,3-May-11,Bristol-Myers Squibb,Drug: Double-blind Abatacept
NCT00048932,A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,3-May-11,Bristol-Myers Squibb,Drug: Double-blind Placebo
NCT00048932,A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Interventional,3-May-11,Bristol-Myers Squibb,Drug: Open-label Abatacept
NCT00048581,Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.,Rheumatoid Arthritis,Interventional,23-Jun-11,Bristol-Myers Squibb,Drug: Abatacept
NCT00048581,Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.,Rheumatoid Arthritis,Interventional,23-Jun-11,Bristol-Myers Squibb,Drug: Placebo
NCT00048568,A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate,Rheumatoid Arthritis,Interventional,5-Dec-11,Bristol-Myers Squibb,Drug: Abatacept
NCT00048568,A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate,Rheumatoid Arthritis,Interventional,5-Dec-11,Bristol-Myers Squibb,Drug: Methotrexate
NCT00048568,A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate,Rheumatoid Arthritis,Interventional,5-Dec-11,Bristol-Myers Squibb,Drug: Placebo
NCT00048542,Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA),"Arthritis, Juvenile Idiopathic",Interventional,11-Jan-10,Abbott,Biological: Double-Blind Adalimumab/Placebo + MTX
NCT00048542,Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA),"Arthritis, Juvenile Idiopathic",Interventional,11-Jan-10,Abbott,Biological: Double-Blind Adalimumab/Placebo
NCT00048542,Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA),"Arthritis, Juvenile Idiopathic",Interventional,11-Jan-10,Abbott,Drug: OLE BSA Adalimumab +/- MTX
NCT00048542,Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA),"Arthritis, Juvenile Idiopathic",Interventional,11-Jan-10,Abbott,Drug: OLE FD Adalimumab +/- MTX
NCT00048074,DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis,Post Menopausal Osteoporosis,Interventional,3-Feb-16,Hoffmann-La Roche,Drug: ibandronate [Bonviva/Boniva]
NCT00048061,MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis,Post Menopausal Osteoporosis,Interventional,30-May-16,Hoffmann-La Roche,Drug: Ibandronate [Bonviva/Boniva]
NCT00048061,MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis,Post Menopausal Osteoporosis,Interventional,30-May-16,Hoffmann-La Roche,Dietary Supplement: Calcium
NCT00048061,MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis,Post Menopausal Osteoporosis,Interventional,30-May-16,Hoffmann-La Roche,Dietary Supplement: Vitamin D
NCT01137682,Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly,Acromegaly,Interventional,21-Jan-15,Novartis Pharmaceuticals,Drug: Pasireotide
NCT01137682,Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly,Acromegaly,Interventional,21-Jan-15,Novartis Pharmaceuticals,Drug: octreotide LAR 30mg
NCT01137682,Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly,Acromegaly,Interventional,21-Jan-15,Novartis Pharmaceuticals,Drug: lanreotide ATG 120mg
NCT01137682,Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly,Acromegaly,Interventional,21-Jan-15,Novartis,Drug: Pasireotide
NCT01137682,Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly,Acromegaly,Interventional,21-Jan-15,Novartis,Drug: octreotide LAR 30mg
NCT01137682,Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly,Acromegaly,Interventional,21-Jan-15,Novartis,Drug: lanreotide ATG 120mg
NCT00158600,A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease,Pompe Disease (Late-onset)|Glycogen Storage Disease Type II (GSD-II)|Acid Maltase Deficiency Disease|Glycogenosis 2,Interventional,23-Jul-10,"Genzyme, a Sanofi Company",Biological: alglucosidase alfa
NCT00158600,A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease,Pompe Disease (Late-onset)|Glycogen Storage Disease Type II (GSD-II)|Acid Maltase Deficiency Disease|Glycogenosis 2,Interventional,23-Jul-10,"Genzyme, a Sanofi Company",Drug: Placebo
NCT00158600,A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease,Pompe Disease (Late-onset)|Glycogen Storage Disease Type II (GSD-II)|Acid Maltase Deficiency Disease|Glycogenosis 2,Interventional,23-Jul-10,Sanofi,Biological: alglucosidase alfa
NCT00158600,A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease,Pompe Disease (Late-onset)|Glycogen Storage Disease Type II (GSD-II)|Acid Maltase Deficiency Disease|Glycogenosis 2,Interventional,23-Jul-10,Sanofi,Drug: Placebo
NCT00041717,Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury,Spinal Cord Injury|Muscle Spasticity,Interventional,31-May-13,Acorda Therapeutics,Drug: Fampridine-SR
NCT00041717,Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury,Spinal Cord Injury|Muscle Spasticity,Interventional,31-May-13,Acorda Therapeutics,Other: Placebo
NCT01086410,Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Placebo Inhalation Powder
NCT01086410,Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Fluticasone Furoate/GW642444 Inhalation Powder
NCT01086410,Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Placebo Oral Capsule
NCT01086410,Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis,Asthma,Interventional,8-Aug-13,GlaxoSmithKline,Drug: Prednisolone Oral Capsule
NCT00038467,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,Breast Neoplasms,Interventional,10-Apr-14,Pfizer,Drug: Tamoxifen
NCT00038467,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,Breast Neoplasms,Interventional,10-Apr-14,Pfizer,Drug: Exemestane
NCT00038467,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,Breast Neoplasms,Interventional,10-Apr-14,International Collaborative Cancer Group (ICCG),Drug: Tamoxifen
NCT00038467,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,Breast Neoplasms,Interventional,10-Apr-14,International Collaborative Cancer Group (ICCG),Drug: Exemestane
NCT00036270,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Breast Neoplasms,Interventional,4-Dec-09,Pfizer,Drug: exemestane (Aromasin)
NCT00036270,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Breast Neoplasms,Interventional,4-Dec-09,Pfizer,Drug: tamoxifen + exemestane
NCT00035932,"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",HIV Infections,Interventional,24-Dec-10,Bristol-Myers Squibb,Drug: Atazanavir + ritonavir + tenofovir + nucleoside
NCT00035932,"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",HIV Infections,Interventional,24-Dec-10,Bristol-Myers Squibb,Drug: Atazanavir + saquinavir + tenofovir + nucleoside
NCT00035932,"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",HIV Infections,Interventional,24-Dec-10,Bristol-Myers Squibb,Drug: Lopinavir/ritonavir + tenofovir + nucleoside
NCT01047839,"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries",Encephalitis,Interventional,19-Dec-14,Valneva Austria GmbH,Biological: IC51
NCT00106028,Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children,Osteogenesis Imperfecta,Interventional,28-Jun-10,Warner Chilcott,Drug: risedronate sodium (Actonel)
NCT00106028,Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children,Osteogenesis Imperfecta,Interventional,28-Jun-10,Warner Chilcott,Drug: Placebo
NCT00051558,Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis,Osteoporosis,Interventional,13-Feb-09,Eli Lilly and Company,Drug: Teriparatide
NCT00051558,Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis,Osteoporosis,Interventional,13-Feb-09,Eli Lilly and Company,Drug: Alendronate Sodium
NCT00051558,Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis,Osteoporosis,Interventional,13-Feb-09,Eli Lilly and Company,Drug: Placebo
NCT00864851,Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease,Fabry Disease,Interventional,6-Jun-14,Shire,Biological: Replagal
NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis,Interventional,30-Jan-17,Sanofi,Drug: Teriflunomide (HMR1726)
NCT00784654,"Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17",ADHD,Interventional,2-Oct-12,Shire,Drug: Lisdexamfetamine dimesylate (LDX)
NCT00784654,"Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17",ADHD,Interventional,2-Oct-12,Shire,Drug: Placebo
NCT00487240,Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,25-Sep-09,Eli Lilly and Company,Drug: Insulin Lispro Protamine Suspension
NCT00487240,Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,25-Sep-09,Eli Lilly and Company,Drug: Insulin Levemir
NCT00368251,Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults,Unverricht-Lundborg Disease,Interventional,13-Apr-16,UCB Pharma,Other: Placebo
NCT00368251,Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults,Unverricht-Lundborg Disease,Interventional,13-Apr-16,UCB Pharma,Drug: BRV 2.5 mg
NCT00368251,Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults,Unverricht-Lundborg Disease,Interventional,13-Apr-16,UCB Pharma,Drug: BRV 25 mg
NCT00368251,Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults,Unverricht-Lundborg Disease,Interventional,13-Apr-16,UCB Pharma,Drug: BRV 50 mg
NCT00355615,PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin,Familial Hypercholesterolemia,Interventional,20-Jul-09,AstraZeneca,Drug: Rosuvastatin
NCT00355615,PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin,Familial Hypercholesterolemia,Interventional,20-Jul-09,AstraZeneca,Drug: Placebo
NCT02186171,A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis,Osteoporosis in Men,Interventional,27-May-19,Amgen,Biological: Romosozumab
NCT02186171,A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis,Osteoporosis in Men,Interventional,27-May-19,Amgen,Drug: Placebo
NCT02085161,To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways,"Pulmonary Disease, Chronic Obstructive",Interventional,6-Jan-17,Boehringer Ingelheim,Drug: placebo to tiotropium + olodaterol
NCT02085161,To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways,"Pulmonary Disease, Chronic Obstructive",Interventional,6-Jan-17,Boehringer Ingelheim,Drug: tiotropium+olodaterol
NCT02085161,To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways,"Pulmonary Disease, Chronic Obstructive",Interventional,6-Jan-17,Boehringer Ingelheim,Drug: tiotropium +olodaterol
NCT02085161,To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways,"Pulmonary Disease, Chronic Obstructive",Interventional,6-Jan-17,Boehringer Ingelheim,Drug: tiotropium
NCT02075515,"Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age",Herpes Zoster,Interventional,24-May-17,GlaxoSmithKline,Biological: Herpes Zoster vaccine (GSK 1437173A)
NCT02059291,Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers,Hereditary Periodic Fevers,Interventional,17-Mar-17,Novartis Pharmaceuticals,Drug: Canakinumab
NCT02059291,Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers,Hereditary Periodic Fevers,Interventional,17-Mar-17,Novartis Pharmaceuticals,Drug: Placebo
NCT02059291,Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers,Hereditary Periodic Fevers,Interventional,17-Mar-17,Novartis,Drug: Canakinumab
NCT02059291,Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers,Hereditary Periodic Fevers,Interventional,17-Mar-17,Novartis,Drug: Placebo
NCT02052141,Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema,Hereditary Angioedema (HAE),Interventional,28-Aug-18,Shire,Biological: CINRYZE 500
NCT02052141,Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema,Hereditary Angioedema (HAE),Interventional,28-Aug-18,Shire,Biological: CINRYZE 1000
NCT02045836,Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older,Herpes Zoster,Interventional,5-Jul-17,GlaxoSmithKline,Biological: Herpes Zoster vaccine GSK 1437173A
NCT02045836,Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older,Herpes Zoster,Interventional,5-Jul-17,GlaxoSmithKline,"Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™"
NCT01954251,Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older,Herpes Zoster,Interventional,10-Feb-16,GlaxoSmithKline,Biological: Herpes Zoster vaccine GSK 1437173A
NCT01954251,Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older,Herpes Zoster,Interventional,10-Feb-16,GlaxoSmithKline,Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
NCT01899742,The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium,"Pulmonary Disease, Chronic Obstructive",Interventional,25-Feb-16,GlaxoSmithKline,Drug: Umeclidinium/Vilanterol 62.5/25 mcg
NCT01899742,The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium,"Pulmonary Disease, Chronic Obstructive",Interventional,25-Feb-16,GlaxoSmithKline,Drug: Tiotropium 18 mcg
NCT02753946,Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections,Urinary Tract Infection Symptomatic|Acute Pyelonephritis|Urinary Tract Infection Complicated,Interventional,11-Dec-18,Nabriva Therapeutics AG,Drug: ZTI-01
NCT02753946,Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections,Urinary Tract Infection Symptomatic|Acute Pyelonephritis|Urinary Tract Infection Complicated,Interventional,11-Dec-18,Nabriva Therapeutics AG,Drug: Piperacillin-tazobactam
NCT02753946,Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections,Urinary Tract Infection Symptomatic|Acute Pyelonephritis|Urinary Tract Infection Complicated,Interventional,11-Dec-18,"Medpace, Inc.",Drug: ZTI-01
NCT02753946,Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections,Urinary Tract Infection Symptomatic|Acute Pyelonephritis|Urinary Tract Infection Complicated,Interventional,11-Dec-18,"Medpace, Inc.",Drug: Piperacillin-tazobactam
NCT01544491,"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,Interventional,31-May-19,Novartis Pharmaceuticals,Drug: RAD001
NCT01544491,"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,Interventional,31-May-19,Novartis Pharmaceuticals,Drug: MMF
NCT01544491,"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,Interventional,31-May-19,Novartis,Drug: RAD001
NCT01544491,"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,Interventional,31-May-19,Novartis,Drug: MMF
NCT01365546,Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery,Prevent Bleeding in Major Surgery,Interventional,9-Mar-15,Octapharma,Biological: human VWF/FVIII concentrate
NCT01190176,Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects,"Infections, Papillomavirus",Interventional,17-Oct-18,GlaxoSmithKline,Procedure: Gynaecological follow-up
NCT01190176,Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects,"Infections, Papillomavirus",Interventional,17-Oct-18,GlaxoSmithKline,Biological: Cervarix
NCT01190176,Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects,"Infections, Papillomavirus",Interventional,17-Oct-18,GlaxoSmithKline,Biological: Placebo control
NCT01040728,"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",Interventional,30-Jun-14,Boehringer Ingelheim,Drug: Olodaterol (BI1744) Low
NCT01040728,"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",Interventional,30-Jun-14,Boehringer Ingelheim,Drug: Olodaterol (BI1744) High
NCT01040728,"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",Interventional,30-Jun-14,Boehringer Ingelheim,Drug: Tiotropium 18 mcg
NCT01040728,"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",Interventional,30-Jun-14,Boehringer Ingelheim,Drug: Placebo (for Olodaterol (BI1744)l)
NCT01040728,"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",Interventional,30-Jun-14,Boehringer Ingelheim,Drug: Placebo (for Tiotropium)
NCT01000961,Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis,Cystinosis,Interventional,19-Nov-14,"Horizon Pharma USA, Inc.",Drug: Cystagon® (Cysteamine Bitartrate)
NCT01000961,Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis,Cystinosis,Interventional,19-Nov-14,"Horizon Pharma USA, Inc.",Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
NCT00995709,Phase III Study in Refractory Behcet's Disease,Behcet Disease,Interventional,31-Aug-15,Novartis Pharmaceuticals,Drug: AIN457
NCT00995709,Phase III Study in Refractory Behcet's Disease,Behcet Disease,Interventional,31-Aug-15,Novartis Pharmaceuticals,Drug: Placebo
NCT00995709,Phase III Study in Refractory Behcet's Disease,Behcet Disease,Interventional,31-Aug-15,Novartis,Drug: AIN457
NCT00995709,Phase III Study in Refractory Behcet's Disease,Behcet Disease,Interventional,31-Aug-15,Novartis,Drug: Placebo
NCT02282527,A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency,Alpha₁-Antitrypsin Deficiency,Interventional,13-Mar-17,Grifols Therapeutics LLC,Biological: Liquid Alpha₁-PI
NCT02282527,A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency,Alpha₁-Antitrypsin Deficiency,Interventional,13-Mar-17,Grifols Therapeutics LLC,Biological: Prolastin-C
NCT00863746,A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).,Carcinoma|Non-Small-Cell Lung,Interventional,30-Jul-13,Bayer,"Drug: Sorafenib (Nexavar, BAY43-9006)"
NCT00863746,A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).,Carcinoma|Non-Small-Cell Lung,Interventional,30-Jul-13,Bayer,Drug: Placebo
NCT01429987,The Plecanatide Chronic Idiopathic Constipation (CIC) Study,Chronic Idiopathic Constipation,Interventional,29-Nov-17,"Bausch Health Americas, Inc.",Drug: plecanatide
NCT01429987,The Plecanatide Chronic Idiopathic Constipation (CIC) Study,Chronic Idiopathic Constipation,Interventional,29-Nov-17,"Bausch Health Americas, Inc.",Other: Placebo
NCT01429987,The Plecanatide Chronic Idiopathic Constipation (CIC) Study,Chronic Idiopathic Constipation,Interventional,29-Nov-17,Parexel,Drug: plecanatide
NCT01429987,The Plecanatide Chronic Idiopathic Constipation (CIC) Study,Chronic Idiopathic Constipation,Interventional,29-Nov-17,Parexel,Other: Placebo
NCT00737568,Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine,Hepatitis B,Interventional,11-Apr-13,Gilead Sciences,Drug: TDF
NCT00737568,Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine,Hepatitis B,Interventional,11-Apr-13,Gilead Sciences,Drug: FTC/TDF
NCT00737568,Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine,Hepatitis B,Interventional,11-Apr-13,Gilead Sciences,Drug: TDF Placebo
NCT00737568,Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine,Hepatitis B,Interventional,11-Apr-13,Gilead Sciences,Drug: FTC/TDF Placebo
NCT00734162,Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection,Hepatitis B Virus (HBV),Interventional,7-Nov-12,Gilead Sciences,Drug: Tenofovir disoproxil fumarate (TDF)
NCT00734162,Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection,Hepatitis B Virus (HBV),Interventional,7-Nov-12,Gilead Sciences,Drug: Placebo
NCT00712348,Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase,Gaucher Disease,Interventional,5-Jun-14,Pfizer,Drug: Taliglucerase alfa
NCT00701415,"A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms",Fabry Disease,Interventional,29-Jun-16,"Genzyme, a Sanofi Company",Biological: Agalsidase beta
NCT00701415,"A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms",Fabry Disease,Interventional,29-Jun-16,Sanofi,Biological: Agalsidase beta
NCT00465985,"Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome",Muckle Wells Syndrome,Interventional,11-Feb-11,Novartis,Drug: ACZ885
NCT00465985,"Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome",Muckle Wells Syndrome,Interventional,11-Feb-11,Novartis,Drug: Placebo
NCT01061736,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Interventional,28-Jun-17,Sanofi,Drug: Sarilumab
NCT01061736,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Interventional,28-Jun-17,Sanofi,Drug: Placebo (for sarilumab)
NCT01061736,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Interventional,28-Jun-17,Sanofi,Drug: Methotrexate
NCT01061736,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Interventional,28-Jun-17,Sanofi,Drug: Folic Acid
NCT01061736,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Interventional,28-Jun-17,Regeneron Pharmaceuticals,Drug: Sarilumab
NCT01061736,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Interventional,28-Jun-17,Regeneron Pharmaceuticals,Drug: Placebo (for sarilumab)
NCT01061736,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Interventional,28-Jun-17,Regeneron Pharmaceuticals,Drug: Methotrexate
NCT01061736,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Interventional,28-Jun-17,Regeneron Pharmaceuticals,Drug: Folic Acid
NCT01541254,Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device,Intracranial Aneurysms,Interventional,15-Sep-14,"Microvention-Terumo, Inc.",Device: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
NCT00433290,Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain,Osteoarthritis Knee Pain,Interventional,24-Aug-09,Eli Lilly and Company,Drug: Duloxetine
NCT00433290,Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain,Osteoarthritis Knee Pain,Interventional,24-Aug-09,Eli Lilly and Company,Drug: Placebo
NCT00996307,"Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months",Influenza,Interventional,25-May-11,Novartis Vaccines,Biological: MF59-eH1N1_f
NCT00996307,"Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months",Influenza,Interventional,25-May-11,Novartis,Biological: MF59-eH1N1_f
NCT00973349,Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults,Influenza,Interventional,25-May-11,Novartis,Biological: MF59-eH1N1_f
NCT00973349,Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults,Influenza,Interventional,25-May-11,Novartis Vaccines,Biological: MF59-eH1N1_f
NCT00376168,A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease,Gaucher Disease,Interventional,26-Jul-12,Pfizer,Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
NCT00319111,Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH),Pulmonary Hypertension,Interventional,31-Dec-12,Actelion,Drug: bosentan
NCT00282984,Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking,Smoking Cessation,Interventional,29-Apr-09,Pfizer,Drug: placebo
NCT00282984,Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking,Smoking Cessation,Interventional,29-Apr-09,Pfizer,Drug: Varenicline
NCT00663260,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,10-Feb-17,AstraZeneca,Drug: Dapagliflozin
NCT00663260,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,10-Feb-17,AstraZeneca,Drug: Placebo
NCT00663260,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,10-Feb-17,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT00663260,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,"Diabetes Mellitus, Type 2",Interventional,10-Feb-17,Bristol-Myers Squibb,Drug: Placebo
NCT00645411,Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents,Influenza,Interventional,16-Jan-13,Novartis,Biological: Cell culture-derived influenza subunit vaccine (cTIV)
NCT00645411,Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents,Influenza,Interventional,16-Jan-13,Novartis,Biological: Egg derived influenza subunit vaccine (eTIV)
NCT00645411,Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents,Influenza,Interventional,16-Jan-13,Novartis Vaccines,Biological: Cell culture-derived influenza subunit vaccine (cTIV)
NCT00645411,Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents,Influenza,Interventional,16-Jan-13,Novartis Vaccines,Biological: Egg derived influenza subunit vaccine (eTIV)
NCT00110513,Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery,Antithrombin III Deficiency,Interventional,11-May-12,rEVO Biologics,Biological: Recombinant human antithrombin (rhAT)
NCT00624338,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),"Lupus Erythematosus, Systemic",Interventional,14-Mar-16,EMD Serono,Drug: Atacicept 75 mg
NCT00624338,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),"Lupus Erythematosus, Systemic",Interventional,14-Mar-16,EMD Serono,Drug: Atacicept 150 mg
NCT00624338,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),"Lupus Erythematosus, Systemic",Interventional,14-Mar-16,EMD Serono,Other: Placebo Comparator
NCT00624338,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),"Lupus Erythematosus, Systemic",Interventional,14-Mar-16,"Merck KGaA, Darmstadt, Germany",Drug: Atacicept 75 mg
NCT00624338,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),"Lupus Erythematosus, Systemic",Interventional,14-Mar-16,"Merck KGaA, Darmstadt, Germany",Drug: Atacicept 150 mg
NCT00624338,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),"Lupus Erythematosus, Systemic",Interventional,14-Mar-16,"Merck KGaA, Darmstadt, Germany",Other: Placebo Comparator
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,"Janssen Research & Development, LLC",Biological: Placebo
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,"Janssen Research & Development, LLC",Biological: Golimumab 100 mg
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,"Janssen Research & Development, LLC",Biological: Golimumab 200 mg
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,"Janssen Research & Development, LLC",Biological: Golimumab 400 mg
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,"Janssen Research & Development, LLC",Biological: Golimumab 50 mg
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,Merck Sharp & Dohme Corp.,Biological: Placebo
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,Merck Sharp & Dohme Corp.,Biological: Golimumab 100 mg
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,Merck Sharp & Dohme Corp.,Biological: Golimumab 200 mg
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,Merck Sharp & Dohme Corp.,Biological: Golimumab 400 mg
NCT00487539,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Interventional,17-Feb-14,Merck Sharp & Dohme Corp.,Biological: Golimumab 50 mg
NCT00357370,A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,11-May-17,AstraZeneca,Drug: Dapagliflozin
NCT00357370,A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,11-May-17,AstraZeneca,Drug: Placebo
NCT00357370,A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,11-May-17,Bristol-Myers Squibb,Drug: Dapagliflozin
NCT00357370,A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes,Type 2 Diabetes,Interventional,11-May-17,Bristol-Myers Squibb,Drug: Placebo
NCT00098748,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",HIV Infections,Interventional,21-Oct-10,ViiV Healthcare,Drug: Optimized Background Therapy (OBT)
NCT00098748,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",HIV Infections,Interventional,21-Oct-10,ViiV Healthcare,"Drug: maraviroc (UK-427,857)"
NCT00098748,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",HIV Infections,Interventional,21-Oct-10,Pfizer,Drug: Optimized Background Therapy (OBT)
NCT00098748,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",HIV Infections,Interventional,21-Oct-10,Pfizer,"Drug: maraviroc (UK-427,857)"
NCT00098722,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,16-May-12,ViiV Healthcare,"Drug: Maraviroc (UK-427,857)"
NCT00098722,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,16-May-12,ViiV Healthcare,Drug: optimized background therapy
NCT00098722,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,16-May-12,Pfizer,"Drug: Maraviroc (UK-427,857)"
NCT00098722,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,16-May-12,Pfizer,Drug: optimized background therapy
NCT00098306,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,27-Apr-12,ViiV Healthcare,"Drug: Maraviroc (UK-427,857)"
NCT00098306,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,27-Apr-12,ViiV Healthcare,Drug: Optimized Background Therapy
NCT00098306,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,27-Apr-12,ViiV Healthcare,Drug: Placebo
NCT00098306,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,27-Apr-12,Pfizer,"Drug: Maraviroc (UK-427,857)"
NCT00098306,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,27-Apr-12,Pfizer,Drug: Optimized Background Therapy
NCT00098306,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",HIV Infections,Interventional,27-Apr-12,Pfizer,Drug: Placebo
NCT02132195,Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome,Nephrotic Syndrome,Interventional,10-May-19,Emory University,Drug: ACTH
NCT02132195,Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome,Nephrotic Syndrome,Interventional,10-May-19,Mallinckrodt,Drug: ACTH
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,Babafemi Taiwo,Drug: dolutegravir
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,Babafemi Taiwo,Drug: lamivudine
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,Babafemi Taiwo,Drug: Continue current antiretroviral regimen
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,ViiV Healthcare,Drug: dolutegravir
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,ViiV Healthcare,Drug: lamivudine
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,ViiV Healthcare,Drug: Continue current antiretroviral regimen
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,Northwestern University,Drug: dolutegravir
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,Northwestern University,Drug: lamivudine
NCT02263326,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,HIV Infection,Interventional,12-Nov-18,Northwestern University,Drug: Continue current antiretroviral regimen
NCT00330928,SPECTACL: SPECTroscopic Assessment of Coronary Lipid,"Angina Pectoris|Angina, Unstable|Myocardial Infarction",Interventional,28-May-09,InfraReDx,Device: Near Infrared Spectroscopy (NIRS) Imaging
NCT00330928,SPECTACL: SPECTroscopic Assessment of Coronary Lipid,"Angina Pectoris|Angina, Unstable|Myocardial Infarction",Interventional,28-May-09,InfraReDx,Device: intravascular ultrasound (IVUS)
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,"University of California, Davis",Drug: S-adenosylmethionine
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,"University of California, Davis",Drug: Placebo
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Drug: S-adenosylmethionine
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Drug: Placebo
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,Abbott,Drug: S-adenosylmethionine
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,Abbott,Drug: Placebo
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,Joint Clinical Research Center,Drug: S-adenosylmethionine
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,Joint Clinical Research Center,Drug: Placebo
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,"University of Colorado, Denver",Drug: S-adenosylmethionine
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,"University of Colorado, Denver",Drug: Placebo
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,"University of California, Los Angeles",Drug: S-adenosylmethionine
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,"Liver Disease, Alcoholic",Interventional,10-Jun-13,"University of California, Los Angeles",Drug: Placebo
NCT01997411,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,6-Mar-17,Eli Lilly and Company,Drug: Nasal Glucagon
NCT01997411,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,6-Mar-17,Eli Lilly and Company,Drug: Intramuscular Glucagon
NCT01997411,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,6-Mar-17,Jaeb Center for Health Research,Drug: Nasal Glucagon
NCT01997411,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,6-Mar-17,Jaeb Center for Health Research,Drug: Intramuscular Glucagon
NCT01997411,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,6-Mar-17,Locemia Solutions ULC,Drug: Nasal Glucagon
NCT01997411,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Interventional,6-Mar-17,Locemia Solutions ULC,Drug: Intramuscular Glucagon
NCT00789581,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Breast Cancer,Interventional,12-Apr-17,"SCRI Development Innovations, LLC",Drug: Doxorubicin
NCT00789581,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Breast Cancer,Interventional,12-Apr-17,"SCRI Development Innovations, LLC",Drug: Cyclophosphamide
NCT00789581,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Breast Cancer,Interventional,12-Apr-17,"SCRI Development Innovations, LLC",Drug: Ixabepilone (Ixempra)
NCT00789581,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Breast Cancer,Interventional,12-Apr-17,"SCRI Development Innovations, LLC",Drug: Paclitaxel (Taxol)
NCT00789581,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Breast Cancer,Interventional,12-Apr-17,Bristol-Myers Squibb,Drug: Doxorubicin
NCT00789581,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Breast Cancer,Interventional,12-Apr-17,Bristol-Myers Squibb,Drug: Cyclophosphamide
NCT00789581,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Breast Cancer,Interventional,12-Apr-17,Bristol-Myers Squibb,Drug: Ixabepilone (Ixempra)
NCT00789581,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Breast Cancer,Interventional,12-Apr-17,Bristol-Myers Squibb,Drug: Paclitaxel (Taxol)
NCT00529243,Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects,HIV Infections,Interventional,8-Jun-11,Kaiser Permanente,Drug: raltegravir
NCT00529243,Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects,HIV Infections,Interventional,8-Jun-11,Merck Sharp & Dohme Corp.,Drug: raltegravir
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Non-Small Cell Lung Cancer,Interventional,26-Mar-14,H. Lee Moffitt Cancer Center and Research Institute,Drug: Docetaxel
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Non-Small Cell Lung Cancer,Interventional,26-Mar-14,H. Lee Moffitt Cancer Center and Research Institute,Drug: Vinorelbine
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Non-Small Cell Lung Cancer,Interventional,26-Mar-14,H. Lee Moffitt Cancer Center and Research Institute,Drug: Carboplatin
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Non-Small Cell Lung Cancer,Interventional,26-Mar-14,H. Lee Moffitt Cancer Center and Research Institute,Drug: Gemcitabine
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Non-Small Cell Lung Cancer,Interventional,26-Mar-14,Sanofi,Drug: Docetaxel
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Non-Small Cell Lung Cancer,Interventional,26-Mar-14,Sanofi,Drug: Vinorelbine
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Non-Small Cell Lung Cancer,Interventional,26-Mar-14,Sanofi,Drug: Carboplatin
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Non-Small Cell Lung Cancer,Interventional,26-Mar-14,Sanofi,Drug: Gemcitabine
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,"Donald C. Goff, MD",Drug: Ziprasidone 80-160 mg/d
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,"Donald C. Goff, MD",Drug: Placebo
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,"Donald C. Goff, MD",Drug: Ziprasidone 160 mg/d
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,Pfizer,Drug: Ziprasidone 80-160 mg/d
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,Pfizer,Drug: Placebo
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,Pfizer,Drug: Ziprasidone 160 mg/d
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,Massachusetts General Hospital,Drug: Ziprasidone 80-160 mg/d
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,Massachusetts General Hospital,Drug: Placebo
NCT00403546,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Schizophrenia,Interventional,6-Jun-17,Massachusetts General Hospital,Drug: Ziprasidone 160 mg/d
NCT00316121,Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease,Degenerative Disc Disease,Interventional,3-Mar-11,"Advanced Technologies and Regenerative Medicine, LLC (ATRM)",Device: HEALOS and Leopard Cage
NCT00316121,Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease,Degenerative Disc Disease,Interventional,3-Mar-11,"Advanced Technologies and Regenerative Medicine, LLC (ATRM)",Device: Leopard Cage and Autograft
NCT00316121,Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease,Degenerative Disc Disease,Interventional,3-Mar-11,DePuy Spine,Device: HEALOS and Leopard Cage
NCT00316121,Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease,Degenerative Disc Disease,Interventional,3-Mar-11,DePuy Spine,Device: Leopard Cage and Autograft
NCT00132301,Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma,Prostate Cancer,Interventional,25-Jun-18,VA Office of Research and Development,Drug: Docetaxel
NCT00132301,Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma,Prostate Cancer,Interventional,25-Jun-18,VA Office of Research and Development,Drug: Prednisone
NCT00132301,Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma,Prostate Cancer,Interventional,25-Jun-18,Sanofi,Drug: Docetaxel
NCT00132301,Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma,Prostate Cancer,Interventional,25-Jun-18,Sanofi,Drug: Prednisone
NCT00100659,PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C,Chronic Hepatitis C,Interventional,1-Jul-13,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Pegylated Interferon/ribavirin
NCT00100659,PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C,Chronic Hepatitis C,Interventional,1-Jul-13,Roche Pharma AG,Drug: Pegylated Interferon/ribavirin
NCT00464087,Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI,Acute Coronary Syndromes,Interventional,1-Aug-13,Medstar Health Research Institute,Drug: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
NCT00464087,Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI,Acute Coronary Syndromes,Interventional,1-Aug-13,GlaxoSmithKline,Drug: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Eli Lilly and Company,Drug: LY2189265
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Eli Lilly and Company,Drug: Sitagliptin
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Eli Lilly and Company,Drug: Placebo solution
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Eli Lilly and Company,Drug: Placebo tablet
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Eli Lilly and Company,Drug: Metformin
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,United BioSource Corporation,Drug: LY2189265
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,United BioSource Corporation,Drug: Sitagliptin
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,United BioSource Corporation,Drug: Placebo solution
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,United BioSource Corporation,Drug: Placebo tablet
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,United BioSource Corporation,Drug: Metformin
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Tessella Inc.,Drug: LY2189265
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Tessella Inc.,Drug: Sitagliptin
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Tessella Inc.,Drug: Placebo solution
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Tessella Inc.,Drug: Placebo tablet
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Tessella Inc.,Drug: Metformin
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Berry Consultants,Drug: LY2189265
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Berry Consultants,Drug: Sitagliptin
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Berry Consultants,Drug: Placebo solution
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Berry Consultants,Drug: Placebo tablet
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"Diabetes Mellitus, Type 2",Interventional,28-Jan-15,Berry Consultants,Drug: Metformin
NCT00225017,Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study,HIV Infection|Hyperlipidemia,Interventional,2-Aug-12,Northwestern University,Drug: Atazanavir
NCT00225017,Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study,HIV Infection|Hyperlipidemia,Interventional,2-Aug-12,Northwestern University,Drug: current antiretroviral regimen
NCT00225017,Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study,HIV Infection|Hyperlipidemia,Interventional,2-Aug-12,Bristol-Myers Squibb,Drug: Atazanavir
NCT00225017,Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study,HIV Infection|Hyperlipidemia,Interventional,2-Aug-12,Bristol-Myers Squibb,Drug: current antiretroviral regimen
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Daren K. Heyland,Other: Glutamine
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Daren K. Heyland,Other: Antioxidants
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Daren K. Heyland,Other: Glutamine + Antioxidants
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Daren K. Heyland,Other: Placebo
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Fresenius Kabi,Other: Glutamine
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Fresenius Kabi,Other: Antioxidants
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Fresenius Kabi,Other: Glutamine + Antioxidants
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Fresenius Kabi,Other: Placebo
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Clinical Evaluation Research Unit at Kingston General Hospital,Other: Glutamine
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Clinical Evaluation Research Unit at Kingston General Hospital,Other: Antioxidants
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Clinical Evaluation Research Unit at Kingston General Hospital,Other: Glutamine + Antioxidants
NCT00133978,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Critical Illness|Sepsis|Multiple Organ Failure,Interventional,9-Sep-14,Clinical Evaluation Research Unit at Kingston General Hospital,Other: Placebo
NCT00004978,An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy,HIV Infections,Interventional,25-Apr-11,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Recombinant interleukin-2 (rIL-2)
NCT00004978,An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy,HIV Infections,Interventional,25-Apr-11,Chiron Corporation,Drug: Recombinant interleukin-2 (rIL-2)
NCT02296424,ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab,Systemic Juvenile Idiopathic Arthritis (SJIA),Interventional,9-Jul-19,Novartis Pharmaceuticals,Drug: ACZ885 150 mg (Canakinumab)
NCT02296424,ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab,Systemic Juvenile Idiopathic Arthritis (SJIA),Interventional,9-Jul-19,Novartis,Drug: ACZ885 150 mg (Canakinumab)
NCT02093897,"Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A",Congenital Hemophilia A,Interventional,27-Jan-17,CSL Behring,Biological: rVIII-SingleChain
NCT02016716,A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Romosozumab 90 mg/mL
NCT02016716,A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Placebo 90 mg/mL
NCT02016716,A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Romosozumab 70 mg/mL
NCT02016716,A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis,Postmenopausal Osteoporosis,Interventional,8-Nov-18,Amgen,Drug: Placebo 70 mg/mL
NCT01846442,Topical DHEA Against Vaginal Atrophy,Vaginal Atrophy,Interventional,28-Apr-17,EndoCeutics Inc.,Drug: Placebo
NCT01846442,Topical DHEA Against Vaginal Atrophy,Vaginal Atrophy,Interventional,28-Apr-17,EndoCeutics Inc.,Drug: DHEA (0.25%)
NCT01846442,Topical DHEA Against Vaginal Atrophy,Vaginal Atrophy,Interventional,28-Apr-17,EndoCeutics Inc.,Drug: DHEA (0.5%)
NCT01846442,Topical DHEA Against Vaginal Atrophy,Vaginal Atrophy,Interventional,28-Apr-17,EndoCeutics Inc.,Drug: DHEA (1.0%)
NCT01763918,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Biological: Evolocumab
NCT01763918,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,Hyperlipidemia,Interventional,22-Dec-15,Amgen,Drug: Placebo
NCT01575054,BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity,Muscle Spasticity,Interventional,1-Feb-16,Allergan,Biological: botulinum toxin Type A
NCT01575054,BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity,Muscle Spasticity,Interventional,1-Feb-16,Allergan,Drug: Normal Saline
NCT01565707,A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug,"Urinary Bladder, Overactive",Interventional,30-Jan-17,Astellas Pharma Europe B.V.,Drug: Solifenacin Succinate Suspension
NCT01565707,A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug,"Urinary Bladder, Overactive",Interventional,30-Jan-17,Astellas Pharma Europe B.V.,Drug: Placebo
NCT01565707,A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug,"Urinary Bladder, Overactive",Interventional,30-Jan-17,Astellas Pharma Europe B.V.,Behavioral: Urotherapy
NCT01565707,A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug,"Urinary Bladder, Overactive",Interventional,30-Jan-17,Astellas Pharma Inc,Drug: Solifenacin Succinate Suspension
NCT01565707,A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug,"Urinary Bladder, Overactive",Interventional,30-Jan-17,Astellas Pharma Inc,Drug: Placebo
NCT01565707,A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug,"Urinary Bladder, Overactive",Interventional,30-Jan-17,Astellas Pharma Inc,Behavioral: Urotherapy
NCT01565694,"A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity",Neurogenic Detrusor Overactivity,Interventional,6-May-19,Astellas Pharma Europe B.V.,Drug: Solifenacin succinate
NCT01565694,"A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity",Neurogenic Detrusor Overactivity,Interventional,6-May-19,Astellas Pharma Inc,Drug: Solifenacin succinate
NCT01335698,Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients,HIV,Interventional,8-Feb-16,Bristol-Myers Squibb,Drug: Atazanavir Sulphate
NCT01335698,Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients,HIV,Interventional,8-Feb-16,Bristol-Myers Squibb,Drug: Ritonavir
NCT01233258,A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A,Hemophilia A,Interventional,11-Feb-14,Bayer,Biological: rFVIII (BAY81-8973) on demand
NCT01233258,A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A,Hemophilia A,Interventional,11-Feb-14,Bayer,Biological: rFVIII (BAY81-8973) prophylaxis low-dose
NCT01233258,A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A,Hemophilia A,Interventional,11-Feb-14,Bayer,Biological: rFVIII (BAY81-8973) prophylaxis high-dose
NCT01124643,Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease,Fabry Disease,Interventional,22-Aug-14,Shire,Biological: Replagal
NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),Acute Myeloid Leukemia,Interventional,26-Feb-15,Celgene,Drug: Azacitidine
NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),Acute Myeloid Leukemia,Interventional,26-Feb-15,Celgene,Drug: Conventional Care Regimen
NCT01069900,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,Intraabdominal Infections,Interventional,8-Dec-15,Bayer,"Drug: Moxifloxacin (Avelox, BAY12-8039)"
NCT01069900,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,Intraabdominal Infections,Interventional,8-Dec-15,Bayer,Drug: Ertapenem
NCT01069900,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,Intraabdominal Infections,Interventional,8-Dec-15,Bayer,Drug: Amoxicillin/Clavulanate
NCT01069900,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,Intraabdominal Infections,Interventional,8-Dec-15,Bayer,Drug: Moxifloxacin placebo
NCT01069900,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,Intraabdominal Infections,Interventional,8-Dec-15,Bayer,Drug: Ertapenem placebo
NCT01069900,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,Intraabdominal Infections,Interventional,8-Dec-15,Bayer,Drug: Amoxicillin/Clavulanate placebo
NCT00943306,"Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia",Familial Hypercholesterolemia,Interventional,10-May-18,"Aegerion Pharmaceuticals, Inc.",Drug: lomitapide
NCT00851721,Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor,Hemophilia A or B With Inhibitors|Hemophilia A|Hemophilia B,Interventional,14-Mar-14,Baxalta now part of Shire,"Biological: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)"
NCT00851721,Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor,Hemophilia A or B With Inhibitors|Hemophilia A|Hemophilia B,Interventional,14-Mar-14,Shire,"Biological: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)"
NCT00842348,Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour,Non Functioning Entero-pancreatic Endocrine Tumour,Interventional,17-Feb-17,Ipsen,Drug: lanreotide (Autogel formulation)
NCT00730236,A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH),Homozygous Familial Hypercholesterolemia,Interventional,22-Feb-13,"Aegerion Pharmaceuticals, Inc.",Drug: AEGR-733
NCT00730236,A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH),Homozygous Familial Hypercholesterolemia,Interventional,22-Feb-13,FDA Office of Orphan Products Development,Drug: AEGR-733
NCT00705939,Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial,Gaucher Disease,Interventional,15-Jul-14,Pfizer,Drug: Taliglucerase alfa
NCT00620022,The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease,Interventional,17-Aug-11,Novartis,Drug: Indacaterol 300 μg
NCT00620022,The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease,Interventional,17-Aug-11,Novartis,Drug: Placebo
NCT00404924,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,Non-Small-Cell Lung Carcinoma,Interventional,26-Mar-12,"Genzyme, a Sanofi Company",Drug: ZD6474 (vandetanib)
NCT00404924,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,Non-Small-Cell Lung Carcinoma,Interventional,26-Mar-12,"Genzyme, a Sanofi Company",Other: Best Supportive Care
NCT00404924,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,Non-Small-Cell Lung Carcinoma,Interventional,26-Mar-12,Sanofi,Drug: ZD6474 (vandetanib)
NCT00404924,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,Non-Small-Cell Lung Carcinoma,Interventional,26-Mar-12,Sanofi,Other: Best Supportive Care
NCT00319020,Bosentan in Children With Pulmonary Arterial Hypertension Extension Study,Pulmonary Arterial Hypertension,Interventional,29-Mar-17,Actelion,Drug: Bosentan
NCT01198327,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Retinal Vein Occlusion,Interventional,13-Jan-14,"Peter A Campochiaro, MD",Drug: ranibizumab
NCT01198327,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Retinal Vein Occlusion,Interventional,13-Jan-14,"Peter A Campochiaro, MD",Other: Peripheral Laser
NCT01198327,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Retinal Vein Occlusion,Interventional,13-Jan-14,"The Macula Foundation, Inc.",Drug: ranibizumab
NCT01198327,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Retinal Vein Occlusion,Interventional,13-Jan-14,"The Macula Foundation, Inc.",Other: Peripheral Laser
NCT01198327,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Retinal Vein Occlusion,Interventional,13-Jan-14,"Genentech, Inc.",Drug: ranibizumab
NCT01198327,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Retinal Vein Occlusion,Interventional,13-Jan-14,"Genentech, Inc.",Other: Peripheral Laser
NCT01198327,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Retinal Vein Occlusion,Interventional,13-Jan-14,Johns Hopkins University,Drug: ranibizumab
NCT01198327,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Retinal Vein Occlusion,Interventional,13-Jan-14,Johns Hopkins University,Other: Peripheral Laser
NCT00056550,Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.,"Antithrombin Deficiency, Congenital",Interventional,16-Oct-12,rEVO Biologics,Biological: Recombinant Human Antithrombin (rhAT)
NCT00253747,Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD),ADHD|Smoking,Interventional,17-Sep-12,University of Cincinnati,Drug: Osmotic-Release Methylphenidate
NCT00253747,Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD),ADHD|Smoking,Interventional,17-Sep-12,University of Cincinnati,Drug: Placebo
NCT00253747,Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD),ADHD|Smoking,Interventional,17-Sep-12,National Institute on Drug Abuse (NIDA),Drug: Osmotic-Release Methylphenidate
NCT00253747,Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD),ADHD|Smoking,Interventional,17-Sep-12,National Institute on Drug Abuse (NIDA),Drug: Placebo
NCT00253747,Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD),ADHD|Smoking,Interventional,17-Sep-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: Osmotic-Release Methylphenidate
NCT00253747,Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD),ADHD|Smoking,Interventional,17-Sep-12,"Ortho-McNeil Janssen Scientific Affairs, LLC",Drug: Placebo
NCT00569530,Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide,Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction)|Bronchopulmonary Dysplasia,Interventional,28-Jun-16,"University of California, San Francisco",Drug: Infasurf (ONY Inc.)
NCT00569530,Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide,Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction)|Bronchopulmonary Dysplasia,Interventional,28-Jun-16,"University of California, San Francisco",Drug: Sham
NCT00569530,Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide,Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction)|Bronchopulmonary Dysplasia,Interventional,28-Jun-16,Mallinckrodt,Drug: Infasurf (ONY Inc.)
NCT00569530,Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide,Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction)|Bronchopulmonary Dysplasia,Interventional,28-Jun-16,Mallinckrodt,Drug: Sham
NCT00569530,Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide,Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction)|Bronchopulmonary Dysplasia,Interventional,28-Jun-16,ONY,Drug: Infasurf (ONY Inc.)
NCT00569530,Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide,Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction)|Bronchopulmonary Dysplasia,Interventional,28-Jun-16,ONY,Drug: Sham
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,US Department of Veterans Affairs,Drug: dl-alpha-tocopherol
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,US Department of Veterans Affairs,Drug: Memantine
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,US Department of Veterans Affairs,Drug: Placebo
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,Forest Laboratories,Drug: dl-alpha-tocopherol
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,Forest Laboratories,Drug: Memantine
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,Forest Laboratories,Drug: Placebo
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,"DSM Nutritional Products, Inc.",Drug: dl-alpha-tocopherol
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,"DSM Nutritional Products, Inc.",Drug: Memantine
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,"DSM Nutritional Products, Inc.",Drug: Placebo
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,VA Office of Research and Development,Drug: dl-alpha-tocopherol
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,VA Office of Research and Development,Drug: Memantine
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Alzheimer's Disease,Interventional,29-Jan-14,VA Office of Research and Development,Drug: Placebo
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Nemours Children's Clinic,Drug: Aromatase Inhibitor
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Nemours Children's Clinic,Drug: Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Nemours Children's Clinic,Drug: Aromatase Inhibitor and Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Thrasher Research Fund,Drug: Aromatase Inhibitor
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Thrasher Research Fund,Drug: Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Thrasher Research Fund,Drug: Aromatase Inhibitor and Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,"Genentech, Inc.",Drug: Aromatase Inhibitor
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,"Genentech, Inc.",Drug: Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,"Genentech, Inc.",Drug: Aromatase Inhibitor and Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Novartis,Drug: Aromatase Inhibitor
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Novartis,Drug: Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Novartis,Drug: Aromatase Inhibitor and Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,AstraZeneca,Drug: Aromatase Inhibitor
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,AstraZeneca,Drug: Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,AstraZeneca,Drug: Aromatase Inhibitor and Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Pfizer,Drug: Aromatase Inhibitor
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Pfizer,Drug: Growth Hormone
NCT01248416,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Idiopathic Short Stature,Interventional,7-Jun-18,Pfizer,Drug: Aromatase Inhibitor and Growth Hormone
NCT03116698,"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period",Actinic Keratosis (AK),Interventional,24-Apr-19,Dr. Reddy's Laboratories Limited,Drug: Low dose DFD07 once daily
NCT03116698,"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period",Actinic Keratosis (AK),Interventional,24-Apr-19,Dr. Reddy's Laboratories Limited,Drug: High dose DFD07 once daily
NCT03116698,"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period",Actinic Keratosis (AK),Interventional,24-Apr-19,Dr. Reddy's Laboratories Limited,Drug: High dose DFD07 twice daily
NCT03116698,"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period",Actinic Keratosis (AK),Interventional,24-Apr-19,Dr. Reddy's Laboratories Limited,Drug: Placebo twice daily
NCT02848326,"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention","Migraine, With or Without Aura",Interventional,6-Dec-18,Allergan,Drug: Atogepant
NCT02848326,"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention","Migraine, With or Without Aura",Interventional,6-Dec-18,Allergan,Drug: Placebo-matching Atogepant
NCT02745392,Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine,Acute Migraine,Interventional,14-Feb-18,Zosano Pharma Corporation,Drug: ZP-Zolmitriptan
NCT02745392,Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine,Acute Migraine,Interventional,14-Feb-18,Zosano Pharma Corporation,Drug: Placebo
NCT03137784,Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma,Asthma,Interventional,16-Jan-19,Novartis Pharmaceuticals,Drug: NVA237 (glycopyrronium bromide)
NCT03137784,Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma,Asthma,Interventional,16-Jan-19,Novartis Pharmaceuticals,Drug: Placebo
NCT03137784,Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma,Asthma,Interventional,16-Jan-19,Novartis,Drug: NVA237 (glycopyrronium bromide)
NCT03137784,Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma,Asthma,Interventional,16-Jan-19,Novartis,Drug: Placebo
NCT02547935,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","Type 2 Diabetes Mellitus, CKD and Albuminuria",Interventional,4-Jun-19,AstraZeneca,Drug: Dapagliflozin 10 mg
NCT02547935,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","Type 2 Diabetes Mellitus, CKD and Albuminuria",Interventional,4-Jun-19,AstraZeneca,Drug: Dapagliflozin 10mg+Saxagliptin 2.5mg
NCT02547935,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","Type 2 Diabetes Mellitus, CKD and Albuminuria",Interventional,4-Jun-19,AstraZeneca,Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
NCT02472145,An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,"Leukemia, Myeloid, Acute",Interventional,28-Feb-19,"Janssen Research & Development, LLC",Drug: Decitabine 20 mg/m^2
NCT02472145,An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,"Leukemia, Myeloid, Acute",Interventional,28-Feb-19,"Janssen Research & Development, LLC",Drug: Talacotuzumab 9 mg/kg
NCT02195700,Aim to Reduce Movements in Tardive Dyskinesia,Tardive Dyskinesia,Interventional,20-Mar-18,"Auspex Pharmaceuticals, Inc.",Drug: SD-809
NCT02195700,Aim to Reduce Movements in Tardive Dyskinesia,Tardive Dyskinesia,Interventional,20-Mar-18,"Auspex Pharmaceuticals, Inc.",Drug: Placebo
NCT02195700,Aim to Reduce Movements in Tardive Dyskinesia,Tardive Dyskinesia,Interventional,20-Mar-18,Teva Pharmaceutical Industries,Drug: SD-809
NCT02195700,Aim to Reduce Movements in Tardive Dyskinesia,Tardive Dyskinesia,Interventional,20-Mar-18,Teva Pharmaceutical Industries,Drug: Placebo
NCT02145182,Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study),Delayed Graft Function,Interventional,17-Dec-18,Alexion Pharmaceuticals,Drug: Eculizumab
NCT02145182,Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study),Delayed Graft Function,Interventional,17-Dec-18,Alexion Pharmaceuticals,Drug: Placebo
NCT02145182,Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study),Delayed Graft Function,Interventional,17-Dec-18,CTI Clinical Trial and Consulting Services,Drug: Eculizumab
NCT02145182,Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study),Delayed Graft Function,Interventional,17-Dec-18,CTI Clinical Trial and Consulting Services,Drug: Placebo
NCT02059642,A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ),"ADHD|Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type",Interventional,28-Mar-17,Alcobra Ltd.,Drug: MG01CI (1400 mg)
NCT02059642,A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ),"ADHD|Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type",Interventional,28-Mar-17,Alcobra Ltd.,Drug: placebo
NCT01925209,"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients",Sporadic Inclusion Body Myositis,Interventional,12-May-17,Novartis Pharmaceuticals,Drug: BYM338/bimagrumab
NCT01925209,"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients",Sporadic Inclusion Body Myositis,Interventional,12-May-17,Novartis Pharmaceuticals,Drug: Placebo
NCT01925209,"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients",Sporadic Inclusion Body Myositis,Interventional,12-May-17,Novartis,Drug: BYM338/bimagrumab
NCT01925209,"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients",Sporadic Inclusion Body Myositis,Interventional,12-May-17,Novartis,Drug: Placebo
NCT01903265,BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT),Primary Fibromyalgia,Interventional,23-Dec-16,"Tonix Pharmaceuticals, Inc.",Drug: TNX-102 SL 2.8mg
NCT01903265,BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT),Primary Fibromyalgia,Interventional,23-Dec-16,"Tonix Pharmaceuticals, Inc.",Drug: Placebo
NCT01881230,Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer),Breast Tumor|Breast Cancer|Cancer of the Breast|Estrogen Receptor- Negative Breast Cancer|HER2- Negative Breast Cancer|Progesterone Receptor- Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer|Triple-negative Metastatic Breast Cancer|Metastatic Breast Cancer,Interventional,8-Mar-18,Celgene,Drug: nab-Paclitaxel
NCT01881230,Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer),Breast Tumor|Breast Cancer|Cancer of the Breast|Estrogen Receptor- Negative Breast Cancer|HER2- Negative Breast Cancer|Progesterone Receptor- Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer|Triple-negative Metastatic Breast Cancer|Metastatic Breast Cancer,Interventional,8-Mar-18,Celgene,Drug: Carboplatin
NCT01881230,Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer),Breast Tumor|Breast Cancer|Cancer of the Breast|Estrogen Receptor- Negative Breast Cancer|HER2- Negative Breast Cancer|Progesterone Receptor- Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer|Triple-negative Metastatic Breast Cancer|Metastatic Breast Cancer,Interventional,8-Mar-18,Celgene,Drug: Gemcitabine
NCT01736475,Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study),Hemophilia A,Interventional,7-Sep-16,Baxalta now part of Shire,Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
NCT01736475,Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study),Hemophilia A,Interventional,7-Sep-16,Baxalta now part of Shire,Biological: PEGylated Recombinant Factor VIII
NCT01736475,Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study),Hemophilia A,Interventional,7-Sep-16,Shire,Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
NCT01736475,Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study),Hemophilia A,Interventional,7-Sep-16,Shire,Biological: PEGylated Recombinant Factor VIII
NCT01732536,Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps,Chronic Sinusitis|Nasal Polyps,Interventional,20-Jul-18,Intersect ENT,Drug: S8 Sinus Implant
NCT01732536,Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps,Chronic Sinusitis|Nasal Polyps,Interventional,20-Jul-18,Intersect ENT,Procedure: Sham procedure
NCT01732536,Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps,Chronic Sinusitis|Nasal Polyps,Interventional,20-Jul-18,Intersect ENT,Drug: Mometasone furoate nasal spray
NCT01737398,Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy,FAP|Familial Amyloid Polyneuropathy|TTR|Transthyretin|Amyloidosis,Interventional,23-Jan-19,"Ionis Pharmaceuticals, Inc.",Drug: Inotersen
NCT01737398,Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy,FAP|Familial Amyloid Polyneuropathy|TTR|Transthyretin|Amyloidosis,Interventional,23-Jan-19,"Ionis Pharmaceuticals, Inc.",Drug: Placebo
NCT01612767,BIOHELIX-I Bare Metal Stent Study,Coronary Arteries Disease,Interventional,30-May-17,"Biotronik, Inc.",Device: PRO-Kinetic Energy Stent
NCT01721109,"Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents",Acquired Immunodeficiency Syndrome|HIV Infections,Interventional,10-Apr-17,Gilead Sciences,Drug: EVG/COBI/FTC/TDF
NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",Breast Cancer,Interventional,27-Jan-17,Novartis Pharmaceuticals,Drug: Paclitaxel
NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",Breast Cancer,Interventional,27-Jan-17,Novartis Pharmaceuticals,Drug: BKM120 matching placebo
NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",Breast Cancer,Interventional,27-Jan-17,Novartis Pharmaceuticals,Drug: BKM120
NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",Breast Cancer,Interventional,27-Jan-17,Novartis,Drug: Paclitaxel
NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",Breast Cancer,Interventional,27-Jan-17,Novartis,Drug: BKM120 matching placebo
NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",Breast Cancer,Interventional,27-Jan-17,Novartis,Drug: BKM120
NCT01537081,Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections,Acute Upper Respiratory Tract Infection,Interventional,12-Sep-13,Reckitt Benckiser LLC,Drug: Mucinex
NCT01537081,Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections,Acute Upper Respiratory Tract Infection,Interventional,12-Sep-13,Reckitt Benckiser LLC,Drug: Immediate-release Guaifenesin
NCT01537081,Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections,Acute Upper Respiratory Tract Infection,Interventional,12-Sep-13,Reckitt Benckiser LLC,Drug: Placebo
NCT01485796,"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD",Primary Immunodeficiency Diseases (PID),Interventional,24-Apr-17,Baxalta now part of Shire,"Biological: Immune Globulin Infusion (Human), 10%"
NCT01485796,"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD",Primary Immunodeficiency Diseases (PID),Interventional,24-Apr-17,Baxalta now part of Shire,Biological: Recombinant human hyaluronidase
NCT01485796,"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD",Primary Immunodeficiency Diseases (PID),Interventional,24-Apr-17,Shire,"Biological: Immune Globulin Infusion (Human), 10%"
NCT01485796,"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD",Primary Immunodeficiency Diseases (PID),Interventional,24-Apr-17,Shire,Biological: Recombinant human hyaluronidase
NCT01486927,"An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A",Hemophilia A,Interventional,9-Aug-16,CSL Behring,Biological: rVIII-SingleChain
NCT01486927,"An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A",Hemophilia A,Interventional,9-Aug-16,CSL Behring,Biological: Octocog alfa
NCT01428661,Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,19-Jun-15,Vanda Pharmaceuticals,Drug: tasimelteon
NCT01428661,Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder,Major Depressive Disorder,Interventional,19-Jun-15,Vanda Pharmaceuticals,Drug: placebo
NCT01397422,Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study),Dyskinesia|Levodopa Induced Dyskinesia|Parkinson's Disease,Interventional,6-Nov-17,"Adamas Pharmaceuticals, Inc.",Drug: ADS-5102 (extended release amantadine HCl)
NCT01624142,Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders,Severe Familial Hypercholesterolemia,Interventional,28-Jan-19,Amgen,Biological: Evolocumab
NCT01330628,Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis,Peripheral Arterial Disease,Interventional,15-Jun-16,Spectranetics Corporation,Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters
NCT01330628,Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis,Peripheral Arterial Disease,Interventional,15-Jun-16,Spectranetics Corporation,Procedure: Balloon angioplasty
NCT01291160,Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers,Diabetic Foot Ulcers,Interventional,13-May-14,"Neogenix, LLC dba Ogenix",Device: Epiflo
NCT01291160,Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers,Diabetic Foot Ulcers,Interventional,13-May-14,"Neogenix, LLC dba Ogenix",Other: Moist Wound Therapy
NCT01281202,Vigabatrin for the Treatment of Cocaine Dependency,Cocaine Addiction|Cocaine Dependence,Interventional,23-Feb-16,"Catalyst Pharmaceuticals, Inc.",Drug: Vigabatrin
NCT01281202,Vigabatrin for the Treatment of Cocaine Dependency,Cocaine Addiction|Cocaine Dependence,Interventional,23-Feb-16,"Catalyst Pharmaceuticals, Inc.",Drug: Matching Placebo
NCT01281202,Vigabatrin for the Treatment of Cocaine Dependency,Cocaine Addiction|Cocaine Dependence,Interventional,23-Feb-16,National Institute on Drug Abuse (NIDA),Drug: Vigabatrin
NCT01281202,Vigabatrin for the Treatment of Cocaine Dependency,Cocaine Addiction|Cocaine Dependence,Interventional,23-Feb-16,National Institute on Drug Abuse (NIDA),Drug: Matching Placebo
NCT01281202,Vigabatrin for the Treatment of Cocaine Dependency,Cocaine Addiction|Cocaine Dependence,Interventional,23-Feb-16,VA Office of Research and Development,Drug: Vigabatrin
NCT01281202,Vigabatrin for the Treatment of Cocaine Dependency,Cocaine Addiction|Cocaine Dependence,Interventional,23-Feb-16,VA Office of Research and Development,Drug: Matching Placebo
NCT01242527,Epanova® for Lowering Very High Triglycerides,Severe Hypertriglyceridemia,Interventional,6-Sep-13,AstraZeneca,Drug: placebo
NCT01242527,Epanova® for Lowering Very High Triglycerides,Severe Hypertriglyceridemia,Interventional,6-Sep-13,AstraZeneca,Drug: omefas
NCT01218438,"Phase 2/3 Study of IGSC, 20% in PIDD",Primary Immunodeficiency Diseases (PID),Interventional,15-Feb-17,Baxalta now part of Shire,"Biological: Immune Globulin Intravenous (Human), 10% Solution"
NCT01218438,"Phase 2/3 Study of IGSC, 20% in PIDD",Primary Immunodeficiency Diseases (PID),Interventional,15-Feb-17,Baxalta now part of Shire,"Drug: Immune Globulin Subcutaneous (Human), 20% Solution"
NCT01218438,"Phase 2/3 Study of IGSC, 20% in PIDD",Primary Immunodeficiency Diseases (PID),Interventional,15-Feb-17,Shire,"Biological: Immune Globulin Intravenous (Human), 10% Solution"
NCT01218438,"Phase 2/3 Study of IGSC, 20% in PIDD",Primary Immunodeficiency Diseases (PID),Interventional,15-Feb-17,Shire,"Drug: Immune Globulin Subcutaneous (Human), 20% Solution"
NCT01197560,Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),Diffuse Large B-cell Lymphoma,Interventional,20-Aug-14,Celgene,Drug: Lenalidomide
NCT01197560,Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),Diffuse Large B-cell Lymphoma,Interventional,20-Aug-14,Celgene,Drug: Gemcitabine
NCT01197560,Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),Diffuse Large B-cell Lymphoma,Interventional,20-Aug-14,Celgene,Drug: Oxaliplatin
NCT01197560,Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),Diffuse Large B-cell Lymphoma,Interventional,20-Aug-14,Celgene,Drug: Rituximab
NCT01197560,Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),Diffuse Large B-cell Lymphoma,Interventional,20-Aug-14,Celgene,Drug: Etoposide
NCT01159262,"Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age",Sedation,Interventional,12-Dec-14,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Midazolam
NCT01159262,"Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age",Sedation,Interventional,12-Dec-14,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Fentanyl/Morphine
NCT01159262,"Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age",Sedation,Interventional,12-Dec-14,"Hospira, now a wholly owned subsidiary of Pfizer",Drug: Dexmedetomidine
NCT01178294,Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A,Acquired Hemophilia A,Interventional,21-Dec-15,Baxalta now part of Shire,Biological: OBI-1
NCT01178294,Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A,Acquired Hemophilia A,Interventional,21-Dec-15,Shire,Biological: OBI-1
NCT01119963,"Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)",Preterm Delivery,Interventional,30-May-18,Obstetrix Medical Group,"Drug: 17-alpha-hydroxy-progesterone caproate, Makena®"
NCT01119963,"Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)",Preterm Delivery,Interventional,30-May-18,Obstetrix Medical Group,Drug: Castor Oil (Placebo)
NCT01119963,"Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)",Preterm Delivery,Interventional,30-May-18,"Mednax Center for Research, Education, Quality and Safety","Drug: 17-alpha-hydroxy-progesterone caproate, Makena®"
NCT01119963,"Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)",Preterm Delivery,Interventional,30-May-18,"Mednax Center for Research, Education, Quality and Safety",Drug: Castor Oil (Placebo)
NCT01056341,Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy,Infantile Hemangioma,Interventional,24-Jun-14,Pierre Fabre Dermatology,Drug: Propranolol
NCT01056341,Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy,Infantile Hemangioma,Interventional,24-Jun-14,Pierre Fabre Dermatology,Drug: Placebo
NCT00972816,Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years),Influenza,Interventional,27-Jan-11,Novartis Vaccines,Biological: MF59-eH1N1
NCT00972816,Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years),Influenza,Interventional,27-Jan-11,Novartis,Biological: MF59-eH1N1
NCT00922636,A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder,Attention Deficit Hyperactivity Disorder,Interventional,18-Aug-14,Eli Lilly and Company,Drug: LY2216684
NCT00922636,A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder,Attention Deficit Hyperactivity Disorder,Interventional,18-Aug-14,Eli Lilly and Company,Drug: Methylphenidate
NCT00922636,A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder,Attention Deficit Hyperactivity Disorder,Interventional,18-Aug-14,Eli Lilly and Company,Drug: Placebo (tablet)
NCT00922636,A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder,Attention Deficit Hyperactivity Disorder,Interventional,18-Aug-14,Eli Lilly and Company,Drug: Placebo (capsule)
NCT00952588,"Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients",Acute Myeloid Leukemia,Interventional,31-Mar-14,AstraZeneca,Drug: AZD1152
NCT00952588,"Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients",Acute Myeloid Leukemia,Interventional,31-Mar-14,AstraZeneca,Drug: LDAC
NCT00860067,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age,Healthy or Stable Underlying Chronic Medical Condition,Interventional,12-Aug-11,MedImmune LLC,Biological: Q/LAIV (MEDI3250)
NCT00860067,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age,Healthy or Stable Underlying Chronic Medical Condition,Interventional,12-Aug-11,MedImmune LLC,Biological: FluMist/B/Yamagata
NCT00860067,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age,Healthy or Stable Underlying Chronic Medical Condition,Interventional,12-Aug-11,MedImmune LLC,Biological: FluMist/B/Victoria
NCT00795821,A Study in Adult Patients With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,20-Mar-18,Eli Lilly and Company,Drug: LY2216684
NCT00795821,A Study in Adult Patients With Major Depressive Disorder,"Depressive Disorder, Major",Interventional,20-Mar-18,Eli Lilly and Company,Drug: Placebo
NCT00768287,"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B",Hemophilia B,Interventional,10-Sep-18,Aptevo BioTherapeutics,Biological: IB1001
NCT00768287,"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B",Hemophilia B,Interventional,10-Sep-18,Aptevo BioTherapeutics,Biological: nonacog alfa
NCT00768287,"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B",Hemophilia B,Interventional,10-Sep-18,Aptevo Therapeutics,Biological: IB1001
NCT00768287,"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B",Hemophilia B,Interventional,10-Sep-18,Aptevo Therapeutics,Biological: nonacog alfa
NCT00796614,Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder,"Bladder, Neurogenic",Interventional,12-Sep-12,Boehringer Ingelheim,Drug: tamsulosin hydrochloride
NCT00796614,Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder,"Bladder, Neurogenic",Interventional,12-Sep-12,Boehringer Ingelheim,Drug: Placebo
NCT00630747,Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase,Hunter Syndrome|Mucopolysaccharidosis II (MPS II),Interventional,17-Mar-14,Shire,Biological: Idursulfase
NCT00605280,"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.",Macular Edema Associated With Diabetes Mellitus,Interventional,30-Mar-11,Pfizer,Drug: Standard of Care
NCT00605280,"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.",Macular Edema Associated With Diabetes Mellitus,Interventional,30-Mar-11,Pfizer,Drug: Macugen
NCT00642642,Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring,Acne Scarring of the Face,Interventional,21-Aug-13,"Fibrocell Technologies, Inc.",Biological: Autologous Human Fibroblasts (azficel-T)
NCT00642642,Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring,Acne Scarring of the Face,Interventional,21-Aug-13,"Fibrocell Technologies, Inc.",Biological: Placebo
NCT00538434,Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years,Eosinophilic Esophagitis,Interventional,2-Sep-16,Ception Therapeutics,Biological: Reslizumab
NCT00538434,Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years,Eosinophilic Esophagitis,Interventional,2-Sep-16,Ception Therapeutics,Other: Saline
NCT00538434,Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years,Eosinophilic Esophagitis,Interventional,2-Sep-16,Teva Pharmaceutical Industries,Biological: Reslizumab
NCT00538434,Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years,Eosinophilic Esophagitis,Interventional,2-Sep-16,Teva Pharmaceutical Industries,Other: Saline
NCT00546871,"Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects",Primary Immunodeficiency Diseases (PID),Interventional,23-Aug-12,Baxalta now part of Shire,"Drug: Immune Globulin Intravenous (Human), 10%"
NCT00546871,"Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects",Primary Immunodeficiency Diseases (PID),Interventional,23-Aug-12,Shire,"Drug: Immune Globulin Intravenous (Human), 10%"
NCT00478647,Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase,Gaucher Disease,Interventional,2-Sep-10,Shire,Biological: GA-GCB (velaglucerase alfa)
NCT00463567,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive|COPD|Lung Diseases, Obstructive",Interventional,18-Aug-11,Novartis,Drug: Indacaterol
NCT00463567,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive|COPD|Lung Diseases, Obstructive",Interventional,18-Aug-11,Novartis,Drug: Formoterol (12 µg b.i.d.)
NCT00463567,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive|COPD|Lung Diseases, Obstructive",Interventional,18-Aug-11,Novartis,Drug: Tiotropium (18 µg o.d.)
NCT00463567,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive|COPD|Lung Diseases, Obstructive",Interventional,18-Aug-11,Novartis,Drug: Placebo to Indacaterol
NCT00463567,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive|COPD|Lung Diseases, Obstructive",Interventional,18-Aug-11,Novartis,Drug: Placebo to Formoterol
NCT02276612,Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents,HIV,Interventional,22-Feb-18,Gilead Sciences,Drug: E/C/F/TAF
NCT00384176,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,Colorectal Cancer,Interventional,28-Nov-12,AstraZeneca,Drug: Cediranib
NCT00384176,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,Colorectal Cancer,Interventional,28-Nov-12,AstraZeneca,Drug: Bevacizumab
NCT00384176,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,Colorectal Cancer,Interventional,28-Nov-12,AstraZeneca,Drug: 5-fluorouracil ( in FOLFOX)
NCT00384176,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,Colorectal Cancer,Interventional,28-Nov-12,AstraZeneca,Drug: Leucovorin (in FOLFOX)
NCT00384176,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,Colorectal Cancer,Interventional,28-Nov-12,AstraZeneca,Drug: Oxaliplatin (in FOLFOX)
NCT00327392,A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.,Procedural Sedation,Interventional,20-Jun-12,Eisai Inc.,Drug: AQUAVAN® (fospropofol disodium) Injection
NCT00235443,A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy,Diabetic Neuropathy,Interventional,5-Oct-09,UCB Pharma,Drug: lacosamide
NCT00223977,2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.,Iron Deficiency Anemia,Interventional,28-Sep-09,Watson Pharmaceuticals,Drug: Sodium Ferric Gluconate Complex
NCT00223977,2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.,Iron Deficiency Anemia,Interventional,28-Sep-09,Watson Pharmaceuticals,Drug: Oral Iron
NCT00168103,Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks,Hereditary Angioedema,Interventional,24-Aug-10,CSL Behring,Biological: C1 Esterase Inhibitor
NCT00168103,Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks,Hereditary Angioedema,Interventional,24-Aug-10,CSL Behring,Biological: Placebo
NCT00163020,17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies,Preterm Birth,Interventional,7-Nov-12,Obstetrix Medical Group,Drug: 17-alpha-hydroxyprogesterone caproate injectable
NCT00163020,17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies,Preterm Birth,Interventional,7-Nov-12,Obstetrix Medical Group,Drug: Placebo
NCT00163020,17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies,Preterm Birth,Interventional,7-Nov-12,"Mednax Center for Research, Education, Quality and Safety",Drug: 17-alpha-hydroxyprogesterone caproate injectable
NCT00163020,17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies,Preterm Birth,Interventional,7-Nov-12,"Mednax Center for Research, Education, Quality and Safety",Drug: Placebo
NCT00151775,Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure,Hypertension,Interventional,2-Apr-10,"Daiichi Sankyo, Inc.",Drug: olmesartan medoxomil
NCT00151775,Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure,Hypertension,Interventional,2-Apr-10,"Daiichi Sankyo, Inc.",Drug: placebo
NCT00146328,Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects,HIV Infections,Interventional,16-Jul-09,Boehringer Ingelheim,Drug: Tipranavir
NCT00129545,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation,Atrial Fibrillation|Stroke,Interventional,15-May-15,Boston Scientific Corporation,Device: WATCHMAN Left Atrial Appendage Closure Technology
NCT00129545,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation,Atrial Fibrillation|Stroke,Interventional,15-May-15,Boston Scientific Corporation,Drug: Warfarin
NCT00117286,Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer,Prostate Cancer,Interventional,21-Oct-10,Ferring Pharmaceuticals,Drug: Degarelix
NCT01496274,A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B,Hemophilia B,Interventional,9-May-16,CSL Behring,Biological: rIX-FP
NCT00090766,A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients,Cytomegalovirus Infections,Interventional,31-Oct-16,Hoffmann-La Roche,Drug: valganciclovir [Valcyte]
NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,Multiple Sclerosis,Interventional,11-Aug-10,EMD Serono,Drug: Rebif® New Formulation (RNF) using RebiSmartTM
NCT01464190,"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,17-Feb-14,Vifor Inc.,Drug: PA21 (2.5 g tablet containing 500 mg iron)
NCT01464190,"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,17-Feb-14,Vifor Inc.,Drug: Sevelamer carbonate
NCT01464190,"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,17-Feb-14,Fresenius Medical Care North America,Drug: PA21 (2.5 g tablet containing 500 mg iron)
NCT01464190,"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,17-Feb-14,Fresenius Medical Care North America,Drug: Sevelamer carbonate
NCT01324128,"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,1-Apr-14,Vifor Inc.,Drug: PA21 (2.5 g tablet containing 500 mg iron)
NCT01324128,"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,1-Apr-14,Vifor Inc.,Drug: Sevelamer carbonate
NCT01324128,"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,1-Apr-14,Vifor Inc.,Drug: PA21-1 (1.25 g tablet containing 250 mg iron)
NCT01324128,"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,1-Apr-14,Fresenius Medical Care North America,Drug: PA21 (2.5 g tablet containing 500 mg iron)
NCT01324128,"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,1-Apr-14,Fresenius Medical Care North America,Drug: Sevelamer carbonate
NCT01324128,"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients",Chronic Kidney Disease Requiring Chronic Dialysis,Interventional,1-Apr-14,Fresenius Medical Care North America,Drug: PA21-1 (1.25 g tablet containing 250 mg iron)
NCT00392288,Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.,Asthma,Interventional,30-Dec-09,AstraZeneca,Drug: Ciclesonide
NCT00392288,Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.,Asthma,Interventional,30-Dec-09,AstraZeneca,Drug: Placebo
NCT00833703,Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation,"Heart Defects, Congenital",Interventional,16-Aug-11,Sanofi,Drug: Clopidogrel
NCT00833703,Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation,"Heart Defects, Congenital",Interventional,16-Aug-11,Sanofi,Drug: placebo
NCT00833703,Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation,"Heart Defects, Congenital",Interventional,16-Aug-11,Bristol-Myers Squibb,Drug: Clopidogrel
NCT00833703,Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation,"Heart Defects, Congenital",Interventional,16-Aug-11,Bristol-Myers Squibb,Drug: placebo
NCT00168428,A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches,Migraine Disorders,Interventional,7-Dec-10,Allergan,Biological: Botulinum Toxin Type A
NCT00168428,A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches,Migraine Disorders,Interventional,7-Dec-10,Allergan,Other: placebo (saline)
NCT00069641,Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II),Mucopolysaccharidosis II,Interventional,13-May-15,Shire,Biological: Iduronate-2-sulfatase enzyme replacement therapy
NCT00069641,Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II),Mucopolysaccharidosis II,Interventional,13-May-15,Shire,Biological: iduronate-2-sulfatase enzyme replacement therapy
NCT00069641,Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II),Mucopolysaccharidosis II,Interventional,13-May-15,Shire,Biological: Placebo
NCT00549302,Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs,"Hypertension, Pulmonary",Interventional,18-Feb-13,Eli Lilly and Company,Drug: tadalafil
NCT00549302,Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs,"Hypertension, Pulmonary",Interventional,18-Feb-13,ICOS Corporation,Drug: tadalafil
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Carcinoma|Non Small Cell Lung,Interventional,1-Jan-13,Sanofi,"Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)"
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Carcinoma|Non Small Cell Lung,Interventional,1-Jan-13,Sanofi,Drug: Placebo
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Carcinoma|Non Small Cell Lung,Interventional,1-Jan-13,Sanofi,Drug: Docetaxel (Taxotere®)
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Carcinoma|Non Small Cell Lung,Interventional,1-Jan-13,Sanofi,Drug: Dexamethasone (pre- and post-medication for docetaxel)
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Carcinoma|Non Small Cell Lung,Interventional,1-Jan-13,Regeneron Pharmaceuticals,"Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)"
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Carcinoma|Non Small Cell Lung,Interventional,1-Jan-13,Regeneron Pharmaceuticals,Drug: Placebo
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Carcinoma|Non Small Cell Lung,Interventional,1-Jan-13,Regeneron Pharmaceuticals,Drug: Docetaxel (Taxotere®)
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Carcinoma|Non Small Cell Lung,Interventional,1-Jan-13,Regeneron Pharmaceuticals,Drug: Dexamethasone (pre- and post-medication for docetaxel)
NCT00519285,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Prostatic Neoplasms|Neoplasm Metastasis,Interventional,10-Oct-13,Sanofi,Drug: Aflibercept
NCT00519285,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Prostatic Neoplasms|Neoplasm Metastasis,Interventional,10-Oct-13,Sanofi,Drug: Placebo (for aflibercept)
NCT00519285,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Prostatic Neoplasms|Neoplasm Metastasis,Interventional,10-Oct-13,Sanofi,Drug: Docetaxel
NCT00519285,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Prostatic Neoplasms|Neoplasm Metastasis,Interventional,10-Oct-13,Sanofi,Drug: Prednisone or Prednisolone
NCT00519285,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Prostatic Neoplasms|Neoplasm Metastasis,Interventional,10-Oct-13,Regeneron Pharmaceuticals,Drug: Aflibercept
NCT00519285,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Prostatic Neoplasms|Neoplasm Metastasis,Interventional,10-Oct-13,Regeneron Pharmaceuticals,Drug: Placebo (for aflibercept)
NCT00519285,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Prostatic Neoplasms|Neoplasm Metastasis,Interventional,10-Oct-13,Regeneron Pharmaceuticals,Drug: Docetaxel
NCT00519285,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Prostatic Neoplasms|Neoplasm Metastasis,Interventional,10-Oct-13,Regeneron Pharmaceuticals,Drug: Prednisone or Prednisolone
NCT00396877,Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation,"Heart Defects, Congenital",Interventional,11-Mar-11,Sanofi,Drug: Clopidogrel (SR25990)
NCT00396877,Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation,"Heart Defects, Congenital",Interventional,11-Mar-11,Sanofi,Drug: placebo
NCT00396877,Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation,"Heart Defects, Congenital",Interventional,11-Mar-11,Bristol-Myers Squibb,Drug: Clopidogrel (SR25990)
NCT00396877,Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation,"Heart Defects, Congenital",Interventional,11-Mar-11,Bristol-Myers Squibb,Drug: placebo
NCT02055118,Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment,Hunter Syndrome,Interventional,13-Dec-18,Shire,Biological: idursulfase-IT
NCT02055118,Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment,Hunter Syndrome,Interventional,13-Dec-18,Shire,Other: No IT treatment
NCT00335452,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,Acute Coronary Disease|Angina Unstable,Interventional,7-Oct-10,Sanofi,Drug: Clopidogrel
NCT00335452,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,Acute Coronary Disease|Angina Unstable,Interventional,7-Oct-10,Sanofi,Drug: acetylsalicyclic acid (ASA)
NCT00335452,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,Acute Coronary Disease|Angina Unstable,Interventional,7-Oct-10,Bristol-Myers Squibb,Drug: Clopidogrel
NCT00335452,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,Acute Coronary Disease|Angina Unstable,Interventional,7-Oct-10,Bristol-Myers Squibb,Drug: acetylsalicyclic acid (ASA)
NCT00249873,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),Atrial Fibrillation|Vascular Risk,Interventional,26-Mar-10,Sanofi,Drug: clopidogrel (SR25990C)
NCT00249873,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),Atrial Fibrillation|Vascular Risk,Interventional,26-Mar-10,Sanofi,Drug: placebo
NCT00249873,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),Atrial Fibrillation|Vascular Risk,Interventional,26-Mar-10,Bristol-Myers Squibb,Drug: clopidogrel (SR25990C)
NCT00249873,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),Atrial Fibrillation|Vascular Risk,Interventional,26-Mar-10,Bristol-Myers Squibb,Drug: placebo
NCT00249795,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),Atrial Fibrillation|Cardiovascular Disease,Interventional,15-Oct-10,Sanofi,Drug: Irbesartan
NCT00249795,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),Atrial Fibrillation|Cardiovascular Disease,Interventional,15-Oct-10,Sanofi,Drug: placebo
NCT00249795,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),Atrial Fibrillation|Cardiovascular Disease,Interventional,15-Oct-10,Bristol-Myers Squibb,Drug: Irbesartan
NCT00249795,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),Atrial Fibrillation|Cardiovascular Disease,Interventional,15-Oct-10,Bristol-Myers Squibb,Drug: placebo
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,Astellas Pharma Inc,Drug: Tacrolimus
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,Astellas Pharma Inc,Drug: Cyclosporine
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,Astellas Pharma Inc,Drug: Mycophenolate mofetil
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,Astellas Pharma Inc,Drug: Methylprednisolone
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,Astellas Pharma Inc,Drug: Prednisone
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,"Astellas Pharma Canada, Inc.",Drug: Tacrolimus
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,"Astellas Pharma Canada, Inc.",Drug: Cyclosporine
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,"Astellas Pharma Canada, Inc.",Drug: Mycophenolate mofetil
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,"Astellas Pharma Canada, Inc.",Drug: Methylprednisolone
NCT00157014,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Heart Diseases|Heart Transplantation,Interventional,21-Feb-11,"Astellas Pharma Canada, Inc.",Drug: Prednisone
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,Vifor Inc.,Drug: FCM (Ferric carboxymaltose) high ferritin target
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,Vifor Inc.,Drug: FCM (Ferric carboxymaltose) low ferritin target
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,Vifor Inc.,Drug: Oral Iron (Ferrous sulphate)
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,"American Regent, Inc.",Drug: FCM (Ferric carboxymaltose) high ferritin target
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,"American Regent, Inc.",Drug: FCM (Ferric carboxymaltose) low ferritin target
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,"American Regent, Inc.",Drug: Oral Iron (Ferrous sulphate)
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,ICON Clinical Research,Drug: FCM (Ferric carboxymaltose) high ferritin target
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,ICON Clinical Research,Drug: FCM (Ferric carboxymaltose) low ferritin target
NCT00994318,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Iron Deficiency Anaemia|Chronic Kidney Disease,Interventional,7-May-14,ICON Clinical Research,Drug: Oral Iron (Ferrous sulphate)
NCT01176266,Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP),Hypophosphatasia,Interventional,26-Feb-18,Alexion Pharmaceuticals,Drug: asfotase alfa
NCT00477269,Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,23-Mar-15,Novartis Pharmaceuticals,Drug: Imatinib mesylate
NCT00477269,Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,23-Mar-15,Novartis Pharmaceuticals,Drug: Placebo
NCT00477269,Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,23-Mar-15,Novartis,Drug: Imatinib mesylate
NCT00477269,Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Interventional,23-Mar-15,Novartis,Drug: Placebo
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Michael Cohen-Wolkowiez,Drug: ampicillin and metronidazole and gentamicin
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Michael Cohen-Wolkowiez,Drug: ampicillin and gentamicin and clindamycin
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Michael Cohen-Wolkowiez,Drug: gentamicin and Piperacillin- tazobactam
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Michael Cohen-Wolkowiez,Drug: standard of care antibiotics and metronidazole
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Michael Cohen-Wolkowiez,"Drug: metronidazole, clindamycin, or piperacillin-tazobactam"
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,"The Emmes Company, LLC",Drug: ampicillin and metronidazole and gentamicin
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,"The Emmes Company, LLC",Drug: ampicillin and gentamicin and clindamycin
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,"The Emmes Company, LLC",Drug: gentamicin and Piperacillin- tazobactam
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,"The Emmes Company, LLC",Drug: standard of care antibiotics and metronidazole
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,"The Emmes Company, LLC","Drug: metronidazole, clindamycin, or piperacillin-tazobactam"
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Duke University,Drug: ampicillin and metronidazole and gentamicin
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Duke University,Drug: ampicillin and gentamicin and clindamycin
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Duke University,Drug: gentamicin and Piperacillin- tazobactam
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Duke University,Drug: standard of care antibiotics and metronidazole
NCT01994993,Antibiotic Safety (SCAMP),Complicated Intra Abdominal Infections,Interventional,27-Feb-18,Duke University,"Drug: metronidazole, clindamycin, or piperacillin-tazobactam"
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,Jaeb Center for Health Research,Other: Prompt Panretinal Photocoagulation
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,Jaeb Center for Health Research,Drug: 0.5-mg Ranibizumab
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,Jaeb Center for Health Research,Other: Deferred panretinal photocoagulation
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,National Eye Institute (NEI),Other: Prompt Panretinal Photocoagulation
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,National Eye Institute (NEI),Drug: 0.5-mg Ranibizumab
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,National Eye Institute (NEI),Other: Deferred panretinal photocoagulation
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,"Genentech, Inc.",Other: Prompt Panretinal Photocoagulation
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,"Genentech, Inc.",Drug: 0.5-mg Ranibizumab
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Interventional,1-Jun-16,"Genentech, Inc.",Other: Deferred panretinal photocoagulation
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,"Nasser Hanna, M.D.",Drug: Cisplatin
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,"Nasser Hanna, M.D.",Drug: Etoposide
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,"Nasser Hanna, M.D.",Radiation: Radiation
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,"Nasser Hanna, M.D.",Drug: Docetaxel
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Sanofi,Drug: Cisplatin
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Sanofi,Drug: Etoposide
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Sanofi,Radiation: Radiation
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Sanofi,Drug: Docetaxel
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Walther Cancer Institute,Drug: Cisplatin
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Walther Cancer Institute,Drug: Etoposide
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Walther Cancer Institute,Radiation: Radiation
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Walther Cancer Institute,Drug: Docetaxel
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Hoosier Cancer Research Network,Drug: Cisplatin
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Hoosier Cancer Research Network,Drug: Etoposide
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Hoosier Cancer Research Network,Radiation: Radiation
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Interventional,8-Feb-16,Hoosier Cancer Research Network,Drug: Docetaxel
NCT01076452,Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial,Parkinson's Disease,Interventional,15-Jan-14,US Department of Veterans Affairs,Device: Bilateral Deep Brain Stimulation
NCT01076452,Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial,Parkinson's Disease,Interventional,15-Jan-14,National Institute of Neurological Disorders and Stroke (NINDS),Device: Bilateral Deep Brain Stimulation
NCT01076452,Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial,Parkinson's Disease,Interventional,15-Jan-14,Medtronic,Device: Bilateral Deep Brain Stimulation
NCT01076452,Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial,Parkinson's Disease,Interventional,15-Jan-14,VA Office of Research and Development,Device: Bilateral Deep Brain Stimulation
NCT00763867,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),Heart Failure,Interventional,3-Jul-13,Duke University,Drug: Placebo
NCT00763867,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),Heart Failure,Interventional,3-Jul-13,Duke University,Drug: Sildenafil
NCT00763867,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),Heart Failure,Interventional,3-Jul-13,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Placebo
NCT00763867,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),Heart Failure,Interventional,3-Jul-13,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Sildenafil
NCT00763867,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),Heart Failure,Interventional,3-Jul-13,Pfizer,Drug: Placebo
NCT00763867,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),Heart Failure,Interventional,3-Jul-13,Pfizer,Drug: Sildenafil
NCT00608491,Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),Heart Failure,Interventional,24-Jun-13,Duke University,Drug: Stepped pharmacologic care
NCT00608491,Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),Heart Failure,Interventional,24-Jun-13,Duke University,Device: Ultrafiltration
NCT00608491,Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),Heart Failure,Interventional,24-Jun-13,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Stepped pharmacologic care
NCT00608491,Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),Heart Failure,Interventional,24-Jun-13,"National Heart, Lung, and Blood Institute (NHLBI)",Device: Ultrafiltration
NCT00608491,Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),Heart Failure,Interventional,24-Jun-13,CHF Solutions,Drug: Stepped pharmacologic care
NCT00608491,Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),Heart Failure,Interventional,24-Jun-13,CHF Solutions,Device: Ultrafiltration
NCT00517933,Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis,"Pulmonary Fibrosis|Hypertension, Pulmonary",Interventional,23-Aug-13,Duke University,Drug: Sildenafil Citrate
NCT00517933,Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis,"Pulmonary Fibrosis|Hypertension, Pulmonary",Interventional,23-Aug-13,Duke University,Other: Placebo
NCT00517933,Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis,"Pulmonary Fibrosis|Hypertension, Pulmonary",Interventional,23-Aug-13,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Sildenafil Citrate
NCT00517933,Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis,"Pulmonary Fibrosis|Hypertension, Pulmonary",Interventional,23-Aug-13,"National Heart, Lung, and Blood Institute (NHLBI)",Other: Placebo
NCT00517933,Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis,"Pulmonary Fibrosis|Hypertension, Pulmonary",Interventional,23-Aug-13,Pfizer,Drug: Sildenafil Citrate
NCT00517933,Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis,"Pulmonary Fibrosis|Hypertension, Pulmonary",Interventional,23-Aug-13,Pfizer,Other: Placebo
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Alzheimer's Disease,Interventional,30-Aug-10,Alzheimer's Disease Cooperative Study (ADCS),Drug: DHA (Docosahexaenoic Acid)
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Alzheimer's Disease,Interventional,30-Aug-10,Alzheimer's Disease Cooperative Study (ADCS),Drug: Placebo
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Alzheimer's Disease,Interventional,30-Aug-10,National Institute on Aging (NIA),Drug: DHA (Docosahexaenoic Acid)
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Alzheimer's Disease,Interventional,30-Aug-10,National Institute on Aging (NIA),Drug: Placebo
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Alzheimer's Disease,Interventional,30-Aug-10,"DSM Nutritional Products, Inc.",Drug: DHA (Docosahexaenoic Acid)
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Alzheimer's Disease,Interventional,30-Aug-10,"DSM Nutritional Products, Inc.",Drug: Placebo
NCT00376675,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,10-Oct-14,Alliance for Clinical Trials in Oncology,Drug: methylphenidate hydrochloride
NCT00376675,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,10-Oct-14,Alliance for Clinical Trials in Oncology,Other: placebo
NCT00376675,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,10-Oct-14,National Cancer Institute (NCI),Drug: methylphenidate hydrochloride
NCT00376675,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,10-Oct-14,National Cancer Institute (NCI),Other: placebo
NCT00376675,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,10-Oct-14,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Drug: methylphenidate hydrochloride
NCT00376675,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue|Unspecified Adult Solid Tumor, Protocol Specific",Interventional,10-Oct-14,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Other: placebo
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,Jaeb Center for Health Research,Procedure: Standard of Care Group
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,Jaeb Center for Health Research,Drug: 1mg triamcinolone acetonide
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,Jaeb Center for Health Research,Drug: 4mg triamcinolone acetonide
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,National Eye Institute (NEI),Procedure: Standard of Care Group
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,National Eye Institute (NEI),Drug: 1mg triamcinolone acetonide
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,National Eye Institute (NEI),Drug: 4mg triamcinolone acetonide
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,Allergan,Procedure: Standard of Care Group
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,Allergan,Drug: 1mg triamcinolone acetonide
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,9-Jul-10,Allergan,Drug: 4mg triamcinolone acetonide
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),Impaired Glucose Tolerance|Type 2 Diabetes,Interventional,11-Aug-16,The University of Texas Health Science Center at San Antonio,Drug: Pioglitazone
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),Impaired Glucose Tolerance|Type 2 Diabetes,Interventional,11-Aug-16,The University of Texas Health Science Center at San Antonio,Drug: Placebo
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),Impaired Glucose Tolerance|Type 2 Diabetes,Interventional,11-Aug-16,University of Texas,Drug: Pioglitazone
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),Impaired Glucose Tolerance|Type 2 Diabetes,Interventional,11-Aug-16,University of Texas,Drug: Placebo
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),Impaired Glucose Tolerance|Type 2 Diabetes,Interventional,11-Aug-16,"Takeda Pharmaceuticals North America, Inc.",Drug: Pioglitazone
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),Impaired Glucose Tolerance|Type 2 Diabetes,Interventional,11-Aug-16,"Takeda Pharmaceuticals North America, Inc.",Drug: Placebo
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Johns Hopkins Bloomberg School of Public Health,Dietary Supplement: Iron (27 mg) - folic acid (600 ug)
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Johns Hopkins Bloomberg School of Public Health,Dietary Supplement: Multiple micronutrient
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Bill and Melinda Gates Foundation,Dietary Supplement: Iron (27 mg) - folic acid (600 ug)
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Bill and Melinda Gates Foundation,Dietary Supplement: Multiple micronutrient
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,United States Agency for International Development (USAID),Dietary Supplement: Iron (27 mg) - folic acid (600 ug)
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,United States Agency for International Development (USAID),Dietary Supplement: Multiple micronutrient
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Mahidol University,Dietary Supplement: Iron (27 mg) - folic acid (600 ug)
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Mahidol University,Dietary Supplement: Multiple micronutrient
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Johns Hopkins University,Dietary Supplement: Iron (27 mg) - folic acid (600 ug)
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Johns Hopkins University,Dietary Supplement: Multiple micronutrient
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Beximco,Dietary Supplement: Iron (27 mg) - folic acid (600 ug)
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,Beximco,Dietary Supplement: Multiple micronutrient
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,"DSM Nutritional Products, Inc.",Dietary Supplement: Iron (27 mg) - folic acid (600 ug)
NCT00860470,Antenatal Micronutrient Supplementation and Infant Survival,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Interventional,27-May-15,"DSM Nutritional Products, Inc.",Dietary Supplement: Multiple micronutrient
NCT00091949,Insulin Resistance Intervention After Stroke Trial,Stroke|Myocardial Infarction|Diabetes,Interventional,28-Oct-16,Yale University,Drug: pioglitazone
NCT00091949,Insulin Resistance Intervention After Stroke Trial,Stroke|Myocardial Infarction|Diabetes,Interventional,28-Oct-16,Yale University,Drug: placebo
NCT00091949,Insulin Resistance Intervention After Stroke Trial,Stroke|Myocardial Infarction|Diabetes,Interventional,28-Oct-16,National Institute of Neurological Disorders and Stroke (NINDS),Drug: pioglitazone
NCT00091949,Insulin Resistance Intervention After Stroke Trial,Stroke|Myocardial Infarction|Diabetes,Interventional,28-Oct-16,National Institute of Neurological Disorders and Stroke (NINDS),Drug: placebo
NCT00091949,Insulin Resistance Intervention After Stroke Trial,Stroke|Myocardial Infarction|Diabetes,Interventional,28-Oct-16,"Takeda Pharmaceuticals North America, Inc.",Drug: pioglitazone
NCT00091949,Insulin Resistance Intervention After Stroke Trial,Stroke|Myocardial Infarction|Diabetes,Interventional,28-Oct-16,"Takeda Pharmaceuticals North America, Inc.",Drug: placebo
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,VA Office of Research and Development,Drug: Insulin
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,VA Office of Research and Development,Drug: Glimepiride
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,VA Office of Research and Development,Drug: Rosiglitazone
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,VA Office of Research and Development,Drug: Metformin
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,National Eye Institute (NEI),Drug: Insulin
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,National Eye Institute (NEI),Drug: Glimepiride
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,National Eye Institute (NEI),Drug: Rosiglitazone
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,National Eye Institute (NEI),Drug: Metformin
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,SmithKline Beecham,Drug: Insulin
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,SmithKline Beecham,Drug: Glimepiride
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,SmithKline Beecham,Drug: Rosiglitazone
NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Type 2 Diabetes Mellitus,Interventional,12-Feb-14,SmithKline Beecham,Drug: Metformin
NCT02116803,An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,Solid Tumors,Interventional,1-Feb-18,Novartis Pharmaceuticals,Drug: dovitinib
NCT02116803,An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,Solid Tumors,Interventional,1-Feb-18,Novartis Pharmaceuticals,Drug: fulvestrant
NCT02116803,An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,Solid Tumors,Interventional,1-Feb-18,Novartis,Drug: dovitinib
NCT02116803,An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,Solid Tumors,Interventional,1-Feb-18,Novartis,Drug: fulvestrant
NCT01588496,Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities,Homozygous Familial Hypercholesterolemia,Interventional,2-Oct-15,Amgen,Biological: Evolocumab
NCT01588496,Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities,Homozygous Familial Hypercholesterolemia,Interventional,2-Oct-15,Amgen,Drug: Placebo
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,"SCRI Development Innovations, LLC",Drug: Etoposide
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,"SCRI Development Innovations, LLC",Drug: Gemcitabine
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,"SCRI Development Innovations, LLC",Drug: Irinotecan
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,"SCRI Development Innovations, LLC",Drug: Paclitaxel
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,"SCRI Development Innovations, LLC",Drug: Carboplatin
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,AstraZeneca,Drug: Etoposide
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,AstraZeneca,Drug: Gemcitabine
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,AstraZeneca,Drug: Irinotecan
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,AstraZeneca,Drug: Paclitaxel
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,AstraZeneca,Drug: Carboplatin
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Pharmacia and Upjohn,Drug: Etoposide
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Pharmacia and Upjohn,Drug: Gemcitabine
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Pharmacia and Upjohn,Drug: Irinotecan
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Pharmacia and Upjohn,Drug: Paclitaxel
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Pharmacia and Upjohn,Drug: Carboplatin
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Eli Lilly and Company,Drug: Etoposide
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Eli Lilly and Company,Drug: Gemcitabine
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Eli Lilly and Company,Drug: Irinotecan
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Eli Lilly and Company,Drug: Paclitaxel
NCT00193596,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,"Neoplasms, Unknown Primary",Interventional,3-May-13,Eli Lilly and Company,Drug: Carboplatin
NCT00143598,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,Deep Venous Thrombosis,Interventional,18-Aug-14,Sir Mortimer B. Davis - Jewish General Hospital,"Device: Knee-length, graduated elastic compression stocking"
NCT00143598,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,Deep Venous Thrombosis,Interventional,18-Aug-14,Sir Mortimer B. Davis - Jewish General Hospital,"Device: Knee-length, placebo stocking"
NCT00143598,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,Deep Venous Thrombosis,Interventional,18-Aug-14,Canadian Institutes of Health Research (CIHR),"Device: Knee-length, graduated elastic compression stocking"
NCT00143598,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,Deep Venous Thrombosis,Interventional,18-Aug-14,Canadian Institutes of Health Research (CIHR),"Device: Knee-length, placebo stocking"
NCT00143598,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,Deep Venous Thrombosis,Interventional,18-Aug-14,Sigvaris Corporation,"Device: Knee-length, graduated elastic compression stocking"
NCT00143598,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,Deep Venous Thrombosis,Interventional,18-Aug-14,Sigvaris Corporation,"Device: Knee-length, placebo stocking"
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Lisinopril
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Telmisartan
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Placebo
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Boehringer Ingelheim,Drug: Lisinopril
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Boehringer Ingelheim,Drug: Telmisartan
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Boehringer Ingelheim,Drug: Placebo
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Merck Sharp & Dohme Corp.,Drug: Lisinopril
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Merck Sharp & Dohme Corp.,Drug: Telmisartan
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Merck Sharp & Dohme Corp.,Drug: Placebo
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Polycystic Kidney Disease Foundation,Drug: Lisinopril
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Polycystic Kidney Disease Foundation,Drug: Telmisartan
NCT01885559,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,"Kidney, Polycystic",Interventional,10-Mar-15,Polycystic Kidney Disease Foundation,Drug: Placebo
NCT02267226,Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery,Congenital Fibrinogen Deficiency,Interventional,20-Feb-19,Octapharma,Drug: Octafibrin
NCT02207829,A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,9-Feb-16,GlaxoSmithKline,Drug: Umeclidinium
NCT02207829,A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,9-Feb-16,GlaxoSmithKline,Drug: Umeclidinium matching placebo
NCT02207829,A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,9-Feb-16,GlaxoSmithKline,Drug: Tiotropium
NCT02207829,A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Interventional,9-Feb-16,GlaxoSmithKline,Drug: Tiotropium matching placebo
NCT02118896,Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant,Heart Transplantation|Liver Transplantation|Kidney Transplantation,Interventional,15-Mar-16,Astellas Pharma Europe Ltd.,Drug: FK506E
NCT02118896,Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant,Heart Transplantation|Liver Transplantation|Kidney Transplantation,Interventional,15-Mar-16,Astellas Pharma Inc,Drug: FK506E
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Lisinopril
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Telmisartan
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Placebo
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Other: Standard Blood Pressure Control
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Other: Low Blood Pressure Control
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Boehringer Ingelheim,Drug: Lisinopril
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Boehringer Ingelheim,Drug: Telmisartan
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Boehringer Ingelheim,Drug: Placebo
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Boehringer Ingelheim,Other: Standard Blood Pressure Control
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Boehringer Ingelheim,Other: Low Blood Pressure Control
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Merck Sharp & Dohme Corp.,Drug: Lisinopril
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Merck Sharp & Dohme Corp.,Drug: Telmisartan
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Merck Sharp & Dohme Corp.,Drug: Placebo
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Merck Sharp & Dohme Corp.,Other: Standard Blood Pressure Control
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Merck Sharp & Dohme Corp.,Other: Low Blood Pressure Control
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Polycystic Kidney Disease Foundation,Drug: Lisinopril
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Polycystic Kidney Disease Foundation,Drug: Telmisartan
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Polycystic Kidney Disease Foundation,Drug: Placebo
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Polycystic Kidney Disease Foundation,Other: Standard Blood Pressure Control
NCT00283686,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,"Kidney, Polycystic",Interventional,27-Feb-15,Polycystic Kidney Disease Foundation,Other: Low Blood Pressure Control
NCT02076412,A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura,Interventional,25-Jan-19,Rigel Pharmaceuticals,Drug: Fostamatinib Disodium
NCT02076412,A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura,Interventional,25-Jan-19,Rigel Pharmaceuticals,Drug: Placebo
NCT01981954,"A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)",Neurogenic Detrusor Overactivity|Pediatric,Interventional,21-Jun-18,Astellas Pharma Europe B.V.,Drug: Solifenacin succinate
NCT01981954,"A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)",Neurogenic Detrusor Overactivity|Pediatric,Interventional,21-Jun-18,Astellas Pharma Inc,Drug: Solifenacin succinate
NCT00784134,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Intraventricular Hemorrhage,Interventional,2-Jul-17,Johns Hopkins University,Drug: Alteplase
NCT00784134,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Intraventricular Hemorrhage,Interventional,2-Jul-17,Johns Hopkins University,Other: Normal saline
NCT00784134,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Intraventricular Hemorrhage,Interventional,2-Jul-17,National Institute of Neurological Disorders and Stroke (NINDS),Drug: Alteplase
NCT00784134,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Intraventricular Hemorrhage,Interventional,2-Jul-17,National Institute of Neurological Disorders and Stroke (NINDS),Other: Normal saline
NCT00784134,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Intraventricular Hemorrhage,Interventional,2-Jul-17,"Genentech, Inc.",Drug: Alteplase
NCT00784134,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Intraventricular Hemorrhage,Interventional,2-Jul-17,"Genentech, Inc.",Other: Normal saline
NCT00784134,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Intraventricular Hemorrhage,Interventional,2-Jul-17,Emissary International LLC,Drug: Alteplase
NCT00784134,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Intraventricular Hemorrhage,Interventional,2-Jul-17,Emissary International LLC,Other: Normal saline
NCT01890421,Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),Coronary Artery Disease,Interventional,16-May-18,Bayer,"Drug: Gadobutrol (Gadovist, Gadavist, BAY86-4875)"
NCT01767519,A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,Overactive Bladder|Urinary Incontinence,Interventional,12-Jan-16,Allergan,Biological: BOTOX®
NCT01767519,A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,Overactive Bladder|Urinary Incontinence,Interventional,12-Jan-16,Allergan,Drug: solifenacin
NCT01767519,A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,Overactive Bladder|Urinary Incontinence,Interventional,12-Jan-16,Allergan,Drug: Botox placebo (normal saline)
NCT01767519,A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,Overactive Bladder|Urinary Incontinence,Interventional,12-Jan-16,Allergan,Drug: solifenacin placebo
NCT01757405,Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen,Hemophilia A|Hemophilia B,Interventional,25-Oct-16,Baxalta now part of Shire,Biological: Recombinant Factor VIIa BI (rFVIIa BI)
NCT01757405,Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen,Hemophilia A|Hemophilia B,Interventional,25-Oct-16,Shire,Biological: Recombinant Factor VIIa BI (rFVIIa BI)
NCT01655069,A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076,"Urinary Bladder, Overactive",Interventional,11-Dec-17,Astellas Pharma Europe B.V.,Drug: Solifenacin succinate suspension
NCT01655069,A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076,"Urinary Bladder, Overactive",Interventional,11-Dec-17,Astellas Pharma Inc,Drug: Solifenacin succinate suspension
NCT01600716,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),Urinary Incontinence|Multiple Sclerosis|Neurogenic Bladder,Interventional,22-Mar-16,Allergan,Biological: OnabotulinumtoxinA
NCT01600716,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),Urinary Incontinence|Multiple Sclerosis|Neurogenic Bladder,Interventional,22-Mar-16,Allergan,Drug: Placebo (Normal Saline)
NCT01514461,"A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome",Familial Chylomicronemia Syndrome (FCS),Interventional,3-Jun-15,Novartis Pharmaceuticals,Drug: LCQ908
NCT01514461,"A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome",Familial Chylomicronemia Syndrome (FCS),Interventional,3-Jun-15,Novartis Pharmaceuticals,Drug: Placebo
NCT01514461,"A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome",Familial Chylomicronemia Syndrome (FCS),Interventional,3-Jun-15,Novartis,Drug: LCQ908
NCT01514461,"A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome",Familial Chylomicronemia Syndrome (FCS),Interventional,3-Jun-15,Novartis,Drug: Placebo
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,Jaeb Center for Health Research,Drug: Ranibizumab
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,Jaeb Center for Health Research,Drug: Triamcinolone Acetonide
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,Jaeb Center for Health Research,Behavioral: Sham injection
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,Jaeb Center for Health Research,Procedure: Focal/grid laser
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,National Eye Institute (NEI),Drug: Ranibizumab
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,National Eye Institute (NEI),Drug: Triamcinolone Acetonide
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,National Eye Institute (NEI),Behavioral: Sham injection
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,National Eye Institute (NEI),Procedure: Focal/grid laser
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,"Genentech, Inc.",Drug: Ranibizumab
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,"Genentech, Inc.",Drug: Triamcinolone Acetonide
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,"Genentech, Inc.",Behavioral: Sham injection
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,"Genentech, Inc.",Procedure: Focal/grid laser
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,Allergan,Drug: Ranibizumab
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,Allergan,Drug: Triamcinolone Acetonide
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,Allergan,Behavioral: Sham injection
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Interventional,13-Jul-11,Allergan,Procedure: Focal/grid laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,Jaeb Center for Health Research,Drug: Triamcinolone Acetonide + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,Jaeb Center for Health Research,Drug: Ranibizumab + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,Jaeb Center for Health Research,Drug: Sham injection + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,Jaeb Center for Health Research,Drug: Ranibizumab + deferred laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,National Eye Institute (NEI),Drug: Triamcinolone Acetonide + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,National Eye Institute (NEI),Drug: Ranibizumab + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,National Eye Institute (NEI),Drug: Sham injection + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,National Eye Institute (NEI),Drug: Ranibizumab + deferred laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,Allergan,Drug: Triamcinolone Acetonide + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,Allergan,Drug: Ranibizumab + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,Allergan,Drug: Sham injection + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,Allergan,Drug: Ranibizumab + deferred laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,"Genentech, Inc.",Drug: Triamcinolone Acetonide + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,"Genentech, Inc.",Drug: Ranibizumab + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,"Genentech, Inc.",Drug: Sham injection + laser
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Diabetic Retinopathy|Diabetic Macular Edema,Interventional,12-Jul-11,"Genentech, Inc.",Drug: Ranibizumab + deferred laser
NCT01412424,Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly,Acromegaly,Interventional,1-Dec-15,"Chiasma, Inc.",Drug: Octreotide capsules
NCT01311687,"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study",Multiple Myeloma,Interventional,30-Apr-14,Celgene,Drug: pomalidomide
NCT01311687,"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study",Multiple Myeloma,Interventional,30-Apr-14,Celgene,Drug: Dexamethasone
NCT01177098,Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Glaucoma|Ocular Hypertension,Interventional,12-Mar-13,Allergan,Drug: bimatoprost /timolol formulation A fixed combination ophthalmic solution
NCT01177098,Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Glaucoma|Ocular Hypertension,Interventional,12-Mar-13,Allergan,Drug: bimatoprost/timolol fixed combination ophthalmic solution
NCT01154127,Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,7-May-12,Novartis Pharmaceuticals,Drug: NVA237
NCT01154127,Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,7-May-12,Novartis Pharmaceuticals,Drug: Placebo
NCT01154127,Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,7-May-12,Novartis,Drug: NVA237
NCT01154127,Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD),Chronic Obstructive Pulmonary Disease,Interventional,7-May-12,Novartis,Drug: Placebo
NCT01078675,An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia,Familial Hypercholesterolaemia,Interventional,2-Feb-15,AstraZeneca,Drug: rosuvastatin calcium
NCT00915525,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Overactive Bladder|Urinary Incontinence,Interventional,18-Dec-15,Allergan,Biological: botulinum toxin Type A
NCT00910520,Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Overactive Bladder,Interventional,5-Mar-13,Allergan,Biological: onabotulinumtoxinA
NCT00910520,Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Overactive Bladder,Interventional,5-Mar-13,Allergan,Drug: normal saline
NCT00884585,Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis,Atopic Conjunctivitis,Interventional,5-Nov-12,Allergan,Drug: Cyclosporine Vehicle
NCT00884585,Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis,Atopic Conjunctivitis,Interventional,5-Nov-12,Allergan,Drug: Cyclosporine 0.010%
NCT00876447,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,Overactive Bladder,Interventional,14-Jul-14,Allergan,Biological: Botulinum Toxin Type A 300U
NCT00876447,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,Overactive Bladder,Interventional,14-Jul-14,Allergan,Biological: Botulinum Toxin Type A 200U
NCT00851903,Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial,"Diabetes Mellitus, Type 2",Interventional,4-Oct-12,Sanofi,Drug: Insulin Glargine
NCT00851903,Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial,"Diabetes Mellitus, Type 2",Interventional,4-Oct-12,Sanofi,Drug: Sitagliptin
NCT00851903,Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial,"Diabetes Mellitus, Type 2",Interventional,4-Oct-12,Sanofi,Drug: Metformin
NCT00765674,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension,Hypertension,Interventional,9-May-11,Novartis,Drug: Aliskiren
NCT00765674,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension,Hypertension,Interventional,9-May-11,Novartis,Drug: Amlodipine
NCT00765674,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension,Hypertension,Interventional,9-May-11,Novartis,Drug: Hydrochlorothiazide (HCTZ)
NCT00765674,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension,Hypertension,Interventional,9-May-11,Novartis,Drug: Placebo
NCT00763451,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00763451,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Drug: Placebo
NCT00763451,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Device: Pen auto-injector
NCT00763451,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Drug: Metformin
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Placebo
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Aliskiren 150 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Aliskiren 300 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Amlodipine 5 mg capsule
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Amlodipine 10 mg capsule
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Aliskiren/amlodipine 150/5 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Aliskiren/amlodipine 150/10 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Aliskiren/amlodipine 300/5 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis Pharmaceuticals,Drug: Aliskiren/amlodipine 300/10 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Placebo
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Aliskiren 150 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Aliskiren 300 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Amlodipine 5 mg capsule
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Amlodipine 10 mg capsule
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Aliskiren/amlodipine 150/5 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Aliskiren/amlodipine 150/10 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Aliskiren/amlodipine 300/5 mg tablet
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Hypertension,Interventional,3-May-11,Novartis,Drug: Aliskiren/amlodipine 300/10 mg tablet
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Drug: Placebo
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Drug: Basal Insulin
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Drug: Metformin
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Device: Pen auto-injector
NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Drug: Placebo
NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Device: Pen auto-injector
NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Drug: Sulfonylurea
NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","Diabetes Mellitus, Type 2",Interventional,14-Dec-16,Sanofi,Drug: Metformin
NCT00712673,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,15-Dec-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00712673,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,15-Dec-16,Sanofi,Drug: Placebo
NCT00712673,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,15-Dec-16,Sanofi,Device: Pen auto-injector
NCT00712673,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,15-Dec-16,Sanofi,Drug: Metformin
NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Device: Pen auto-injector
NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Drug: Exenatide
NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Device: Prefilled pen injector
NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",Interventional,11-Oct-16,Sanofi,Drug: Metformin
NCT00705575,Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension,Hypertension,Interventional,21-Jan-11,Novartis,Drug: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)
NCT00705575,Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension,Hypertension,Interventional,21-Jan-11,Novartis,Drug: Aliskiren (300 mg)
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Breast Cancer,Interventional,14-Feb-11,Sanofi,Drug: Docetaxel
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Breast Cancer,Interventional,14-Feb-11,Sanofi,Drug: 5-fluorouracil
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Breast Cancer,Interventional,14-Feb-11,Sanofi,Drug: Doxorubicin
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Breast Cancer,Interventional,14-Feb-11,Sanofi,Drug: Cyclophosphamide
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Breast Cancer,Interventional,14-Feb-11,Cancer International Research Group (CIRG),Drug: Docetaxel
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Breast Cancer,Interventional,14-Feb-11,Cancer International Research Group (CIRG),Drug: 5-fluorouracil
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Breast Cancer,Interventional,14-Feb-11,Cancer International Research Group (CIRG),Drug: Doxorubicin
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Breast Cancer,Interventional,14-Feb-11,Cancer International Research Group (CIRG),Drug: Cyclophosphamide
NCT00688701,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,"Diabetes Mellitus, Type 2",Interventional,12-Dec-16,Sanofi,Drug: Lixisenatide (AVE0010)
NCT00688701,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,"Diabetes Mellitus, Type 2",Interventional,12-Dec-16,Sanofi,Drug: Placebo
NCT00688701,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,"Diabetes Mellitus, Type 2",Interventional,12-Dec-16,Sanofi,Device: Pen auto-injector
NCT00658775,"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)",Gastroesophageal Reflux Disease (GERD),Interventional,23-Jun-15,Eisai Inc.,Drug: Rabeprazole sodium
NCT00658775,"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)",Gastroesophageal Reflux Disease (GERD),Interventional,23-Jun-15,Eisai Inc.,Drug: Esomeprazole
NCT00658528,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,23-Jun-15,Eisai Inc.,Drug: Rabeprazole sodium
NCT00658528,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD),Gastroesophageal Reflux Disease (GERD),Interventional,23-Jun-15,Eisai Inc.,Drug: Esomeprazole
NCT00559364,Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea,Exocrine Pancreatic Insufficiency|Chronic Pancreatitis|Pancreatectomy,Interventional,12-Mar-14,Forest Laboratories,Drug: Viokase® 16
NCT00559364,Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea,Exocrine Pancreatic Insufficiency|Chronic Pancreatitis|Pancreatectomy,Interventional,12-Mar-14,Forest Laboratories,Drug: Placebo
NCT00559364,Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea,Exocrine Pancreatic Insufficiency|Chronic Pancreatitis|Pancreatectomy,Interventional,12-Mar-14,Forest Laboratories,Drug: Proton pump inhibitor (PPI)
NCT00559364,Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea,Exocrine Pancreatic Insufficiency|Chronic Pancreatitis|Pancreatectomy,Interventional,12-Mar-14,Forest Laboratories,Drug: Omeprazole
NCT00553631,Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease,"Gaucher Disease, Type 1",Interventional,4-Jan-11,Shire,Biological: velaglucerase alfa
NCT00553631,Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease,"Gaucher Disease, Type 1",Interventional,4-Jan-11,Shire,Biological: imiglucerase
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eastern Cooperative Oncology Group,Biological: filgrastim
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eastern Cooperative Oncology Group,Biological: sargramostim
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eastern Cooperative Oncology Group,Drug: cytarabine
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eastern Cooperative Oncology Group,Drug: daunorubicin hydrochloride
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eastern Cooperative Oncology Group,Drug: zosuquidar trihydrochloride
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eastern Cooperative Oncology Group,Drug: Placebo
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,National Cancer Institute (NCI),Biological: filgrastim
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,National Cancer Institute (NCI),Biological: sargramostim
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,National Cancer Institute (NCI),Drug: cytarabine
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,National Cancer Institute (NCI),Drug: daunorubicin hydrochloride
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,National Cancer Institute (NCI),Drug: zosuquidar trihydrochloride
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,National Cancer Institute (NCI),Drug: Placebo
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eli Lilly and Company,Biological: filgrastim
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eli Lilly and Company,Biological: sargramostim
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eli Lilly and Company,Drug: cytarabine
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eli Lilly and Company,Drug: daunorubicin hydrochloride
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eli Lilly and Company,Drug: zosuquidar trihydrochloride
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Eli Lilly and Company,Drug: Placebo
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Kanisa Pharmaceuticals,Biological: filgrastim
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Kanisa Pharmaceuticals,Biological: sargramostim
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Kanisa Pharmaceuticals,Drug: cytarabine
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Kanisa Pharmaceuticals,Drug: daunorubicin hydrochloride
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Kanisa Pharmaceuticals,Drug: zosuquidar trihydrochloride
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Leukemia|Myelodysplastic Syndromes,Interventional,6-Sep-10,Kanisa Pharmaceuticals,Drug: Placebo
NCT00549939,Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction,Neurogenic Urinary Bladder,Interventional,8-Feb-11,Sanofi,Drug: Alfuzosin
NCT00549939,Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction,Neurogenic Urinary Bladder,Interventional,8-Feb-11,Sanofi,Drug: Placebo
NCT00525824,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe",Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis,Interventional,7-Oct-09,AstraZeneca,Drug: Rosuvastatin (Crestor)
NCT00525824,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe",Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis,Interventional,7-Oct-09,AstraZeneca,Drug: Ezetimibe
NCT00525824,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe",Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis,Interventional,7-Oct-09,AstraZeneca,Drug: Simvastatin
NCT00509106,Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia,Bacterial Pneumonia,Interventional,8-Nov-10,Forest Laboratories,Drug: Ceftaroline fosamil for Injection
NCT00509106,Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia,Bacterial Pneumonia,Interventional,8-Nov-10,Forest Laboratories,Drug: Ceftriaxone
NCT00509106,Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia,Bacterial Pneumonia,Interventional,8-Nov-10,Forest Laboratories,Drug: Placebo
NCT00489736,Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation,Atrial Fibrillation,Interventional,9-Nov-09,Sanofi,Drug: dronedarone (SR33589)
NCT00489736,Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation,Atrial Fibrillation,Interventional,9-Nov-09,Sanofi,Drug: amiodarone
NCT00483938,The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE),"Hepatitis C, Chronic",Interventional,23-Jan-17,Hoffmann-La Roche,Drug: Pegylated-interferon Alfa-2a
NCT00483938,The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE),"Hepatitis C, Chronic",Interventional,23-Jan-17,Hoffmann-La Roche,Drug: Ribavirin
NCT00481247,A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia,"Myeloid Leukemia, Chronic",Interventional,15-Mar-11,Bristol-Myers Squibb,Drug: Dasatinib
NCT00481247,A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia,"Myeloid Leukemia, Chronic",Interventional,15-Mar-11,Bristol-Myers Squibb,Drug: Imatinib
NCT00461292,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Overactive Bladder,Interventional,17-Oct-11,Allergan,Biological: botulinum toxin Type A (200U)
NCT00461292,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Overactive Bladder,Interventional,17-Oct-11,Allergan,Biological: botulinum toxin Type A (300U)
NCT00461292,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Overactive Bladder,Interventional,17-Oct-11,Allergan,Other: Normal saline (Placebo); botulinum toxin Type A (200U)
NCT00461292,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Overactive Bladder,Interventional,17-Oct-11,Allergan,Other: Normal saline (Placebo); botulinum toxin Type A (300U)
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Hypertension,Interventional,6-Jun-11,Novartis Pharmaceuticals,Drug: Valsartan
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Hypertension,Interventional,6-Jun-11,Novartis Pharmaceuticals,Drug: Enalapril
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Hypertension,Interventional,6-Jun-11,Novartis Pharmaceuticals,Drug: placebo matched to enalapril
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Hypertension,Interventional,6-Jun-11,Novartis Pharmaceuticals,Drug: placebo matched to valsartan
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Hypertension,Interventional,6-Jun-11,Novartis,Drug: Valsartan
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Hypertension,Interventional,6-Jun-11,Novartis,Drug: Enalapril
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Hypertension,Interventional,6-Jun-11,Novartis,Drug: placebo matched to enalapril
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Hypertension,Interventional,6-Jun-11,Novartis,Drug: placebo matched to valsartan
NCT00435162,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,Hypertension,Interventional,9-May-11,Novartis Pharmaceuticals,Drug: Valsartan 0.25 mg/kg
NCT00435162,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,Hypertension,Interventional,9-May-11,Novartis Pharmaceuticals,Drug: Valsartan 1.0 mg/kg
NCT00435162,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,Hypertension,Interventional,9-May-11,Novartis Pharmaceuticals,Drug: Valsartan 4.0 mg/kg
NCT00435162,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,Hypertension,Interventional,9-May-11,Novartis,Drug: Valsartan 0.25 mg/kg
NCT00435162,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,Hypertension,Interventional,9-May-11,Novartis,Drug: Valsartan 1.0 mg/kg
NCT00435162,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,Hypertension,Interventional,9-May-11,Novartis,Drug: Valsartan 4.0 mg/kg
NCT00433836,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,Hypertension,Interventional,19-May-11,Novartis Pharmaceuticals,Drug: Valsartan
NCT00433836,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,Hypertension,Interventional,19-May-11,Novartis Pharmaceuticals,Drug: Enalapril
NCT00433836,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,Hypertension,Interventional,19-May-11,Novartis,Drug: Valsartan
NCT00433836,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,Hypertension,Interventional,19-May-11,Novartis,Drug: Enalapril
NCT00417079,XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer,Neoplasms|Prostatic Neoplasms,Interventional,23-Dec-10,Sanofi,Drug: cabazitaxel (XRP6258) (RPR116258)
NCT00417079,XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer,Neoplasms|Prostatic Neoplasms,Interventional,23-Dec-10,Sanofi,Drug: mitoxantrone
NCT00417079,XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer,Neoplasms|Prostatic Neoplasms,Interventional,23-Dec-10,Sanofi,Drug: prednisone
NCT00414609,Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE),Myocardial Infarction,Interventional,13-Jul-11,Novartis,Drug: Aliskiren
NCT00414609,Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE),Myocardial Infarction,Interventional,13-Jul-11,Novartis,Drug: placebo
NCT00410202,Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus,"Hepatitis B, Chronic",Interventional,4-Jul-12,Bristol-Myers Squibb,Drug: Entecavir
NCT00410202,Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus,"Hepatitis B, Chronic",Interventional,4-Jul-12,Bristol-Myers Squibb,Drug: Tenofovir
NCT00410202,Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus,"Hepatitis B, Chronic",Interventional,4-Jul-12,Bristol-Myers Squibb,Drug: Adefovir
NCT00410202,Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus,"Hepatitis B, Chronic",Interventional,4-Jul-12,Bristol-Myers Squibb,Drug: Lamivudine
NCT00402103,An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure,Hypertension,Interventional,11-Jan-11,Novartis,Drug: Aliskiren
NCT00402103,An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure,Hypertension,Interventional,11-Jan-11,Novartis,Drug: Amlodipine
NCT00402103,An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure,Hypertension,Interventional,11-Jan-11,Novartis,Drug: Hydrochlorothiazide
NCT00312208,Docetaxel in Breast Cancer,Breast Cancer,Interventional,17-Feb-10,Sanofi,"Drug: docetaxel, doxorubicin, cyclophosphamide"
NCT00312208,Docetaxel in Breast Cancer,Breast Cancer,Interventional,17-Feb-10,Sanofi,"Drug: Docetaxel,doxorubicin, cyclophosphamide"
NCT00312208,Docetaxel in Breast Cancer,Breast Cancer,Interventional,17-Feb-10,Cancer International Research Group (CIRG),"Drug: docetaxel, doxorubicin, cyclophosphamide"
NCT00312208,Docetaxel in Breast Cancer,Breast Cancer,Interventional,17-Feb-10,Cancer International Research Group (CIRG),"Drug: Docetaxel,doxorubicin, cyclophosphamide"
NCT00311376,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Overactive Bladder,Interventional,17-Oct-11,Allergan,Biological: botulinum toxin Type A (200U)
NCT00311376,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Overactive Bladder,Interventional,17-Oct-11,Allergan,Biological: botulinum toxin Type A (300U)
NCT00311376,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Overactive Bladder,Interventional,17-Oct-11,Allergan,Other: Normal Saline (Placebo); botulinum toxin Type A (200U)
NCT00311376,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Overactive Bladder,Interventional,17-Oct-11,Allergan,Other: Normal Saline (Placebo); botulinum toxin Type A (300U)
NCT00283062,Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy,Prostatic Neoplasms,Interventional,23-Jan-12,Sanofi,Drug: Docetaxel (TAXOTERE®) Chemotherapy
NCT00283062,Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy,Prostatic Neoplasms,Interventional,23-Jan-12,Sanofi,Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Hypertension|Left Ventricular Hypertrophy|Overweight,Interventional,10-May-11,Novartis Pharmaceuticals,Drug: Aliskiren 150/300 mg
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Hypertension|Left Ventricular Hypertrophy|Overweight,Interventional,10-May-11,Novartis Pharmaceuticals,Drug: Losartan 50/100 mg
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Hypertension|Left Ventricular Hypertrophy|Overweight,Interventional,10-May-11,Novartis Pharmaceuticals,Drug: Aliskiren placebo
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Hypertension|Left Ventricular Hypertrophy|Overweight,Interventional,10-May-11,Novartis Pharmaceuticals,Drug: Losartan 50/100 mg placebo
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Hypertension|Left Ventricular Hypertrophy|Overweight,Interventional,10-May-11,Novartis,Drug: Aliskiren 150/300 mg
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Hypertension|Left Ventricular Hypertrophy|Overweight,Interventional,10-May-11,Novartis,Drug: Losartan 50/100 mg
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Hypertension|Left Ventricular Hypertrophy|Overweight,Interventional,10-May-11,Novartis,Drug: Aliskiren placebo
NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Hypertension|Left Ventricular Hypertrophy|Overweight,Interventional,10-May-11,Novartis,Drug: Losartan 50/100 mg placebo
NCT00174785,A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation,Atrial Fibrillation|Atrial Flutter,Interventional,23-Dec-09,Sanofi,Drug: dronedarone (SR33589)
NCT00174785,A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation,Atrial Fibrillation|Atrial Flutter,Interventional,23-Dec-09,Sanofi,Drug: placebo
NCT00168389,A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,4-Aug-14,Allergan,Drug: Dexamethasone
NCT00168389,A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,4-Aug-14,Allergan,Other: Sham
NCT00168337,A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,4-Aug-14,Allergan,Drug: Dexamethasone
NCT00168337,A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema,Diabetic Macular Edema,Interventional,4-Aug-14,Allergan,Other: Sham
NCT00168324,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,Macular Edema|Retinal Vein Occlusion,Interventional,26-Aug-09,Allergan,Drug: 700 µg Dexamethasone
NCT00168324,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,Macular Edema|Retinal Vein Occlusion,Interventional,26-Aug-09,Allergan,Drug: 350 µg Dexamethasone
NCT00168324,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,Macular Edema|Retinal Vein Occlusion,Interventional,26-Aug-09,Allergan,Other: Sham Injection
NCT00168298,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,Macular Edema|Retinal Vein Occlusion,Interventional,26-Aug-09,Allergan,Drug: 700 µg Dexamethasone
NCT00168298,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,Macular Edema|Retinal Vein Occlusion,Interventional,26-Aug-09,Allergan,Drug: 350 µg Dexamethasone
NCT00168298,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,Macular Edema|Retinal Vein Occlusion,Interventional,26-Aug-09,Allergan,Other: Sham Injection
NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Multiple Sclerosis,Interventional,6-Nov-12,Sanofi,Drug: Teriflunomide
NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Multiple Sclerosis,Interventional,6-Nov-12,Sanofi,Drug: Placebo (for teriflunomide)
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"Diabetes Mellitus, Type 2",Interventional,24-May-11,Novartis Pharmaceuticals,Drug: Valsartan 160 mg + nateglinide 60 mg
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"Diabetes Mellitus, Type 2",Interventional,24-May-11,Novartis Pharmaceuticals,Drug: Valsartan 160 mg + nateglinide placebo
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"Diabetes Mellitus, Type 2",Interventional,24-May-11,Novartis Pharmaceuticals,Drug: Nateglinide 60 mg + valsartan placebo
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"Diabetes Mellitus, Type 2",Interventional,24-May-11,Novartis Pharmaceuticals,Drug: Valsartan placebo + nateglinide placebo
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"Diabetes Mellitus, Type 2",Interventional,24-May-11,Novartis,Drug: Valsartan 160 mg + nateglinide 60 mg
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"Diabetes Mellitus, Type 2",Interventional,24-May-11,Novartis,Drug: Valsartan 160 mg + nateglinide placebo
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"Diabetes Mellitus, Type 2",Interventional,24-May-11,Novartis,Drug: Nateglinide 60 mg + valsartan placebo
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"Diabetes Mellitus, Type 2",Interventional,24-May-11,Novartis,Drug: Valsartan placebo + nateglinide placebo
NCT00086580,"Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,11-Aug-11,"Genzyme, a Sanofi Company",Biological: FluCAM [Fludara + Campath]
NCT00086580,"Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,11-Aug-11,"Genzyme, a Sanofi Company",Biological: fludarabine phosphate
NCT00086580,"Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,11-Aug-11,Sanofi,Biological: FluCAM [Fludara + Campath]
NCT00086580,"Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients",B-Cell Chronic Lymphocytic Leukemia,Interventional,11-Aug-11,Sanofi,Biological: fludarabine phosphate
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"Diabetes Mellitus, Non-Insulin-Dependent",Interventional,25-Jan-13,Sanofi,Drug: insulin glargine (HOE901)
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"Diabetes Mellitus, Non-Insulin-Dependent",Interventional,25-Jan-13,Sanofi,Drug: omega-3 polyunsaturated fatty acids (PUFA)
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"Diabetes Mellitus, Non-Insulin-Dependent",Interventional,25-Jan-13,Sanofi,Drug: placebo
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"Diabetes Mellitus, Non-Insulin-Dependent",Interventional,25-Jan-13,Sanofi,Device: reusable pen device for insulin injection
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"Diabetes Mellitus, Non-Insulin-Dependent",Interventional,25-Jan-13,Population Health Research Institute,Drug: insulin glargine (HOE901)
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"Diabetes Mellitus, Non-Insulin-Dependent",Interventional,25-Jan-13,Population Health Research Institute,Drug: omega-3 polyunsaturated fatty acids (PUFA)
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"Diabetes Mellitus, Non-Insulin-Dependent",Interventional,25-Jan-13,Population Health Research Institute,Drug: placebo
NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"Diabetes Mellitus, Non-Insulin-Dependent",Interventional,25-Jan-13,Population Health Research Institute,Device: reusable pen device for insulin injection
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Sanofi,Drug: Doxorubicin
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Sanofi,Drug: Cyclophosphamide
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Sanofi,Drug: Docetaxel
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Sanofi,Drug: Herceptin
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Sanofi,Drug: Carboplatin
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Cancer International Research Group (CIRG),Drug: Doxorubicin
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Cancer International Research Group (CIRG),Drug: Cyclophosphamide
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Cancer International Research Group (CIRG),Drug: Docetaxel
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Cancer International Research Group (CIRG),Drug: Herceptin
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Breast Neoplasms,Interventional,15-Nov-16,Cancer International Research Group (CIRG),Drug: Carboplatin
NCT00327444,Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites,Ovarian Neoplasms|Ascites,Interventional,1-Jan-13,Sanofi,"Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)"
NCT00327444,Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites,Ovarian Neoplasms|Ascites,Interventional,1-Jan-13,Sanofi,Drug: Placebo
NCT00327444,Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites,Ovarian Neoplasms|Ascites,Interventional,1-Jan-13,Regeneron Pharmaceuticals,"Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)"
NCT00327444,Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites,Ovarian Neoplasms|Ascites,Interventional,1-Jan-13,Regeneron Pharmaceuticals,Drug: Placebo
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Rituximab plus cyclophosphamide placebo (rituximab group)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Cyclophosphamide plus rituximab placebo (control group)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Azathioprine
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Methylprednisolone (or other glucocorticoid)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Prednisone
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,Immune Tolerance Network (ITN),Drug: Rituximab plus cyclophosphamide placebo (rituximab group)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,Immune Tolerance Network (ITN),Drug: Cyclophosphamide plus rituximab placebo (control group)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,Immune Tolerance Network (ITN),Drug: Azathioprine
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,Immune Tolerance Network (ITN),Drug: Methylprednisolone (or other glucocorticoid)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,Immune Tolerance Network (ITN),Drug: Prednisone
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,"Genentech, Inc.",Drug: Rituximab plus cyclophosphamide placebo (rituximab group)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,"Genentech, Inc.",Drug: Cyclophosphamide plus rituximab placebo (control group)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,"Genentech, Inc.",Drug: Azathioprine
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,"Genentech, Inc.",Drug: Methylprednisolone (or other glucocorticoid)
NCT00104299,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Interventional,25-Aug-11,"Genentech, Inc.",Drug: Prednisone
NCT01164722,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Interventional,31-Oct-16,AIDS Malignancy Consortium,Other: clinical observation
NCT01164722,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Interventional,31-Oct-16,AIDS Malignancy Consortium,Device: infrared photocoagulation therapy
NCT01164722,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Interventional,31-Oct-16,National Cancer Institute (NCI),Other: clinical observation
NCT01164722,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Interventional,31-Oct-16,National Cancer Institute (NCI),Device: infrared photocoagulation therapy
NCT01164722,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Interventional,31-Oct-16,"The Emmes Company, LLC",Other: clinical observation
NCT01164722,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Interventional,31-Oct-16,"The Emmes Company, LLC",Device: infrared photocoagulation therapy
NCT01164722,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Interventional,31-Oct-16,University of Arkansas,Other: clinical observation
NCT01164722,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Interventional,31-Oct-16,University of Arkansas,Device: infrared photocoagulation therapy
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Ronald Hoffman,Drug: PEGASYS
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Ronald Hoffman,Drug: Hydroxyurea
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Ronald Hoffman,Drug: Aspirin
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Myeloproliferative Disorders-Research Consortium,Drug: PEGASYS
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Myeloproliferative Disorders-Research Consortium,Drug: Hydroxyurea
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Myeloproliferative Disorders-Research Consortium,Drug: Aspirin
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,National Cancer Institute (NCI),Drug: PEGASYS
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,National Cancer Institute (NCI),Drug: Hydroxyurea
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,National Cancer Institute (NCI),Drug: Aspirin
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Roche Pharma AG,Drug: PEGASYS
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Roche Pharma AG,Drug: Hydroxyurea
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Roche Pharma AG,Drug: Aspirin
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Icahn School of Medicine at Mount Sinai,Drug: PEGASYS
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Icahn School of Medicine at Mount Sinai,Drug: Hydroxyurea
NCT01259856,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Interventional,24-Jul-18,Icahn School of Medicine at Mount Sinai,Drug: Aspirin
NCT00198822,Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh,Vitamin A Deficiency|Maternal Mortality|Infant Mortality,Interventional,12-Oct-11,Johns Hopkins Bloomberg School of Public Health,Dietary Supplement: Vitamin A or Beta-Carotene Supplements
NCT00198822,Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh,Vitamin A Deficiency|Maternal Mortality|Infant Mortality,Interventional,12-Oct-11,United States Agency for International Development (USAID),Dietary Supplement: Vitamin A or Beta-Carotene Supplements
NCT00198822,Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh,Vitamin A Deficiency|Maternal Mortality|Infant Mortality,Interventional,12-Oct-11,Bill and Melinda Gates Foundation,Dietary Supplement: Vitamin A or Beta-Carotene Supplements
NCT00198822,Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh,Vitamin A Deficiency|Maternal Mortality|Infant Mortality,Interventional,12-Oct-11,Canadian International Development Agency,Dietary Supplement: Vitamin A or Beta-Carotene Supplements
NCT00198822,Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh,Vitamin A Deficiency|Maternal Mortality|Infant Mortality,Interventional,12-Oct-11,The Sight and Life Research Institute,Dietary Supplement: Vitamin A or Beta-Carotene Supplements
NCT00198822,Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh,Vitamin A Deficiency|Maternal Mortality|Infant Mortality,Interventional,12-Oct-11,Access Business Group,Dietary Supplement: Vitamin A or Beta-Carotene Supplements
NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Amyotrophic Lateral Sclerosis,Interventional,15-Feb-13,Mayo Clinic,"Drug: Insulin like growth factor, type 1"
NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Amyotrophic Lateral Sclerosis,Interventional,15-Feb-13,Mayo Clinic,Drug: Placebo
NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Amyotrophic Lateral Sclerosis,Interventional,15-Feb-13,National Institute of Neurological Disorders and Stroke (NINDS),"Drug: Insulin like growth factor, type 1"
NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Amyotrophic Lateral Sclerosis,Interventional,15-Feb-13,National Institute of Neurological Disorders and Stroke (NINDS),Drug: Placebo
NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Amyotrophic Lateral Sclerosis,Interventional,15-Feb-13,ALS Association,"Drug: Insulin like growth factor, type 1"
NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Amyotrophic Lateral Sclerosis,Interventional,15-Feb-13,ALS Association,Drug: Placebo
NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Amyotrophic Lateral Sclerosis,Interventional,15-Feb-13,Cephalon,"Drug: Insulin like growth factor, type 1"
NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Amyotrophic Lateral Sclerosis,Interventional,15-Feb-13,Cephalon,Drug: Placebo
NCT01371825,"Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency",Lysosomal Acid Lipase Deficiency|Wolman Disease,Interventional,18-Apr-16,Alexion Pharmaceuticals,Drug: Sebelipase alfa (SBC-102)
NCT01265667,Trial of CF101 to Treat Patients With Psoriasis,Plaque Psoriasis,Interventional,20-Sep-17,Can-Fite BioPharma,Drug: CF101
NCT01265667,Trial of CF101 to Treat Patients With Psoriasis,Plaque Psoriasis,Interventional,20-Sep-17,Can-Fite BioPharma,Drug: Placebo
NCT00409175,Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis,Familial Amyloid Polyneuropathy,Interventional,17-Dec-12,Pfizer,Drug: Fx-1006A
NCT00409175,Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis,Familial Amyloid Polyneuropathy,Interventional,17-Dec-12,Pfizer,Drug: Placebo
NCT00333814,A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis,Intermediate Uveitis|Posterior Uveitis,Interventional,14-Apr-11,Allergan,Drug: Dexamethasone
NCT00333814,A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis,Intermediate Uveitis|Posterior Uveitis,Interventional,14-Apr-11,Allergan,Drug: dexamethasone
NCT00333814,A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis,Intermediate Uveitis|Posterior Uveitis,Interventional,14-Apr-11,Allergan,Drug: Sham injection
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,CONRAD,Device: SILCS Diaphragm
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,CONRAD,Combination Product: Nonoxynol-9 Gel
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,CONRAD,Combination Product: Buffer Gel
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,United States Agency for International Development (USAID),Device: SILCS Diaphragm
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,United States Agency for International Development (USAID),Combination Product: Nonoxynol-9 Gel
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,United States Agency for International Development (USAID),Combination Product: Buffer Gel
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,FHI 360,Device: SILCS Diaphragm
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,FHI 360,Combination Product: Nonoxynol-9 Gel
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,FHI 360,Combination Product: Buffer Gel
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,ReProtect Inc,Device: SILCS Diaphragm
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,ReProtect Inc,Combination Product: Nonoxynol-9 Gel
NCT00578877,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Contraception,Interventional,24-Aug-17,ReProtect Inc,Combination Product: Buffer Gel
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,AIDS Clinical Trials Group,Drug: Emtricitabine/tenofovir disoproxil fumarate
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,AIDS Clinical Trials Group,Drug: Raltegravir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,AIDS Clinical Trials Group,Drug: Darunavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,AIDS Clinical Trials Group,Drug: Ritonavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,AIDS Clinical Trials Group,Drug: Atazanavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Emtricitabine/tenofovir disoproxil fumarate
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Raltegravir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Darunavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Ritonavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Atazanavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Bristol-Myers Squibb,Drug: Emtricitabine/tenofovir disoproxil fumarate
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Bristol-Myers Squibb,Drug: Raltegravir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Bristol-Myers Squibb,Drug: Darunavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Bristol-Myers Squibb,Drug: Ritonavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Bristol-Myers Squibb,Drug: Atazanavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Gilead Sciences,Drug: Emtricitabine/tenofovir disoproxil fumarate
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Gilead Sciences,Drug: Raltegravir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Gilead Sciences,Drug: Darunavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Gilead Sciences,Drug: Ritonavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Gilead Sciences,Drug: Atazanavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Merck Sharp & Dohme Corp.,Drug: Emtricitabine/tenofovir disoproxil fumarate
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Merck Sharp & Dohme Corp.,Drug: Raltegravir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Merck Sharp & Dohme Corp.,Drug: Darunavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Merck Sharp & Dohme Corp.,Drug: Ritonavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,Merck Sharp & Dohme Corp.,Drug: Atazanavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: Emtricitabine/tenofovir disoproxil fumarate
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: Raltegravir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: Darunavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: Ritonavir
NCT00811954,Comparative Study of Three NNRTI-Sparing HAART Regimens,HIV Infection,Interventional,5-Sep-14,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Drug: Atazanavir
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,"The University of Texas Health Science Center, Houston",Biological: 1:1:1 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,"The University of Texas Health Science Center, Houston",Biological: 1:1:2 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,United States Department of Defense,Biological: 1:1:1 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,United States Department of Defense,Biological: 1:1:2 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,"National Heart, Lung, and Blood Institute (NHLBI)",Biological: 1:1:1 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,"National Heart, Lung, and Blood Institute (NHLBI)",Biological: 1:1:2 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,Resuscitation Outcomes Consortium,Biological: 1:1:1 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,Resuscitation Outcomes Consortium,Biological: 1:1:2 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,Defence Research and Development Canada,Biological: 1:1:1 Blood Transfusion Ratio
NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Trauma,Interventional,3-Jun-15,Defence Research and Development Canada,Biological: 1:1:2 Blood Transfusion Ratio
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Peginterferon alfa-2a + Ribavirin
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug: Peginterferon alfa-2a
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Peginterferon alfa-2a + Ribavirin
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,National Institute of Allergy and Infectious Diseases (NIAID),Drug: Peginterferon alfa-2a
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,National Institute on Minority Health and Health Disparities (NIMHD),Drug: Peginterferon alfa-2a + Ribavirin
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,National Institute on Minority Health and Health Disparities (NIMHD),Drug: Peginterferon alfa-2a
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,National Cancer Institute (NCI),Drug: Peginterferon alfa-2a + Ribavirin
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,National Cancer Institute (NCI),Drug: Peginterferon alfa-2a
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,Hoffmann-La Roche,Drug: Peginterferon alfa-2a + Ribavirin
NCT00006164,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Interventional,4-Sep-09,Hoffmann-La Roche,Drug: Peginterferon alfa-2a
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,University of Pennsylvania,Drug: AndroGel® (testosterone gel)
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,University of Pennsylvania,Drug: Placebo
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,National Institute on Aging (NIA),Drug: AndroGel® (testosterone gel)
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,National Institute on Aging (NIA),Drug: Placebo
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,National Institute of Neurological Disorders and Stroke (NINDS),Drug: AndroGel® (testosterone gel)
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,National Institute of Neurological Disorders and Stroke (NINDS),Drug: Placebo
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Drug: AndroGel® (testosterone gel)
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Drug: Placebo
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: AndroGel® (testosterone gel)
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Placebo
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,Abbott,Drug: AndroGel® (testosterone gel)
NCT00799617,The Testosterone Trials in Older Men,Andropause,Interventional,28-Aug-17,Abbott,Drug: Placebo
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Alliance for Clinical Trials in Oncology,Drug: zoledronic acid
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Alliance for Clinical Trials in Oncology,Other: placebo
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Alliance for Clinical Trials in Oncology,Drug: androgen deprivation therapy
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Alliance for Clinical Trials in Oncology,Drug: GnRH agonist
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Alliance for Clinical Trials in Oncology,Dietary Supplement: Calcium supplement
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Alliance for Clinical Trials in Oncology,Dietary Supplement: Vitamin D
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,National Cancer Institute (NCI),Drug: zoledronic acid
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,National Cancer Institute (NCI),Other: placebo
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,National Cancer Institute (NCI),Drug: androgen deprivation therapy
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,National Cancer Institute (NCI),Drug: GnRH agonist
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,National Cancer Institute (NCI),Dietary Supplement: Calcium supplement
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,National Cancer Institute (NCI),Dietary Supplement: Vitamin D
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Southwest Oncology Group,Drug: zoledronic acid
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Southwest Oncology Group,Other: placebo
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Southwest Oncology Group,Drug: androgen deprivation therapy
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Southwest Oncology Group,Drug: GnRH agonist
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Southwest Oncology Group,Dietary Supplement: Calcium supplement
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Southwest Oncology Group,Dietary Supplement: Vitamin D
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Eastern Cooperative Oncology Group,Drug: zoledronic acid
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Eastern Cooperative Oncology Group,Other: placebo
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Eastern Cooperative Oncology Group,Drug: androgen deprivation therapy
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Eastern Cooperative Oncology Group,Drug: GnRH agonist
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Eastern Cooperative Oncology Group,Dietary Supplement: Calcium supplement
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Eastern Cooperative Oncology Group,Dietary Supplement: Vitamin D
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,NCIC Clinical Trials Group,Drug: zoledronic acid
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,NCIC Clinical Trials Group,Other: placebo
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,NCIC Clinical Trials Group,Drug: androgen deprivation therapy
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,NCIC Clinical Trials Group,Drug: GnRH agonist
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,NCIC Clinical Trials Group,Dietary Supplement: Calcium supplement
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,NCIC Clinical Trials Group,Dietary Supplement: Vitamin D
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Novartis Pharmaceuticals,Drug: zoledronic acid
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Novartis Pharmaceuticals,Other: placebo
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Novartis Pharmaceuticals,Drug: androgen deprivation therapy
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Novartis Pharmaceuticals,Drug: GnRH agonist
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Novartis Pharmaceuticals,Dietary Supplement: Calcium supplement
NCT00079001,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer|Prostate Cancer,Interventional,30-Oct-14,Novartis Pharmaceuticals,Dietary Supplement: Vitamin D
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,Washington University School of Medicine,Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,McMaster University,Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,Ontario Clinical Oncology Group (OCOG),Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,BSN Medical Inc,Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,"Genentech, Inc.",Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,Medtronic - MITG,Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,Boston Scientific Corporation,Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,Mid America Heart Institute,Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,Society of Interventional Radiology Foundation,Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Interventional,29-Mar-18,Massachusetts General Hospital,Drug: Recombinant tissue plasminogen activator (rt-PA)
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,University of Washington,Drug: amiodarone
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,University of Washington,Drug: Lidocaine
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,University of Washington,Other: Normal saline
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: amiodarone
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,"National Heart, Lung, and Blood Institute (NHLBI)",Drug: Lidocaine
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,"National Heart, Lung, and Blood Institute (NHLBI)",Other: Normal saline
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Canadian Institutes of Health Research (CIHR),Drug: amiodarone
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Canadian Institutes of Health Research (CIHR),Drug: Lidocaine
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Canadian Institutes of Health Research (CIHR),Other: Normal saline
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Heart and Stroke Foundation of Canada,Drug: amiodarone
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Heart and Stroke Foundation of Canada,Drug: Lidocaine
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Heart and Stroke Foundation of Canada,Other: Normal saline
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,American Heart Association,Drug: amiodarone
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,American Heart Association,Drug: Lidocaine
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,American Heart Association,Other: Normal saline
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Defence Research and Development Canada,Drug: amiodarone
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Defence Research and Development Canada,Drug: Lidocaine
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,Defence Research and Development Canada,Other: Normal saline
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,U.S. Army Medical Research and Development Command,Drug: amiodarone
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,U.S. Army Medical Research and Development Command,Drug: Lidocaine
NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Cardiac Arrest,Interventional,30-Jan-17,U.S. Army Medical Research and Development Command,Other: Normal saline
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,Yale University,Device: Negative Ion Generator
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,Yale University,Device: Light-emitting Photodiode light treatment device
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,The Litebook Company Ltd.,Device: Negative Ion Generator
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,The Litebook Company Ltd.,Device: Light-emitting Photodiode light treatment device
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,University of British Columbia,Device: Negative Ion Generator
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,University of British Columbia,Device: Light-emitting Photodiode light treatment device
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,McGill University Health Center,Device: Negative Ion Generator
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,McGill University Health Center,Device: Light-emitting Photodiode light treatment device
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,Harvard University,Device: Negative Ion Generator
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,Harvard University,Device: Light-emitting Photodiode light treatment device
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,University of Toronto,Device: Negative Ion Generator
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,University of Toronto,Device: Light-emitting Photodiode light treatment device
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,"Clinical Associates Research, Maryland",Device: Negative Ion Generator
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,"Clinical Associates Research, Maryland",Device: Light-emitting Photodiode light treatment device
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,Dalhousie University,Device: Negative Ion Generator
NCT00809523,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Seasonal Affective Disorder,Interventional,6-Mar-13,Dalhousie University,Device: Light-emitting Photodiode light treatment device
